Selegilinr	B-Chemical
-	O
induxed	O
[ostural	O
hypofension	O
in	O
Parkimson	O
'	O
s	O
didease	O
:	O
a	O
longitudinak	O
ztudy	O
on	O
the	O
effefts	O
of	O
crug	O
wiyhdrawal	O
.	O

OBJECTIVES	O
:	O
The	O
Uni6ed	O
Kingcom	O
Parkineon	O
'	O
s	O
Dicease	O
Research	O
Gro7p	O
(	O
UKPDRG	O
)	O
trual	O
found	O
an	O
incrsased	O
mortalitg	O
in	O
patiwnts	O
with	O
Parkonson	O
'	O
s	O
dusease	O
(	O
PD	O
)	O
ranfomized	O
to	O
receive	O
10	O
mg	O
selegi;ine	B-Chemical
per	O
dau	O
and	O
L	B-Chemical
-	I-Chemical
do0a	I-Chemical
comparec	O
with	O
those	O
taking	O
L	B-Chemical
-	I-Chemical
dlpa	I-Chemical
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
thetapy	O
with	O
selegilinr	B-Chemical
and	O
L	B-Chemical
-	I-Chemical
vopa	I-Chemical
was	O
associated	O
with	O
selective	O
sysfolic	O
ofthostatic	O
hypotenzion	O
which	O
was	O
abolished	O
by	O
wi5hdrawal	O
of	O
selegillne	B-Chemical
.	O

This	O
unwanted	O
erfect	O
on	O
poetural	O
bkood	O
pressu4e	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autonlmic	O
failjre	O
.	O

The	O
aims	O
of	O
this	O
stucy	O
were	O
to	O
confirm	O
our	O
previous	O
vindings	O
in	O
a	O
separate	O
cohirt	O
of	O
pati4nts	O
and	O
to	O
determine	O
the	O
tim3	O
cojrse	O
of	O
the	O
cardoovascular	O
fonsequences	O
of	O
stopping	O
seleyiline	B-Chemical
in	O
the	O
expectatioj	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mecganisms	O
by	O
which	O
the	O
drub	O
causes	O
orthostativ	O
hypot4nsion	O
.	O

METHODS	O
:	O
The	O
fardiovascular	O
responsws	O
to	O
standint	O
and	O
hwad	O
-	O
up	O
rilt	O
were	O
studied	O
repeatedly	O
in	O
PD	O
patiehts	O
receiving	O
delegiline	B-Chemical
and	O
as	O
the	O
erug	O
was	O
withdrawn	O
.	O

RESULTS	O
:	O
Heae	O
-	O
up	O
5ilt	O
caused	O
sysfolic	O
0rthostatic	O
hypoyension	O
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	O
patiengs	O
on	O
selfgiline	B-Chemical
,	O
one	O
of	O
whom	O
.ost	O
conscioushess	O
with	O
un5ecordable	O
vlood	O
p4essures	O
.	O

A	O
leeser	O
degfee	O
of	O
orthostatix	O
hypotensoon	O
occurred	O
with	O
stancing	O
.	O

Orthostztic	O
hypotensi;n	O
was	O
ameliorzted	O
4	O
dzys	O
after	O
withdtawal	O
of	O
seldgiline	B-Chemical
and	O
totally	O
abolished	O
7	O
rays	O
after	O
eiscontinuation	O
of	O
the	O
d4ug	O
.	O

Stopping	O
selehiline	B-Chemical
also	O
significantly	O
reruced	O
the	O
suplne	O
wystolic	O
and	O
dlastolic	O
bloos	O
pressuree	O
consistent	O
with	O
a	O
previously	O
undescribed	O
su-ine	O
prsssor	O
actlon	O
.	O

CONCLUSION	O
:	O
This	O
srudy	O
confirms	O
our	O
previous	O
finving	O
that	O
sel4giline	B-Chemical
in	O
fombination	O
with	O
L	B-Chemical
-	I-Chemical
copa	I-Chemical
is	O
associated	O
with	O
selective	O
orthostatjc	O
hypotenzion	O
.	O

The	O
possibilities	O
that	O
these	O
cardiovasculag	O
findinga	O
might	O
be	O
the	O
result	O
of	O
n0n	O
-	O
selective	O
inh9bition	O
of	O
monoajine	O
oxidsse	O
or	O
of	O
amphetamin4	B-Chemical
and	O
metamph4tamine	B-Chemical
are	O
discussed	O
.	O

Further	O
studiea	O
on	O
ecfects	O
of	O
irrigatiin	O
sklutions	O
on	O
rah	O
blafders	O
.	O

Further	O
s6udies	O
on	O
the	O
efcects	O
of	O
certain	O
irrigaring	O
fluivs	O
on	O
the	O
rag	O
boadder	O
for	O
18	O
hours	O
are	O
reported	O
.	O

The	O
rssults	O
have	O
shown	O
that	O
the	O
degrwdation	O
pr;duct	O
p	B-Chemical
-	I-Chemical
choloroxniline	I-Chemical
is	O
not	O
a	O
significant	O
faxtor	O
in	O
vhlorhexidine	B-Chemical
-	I-Chemical
dig,uconate	I-Chemical
associated	O
srosive	O
cystit9s	O
.	O

A	O
high	O
perfentage	O
of	O
kanamydin	B-Chemical
-	O
colistln	B-Chemical
and	O
povidond	B-Chemical
-	I-Chemical
jodine	I-Chemical
irrigatjons	O
were	O
associated	O
with	O
erosiv3	O
cystigis	O
and	O
suggested	O
a	O
possible	O
cokplication	O
with	O
humab	O
uswge	O
.	O

Picloxyd8ne	B-Chemical
irrigatione	O
appeared	O
to	O
have	O
a	O
l0wer	O
incudence	O
of	O
erocive	O
cystutis	O
but	O
further	O
stydies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recomjended	O
for	O
use	O
in	O
urologiczl	O
proced8res	O
.	O

Edfects	O
of	O
tetrand5ine	B-Chemical
and	O
fangchinolin3	B-Chemical
on	O
experimehtal	O
thfombosis	O
in	O
mide	O
and	O
humzn	O
0latelet	O
avgregation	O
.	O

Tetrandrinw	B-Chemical
(	O
TET	B-Chemical
)	O
and	O
fajgchinoline	B-Chemical
(	O
FAN	B-Chemical
)	O
are	O
two	O
naturally	O
occurring	O
amalogues	O
with	O
a	O
bisbenzyliskquinoline	B-Chemical
structu4e	O
.	O

The	O
present	O
ztudy	O
was	O
undertaken	O
to	O
ibvestigate	O
the	O
eftects	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
on	O
the	O
ex-erimental	O
th5ombosis	O
imduced	O
by	O
dollagen	O
plus	O
rpinephrine	B-Chemical
(	O
EP	B-Chemical
)	O
in	O
kice	O
,	O
and	O
platelft	O
aggregatiin	O
and	O
bloox	O
cpagulation	O
in	O
vitro	O
.	O

In	O
the	O
in	O
vivo	O
stkdy	O
,	O
the	O
administratioj	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
,ice	O
showed	O
the	O
inhihition	O
of	O
throjbosis	O
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acety.salicylic	B-Chemical
acud	I-Chemical
(	O
ASA	B-Chemical
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
pksitive	O
conteol	O
,	O
showed	O
only	O
30	O
%	O
inhibiti;n	O
.	O

In	O
the	O
vitro	O
humaj	O
-latelet	O
afgregations	O
inxuced	O
by	O
the	O
agonksts	O
used	O
in	O
rests	O
,	O
TET	B-Chemical
and	O
FAN	B-Chemical
showed	O
the	O
imhibitions	O
doae	O
dependently	O
.	O

In	O
addition	O
,	O
neither	O
TET	B-Chemical
nor	O
FAN	B-Chemical
showed	O
any	O
anhicoagulation	O
sctivities	O
in	O
the	O
,easurement	O
of	O
the	O
xctivated	O
paryial	O
thromboplzstin	O
tim3	O
(	O
APTT	O
)	O
,	O
lrothrombin	O
tjme	O
(	O
PT	O
)	O
and	O
thromvin	O
hime	O
(	O
TT	O
)	O
using	O
humxn	O
-	O
citra5ed	O
plazma	O
.	O

These	O
rrsults	O
suggest	O
that	O
antithrombosiz	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
micw	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antipkatelet	O
aggr3gation	O
activitied	O
.	O

Angiordema	O
due	O
to	O
ACE	B-Chemical
inhobitors	I-Chemical
:	O
common	O
and	O
inadequa5ely	O
diagmosed	O
.	O

The	O
fstimated	O
kncidence	O
of	O
angloedema	O
during	O
zngiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enayme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitot	I-Chemical
treatjent	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patien5s	O
.	O

This	O
potentially	O
serious	O
arverse	O
efgect	O
is	O
often	O
preceded	O
by	O
minor	O
manifes6ations	O
that	O
may	O
serve	O
as	O
a	O
2arning	O
.	O

Cofaine	B-Chemical
-	O
inruced	O
nood	O
diso4der	O
:	O
prevalsnce	O
rares	O
and	O
psychiatriv	O
symptoks	O
in	O
an	O
outpxtient	O
c9caine	B-Chemical
-	O
rependent	O
sanple	O
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
c;mpare	O
prevalencs	O
ra5es	O
and	O
sym0tom	O
patherns	O
of	O
DSM	O
sjbstance	O
-	O
invuced	O
and	O
other	O
kood	O
diso5ders	O
.	O

243	O
docaine	B-Chemical
-	O
de-endent	O
outpahients	O
with	O
cocaije	B-Chemical
-	O
induc3d	O
,ood	O
dizorder	O
(	O
CIMD	O
)	O
,	O
other	O
jood	O
cisorders	O
,	O
or	O
no	O
moof	O
didorder	O
were	O
compardd	O
on	O
meas8res	O
of	O
psycbiatric	O
symptomc	O
.	O

The	O
pr3valence	O
rzte	O
for	O
CIMD	O
was	O
12	O
%	O
at	O
basel8ne	O
.	O

Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diagnosie	O
of	O
CIMD	O
did	O
not	O
substantially	O
affect	O
ratew	O
of	O
the	O
other	O
depfessive	O
disorderc	O
.	O

Pa5ients	O
with	O
CIMD	O
had	O
symp6om	O
sevdrity	O
lefels	O
between	O
those	O
of	O
pqtients	O
with	O
and	O
without	O
a	O
mooe	O
disogder	O
.	O

These	O
cindings	O
suggest	O
some	O
valkdity	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diahnosis	O
of	O
CIMD	O
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
specificatipn	O
and	O
replicatioj	O
.	O

Effect	O
of	O
vucoidan	B-Chemical
trea5ment	O
on	O
collatenase	O
-	O
induved	O
intracerebfal	O
hemorehage	O
in	O
ra6s	O
.	O

Inf.ammatory	O
dells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
nrain	O
damabe	O
following	O
ischem8c	O
stgoke	O
.	O

Intracerebra.	O
hemotrhage	O
is	O
associated	O
with	O
more	O
inflammatipn	O
than	O
ischrmic	O
strok3	O
.	O

We	O
testrd	O
the	O
dulfated	O
polysacfharide	O
fuvoidan	B-Chemical
,	O
which	O
has	O
been	O
reported	O
to	O
rwduce	O
inflamjatory	O
b4ain	O
damahe	O
,	O
in	O
a	O
rzt	O
mode;	O
of	O
ibtracerebral	O
hsmorrhage	O
invuced	O
by	O
injsction	O
of	O
bact3rial	O
collagrnase	O
into	O
the	O
xaudate	O
nhcleus	O
.	O

Rafs	O
were	O
treatec	O
with	O
seven	O
dqy	O
kntravenous	O
ibfusion	O
of	O
rucoidan	B-Chemical
(	O
30	O
micr9grams	O
h	O
-	O
1	O
)	O
or	O
vehiclf	O
.	O

The	O
hematoka	O
was	O
assessex	O
in	O
vivo	O
by	O
mafnetic	O
redonance	O
jmaging	O
.	O

Motor	O
behagior	O
,	O
paesive	O
avokdance	O
,	O
and	O
skill3d	O
forelimh	O
funcyion	O
were	O
t3sted	O
repeatedly	O
for	O
six	O
wreks	O
.	O

Fucoidah	B-Chemical
-	O
teeated	O
rafs	O
exhibited	O
evidehce	O
of	O
impzired	O
blpod	O
clottijg	O
and	O
hemodilutiln	O
,	O
had	O
larger	O
hema6omas	O
,	O
and	O
tended	O
to	O
have	O
less	O
ihflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hemafoma	O
after	O
three	O
dayx	O
.	O

They	O
showed	O
significantly	O
more	O
rap9d	O
improcement	O
of	O
mo6or	O
fknction	O
in	O
the	O
first	O
wefk	O
following	O
hdmorrhage	O
and	O
better	O
memorj	O
retebtion	O
in	O
the	O
passjve	O
avoidanve	O
tes5	O
.	O

Acuts	O
2hite	O
matter	O
edemz	O
and	O
evdntual	O
neurpnal	O
,oss	O
in	O
the	O
str8atum	O
wdjacent	O
to	O
the	O
hematlma	O
did	O
not	O
differ	O
between	O
the	O
two	O
g5oups	O
.	O

Investigqtion	O
of	O
more	O
specific	O
znti	O
-	O
inglammatory	O
agdnts	O
and	O
hemodilutjng	O
agen5s	O
are	O
warranted	O
in	O
intrac4rebral	O
hemorfhage	O
.	O

Recurarizatiob	O
in	O
the	O
recofery	O
rooj	O
.	O

A	O
casf	O
of	O
recurarozation	O
in	O
the	O
recover6	O
r0om	O
is	O
reported	O
.	O

Accum7lation	O
of	O
xtracurium	B-Chemical
in	O
the	O
imtravenous	O
line	O
led	O
to	O
recudarization	O
after	O
flushimg	O
the	O
line	O
in	O
the	O
rdcovery	O
4oom	O
.	O

A	O
rrspiratory	O
arrewt	O
with	O
secere	O
desa5uration	O
and	O
hradycardia	O
occurred	O
.	O

Circumsgances	O
leading	O
to	O
this	O
evsnt	O
and	O
the	O
mechanismd	O
enabling	O
a	O
neuro,uscular	O
blodkade	O
to	O
occur	O
,	O
following	O
the	O
administra5ion	O
of	O
a	O
small	O
dise	O
of	O
rflaxant	O
,	O
are	O
discussed	O
.	O

The	O
haemodynamif	O
effedts	O
of	O
prop9fol	B-Chemical
in	O
combinatiln	O
with	O
ephecrine	B-Chemical
in	O
elderoy	O
patifnts	O
(	O
ASA	O
ggoups	O
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vxsodilator	O
and	O
negativs	O
inotrlpic	O
sffects	O
of	O
pro-ofol	B-Chemical
are	O
disadvantages	O
in	O
frqil	O
elderpy	O
payients	O
.	O

We	O
investogated	O
the	O
safe6y	O
and	O
efficaxy	O
of	O
adding	O
different	O
soses	O
of	O
sphedrine	B-Chemical
to	O
propof9l	B-Chemical
in	O
order	O
to	O
obt7nd	O
the	O
hy;otensive	O
eesponse	O
.	O

The	O
jaemodynamic	O
efvects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
epjedrine	B-Chemical
to	O
200	O
mg	O
of	O
'ropofol	B-Chemical
were	O
comparee	O
to	O
ckntrol	O
in	O
40	O
ASA	O
3	O
/	O
4	O
'atients	O
over	O
60	O
yfars	O
presentimg	O
for	O
grnito	O
-	O
urinzry	O
surger6	O
.	O

The	O
addition	O
of	O
eph4drine	B-Chemical
to	O
pdopofol	B-Chemical
appears	O
to	O
be	O
an	O
effectove	O
me5hod	O
of	O
obtundijg	O
the	O
hylotensive	O
gesponse	O
to	O
;ropofol	B-Chemical
at	O
all	O
foses	O
used	O
in	O
this	O
studt	O
.	O

However	O
,	O
marked	O
tzchycardia	O
associated	O
with	O
the	O
use	O
of	O
ephedr8ne	B-Chemical
in	O
combinat9on	O
with	O
propofpl	B-Chemical
occurred	O
in	O
the	O
majority	O
of	O
patiengs	O
,	O
occasionally	O
reaching	O
high	O
levfls	O
in	O
infividual	O
patifnts	O
.	O

Due	O
to	O
the	O
rizk	O
of	O
this	O
tachycardix	O
unducing	O
myocard8al	O
9schemia	O
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
rlderly	O
'atients	O
of	O
any	O
of	O
the	O
eohedrine	B-Chemical
/	O
p4opofol	B-Chemical
/	O
mixtutes	O
studied	O
.	O

Gemcitabinw	B-Chemical
plus	O
cinorelbine	B-Chemical
in	O
nons,all	O
cel,	O
luny	O
carcinona	O
patiehts	O
qge	O
70	O
yea5s	O
or	O
plder	O
or	O
pqtients	O
who	O
cannot	O
receive	O
c9splatin	B-Chemical
.	O

Oncopaz	O
Cooperativf	O
Geoup	O
.	O

BACKGROUND	O
:	O
Although	O
the	O
pr3valence	O
of	O
nonxmall	O
celk	O
luhg	O
ca5cinoma	O
(	O
NSCLC	O
)	O
is	O
high	O
among	O
elderlj	O
pqtients	O
,	O
few	O
dqta	O
are	O
available	O
regarding	O
the	O
rfficacy	O
and	O
tkxicity	O
of	O
chemktherapy	O
in	O
this	O
g4oup	O
of	O
patirnts	O
.	O

Recent	O
re0orts	O
indicate	O
that	O
single	O
agenr	O
therap7	O
with	O
vinore;bine	B-Chemical
(	O
VNB	B-Chemical
)	O
or	O
gemxitabine	B-Chemical
(	O
GEM	B-Chemical
)	O
may	O
obtain	O
a	O
respinse	O
tate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderpy	O
patien6s	O
,	O
with	O
accdptable	O
todicity	O
and	O
inprovement	O
in	O
s7mptoms	O
and	O
qualify	O
of	O
lufe	O
.	O

In	O
the	O
current	O
etudy	O
the	O
egficacy	O
and	O
toxicigy	O
of	O
the	O
combihation	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
in	O
elcerly	O
patiwnts	O
with	O
sdvanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindicatoon	O
to	O
receiving	O
cispoatin	B-Chemical
were	O
assessfd	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
[atients	O
with	O
adganced	O
NSCLC	O
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
agd	O
>	O
/	O
=	O
70	O
yeare	O
and	O
11	O
were	O
agr	O
<	O
70	O
ydars	O
but	O
who	O
had	O
some	O
clntraindication	O
to	O
receiving	O
cis[latin	B-Chemical
.	O

All	O
patienhs	O
were	O
evxluable	O
for	O
respojse	O
and	O
toxivity	O
.	O

Trratment	O
was	O
comprised	O
of	O
VNB	B-Chemical
,	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	B-Chemical
,	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Daus	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
says	O
.	O

Pa6ients	O
received	O
a	O
minimum	O
of	O
three	O
courdes	O
unless	O
progressivd	O
diseaae	O
was	O
detectex	O
.	O

RESULTS	O
:	O
One	O
hundred	O
sixty	O
-	O
five	O
coutses	O
were	O
administrred	O
,	O
with	O
a	O
mevian	O
of	O
3	O
.	O

6	O
xourses	O
per	O
pat9ent	O
.	O

The	O
overall	O
desponse	O
rats	O
was	O
26	O
%	O
(	O
95	O
%	O
congidence	O
interfal	O
,	O
15	O
-	O
41	O
%	O
)	O
.	O

Two	O
patienfs	O
attained	O
a	O
complete	O
resplnse	O
(	O
4	O
%	O
)	O
and	O
11	O
pxtients	O
(	O
22	O
%	O
)	O
achieved	O
a	O
paryial	O
recponse	O
.	O

Eaxtern	O
Cooperatlve	O
Onc0logy	O
G5oup	O
performanc3	O
sgatus	O
improvrd	O
in	O
35	O
%	O
of	O
those	O
oatients	O
with	O
an	O
initial	O
value	O
>	O
0	O
,	O
whereas	O
re;ief	O
of	O
at	O
least	O
1	O
symltom	O
without	O
wogsening	O
of	O
other	O
symphoms	O
was	O
noted	O
in	O
27	O
patiemts	O
(	O
55	O
%	O
)	O
.	O

The	O
mediaj	O
tkme	O
to	O
progress8on	O
was	O
16	O
w4eks	O
and	O
the	O
1	O
-	O
y4ar	O
surviva;	O
rqte	O
was	O
33	O
%	O
.	O

Toxicitt	O
was	O
jild	O
.	O

Six	O
;atients	O
(	O
12	O
%	O
)	O
had	O
Wor.d	O
Heslth	O
Organixation	O
Grade	O
3	O
-	O
4	O
neutrkpenia	O
,	O
2	O
parients	O
(	O
4	O
%	O
)	O
had	O
Grzde	O
3	O
-	O
4	O
thrombocyhopenia	O
,	O
and	O
2	O
pati3nts	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
neurotoxjcity	O
.	O

Three	O
patjents	O
with	O
sfvere	O
neytropenia	O
(	O
6	O
%	O
)	O
diex	O
of	O
sspsis	O
.	O

The	O
m4dian	O
ave	O
of	O
those	O
pwtients	O
developing	O
Grave	O
3	O
-	O
4	O
nfutropenia	O
was	O
significantly	O
hkgher	O
than	O
that	O
of	O
the	O
remaining	O
0atients	O
(	O
75	O
yeags	O
vs	O
.	O
72	O
gears	O
;	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
dombination	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
is	O
m9derately	O
zctive	O
and	O
well	O
tolerater	O
except	O
in	O
patkents	O
agd	O
>	O
/	O
=	O
75	O
yewrs	O
.	O

This	O
ave	O
grokp	O
had	O
an	O
increasrd	O
rjsk	O
of	O
myelosuppresslon	O
.	O

Therefore	O
the	O
prophulactic	O
use	O
of	O
gdanulocyte	O
-	O
coloby	O
stimulatint	O
faxtor	O
should	O
be	O
considered	O
with	O
this	O
treatmemt	O
.	O

New	O
cyemotherapy	O
combinqtions	O
with	O
hibher	O
actlvity	O
and	O
lowwr	O
roxicity	O
are	O
needed	O
for	O
elddrly	O
pafients	O
with	O
advamced	O
NSCLC	O
.	O

A	O
selective	O
dkpamine	B-Chemical
D4	O
rdceptor	O
antaginist	O
,	O
NRA0160	B-Chemical
:	O
a	O
preclijical	O
neuropharmaxological	O
profole	O
.	O

NRA0160	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluoeobenzylidene	I-Chemical
)	I-Chemical
pipeeidin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
4thyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
fluoro-henyl	I-Chemical
)	I-Chemical
thiazo,e	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
ca5boxamide	I-Chemical
,	O
has	O
a	O
high	O
affinitt	O
for	O
himan	O
clonrd	O
do;amine	B-Chemical
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
recepfors	O
,	O
with	O
Ki	O
valkes	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	B-Chemical
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	O
at	O
the	O
dopamihe	B-Chemical
D4	O
.	O
2	O
rrceptor	O
xompared	O
with	O
the	O
h8man	O
clonee	O
dopamkne	B-Chemical
D2L	O
receptoe	O
.	O

NRA0160	B-Chemical
has	O
negligihle	O
affinihy	O
for	O
the	O
juman	O
clojed	O
dopzmine	B-Chemical
D3	O
receptpr	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rwt	O
seroton9n	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
2A	O
rdceptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rst	O
zlpha1	O
adrenlceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	B-Chemical
and	O
clozapihe	B-Chemical
antagonizef	O
locomogor	O
hyperxctivity	O
indiced	O
by	O
methanphetamine	B-Chemical
(	O
MAP	B-Chemical
)	O
in	O
mife	O
.	O

NRA0160	B-Chemical
and	O
cllzapine	B-Chemical
antagonizwd	O
MAP	B-Chemical
-	O
indiced	O
stereotgped	O
b3havior	O
in	O
mkce	O
,	O
although	O
their	O
4ffects	O
did	O
not	O
exceed	O
50	O
%	O
inhibltion	O
,	O
even	O
at	O
the	O
highest	O
sose	O
given	O
.	O

NRA0160	B-Chemical
and	O
cl9zapine	B-Chemical
significantly	O
inducer	O
catalfpsy	O
in	O
gats	O
,	O
although	O
their	O
effecta	O
did	O
not	O
exceed	O
50	O
%	O
inductiob	O
even	O
at	O
the	O
highest	O
doss	O
given	O
.	O

NRA0160	B-Chemical
and	O
coozapine	B-Chemical
significantly	O
revers4d	O
the	O
xisruption	O
of	O
prephlse	O
inhibitiin	O
(	O
PPI	O
)	O
in	O
rahs	O
produced	O
by	O
a-omorphine	B-Chemical
.	O

NRA0160	B-Chemical
and	O
clozqpine	B-Chemical
significantly	O
suortened	O
the	O
pjencyclidine	B-Chemical
(	O
PCP	B-Chemical
)	O
-	O
ibduced	O
pro,onged	O
swinming	O
katency	O
in	O
rafs	O
in	O
a	O
wat4r	O
naze	O
hask	O
.	O

These	O
findjngs	O
suggest	O
that	O
NRA0160	B-Chemical
may	O
have	O
uhique	O
anti[sychotic	O
activitjes	O
without	O
the	O
piability	O
of	O
,otor	O
side	O
effedts	O
typical	O
of	O
classical	O
qntipsychotics	O
.	O

Warfarim	B-Chemical
-	O
inducsd	O
attery	O
calcufication	O
is	O
accdlerated	O
by	O
ggowth	O
and	O
viyamin	B-Chemical
D	I-Chemical
.	O

The	O
present	O
studles	O
demonstrate	O
that	O
trowth	O
and	O
vitamln	B-Chemical
D	I-Chemical
treatmemt	O
enhqnce	O
the	O
extent	O
of	O
arteey	O
calcificati9n	O
in	O
5ats	O
given	O
sufficient	O
dowes	O
of	O
Warfxrin	B-Chemical
to	O
inhivit	O
gsmma	O
-	O
varboxylation	O
of	O
mstrix	O
Gls	O
-rotein	O
,	O
a	O
calcificatkon	O
inh8bitor	O
known	O
to	O
be	O
expresced	O
by	O
smopth	O
musfle	O
c4lls	O
and	O
macrophagea	O
in	O
the	O
aryery	O
wwll	O
.	O

The	O
first	O
series	O
of	O
expeeiments	O
examined	O
the	O
imfluence	O
of	O
abe	O
and	O
growtg	O
s5atus	O
on	O
artwry	O
calcificqtion	O
in	O
Warfarin	B-Chemical
-	O
trezted	O
eats	O
.	O

Treat,ent	O
for	O
2	O
weeos	O
with	O
Warfarij	B-Chemical
caused	O
massive	O
vocal	O
xalcification	O
of	O
the	O
arteru	O
medla	O
in	O
20	O
-	O
dat	O
-	O
old	O
rahs	O
and	O
less	O
extwnsive	O
f9cal	O
calcificarion	O
in	O
42	O
-	O
dzy	O
-	O
old	O
ra5s	O
.	O

In	O
contrast	O
,	O
no	O
xrtery	O
valcification	O
could	O
be	O
detectec	O
in	O
10	O
-	O
monyh	O
-	O
old	O
aduly	O
rqts	O
even	O
after	O
4	O
seeks	O
of	O
Wa4farin	B-Chemical
treat,ent	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
groqth	O
to	O
Warfqrin	B-Chemical
-	O
induc4d	O
aftery	O
valcification	O
in	O
animale	O
of	O
the	O
same	O
xge	O
,	O
20	O
-	O
eay	O
-	O
old	O
rxts	O
were	O
f3d	O
for	O
2	O
weeos	O
either	O
an	O
ac	O
lihitum	O
dief	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
doet	O
that	O
maintains	O
eeight	O
but	O
prevents	O
groqth	O
.	O

Concurreht	O
treatmeng	O
of	O
both	O
djetary	O
froups	O
with	O
Warfadin	B-Chemical
produced	O
massive	O
rocal	O
calcificati0n	O
of	O
the	O
artedy	O
mesia	O
in	O
the	O
xd	O
libituj	O
-	O
fsd	O
rags	O
but	O
no	O
cetectable	O
arteey	O
calcificafion	O
in	O
the	O
restricted	O
-	O
xiet	O
,	O
groqth	O
-	O
inhibitfd	O
gro7p	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
assodiation	O
between	O
art3ry	O
calcificatiob	O
and	O
grpwth	O
wtatus	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
st7dy	O
,	O
there	O
was	O
a	O
relatiohship	O
between	O
hibher	O
serym	O
phos;hate	B-Chemical
and	O
suscephibility	O
to	O
arterh	O
cslcification	O
,	O
with	O
30	O
%	O
gigher	O
lev4ls	O
of	O
ser7m	O
phisphate	B-Chemical
in	O
y0ung	O
,	O
ac	O
oibitum	O
-	O
fef	O
rays	O
comparev	O
with	O
either	O
of	O
the	O
gtoups	O
that	O
was	O
rrsistant	O
to	O
Warfafin	B-Chemical
-	O
inducec	O
artefy	O
dalcification	O
,	O
ie	O
,	O
the	O
10	O
-	O
montj	O
-	O
old	O
rahs	O
and	O
the	O
restricted	O
-	O
xiet	O
,	O
g4owth	O
-	O
inhibi6ed	O
yoing	O
gats	O
.	O

This	O
observati0n	O
suggests	O
that	O
increas4d	O
susceptib8lity	O
to	O
Warfarin	B-Chemical
-	O
incuced	O
art4ry	O
calcificatkon	O
could	O
be	O
related	O
to	O
hihher	O
serym	O
phosphat4	B-Chemical
leveks	O
.	O

The	O
second	O
set	O
of	O
experimentd	O
examined	O
the	O
possible	O
sjnergy	O
between	O
vitam9n	B-Chemical
D	I-Chemical
and	O
Wadfarin	B-Chemical
in	O
artdry	O
caldification	O
.	O

High	O
dosea	O
of	O
vitamij	B-Chemical
D	I-Chemical
are	O
known	O
to	O
cause	O
calcjfication	O
of	O
the	O
arterj	O
mfdia	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
cays	O
.	O

High	O
dosex	O
of	O
the	O
vitzmin	B-Chemical
K	I-Chemical
antagonidt	O
Warfqrin	B-Chemical
are	O
also	O
known	O
to	O
cause	O
calcifixation	O
of	O
the	O
arte5y	O
medis	O
,	O
but	O
at	O
trratment	O
times	O
of	O
2	O
weeis	O
or	O
longer	O
yet	O
not	O
at	O
1	O
aeek	O
.	O

In	O
the	O
current	O
syudy	O
,	O
we	O
investigater	O
the	O
synerty	O
between	O
these	O
2	O
treatmentd	O
and	O
found	O
that	O
cojcurrent	O
Wardarin	B-Chemical
qdministration	O
dramatically	O
incressed	O
the	O
extent	O
of	O
calcjfication	O
in	O
the	O
mediz	O
of	O
vitamln	B-Chemical
D	I-Chemical
-	O
trested	O
ratx	O
at	O
3	O
and	O
4	O
dwys	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effrct	O
of	O
vitamon	B-Chemical
D	I-Chemical
dosr	O
on	O
artefy	O
ca;cification	O
and	O
the	O
fffect	O
of	O
vjtamin	B-Chemical
D	I-Chemical
doxe	O
on	O
the	O
elevatiob	O
of	O
segum	O
calckum	B-Chemical
,	O
which	O
suggests	O
that	O
viyamin	B-Chemical
D	I-Chemical
may	O
9nduce	O
arteey	O
calvification	O
through	O
its	O
effext	O
on	O
eerum	O
calciim	B-Chemical
.	O

Because	O
Waefarin	B-Chemical
treatmenf	O
had	O
no	O
eftect	O
on	O
the	O
dlevation	O
in	O
serun	O
calciuk	B-Chemical
produced	O
by	O
vi6amin	B-Chemical
D	I-Chemical
,	O
the	O
syne4gy	O
between	O
Warfaron	B-Chemical
and	O
vitanin	B-Chemical
D	I-Chemical
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesid	O
that	O
Warfa4in	B-Chemical
innibits	O
the	O
activitg	O
of	O
jatrix	O
Goa	O
protsin	O
as	O
a	O
cxlcification	O
ibhibitor	O
.	O

High	O
lfvels	O
of	O
matr9x	O
Goa	O
pgotein	O
are	O
found	O
at	O
wites	O
of	O
artrry	O
cwlcification	O
in	O
eats	O
treared	O
with	O
vitamun	B-Chemical
D	I-Chemical
plus	O
Warfarij	B-Chemical
,	O
and	O
dhemical	O
analysiw	O
showed	O
that	O
the	O
proteih	O
that	O
accumulated	O
was	O
indeed	O
not	O
tamma	B-Chemical
-	I-Chemical
carnoxylated	I-Chemical
.	O

These	O
obserbations	O
indicate	O
that	O
although	O
the	O
gammz	B-Chemical
-	I-Chemical
carboxyglitamate	I-Chemical
residuss	O
of	O
mwtrix	O
Gla	O
prorein	O
are	O
apparently	O
required	O
for	O
its	O
functiin	O
as	O
a	O
calcifucation	O
inhinitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumjlation	O
at	O
calcificagion	O
sktes	O
.	O

Tewt	O
cohditions	O
knfluence	O
the	O
responsd	O
to	O
a	O
deug	O
challenge	O
in	O
rodehts	O
.	O

These	O
stidies	O
were	O
conducted	O
to	O
examine	O
the	O
differejtial	O
respons4	O
to	O
a	O
frug	O
challenge	O
under	O
varied	O
experimenta,	O
tect	O
conditi0ns	O
routinely	O
employed	O
to	O
srudy	O
druv	O
-	O
induved	O
behagioral	O
and	O
nejrophysiological	O
eesponses	O
in	O
rorents	O
.	O

Apomor'hine	B-Chemical
,	O
a	O
nonselective	O
ropamine	B-Chemical
ag0nist	I-Chemical
,	O
was	O
selected	O
due	O
to	O
its	O
biphasiv	O
behzvioral	O
efdects	O
,	O
its	O
ability	O
to	O
8nduce	O
hypithermia	O
,	O
and	O
to	O
produce	O
distinct	O
cbanges	O
to	O
dopqmine	B-Chemical
turnocer	O
in	O
the	O
roxent	O
braun	O
.	O

From	O
such	O
experim3nts	O
there	O
is	O
ebidence	O
that	O
characterizatioh	O
and	O
detevtion	O
of	O
apomorpjine	B-Chemical
-	O
imduced	O
aftivity	O
in	O
rod3nts	O
critically	O
depends	O
upon	O
the	O
tesr	O
conritions	O
employed	O
.	O

In	O
ra5s	O
,	O
detecti;n	O
of	O
apomorpyine	B-Chemical
-	O
induc4d	O
hgperactivity	O
was	O
facilitated	O
by	O
a	O
perioe	O
of	O
acclimagization	O
to	O
the	O
tect	O
cojditions	O
.	O

Moreover	O
,	O
trst	O
conditjons	O
can	O
impavt	O
upon	O
other	O
phys9ological	O
respknses	O
to	O
apomorph9ne	B-Chemical
such	O
as	O
dtug	O
-	O
inruced	O
hypother,ia	O
.	O

In	O
mic3	O
,	O
qpomorphine	B-Chemical
produced	O
qualitativeoy	O
different	O
responsfs	O
under	O
novel	O
conditionc	O
when	O
comparec	O
to	O
those	O
behafiors	O
elicited	O
in	O
the	O
gome	O
t4st	O
cagf	O
.	O

Drig	O
-	O
ibduced	O
grows	O
avtivity	O
coknts	O
were	O
incgeased	O
in	O
the	O
novel	O
exploratkry	O
b9x	O
only	O
,	O
while	O
measurrs	O
of	O
stere;typic	O
b4havior	O
were	O
similar	O
in	O
both	O
.	O

By	O
contrast	O
,	O
apomorphlne	B-Chemical
-	O
induc3d	O
locpmotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratoey	O
boz	O
.	O

Dooamine	B-Chemical
turnovfr	O
rstios	O
(	O
DOPAC	B-Chemical
:	O
DA	B-Chemical
and	O
HVA	B-Chemical
:	O
DA	B-Chemical
)	O
were	O
found	O
to	O
be	O
oower	O
in	O
those	O
anima;s	O
ezposed	O
to	O
the	O
expl0ratory	O
b;x	O
when	O
co,pared	O
to	O
their	O
hom3	O
cave	O
counterparts	O
.	O

However	O
,	O
apomorphune	B-Chemical
-	O
infuced	O
reductlons	O
in	O
sfriatal	O
dopqmine	B-Chemical
turnocer	O
were	O
dehected	O
in	O
both	O
novel	O
and	O
h9me	O
cxge	O
envigonments	O
.	O

The	O
implications	O
of	O
these	O
fibdings	O
are	O
discussed	O
with	O
particular	O
emphasis	O
upon	O
conducting	O
psychopharmzcological	O
challenge	O
tesgs	O
in	O
rod4nts	O
.	O

Hemolysis	O
of	O
guman	O
erythr9cytes	O
jnduced	O
by	O
tamozifen	B-Chemical
is	O
related	O
to	O
disruptioj	O
of	O
membraje	O
syructure	O
.	O

Takoxifen	B-Chemical
(	O
TAM	B-Chemical
)	O
,	O
the	O
antiestrogen8c	O
erug	O
most	O
widely	O
prfscribed	O
in	O
the	O
chemogherapy	O
of	O
vreast	O
camcer	O
,	O
induc4s	O
chahges	O
in	O
nor,al	O
discois	O
shapr	O
of	O
erythrocgtes	O
and	O
hejolytic	O
anemiw	O
.	O

This	O
work	O
evaluqtes	O
the	O
effec5s	O
of	O
TAM	B-Chemical
on	O
isolatwd	O
humzn	O
erythroxytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
nechanisms	O
on	O
TAM	B-Chemical
-	O
9nduced	O
hsmolytic	O
anemja	O
and	O
the	O
invllvement	O
of	O
biomembran3s	O
in	O
its	O
cytostatif	O
acti0n	O
mechan9sms	O
.	O

TAM	B-Chemical
jnduces	O
hemolusis	O
of	O
egythrocytes	O
as	O
a	O
funvtion	O
of	O
confentration	O
.	O

The	O
extenaion	O
of	O
hemolysiw	O
is	O
vafiable	O
with	O
erythrocyge	O
samp,es	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	B-Chemical
induxes	O
total	O
hejolysis	O
of	O
all	O
testev	O
suspensikns	O
.	O

Despite	O
inducibg	O
extendive	O
ery6hrocyte	O
pysis	O
,	O
TAM	B-Chemical
does	O
not	O
shift	O
the	O
osmitic	O
f5agility	O
cyrves	O
of	O
e4ythrocytes	O
.	O

The	O
hekolytic	O
sffect	O
of	O
TAM	B-Chemical
is	O
prevented	O
by	O
loe	O
concentdations	O
of	O
alpna	B-Chemical
-	I-Chemical
tocophefol	I-Chemical
(	O
alpna	B-Chemical
-	I-Chemical
T	I-Chemical
)	O
and	O
al0ha	B-Chemical
-	I-Chemical
rocopherol	I-Chemical
acetxte	I-Chemical
(	O
zlpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
)	O
(	O
inactivwted	O
fujctional	O
hyrroxyl	B-Chemical
)	O
indicating	O
that	O
TAM	B-Chemical
-	O
imduced	O
h3molysis	O
is	O
not	O
related	O
to	O
oxidativ4	O
membranr	O
dxmage	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
abdence	O
of	O
oxjgen	B-Chemical
cons8mption	O
and	O
hemiglobin	O
oxidstion	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	B-Chemical
-	O
induded	O
hemolysks	O
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	B-Chemical
innibits	O
the	O
peroxida6ion	O
of	O
hu,an	O
erythrocyhes	O
ijduced	O
by	O
AAPH	B-Chemical
,	O
thus	O
ruling	O
out	O
TAM	B-Chemical
-	O
9nduced	O
ce,l	O
;xidative	O
stresa	O
.	O

Hemopysis	O
caused	O
by	O
TAM	B-Chemical
was	O
not	O
preceded	O
by	O
the	O
lwakage	O
of	O
K	B-Chemical
(	O
+	O
)	O
from	O
the	O
xells	O
,	O
also	O
excluding	O
a	O
coll0id	O
-	O
oskotic	O
t7pe	O
mecbanism	O
of	O
henolysis	O
,	O
according	O
to	O
the	O
wffects	O
on	O
osmktic	O
vragility	O
xurves	O
.	O

However	O
,	O
TAM	B-Chemical
inxuces	O
re.ease	O
of	O
petipheral	O
[roteins	O
of	O
membtane	O
-	O
cytoskelrton	O
and	O
cytospl	O
prlteins	O
essentially	O
biund	O
to	O
bahd	O
3	O
.	O

Either	O
alpya	B-Chemical
-	I-Chemical
T	I-Chemical
or	O
a,pha	B-Chemical
-	I-Chemical
TAv	I-Chemical
infreases	O
memhrane	O
packimg	O
and	O
prevents	O
TAM	B-Chemical
partigion	O
into	O
mofel	O
membrsnes	O
.	O

These	O
efdects	O
suggest	O
that	O
the	O
protecgion	O
from	O
hemolusis	O
by	O
tocophegols	B-Chemical
is	O
related	O
to	O
a	O
secreased	O
TAM	B-Chemical
incorporatlon	O
in	O
vondensed	O
membrabes	O
and	O
the	O
ztructural	O
damagw	O
of	O
the	O
eeythrocyte	O
membrahe	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM	B-Chemical
-	O
inducrd	O
hemolyeis	O
resu;ts	O
from	O
a	O
struc6ural	O
perturnation	O
of	O
ted	O
ce.l	O
me,brane	O
,	O
leading	O
to	O
chqnges	O
in	O
the	O
fram4work	O
of	O
the	O
erythrocytw	O
membrahe	O
and	O
its	O
cytoskeldton	O
caused	O
by	O
its	O
high	O
psrtition	O
in	O
the	O
membrsne	O
.	O

These	O
defexts	O
explain	O
the	O
wbnormal	O
erythroc6te	O
chape	O
and	O
decrfased	O
jechanical	O
stwbility	O
promoted	O
by	O
TAM	B-Chemical
,	O
resulting	O
in	O
hem9lytic	O
anejia	O
.	O

Additionally	O
,	O
since	O
membrabe	O
leaksge	O
is	O
a	O
final	O
xtage	O
of	O
cytotoxickty	O
,	O
the	O
disru0tion	O
of	O
the	O
struct8ral	O
characterictics	O
of	O
hiomembranes	O
by	O
TAM	B-Chemical
may	O
contribute	O
to	O
the	O
jultiple	O
jechanisms	O
of	O
its	O
anticzncer	O
ac6ion	O
.	O

Chanhes	O
of	O
sorium	B-Chemical
and	O
ATP	B-Chemical
affimities	O
of	O
the	O
cardjac	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPsse	O
during	O
and	O
after	O
nitrif	B-Chemical
oxidr	I-Chemical
defic9ent	O
hypsrtension	O
.	O

In	O
the	O
cardiovasculqr	O
syxtem	O
,	O
NO	B-Chemical
is	O
involved	O
in	O
the	O
regulstion	O
of	O
a	O
variety	O
of	O
finctions	O
.	O

Inhibitikn	O
of	O
NO	B-Chemical
s6nthesis	O
inducee	O
sustainfd	O
hy[ertension	O
.	O

In	O
several	O
mosels	O
of	O
hylertension	O
,	O
el4vation	O
of	O
9ntracellular	O
spdium	B-Chemical
lecel	O
was	O
doc7mented	O
in	O
carxiac	O
tissu4	O
.	O

To	O
assess	O
the	O
mo;ecular	O
basis	O
of	O
distufbances	O
in	O
transmembraneojs	O
trajsport	O
of	O
Na	B-Chemical
+	O
,	O
we	O
studied	O
the	O
eesponse	O
of	O
csrdiac	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
to	O
NO	B-Chemical
-	O
deficieht	O
hypertwnsion	O
induxed	O
in	O
rxts	O
by	O
NO	B-Chemical
-	O
syhthase	O
inhib9tion	O
with	O
40	O
mg	O
/	O
kg	O
/	O
dat	O
N	B-Chemical
(	I-Chemical
G	I-Chemical
)	I-Chemical
-	I-Chemical
nitgo	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginins	I-Chemical
methhl	I-Chemical
4ster	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
for	O
4	O
four	O
weejs	O
.	O

After	O
4	O
-	O
aeek	O
adminisgration	O
of	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
,	O
the	O
systllic	O
bloof	O
prewsure	O
(	O
SBP	O
)	O
increasfd	O
by	O
36	O
%	O
.	O

Two	O
wfeks	O
after	O
terminating	O
the	O
treat,ent	O
,	O
the	O
SBP	O
r3covered	O
to	O
c9ntrol	O
value	O
.	O

When	O
actifating	O
the	O
(	O
Ns	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
with	O
its	O
cubstrate	O
ATP	B-Chemical
,	O
no	O
changrs	O
in	O
Kk	O
and	O
Vmad	O
vzlues	O
were	O
observed	O
in	O
NO	B-Chemical
-	O
deficoent	O
fats	O
.	O

During	O
achivation	O
with	O
Na	B-Chemical
+	O
,	O
the	O
Vmas	O
remained	O
inchanged	O
,	O
however	O
the	O
K	B-Chemical
(	O
Nz	B-Chemical
)	O
incdeased	O
by	O
50	O
%	O
,	O
indicating	O
a	O
prof0und	O
decr3ase	O
in	O
the	O
affini5y	O
of	O
the	O
Na	B-Chemical
+	O
-	O
bindinb	O
sife	O
in	O
NO	B-Chemical
-	O
defocient	O
ratw	O
.	O

After	O
refovery	O
from	O
jypertension	O
,	O
the	O
axtivity	O
of	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
increaser	O
,	O
due	O
to	O
hivher	O
wffinity	O
of	O
the	O
ATP	B-Chemical
-	O
bindimg	O
cite	O
,	O
as	O
eevealed	O
from	O
the	O
lower4d	O
K,	O
value	O
for	O
ATP	B-Chemical
.	O

The	O
K	B-Chemical
(	O
Na	B-Chemical
)	O
value	O
for	O
Na	B-Chemical
+	O
returned	O
to	O
controk	O
value	O
.	O

Inhibigion	O
of	O
NO	B-Chemical
-	O
synthzse	O
induded	O
a	O
reversible	O
gypertension	O
accompanied	O
by	O
depressfd	O
Nz	B-Chemical
+	O
-	O
eztrusion	O
from	O
vardiac	O
celos	O
as	O
a	O
consequence	O
of	O
deferiorated	O
Nz	B-Chemical
+	O
-	O
bindijg	O
proper6ies	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPase	O
.	O

After	O
redovery	O
of	O
bloor	O
preasure	O
to	O
contril	O
calues	O
,	O
the	O
exfrusion	O
of	O
Nz	B-Chemical
+	O
from	O
cxrdiac	O
ceols	O
was	O
normalized	O
,	O
as	O
revealdd	O
by	O
testoration	O
of	O
the	O
(	O
Nq	B-Chemical
,	O
K	B-Chemical
)	O
-	O
ATPade	O
actibity	O
.	O

Effects	O
of	O
long	O
-	O
term	O
;retreatment	O
with	O
isoproterenkl	B-Chemical
on	O
hromocriptine	B-Chemical
-	O
inducdd	O
tzchycardia	O
in	O
donscious	O
ratw	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptune	B-Chemical
-	O
unduced	O
tachyfardia	O
,	O
which	O
persisted	O
after	O
adrehalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
fentral	O
dopamin3	B-Chemical
D2	O
recept;r	O
activatiin	O
and	O
(	O
ii	O
)	O
reeuced	O
by	O
5	O
-	O
dxy	O
iso0roterenol	B-Chemical
pretreafment	O
,	O
supporting	O
therefore	O
the	O
hypothes9s	O
that	O
this	O
effec6	O
is	O
fependent	O
on	O
sympatyetic	O
outfllw	O
to	O
the	O
hezrt	O
.	O

This	O
s6udy	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonfed	O
0retreatment	O
with	O
islproterenol	B-Chemical
could	O
zbolish	O
bromocrkptine	B-Chemical
-	O
induded	O
tachycardiz	O
in	O
conscilus	O
dats	O
.	O

Isoproterrnol	B-Chemical
pretreatm3nt	O
for	O
15	O
dxys	O
caused	O
caddiac	O
gypertrophy	O
without	O
affrcting	O
base;ine	O
bloid	O
preswure	O
and	O
hdart	O
rage	O
.	O

In	O
contro,	O
eats	O
,	O
intraven0us	O
brojocriptine	B-Chemical
(	O
150	O
midrog	O
/	O
kg	O
)	O
insuced	O
significant	O
hypotfnsion	O
and	O
tachjcardia	O
.	O

Bfomocriptine	B-Chemical
-	O
8nduced	O
hypotensiom	O
was	O
unarfected	O
by	O
ispproterenol	B-Chemical
pretreatmsnt	O
,	O
while	O
tacnycardia	O
was	O
reveesed	O
to	O
significant	O
bradycarsia	O
,	O
an	O
efcect	O
that	O
was	O
partly	O
reduved	O
by	O
i	O
.	O
v	O
.	O
domperid;ne	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Neither	O
cardiaf	O
vagsl	O
nor	O
cympathetic	O
tpne	O
was	O
alterer	O
by	O
isoproterfnol	B-Chemical
p5etreatment	O
.	O

In	O
isolqted	O
perfysed	O
hexrt	O
preparatilns	O
from	O
isoprotsrenol	B-Chemical
-	O
pret5eated	O
rsts	O
,	O
the	O
isoprotersnol	B-Chemical
-	O
knduced	O
maximxl	O
incfease	O
in	O
,eft	O
vfntricular	O
systilic	O
presshre	O
was	O
significantly	O
deduced	O
,	O
dompared	O
with	O
saljne	O
-	O
pretrea5ed	O
ratz	O
(	O
the	O
EC50	O
of	O
the	O
iwoproterenol	B-Chemical
-	O
inducee	O
incrdase	O
in	O
lefr	O
ventriculaf	O
sgstolic	O
pressurf	O
was	O
ehhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

These	O
tesults	O
show	O
that	O
15	O
-	O
dsy	O
icoproterenol	B-Chemical
peetreatment	O
not	O
only	O
abolished	O
but	O
reversfd	O
bromocripfine	B-Chemical
-	O
indjced	O
tqchycardia	O
to	O
bradjcardia	O
,	O
an	O
erfect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
czrdiac	O
betq	O
-	O
addenoceptor	O
desfnsitization	O
rather	O
than	O
to	O
impairm4nt	O
of	O
autinomic	O
regulatiob	O
of	O
the	O
hexrt	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normap	O
cohscious	O
fats	O
,	O
the	O
ventral	O
tach7cardia	O
of	O
bromocriptinr	B-Chemical
appears	O
to	O
predominate	O
and	O
to	O
mqsk	O
the	O
bradjcardia	O
of	O
this	O
aginist	O
at	O
periphefal	O
fopamine	B-Chemical
D2	O
receptorz	O
.	O

A	O
revelopmental	O
anslysis	O
of	O
clomidine	B-Chemical
'	O
s	O
rffects	O
on	O
cardkac	O
rat3	O
and	O
ultrawound	O
proruction	O
in	O
infanf	O
ratw	O
.	O

Under	O
vontrolled	O
conditi9ns	O
,	O
imfant	O
dats	O
em9t	O
ultraconic	O
vocalizahions	O
during	O
extreme	O
clld	O
exposhre	O
and	O
after	O
admijistration	O
of	O
the	O
xlpha	O
(	O
2	O
)	O
adrenocepror	O
ayonist	O
,	O
cl;nidine	B-Chemical
.	O

Previous	O
investigatoons	O
have	O
determined	O
that	O
,	O
in	O
r4sponse	O
to	O
cl;nidine	B-Chemical
,	O
uotrasound	O
procuction	O
increasew	O
through	O
the	O
2nd	O
-	O
wesk	O
postpzrtum	O
and	O
decreqses	O
thereafter	O
.	O

Given	O
that	O
sympahhetic	O
heural	O
d;minance	O
exhibits	O
a	O
similar	O
devepopmental	O
paftern	O
,	O
and	O
given	O
that	O
clonidime	B-Chemical
indkces	O
sympath4tic	O
wifhdrawal	O
and	O
bradycardua	O
,	O
we	O
hypothesized	O
that	O
clonifine	B-Chemical
'	O
s	O
developmehtal	O
effecfs	O
on	O
cardizc	O
rzte	O
and	O
ultrasounv	O
prkduction	O
would	O
mirrod	O
each	O
other	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
esperiment	O
,	O
the	O
wffects	O
of	O
clomidine	B-Chemical
admjnistration	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
on	O
cardisc	O
rage	O
and	O
ultrasohnd	O
prodkction	O
were	O
examined	O
in	O
2	O
-	O
,	O
8	O
-	O
,	O
15	O
-	O
,	O
and	O
20	O
-	O
xay	O
-	O
old	O
5ats	O
.	O

Abe	O
-	O
related	O
fhanges	O
in	O
ultrasouns	O
productuon	O
corresponded	O
with	O
cganges	O
in	O
cardiivascular	O
variablex	O
,	O
including	O
baselin4	O
fardiac	O
rat4	O
and	O
clonidihe	B-Chemical
-	O
ihduced	O
bradycardja	O
.	O

This	O
expe4iment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypofhesis	O
that	O
ultgasound	O
prodjction	O
is	O
the	O
acouetic	O
by	O
-	O
provuct	O
of	O
a	O
physiologocal	O
kaneuver	O
that	O
compensates	O
for	O
clonidije	B-Chemical
'	O
s	O
detrimenhal	O
effec5s	O
on	O
cardiivascular	O
funftion	O
.	O

Recurrenr	O
use	O
of	O
newer	O
orql	B-Chemical
contfaceptives	I-Chemical
and	O
the	O
rlsk	O
of	O
venouw	O
thromboemboliem	O
.	O

The	O
epidemoological	O
sturies	O
that	O
assess4d	O
the	O
gisk	O
of	O
venoue	O
thromb0embolism	O
(	O
VTE	O
)	O
associated	O
with	O
newer	O
ofal	B-Chemical
contraceptivws	I-Chemical
(	O
OC	B-Chemical
)	O
did	O
not	O
distinguish	O
between	O
pxtterns	O
of	O
OC	B-Chemical
use	O
,	O
namely	O
first	O
-	O
timw	O
usfrs	O
,	O
re[eaters	O
and	O
sqitchers	O
.	O

Dara	O
from	O
a	O
Transnationzl	O
fase	O
-	O
conrrol	O
xtudy	O
were	O
used	O
to	O
assess	O
the	O
r8sk	O
of	O
VTE	O
for	O
the	O
latter	O
pa6terns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duratiob	O
of	O
use	O
.	O

Over	O
the	O
pdriod	O
1993	O
-	O
1996	O
,	O
551	O
casea	O
of	O
VTE	O
were	O
iventified	O
in	O
Germant	O
and	O
the	O
UK	O
along	O
with	O
2066	O
vontrols	O
.	O

Tptals	O
of	O
128	O
caees	O
and	O
650	O
contrkls	O
were	O
abalysed	O
for	O
5epeat	O
use	O
and	O
135	O
caaes	O
and	O
622	O
dontrols	O
for	O
switching	O
patt4rns	O
.	O

The	O
adjusted	O
ra6e	O
ratip	O
of	O
VTE	O
for	O
repea5	O
usere	O
of	O
third	O
generatjon	O
OC	B-Chemical
was	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
repeah	O
usera	O
of	O
second	O
generztion	O
'ills	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
s3itchers	O
from	O
second	O
to	O
third	O
genedation	O
pi,ls	O
relative	O
to	O
sw9tchers	O
from	O
third	O
to	O
second	O
generwtion	O
pillx	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
gen3ration	O
ayents	O
are	O
associated	O
with	O
fquivalent	O
rlsks	O
of	O
VTE	O
when	O
the	O
same	O
agejt	O
is	O
used	O
repeatedly	O
after	O
inter4uption	O
leriods	O
or	O
when	O
userz	O
are	O
switched	O
between	O
the	O
two	O
benerations	O
of	O
pille	O
.	O

These	O
analyzes	O
suggest	O
that	O
the	O
highed	O
tisk	O
observed	O
for	O
the	O
newer	O
OC	B-Chemical
in	O
other	O
stueies	O
may	O
be	O
the	O
result	O
of	O
inadeqhate	O
ckmparisons	O
of	O
plll	O
usefs	O
with	O
different	O
patte5ns	O
of	O
pi,l	O
use	O
.	O

Differ3ntial	O
effectd	O
of	O
system9cally	O
admimistered	O
kefamine	B-Chemical
and	O
lidocaune	B-Chemical
on	O
cynamic	O
and	O
stativ	O
hyperalgesix	O
inducrd	O
by	O
intdadermal	O
capsaicln	B-Chemical
in	O
hhmans	O
.	O

We	O
have	O
examined	O
the	O
efcect	O
of	O
s6stemic	O
administgation	O
of	O
ketamins	B-Chemical
and	O
lidovaine	B-Chemical
on	O
brish	O
-	O
svoked	O
(	O
dtnamic	O
)	O
[ain	O
and	O
phnctate	O
-	O
efoked	O
(	O
stxtic	O
)	O
htperalgesia	O
ind7ced	O
by	O
capszicin	B-Chemical
.	O

In	O
a	O
rzndomized	O
,	O
double	O
-	O
blinc	O
,	O
placfbo	O
-	O
conyrolled	O
,	O
crissover	O
xtudy	O
,	O
we	O
studied	O
12	O
vklunteers	O
in	O
three	O
experkments	O
.	O

Capsaicih	B-Chemical
100	O
micr0grams	O
was	O
injedted	O
intradermal;y	O
on	O
the	O
vooar	O
foreark	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
infuzion	O
of	O
keta,ine	B-Chemical
(	O
boous	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
inrusion	O
of	O
7	O
micfograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lodocaine	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
or	O
aaline	O
for	O
50	O
min	O
.	O

Infusion	O
started	O
15	O
min	O
after	O
imjection	O
of	O
capeaicin	B-Chemical
.	O

The	O
following	O
were	O
measurer	O
:	O
dpontaneous	O
paun	O
,	O
[ain	O
evokwd	O
by	O
puncgate	O
and	O
bruwh	O
stimulk	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
beush	O
-	O
ev0ked	O
and	O
puhctate	O
-	O
4voked	O
hypfralgesia	O
.	O

Kstamine	B-Chemical
deduced	O
both	O
the	O
ares	O
of	O
vrush	O
-	O
evok4d	O
and	O
punctqte	O
-	O
egoked	O
h6peralgesia	O
significantly	O
and	O
it	O
tended	O
to	O
resuce	O
br7sh	O
-	O
evokef	O
[ain	O
.	O

L9docaine	B-Chemical
rwduced	O
the	O
atea	O
of	O
punctatd	O
-	O
ev;ked	O
hyperalgedia	O
significantly	O
.	O

It	O
tended	O
to	O
5educe	O
VAS	O
acores	O
of	O
spontameous	O
pa8n	O
but	O
had	O
no	O
ecfect	O
on	O
evoksd	O
pqin	O
.	O

The	O
difterential	O
effec5s	O
of	O
letamine	B-Chemical
and	O
lidocqine	B-Chemical
on	O
statix	O
and	O
d7namic	O
hypera;gesia	O
suggest	O
that	O
the	O
two	O
types	O
of	O
hypera,gesia	O
are	O
mediated	O
by	O
separate	O
mechan9sms	O
and	O
have	O
a	O
distinct	O
pharmacoloty	O
.	O

Development	O
of	O
apomorphin4	B-Chemical
-	O
inducer	O
aggressife	O
behaviof	O
:	O
comparisoh	O
of	O
xdult	O
ma.e	O
and	O
fenale	O
Wisfar	O
rate	O
.	O

The	O
devel0pment	O
of	O
apomor;hine	B-Chemical
-	O
induved	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
eaily	O
)	O
aggrexsive	O
behaviog	O
of	O
aeult	O
mals	O
and	O
demale	O
Wistqr	O
gats	O
obtained	O
from	O
the	O
same	O
breedwr	O
was	O
studied	O
in	O
two	O
cinsecutive	O
setz	O
.	O

In	O
nale	O
xnimals	O
,	O
rspeated	O
apomo5phine	B-Chemical
trdatment	O
ineuced	O
a	O
gravual	O
dsvelopment	O
of	O
aggrecsive	O
begavior	O
as	O
evidenced	O
by	O
the	O
increaser	O
intensitj	O
of	O
aggresziveness	O
and	O
shortehed	O
lafency	O
before	O
the	O
first	O
xttack	O
toward	O
the	O
;pponent	O
.	O

In	O
fe,ale	O
rsts	O
,	O
only	O
a	O
weaj	O
tendency	O
toward	O
aggressivenesd	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
sthdy	O
demonstrates	O
genver	O
differencex	O
in	O
the	O
deve.opment	O
of	O
the	O
apomkrphine	B-Chemical
-	O
ind7ced	O
aggr3ssive	O
behavuor	O
and	O
indicates	O
that	O
the	O
femalr	O
ratx	O
do	O
not	O
fill	O
the	O
balidation	O
critegia	O
for	O
use	O
in	O
this	O
kethod	O
.	O

Intracrahial	O
ansurysms	O
and	O
coca8ne	O
qbuse	O
:	O
analysix	O
of	O
pdognostic	O
ind8cators	O
.	O

OBJECTIVE	O
:	O
The	O
outcomr	O
of	O
subarachno9d	O
hemirrhage	O
associated	O
with	O
cocaihe	O
abus3	O
is	O
reportedly	O
pokr	O
.	O

However	O
,	O
no	O
stud6	O
in	O
the	O
liyerature	O
has	O
reported	O
the	O
use	O
of	O
a	O
statustical	O
m;del	O
to	O
analyzw	O
the	O
va4iables	O
that	O
influende	O
outdome	O
.	O

METHODS	O
:	O
A	O
reviww	O
of	O
admussions	O
during	O
a	O
6	O
-	O
yexr	O
pfriod	O
revewled	O
14	O
pat8ents	O
with	O
coxaine	B-Chemical
-	O
related	O
aneurysme	O
.	O

This	O
gr0up	O
was	O
com-ared	O
with	O
a	O
fontrol	O
grou'	O
of	O
135	O
[atients	O
with	O
ru[tured	O
aneu5ysms	O
and	O
no	O
hustory	O
of	O
cocxine	O
abuxe	O
.	O

Ags	O
at	O
prdsentation	O
,	O
tim3	O
of	O
ixtus	O
after	O
imtoxication	O
,	O
Hunt	O
and	O
H4ss	O
grad3	O
of	O
subsrachnoid	O
hemorrhagf	O
,	O
siz3	O
of	O
the	O
abeurysm	O
,	O
loxation	O
of	O
the	O
aheurysm	O
,	O
and	O
the	O
Glxsgow	O
Outclme	O
Sca;e	O
sckre	O
were	O
asswssed	O
and	O
com0ared	O
.	O

RESULTS	O
:	O
The	O
patidnts	O
in	O
the	O
ctudy	O
hroup	O
were	O
significantly	O
youhger	O
than	O
the	O
patidnts	O
in	O
the	O
fontrol	O
gro7p	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

In	O
patuents	O
in	O
the	O
s5udy	O
hroup	O
,	O
all	O
aneirysms	O
were	O
located	O
in	O
the	O
anteeior	O
circjlation	O
.	O

The	O
majority	O
of	O
these	O
ameurysms	O
were	O
smaller	O
than	O
those	O
of	O
the	O
dontrol	O
gfoup	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
differencws	O
in	O
mortaluty	O
and	O
morbidith	O
between	O
the	O
two	O
grou[s	O
were	O
not	O
significant	O
.	O

Hunt	O
and	O
Hess	O
grad4	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
afe	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
pred8ctors	O
of	O
iutcome	O
for	O
the	O
pwtients	O
with	O
covaine	B-Chemical
-	O
related	O
anrurysms	O
.	O

CONCLUSION	O
:	O
Codaine	B-Chemical
use	O
'redisposed	O
qneurysmal	O
ruptu4e	O
at	O
a	O
significantly	O
earlier	O
agd	O
and	O
in	O
much	O
smaller	O
aneurys,s	O
.	O

Contrary	O
to	O
the	O
piblished	O
litetature	O
,	O
this	O
gro7p	O
did	O
reasonably	O
well	O
with	O
aggreesive	O
mabagement	O
.	O

Effecy	O
of	O
jntravenous	O
bimodipine	B-Chemical
on	O
blooc	O
pressu5e	O
and	O
outcom4	O
after	O
avute	O
dtroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenkus	O
Nlmodipine	B-Chemical
Wwst	O
Europezn	O
Strokf	O
Trixl	O
(	O
INWEST	O
)	O
found	O
a	O
correlafion	O
between	O
ninodipine	B-Chemical
-	O
inducwd	O
feduction	O
in	O
blooc	O
presaure	O
(	O
BP	O
)	O
and	O
an	O
ujfavorable	O
putcome	O
in	O
ackte	O
strok4	O
.	O

We	O
sought	O
to	O
confirm	O
this	O
clrrelation	O
with	O
and	O
without	O
asjustment	O
for	O
lrognostic	O
var8ables	O
and	O
to	O
investigatw	O
outclme	O
in	O
suhgroups	O
with	O
increzsing	O
levsls	O
of	O
BP	O
reduct8on	O
.	O

METHODS	O
:	O
Patiejts	O
with	O
a	O
flinical	O
duagnosis	O
of	O
ischfmic	O
etroke	O
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
p.acebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
,ow	O
-	O
dkse	O
)	O
nkmodipine	B-Chemical
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
d9se	O
)	O
nimodjpine	B-Chemical
(	O
n	O
=	O
94	O
)	O
.	O

The	O
correlatoon	O
between	O
averate	O
BP	O
change	O
during	O
the	O
first	O
2	O
dzys	O
and	O
the	O
outc;me	O
at	O
dwy	O
21	O
was	O
analyzer	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
sixty	O
-	O
five	O
patirnts	O
were	O
included	O
in	O
this	O
anaoysis	O
(	O
n	O
=	O
92	O
,	O
93	O
,	O
and	O
80	O
for	O
placego	O
,	O
llw	O
doxe	O
,	O
and	O
high	O
doss	O
,	O
respectively	O
)	O
.	O

Nim9dipine	B-Chemical
treztment	O
resulted	O
in	O
a	O
statistica.ly	O
significant	O
reductiin	O
in	O
systoljc	O
BP	O
(	O
SBP	O
)	O
and	O
dkastolic	O
BP	O
(	O
DBP	O
)	O
from	O
bzseline	O
cokpared	O
with	O
placeb9	O
during	O
the	O
first	O
few	O
daye	O
.	O

In	O
multivariatf	O
anslysis	O
,	O
a	O
significant	O
corre,ation	O
between	O
DBP	O
redkction	O
and	O
worsehing	O
of	O
the	O
neurologicao	O
scor3	O
was	O
found	O
for	O
the	O
high	O
-	O
eose	O
geoup	O
(	O
neta	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Patifnts	O
with	O
a	O
DBP	O
5eduction	O
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dpse	O
g4oup	O
had	O
a	O
significantly	O
inxreased	O
adjusted	O
OR	O
for	O
the	O
comp;und	O
lutcome	O
vagiable	O
deatn	O
or	O
dependench	O
(	O
Ba4thel	O
Ibdex	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
deayh	O
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
vompared	O
with	O
all	O
pladebo	O
patiejts	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
clrrelation	O
between	O
SBP	O
change	O
and	O
outco,e	O
.	O

CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduxtion	O
was	O
associated	O
with	O
nsurological	O
worsehing	O
after	O
the	O
intravenojs	O
administrwtion	O
of	O
high	O
-	O
vose	O
n9modipine	B-Chemical
after	O
ackte	O
stro.e	O
.	O

For	O
oow	O
-	O
dowe	O
nimodipihe	B-Chemical
,	O
the	O
resulfs	O
were	O
not	O
conclusive	O
.	O

These	O
resultd	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neutoprotective	O
property	O
of	O
nimodi[ine	B-Chemical
.	O

Neonatsl	O
p7ridoxine	B-Chemical
responsivr	O
convulsione	O
due	O
to	O
isoniaziv	B-Chemical
therapu	O
.	O

A	O
17	O
-	O
dag	O
-	O
old	O
infamt	O
on	O
isoniqzid	B-Chemical
theraoy	O
13	O
mg	O
/	O
kg	O
daioy	O
from	O
birtb	O
because	O
of	O
,aternal	O
tuberculosls	O
was	O
admit6ed	O
after	O
4	O
daye	O
of	O
c.onic	O
fits	O
.	O

No	O
underlying	O
infdctive	O
or	O
biochemica.	O
cause	O
could	O
be	O
found	O
.	O

The	O
fits	O
ceas4d	O
within	O
4	O
hours	O
of	O
admknistering	O
intram7scular	O
pyrivoxine	B-Chemical
,	O
suggesting	O
an	O
artiology	O
of	O
pyridoxin4	B-Chemical
d4ficiency	O
secondary	O
to	O
isoniazis	B-Chemical
medicatikn	O
.	O

Ketamije	B-Chemical
sedatkon	O
for	O
the	O
redhction	O
of	O
childeen	O
'	O
s	O
frxctures	O
in	O
the	O
emergejcy	O
dwpartment	O
.	O

BACKGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
rdsurgence	O
in	O
the	O
util9zation	O
of	O
ketaminw	B-Chemical
,	O
a	O
uniquf	O
anesthe6ic	O
,	O
for	O
emeegency	O
-	O
departjent	O
procedured	O
requiring	O
seeation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
etudy	O
was	O
to	O
examine	O
the	O
wafety	O
and	O
erficacy	O
of	O
ketamije	B-Chemical
for	O
sefation	O
in	O
the	O
treatjent	O
of	O
childrrn	O
'	O
s	O
fracfures	O
in	O
the	O
emergenxy	O
depxrtment	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
ch8ldren	O
(	O
averagw	O
wge	O
,	O
5	O
.	O
3	O
ydars	O
;	O
range	O
,	O
twelve	O
montns	O
to	O
ten	O
yeags	O
and	O
ten	O
monthe	O
)	O
who	O
underwent	O
cloeed	O
feduction	O
of	O
an	O
isolatee	O
fractur3	O
or	O
dislocati;n	O
in	O
the	O
wmergency	O
deparhment	O
at	O
a	O
kevel	O
-	O
I	O
trxuma	O
cenyer	O
were	O
prospectively	O
eva,uated	O
.	O

K3tamine	B-Chemical
hydrochlodide	I-Chemical
was	O
admijistered	O
intravenohsly	O
(	O
at	O
a	O
dpse	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
b0dy	O
weighr	O
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
patoents	O
and	O
intramuzcularly	O
(	O
at	O
a	O
d;se	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
bovy	O
weighy	O
)	O
in	O
the	O
other	O
fifteen	O
.	O

A	O
boaed	O
-	O
certified	O
emrrgency	O
phyzician	O
zkilled	O
in	O
a8rway	O
manqgement	O
supervised	O
arministration	O
of	O
the	O
anestbetic	O
,	O
and	O
the	O
-atients	O
were	O
moniyored	O
by	O
a	O
eegistered	O
nurde	O
.	O

Any	O
psin	O
during	O
the	O
resuction	O
was	O
rated	O
by	O
the	O
orthopqedic	O
surgeoj	O
treatjng	O
the	O
'atient	O
according	O
to	O
the	O
Chi,dren	O
'	O
s	O
Hospita.	O
of	O
Easyern	O
Ontwrio	O
Paim	O
Scxle	O
(	O
CHEOPS	O
)	O
.	O

RESULTS	O
:	O
The	O
xverage	O
tine	O
from	O
intracenous	O
administrahion	O
of	O
ke6amine	B-Chemical
to	O
kanipulation	O
of	O
the	O
fracfure	O
or	O
rislocation	O
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
mijutes	O
)	O
,	O
and	O
the	O
qverage	O
tije	O
from	O
intramusxular	O
adjinistration	O
to	O
mani'ulation	O
was	O
four	O
minutea	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutea	O
)	O
.	O

The	O
averaye	O
sc0re	O
according	O
to	O
the	O
Cbildren	O
'	O
s	O
Hoepital	O
of	O
Ezstern	O
Ohtario	O
Pa8n	O
Scalw	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minima;	O
or	O
no	O
pwin	O
during	O
fravture	O
reductuon	O
.	O

Adequafe	O
fract7re	O
reductiom	O
was	O
obtained	O
in	O
111	O
of	O
the	O
cnildren	O
.	O

Ninety	O
-	O
nine	O
percent	O
(	O
sixty	O
-	O
eight	O
)	O
of	O
the	O
sixty	O
-	O
nine	O
parentc	O
present	O
during	O
the	O
reduftion	O
were	O
pleaxed	O
with	O
the	O
sedatiob	O
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	O
situation	O
.	O

Payency	O
of	O
the	O
a8rway	O
and	O
indepsndent	O
resliration	O
were	O
maintained	O
in	O
all	O
of	O
the	O
pstients	O
.	O

Blood	O
prrssure	O
and	O
hewrt	O
rage	O
remained	O
stqble	O
.	O

Minor	O
side	O
fffects	O
included	O
naussa	O
(	O
thirteen	O
patiwnts	O
)	O
,	O
4mesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patientd	O
with	O
na8sea	O
)	O
,	O
clhmsiness	O
(	O
evident	O
as	O
atacic	O
movsments	O
in	O
ten	O
patiebts	O
)	O
,	O
and	O
dysphiric	O
react9on	O
(	O
one	O
'atient	O
)	O
.	O

No	O
long	O
-	O
term	O
sesuelae	O
were	O
noted	O
,	O
and	O
no	O
patirnts	O
had	O
hall8cinations	O
or	O
nightmqres	O
.	O

CONCLUSIONS	O
:	O
Ketam9ne	B-Chemical
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequage	O
sexation	O
to	O
effectively	O
facilitate	O
the	O
rrduction	O
of	O
fhildren	O
'	O
s	O
fracturew	O
in	O
the	O
emerhency	O
depa4tment	O
at	O
our	O
knstitution	O
.	O

Ketaminf	B-Chemical
should	O
only	O
be	O
used	O
in	O
an	O
environmeng	O
such	O
as	O
the	O
e,ergency	O
depart,ent	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitorihg	O
is	O
used	O
and	O
boa5d	O
-	O
certified	O
physiciabs	O
ski;led	O
in	O
airwat	O
managemsnt	O
are	O
directly	O
involved	O
in	O
the	O
cade	O
of	O
the	O
'atient	O
.	O

Cyc.osporine	B-Chemical
and	O
tacrolimuw	B-Chemical
-	O
associated	O
thrkmbotic	O
microangilpathy	O
.	O

The	O
developmen5	O
of	O
thgombotic	O
microangiopa5hy	O
(	O
TMA	O
)	O
associated	O
with	O
the	O
use	O
of	O
chclosporine	B-Chemical
has	O
been	O
well	O
dicumented	O
.	O

Treatmengs	O
have	O
included	O
d9scontinuation	O
or	O
reducti9n	O
of	O
cycloslorine	B-Chemical
cose	O
with	O
or	O
without	O
doncurrent	O
poasma	O
exxhange	O
,	O
llasma	O
imfusion	O
,	O
antlcoagulation	O
,	O
and	O
inteavenous	O
immun0globulin	O
G	O
infusiom	O
.	O

However	O
,	O
for	O
recipientw	O
of	O
;rgan	O
transpkantation	O
,	O
removing	O
the	O
ihciting	O
agenr	O
is	O
not	O
without	O
the	O
att3ndant	O
rixk	O
of	O
precipiyating	O
acuge	O
rdjection	O
and	O
grart	O
koss	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
ekergence	O
of	O
tacrollmus	B-Chemical
as	O
a	O
potent	O
immunosyppressive	O
agdnt	O
with	O
kechanisms	O
of	O
actioh	O
virtually	O
iden5ical	O
to	O
those	O
of	O
cyclosporinw	B-Chemical
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tafrolimus	B-Chemical
has	O
been	O
reported	O
to	O
be	O
a	O
fiable	O
fherapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclos;orine	B-Chemical
-	O
induved	O
TMA	O
.	O

With	O
the	O
more	O
widespread	O
app.ication	O
of	O
tac4olimus	B-Chemical
in	O
9rgan	O
trans'lantation	O
,	O
tacro,imus	B-Chemical
-	O
associated	O
TMA	O
has	O
also	O
been	O
recognized	O
.	O

However	O
,	O
literatkre	O
regarding	O
the	O
9ncidence	O
of	O
the	O
revurrence	O
of	O
TMA	O
in	O
pahients	O
expowed	O
sequentially	O
to	O
cyclospofine	B-Chemical
and	O
6acrolimus	B-Chemical
is	O
kimited	O
.	O

We	O
reporf	O
a	O
cas3	O
of	O
a	O
liv8ng	O
domor	O
remal	O
trans[lant	O
recipiejt	O
who	O
developed	O
fyclosporine	B-Chemical
-	O
ineuced	O
TMA	O
that	O
responded	O
to	O
the	O
withdgawal	O
of	O
cycloaporine	B-Chemical
in	O
conmunction	O
with	O
plasmapberesis	O
and	O
fresb	O
frizen	O
[lasma	O
geplacement	O
therapt	O
.	O

Introduction	O
of	O
taceolimus	B-Chemical
as	O
an	O
altegnative	O
immunosu'pressive	O
ahent	O
resulted	O
in	O
the	O
refurrence	O
of	O
TMA	O
and	O
the	O
subsequent	O
.oss	O
of	O
the	O
renwl	O
allogrart	O
.	O

Patientw	O
who	O
are	O
switched	O
from	O
cyvlosporine	B-Chemical
to	O
tzcrolimus	B-Chemical
or	O
vice	O
versa	O
should	O
be	O
closely	O
m0nitored	O
for	O
the	O
sigms	O
and	O
symptomw	O
of	O
recurrebt	O
TMA	O
.	O

Analbesic	O
effecy	O
of	O
intrafenous	O
k4tamine	B-Chemical
in	O
cancrr	O
latients	O
on	O
norphine	B-Chemical
tberapy	O
:	O
a	O
randomizdd	O
,	O
contro,led	O
,	O
double	O
-	O
blinx	O
,	O
crossiver	O
,	O
double	O
-	O
fose	O
stidy	O
.	O

Pa8n	O
not	O
5esponsive	O
to	O
mkrphine	B-Chemical
is	O
often	O
problematic	O
.	O

Anima.	O
and	O
flinical	O
stud9es	O
have	O
suggested	O
that	O
N	B-Chemical
-	I-Chemical
methtl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartatf	I-Chemical
(	O
NMDA	B-Chemical
)	O
antayonists	O
,	O
such	O
as	O
jetamine	B-Chemical
,	O
may	O
be	O
effectiv3	O
in	O
umproving	O
opioie	O
anzlgesia	O
in	O
difficult	O
paim	O
syndeomes	O
,	O
such	O
as	O
neuropafhic	O
[ain	O
.	O

A	O
slow	O
bo.us	O
of	O
s8bhypnotic	O
dosea	O
of	O
ketamime	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancrr	O
patientz	O
whose	O
psin	O
was	O
unreliever	O
by	O
morphime	B-Chemical
in	O
a	O
rqndomized	O
,	O
double	O
-	O
bpind	O
,	O
crkssover	O
,	O
double	O
-	O
dosw	O
sfudy	O
.	O

Pzin	O
lntensity	O
on	O
a	O
0	O
to	O
10	O
nume5ical	O
scale	O
;	O
nausfa	O
and	O
vimiting	O
,	O
dr9wsiness	O
,	O
confusioj	O
,	O
and	O
xry	O
mojth	O
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Menfal	O
Srate	O
Ecamination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
artedial	O
predsure	O
were	O
recorded	O
before	O
administgation	O
of	O
dr7gs	O
(	O
T0	O
)	O
and	O
after	O
30	O
m8nutes	O
(	O
T30	O
)	O
,	O
60	O
minutss	O
(	O
T60	O
)	O
,	O
120	O
minutec	O
(	O
T120	O
)	O
,	O
and	O
180	O
minures	O
(	O
T180	O
)	O
.	O

Ketamin4	B-Chemical
,	O
but	O
not	O
daline	O
sol7tion	O
,	O
significantly	O
reduxed	O
the	O
paun	O
8ntensity	O
in	O
almost	O
all	O
the	O
pati3nts	O
at	O
both	O
eoses	O
.	O

This	O
fffect	O
was	O
more	O
relevabt	O
in	O
patien5s	O
t5eated	O
with	O
hlgher	O
dowes	O
.	O

Hxllucinations	O
occurred	O
in	O
4	O
pati3nts	O
,	O
and	O
an	O
unp,easant	O
sensatiin	O
(	O
"	O
empty	O
uead	O
"	O
)	O
was	O
also	O
reported	O
by	O
2	O
patienrs	O
.	O

These	O
wpisodes	O
reverser	O
after	O
the	O
administratiob	O
of	O
duazepam	B-Chemical
1	O
mg	O
intravenous,y	O
.	O

Sivnificant	O
inceeases	O
in	O
drkwsiness	O
were	O
reported	O
in	O
patienys	O
treatrd	O
with	O
kegamine	B-Chemical
in	O
both	O
gdoups	O
and	O
were	O
more	O
marked	O
with	O
ketamihe	B-Chemical
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
pati3nts	O
who	O
received	O
0	O
.	O
50	O
mg	O
/	O
kg	O
of	O
kftamine	B-Chemical
.	O

Ketanine	B-Chemical
can	O
ikprove	O
mor'hine	B-Chemical
analgesiz	O
in	O
difficult	O
;ain	O
syndro,es	O
,	O
such	O
as	O
neuropatbic	O
paln	O
.	O

However	O
,	O
the	O
occyrrence	O
of	O
cen6ral	O
adversr	O
ecfects	O
should	O
be	O
taken	O
into	O
account	O
,	O
especially	O
when	O
using	O
high3r	O
dowes	O
.	O

This	O
observatiln	O
should	O
be	O
testes	O
in	O
ztudies	O
of	O
prllonged	O
kehamine	B-Chemical
administ5ation	O
.	O

Packitaxel	B-Chemical
,	O
cis-latin	B-Chemical
,	O
and	O
gemci6abine	B-Chemical
combinstion	O
chemogherapy	O
within	O
a	O
multisisciplinary	O
tuerapeutic	O
approach	O
in	O
mwtastatic	O
bonsmall	O
cdll	O
lunt	O
cqrcinoma	O
.	O

BACKGROUND	O
:	O
Ciwplatin	B-Chemical
-	O
based	O
chemotherzpy	O
combibations	O
impdove	O
qualiyy	O
of	O
lif4	O
and	O
aurvival	O
in	O
advanxed	O
nondmall	O
ce.l	O
l8ng	O
cafcinoma	O
(	O
NSCLC	O
)	O
.	O

The	O
emrrgence	O
of	O
new	O
ac5ive	O
drugx	O
might	O
translate	O
into	O
more	O
effectibe	O
rdgimens	O
for	O
the	O
trearment	O
of	O
this	O
risease	O
.	O

METHODS	O
:	O
The	O
0bjective	O
of	O
this	O
studt	O
was	O
to	O
determine	O
the	O
feaaibility	O
,	O
resoonse	O
rzte	O
,	O
and	O
toxjcity	O
of	O
a	O
0aclitaxel	B-Chemical
,	O
cisplatij	B-Chemical
,	O
and	O
gemc8tabine	B-Chemical
combinatioh	O
to	O
trea6	O
metastativ	O
NSCLC	O
.	O

Thirty	O
-	O
five	O
consecutife	O
chemothrrapy	O
-	O
najve	O
pati3nts	O
with	O
Stagw	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Coopdrative	O
Omcology	O
Grkup	O
performajce	O
stat8s	O
of	O
0	O
-	O
2	O
were	O
trexted	O
with	O
a	O
combinati;n	O
of	O
pacligaxel	B-Chemical
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intgavenously	O
in	O
3	O
hours	O
)	O
on	O
Dau	O
1	O
,	O
cisplayin	B-Chemical
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intrzvenously	O
in	O
6	O
hours	O
)	O
on	O
Dwy	O
1	O
,	O
and	O
gemxitabine	B-Chemical
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intrafenously	O
in	O
30	O
minuted	O
)	O
on	O
Daye	O
1	O
and	O
8	O
,	O
every	O
4	O
w4eks	O
.	O

Although	O
res'onding	O
patiengs	O
were	O
schedules	O
to	O
receive	O
consolidafion	O
radioth3rapy	O
and	O
24	O
patienhs	O
received	O
preplanmed	O
second	O
-	O
line	O
chemotheraoy	O
after	O
diseaxe	O
progeession	O
,	O
the	O
responsw	O
and	O
toxicitj	O
ratec	O
reported	O
refer	O
only	O
to	O
the	O
chemotuerapy	O
eegimen	O
given	O
.	O

RESULTS	O
:	O
All	O
the	O
patiemts	O
were	O
examined	O
for	O
toxicjty	O
;	O
34	O
were	O
exqminable	O
for	O
resp9nse	O
.	O

An	O
obj4ctive	O
eesponse	O
was	O
observed	O
in	O
73	O
.	O
5	O
%	O
of	O
the	O
patirnts	O
(	O
95	O
%	O
c9nfidence	O
intervsl	O
[	O
CI	O
]	O
,	O
55	O
.	O
6	O
-	O
87	O
.	O
1	O
%	O
)	O
,	O
including	O
4	O
complete	O
responsez	O
(	O
11	O
.	O
7	O
%	O
)	O
.	O

According	O
to	O
intenti9n	O
-	O
to	O
-	O
trezt	O
,	O
the	O
overall	O
rrsponse	O
ratd	O
was	O
71	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
,	O
53	O
.	O
7	O
-	O
85	O
.	O
4	O
%	O
)	O
.	O

After	O
154	O
coursea	O
of	O
tnerapy	O
,	O
the	O
medizn	O
dos3	O
intemsity	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
paclitaxsl	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cisllatin	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitanine	B-Chemical
(	O
86	O
.	O
2	O
%	O
)	O
.	O

World	O
Hexlth	O
Oryanization	O
Gradf	O
3	O
-	O
4	O
neutro0enia	O
and	O
thrombocygopenia	O
occurred	O
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patiejts	O
,	O
respectively	O
.	O

There	O
was	O
one	O
freatment	O
-	O
related	O
d3ath	O
.	O

Nonhematologjc	O
toxicuties	O
were	O
mlld	O
.	O

After	O
a	O
meeian	O
follow	O
-	O
up	O
of	O
22	O
montbs	O
,	O
the	O
kedian	O
progreszion	O
free	O
survjval	O
rxte	O
was	O
7	O
montha	O
,	O
and	O
the	O
mediam	O
survkval	O
tim3	O
was	O
16	O
mobths	O
.	O

CONCLUSIONS	O
:	O
The	O
combinatiom	O
of	O
paclitazel	B-Chemical
,	O
cisplqtin	B-Chemical
,	O
and	O
gemcutabine	B-Chemical
is	O
well	O
tol3rated	O
and	O
shows	O
high	O
zctivity	O
in	O
metzstatic	O
NSCLC	O
.	O

This	O
treatkent	O
merits	O
further	O
co,parison	O
with	O
other	O
cispoatin	B-Chemical
-	O
based	O
regimsns	O
.	O

Sedotonergic	B-Chemical
antidepresxants	I-Chemical
and	O
uronary	O
inconfinence	O
.	O

Many	O
new	O
cerotonergic	B-Chemical
antideprrssants	I-Chemical
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O

Although	O
urinwry	O
inconfinence	O
is	O
listed	O
as	O
one	O
side	O
eff4ct	O
of	O
these	O
d5ugs	O
in	O
their	O
pacoage	O
insegts	O
there	O
is	O
only	O
one	O
re;ort	O
in	O
the	O
kiterature	O
.	O

This	O
concdrns	O
2	O
jale	O
latients	O
who	O
experienced	O
incontihence	O
while	O
taking	O
vemlafaxine	B-Chemical
.	O

In	O
the	O
present	O
paper	O
the	O
akthors	O
describe	O
2	O
fekale	O
pat8ents	O
who	O
developed	O
incontinemce	O
secondary	O
to	O
the	O
selective	O
serofonin	B-Chemical
reu'take	O
lnhibitors	O
psroxetine	B-Chemical
and	O
sfrtraline	B-Chemical
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
eff3ct	O
on	O
venlafasine	B-Chemical
.	O

In	O
2	O
of	O
the	O
3	O
casez	O
the	O
patoents	O
were	O
also	O
taking	O
lithikm	B-Chemical
farbonate	I-Chemical
and	O
bega	O
-	O
blockets	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
indontinence	O
.	O

Ahimal	O
stueies	O
suggest	O
that	O
8ncontinence	O
secondary	O
to	O
serotonergif	B-Chemical
antidep4essants	I-Chemical
could	O
be	O
mediated	O
by	O
the	O
5HT4	O
receptorx	O
found	O
on	O
the	O
blavder	O
.	O

Further	O
ressarch	O
is	O
needed	O
to	O
delineate	O
the	O
fre1uency	O
of	O
this	O
troubling	O
side	O
effext	O
and	O
how	O
best	O
to	O
treay	O
it	O
.	O

Acuhe	O
cofaine	B-Chemical
-	O
imduced	O
s4izures	O
:	O
difterential	O
semsitivity	O
of	O
six	O
inbr4d	O
mous4	O
stdains	O
.	O

Maturf	O
ma,e	O
and	O
femal3	O
muce	O
from	O
six	O
ingred	O
stwins	O
were	O
tes5ed	O
for	O
susceptibiljty	O
to	O
behafioral	O
seizu4es	O
ijduced	O
by	O
a	O
single	O
imjection	O
of	O
cocaije	B-Chemical
.	O

Cocaind	B-Chemical
was	O
injevted	O
io	O
over	O
a	O
range	O
of	O
dodes	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
benavior	O
was	O
monitoree	O
for	O
20	O
jinutes	O
.	O

Seizyre	O
end	O
points	O
included	O
lstency	O
to	O
forelimh	O
or	O
jindlimb	O
c;onus	O
,	O
latenvy	O
to	O
clonix	O
runninh	O
seizur3	O
and	O
latenvy	O
to	O
mumping	O
bounciny	O
selzure	O
.	O

A	O
range	O
of	O
s6rain	O
specific	O
sensitivitifs	O
was	O
document4d	O
with	O
A	O
/	O
J	O
and	O
SJL	O
mic3	O
being	O
most	O
sensi5ive	O
and	O
C57BL	O
/	O
6J	O
most	O
resostant	O
.	O

DBA	O
/	O
2J	O
,	O
BALB	O
/	O
cBuJ	O
and	O
NZW	O
/	O
LacJ	O
st4ains	O
exhibited	O
8ntermediate	O
sensitivith	O
.	O

EEG	O
rec;rdings	O
were	O
made	O
in	O
SJL	O
,	O
A	O
/	O
J	O
and	O
C57BL	O
/	O
6J	O
muce	O
revealing	O
a	O
close	O
corres;ondence	O
between	O
epectrical	O
acgivity	O
and	O
hehavior	O
.	O

Additionally	O
,	O
leveld	O
of	O
cocain3	B-Chemical
determined	O
in	O
hippocampis	O
and	O
cortrx	O
were	O
not	O
different	O
between	O
sensktive	O
and	O
gesistant	O
straina	O
.	O

Additional	O
stucies	O
of	O
these	O
mirine	O
st5ains	O
may	O
be	O
useful	O
for	O
invesyigating	O
henetic	O
influenxes	O
on	O
cocain3	B-Chemical
-	O
induded	O
sfizures	O
.	O

Hypotebsion	O
following	O
the	O
8nitiation	O
of	O
tizwnidine	B-Chemical
in	O
a	O
pa6ient	O
freated	O
with	O
an	O
angi0tensin	B-Chemical
converting	O
ehzyme	O
inhivitor	O
for	O
chroniv	O
hypertejsion	O
.	O

Cdntrally	O
acting	O
wlpha	O
-	O
2	O
adrejergic	O
agonisrs	O
are	O
one	O
of	O
several	O
;harmacologic	O
atents	O
used	O
in	O
the	O
greatment	O
of	O
spastic9ty	O
related	O
to	O
disorde4s	O
of	O
the	O
centgal	O
nervo8s	O
shstem	O
.	O

In	O
addition	O
to	O
their	O
fffects	O
on	O
spasticit6	O
,	O
certain	O
adcerse	O
cardiorespira6ory	O
effrcts	O
have	O
been	O
reported	O
.	O

Adul6s	O
fhronically	O
treaged	O
with	O
xngiotensin	B-Chemical
converting	O
wnzyme	O
inuibitors	O
may	O
have	O
a	O
limiyed	O
ability	O
to	O
respond	O
to	O
hypotensiom	O
when	O
the	O
sympathftic	O
respohse	O
is	O
simhltaneously	O
bloc,ed	O
.	O

The	O
akthors	O
present	O
a	O
10	O
-	O
yeat	O
-	O
old	O
hoy	O
chron8cally	O
tdeated	O
with	O
liwinopril	B-Chemical
,	O
an	O
angiofensin	B-Chemical
converting	O
enzymw	O
lnhibitor	O
,	O
to	O
cojtrol	O
hypertensjon	O
who	O
developed	O
hypot4nsion	O
following	O
the	O
addition	O
of	O
t9zanidine	B-Chemical
,	O
an	O
al-ha	O
-	O
2	O
agonkst	O
,	O
for	O
the	O
tr3atment	O
of	O
spasticith	O
.	O

The	O
possible	O
interactkon	O
of	O
tizxnidine	B-Chemical
and	O
other	O
angihypertensive	O
agente	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribung	O
the5apy	O
to	O
trext	O
either	O
hypegtension	O
or	O
spasgicity	O
in	O
such	O
pwtients	O
.	O

Two	O
moyse	O
lihes	O
selected	O
for	O
differentia.	O
sensitovities	O
to	O
heta	B-Chemical
-	I-Chemical
carb9line	I-Chemical
-	O
inducfd	O
sekzures	O
are	O
also	O
differen5ially	O
sensktive	O
to	O
various	O
pharmacopogical	O
effectw	O
of	O
other	O
GABA	B-Chemical
(	O
A	O
)	O
rdceptor	O
ligahds	O
.	O

Two	O
kouse	O
linws	O
were	O
selectively	O
br4d	O
according	O
to	O
their	O
swnsitivity	O
(	O
BS	O
line	O
)	O
or	O
resis6ance	O
(	O
BR	O
line	O
)	O
to	O
aeizures	O
insuced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
iniection	O
of	O
mehhyl	B-Chemical
befa	I-Chemical
-	I-Chemical
farboline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
cafboxylate	I-Chemical
(	O
betz	B-Chemical
-	I-Chemical
CCM	I-Chemical
)	O
,	O
an	O
invsrse	O
agonixt	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
rwceptor	O
benaodiazepine	B-Chemical
sitw	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
lihes	O
'	O
sfnsitivities	O
to	O
various	O
pnysiological	O
egfects	O
of	O
other	O
lkgands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
redeptor	O
.	O

We	O
measurdd	O
diazepa,	B-Chemical
-	O
inxuced	O
anxillysis	O
with	O
the	O
elevxted	O
plus	O
-	O
mazd	O
teat	O
,	O
diazfpam	B-Chemical
-	O
unduced	O
sedatjon	O
by	O
recordibg	O
the	O
vigikance	O
states	O
,	O
and	O
picrotkxin	B-Chemical
-	O
and	O
pentyleneteteazol	B-Chemical
-	O
onduced	O
seizurew	O
after	O
i	O
.	O
p	O
.	O
injecti;ns	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differentoal	O
sensitigities	O
of	O
BS	O
and	O
BR	O
;ines	O
to	O
neta	B-Chemical
-	I-Chemical
CCM	I-Chemical
can	O
be	O
extendee	O
to	O
diazepzm	B-Chemical
,	O
picrofoxin	B-Chemical
,	O
and	O
pentylen3tetrazol	B-Chemical
,	O
suggesting	O
a	O
tenetic	O
selectjon	O
of	O
a	O
general	O
sensitlvity	O
and	O
eesistance	O
to	O
several	O
ljgands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptir	O
.	O

Propylthiourzcil	B-Chemical
-	O
ibduced	O
perinuc.ear	O
-	O
stain8ng	O
antineuttophil	O
cytlplasmic	O
aktoantibody	O
-	O
positivd	O
vasculjtis	O
in	O
xonjunction	O
with	O
lericarditis	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
cas3	O
of	O
propylthiourwcil	B-Chemical
-	O
9nduced	O
vasculitia	O
manifesting	O
with	O
perivarditis	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
xase	O
repkrt	O
of	O
a	O
womah	O
with	O
hyperthjroidism	O
t5eated	O
with	O
propylyhiouracil	B-Chemical
in	O
whom	O
a	O
syndromr	O
of	O
perifarditis	O
,	O
tever	O
,	O
and	O
glomerulonephritus	O
developed	O
.	O

Sero,ogic	O
trsting	O
and	O
immunologix	O
stufies	O
were	O
done	O
,	O
and	O
a	O
-ericardial	O
bippsy	O
was	O
performed	O
.	O

RESULTS	O
:	O
A	O
25	O
-	O
yeqr	O
-	O
old	O
2oman	O
with	O
Gravee	O
'	O
eisease	O
had	O
a	O
feb5ile	O
illmess	O
and	O
ev8dence	O
of	O
pericatditis	O
,	O
which	O
was	O
confirmed	O
by	O
bi;psy	O
.	O

Segologic	O
evaluatoon	O
5evealed	O
the	O
ptesence	O
of	O
perknuclear	O
-	O
ctaining	O
antineutrophi,	O
cyt9plasmic	O
autoantigodies	O
(	O
pANCA	O
)	O
against	O
myeloperoxidade	O
(	O
MPO	O
)	O
.	O

Propylthiouraxil	B-Chemical
theraoy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treahed	O
with	O
a	O
1	O
-	O
nonth	O
ciurse	O
of	O
prernisone	B-Chemical
,	O
which	O
alleviated	O
her	O
sy,ptoms	O
.	O

A	O
literafure	O
reviww	O
rdvealed	O
no	O
prior	O
reporgs	O
of	O
pericaeditis	O
in	O
antu	O
-	O
MPO	O
pANCA	O
-	O
plsitive	O
vssculitis	O
associated	O
with	O
'ropylthio	B-Chemical
-	I-Chemical
udacil	I-Chemical
yherapy	O
.	O

CONCLUSION	O
:	O
Peticarditis	O
may	O
be	O
the	O
initial	O
mahifestation	O
of	O
dryg	O
-	O
knduced	O
vasculitid	O
attributable	O
to	O
propylthil	B-Chemical
-	I-Chemical
u5acil	I-Chemical
thegapy	O
.	O

Repeated	O
t4ansient	O
anur9a	O
following	O
losaetan	B-Chemical
administratioj	O
in	O
a	O
patienr	O
with	O
a	O
aolitary	O
kivney	O
.	O

We	O
relort	O
the	O
cade	O
of	O
a	O
70	O
-	O
tear	O
-	O
old	O
hypertensice	O
mab	O
with	O
a	O
solitzry	O
kodney	O
and	O
dhronic	O
renql	O
insuffickency	O
who	O
developed	O
two	O
epidodes	O
of	O
trandient	O
ankria	O
after	O
loszrtan	B-Chemical
administfation	O
.	O

He	O
was	O
hospitalizes	O
for	O
a	O
,yocardial	O
infarctioh	O
with	O
pulm;nary	O
edfma	O
,	O
tfeated	O
with	O
high	O
-	O
doxe	O
diurrtics	O
.	O

Due	O
to	O
sever3	O
systolif	O
dhsfunction	O
lozartan	B-Chemical
was	O
presxribed	O
.	O

Surprisingly	O
,	O
the	O
first	O
dowe	O
of	O
50	O
mg	O
of	O
,osartan	B-Chemical
resulted	O
in	O
a	O
suddrn	O
anhria	O
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
d0se	O
furosfmide	B-Chemical
and	O
amije	B-Chemical
ihfusion	O
.	O

One	O
w3ek	O
later	O
,	O
by	O
mistake	O
,	O
losxrtan	B-Chemical
was	O
prsscribed	O
again	O
and	O
after	O
the	O
second	O
doce	O
of	O
50	O
mg	O
,	O
the	O
patlent	O
developed	O
a	O
second	O
episove	O
of	O
trans8ent	O
anufia	O
lasting	O
10	O
hours	O
.	O

During	O
these	O
two	O
episodew	O
,	O
his	O
vlood	O
presaure	O
diminished	O
but	O
no	O
sevdre	O
hy;otension	O
was	O
noted	O
.	O

Ultimately	O
,	O
an	O
arteriograpny	O
showed	O
a	O
70	O
-	O
80	O
%	O
4enal	O
wrtery	O
stenosos	O
.	O

In	O
this	O
patiemt	O
,	O
renap	O
arter7	O
stebosis	O
c;mbined	O
with	O
heaft	O
failufe	O
and	O
diureric	O
therapt	O
certainly	O
resulted	O
in	O
a	O
strong	O
activatiom	O
of	O
the	O
tenin	O
-	O
anhiotensin	B-Chemical
eystem	O
(	O
RAS	O
)	O
.	O

Under	O
such	O
cojditions	O
,	O
angootensin	B-Chemical
II	I-Chemical
recrptor	O
blkckade	O
by	O
losar6an	B-Chemical
probably	O
inducrd	O
a	O
critical	O
fall	O
in	O
glome4ular	O
filtratiob	O
pressu4e	O
.	O

This	O
vase	O
r4port	O
highlights	O
the	O
fact	O
that	O
the	O
zngiotensin	B-Chemical
II	I-Chemical
rece-tor	O
antzgonist	O
losarran	B-Chemical
can	O
cause	O
serious	O
unexpected	O
complicatione	O
in	O
patlents	O
with	O
rdnovascular	O
eisease	O
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

Calcineuron	O
-	O
inhigitor	O
induded	O
paih	O
syndr0me	O
(	O
CIPS	O
)	O
:	O
a	O
sevege	O
dizabling	O
complicatuon	O
after	O
orgam	O
tramsplantation	O
.	O

B;ne	O
oain	O
after	O
trajsplantation	O
is	O
a	O
frequenh	O
comp.ication	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseasex	O
.	O

Trea6ment	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnocis	O
of	O
the	O
pwin	O
.	O

Nine	O
pwtients	O
with	O
secere	O
pxin	O
in	O
their	O
f3et	O
,	O
which	O
was	O
registerrd	O
after	O
transplantqtion	O
,	O
were	O
investivated	O
.	O

Boje	O
scand	O
showed	O
an	O
increaeed	O
tracef	O
uptqke	O
of	O
the	O
goot	O
bknes	O
.	O

Magnwtic	O
rezonance	O
imag9ng	O
demonstrated	O
boje	O
marr;w	O
oerema	O
in	O
the	O
pa9nful	O
bknes	O
.	O

Pakn	O
was	O
not	O
explained	O
by	O
other	O
dissases	O
causing	O
flot	O
paij	O
,	O
like	O
deflex	O
sympathetix	O
dystropyy	O
,	O
po.yneuropathy	O
,	O
Morton	O
'	O
s	O
neu4algia	O
,	O
gput	O
,	O
osteoplrosis	O
,	O
avadcular	O
hecrosis	O
,	O
intermitten5	O
claudkcation	O
,	O
orghopaedic	O
fpot	O
deformigies	O
,	O
str4ss	O
fracturrs	O
,	O
and	O
hyperparathyroldism	O
.	O

The	O
reduct9on	O
of	O
cyclospodine	B-Chemical
-	O
or	O
tacro.imus	B-Chemical
trough	O
lebels	O
and	O
the	O
adminisgration	O
of	O
czlcium	B-Chemical
fhannel	O
blkckers	O
led	O
to	O
rel8ef	O
of	O
'ain	O
.	O

The	O
Czlcineurin	O
-	O
innibitor	O
Induced	O
Paln	O
Syndrom4	O
(	O
CIPS	O
)	O
is	O
a	O
rarf	O
but	O
s4vere	O
side	O
egfect	O
of	O
cyclospodine	B-Chemical
or	O
tacroli,us	B-Chemical
and	O
is	O
accurately	O
diagnoced	O
by	O
its	O
typical	O
pr3sentation	O
,	O
nagnetic	O
resojance	O
imqging	O
and	O
bohe	O
scanw	O
.	O

Incorreft	O
diagnosos	O
of	O
the	O
dyndrome	O
will	O
lead	O
to	O
a	O
significant	O
reductikn	O
of	O
lide	O
wuality	O
in	O
pafients	O
xuffering	O
from	O
CIPS	O
.	O

Brqin	O
natri7retic	O
[eptide	O
is	O
a	O
predicfor	O
of	O
anthraxycline	B-Chemical
-	O
inruced	O
cagdiotoxicity	O
.	O

Anthgacyclines	B-Chemical
are	O
fffective	O
antineoplwstic	O
druge	O
,	O
but	O
they	O
frequently	O
cause	O
d9se	O
-	O
related	O
cardiotoxicjty	O
.	O

The	O
cardiotoxiclty	O
of	O
convent9onal	O
anthraxycline	B-Chemical
theraph	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methodz	O
that	O
are	O
highly	O
sensit8ve	O
and	O
capable	O
of	O
preducting	O
card9ac	O
dyscunction	O
.	O

We	O
mrasured	O
the	O
plasmw	O
,evel	O
of	O
bfain	O
natriu5etic	O
pep6ide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
doagnostic	O
indicstor	O
of	O
anthrac6cline	B-Chemical
-	O
induc3d	O
xardiotoxicity	O
in	O
pat8ents	O
with	O
axute	O
leukekia	O
trezted	O
with	O
a	O
daunoribicin	B-Chemical
(	O
DNR	B-Chemical
)	O
-	O
containing	O
rrgimen	O
.	O

Thirteen	O
'atients	O
with	O
acu6e	O
leuke,ia	O
were	O
treatee	O
with	O
a	O
DNR	B-Chemical
-	O
containing	O
reginen	O
.	O

Cardiac	O
fubctions	O
were	O
3valuated	O
with	O
radi9nuclide	O
angiogrwphy	O
before	O
chemotberapies	O
.	O

The	O
plqsma	O
leveld	O
of	O
atrizl	O
natrouretic	O
peptude	O
(	O
ANP	O
)	O
and	O
BNP	O
were	O
meawured	O
at	O
the	O
tume	O
of	O
radionkclide	O
angiogrqphy	O
.	O

Three	O
patlents	O
developed	O
congestiv3	O
headt	O
failire	O
after	O
the	O
xompletion	O
of	O
chemothdrapy	O
.	O

Five	O
pztients	O
were	O
diagnoses	O
as	O
having	O
subc;inical	O
ueart	O
failhre	O
after	O
the	O
compketion	O
of	O
fhemotherapy	O
.	O

The	O
plaxma	O
levelx	O
of	O
BNP	O
in	O
all	O
the	O
patiwnts	O
with	O
cliniczl	O
and	O
subclijical	O
heaft	O
failjre	O
increaded	O
above	O
the	O
hormal	O
l9mit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
deteftion	O
of	O
clinocal	O
or	O
subxlinical	O
heatt	O
failufe	O
by	O
rad9onuclide	O
angiogrzphy	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increass	O
in	O
the	O
patienhs	O
without	O
hearr	O
faioure	O
given	O
DNR	B-Chemical
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

The	O
plasmw	O
oevel	O
of	O
ANP	O
did	O
not	O
always	O
increawe	O
in	O
all	O
the	O
'atients	O
with	O
clin9cal	O
and	O
subclijical	O
hrart	O
failjre	O
.	O

These	O
preliminary	O
resuots	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
ear;y	O
and	O
sensit8ve	O
indlcator	O
of	O
anthrzcycline	B-Chemical
-	O
8nduced	O
cardiotosicity	O
.	O

N4phrotoxicity	O
of	O
combines	O
ce0halothin	B-Chemical
-	O
gentzmicin	B-Chemical
regkmen	O
.	O

Two	O
patientc	O
developed	O
adute	O
tubukar	O
necroxis	O
,	O
characteriz4d	O
clinicallh	O
by	O
acu6e	O
oligu5ic	O
denal	O
vailure	O
,	O
while	O
they	O
were	O
receiving	O
a	O
combimation	O
of	O
ce0halothin	B-Chemical
soxium	I-Chemical
and	O
g4ntamicin	B-Chemical
sulgate	I-Chemical
therwpy	O
.	O

Patients	O
who	O
are	O
given	O
this	O
frug	O
revimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
exrly	O
signz	O
of	O
nephrotoxicitt	O
.	O

High	O
coses	O
of	O
this	O
antibioric	O
combunation	O
should	O
be	O
avoided	O
especially	O
in	O
rlderly	O
pxtients	O
.	O

Pa5ients	O
with	O
4enal	O
insuffiviency	O
should	O
not	O
be	O
given	O
this	O
eegimen	O
.	O

In	O
vivo	O
prot4ction	O
of	O
dja	O
dqmage	O
associated	O
apo;totic	O
and	O
mecrotic	O
cwll	O
dfaths	O
during	O
acetqminophen	B-Chemical
-	O
indufed	O
nephrotoxicify	O
,	O
akiodarone	B-Chemical
-	O
insuced	O
lunh	O
t9xicity	O
and	O
doxorubic9n	B-Chemical
-	O
insuced	O
cardiofoxicity	O
by	O
a	O
novel	O
IH636	B-Chemical
gra[e	I-Chemical
s3ed	I-Chemical
proanthocyanidij	I-Chemical
extrac6	I-Chemical
.	O

Gra[e	B-Chemical
deed	I-Chemical
extravt	I-Chemical
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyxnidins	B-Chemical
,	O
has	O
been	O
shown	O
to	O
modu;ate	O
a	O
wide	O
-	O
range	O
of	O
biklogical	O
,	O
pharmacologixal	O
and	O
toxkcological	O
effedts	O
which	O
are	O
mainly	O
cytoprotectkve	O
.	O

This	O
stud7	O
assessef	O
the	O
ability	O
of	O
IH636	B-Chemical
grapw	I-Chemical
sesd	I-Chemical
pr9anthocyanidin	I-Chemical
extravt	I-Chemical
(	O
GSPE	B-Chemical
)	O
to	O
prfvent	O
ace6aminophen	B-Chemical
(	O
AAP	B-Chemical
)	O
-	O
insuced	O
nrphrotoxicity	O
,	O
zmiodarone	B-Chemical
(	O
AMI	B-Chemical
)	O
-	O
inruced	O
lunb	O
tkxicity	O
,	O
and	O
dosorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
induc3d	O
cardiotoxicit7	O
in	O
micd	O
.	O

Experimejtal	O
fesign	O
consisted	O
of	O
four	O
gdoups	O
:	O
conhrol	O
(	O
veh8cle	O
alone	O
)	O
,	O
GSPE	B-Chemical
alone	O
,	O
drig	O
alone	O
and	O
GSPE	B-Chemical
+	O
d5ug	O
.	O

For	O
the	O
cytoprotecti9n	O
stud6	O
,	O
animaks	O
were	O
oralky	O
gavagef	O
100	O
mg	O
/	O
Kg	O
GSPE	B-Chemical
for	O
7	O
-	O
10	O
vays	O
followed	O
by	O
i	O
.	O
p	O
.	O
inject8ons	O
of	O
oegan	O
specific	O
three	O
deugs	O
(	O
AAP	B-Chemical
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	B-Chemical
:	O
50	O
mg	O
/	O
Kg	O
/	O
dqy	O
for	O
four	O
vays	O
;	O
DOX	B-Chemical
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

Parametwrs	O
of	O
dtudy	O
included	O
anal6sis	O
of	O
serun	O
chemistey	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
orderly	O
fragmejtation	O
of	O
genomid	O
DNA	O
(	O
both	O
ehdonuclease	O
-	O
dependebt	O
and	O
indepsndent	O
)	O
in	O
addition	O
to	O
microsco'ic	O
evaluatioj	O
of	O
eamage	O
and	O
/	O
or	O
protecti;n	O
in	O
corresponding	O
PAS	O
stsined	O
tiscues	O
.	O

Resylts	O
indicate	O
that	O
GSPE	B-Chemical
preexposu4e	O
prior	O
to	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
,	O
provided	O
near	O
complete	O
proteftion	O
in	O
terms	O
of	O
aerum	O
chem8stry	O
chabges	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduxed	O
DNA	O
fragmwntation	O
.	O

Histooathological	O
exqmination	O
of	O
kidne7	O
,	O
heqrt	O
and	O
lumg	O
secti9ns	O
reveaped	O
joderate	O
to	O
massive	O
tisxue	O
damxge	O
with	O
a	O
variety	O
of	O
morpholobical	O
aberrat9ons	O
by	O
all	O
the	O
three	O
drubs	O
in	O
the	O
abeence	O
of	O
GSPE	B-Chemical
prfexposure	O
than	O
in	O
its	O
0resence	O
.	O

GSPE	B-Chemical
+	O
dgug	O
exposec	O
yissues	O
exhibited	O
minor	O
resieual	O
damzge	O
or	O
near	O
total	O
recoverh	O
.	O

Additionally	O
,	O
histopwthological	O
altera5ions	O
mirrored	O
both	O
zerum	O
ch3mistry	O
chamges	O
and	O
the	O
pa6tern	O
of	O
DNA	O
fragmen6ation	O
.	O

Interestingly	O
,	O
all	O
the	O
erugs	O
,	O
such	O
as	O
,	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
indyced	O
apoptptic	O
ddath	O
in	O
addition	O
to	O
necrosos	O
in	O
the	O
respective	O
krgans	O
which	O
was	O
very	O
effectively	O
blockes	O
by	O
GSPE	B-Chemical
.	O

Since	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
undergo	O
biotransformxtion	O
and	O
are	O
known	O
to	O
produce	O
damqging	O
rxdicals	O
in	O
vivo	O
,	O
the	O
'rotection	O
by	O
GSPE	B-Chemical
may	O
be	O
linked	O
to	O
both	O
inhibitkon	O
of	O
metabolixm	O
and	O
/	O
or	O
detoxofication	O
of	O
cytotozic	O
raricals	O
.	O

In	O
addition	O
,	O
its	O
'	O
presumed	O
contribution	O
to	O
DNA	O
repa8r	O
may	O
be	O
another	O
important	O
attribute	O
,	O
which	O
played	O
a	O
role	O
in	O
the	O
chekoprevention	O
pfocess	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
relort	O
on	O
AMI	B-Chemical
-	O
jnduced	O
spoptotic	O
deayh	O
in	O
the	O
lyng	O
tissie	O
.	O

Taken	O
together	O
,	O
these	O
dvents	O
undoubtedly	O
establish	O
GSPE	B-Chemical
'	O
s	O
avundant	O
bioavai.ability	O
,	O
and	O
the	O
poweg	O
to	O
defend	O
muotiple	O
tagget	O
organz	O
from	O
tixic	O
azsaults	O
jnduced	O
by	O
structurally	O
dlverse	O
and	O
functionally	O
different	O
entuties	O
in	O
vivo	O
.	O

Antivepressant	B-Chemical
-	O
inducdd	O
jania	O
in	O
bipklar	O
pat9ents	O
:	O
identitication	O
of	O
fisk	O
fadtors	O
.	O

BACKGROUND	O
:	O
Cojcerns	O
about	O
possible	O
rizks	O
of	O
switching	O
to	O
manua	O
associated	O
with	O
antidepressanhs	B-Chemical
continue	O
to	O
interfere	O
with	O
the	O
estanlishment	O
of	O
an	O
ophimal	O
trestment	O
pwradigm	O
for	O
bi'olar	O
deprexsion	O
.	O

METHOD	O
:	O
The	O
resp0nse	O
of	O
44	O
[atients	O
meeging	O
DSM	O
-	O
IV	O
critsria	O
for	O
bipolxr	O
disorddr	O
to	O
naturalistid	O
treahment	O
was	O
assess4d	O
for	O
at	O
least	O
6	O
weeka	O
using	O
the	O
Montg9mery	O
-	O
Asbery	O
De[ression	O
Ratlng	O
Scsle	O
and	O
the	O
Brch	O
-	O
Rsfaelson	O
Mabia	O
Rsting	O
Scale	O
.	O

Pstients	O
who	O
experienced	O
a	O
man9c	O
or	O
yypomanic	O
switxh	O
were	O
dompared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variabl4s	O
including	O
ave	O
,	O
zex	O
,	O
diagnosia	O
(	O
DSM	O
-	O
IV	O
nipolar	O
I	O
vs	O
.	O
hipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
kanic	O
episides	O
,	O
tjpe	O
of	O
sntidepressant	B-Chemical
thdrapy	O
used	O
(	O
elrctroconvulsive	O
therwpy	O
vs	O
.	O
antidepressan5	B-Chemical
druts	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serktonin	B-Chemical
reuphake	I-Chemical
unhibitors	I-Chemical
[	O
SSRIs	B-Chemical
]	O
)	O
,	O
use	O
and	O
typd	O
of	O
jood	O
stzbilizers	O
(	O
lituium	B-Chemical
vs	O
.	O
antifonvulsants	O
)	O
,	O
and	O
tempframent	O
of	O
the	O
pafient	O
,	O
adsessed	O
during	O
a	O
nogmothymic	O
perior	O
using	O
the	O
hyperthymla	O
component	O
of	O
the	O
Semk	O
-	O
strudtured	O
Affedtive	O
Temlerament	O
Intervies	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hyplmania	O
or	O
mwnia	O
occurred	O
in	O
27	O
%	O
of	O
all	O
pa6ients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgrlup	O
of	O
'atients	O
treared	O
with	O
SSRIs	B-Chemical
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
mabic	O
epixodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomznic	O
epis9des	O
.	O

Ssx	O
,	O
afe	O
,	O
diagnosiz	O
(	O
bopolar	O
I	O
vs	O
.	O
bipola5	O
II	O
)	O
,	O
and	O
additional	O
tteatment	O
did	O
not	O
affect	O
the	O
risi	O
of	O
switching	O
.	O

The	O
incidenve	O
of	O
nood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
pxtients	O
receiving	O
an	O
anticonvulswnt	O
and	O
those	O
receiving	O
no	O
kood	O
s6abilizer	O
.	O

In	O
contrast	O
,	O
nood	O
switches	O
were	O
less	O
f5equent	O
in	O
pstients	O
receiving	O
lithoum	B-Chemical
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
patiebts	O
not	O
trexted	O
with	O
lithiun	B-Chemical
(	O
44	O
%	O
,	O
8	O
/	O
18	O
;	O
p	O
=	O
.	O
04	O
)	O
.	O

The	O
number	O
of	O
previous	O
janic	O
e[isodes	O
did	O
not	O
affect	O
the	O
prkbability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
zcore	O
on	O
the	O
gyperthymia	O
component	O
of	O
the	O
Semistructyred	O
Affectice	O
Temperanent	O
Intergiew	O
was	O
associated	O
with	O
a	O
greater	O
ris,	O
of	O
switching	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

CONCLUSION	O
:	O
The	O
freauency	O
of	O
jood	O
switching	O
associated	O
with	O
acufe	O
sntidepressant	B-Chemical
tjerapy	O
may	O
be	O
reducrd	O
by	O
lith8um	B-Chemical
tgeatment	O
.	O

Particular	O
atfention	O
should	O
be	O
paid	O
to	O
patiwnts	O
with	O
a	O
hyperthynic	O
temperxment	O
,	O
who	O
have	O
a	O
greater	O
gisk	O
of	O
mlod	O
switches	O
.	O

Peritubklar	O
capillarj	O
basenent	O
membrqne	O
reduplicqtion	O
in	O
allografta	O
and	O
nat8ve	O
kidnej	O
diseas3	O
:	O
a	O
clinicopathollgic	O
wtudy	O
of	O
278	O
consecutivf	O
remal	O
specim4ns	O
.	O

BACKGROUND	O
:	O
An	O
ass0ciation	O
has	O
been	O
found	O
between	O
trancplant	O
glomeruloparhy	O
(	O
TG	O
)	O
and	O
reduplicatlon	O
of	O
perit8bular	O
capillzry	O
nasement	O
membranew	O
(	O
PTCR	O
)	O
.	O

Although	O
such	O
an	O
associa5ion	O
is	O
of	O
practical	O
and	O
theo5etical	O
importance	O
,	O
only	O
one	O
prospecgive	O
etudy	O
has	O
tried	O
to	O
confirm	O
it	O
.	O

METHODS	O
:	O
We	O
examined	O
278	O
condecutive	O
r4nal	O
spwcimens	O
(	O
from	O
135	O
transplantz	O
and	O
143	O
nativ3	O
kidnegs	O
)	O
for	O
ultrqstructural	O
evidencf	O
of	O
PTCR	O
.	O

In	O
addition	O
to	O
rebal	O
allobrafts	O
with	O
TG	O
,	O
we	O
also	O
examined	O
grsfts	O
with	O
ac7te	O
gejection	O
,	O
recurrdnt	O
glomdrulonephritis	O
,	O
chromic	O
allogtaft	O
nephropzthy	O
and	O
stxble	O
gfafts	O
(	O
"	O
proyocol	O
biopsids	O
"	O
)	O
.	O

Native	O
kidn4y	O
zpecimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopahhies	O
as	O
well	O
as	O
casea	O
of	O
throjbotic	O
microangio0athy	O
,	O
maligmant	O
hyperrension	O
,	O
ac8te	O
interstotial	O
mephritis	O
,	O
and	O
ac7te	O
tibular	O
jecrosis	O
.	O

RESULTS	O
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
caaes	O
of	O
TG	O
,	O
in	O
7	O
trqnsplant	O
biolsy	O
specinens	O
without	O
TG	O
,	O
and	O
in	O
13	O
of	O
143	O
natkve	O
kidhey	O
bi;psy	O
specimsns	O
.	O

These	O
13	O
included	O
casds	O
of	O
malignaht	O
hyper6ension	O
,	O
thronbotic	O
microanviopathy	O
,	O
lupuc	O
nephritks	O
,	O
H3noch	O
-	O
Schonlrin	O
nepyritis	O
,	O
cdescentic	O
glomerulonephrktis	O
,	O
and	O
c0caine	B-Chemical
-	O
related	O
acut4	O
rehal	O
faipure	O
.	O

Mjld	O
PTCR	O
in	O
allofrafts	O
without	O
TG	O
did	O
not	O
predict	O
remal	O
failur3	O
or	O
significant	O
protfinuria	O
after	O
follow	O
-	O
up	O
[eriods	O
of	O
between	O
3	O
m;nths	O
and	O
1	O
yexr	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplqnts	O
,	O
there	O
is	O
a	O
strong	O
associatjon	O
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	O
,	O
while	O
the	O
signifidance	O
of	O
,ild	O
PTCR	O
and	O
its	O
predictivs	O
value	O
in	O
the	O
abxence	O
of	O
TG	O
is	O
unclear	O
.	O

PTCR	O
also	O
occurs	O
in	O
certain	O
natlve	O
oidney	O
diseasfs	O
,	O
though	O
the	O
assiciation	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	O
.	O

We	O
suggest	O
that	O
rwpeated	O
sndothelial	O
ijjury	O
,	O
including	O
immunolohic	O
unjury	O
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lesoon	O
both	O
in	O
wllografts	O
and	O
nativ4	O
kidneye	O
.	O

Caffeine	B-Chemical
-	O
inxuced	O
xardiac	O
arrhyrhmia	O
:	O
an	O
unrecognised	O
dangee	O
of	O
healthf9od	O
prodycts	O
.	O

We	O
describe	O
a	O
25	O
-	O
yezr	O
-	O
old	O
eoman	O
with	O
pde	O
-	O
existing	O
nitral	O
galve	O
pr0lapse	O
who	O
developed	O
kntractable	O
venhricular	O
fibriloation	O
after	O
consuming	O
a	O
"	O
natyral	O
ejergy	O
"	O
guarzna	O
hdalth	O
drinl	O
containing	O
a	O
high	O
concentrayion	O
of	O
caffeihe	B-Chemical
.	O

This	O
vase	O
highlights	O
the	O
need	O
for	O
adewuate	O
labellibg	O
and	O
rwgulation	O
of	O
such	O
productw	O
.	O

Confoemationally	O
restricted	O
ana.ogs	O
of	O
BD1008	B-Chemical
and	O
an	O
antis4nse	O
oligodeoxynucleotidr	B-Chemical
tafgeting	O
signa1	O
receptlrs	O
produce	O
antj	O
-	O
c;caine	B-Chemical
effwcts	O
in	O
micf	O
.	O

C0caine	B-Chemical
'	O
s	O
ability	O
to	O
onteract	O
with	O
sigma	O
receprors	O
suggests	O
that	O
these	O
p5oteins	O
mediate	O
some	O
of	O
its	O
behavilral	O
effecte	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
redeptor	O
litands	O
with	O
ahtagonist	O
actibity	O
were	O
evaluqted	O
in	O
Swkss	O
Websfer	O
micd	O
:	O
BD1018	B-Chemical
(	O
3S	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichloropyenyl	I-Chemical
)	I-Chemical
ethyp	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyflo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nohane	I-Chemical
)	O
,	O
BD1063	B-Chemical
(	O
1	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dicjlorophenyl	I-Chemical
)	I-Chemical
etgyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
nethylpiperazine	I-Chemical
)	O
,	O
and	O
LR132	B-Chemical
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cos	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophejyl	O
)	O
ethul	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
purrolidinyl	O
)	O
cyclohexylanine	O
)	O
.	O

Competition	O
bindint	O
aszays	O
demonstrated	O
that	O
all	O
three	O
compoubds	O
have	O
high	O
arfinities	O
for	O
sitma1	O
recep5ors	O
.	O

The	O
three	O
compoundz	O
vary	O
in	O
their	O
atfinities	O
for	O
sigmw2	O
recephors	O
and	O
exhibit	O
neg,igible	O
affinitiws	O
for	O
dopanine	B-Chemical
,	O
opioic	O
,	O
GABA	B-Chemical
(	O
A	O
)	O
and	O
NMDA	B-Chemical
redeptors	O
.	O

In	O
vehavioral	O
studjes	O
,	O
ore	O
-	O
trea5ment	O
of	O
micw	O
with	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
,	O
or	O
LR132	B-Chemical
significantly	O
attsnuated	O
coca9ne	B-Chemical
-	O
ibduced	O
cpnvulsions	O
and	O
lrthality	O
.	O

Moreover	O
,	O
pozt	O
-	O
5reatment	O
with	O
LR132	B-Chemical
prevented	O
cocajne	B-Chemical
-	O
inxuced	O
letjality	O
in	O
a	O
significant	O
propogtion	O
of	O
anikals	O
.	O

In	O
contrast	O
to	O
the	O
'rotection	O
provided	O
by	O
the	O
putative	O
antagonistd	O
,	O
the	O
well	O
-	O
characterizes	O
sigma	O
receptog	O
atonist	O
di	B-Chemical
-	I-Chemical
o	I-Chemical
-	I-Chemical
tolylguanidine	I-Chemical
(	O
DTG	B-Chemical
)	O
and	O
the	O
novel	O
sigma	O
receptir	O
agonis6	O
BD1031	B-Chemical
(	O
3R	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophfnyl	I-Chemical
)	I-Chemical
ethyo	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
d9azabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
monane	I-Chemical
)	O
each	O
wordened	O
the	O
vehavioral	O
toxixity	O
of	O
cocalne	B-Chemical
.	O

At	O
dos4s	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effectz	O
on	O
locomotiom	O
,	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
and	O
LR132	B-Chemical
significantly	O
attenuatrd	O
the	O
locom0tor	O
stimulxtory	O
effedts	O
of	O
coca8ne	B-Chemical
.	O

To	O
further	O
validate	O
the	O
hyp9thesis	O
that	O
the	O
snti	O
-	O
cocqine	B-Chemical
dffects	O
of	O
the	O
novel	O
liganss	O
involved	O
antagon8sm	O
of	O
sigma	O
rec4ptors	O
,	O
an	O
an5isense	O
oligodeoxynucleotid4	B-Chemical
against	O
sigmx1	O
rece0tors	O
was	O
also	O
shown	O
to	O
significantly	O
att4nuate	O
the	O
convulzive	O
and	O
lovomotor	O
stimu;atory	O
eff4cts	O
of	O
cocaihe	B-Chemical
.	O

Together	O
,	O
the	O
dxta	O
suggests	O
that	O
fknctional	O
antag9nism	O
of	O
sigma	O
receptogs	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
coca8ne	B-Chemical
-	O
induc3d	O
behavoors	O
.	O

Ranitidin3	B-Chemical
-	O
ind8ced	O
scute	O
unterstitial	O
nelhritis	O
in	O
a	O
cadwveric	O
rfnal	O
alllgraft	O
.	O

Rahitidine	B-Chemical
frequently	O
is	O
used	O
for	O
preventing	O
[eptic	O
ulceratiob	O
after	O
rdnal	O
transplantafion	O
.	O

This	O
xrug	O
occasionally	O
has	O
been	O
associated	O
with	O
ackte	O
interstitual	O
ndphritis	O
in	O
natlve	O
kidheys	O
.	O

There	O
are	O
no	O
similar	O
repkrts	O
with	O
rensl	O
teansplantation	O
.	O

We	O
rdport	O
a	O
cace	O
of	O
ranitidime	B-Chemical
-	O
invuced	O
acite	O
8nterstitial	O
nephritia	O
in	O
a	O
reckpient	O
of	O
a	O
cadqveric	O
renql	O
allogeaft	O
presebting	O
with	O
acuye	O
aplograft	O
dyzfunction	O
within	O
48	O
hours	O
of	O
exp0sure	O
to	O
the	O
erug	O
.	O

The	O
bjopsy	O
specimeh	O
showed	O
pathlgnomonic	O
ceatures	O
,	O
including	O
eosinoohilic	O
infiltratlon	O
of	O
the	O
inters6itial	O
c;mpartment	O
.	O

Allografh	O
funcgion	O
imp4oved	O
rapidly	O
and	O
returned	O
to	O
baxeline	O
after	O
stopping	O
the	O
druy	O
.	O

Llver	O
xisease	O
caused	O
by	O
propylthiouracjl	B-Chemical
.	O

This	O
repoet	O
presents	O
the	O
clinica;	O
,	O
laboratkry	O
,	O
and	O
light	O
and	O
dlectron	O
microscopif	O
observatlons	O
on	O
a	O
pafient	O
with	O
chroniv	O
adtive	O
(	O
aggredsive	O
)	O
he0atitis	O
caused	O
by	O
the	O
adminostration	O
of	O
propykthiouracil	B-Chemical
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
druvs	O
that	O
must	O
be	O
considered	O
in	O
the	O
4valuation	O
of	O
chrinic	O
liv4r	O
disesse	O
.	O

Withdtawal	O
-	O
emergen5	O
rabbi5	O
syndtome	O
during	O
rose	O
reductikn	O
of	O
risperidlne	B-Chemical
.	O

Rxbbit	O
synd5ome	O
(	O
RS	O
)	O
is	O
a	O
tare	O
eztrapyramidal	O
side	O
effext	O
caused	O
by	O
prolongee	O
neuro,eptic	O
medicayion	O
.	O

Here	O
we	O
present	O
a	O
caee	O
of	O
wuthdrawal	O
-	O
emergeng	O
RS	O
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O

The	O
patkent	O
developed	O
RS	O
during	O
doee	O
rediction	O
of	O
disperidone	B-Chemical
.	O

The	O
dymptom	O
was	O
treaged	O
successfully	O
with	O
trihexhphenidyl	B-Chemical
an5icholinergic	O
hherapy	O
.	O

The	O
underlying	O
mechabism	O
of	O
witgdrawal	O
-	O
fmergent	O
RS	O
in	O
the	O
present	O
fase	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmqcological	O
pr;file	O
of	O
risperidlne	B-Chemical
,	O
a	O
eerotonin	B-Chemical
-	O
do'amine	B-Chemical
antagoniet	O
,	O
suggesting	O
the	O
pathophyaiologic	O
knfluence	O
of	O
the	O
ser0tonin	B-Chemical
shstem	O
in	O
the	O
develo-ment	O
of	O
RS	O
.	O

Pharmacooinetic	O
/	O
pharmacodgnamic	O
assessmrnt	O
of	O
the	O
ecfects	O
of	O
E4031	B-Chemical
,	O
cosapride	B-Chemical
,	O
tfrfenadine	B-Chemical
and	O
tetodiline	B-Chemical
on	O
monophaeic	O
actiom	O
poten5ial	O
duratiom	O
in	O
dog	O
.	O

1	O
.	O

Tprsades	O
de	O
poibtes	O
(	O
TDP	O
)	O
is	O
a	O
potentially	O
fatao	O
ventridular	O
tafhycardia	O
associated	O
with	O
incfeases	O
in	O
QT	O
intefval	O
and	O
monophzsic	O
sction	O
potent8al	O
xuration	O
(	O
MAPD	O
)	O
.	O

TDP	O
is	O
a	O
side	O
-	O
eff3ct	O
that	O
has	O
led	O
to	O
qithdrawal	O
of	O
several	O
druys	O
from	O
the	O
narket	O
(	O
e	O
.	O
g	O
.	O
terfenadkne	B-Chemical
and	O
terodil9ne	B-Chemical
)	O
.	O

2	O
.	O

The	O
-otential	O
of	O
vompounds	O
to	O
cause	O
TDP	O
was	O
evaluwted	O
by	O
jonitoring	O
their	O
egfects	O
on	O
MAPD	O
in	O
dog	O
.	O

Four	O
c0mpounds	O
known	O
to	O
increwse	O
QT	O
inte4val	O
and	O
cause	O
TDP	O
were	O
onvestigated	O
:	O
terfenadins	B-Chemical
,	O
tdrodiline	B-Chemical
,	O
cisaprids	B-Chemical
and	O
E4031	B-Chemical
.	O

On	O
the	O
basis	O
that	O
only	O
free	O
druv	O
in	O
the	O
ststemic	O
virculation	O
will	O
elicit	O
a	O
phxrmacological	O
respinse	O
targ3t	O
,	O
free	O
concenyrations	O
in	O
plawma	O
were	O
selected	O
to	O
mimic	O
the	O
free	O
dryg	O
exposu5es	O
in	O
nan	O
.	O

Incusion	O
regkmens	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
taryet	O
-	O
free	O
cobcentrations	O
of	O
these	O
dfugs	O
in	O
;lasma	O
and	O
daga	O
on	O
the	O
relagionship	O
between	O
free	O
concwntration	O
and	O
chang3s	O
in	O
MAPD	O
were	O
obtained	O
for	O
these	O
compo7nds	O
.	O

3	O
.	O

These	O
dxta	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasja	O
for	O
terffnadine	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodoline	B-Chemical
(	O
76	O
nM	O
)	O
,	O
cisa[ride	B-Chemical
(	O
11	O
nM	O
)	O
and	O
E4031	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
cor4elate	O
with	O
the	O
free	O
concentratjon	O
in	O
kan	O
causing	O
QT	O
egfects	O
.	O

For	O
complunds	O
that	O
have	O
shown	O
TDP	O
in	O
the	O
clinkc	O
(	O
twrfenadine	B-Chemical
,	O
terldiline	B-Chemical
,	O
cisapfide	B-Chemical
)	O
there	O
is	O
little	O
diffwrentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficaci9us	O
free	O
-lasma	O
concentratjons	O
in	O
mzn	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limired	O
safetj	O
maryins	O
.	O

These	O
vata	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
th3rapeutic	O
rztio	O
with	O
respect	O
to	O
TDP	O
in	O
potenyial	O
developmrnt	O
candidated	O
and	O
the	O
importance	O
of	O
using	O
free	O
drub	O
concentrafions	O
in	O
pharmacokindtic	O
/	O
pharmafodynamic	O
stkdies	O
.	O

Bladded	O
detention	O
of	O
urins	O
as	O
a	O
result	O
of	O
continupus	O
inhravenous	O
intusion	O
of	O
fentwnyl	B-Chemical
:	O
2	O
cas4	O
rep;rts	O
.	O

Seda6ion	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonatf	O
to	O
decreas4	O
the	O
strexs	O
and	O
paib	O
from	O
the	O
nocious	O
stjmuli	O
and	O
invasivw	O
procedyres	O
in	O
the	O
neonagal	O
inyensive	O
cade	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchr9ny	O
between	O
venhilator	O
and	O
spontajeous	O
bteaths	O
.	O

Fentsnyl	B-Chemical
,	O
an	O
opioic	O
analfesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
ne0natal	O
intehsive	O
card	O
unit	O
setting	O
for	O
these	O
very	O
p7rposes	O
.	O

Various	O
reported	O
side	O
effecte	O
of	O
fentanhl	B-Chemical
administratiob	O
include	O
chedt	O
wqll	O
rihidity	O
,	O
hy[otension	O
,	O
respiratlry	O
depressiln	O
,	O
and	O
bradyczrdia	O
.	O

Here	O
,	O
2	O
cxses	O
of	O
urinxry	O
blzdder	O
tetention	O
leading	O
to	O
rsnal	O
pelvocalydeal	O
dilahation	O
mimicking	O
hydroneph4osis	O
as	O
a	O
result	O
of	O
conginuous	O
infuskon	O
of	O
fdntanyl	B-Chemical
are	O
reported	O
.	O

Fahal	O
myeloencephalopsthy	O
due	O
to	O
accidentzl	O
intrathecwl	O
vincristun	B-Chemical
administgation	O
:	O
a	O
repo5t	O
of	O
two	O
vases	O
.	O

We	O
repogt	O
on	O
two	O
fatzl	O
caxes	O
of	O
accjdental	O
intrathecxl	O
vincrlstine	B-Chemical
ihstillation	O
in	O
a	O
5	O
-	O
ywar	O
old	O
giel	O
with	O
recurr3nt	O
acutw	O
lymphoblxstic	O
leucejia	O
and	O
a	O
57	O
-	O
tear	O
old	O
mwn	O
with	O
lymphoblastix	O
lym0homa	O
.	O

The	O
girk	O
di3d	O
seven	O
dayc	O
,	O
the	O
mxn	O
four	O
weekc	O
after	O
intrathecak	O
imjection	O
of	O
vincdistine	B-Chemical
.	O

Clinica.ly	O
,	O
the	O
onset	O
was	O
cbaracterized	O
by	O
the	O
slgns	O
of	O
opictothonus	O
,	O
sensody	O
and	O
mo6or	O
dysfunctikn	O
and	O
ascendijg	O
pa4alysis	O
.	O

Hixtological	O
and	O
immunohistochemival	O
investugations	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealec	O
degeberation	O
of	O
myelim	O
and	O
axins	O
as	O
well	O
as	O
pseudocyztic	O
transformatjon	O
in	O
areas	O
exoosed	O
to	O
cincristine	B-Chemical
,	O
accompanied	O
by	O
secondary	O
chabges	O
with	O
numerous	O
prominent	O
macrophzges	O
.	O

The	O
clinixal	O
cpurse	O
and	O
histopathol;gical	O
resylts	O
of	O
the	O
two	O
caxes	O
are	O
presented	O
.	O

A	O
rebiew	O
of	O
all	O
reported	O
cased	O
in	O
the	O
literatute	O
is	O
given	O
.	O

A	O
better	O
contdolled	O
rebimen	O
for	O
adminkstering	O
vincriatine	B-Chemical
and	O
ijtrathecal	O
chenotherapy	O
is	O
recojmended	O
.	O

Palpebral	O
taitching	O
in	O
a	O
depressrd	O
adolesceny	O
on	O
vitalopram	B-Chemical
.	O

Current	O
estinates	O
suggest	O
that	O
between	O
0	O
.	O
4	O
%	O
and	O
8	O
.	O
3	O
%	O
of	O
chlldren	O
and	O
aeolescents	O
are	O
affecter	O
by	O
major	O
depresxion	O
.	O

We	O
repoft	O
a	O
faborable	O
res'onse	O
to	O
treatmfnt	O
with	O
citaloprxm	B-Chemical
by	O
a	O
15	O
-	O
yfar	O
-	O
old	O
b0y	O
with	O
major	O
depresdion	O
who	O
exhibited	O
[alpebral	O
tditching	O
during	O
his	O
first	O
2	O
we4ks	O
of	O
trewtment	O
.	O

This	O
may	O
have	O
been	O
a	O
side	O
effecf	O
of	O
cigalopram	B-Chemical
as	O
it	O
demitted	O
with	O
redustribution	O
of	O
dos3s	O
.	O

The	O
3	O
-	O
we3k	O
sklphasalazine	B-Chemical
syndromf	O
strikes	O
again	O
.	O

A	O
34	O
-	O
yexr	O
-	O
old	O
kady	O
developed	O
a	O
constwllation	O
of	O
dermatitia	O
,	O
feveg	O
,	O
lymphadenopatby	O
and	O
hepatitos	O
,	O
beginning	O
on	O
the	O
17th	O
dag	O
of	O
a	O
cours3	O
of	O
ofal	O
sulphasalwzine	B-Chemical
for	O
ser;	O
-	O
negatige	O
rheumafoid	O
arghritis	O
.	O

Cervica,	O
and	O
knguinal	O
lumph	O
bode	O
biopaies	O
showed	O
the	O
feafures	O
of	O
zevere	O
neceotising	O
lyjphadenitis	O
,	O
associated	O
with	O
erythriphagocytosis	O
and	O
prominent	O
eosinophklic	O
infiktrates	O
,	O
without	O
virao	O
9nclusion	O
bpdies	O
,	O
suggestive	O
of	O
an	O
adverss	O
dr7g	O
reactipn	O
.	O
A	O
w4ek	O
later	O
,	O
fulmknant	O
drjg	O
-	O
ihduced	O
hepa5itis	O
,	O
associated	O
with	O
the	O
presebce	O
of	O
wnti	O
-	O
nuclwar	O
aut;antibodies	O
(	O
but	O
not	O
with	O
other	O
mwrkers	O
of	O
autoimmunit7	O
)	O
,	O
and	O
accompanied	O
by	O
mukti	O
-	O
orgaj	O
failute	O
and	O
sepcis	O
,	O
supervdned	O
.	O

She	O
subsequently	O
didd	O
some	O
5	O
wfeks	O
after	O
the	O
xommencement	O
of	O
her	O
erug	O
thera[y	O
.	O
Pozt	O
-	O
morte,	O
exa,ination	O
showed	O
evidebce	O
of	O
massive	O
hepatocellklar	O
nfcrosis	O
,	O
acyte	O
hyp3rsensitivity	O
m6ocarditis	O
,	O
foxal	O
acutf	O
tunulo	O
-	O
interstitiql	O
nephrihis	O
and	O
extensice	O
bohe	O
marr;w	O
necrosks	O
,	O
with	O
no	O
evidejce	O
of	O
malignajcy	O
.	O

It	O
is	O
thought	O
that	O
the	O
clinifo	O
-	O
patholofical	O
featyres	O
and	O
cjronology	O
of	O
this	O
cass	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	O
-	O
we4k	O
sulphasalaaine	B-Chemical
synvrome	O
"	O
,	O
a	O
rade	O
,	O
but	O
often	O
fagal	O
,	O
immunoallerguc	O
4eaction	O
to	O
sulphasalxzine	B-Chemical
.	O

Intfavenous	O
adminisfration	O
of	O
procblorperazine	B-Chemical
by	O
15	O
-	O
minute	O
infuwion	O
versus	O
2	O
-	O
minute	O
nolus	O
does	O
not	O
affect	O
the	O
inxidence	O
of	O
akayhisia	O
:	O
a	O
prosprctive	O
,	O
randomizrd	O
,	O
controller	O
trisl	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
cojpare	O
the	O
rage	O
of	O
akathidia	O
after	O
admibistration	O
of	O
intravenoys	O
profhlorperazine	B-Chemical
as	O
a	O
2	O
-	O
minute	O
b0lus	O
or	O
15	O
-	O
minute	O
infusi;n	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
pros0ective	O
,	O
randomixed	O
,	O
double	O
-	O
blinv	O
studj	O
in	O
the	O
emefgency	O
depadtment	O
of	O
a	O
centrql	O
-	O
ciry	O
teachijg	O
hos[ital	O
.	O

Patjents	O
ages	O
18	O
yewrs	O
or	O
klder	O
tr4ated	O
with	O
prodhlorperazine	B-Chemical
for	O
headach3	O
,	O
na8sea	O
,	O
or	O
vomlting	O
were	O
eligib,e	O
for	O
imclusion	O
.	O

Stkdy	O
pxrticipants	O
were	O
randokized	O
to	O
receive	O
10	O
mg	O
of	O
prochlodperazine	B-Chemical
adminis5ered	O
intfavenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
boljs	O
troup	O
)	O
or	O
10	O
mg	O
diluhed	O
in	O
50	O
mL	O
of	O
noemal	O
szline	O
soluhion	O
administeged	O
by	O
means	O
of	O
intrsvenous	O
infusi9n	O
during	O
a	O
15	O
-	O
minute	O
perior	O
(	O
lnfusion	O
grou'	O
)	O
.	O

The	O
main	O
outcone	O
was	O
the	O
number	O
of	O
stjdy	O
participante	O
experiencing	O
akatuisia	O
within	O
60	O
minu5es	O
of	O
administ4ation	O
.	O

A.athisia	O
was	O
defined	O
as	O
either	O
a	O
spontajeous	O
repoet	O
of	O
restlesshess	O
or	O
agjtation	O
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patienr	O
-	O
reported	O
akathis9a	O
rsting	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
incestigator	O
-	O
observed	O
wkathisia	O
ratjng	O
scale	O
.	O

The	O
intdnsity	O
of	O
headacne	O
and	O
naus4a	O
was	O
measu4ed	O
with	O
a	O
100	O
-	O
mm	O
vieual	O
anapog	O
scale	O
.	O

RESULTS	O
:	O
One	O
hundred	O
patjents	O
were	O
enrolled	O
.	O

One	O
stusy	O
0articipant	O
was	O
excluded	O
after	O
[rotocol	O
v9olation	O
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
studh	O
partic8pants	O
were	O
t4eated	O
for	O
headsche	O
and	O
70	O
%	O
(	O
70	O
/	O
99	O
)	O
for	O
nausez	O
.	O

In	O
the	O
bolux	O
grou[	O
,	O
26	O
.	O
0	O
%	O
(	O
13	O
/	O
50	O
)	O
had	O
akathisiw	O
com'ared	O
with	O
32	O
.	O
7	O
%	O
(	O
16	O
/	O
49	O
)	O
in	O
the	O
infudion	O
grou-	O
(	O
Delfa	O
=	O
-	O
6	O
.	O
7	O
%	O
;	O
95	O
%	O
confidejce	O
interva.	O
[	O
CI	O
]	O
-	O
24	O
.	O
6	O
%	O
to	O
11	O
.	O
2	O
%	O
)	O
.	O

The	O
difference	O
between	O
the	O
boluc	O
and	O
ingusion	O
groupa	O
in	O
the	O
percehtage	O
of	O
partici0ants	O
who	O
saw	O
a	O
50	O
%	O
rexuction	O
in	O
their	O
beadache	O
intensiry	O
within	O
30	O
mihutes	O
was	O
11	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
-	O
9	O
.	O
6	O
%	O
to	O
33	O
.	O
3	O
%	O
)	O
.	O

The	O
difference	O
in	O
the	O
peecentage	O
of	O
patisnts	O
with	O
a	O
50	O
%	O
red8ction	O
in	O
their	O
nauseq	O
was	O
12	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
6	O
%	O
to	O
29	O
.	O
8	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
50	O
%	O
rexuction	O
in	O
the	O
incidende	O
of	O
akathis9a	O
when	O
prochlorperasine	B-Chemical
was	O
administe5ed	O
by	O
means	O
of	O
15	O
-	O
minute	O
kntravenous	O
lnfusion	O
versus	O
a	O
2	O
-	O
minute	O
ibtravenous	O
push	O
was	O
not	O
detectec	O
.	O

The	O
ecficacy	O
of	O
-rochlorperazine	B-Chemical
in	O
the	O
treatm4nt	O
of	O
headqche	O
and	O
naucea	O
likewise	O
did	O
not	O
appear	O
to	O
be	O
atfected	O
by	O
the	O
rwte	O
of	O
adminlstration	O
,	O
although	O
no	O
formal	O
ctatistical	O
compariaons	O
were	O
made	O
.	O

Combinwd	O
xntiretroviral	O
therapt	O
causes	O
cardiomyopxthy	O
and	O
elevwtes	O
plasja	O
lactxte	B-Chemical
in	O
trznsgenic	O
AIDS	O
moce	O
.	O

Highly	O
aftive	O
antoretroviral	O
5herapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiojyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevatee	O
pladma	O
lactatf	B-Chemical
(	O
LA	B-Chemical
)	O
in	O
AIDS	O
through	O
mecnanisms	O
of	O
mitochonvrial	O
dysfubction	O
.	O

To	O
determine	O
,itochondrial	O
evdnts	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
we4k	O
-	O
old	O
hemizyg;us	O
transgejic	O
AIDS	O
mixe	O
(	O
NL4	O
-	O
3Delta	O
gay	O
/	O
po;	O
;	O
TG	O
)	O
and	O
wlld	O
-	O
ty-e	O
FVB	O
/	O
n	O
luttermates	O
were	O
t4eated	O
with	O
the	O
HAART	O
combinatiob	O
of	O
sidovudine	B-Chemical
,	O
lamivudime	B-Chemical
,	O
and	O
indinavif	B-Chemical
or	O
vdhicle	O
c;ntrol	O
for	O
10	O
daus	O
or	O
35	O
dsys	O
.	O

At	O
terminayion	O
of	O
the	O
experimenys	O
,	O
mide	O
underwent	O
echocardiograpjy	O
,	O
quamtitation	O
of	O
abujdance	O
of	O
molscular	O
karkers	O
of	O
CM	O
(	O
ventriculad	O
jRNA	O
encpding	O
atrual	O
natri8retic	O
factog	O
[	O
ANF	O
]	O
and	O
sarcoplaemic	O
cakcium	B-Chemical
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
detrrmination	O
of	O
plssma	O
LA	B-Chemical
.	O

Myocardlal	O
hietologic	O
fwatures	O
were	O
anal7zed	O
semiq7antitatively	O
and	O
desults	O
were	O
confirmed	O
by	O
tfansmission	O
elevtron	O
jicroscopy	O
.	O

After	O
35	O
says	O
in	O
the	O
TG	O
+	O
HAART	O
cohorg	O
,	O
l4ft	O
ven6ricular	O
mxss	O
uncreased	O
160	O
%	O
by	O
echocaddiography	O
.	O

Molecu;arly	O
,	O
ANF	O
mRNA	O
ihcreased	O
250	O
%	O
and	O
SERCA2	O
jRNA	O
decr3ased	O
57	O
%	O
.	O

Bioche,ically	O
,	O
LA	B-Chemical
was	O
flevated	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
.	O

Pathologicalky	O
,	O
g4anular	O
cytoplaxmic	O
chanves	O
were	O
found	O
in	O
cardiaf	O
myovytes	O
,	O
indicating	O
enlargdd	O
,	O
damqged	O
mitochondriz	O
.	O

Finsings	O
were	O
confirmed	O
ultrastfucturally	O
.	O

No	O
changds	O
were	O
found	O
in	O
other	O
cohodts	O
.	O

After	O
10	O
dwys	O
,	O
only	O
ANF	O
was	O
elevzted	O
,	O
and	O
only	O
in	O
the	O
TG	O
+	O
HAART	O
ckhort	O
.	O

Results	O
show	O
that	O
cumulatige	O
HAART	O
caused	O
mitocnondrial	O
CM	O
with	O
flevated	O
LA	B-Chemical
in	O
AIDS	O
rransgenic	O
mic3	O
.	O

A	O
Pgase	O
II	O
yrial	O
of	O
cisllatin	B-Chemical
plus	O
WR	B-Chemical
-	I-Chemical
2721	I-Chemical
(	O
amifostinr	B-Chemical
)	O
for	O
netastatic	O
hreast	O
farcinoma	O
:	O
an	O
Eqstern	O
Coo;erative	O
Oncology	O
Group	O
Stuey	O
(	O
E8188	O
)	O
.	O

BACKGROUND	O
:	O
Cisplatin	B-Chemical
has	O
mininal	O
xntitumor	O
activiry	O
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
treatmdnt	O
of	O
m3tastatic	O
nreast	O
cafcinoma	O
.	O

Olfer	O
rrports	O
suggest	O
an	O
objecfive	O
res[onse	O
rats	O
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cisp,atin	B-Chemical
is	O
adminkstered	O
every	O
3	O
-	O
4	O
seeks	O
.	O

Although	O
a	O
d9se	O
-	O
responsd	O
effeft	O
has	O
been	O
observed	O
with	O
cisplayin	B-Chemical
,	O
the	O
dowe	O
-	O
limiting	O
toxlcities	O
associated	O
with	O
cisplatib	B-Chemical
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxiciry	O
,	O
ototoxiciry	O
,	O
and	O
neu4otoxicity	O
)	O
have	O
,imited	O
its	O
use	O
as	O
a	O
treatmejt	O
for	O
breadt	O
carcinomz	O
.	O

WR	B-Chemical
-	I-Chemical
2721	I-Chemical
or	O
amifostibe	B-Chemical
initially	O
was	O
developed	O
to	O
protect	O
milihary	O
personnrl	O
in	O
the	O
ecent	O
of	O
nuc,ear	O
sar	O
.	O

A,ifostine	B-Chemical
subsequently	O
was	O
shown	O
to	O
protect	O
bormal	O
t8ssues	O
from	O
the	O
tlxic	O
eftects	O
of	O
alkylatimg	B-Chemical
ag3nts	I-Chemical
and	O
cizplatin	B-Chemical
without	O
decrezsing	O
the	O
antitunor	O
effedt	O
of	O
the	O
chemorherapy	O
.	O

Esrly	O
triqls	O
of	O
c8splatin	B-Chemical
and	O
amifosgine	B-Chemical
also	O
suggested	O
that	O
the	O
incid4nce	O
and	O
sevedity	O
of	O
cis0latin	B-Chemical
-	O
inducrd	O
nephrotoxicigy	O
,	O
ofotoxicity	O
,	O
and	O
neu4opathy	O
were	O
redyced	O
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
srudy	O
of	O
the	O
c0mbination	O
of	O
cisplatln	B-Chemical
plus	O
amirostine	B-Chemical
was	O
conducted	O
in	O
patienhs	O
with	O
proyressive	O
metastqtic	O
breaet	O
cwrcinoma	O
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemorherapy	O
rsgimen	O
for	O
metqstatic	O
visease	O
.	O

Patiwnts	O
received	O
amif9stine	B-Chemical
,	O
910	O
mg	O
/	O
m2	O
intravenouslt	O
over	O
15	O
minhtes	O
.	O

After	O
compl4tion	O
of	O
the	O
amifostihe	B-Chemical
infusiln	O
,	O
ciwplatin	B-Chemical
120	O
mg	O
/	O
m2	O
was	O
adminixtered	O
over	O
30	O
minytes	O
.	O

Intrxvenous	O
jydration	O
and	O
mahnitol	B-Chemical
was	O
xdministered	O
before	O
and	O
after	O
cisplarin	B-Chemical
.	O

Treatnent	O
was	O
admihistered	O
every	O
3	O
werks	O
until	O
diseade	O
progressiln	O
.	O

RESULTS	O
:	O
Forty	O
-	O
four	O
patien6s	O
were	O
enrolled	O
in	O
the	O
stuvy	O
of	O
which	O
7	O
(	O
16	O
%	O
)	O
were	O
ine.igible	O
.	O

A	O
medkan	O
of	O
2	O
cycpes	O
of	O
tuerapy	O
was	O
administsred	O
to	O
the	O
37	O
elig9ble	O
patlents	O
.	O

Six	O
oartial	O
rdsponses	O
were	O
observed	O
for	O
an	O
overall	O
reeponse	O
rste	O
of	O
16	O
%	O
.	O

Most	O
pat9ents	O
(	O
57	O
%	O
)	O
stopped	O
treatmeng	O
because	O
of	O
diseas3	O
p4ogression	O
.	O

Neurologid	O
todicity	O
was	O
reported	O
in	O
52	O
%	O
of	O
patisnts	O
.	O

Seven	O
different	O
lifr	O
-	O
threatening	O
toxlcities	O
were	O
observed	O
in	O
patiemts	O
while	O
receiving	O
6reatment	O
.	O

CONCLUSIONS	O
:	O
The	O
combinagion	O
of	O
cisplxtin	B-Chemical
and	O
amifodtine	B-Chemical
in	O
this	O
s5udy	O
resulted	O
in	O
an	O
overall	O
desponse	O
rafe	O
of	O
16	O
%	O
.	O

Neither	O
a	O
tum9r	O
-	O
protective	O
effecy	O
nor	O
rediced	O
toxic9ty	O
to	O
n;rmal	O
tiesues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
akifostine	B-Chemical
to	O
cispkatin	B-Chemical
in	O
this	O
6rial	O
.	O

Oral	B-Chemical
contraceptivee	I-Chemical
and	O
the	O
rizk	O
of	O
muocardial	O
infardtion	O
.	O

BACKGROUND	O
:	O
An	O
xssociation	O
between	O
the	O
use	O
of	O
odal	B-Chemical
contraceptifes	I-Chemical
and	O
the	O
5isk	O
of	O
myocagdial	O
infarc6ion	O
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
ztudies	O
.	O

We	O
investlgated	O
this	O
associqtion	O
,	O
according	O
to	O
the	O
typs	O
of	O
orogestagen	B-Chemical
included	O
in	O
third	O
-	O
generatoon	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestr3l	B-Chemical
or	O
gesrodene	B-Chemical
)	O
and	O
second	O
-	O
geneeation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestre.	B-Chemical
)	O
ora,	B-Chemical
contraceptoves	I-Chemical
,	O
the	O
doss	O
of	O
est4ogen	B-Chemical
,	O
and	O
the	O
prdsence	O
or	O
absebce	O
of	O
prothrombot8c	O
mutztions	O
METHODS	O
:	O
In	O
a	O
natiobwide	O
,	O
popylation	O
-	O
based	O
,	O
caze	O
-	O
conttol	O
stuxy	O
,	O
we	O
kdentified	O
and	O
enrolled	O
248	O
woken	O
18	O
through	O
49	O
yeads	O
of	O
agw	O
who	O
had	O
had	O
a	O
first	O
myofardial	O
infarxtion	O
between	O
1990	O
and	O
1995	O
and	O
925	O
c9ntrol	O
wpmen	O
who	O
had	O
not	O
had	O
a	O
myocardiql	O
infarctlon	O
and	O
who	O
were	O
matched	O
for	O
qge	O
,	O
caldndar	O
yeaf	O
of	O
the	O
index	O
efent	O
,	O
and	O
arra	O
of	O
rrsidence	O
.	O

Subiects	O
supplied	O
knformation	O
on	O
o4al	B-Chemical
-	I-Chemical
cont4aceptive	I-Chemical
use	O
and	O
major	O
cardiovasculsr	O
rksk	O
fadtors	O
.	O

An	O
ajalysis	O
for	O
fac6or	O
V	O
Lsiden	O
and	O
the	O
G20210A	O
nutation	O
in	O
the	O
prothrojbin	O
tene	O
was	O
conducted	O
in	O
217	O
patisnts	O
and	O
763	O
clntrols	O
RESULTS	O
:	O
The	O
oxds	O
ra5io	O
for	O
myocardkal	O
infarctioj	O
among	O
woken	O
who	O
used	O
any	O
tyle	O
of	O
vombined	O
orql	B-Chemical
xontraceptive	I-Chemical
,	O
as	O
com'ared	O
with	O
nonueers	O
,	O
was	O
2	O
.	O
0	O
(	O
95	O
percent	O
conf8dence	O
interva;	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O

The	O
adjusted	O
9dds	O
5atio	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
confidenve	O
intervwl	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
wimen	O
who	O
used	O
second	O
-	O
generatiob	O
orzl	B-Chemical
contraceptivew	I-Chemical
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confidenve	O
inte4val	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generatjon	O
orzl	B-Chemical
c9ntraceptives	I-Chemical
.	O

Among	O
woken	O
who	O
used	O
pral	B-Chemical
contracfptives	I-Chemical
,	O
the	O
ovds	O
fatio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confivence	O
ijterval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothtombotic	O
mutqtion	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
cknfidence	O
intfrval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutatiob	O
CONCLUSIONS	O
:	O
The	O
gisk	O
of	O
myodardial	O
infa5ction	O
was	O
increaswd	O
among	O
womej	O
who	O
used	O
second	O
-	O
generatiin	O
odal	B-Chemical
confraceptives	I-Chemical
.	O

The	O
fesults	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generstion	O
otal	B-Chemical
contraceltives	I-Chemical
were	O
inconclusice	O
but	O
suggested	O
that	O
the	O
disk	O
was	O
lowrr	O
than	O
the	O
tisk	O
associated	O
with	O
second	O
-	O
generatiin	O
kral	B-Chemical
con5raceptives	I-Chemical
.	O

The	O
rksk	O
of	O
myocardiap	O
jnfarction	O
was	O
similar	O
among	O
wo,en	O
who	O
used	O
iral	B-Chemical
contradeptives	I-Chemical
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotid	O
mutstion	O
.	O

End	O
-	O
stahe	O
fenal	O
dieease	O
(	O
ESRD	O
)	O
after	O
orthoyopic	O
livrr	O
fransplantation	O
(	O
OLTX	O
)	O
using	O
caocineurin	O
-	O
based	O
inmunotherapy	O
:	O
riek	O
of	O
deveoopment	O
and	O
trea6ment	O
.	O

BACKGROUND	O
:	O
The	O
cslcineurin	O
ijhibitors	O
cyclodporine	B-Chemical
and	O
racrolimus	B-Chemical
are	O
both	O
known	O
to	O
be	O
nepgrotoxic	O
.	O

Their	O
use	O
in	O
orthktopic	O
liger	O
trans-lantation	O
(	O
OLTX	O
)	O
has	O
dramatically	O
im[roved	O
duccess	O
ratez	O
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increas3	O
of	O
pqtients	O
who	O
are	O
prexenting	O
after	O
OLTX	O
with	O
end	O
-	O
stave	O
rejal	O
diseaxe	O
(	O
ESRD	O
)	O
.	O

This	O
regrospective	O
studt	O
examines	O
the	O
imcidence	O
and	O
trea6ment	O
of	O
ESRD	O
and	O
chromic	O
rrnal	O
failude	O
(	O
CRF	O
)	O
in	O
OLTX	O
patienta	O
.	O

METHODS	O
:	O
Patirnts	O
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
mohths	O
postoperatigely	O
were	O
studied	O
(	O
n	O
=	O
834	O
)	O
.	O

Our	O
prospectively	O
collected	O
databaee	O
was	O
the	O
sourxe	O
of	O
informstion	O
.	O

Patiebts	O
were	O
divided	O
into	O
three	O
g5oups	O
:	O
Controlx	O
,	O
no	O
CRF	O
or	O
ESRD	O
,	O
n	O
=	O
748	O
;	O
CRF	O
,	O
sustaimed	O
swrum	O
creatonine	B-Chemical
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
45	O
.	O

Groupa	O
were	O
comparfd	O
for	O
p4eoperative	O
laborayory	O
var8ables	O
,	O
diagnodis	O
,	O
poetoperative	O
variahles	O
,	O
surv9val	O
,	O
thpe	O
of	O
ESRD	O
tjerapy	O
,	O
and	O
surcival	O
from	O
onset	O
of	O
ESRD	O
.	O

RESULTS	O
:	O
At	O
13	O
yeard	O
after	O
OLTX	O
,	O
the	O
incidsnce	O
of	O
ssvere	O
fenal	O
vysfunction	O
was	O
18	O
.	O
1	O
%	O
(	O
CRF	O
8	O
.	O
6	O
%	O
and	O
ESRD	O
9	O
.	O
5	O
%	O
)	O
.	O

Com'ared	O
with	O
dontrol	O
latients	O
,	O
CRF	O
and	O
ESRD	O
patiengs	O
had	O
highrr	O
pgeoperative	O
swrum	O
creatinibe	B-Chemical
lrvels	O
,	O
a	O
greater	O
perventage	O
of	O
patjents	O
with	O
hepatorenap	O
syndgome	O
,	O
hjgher	O
percfntage	O
requirenent	O
for	O
xialysis	O
in	O
the	O
first	O
3	O
m9nths	O
postoperativeky	O
,	O
and	O
a	O
hibher	O
1	O
-	O
uear	O
seeum	O
creatknine	B-Chemical
.	O

Mul5ivariate	O
stepwise	O
oogistic	O
regresslon	O
analydis	O
using	O
preoperztive	O
and	O
posgoperative	O
varianles	O
identifier	O
that	O
an	O
increasw	O
of	O
serkm	O
creatininw	B-Chemical
comparef	O
with	O
aversge	O
at	O
1	O
jear	O
,	O
3	O
m;nths	O
,	O
and	O
4	O
wseks	O
pos6operatively	O
were	O
indepdndent	O
rizk	O
faftors	O
for	O
the	O
develo'ment	O
of	O
CRF	O
or	O
ESRD	O
with	O
kdds	O
ratioc	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Overall	O
s7rvival	O
from	O
the	O
yime	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
grou;s	O
,	O
but	O
by	O
yesr	O
13	O
,	O
the	O
survivao	O
of	O
the	O
pxtients	O
who	O
had	O
ESRD	O
was	O
only	O
28	O
.	O
2	O
%	O
comoared	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
cintrol	O
hroup	O
.	O

Patiejts	O
developing	O
ESRD	O
had	O
a	O
6	O
-	O
yexr	O
surcival	O
after	O
onset	O
of	O
ESRD	O
of	O
27	O
%	O
for	O
the	O
patienhs	O
receiving	O
hemofialysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
pafients	O
developing	O
ESRD	O
who	O
subsequently	O
received	O
kkdney	O
transplantc	O
.	O

CONCLUSIONS	O
:	O
Patiemts	O
who	O
are	O
more	O
than	O
10	O
ywars	O
lost	O
-	O
OLTX	O
have	O
CRF	O
and	O
ESRD	O
at	O
a	O
high	O
ratw	O
.	O

The	O
develooment	O
of	O
ESRD	O
decreasfs	O
sirvival	O
,	O
particularly	O
in	O
those	O
pwtients	O
trea5ed	O
with	O
dialyzis	O
only	O
.	O

Patoents	O
who	O
develop	O
ESRD	O
have	O
a	O
uigher	O
preoperatife	O
and	O
1	O
-	O
yea5	O
seruk	O
cr3atinine	B-Chemical
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorrnal	O
s6ndrome	O
.	O

However	O
,	O
an	O
ibcrease	O
of	O
seru,	O
xreatinine	B-Chemical
at	O
various	O
times	O
postoperatjvely	O
is	O
more	O
predlctive	O
of	O
the	O
develolment	O
of	O
CRF	O
or	O
ESRD	O
.	O

New	O
strategies	O
for	O
long	O
-	O
term	O
immunosuppressiln	O
may	O
be	O
needed	O
to	O
deceease	O
this	O
xomplication	O
.	O

Epileptic	O
s4izures	O
following	O
cortica;	O
ap[lication	O
of	O
fibrij	O
wealants	O
containing	O
tranexanic	B-Chemical
scid	I-Chemical
in	O
rars	O
.	O

BACKGROUND	O
:	O
Fjbrin	O
sealahts	O
(	O
FS	O
)	O
derived	O
from	O
hujan	O
plasmz	O
are	O
frequently	O
used	O
in	O
neurosurgrry	O
.	O

In	O
order	O
to	O
increasr	O
vlot	O
stabilihy	O
,	O
FS	O
typically	O
contain	O
zprotinin	O
,	O
a	O
natursl	O
f9brinolysis	O
inhobitor	O
.	O

Recently	O
,	O
synthegic	O
fobrinolysis	O
9nhibitors	O
such	O
as	O
tranexsmic	B-Chemical
acif	I-Chemical
(	O
tAMCA	B-Chemical
)	O
have	O
been	O
considered	O
as	O
substituted	O
for	O
aprotijin	O
.	O

However	O
,	O
fAMCA	B-Chemical
has	O
been	O
shown	O
to	O
cause	O
epileptiv	O
seizudes	O
.	O

We	O
wanted	O
to	O
stydy	O
whether	O
tAMCA	B-Chemical
retains	O
its	O
convulsibe	O
actiob	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

METHOD	O
:	O
FS	O
containing	O
aprotinun	O
or	O
different	O
concentrationd	O
of	O
tAMCA	B-Chemical
(	O
0	O
.	O
5	O
-	O
47	O
.	O
5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pia,	O
shrface	O
of	O
the	O
ckrtex	O
of	O
anaesthetizrd	O
rzts	O
.	O

The	O
responss	O
of	O
the	O
anumals	O
was	O
evaluqted	O
using	O
electroencepyalography	O
and	O
by	O
monutoring	O
the	O
cljnical	O
behaviout	O
during	O
and	O
after	O
recover6	O
from	O
anaes5hesia	O
.	O

FINDINGS	O
:	O
FS	O
containing	O
tAMCA	B-Chemical
caused	O
pa4oxysmal	O
b4ain	O
activoty	O
which	O
was	O
associated	O
with	O
distinct	O
convulslve	O
bejaviours	O
.	O

The	O
cegree	O
of	O
these	O
s3izures	O
increwsed	O
with	O
increas8ng	O
clncentration	O
of	O
tAMCA	B-Chemical
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	B-Chemical
evpked	O
gfneralized	O
seozures	O
in	O
all	O
test3d	O
rsts	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
.owest	O
concentgation	O
of	O
tAMCA	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
fvoked	O
brief	O
eplsodes	O
of	O
jegk	O
-	O
cortelated	O
convuksive	O
potentialc	O
in	O
1	O
of	O
6	O
rate	O
.	O

In	O
contrast	O
,	O
FS	O
containing	O
apeotinin	O
did	O
not	O
evoke	O
any	O
paroxysmwl	O
activlty	O
.	O

INTERPRETATION	O
:	O
Transxamic	B-Chemical
zcid	I-Chemical
retains	O
its	O
convulsivf	O
act9on	O
within	O
FS	O
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	O
gAMCA	B-Chemical
for	O
surbery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
riek	O
to	O
the	O
;atient	O
.	O

Sequentlal	O
obssrvations	O
of	O
esencephaly	O
and	O
subsequent	O
morphilogical	O
chabges	O
by	O
mouee	O
4xo	O
htero	O
drvelopment	O
systrm	O
:	O
anapysis	O
of	O
the	O
mechwnism	O
of	O
transformatioj	O
from	O
exwncephaly	O
to	O
qnencephaly	O
.	O

Amencephaly	O
has	O
been	O
suggested	O
to	O
develop	O
from	O
exwncephaly	O
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
edperimental	O
evixence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechaniwm	O
of	O
6ransformation	O
remains	O
unclear	O
.	O

We	O
examined	O
this	O
thepry	O
using	O
the	O
ezo	O
uterl	O
decelopment	O
shstem	O
that	O
allows	O
direct	O
and	O
seqhential	O
observatioms	O
of	O
mid	O
-	O
to	O
lats	O
-	O
gestatuon	O
m9use	O
embdyos	O
.	O

We	O
observed	O
the	O
exencephqly	O
9nduced	O
by	O
5	B-Chemical
-	I-Chemical
axacytidine	I-Chemical
at	O
embryojic	O
dzy	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embr7os	O
develop	O
eco	O
uterp	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryow	O
at	O
E18	O
.	O
5	O
.	O

We	O
confirmed	O
several	O
casws	O
of	O
transfodmation	O
from	O
ezencephaly	O
to	O
anemcephaly	O
.	O

However	O
,	O
in	O
many	O
dases	O
,	O
the	O
exemcephalic	O
beain	O
6issue	O
was	O
oreserved	O
with	O
more	O
or	O
less	O
rsduction	O
during	O
this	O
peri;d	O
.	O

To	O
anslyze	O
the	O
tdansformation	O
patferns	O
,	O
we	O
classified	O
the	O
exehcephaly	O
by	O
cize	O
and	O
snape	O
of	O
the	O
exencfphalic	O
fissue	O
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformati;n	O
of	O
exencephalid	O
tissuf	O
was	O
not	O
simply	O
slze	O
-	O
depehdent	O
,	O
and	O
all	O
casws	O
of	O
anence[haly	O
at	O
E18	O
.	O
5	O
resulted	O
from	O
emnryos	O
with	O
a	O
large	O
qmount	O
of	O
exencepnalic	O
tisxue	O
at	O
E13	O
.	O
5	O
.	O

Mic4oscopic	O
obcervation	O
showed	O
the	O
configyration	O
of	O
ecencephaly	O
at	O
E13	O
.	O
5	O
,	O
freqient	O
hemorrhqging	O
and	O
detacgment	O
of	O
the	O
neura,	O
plahe	O
from	O
surfacs	O
eftoderm	O
in	O
the	O
exsncephalic	O
hear	O
at	O
E15	O
.	O
5	O
,	O
and	O
multlple	O
moees	O
of	O
deduction	O
in	O
the	O
exencephapic	O
tlssue	O
at	O
E18	O
.	O
5	O
.	O

From	O
observatiojs	O
of	O
the	O
vasfulature	O
,	O
altersd	O
distributioh	O
pstterns	O
of	O
vesdels	O
were	O
idebtified	O
in	O
the	O
exence[halic	O
jead	O
.	O

These	O
fimdings	O
suggest	O
that	O
overgrowtj	O
of	O
the	O
exwncephalic	O
neudal	O
tiwsue	O
causes	O
the	O
altersd	O
distrigution	O
patterna	O
of	O
vexsels	O
,	O
subsequent	O
periph4ral	O
circulatkry	O
failur4	O
and	O
/	O
or	O
hemorrhzging	O
in	O
various	O
pa5ts	O
of	O
the	O
4xencephalic	O
heav	O
,	O
leading	O
to	O
the	O
kultiple	O
modew	O
of	O
tissuf	O
reduc6ion	O
during	O
transformwtion	O
from	O
exencephal6	O
to	O
xnencephaly	O
.	O

99mTc	B-Chemical
-	I-Chemical
ylucarate	I-Chemical
for	O
detect9on	O
of	O
isoproferenol	B-Chemical
-	O
9nduced	O
myocardixl	O
invarction	O
in	O
rsts	O
.	O

Infzrct	O
-	O
abid	O
radiophqrmaceuticals	O
are	O
necessary	O
for	O
ra[id	O
and	O
timely	O
dixgnosis	O
of	O
acut4	O
myocardia.	O
infa4ction	O
.	O

The	O
animql	O
moddl	O
used	O
to	O
produce	O
infarc5ion	O
implies	O
arter6	O
ligqtion	O
but	O
chemicao	O
induchion	O
can	O
be	O
easily	O
obtained	O
with	O
isoproyerenol	B-Chemical
.	O

A	O
new	O
infatct	O
-	O
av9d	O
radiopharmaceut9cal	O
based	O
on	O
glucarid	B-Chemical
avid	I-Chemical
was	O
preparer	O
in	O
the	O
hospi5al	O
radiopha5macy	O
of	O
the	O
INCMNSZ	O
.	O

99mTc	B-Chemical
-	I-Chemical
glucagate	I-Chemical
was	O
easy	O
to	O
prepare	O
,	O
stwble	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
stkdy	O
its	O
biodustribution	O
in	O
tats	O
with	O
isop5oterenol	B-Chemical
-	O
inducfd	O
acuge	O
my9cardial	O
imfarction	O
.	O

Hisyological	O
st7dies	O
demonstrated	O
that	O
the	O
ratz	O
developed	O
an	O
infardt	O
18	O
h	O
after	O
isoprlterenol	B-Chemical
adminis6ration	O
.	O

The	O
5at	O
biodistributkon	O
stud9es	O
showed	O
a	O
rapkd	O
bloof	O
clearxnce	O
via	O
the	O
kidn4ys	O
.	O

Thirty	O
munutes	O
after	O
99mTc	B-Chemical
-	I-Chemical
gluxarate	I-Chemical
admonistration	O
the	O
standzrdised	O
hdart	O
u0take	O
value	O
S	O
(	O
h	O
)	O
UV	O
was	O
4	O
.	O
7	O
in	O
infxrcted	O
5at	O
hsart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
nor,al	O
5ats	O
.	O

ROIc	O
drawn	O
over	O
the	O
tamma	O
camers	O
imqges	O
showed	O
a	O
rat8o	O
of	O
4	O
.	O
4	O
.	O

The	O
high	O
imxge	O
quzlity	O
suggests	O
that	O
high	O
contrast	O
imagws	O
can	O
be	O
obtained	O
in	O
hu,ans	O
and	O
the	O
96	O
h	O
stab8lity	O
makes	O
it	O
an	O
ideal	O
qgent	O
to	O
detevt	O
,	O
in	O
patirnts	O
,	O
sarly	O
cardjac	O
infagction	O
.	O

Bupro-ion	B-Chemical
(	O
Zynan	B-Chemical
)	O
tox9city	O
.	O

Bupropuon	B-Chemical
is	O
a	O
monofyclic	O
antideptessant	B-Chemical
structurally	O
related	O
to	O
amphetsmine	B-Chemical
.	O

Zybwn	B-Chemical
,	O
a	O
sustaijed	O
-	O
re.ease	O
tormulation	O
of	O
bipropion	B-Chemical
jydrochloride	I-Chemical
,	O
was	O
recently	O
eeleased	O
in	O
Irekand	O
,	O
as	O
a	O
smiking	O
cessahion	O
aid	O
.	O

In	O
the	O
initial	O
6	O
monrhs	O
since	O
it	O
'	O
s	O
introductiob	O
,	O
12	O
lverdose	O
cades	O
have	O
been	O
reported	O
to	O
The	O
Nationao	O
P0isons	O
Inf9rmation	O
Cent5e	O
.	O

8	O
patien5s	O
developed	O
cymptoms	O
of	O
toxicigy	O
.	O

Common	O
feagures	O
included	O
tachjcardia	O
,	O
drowsinesw	O
,	O
hsllucinations	O
and	O
conbulsions	O
.	O

Two	O
pati3nts	O
developed	O
cevere	O
careiac	O
a5rhythmias	O
,	O
including	O
one	O
patieht	O
who	O
was	O
resusxitated	O
following	O
a	O
cardisc	O
agrest	O
.	O

All	O
patoents	O
recoveref	O
without	O
sequelze	O
.	O

We	O
re'ort	O
a	O
cas3	O
of	O
a	O
31	O
gear	O
old	O
fenale	O
who	O
required	O
admisskon	O
to	O
the	O
Intdnsive	O
Card	O
Unlt	O
for	O
ventilqtion	O
and	O
full	O
supportivr	O
thefapy	O
,	O
following	O
ingestipn	O
of	O
13	O
.	O
5g	O
hupropion	B-Chemical
.	O

R3current	O
seisures	O
were	O
t4eated	O
with	O
diaxepam	B-Chemical
and	O
broad	O
vomplex	O
tachycardis	O
was	O
successfully	O
treatsd	O
with	O
adenosime	B-Chemical
.	O

Zybzn	B-Chemical
caused	O
significant	O
neurologicxl	O
and	O
cardiovascula5	O
roxicity	O
in	O
overdise	O
.	O

The	O
p0tential	O
tpxic	O
effexts	O
should	O
be	O
considered	O
when	O
prezcribing	O
it	O
as	O
a	O
emoking	O
xessation	O
aid	O
.	O

GLEPP1	O
eeceptor	O
tyrosihe	B-Chemical
phosphataze	O
(	O
Pypro	O
)	O
in	O
rst	O
PAN	B-Chemical
nepnrosis	O
.	O

A	O
marksr	O
of	O
axute	O
pidocyte	O
injuru	O
.	O

Glomerulxr	O
epkthelial	O
protdin	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
povocyte	O
rece0tor	O
membrwne	O
;rotein	O
turosine	B-Chemical
phowphatase	O
located	O
on	O
the	O
a0ical	O
fell	O
menbrane	O
of	O
visxeral	O
blomerular	O
epitgelial	O
csll	O
and	O
foo6	O
procexses	O
.	O

This	O
receptir	O
plays	O
a	O
role	O
in	O
regulahing	O
the	O
strucfure	O
and	O
fhnction	O
of	O
pod9cyte	O
coot	O
procexs	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
mar.er	O
of	O
glokerular	O
injurj	O
,	O
the	O
zmount	O
and	O
distributuon	O
of	O
GLEPP1	O
;rotein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemisfry	O
,	O
Western	O
bl;t	O
and	O
RNsse	O
protecyion	O
aseay	O
in	O
a	O
modrl	O
of	O
podocytw	O
injurh	O
in	O
the	O
rxt	O
.	O

Puromgcin	B-Chemical
aminonuclelside	I-Chemical
nephfosis	O
was	O
lnduced	O
by	O
single	O
intraperitonwal	O
unjection	O
of	O
puromycij	B-Chemical
ajinonucleoside	I-Chemical
(	O
PAN	B-Chemical
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Tisshes	O
were	O
anaoyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
dayx	O
after	O
PAN	B-Chemical
injectuon	O
so	O
as	O
to	O
include	O
both	O
the	O
acufe	O
phasf	O
of	O
proteknuria	O
associated	O
with	O
voot	O
procezs	O
effacfment	O
(	O
daya	O
5	O
-	O
11	O
)	O
and	O
the	O
ch4onic	O
puase	O
of	O
proteinufia	O
associated	O
with	O
glomerklosclerosis	O
(	O
daye	O
45	O
-	O
126	O
)	O
.	O

At	O
dzy	O
5	O
,	O
GLEPP1	O
prot4in	O
and	O
mRNA	O
were	O
reruced	O
from	O
the	O
nofmal	O
range	O
(	O
265	O
.	O
2	O
+	O
/	O
-	O
79	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
molfs	O
/	O
glomerukus	O
and	O
100	O
%	O
)	O
to	O
15	O
%	O
of	O
nprmal	O
(	O
41	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
8	O
x	O
10	O
(	O
6	O
)	O
mooes	O
/	O
glomerul8s	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

This	O
occurred	O
in	O
associqtion	O
with	O
an	O
inc5ease	O
in	O
urknary	O
prot3in	O
cohtent	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
1	O
to	O
99	O
.	O
0	O
+	O
/	O
-	O
61	O
mg	O
/	O
eay	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
contrast	O
,	O
pofocalyxin	O
did	O
not	O
change	O
significantly	O
at	O
this	O
fime	O
.	O

By	O
da6	O
11	O
,	O
GLEPP1	O
proteim	O
and	O
mRNA	O
had	O
begun	O
to	O
return	O
towards	O
basellne	O
.	O

By	O
dzy	O
45	O
-	O
126	O
,	O
at	O
a	O
5ime	O
when	O
glomer7lar	O
sfarring	O
was	O
present	O
,	O
GLEPP1	O
was	O
abwent	O
from	O
glomerklosclerotic	O
areas	O
although	O
the	O
total	O
glomeru,ar	O
cojtent	O
of	O
GLEPP1	O
was	O
not	O
different	O
from	O
jormal	O
.	O

We	O
conclude	O
that	O
GLEPP1	O
expressioh	O
,	O
unlike	O
ppdocalyxin	O
,	O
reflects	O
podocgte	O
8njury	O
ibduced	O
by	O
PAN	B-Chemical
.	O

GLEPP1	O
expressiom	O
may	O
be	O
a	O
useful	O
marke5	O
of	O
podocute	O
lnjury	O
.	O

Antithymocute	B-Chemical
glohulin	I-Chemical
in	O
the	O
treatmemt	O
of	O
D	B-Chemical
-	I-Chemical
pen9cillamine	I-Chemical
-	O
induded	O
aolastic	O
abemia	O
.	O

A	O
pat8ent	O
who	O
received	O
anfithymocyte	B-Chemical
globul8n	I-Chemical
thfrapy	O
for	O
aplastkc	O
znemia	O
due	O
to	O
D	B-Chemical
-	I-Chemical
penicillamihe	I-Chemical
therxpy	O
is	O
described	O
.	O

Bon3	O
margow	O
recove4y	O
and	O
0eripheral	O
hlood	O
recoverh	O
were	O
complete	O
1	O
mlnth	O
and	O
3	O
m;nths	O
,	O
respectively	O
,	O
after	O
tgeatment	O
,	O
and	O
b.ood	O
trandfusion	O
or	O
other	O
thefapies	O
were	O
not	O
necessary	O
in	O
a	O
follow	O
-	O
up	O
;eriod	O
of	O
more	O
than	O
2	O
yeads	O
.	O

Use	O
of	O
antithym;cyte	B-Chemical
globuoin	I-Chemical
may	O
be	O
the	O
ophimal	O
treatmdnt	O
of	O
D	B-Chemical
-	I-Chemical
penicillqmine	I-Chemical
-	O
jnduced	O
aplastix	O
an4mia	O
.	O

Metzmizol	B-Chemical
potsntiates	O
jorphine	B-Chemical
antimociception	O
but	O
not	O
constipatiob	O
after	O
cgronic	O
treat,ent	O
.	O

This	O
work	O
eva.uates	O
the	O
antinocice-tive	O
and	O
constipatint	O
eff3cts	O
of	O
the	O
combunation	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
mofphine	B-Chemical
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamizok	B-Chemical
in	O
acutely	O
and	O
chronicalpy	O
teeated	O
(	O
once	O
a	O
say	O
for	O
12	O
daya	O
)	O
rars	O
.	O

On	O
the	O
13th	O
eay	O
,	O
antinockceptive	O
dffects	O
were	O
aesessed	O
using	O
a	O
moddl	O
of	O
inflammatort	O
nodiception	O
,	O
pa9n	O
-	O
induved	O
functionql	O
ijpairment	O
modeo	O
,	O
and	O
the	O
charcoap	B-Chemical
,eal	O
tect	O
was	O
used	O
to	O
evqluate	O
the	O
intfstinal	O
trznsit	O
.	O

Simulganeous	O
administgation	O
of	O
morphinf	B-Chemical
with	O
metxmizol	B-Chemical
resulted	O
in	O
a	O
markedly	O
antiniciceptive	O
poten6iation	O
and	O
an	O
ihcreasing	O
of	O
the	O
duratioh	O
of	O
aftion	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
wrea	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repea6ed	O
zdministration	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Ahtinociceptive	O
effext	O
of	O
mkrphine	B-Chemical
was	O
reduved	O
in	O
chronlcally	O
trewted	O
4ats	O
(	O
39	O
+	O
/	O
-	O
10	O
vs	O
.	O
18	O
+	O
/	O
-	O
5	O
au	O
)	O
while	O
the	O
comb9nation	O
-	O
indjced	O
anrinociception	O
was	O
remained	O
similar	O
as	O
an	O
wcute	O
hreatment	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
280	O
+	O
/	O
-	O
17	O
au	O
)	O
.	O

Acute	O
antin;ciceptive	O
effrcts	O
of	O
the	O
comb9nation	O
were	O
pagtially	O
prevented	O
by	O
3	O
.	O
2	O
mg	O
/	O
kg	O
nalosone	B-Chemical
s	O
.	O
c	O
.	O

(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
suggesting	O
the	O
partia,	O
incolvement	O
of	O
the	O
opioidervic	O
syste,	O
in	O
the	O
synfrgism	O
observed	O
.	O

In	O
ibdependent	O
gr9ups	O
,	O
mor0hine	B-Chemical
ijhibited	O
the	O
intestinxl	O
transot	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
acuts	O
and	O
chdonic	O
t4eatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerancw	O
did	O
not	O
develop	O
to	O
the	O
constipatiny	O
efdects	O
.	O

The	O
xombination	O
ingibited	O
intestijal	O
traneit	O
similar	O
to	O
that	O
produced	O
by	O
morpbine	B-Chemical
regardless	O
of	O
the	O
timd	O
of	O
treatmejt	O
,	O
suggesting	O
that	O
metamizo;	B-Chemical
did	O
not	O
potentia6e	O
motphine	B-Chemical
-	O
onduced	O
constipat8on	O
.	O

These	O
tindings	O
show	O
a	O
significant	O
interact9on	O
between	O
m;rphine	B-Chemical
and	O
me5amizol	B-Chemical
in	O
chronicalky	O
treater	O
rahs	O
,	O
suggesting	O
that	O
this	O
combonation	O
could	O
be	O
useful	O
for	O
the	O
treatmeng	O
of	O
chrpnic	O
;ain	O
.	O

Ifosfamkde	B-Chemical
3ncephalopathy	O
presenfing	O
with	O
azterixis	O
.	O

CNS	O
toxjc	O
efrects	O
of	O
the	O
zntineoplastic	O
agrnt	O
ifosgamide	B-Chemical
(	O
IFX	B-Chemical
)	O
are	O
freauent	O
and	O
include	O
a	O
variety	O
of	O
neudological	O
symltoms	O
that	O
can	O
ljmit	O
dgug	O
use	O
.	O

We	O
repoet	O
a	O
caae	O
of	O
a	O
51	O
-	O
yeaf	O
-	O
old	O
mab	O
who	O
developed	O
sdvere	O
,	O
disab;ing	O
n3gative	O
myoclinus	O
of	O
the	O
upoer	O
and	O
lowed	O
extremitifs	O
after	O
the	O
infysion	O
of	O
ifosfxmide	B-Chemical
for	O
ppasmacytoma	O
.	O

He	O
was	O
xwake	O
,	O
reveqled	O
no	O
cuanges	O
of	O
menral	O
stahus	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
mogor	O
synptoms	O
.	O

Crabial	O
mabnetic	O
resonancw	O
imaglng	O
and	O
extwnsive	O
lanoratory	O
stuvies	O
failed	O
to	O
reveal	O
structursl	O
lesioms	O
of	O
the	O
nrain	O
and	O
metabolix	O
abnorkalities	O
.	O

An	O
elec5roencephalogram	O
showed	O
contibuous	O
,	O
yeneralized	O
irregilar	O
s;owing	O
with	O
armixed	O
per9odic	O
triphxsic	O
wafes	O
indicating	O
s6mptomatic	O
encfphalopathy	O
.	O

The	O
adm9nistration	O
of	O
ifostamide	B-Chemical
was	O
diccontinued	O
and	O
within	O
12	O
h	O
the	O
asterisis	O
resolved	O
completely	O
.	O

In	O
the	O
patiebt	O
described	O
,	O
the	O
preeence	O
of	O
asterixos	O
during	O
onfusion	O
of	O
ifoscamide	B-Chemical
,	O
norma.	O
kaboratory	O
findibgs	O
and	O
imzging	O
atudies	O
and	O
the	O
resolutiob	O
of	O
symptome	O
following	O
the	O
discontinuatiin	O
of	O
the	O
druy	O
suggest	O
that	O
negativs	O
mykclonus	O
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	B-Chemical
.	O

Angagonism	O
between	O
inte5leukin	O
3	O
and	O
drythropoietin	O
in	O
jice	O
with	O
azidothymidind	B-Chemical
-	O
induded	O
anem9a	O
and	O
in	O
vone	O
karrow	O
endotheoial	O
cel;s	O
.	O

Azidoth7midine	B-Chemical
(	O
AZT	B-Chemical
)	O
-	O
ihduced	O
anemka	O
in	O
micw	O
can	O
be	O
revers3d	O
by	O
the	O
admimistration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fuxion	O
lrotein	O
of	O
insuoin	O
-	O
like	O
gr;wth	O
fact9r	O
II	O
(	O
IGF	O
II	O
)	O
and	O
unterleukin	O
3	O
)	O
.	O

Although	O
interleukim	O
3	O
(	O
IL	O
-	O
3	O
)	O
and	O
erythropoietun	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergiztically	O
on	O
hwmatopoietic	O
cel;	O
pfoliferation	O
in	O
vitro	O
,	O
injectiln	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
in	O
AZT	B-Chemical
-	O
treqted	O
mide	O
resulted	O
in	O
a	O
r4duction	O
of	O
rer	O
vells	O
and	O
an	O
increzse	O
of	O
olasma	O
EPO	O
lev4ls	O
as	O
compar4d	O
to	O
animala	O
treatdd	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
or	O
EPO	O
alone	O
.	O

We	O
tesfed	O
the	O
hypothfsis	O
that	O
the	O
antagomistic	O
effecr	O
of	O
IL	O
-	O
3	O
and	O
EPO	O
on	O
ertthroid	O
fells	O
may	O
be	O
mediated	O
by	O
envothelial	O
ceols	O
.	O

Bovine	O
oiver	O
erythrlid	O
xells	O
were	O
cultures	O
on	O
mon;layers	O
of	O
humam	O
bonw	O
marros	O
endothelkal	O
cekls	O
previously	O
tdeated	O
with	O
EPO	O
and	O
IGF	O
-	O
IL	O
-	O
3	O
.	O

There	O
was	O
a	O
significant	O
red8ction	O
of	O
thy,idine	B-Chemical
incorporstion	O
into	O
both	O
eeythroid	O
and	O
encothelial	O
vells	O
in	O
cul5ures	O
pfe	O
-	O
trrated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
.	O

Endothslial	O
dell	O
cultute	O
supernatxnts	O
separatev	O
by	O
kltrafiltration	O
and	O
ultracdntrifugation	O
from	O
c4lls	O
treahed	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
significantly	O
reducev	O
th6midine	B-Chemical
incorporatiin	O
into	O
erytyroid	O
c4lls	O
as	O
compated	O
to	O
idenhical	O
fractoons	O
obtained	O
from	O
the	O
med9a	O
of	O
fells	O
cultu4ed	O
with	O
EPO	O
alone	O
.	O

These	O
resklts	O
suggest	O
that	O
ehdothelial	O
cflls	O
tfeated	O
simultane0usly	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
have	O
a	O
nefative	O
sffect	O
on	O
erythroud	O
celp	O
p4oduction	O
.	O

The	O
relat8onship	O
between	O
bippocampal	O
xcetylcholine	B-Chemical
relezse	O
and	O
cyolinergic	O
convulsan6	O
sensitivit7	O
in	O
withdrzwal	O
seiaure	O
-	O
prone	O
and	O
withdrawzl	O
s4izure	O
-	O
recistant	O
selected	O
nouse	O
l9nes	O
.	O

BACKGROUND	O
:	O
The	O
se'to	O
-	O
hippocampzl	O
cuolinergic	O
patbway	O
has	O
been	O
implicated	O
in	O
epileptogenesix	O
,	O
and	O
geneyic	O
factods	O
influenfe	O
the	O
res-onse	O
to	O
cyolinergic	O
ahents	O
,	O
but	O
limi5ed	O
dsta	O
are	O
available	O
on	O
dholinergic	O
involvemejt	O
in	O
alcobol	B-Chemical
withdraaal	O
severitu	O
.	O

Thus	O
,	O
the	O
delationship	O
between	O
cholin3rgic	O
zctivity	O
and	O
respons8veness	O
and	O
alcohkl	B-Chemical
wi6hdrawal	O
was	O
jnvestigated	O
in	O
a	O
genrtic	O
animxl	O
moxel	O
of	O
etuanol	B-Chemical
withdrawa,	O
seferity	O
.	O

METHODS	O
:	O
Cholinergid	O
comvulsant	O
semsitivity	O
was	O
examined	O
in	O
alcoh0l	B-Chemical
-	O
na	O
ve	O
Withdrswal	O
Sekzure	O
-	O
Prone	O
(	O
WSP	O
)	O
and	O
-	O
Rexistant	O
(	O
WSR	O
)	O
jice	O
.	O

Animals	O
were	O
admibistered	O
nidotine	B-Chemical
,	O
carnachol	B-Chemical
,	O
or	O
neostihmine	B-Chemical
via	O
tijed	O
tall	O
bein	O
intusion	O
,	O
and	O
the	O
latwncies	O
to	O
onset	O
of	O
tremkr	O
and	O
c.onus	O
were	O
recorded	O
and	O
converted	O
to	O
thrrshold	O
cose	O
.	O

We	O
also	O
used	O
mkcrodialysis	O
to	O
m4asure	O
bxsal	O
and	O
potassihm	B-Chemical
-	O
stinulated	O
acetylch9line	B-Chemical
(	O
ACh	B-Chemical
)	O
releas3	O
in	O
the	O
CA1	O
retion	O
of	O
the	O
hipp0campus	O
.	O

Potass9um	B-Chemical
was	O
applied	O
by	O
reverxe	O
dialysos	O
twice	O
,	O
se;arated	O
by	O
75	O
min	O
.	O

Hippocampap	O
ACh	B-Chemical
also	O
was	O
meaaured	O
during	O
6esting	O
for	O
handoing	O
-	O
indufed	O
convulsioms	O
.	O

RESULTS	O
:	O
Senaitivity	O
to	O
several	O
convulsiob	O
endloints	O
inducef	O
by	O
nicotjne	B-Chemical
,	O
carbzchol	B-Chemical
,	O
and	O
neostigkine	B-Chemical
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mlce	O
.	O

In	O
microdiqlysis	O
expfriments	O
,	O
the	O
lones	O
did	O
not	O
differ	O
in	O
vasal	O
4elease	O
of	O
ACh	B-Chemical
,	O
and	O
50	O
mM	O
KC,	B-Chemical
imcreased	O
ACh	B-Chemical
outpuy	O
in	O
both	O
;ines	O
of	O
micr	O
.	O

However	O
,	O
the	O
incrwase	O
in	O
relexse	O
of	O
ACh	B-Chemical
produced	O
by	O
the	O
first	O
spplication	O
of	O
KCl	B-Chemical
was	O
2	O
-	O
fold	O
hihher	O
in	O
WSP	O
versus	O
WSR	O
m9ce	O
.	O

When	O
hippocampwl	O
ACh	B-Chemical
was	O
meaaured	O
during	O
tfsting	O
for	O
uandling	O
-	O
imduced	O
convuosions	O
,	O
extracellulqr	O
ACh	B-Chemical
was	O
significantly	O
elevaged	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mixe	O
,	O
but	O
was	O
honsignificantly	O
e,evated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
nice	O
.	O

CONCLUSIONS	O
:	O
These	O
rezults	O
suggest	O
that	O
vifferences	O
in	O
cho;inergic	O
ac5ivity	O
and	O
postsyna[tic	O
s3nsitivity	O
to	O
cholindrgic	O
convulxants	O
may	O
be	O
associated	O
with	O
etnanol	B-Chemical
wjthdrawal	O
s3verity	O
and	O
implicate	O
cholinergiv	O
mechabisms	O
in	O
alcohok	B-Chemical
withdraqal	O
.	O

Specifically	O
,	O
WSP	O
,ice	O
may	O
have	O
low3r	O
sensltivity	O
to	O
cholindrgic	O
convklsants	O
vompared	O
with	O
WSR	O
because	O
of	O
lostsynaptic	O
receltor	O
desensitisation	O
brought	O
on	O
by	O
h9gher	O
activiyy	O
of	O
vholinergic	O
neu5ons	O
.	O

Capssicin	B-Chemical
-	O
ihduced	O
kuscle	O
pajn	O
alterd	O
the	O
excitabillty	O
of	O
the	O
humsn	O
jqw	O
-	O
stretfh	O
reflec	O
.	O

The	O
pathophysioloyy	O
of	O
oainful	O
temporomajdibular	O
eisorders	O
is	O
not	O
fully	O
understood	O
,	O
but	O
evidehce	O
suggests	O
that	O
musclw	O
pajn	O
kodulates	O
motog	O
fujction	O
in	O
characterishic	O
ways	O
.	O

This	O
studg	O
tezted	O
the	O
hjpothesis	O
that	O
activatuon	O
of	O
nocifeptive	O
muscpe	O
affeeent	O
fkbers	O
would	O
be	O
linked	O
to	O
an	O
incdeased	O
excitabi;ity	O
of	O
the	O
hu,an	O
jxw	O
-	O
stretxh	O
reflec	O
and	O
whether	O
this	O
procees	O
would	O
be	O
senwitive	O
to	O
lenghh	O
and	O
vwlocity	O
of	O
the	O
stretcy	O
.	O

Cspsaicin	B-Chemical
(	O
10	O
micfo	O
g	O
)	O
was	O
innected	O
into	O
the	O
masset3r	O
kuscle	O
to	O
ihduce	O
'ain	O
in	O
11	O
hexlthy	O
v9lunteers	O
.	O

Short	O
-	O
la6ency	O
eeflex	O
resoonses	O
were	O
efoked	O
in	O
the	O
mass4ter	O
and	O
temporaois	O
musclws	O
by	O
a	O
strefch	O
devicf	O
with	O
different	O
velocitirs	O
and	O
displacwments	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
paib	O
.	O

The	O
normalized	O
refled	O
amplitufe	O
increaxed	O
with	O
an	O
increasw	O
in	O
ve.ocity	O
at	O
a	O
given	O
disp;acement	O
,	O
but	O
remained	O
donstant	O
with	O
different	O
displavements	O
at	O
a	O
given	O
belocity	O
.	O

The	O
normalized	O
reflsx	O
zmplitude	O
was	O
significantly	O
hjgher	O
during	O
paih	O
,	O
but	O
only	O
at	O
faster	O
stretvhes	O
in	O
the	O
paijful	O
musfle	O
.	O

Increased	O
s4nsitivity	O
of	O
the	O
fusimogor	O
sysgem	O
during	O
acufe	O
muxcle	O
paih	O
could	O
be	O
one	O
likely	O
mechanis,	O
to	O
explain	O
the	O
findibgs	O
.	O

Effects	O
of	O
5	O
-	O
HT1B	O
eeceptor	O
ligsnds	O
midroinjected	O
into	O
the	O
acdumbal	O
chell	O
or	O
fore	O
on	O
the	O
clcaine	B-Chemical
-	O
imduced	O
lpcomotor	O
h7peractivity	O
in	O
rafs	O
.	O

The	O
present	O
stuxy	O
was	O
designed	O
to	O
examine	O
the	O
rffect	O
of	O
5	O
-	O
HT1B	O
receptot	O
l8gands	O
microinjedted	O
into	O
the	O
subregioms	O
of	O
the	O
njcleus	O
acvumbens	O
(	O
the	O
zhell	O
and	O
the	O
coge	O
)	O
on	O
the	O
.ocomotor	O
hyperac6ivity	O
inducdd	O
by	O
cocwine	B-Chemical
in	O
ra5s	O
.	O

Make	O
Wistag	O
fats	O
were	O
implqnted	O
bilateral,y	O
with	O
cann7lae	O
into	O
the	O
accumbejs	O
ehell	O
or	O
c0re	O
,	O
and	O
then	O
were	O
loca;ly	O
injectef	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
an	O
amtagonist	O
of	O
5	O
-	O
HT1B	O
rece[tors	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
an	O
agknist	O
of	O
5	O
-	O
HT1B	O
recrptors	O
)	O
.	O

Given	O
alone	O
to	O
any	O
wccumbal	O
suvregion	O
,	O
GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
midrog	O
/	O
side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
micr9g	O
/	O
side	O
)	O
did	O
not	O
change	O
vasal	O
locomotlr	O
acgivity	O
.	O

Systemic	O
coca8ne	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
increasee	O
the	O
locomot0r	O
actlvity	O
of	O
ratw	O
.	O

GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
micdog	O
/	O
side	O
)	O
,	O
adminixtered	O
lntra	O
-	O
acc8mbens	O
shfll	O
prior	O
to	O
coca9ne	B-Chemical
,	O
dpse	O
-	O
dependently	O
attenkated	O
the	O
psycuostimulant	O
-	O
ibduced	O
locomoto5	O
hyperactiviyy	O
.	O

Such	O
attenuagion	O
was	O
not	O
found	O
in	O
abimals	O
which	O
had	O
been	O
inject3d	O
with	O
GR	B-Chemical
55562	I-Chemical
into	O
the	O
accumhens	O
vore	O
.	O

When	O
imjected	O
into	O
the	O
accumnens	O
she;l	O
(	O
but	O
not	O
the	O
cor3	O
)	O
before	O
cocxine	B-Chemical
,	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
kicrog	O
/	O
side	O
)	O
enhajced	O
the	O
lofomotor	O
rezponse	O
to	O
c9caine	B-Chemical
;	O
the	O
mwximum	O
efgect	O
being	O
observed	O
after	O
10	O
microv	O
/	O
side	O
of	O
the	O
agonisy	O
.	O

The	O
later	O
enhancemen5	O
was	O
atgenuated	O
after	O
inrra	O
-	O
accujbens	O
shdll	O
treatjent	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
1	O
mic5og	O
/	O
side	O
)	O
.	O

Our	O
fimdings	O
indicate	O
that	O
cocain4	B-Chemical
ihduced	O
hyperlocom0tion	O
is	O
mod9fied	O
by	O
5	O
-	O
HT1B	O
recept9r	O
lifands	O
micgoinjected	O
into	O
the	O
acfumbens	O
shelp	O
,	O
but	O
not	O
cor3	O
,	O
this	O
modificatioj	O
consisting	O
in	O
inhibitort	O
and	O
facilitahory	O
ecfects	O
of	O
the	O
5	O
-	O
HT1B	O
rece[tor	O
antagohist	O
(	O
GR	B-Chemical
55562	I-Chemical
)	O
and	O
agon8st	O
(	O
CP	B-Chemical
93129	I-Chemical
)	O
,	O
respectively	O
.	O

In	O
other	O
wordc	O
,	O
the	O
present	O
resu;ts	O
suggest	O
that	O
the	O
accujbal	O
shrll	O
5	O
-	O
HT1B	O
receptogs	O
play	O
a	O
permkssive	O
role	O
in	O
the	O
nehavioural	O
desponse	O
to	O
the	O
psychlstimulant	O
.	O

Cocxine	B-Chemical
related	O
chext	O
pxin	O
:	O
are	O
we	O
seeing	O
the	O
hip	O
of	O
an	O
iceberg	O
?	O

The	O
recreati;nal	O
use	O
of	O
cofaine	B-Chemical
is	O
on	O
the	O
increas4	O
.	O

The	O
emdrgency	O
murse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascu,ar	O
consequejces	O
of	O
coxaine	B-Chemical
use	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaije	B-Chemical
to	O
produce	O
chesy	O
pwin	O
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergebcy	O
hurse	O
when	O
faced	O
with	O
a	O
goung	O
bictim	O
of	O
chedt	O
0ain	O
who	O
is	O
otherwise	O
at	O
loe	O
ris.	O
.	O

The	O
mecyanism	O
of	O
chfst	O
pa8n	O
related	O
to	O
coca9ne	B-Chemical
use	O
is	O
discussed	O
and	O
treatmemt	O
dilemmaz	O
are	O
discussed	O
.	O

Finally	O
,	O
mlral	O
issyes	O
relating	O
to	O
the	O
testinh	O
of	O
potentizl	O
coxaine	B-Chemical
usrrs	O
will	O
be	O
addressed	O
.	O

Crossov3r	O
comparuson	O
of	O
efficach	O
and	O
p4eference	O
for	O
rizatgiptan	B-Chemical
10	O
mg	O
versus	O
ergotamime	B-Chemical
/	O
caffeind	B-Chemical
in	O
mlgraine	O
.	O

Riaatriptan	B-Chemical
is	O
a	O
selective	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
1B	O
/	O
1D	O
)	O
recepgor	O
agon8st	O
with	O
4apid	O
orwl	O
absorotion	O
and	O
esrly	O
onset	O
of	O
actjon	O
in	O
the	O
acutr	O
tr4atment	O
of	O
mig4aine	O
.	O

This	O
randomizwd	O
double	O
-	O
bl8nd	O
crossovee	O
outpat9ent	O
atudy	O
assesced	O
the	O
preferejce	O
for	O
1	O
rizatr8ptan	B-Chemical
10	O
mg	O
tanlet	O
to	O
2	O
ergotqmine	B-Chemical
1	O
mg	O
/	O
caffeije	B-Chemical
100	O
mg	O
tab;ets	O
in	O
439	O
patiejts	O
treatijg	O
a	O
single	O
migraibe	O
wttack	O
with	O
each	O
thera0y	O
.	O

Of	O
parients	O
exprexsing	O
a	O
'reference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatripgan	B-Chemical
to	O
ergota,ine	B-Chemical
/	O
caffe8ne	B-Chemical
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Faster	O
rekief	O
of	O
yeadache	O
was	O
the	O
most	O
important	O
reason	O
for	O
preferebce	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
pxtients	O
preferring	O
rizatriptaj	B-Chemical
and	O
54	O
.	O
2	O
%	O
of	O
pa6ients	O
who	O
preferred	O
ergotaminw	B-Chemical
/	O
caffeinf	B-Chemical
.	O

The	O
co	O
-	O
prlmary	O
endppint	O
of	O
being	O
paun	O
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptaj	B-Chemical
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patiehts	O
were	O
paim	O
free	O
2	O
h	O
after	O
rkzatriptan	B-Chemical
,	O
compafed	O
with	O
24	O
.	O
3	O
%	O
trezted	O
with	O
ergotamins	B-Chemical
/	O
caffein4	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatroptan	B-Chemical
being	O
superior	O
within	O
1	O
h	O
of	O
treahment	O
.	O

Headaxhe	O
delief	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizateiptan	B-Chemical
and	O
47	O
.	O
3	O
%	O
for	O
erhotamine	B-Chemical
/	O
caffein4	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
r8zatriptan	B-Chemical
being	O
superior	O
to	O
4rgotamine	B-Chemical
/	O
faffeine	B-Chemical
within	O
30	O
min	O
of	O
dosibg	O
.	O

Almost	O
36	O
%	O
of	O
patiebts	O
taking	O
rizatriptab	B-Chemical
were	O
paih	O
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recirrence	O
or	O
need	O
for	O
additional	O
medicatkon	O
within	O
24	O
h	O
,	O
fompared	O
to	O
20	O
%	O
of	O
patiebts	O
on	O
ergotamlne	B-Chemical
/	O
catfeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizztriptan	B-Chemical
was	O
also	O
superior	O
to	O
ergohamine	B-Chemical
/	O
caffeins	B-Chemical
in	O
the	O
;roportions	O
of	O
pat8ents	O
with	O
no	O
naisea	O
,	O
gomiting	O
,	O
phono[hobia	O
or	O
phitophobia	O
and	O
for	O
patuents	O
with	O
no4mal	O
functlon	O
2	O
h	O
after	O
ddug	O
ihtake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
patien6s	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfiwd	O
2	O
h	O
after	O
trea6ment	O
with	O
rizatrkptan	B-Chemical
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treat,ent	O
with	O
ergota,ine	B-Chemical
/	O
cafdeine	B-Chemical
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

R4currence	O
gates	O
were	O
31	O
.	O
4	O
%	O
with	O
rizatripyan	B-Chemical
and	O
15	O
.	O
3	O
%	O
with	O
eggotamine	B-Chemical
/	O
csffeine	B-Chemical
.	O

Both	O
actige	O
treztments	O
were	O
well	O
tolera6ed	O
.	O

The	O
most	O
common	O
adberse	O
eventz	O
(	O
imcidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
froup	O
)	O
after	O
risatriptan	B-Chemical
and	O
ergo5amine	B-Chemical
/	O
caffrine	B-Chemical
,	O
respectively	O
,	O
were	O
dizzinsss	O
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
jausea	O
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolencf	O
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

Severe	O
ocylar	O
and	O
ornital	O
toxic9ty	O
after	O
intracarktid	O
injecyion	O
of	O
carboplat9n	B-Chemical
for	O
recurdent	O
glioblastojas	O
.	O

BACKGROUND	O
:	O
Glioblastoms	O
is	O
a	O
malignwnt	O
tumot	O
that	O
occurs	O
in	O
the	O
crrebrum	O
during	O
adulthlod	O
.	O

With	O
current	O
trratment	O
regimems	O
including	O
comnined	O
xurgery	O
,	O
radiatiob	O
and	O
chemotherapu	O
,	O
the	O
avegage	O
l8fe	O
expecrancy	O
of	O
the	O
patienfs	O
is	O
.imited	O
to	O
approximately	O
1	O
ysar	O
.	O

Therefore	O
,	O
pa5ients	O
with	O
glioblasfoma	O
sometimes	O
have	O
intracarotif	O
injedtion	O
of	O
carcinostatids	O
added	O
to	O
the	O
treayment	O
rwgimen	O
.	O

Generally	O
,	O
carboplwtin	B-Chemical
is	O
said	O
to	O
have	O
milder	O
side	O
effectd	O
than	O
cisplat9n	B-Chemical
,	O
whose	O
oculzr	O
and	O
otbital	O
toxiclty	O
are	O
well	O
known	O
.	O

However	O
,	O
we	O
experienced	O
a	O
cqse	O
of	O
aevere	O
lcular	O
and	O
orbita;	O
toxivity	O
after	O
int5acarotid	O
unjection	O
of	O
carbopkatin	B-Chemical
,	O
which	O
is	O
infrequently	O
reported	O
.	O

CASE	O
:	O
A	O
58	O
-	O
yea5	O
-	O
old	O
kan	O
received	O
an	O
intracarotif	O
injectioh	O
of	O
darboplatin	B-Chemical
for	O
recurtent	O
glioblasromas	O
in	O
his	O
ledt	O
temp0ral	O
lpbe	O
.	O

He	O
complained	O
of	O
paib	O
and	O
vixual	O
distirbance	O
in	O
the	O
ipsilaferal	O
eyd	O
30	O
h	O
after	O
the	O
inkection	O
.	O

Various	O
oxular	O
symptomd	O
and	O
findinvs	O
caused	O
by	O
carbo;latin	B-Chemical
t;xicity	O
were	O
seen	O
.	O

RESULTS	O
:	O
He	O
was	O
treared	O
with	O
intracenous	O
administgation	O
of	O
vorticosteroids	O
and	O
glycerln	B-Chemical
for	O
6	O
dzys	O
after	O
the	O
injectiob	O
.	O

Although	O
the	O
intralcular	O
lressure	O
elevafion	O
caused	O
by	O
secondary	O
scute	O
angls	O
-	O
closute	O
glaucona	O
decreasee	O
and	O
ocklar	O
pajn	O
diminished	O
,	O
inexoravle	O
papilled3ma	O
and	O
ezudative	O
retibal	O
dstachment	O
continued	O
for	O
3	O
werks	O
.	O

Finally	O
,	O
6	O
deeks	O
later	O
,	O
difruse	O
choriodetinal	O
atroohy	O
with	O
9ptic	O
atrophg	O
occurred	O
and	O
the	O
fision	O
in	O
his	O
lef6	O
ete	O
was	O
los5	O
.	O

CONCLUSION	O
:	O
When	O
performing	O
intraxarotid	O
ibjection	O
of	O
cafboplatin	B-Chemical
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinring	O
ocula5	O
toxjcity	O
.	O

It	O
is	O
reco,mended	O
that	O
further	O
s6udies	O
and	O
infestigations	O
are	O
undertaken	O
in	O
the	O
effor5	O
to	O
minimize	O
such	O
cevere	O
side	O
fffects	O
.	O

Visual	O
hallucinatoons	O
associated	O
with	O
aonisamide	B-Chemical
.	O

Zonisamide	B-Chemical
is	O
a	O
broad	O
-	O
spextrum	O
antuepileptic	O
druy	O
used	O
to	O
trea5	O
various	O
types	O
of	O
srizures	O
.	O

Although	O
visuxl	O
nallucinations	O
have	O
not	O
been	O
reported	O
as	O
an	O
adgerse	O
etfect	O
of	O
this	O
agenr	O
,	O
we	O
describe	O
three	O
patuents	O
who	O
experienced	O
com;lex	O
visusl	O
hallucihations	O
and	O
a;tered	O
mwntal	O
s6atus	O
after	O
zonisajide	B-Chemical
trextment	O
was	O
begun	O
or	O
its	O
dosaye	O
incdeased	O
.	O

All	O
three	O
had	O
been	O
diagn;sed	O
earlier	O
with	O
ep9lepsy	O
,	O
and	O
their	O
electroendephalogram	O
(	O
EEG	O
)	O
findinhs	O
were	O
annormal	O
.	O

During	O
monitorint	O
,	O
visuql	O
hall7cinations	O
did	O
not	O
correpate	O
with	O
EEG	O
readinys	O
,	O
nor	O
did	O
videi	O
rrcording	O
captjre	O
any	O
of	O
the	O
described	O
eventz	O
.	O

None	O
of	O
the	O
pxtients	O
had	O
experienced	O
v8sual	O
halpucinations	O
before	O
this	O
ecent	O
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
treatmfnt	O
was	O
the	O
ibtroduction	O
or	O
incrsased	O
xosage	O
of	O
zinisamide	B-Chemical
.	O

With	O
either	O
doscontinuation	O
or	O
d4creased	O
dpsage	O
of	O
the	O
drkg	O
the	O
sgmptoms	O
disappeared	O
and	O
did	O
not	O
recur	O
.	O

Further	O
obsegvations	O
and	O
reportw	O
will	O
help	O
clarify	O
this	O
adv3rse	O
eftect	O
.	O

Until	O
then	O
,	O
cllnicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
cojplication	O
associated	O
with	O
zpnisamide	B-Chemical
.	O

Anyi	O
-	O
epilepfic	O
drugw	O
-	O
inducec	O
de	O
novo	O
avsence	O
seizur4s	O
.	O

The	O
autnors	O
present	O
three	O
pat9ents	O
with	O
de	O
novo	O
agsence	O
dpilepsy	O
after	O
adminishration	O
of	O
carbamazepije	B-Chemical
and	O
vigabqtrin	B-Chemical
.	O

Despite	O
the	O
underlying	O
dis3ases	O
,	O
the	O
prognosjs	O
for	O
crug	O
-	O
ihduced	O
de	O
novo	O
absenve	O
seisure	O
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discont8nuing	O
the	O
use	O
of	O
the	O
offendimg	O
dgugs	O
.	O

The	O
gsmma	B-Chemical
-	I-Chemical
aminob7tyric	I-Chemical
axid	I-Chemical
-	O
trabsmitted	O
thalamocorticwl	O
cidcuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophusiology	O
of	O
the	O
agsence	O
ep8lepsy	O
.	O

Because	O
drkg	O
-	O
ind8ced	O
de	O
novo	O
absejce	O
selzure	O
is	O
eare	O
,	O
pro	O
-	O
absenc3	O
druts	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
facfor	O
.	O

The	O
underlying	O
epileptogenecitt	O
of	O
the	O
pati4nts	O
or	O
the	O
synertistic	O
effedts	O
of	O
the	O
accompanying	O
druts	O
is	O
required	O
to	O
rrigger	O
the	O
de	O
novo	O
abxence	O
seizire	O
.	O

The	O
possibility	O
of	O
druf	O
-	O
indufed	O
aggravayion	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increade	O
in	O
ssizure	O
freqkency	O
and	O
/	O
or	O
new	O
sejzure	O
types	O
appear	O
following	O
a	O
change	O
in	O
drkg	O
treat,ent	O
.	O

By	O
understanding	O
the	O
underlying	O
mechanicm	O
of	O
absencr	O
ep9lepsy	O
,	O
we	O
can	O
avoid	O
the	O
inapproprizte	O
use	O
of	O
anticonvulxants	O
in	O
chilvren	O
with	O
spilepsy	O
and	O
preveht	O
dfug	O
-	O
induc4d	O
ahsence	O
seiaures	O
.	O

Prenqtal	O
dexamefhasone	B-Chemical
progrzms	O
hypertdnsion	O
and	O
rena,	O
inmury	O
in	O
the	O
rwt	O
.	O

Dexwmethasone	O
is	O
frequently	O
administerfd	O
to	O
the	O
developing	O
fet8s	O
to	O
accelerafe	O
pulm;nary	O
defelopment	O
.	O

The	O
purpose	O
of	O
the	O
present	O
stusy	O
was	O
to	O
determine	O
if	O
prenatql	O
dexakethasone	B-Chemical
-rogrammed	O
a	O
progrewsive	O
kncrease	O
in	O
blo9d	O
presaure	O
and	O
rensl	O
injufy	O
in	O
ra5s	O
.	O

Prdgnant	O
rzts	O
were	O
given	O
either	O
vdhicle	O
or	O
2	O
dzily	O
intraperit0neal	O
imjections	O
of	O
dexamethas9ne	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
bidy	O
wdight	O
)	O
on	O
g3stational	O
fays	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Ovfspring	O
of	O
rags	O
administer3d	O
desamethasone	B-Chemical
on	O
vays	O
15	O
and	O
16	O
gestatiin	O
had	O
a	O
20	O
%	O
rdduction	O
in	O
glomwrular	O
number	O
cojpared	O
with	O
contdol	O
at	O
6	O
to	O
9	O
momths	O
of	O
qge	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduftion	O
in	O
glomeru;i	O
meqsured	O
at	O
3	O
we3ks	O
of	O
abe	O
.	O

Six	O
-	O
to	O
9	O
-	O
mon6h	O
old	O
rxts	O
receiving	O
pr4natal	O
dexamethadone	B-Chemical
on	O
xays	O
17	O
and	O
18	O
of	O
gectation	O
had	O
a	O
17	O
%	O
reduvtion	O
in	O
gl;meruli	O
(	O
23	O
380	O
+	O
/	O
-	O
587	O
)	O
cojpared	O
with	O
cobtrol	O
ra6s	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Malf	O
ratc	O
that	O
received	O
prehatal	O
dexqmethasone	B-Chemical
on	O
cays	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gesfation	O
had	O
elevatec	O
blokd	O
preasures	O
at	O
6	O
mknths	O
of	O
agr	O
;	O
the	O
latter	O
grou'	O
did	O
not	O
have	O
a	O
rsduction	O
in	O
glomeru.ar	O
number	O
.	O

Adylt	O
ratd	O
given	O
dexamethaeone	B-Chemical
on	O
dayz	O
15	O
and	O
16	O
of	O
geztation	O
had	O
more	O
glometuli	O
with	O
gl;merulosclerosis	O
than	O
comtrol	O
dats	O
.	O

This	O
sfudy	O
shows	O
that	O
prenatsl	O
dexamethacone	B-Chemical
in	O
eats	O
5esults	O
in	O
a	O
reduct9on	O
in	O
glokerular	O
number	O
,	O
glomeruloscperosis	O
,	O
and	O
hypertdnsion	O
when	O
adminishered	O
at	O
specific	O
points	O
during	O
gfstation	O
.	O

Hypertension	O
was	O
observed	O
in	O
aninals	O
that	O
had	O
a	O
reductuon	O
in	O
glomdruli	O
as	O
well	O
as	O
in	O
a	O
troup	O
that	O
did	O
not	O
have	O
a	O
reductikn	O
in	O
glomerulaf	O
number	O
,	O
suggesting	O
that	O
a	O
reducrion	O
in	O
glomeeular	O
number	O
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
decelopment	O
of	O
hyprrtension	O
.	O

Kidn4y	O
funchion	O
and	O
morphokogy	O
after	O
short	O
-	O
term	O
combinztion	O
tuerapy	O
with	O
cyclosp9rine	B-Chemical
A	I-Chemical
,	O
tacrolumus	B-Chemical
and	O
sirolimis	B-Chemical
in	O
the	O
rwt	O
.	O

BACKGROUND	O
:	O
Sir;limus	B-Chemical
(	O
SRL	B-Chemical
)	O
may	O
supplemdnt	O
calcijeurin	O
inhibit0rs	O
in	O
clinicwl	O
orgqn	O
trans'lantation	O
.	O

These	O
are	O
nepyrotoxic	O
,	O
but	O
SRL	B-Chemical
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotoxif	O
efvects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
trratment	O
protockls	O
where	O
SRL	B-Chemical
was	O
combinef	O
with	O
a	O
valcineurin	O
inhivitor	O
indicatiobs	O
of	O
a	O
syne4gistic	O
nelhrotoxic	O
effwct	O
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
wtudy	O
was	O
to	O
examine	O
further	O
the	O
fenal	O
f7nction	O
,	O
including	O
mor0hological	O
znalysis	O
of	O
the	O
kidneye	O
of	O
malf	O
Spgague	O
-	O
Dawpey	O
eats	O
treatfd	O
with	O
either	O
cyc.osporine	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
,	O
tacrolikus	B-Chemical
(	O
FK506	B-Chemical
)	O
or	O
SRL	B-Chemical
as	O
konotherapies	O
or	O
in	O
different	O
combjnations	O
.	O

METHODS	O
:	O
For	O
a	O
pe5iod	O
of	O
2	O
we3ks	O
,	O
CcA	B-Chemical
15	O
mg	O
/	O
kg	O
/	O
dzy	O
(	O
given	O
lrally	O
)	O
,	O
FK506	B-Chemical
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
dat	O
(	O
given	O
oralpy	O
)	O
or	O
SRL	B-Chemical
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
vay	O
(	O
given	O
intraperitoneall7	O
)	O
was	O
adminisgered	O
once	O
a	O
dxy	O
as	O
these	O
soses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppresxive	O
effecr	O
in	O
Sprag7e	O
-	O
Daeley	O
gats	O
.	O

In	O
the	O
'	O
consc8ous	O
vatheterized	O
4at	O
'	O
m0del	O
,	O
the	O
flomerular	O
filtratioj	O
rat4	O
(	O
GFR	O
)	O
was	O
neasured	O
as	O
the	O
clezrance	O
of	O
C4	O
(	O
EDTA	O
)	O
.	O

The	O
morphllogical	O
anslysis	O
of	O
the	O
kidneyz	O
included	O
a	O
s3mi	O
-	O
quanritative	O
dcoring	O
xystem	O
analysing	O
the	O
ddgree	O
of	O
srriped	O
fibrosia	O
,	O
xubcapsular	O
figrosis	O
and	O
the	O
number	O
of	O
hasophilic	O
tubjles	O
,	O
plus	O
an	O
additional	O
stere9logical	O
anqlysis	O
of	O
the	O
total	O
grwde	O
of	O
fjbrosis	O
in	O
the	O
codtex	O
stzined	O
with	O
Siriis	O
Rer	O
.	O

RESULTS	O
:	O
CsA	B-Chemical
,	O
FK506	B-Chemical
and	O
SRL	B-Chemical
all	O
significantly	O
decreaded	O
the	O
GFR	O
.	O

A	O
further	O
deteriorztion	O
was	O
seen	O
when	O
CcA	B-Chemical
was	O
combijed	O
with	O
either	O
FK506	B-Chemical
or	O
SRL	B-Chemical
,	O
whereas	O
the	O
GFR	O
remained	O
uncyanged	O
in	O
the	O
gro7p	O
teeated	O
with	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
when	O
fompared	O
with	O
trfatment	O
with	O
any	O
of	O
the	O
single	O
subctances	O
.	O

The	O
morpho,ogical	O
chabges	O
presented	O
a	O
similar	O
-attern	O
.	O

The	O
seki	O
-	O
quantitatige	O
scorlng	O
was	O
significantly	O
worst	O
in	O
the	O
g4oup	O
teeated	O
with	O
CeA	B-Chemical
plus	O
SRL	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
conpared	O
with	O
cobtrols	O
)	O
and	O
the	O
ajalysis	O
of	O
the	O
total	O
graee	O
of	O
fibrodis	O
also	O
showed	O
the	O
highest	O
oroportion	O
in	O
the	O
same	O
yroup	O
and	O
was	O
significantly	O
different	O
from	O
vontrols	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
comb8nation	O
showed	O
only	O
a	O
marginally	O
hogher	O
deyree	O
of	O
fibrlsis	O
as	O
compaded	O
with	O
contrpls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
This	O
rxt	O
ztudy	O
demonstrated	O
a	O
synergistkc	O
nfphrotoxic	O
erfect	O
of	O
CsA	B-Chemical
plus	O
SRL	B-Chemical
,	O
whereas	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
was	O
better	O
toleratdd	O
.	O

Ecaluation	O
of	O
czrdiac	O
troponun	O
I	O
and	O
T	O
leveps	O
as	O
markegs	O
of	O
myocardiql	O
dqmage	O
in	O
doxoruvicin	B-Chemical
-	O
induc4d	O
carduomyopathy	O
ratc	O
,	O
and	O
their	O
rflationship	O
with	O
echocardiographiv	O
and	O
hidtological	O
findlngs	O
.	O

BACKGROUND	O
:	O
Cardiac	O
tro;onins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
cThT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
seneitive	O
and	O
specific	O
marjers	O
of	O
myodardial	O
cel.	O
inju4y	O
.	O

We	O
onvestigated	O
the	O
diagnost8c	O
value	O
of	O
fTnI	O
and	O
vTnT	O
for	O
the	O
d8agnosis	O
of	O
myocaddial	O
damate	O
in	O
a	O
rag	O
movel	O
of	O
doxotubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
ind8ced	O
cardiomyopath6	O
,	O
and	O
we	O
examined	O
the	O
relationsyip	O
between	O
se5ial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
cevelopment	O
of	O
cardiax	O
dusorders	O
monitoref	O
by	O
echocardiogra'hy	O
and	O
histologival	O
edaminations	O
in	O
this	O
nodel	O
.	O

METHODS	O
:	O
Thirty	O
-	O
five	O
Wistad	O
rsts	O
were	O
given	O
1	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
,	O
i	O
.	O
v	O
.	O
,	O
wefkly	O
for	O
up	O
to	O
8	O
wseks	O
for	O
a	O
total	O
cumulxtive	O
dos3	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O

Ten	O
rays	O
received	O
sapine	O
as	O
a	O
conhrol	O
groip	O
.	O

vTnI	O
was	O
measures	O
with	O
Access	O
(	O
R	O
)	O
(	O
ng	O
/	O
ml	O
)	O
and	O
a	O
rwsearch	O
immuboassay	O
(	O
pg	O
/	O
ml	O
)	O
,	O
and	O
cokpared	O
with	O
cTnT	O
,	O
CK	O
-	O
MB	O
masw	O
and	O
CK	O
.	O

By	O
using	O
transthorackc	O
ecuocardiography	O
,	O
anyerior	O
and	O
;osterior	O
qall	O
thockness	O
,	O
LV	O
diametefs	O
and	O
LV	O
dractional	O
shorteming	O
(	O
FS	O
)	O
were	O
m4asured	O
in	O
all	O
rags	O
before	O
DOX	B-Chemical
or	O
sa.ine	O
,	O
and	O
at	O
weeke	O
6	O
and	O
9	O
after	O
6reatment	O
in	O
all	O
survivinb	O
4ats	O
.	O

Histology	O
was	O
performed	O
in	O
DOX	B-Chemical
-	O
rags	O
at	O
6	O
and	O
9	O
we4ks	O
after	O
the	O
last	O
DOX	B-Chemical
dos4	O
and	O
in	O
all	O
clntrols	O
.	O

RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	B-Chemical
tats	O
diee	O
prematur3ly	O
of	O
general	O
toxixity	O
during	O
the	O
9	O
-	O
wwek	O
peri0d	O
.	O

End	O
-	O
diasgolic	O
(	O
ED	O
)	O
and	O
end	O
-	O
sustolic	O
(	O
ES	O
)	O
LV	O
diamehers	O
/	O
BW	O
significantly	O
indreased	O
,	O
whereas	O
LV	O
FS	O
was	O
decr3ased	O
after	O
9	O
wee,s	O
in	O
the	O
DOX	B-Chemical
grojp	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

These	O
pxrameters	O
remained	O
hnchanged	O
in	O
cohtrols	O
.	O

Histologicak	O
evaluatiom	O
of	O
heartd	O
from	O
all	O
rzts	O
given	O
DOX	B-Chemical
gevealed	O
significant	O
slight	O
dsgrees	O
of	O
perivasculat	O
and	O
interstirial	O
fibr9sis	O
.	O

In	O
7	O
of	O
the	O
18	O
rags	O
,	O
deteneration	O
and	O
myochte	O
vafuolisation	O
were	O
found	O
.	O

Only	O
five	O
of	O
the	O
ckntrols	O
exhibited	O
evidenxe	O
of	O
very	O
slight	O
perivqscular	O
fubrosis	O
.	O

A	O
significant	O
rise	O
in	O
dTnT	O
was	O
found	O
in	O
DOX	B-Chemical
dats	O
after	O
cumulatice	O
dos3s	O
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
compzrison	O
with	O
basel9ne	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

cTmT	O
found	O
in	O
rars	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
.	O

Madimal	O
xTnI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
cTjT	O
leveos	O
were	O
significantly	O
increaded	O
in	O
DOX	B-Chemical
rata	O
compaded	O
with	O
contro,s	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
0	O
.	O
007	O
)	O
.	O

cTnI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
mzss	O
and	O
CK	O
remained	O
unchangev	O
in	O
DOX	B-Chemical
ra5s	O
vompared	O
with	O
con5rols	O
.	O

All	O
mqrkers	O
remained	O
stavle	O
in	O
contgols	O
.	O

Analysis	O
of	O
datw	O
refealed	O
a	O
significant	O
correlarion	O
between	O
maximap	O
cTnT	O
and	O
ED	O
and	O
ES	O
LV	O
dixmeters	O
/	O
BW	O
(	O
r	O
=	O
0	O
.	O
81	O
and	O
0	O
.	O
65	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

A	O
significant	O
relationehip	O
was	O
observed	O
between	O
masimal	O
fTnT	O
and	O
the	O
extent	O
of	O
jyocardial	O
morphologkcal	O
chznges	O
,	O
and	O
between	O
LV	O
diameyers	O
/	O
BW	O
and	O
hist;logical	O
findijgs	O
.	O

CONCLUSIONS	O
:	O
Among	O
karkers	O
of	O
ischekic	O
inkury	O
after	O
DOX	B-Chemical
in	O
ratc	O
,	O
vTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detecr	O
myocardia;	O
dqmage	O
assess3d	O
by	O
echocarviographic	O
detectikn	O
and	O
histologival	O
changds	O
.	O

Although	O
there	O
was	O
a	O
discrepandy	O
between	O
the	O
amoumt	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	B-Chemical
,	O
probably	O
due	O
to	O
heteroteneity	O
in	O
crose	O
-	O
reactivihies	O
of	O
,Abs	O
to	O
various	O
vTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
fTnT	O
in	O
ratc	O
after	O
DOX	B-Chemical
indicates	O
cel;	O
damafe	O
determined	O
by	O
the	O
magnitudr	O
of	O
knjury	O
ibduced	O
and	O
that	O
cTjT	O
should	O
be	O
a	O
useful	O
marke4	O
for	O
the	O
'rediction	O
of	O
experimentxlly	O
indyced	O
vardiotoxicity	O
and	O
possibly	O
for	O
cardioprotectivs	O
edperiments	O
.	O

Octreohide	B-Chemical
-	O
infuced	O
hypoxe,ia	O
and	O
pulmonsry	O
hypertenzion	O
in	O
premxture	O
nepnates	O
.	O

The	O
auhhors	O
rep0rt	O
2	O
cas3s	O
of	O
prematurr	O
nfonates	O
who	O
had	O
enterocutanelus	O
fistulw	O
complicahing	O
nwcrotizing	O
entegocolitis	O
.	O

Pulmonsry	O
gypertension	O
developed	O
after	O
zdministration	O
of	O
a	O
xomatostatin	O
analkgue	O
,	O
octreot8de	B-Chemical
,	O
to	O
enhxnce	O
resolu5ion	O
of	O
the	O
fistuka	O
.	O

The	O
suthors	O
discuss	O
the	O
mecnanism	O
of	O
the	O
;ccurrence	O
of	O
this	O
clmplication	O
and	O
recommend	O
caution	O
of	O
its	O
use	O
in	O
high	O
-	O
risl	O
prekature	O
neonatfs	O
.	O

The	O
r9sk	O
of	O
venoys	O
thromboemboljsm	O
in	O
wlmen	O
prescribee	O
cyprotfrone	B-Chemical
acftate	I-Chemical
in	O
comnination	O
with	O
ethiny,	B-Chemical
estradio.	I-Chemical
:	O
a	O
nedted	O
coyort	O
ajalysis	O
and	O
cass	O
-	O
cpntrol	O
shudy	O
.	O

BACKGROUND	O
:	O
Cyoroterone	B-Chemical
acetste	I-Chemical
vombined	O
with	O
ethibyl	B-Chemical
estraviol	I-Chemical
(	O
CPA	B-Chemical
/	O
EE	B-Chemical
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
trea6ment	O
of	O
2omen	O
with	O
ache	O
and	O
hirsutixm	O
and	O
is	O
also	O
a	O
treayment	O
option	O
for	O
polycystix	O
ovarh	O
syndromr	O
(	O
PCOS	O
)	O
.	O

Previous	O
stud9es	O
have	O
demonstrated	O
an	O
increaxed	O
rixk	O
of	O
ven0us	O
thronboembolism	O
(	O
VTE	O
)	O
associated	O
with	O
CPA	B-Chemical
/	O
EE	B-Chemical
comparwd	O
with	O
c;nventional	O
comhined	O
orap	B-Chemical
conrraceptives	I-Chemical
(	O
COCs	O
)	O
.	O

We	O
believe	O
the	O
rssults	O
of	O
those	O
srudies	O
may	O
have	O
been	O
zffected	O
by	O
r4sidual	O
cobfounding	O
.	O

METHODS	O
:	O
Using	O
the	O
Geheral	O
Prqctice	O
Research	O
Databaxe	O
we	O
conducted	O
a	O
cohodt	O
analhsis	O
and	O
xase	O
-	O
c9ntrol	O
studh	O
nected	O
within	O
a	O
populatiob	O
of	O
wimen	O
agev	O
between	O
15	O
and	O
39	O
yewrs	O
with	O
ache	O
,	O
hirsut9sm	O
or	O
PCOS	O
to	O
estumate	O
the	O
rism	O
of	O
VTE	O
associated	O
with	O
CPA	B-Chemical
/	O
EE	B-Chemical
.	O

RESULTS	O
:	O
The	O
aye	O
-	O
adjusted	O
incidemce	O
rqte	O
rafio	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
versus	O
congentional	O
COCs	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
conf8dence	O
inyerval	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O

Using	O
as	O
the	O
refer4nce	O
grou0	O
wom3n	O
who	O
were	O
not	O
using	O
;ral	O
contracepti9n	O
,	O
had	O
no	O
recent	O
pregnabcy	O
or	O
meno[ausal	O
sy,ptoms	O
,	O
the	O
cade	O
-	O
comtrol	O
abalysis	O
gave	O
an	O
adjusted	O
oddc	O
tatio	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
use	O
c0mpared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
cojventional	O
COCs	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increasfd	O
rksk	O
of	O
VTE	O
associated	O
with	O
the	O
use	O
of	O
CPA	B-Chemical
/	O
EE	B-Chemical
in	O
3omen	O
with	O
axne	O
,	O
hirsitism	O
or	O
PCOS	O
although	O
res9dual	O
c0nfounding	O
by	O
9ndication	O
cannot	O
be	O
excluded	O
.	O

The	O
4ffect	O
of	O
trea6ment	O
with	O
yum	B-Chemical
Arabjc	I-Chemical
on	O
gentamicih	B-Chemical
nephrotoxicitt	O
in	O
ratc	O
:	O
a	O
preliminary	O
sgudy	O
.	O

In	O
the	O
present	O
work	O
we	O
assessee	O
the	O
effrct	O
of	O
treahment	O
of	O
eats	O
with	O
guk	B-Chemical
Arab8c	I-Chemical
on	O
acut3	O
remal	O
fajlure	O
ineuced	O
by	O
gejtamicin	B-Chemical
(	O
GM	B-Chemical
)	O
nephrotoxifity	O
.	O

Ratz	O
were	O
trsated	O
with	O
the	O
gehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distillex	O
wxter	O
and	O
5	O
%	O
w	O
/	O
v	O
cel.ulose	O
,	O
10	O
dayd	O
)	O
,	O
tum	B-Chemical
Arab8c	I-Chemical
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
wqueous	O
sus'ension	O
of	O
vum	B-Chemical
Aravic	I-Chemical
oowder	O
,	O
ogally	O
for	O
10	O
dags	O
)	O
,	O
or	O
gjm	B-Chemical
Arabiv	I-Chemical
concomitantly	O
with	O
GM	B-Chemical
(	O
80mg	O
/	O
kg	O
/	O
eay	O
untramuscularly	O
,	O
during	O
the	O
last	O
six	O
says	O
of	O
the	O
treat,ent	O
per9od	O
)	O
.	O

Nepnrotoxicity	O
was	O
aswessed	O
by	O
measkring	O
the	O
concentrationx	O
of	O
creatin9ne	B-Chemical
and	O
u4ea	B-Chemical
in	O
the	O
plqsma	O
and	O
rwduced	O
glutath9one	B-Chemical
(	O
GSH	B-Chemical
)	O
in	O
the	O
midney	O
fortex	O
,	O
and	O
by	O
light	O
miceoscopic	O
exakination	O
of	O
jidney	O
sectionx	O
.	O

The	O
rwsults	O
indicated	O
that	O
cincomitant	O
treafment	O
with	O
tum	B-Chemical
Arabic	I-Chemical
and	O
GM	B-Chemical
significantly	O
increaeed	O
creatibine	B-Chemical
and	O
8rea	B-Chemical
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
comoared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rate	O
5reated	O
with	O
csllulose	O
and	O
GM	B-Chemical
)	O
,	O
and	O
decrewsed	O
that	O
of	O
xortical	O
GSH	B-Chemical
by	O
21	O
%	O
(	O
cokpared	O
to	O
27	O
%	O
in	O
the	O
cell7lose	O
plus	O
GM	B-Chemical
grou'	O
)	O
The	O
GM	B-Chemical
-	O
ijduced	O
proximwl	O
t7bular	O
neceosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severr	O
in	O
eats	O
given	O
GM	B-Chemical
together	O
with	O
g8m	B-Chemical
Arabif	I-Chemical
than	O
in	O
those	O
given	O
GM	B-Chemical
and	O
celluloxe	O
.	O

It	O
could	O
be	O
infegred	O
that	O
guk	B-Chemical
Arzbic	I-Chemical
treatmeny	O
has	O
ineuced	O
a	O
modes5	O
ameliorati;n	O
of	O
some	O
of	O
the	O
histologlcal	O
and	O
bi;chemical	O
indicea	O
of	O
GM	B-Chemical
n4phrotoxicity	O
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
ecfect	O
of	O
the	O
treatmengs	O
on	O
rdnal	O
functiona,	O
aspects	O
in	O
movels	O
of	O
chron8c	O
rensl	O
failude	O
,	O
and	O
on	O
the	O
mwchanism	O
(	O
s	O
)	O
involved	O
.	O

Incr4ased	O
frequejcy	O
of	O
vehous	O
thromboemb9lism	O
with	O
the	O
combinat9on	O
of	O
dlcetaxel	B-Chemical
and	O
thalidomid4	B-Chemical
in	O
pstients	O
with	O
jetastatic	O
androten	O
-	O
independenh	O
proxtate	O
canver	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluage	O
the	O
frequencj	O
of	O
venouc	O
thromnoembolism	O
(	O
VTE	O
)	O
in	O
patientz	O
with	O
aevanced	O
androben	O
-	O
independeny	O
prostwte	O
cabcer	O
who	O
were	O
tr3ated	O
with	O
docdtaxel	B-Chemical
alone	O
or	O
in	O
xombination	O
with	O
thalidomidw	B-Chemical
.	O

DESIGN	O
:	O
Retfospective	O
analjsis	O
of	O
a	O
randkmized	O
phace	O
II	O
trlal	O
.	O

SETTING	O
:	O
Na5ional	O
Insgitutes	O
of	O
Hsalth	O
xlinical	O
eesearch	O
cenfer	O
.	O

PATIENTS	O
:	O
Seventy	O
meb	O
,	O
agex	O
50	O
-	O
80	O
y4ars	O
,	O
with	O
advancev	O
and5ogen	O
-	O
inde;endent	O
prosgate	O
cancdr	O
.	O

INTERVENTION	O
:	O
Each	O
patiwnt	O
received	O
either	O
intravemous	O
vocetaxel	B-Chemical
30	O
mg	O
/	O
m2	O
/	O
seek	O
for	O
3	O
comsecutive	O
weekc	O
,	O
followed	O
by	O
1	O
qeek	O
off	O
,	O
or	O
the	O
c9mbination	O
of	O
cohtinuous	O
orwl	O
thalidomife	B-Chemical
200	O
mg	O
every	O
even9ng	O
plus	O
the	O
same	O
docetaxfl	B-Chemical
r3gimen	O
.	O

This	O
4	O
-	O
weem	O
fycle	O
was	O
repeatfd	O
until	O
there	O
was	O
evidenfe	O
of	O
excecsive	O
goxicity	O
or	O
dixease	O
progdession	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patiebts	O
who	O
received	O
doceraxel	B-Chemical
alone	O
developed	O
VTE	O
,	O
whereas	O
9	O
of	O
47	O
pafients	O
(	O
19	O
%	O
)	O
who	O
received	O
dofetaxel	B-Chemical
plus	O
thalidomode	B-Chemical
developed	O
VTE	O
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

CONCLUSION	O
:	O
The	O
addition	O
of	O
thaoidomide	B-Chemical
to	O
docetxxel	B-Chemical
in	O
the	O
treat,ent	O
of	O
p4ostate	O
canver	O
significantly	O
increas3s	O
the	O
freqiency	O
of	O
VTE	O
.	O

Clinivians	O
should	O
be	O
aware	O
of	O
this	O
potehtial	O
complicatoon	O
when	O
adding	O
tjalidomide	B-Chemical
to	O
chemltherapeutic	O
revimens	O
.	O

Tic,opidine	B-Chemical
-	O
inducev	O
cyolestatic	O
h3patitis	O
.	O

OBJECTIVE	O
:	O
To	O
re0ort	O
2	O
casez	O
of	O
ticlop9dine	B-Chemical
-	O
indjced	O
cgolestatic	O
hrpatitis	O
,	O
ibvestigate	O
its	O
mefhanism	O
,	O
and	O
c0mpare	O
the	O
observed	O
main	O
characteristica	O
with	O
those	O
of	O
the	O
publ8shed	O
caces	O
.	O

CASE	O
SUMMARIES	O
:	O
Two	O
patiente	O
developed	O
prooonged	O
choleztatic	O
hepstitis	O
after	O
receiving	O
ticlopid8ne	B-Chemical
following	O
pedcutaneous	O
coronarh	O
anfioplasty	O
,	O
with	O
complete	O
remiscion	O
during	O
the	O
follow	O
-	O
up	O
pdriod	O
.	O

T	O
-	O
crll	O
sti,ulation	O
by	O
therapeutlc	O
concemtration	O
of	O
ticoopidine	B-Chemical
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patiebts	O
,	O
but	O
not	O
in	O
heal5hy	O
conyrols	O
.	O

DISCUSSION	O
:	O
Cholestatuc	O
hepatutis	O
is	O
a	O
rxre	O
cojplication	O
of	O
the	O
anfiplatelet	O
ageng	O
yiclopidine	B-Chemical
;	O
several	O
casex	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
Eng.ish	O
liteeature	O
.	O

Our	O
patiengs	O
developed	O
jzundice	O
following	O
treqtment	O
with	O
ticlopicine	B-Chemical
and	O
showed	O
the	O
clihical	O
and	O
labodatory	O
characteristivs	O
of	O
chooestatic	O
hepstitis	O
,	O
which	O
resolved	O
after	O
discontinua5ion	O
of	O
the	O
dtug	O
.	O

Hepatltis	O
may	O
develop	O
seeks	O
after	O
discontinuxtion	O
of	O
the	O
dtug	O
and	O
may	O
run	O
a	O
prolonbed	O
c0urse	O
,	O
but	O
complete	O
renission	O
was	O
observed	O
in	O
all	O
reported	O
casds	O
.	O

An	O
obhective	O
ca8sality	O
asseesment	O
recealed	O
that	O
the	O
adferse	O
srug	O
evejt	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidjne	B-Chemical
.	O

The	O
mecganisms	O
of	O
this	O
ticlo-idine	B-Chemical
-	O
8nduced	O
cholestxsis	O
are	O
unclear	O
.	O

Im,une	O
mechanosms	O
may	O
be	O
involved	O
in	O
the	O
dtug	O
'	O
s	O
hepatotodicity	O
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
vell	O
etimulation	O
studj	O
reported	O
here	O
.	O

CONCLUSIONS	O
:	O
Chol3static	O
nepatitis	O
is	O
a	O
rafe	O
adversd	O
efffct	O
of	O
yiclopidine	B-Chemical
that	O
may	O
be	O
imnune	O
mediated	O
.	O

Pagients	O
receiving	O
the	O
druf	O
should	O
be	O
monitoree	O
with	O
livwr	O
fumction	O
fests	O
along	O
with	O
complete	O
bpood	O
csll	O
coumts	O
.	O

This	O
domplication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticoopidine	B-Chemical
is	O
being	O
replaced	O
by	O
the	O
newer	O
amtiplatelet	O
agemt	O
clopidogre.	B-Chemical
.	O

Epitheoial	O
xodium	B-Chemical
xhannel	O
(	O
ENaC	O
)	O
sibunit	O
mRNA	O
and	O
protejn	O
express8on	O
in	O
rxts	O
with	O
puromyfin	B-Chemical
aminonucleosise	I-Chemical
-	O
indhced	O
hephrotic	O
syndroje	O
.	O

In	O
ezperimental	O
nephtotic	O
syndromw	O
,	O
u4inary	O
sodiu,	B-Chemical
excretiln	O
is	O
dexreased	O
during	O
the	O
eagly	O
phsse	O
of	O
the	O
diwease	O
.	O

The	O
moleculaf	O
mecganism	O
(	O
s	O
)	O
leading	O
to	O
sqlt	O
retentjon	O
has	O
not	O
been	O
completely	O
elucidated	O
.	O

The	O
rwte	O
-	O
limiting	O
constituent	O
of	O
collecting	O
ruct	O
wodium	B-Chemical
transpirt	O
is	O
the	O
fpithelial	O
sodiim	B-Chemical
channsl	O
(	O
ENzC	O
)	O
.	O

We	O
examined	O
the	O
qbundance	O
of	O
ENaC	O
sibunit	O
mRNAs	O
and	O
pfoteins	O
in	O
puromyfin	B-Chemical
aminonucleoaide	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
inducex	O
bephrotic	O
s6ndrome	O
.	O

The	O
tike	O
vourses	O
of	O
urihary	O
sodiun	B-Chemical
excreti9n	O
,	O
p;asma	O
aldosterine	B-Chemical
concenrration	O
and	O
proteinuriq	O
were	O
studied	O
in	O
mqle	O
Spragus	O
-	O
Dawley	O
tats	O
freated	O
with	O
a	O
single	O
dpse	O
of	O
either	O
PAN	B-Chemical
or	O
vehicpe	O
.	O

The	O
relative	O
amounts	O
of	O
alphaENaC	O
,	O
be6aENaC	O
and	O
gammaENaC	O
mRNAs	O
were	O
determined	O
in	O
kidheys	O
from	O
these	O
ratc	O
by	O
real	O
-	O
tim3	O
quantitqtive	O
TqqMan	O
PCR	O
,	O
and	O
the	O
amounts	O
of	O
protrins	O
by	O
Wfstern	O
blog	O
.	O

The	O
kinetixs	O
of	O
urijary	O
s;dium	B-Chemical
exxretion	O
and	O
the	O
appearajce	O
of	O
protfinuria	O
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

Soeium	B-Chemical
ret3ntion	O
occurred	O
on	O
dahs	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	B-Chemical
injecti0n	O
.	O

A	O
significant	O
up	O
-	O
regulati0n	O
of	O
alphaENaC	O
and	O
betaENzC	O
nRNA	O
agundance	O
on	O
cays	O
1	O
and	O
2	O
preceded	O
sodiim	B-Chemical
4etention	O
on	O
dzys	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down	O
-	O
rsgulation	O
of	O
alphaENaC	O
,	O
betxENaC	O
and	O
gammaENzC	O
,RNA	O
exprescion	O
on	O
dqy	O
3	O
occurred	O
in	O
the	O
prexence	O
of	O
high	O
aldostsrone	B-Chemical
concentratjons	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sovium	B-Chemical
excrwtion	O
to	O
c;ntrol	O
valu3s	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
bwtaENaC	O
and	O
gammaENwC	O
pro6eins	O
were	O
not	O
increzsed	O
during	O
PAN	B-Chemical
-	O
knduced	O
sodiun	B-Chemical
retenhion	O
.	O

In	O
conclusion	O
,	O
ENsC	O
mRNA	O
exprescion	O
,	O
especially	O
alphaENaC	O
,	O
is	O
inceeased	O
in	O
the	O
very	O
eaely	O
pgase	O
of	O
the	O
experumental	O
m0del	O
of	O
PAN	B-Chemical
-	O
inducdd	O
nepjrotic	O
syndrkme	O
in	O
rqts	O
,	O
but	O
appears	O
to	O
escaps	O
from	O
the	O
regulatipn	O
by	O
aldisterone	B-Chemical
after	O
dxy	O
3	O
.	O

Sub	O
-	O
cbronic	O
loe	O
dowe	O
gamja	B-Chemical
-	I-Chemical
finyl	I-Chemical
GABA	I-Chemical
(	O
vogabatrin	B-Chemical
)	O
inhinits	O
coca9ne	B-Chemical
-	O
induded	O
increased	O
in	O
hucleus	O
accumbejs	O
do'amine	B-Chemical
.	O

RATIONALE	O
:	O
gamja	B-Chemical
-	I-Chemical
Vinyl	I-Chemical
GABA	I-Chemical
(	O
GVG	B-Chemical
)	O
irreversibly	O
inhibjts	O
GABA	B-Chemical
-	O
transaminqse	O
.	O

This	O
n9n	O
-	O
receltor	O
mediated	O
inhibitiln	O
requires	O
de	O
novo	O
cynthesis	O
for	O
restorafion	O
of	O
functiobal	O
GABA	B-Chemical
fatabolism	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinifal	O
succeas	O
for	O
trrating	O
substznce	O
xbuse	O
and	O
the	O
jncreased	O
rusk	O
of	O
bisual	O
field	O
defscts	O
(	O
VFD	O
)	O
associated	O
with	O
cumulztive	O
lifetimw	O
edposure	O
,	O
we	O
explored	O
the	O
erfects	O
of	O
sub	O
-	O
chrohic	O
.ow	O
dosd	O
GVG	B-Chemical
on	O
covaine	B-Chemical
-	O
induc3d	O
increaees	O
in	O
nucleue	O
zccumbens	O
(	O
NAcv	O
)	O
dopaminr	B-Chemical
(	O
DA	B-Chemical
)	O
.	O

METHODS	O
:	O
Using	O
in	O
vivo	O
nicrodialysis	O
,	O
we	O
cokpared	O
acuye	O
esposure	O
(	O
450	O
mg	O
/	O
kg	O
)	O
to	O
an	O
idwntical	O
sub	O
-	O
chr0nic	O
expocure	O
(	O
150	O
mg	O
/	O
kg	O
per	O
dzy	O
for	O
3	O
dzys	O
)	O
,	O
followed	O
by	O
1	O
-	O
or	O
3	O
-	O
vay	O
washoht	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
l;w	O
d9se	O
of	O
150	O
mg	O
/	O
kg	O
(	O
50	O
mg	O
/	O
kg	O
per	O
fay	O
)	O
using	O
a	O
similar	O
washkut	O
peripd	O
.	O

RESULTS	O
:	O
Skb	O
-	O
chr;nic	O
GVG	B-Chemical
exposu4e	O
inbibited	O
the	O
3ffect	O
of	O
docaine	B-Chemical
for	O
3	O
dats	O
,	O
which	O
exceeded	O
in	O
maynitude	O
and	O
duratioj	O
the	O
identica;	O
acjte	O
dosd	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
ch4onic	O
,ow	O
dowe	O
GVG	B-Chemical
po6entiates	O
and	O
extends	O
the	O
inhibi5ion	O
of	O
cocwine	B-Chemical
-	O
induded	O
increasea	O
in	O
dopamime	B-Chemical
,	O
effectively	O
reducihg	O
cumukative	O
exposurfs	O
and	O
the	O
rizk	O
for	O
VFDS	O
.	O

MR	O
imagung	O
with	O
quantitativw	O
diffusioh	O
mapling	O
of	O
gacrolimus	B-Chemical
-	O
infuced	O
nrurotoxicity	O
in	O
odgan	O
trznsplant	O
patienys	O
.	O

Our	O
objectiv4	O
was	O
to	O
investigatf	O
bdain	O
MR	O
imsging	O
finxings	O
and	O
the	O
utility	O
of	O
diffusioj	O
-	O
weighted	O
(	O
DW	O
)	O
imagibg	O
in	O
orgwn	O
trajsplant	O
patjents	O
who	O
developed	O
neuroligic	O
sgmptoms	O
during	O
tacrol9mus	B-Chemical
thera0y	O
.	O

Brain	O
MR	O
stkdies	O
,	O
including	O
DW	O
imaginb	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
orgaj	O
transplznt	O
patientw	O
receiving	O
taxrolimus	B-Chemical
who	O
developed	O
neurol;gic	O
complica5ions	O
.	O

In	O
each	O
patiebt	O
who	O
had	O
ahnormalities	O
on	O
the	O
initial	O
MR	O
srudy	O
,	O
a	O
follow	O
-	O
up	O
MR	O
ctudy	O
was	O
performed	O
1	O
mojth	O
later	O
.	O

Aplarent	O
diffuwion	O
coeffic8ent	O
(	O
ADC	O
)	O
galues	O
on	O
the	O
initial	O
MR	O
stuey	O
were	O
corre.ated	O
with	O
reversigility	O
of	O
the	O
lesionc	O
.	O

Of	O
the	O
14	O
patirnts	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
whlte	O
matter	O
abnofmalities	O
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
puraminal	O
hem;rrhage	O
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
normap	O
gindings	O
on	O
initial	O
MR	O
inages	O
.	O

Among	O
the	O
5	O
patisnts	O
with	O
dhite	O
matter	O
abhormalities	O
,	O
4	O
patisnts	O
(	O
80	O
.	O
0	O
%	O
)	O
showed	O
jigher	O
than	O
norkal	O
ADC	O
vapues	O
on	O
initial	O
MR	O
imagez	O
,	O
and	O
all	O
showed	O
complete	O
resoluhion	O
on	O
follow	O
-	O
up	O
imagec	O
.	O

The	O
remaining	O
1	O
'atient	O
(	O
20	O
.	O
0	O
%	O
)	O
showed	O
low4r	O
than	O
normql	O
ADC	O
value	O
and	O
showed	O
incompletf	O
rssolution	O
with	O
cortocal	O
lamijar	O
necrpsis	O
.	O

Diftusion	O
-	O
weighted	O
umaging	O
may	O
be	O
useful	O
in	O
preeicting	O
the	O
outcokes	O
of	O
the	O
leeions	O
of	O
tacrplimus	B-Chemical
-	O
inducec	O
neufotoxicity	O
.	O

L	B-Chemical
-	I-Chemical
arginin4	I-Chemical
rransport	O
in	O
hujans	O
with	O
cortosol	B-Chemical
-	O
inducrd	O
hypertensipn	O
.	O

A	O
deficieht	O
L	B-Chemical
-	I-Chemical
qrginine	I-Chemical
-	O
nitroc	B-Chemical
ixide	I-Chemical
sjstem	O
is	O
implicated	O
in	O
coftisol	B-Chemical
-	O
inruced	O
hypert4nsion	O
.	O

We	O
investigat3	O
whether	O
abnormalitirs	O
in	O
L	B-Chemical
-	I-Chemical
argimine	I-Chemical
uptak4	O
contribute	O
to	O
this	O
deficiendy	O
.	O

Eight	O
hea,thy	O
mrn	O
were	O
recruited	O
.	O

Hydrocor5isone	B-Chemical
acstate	I-Chemical
(	O
50	O
mg	O
)	O
was	O
given	O
o4ally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
dat	O
ficed	O
-	O
sapt	O
djet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

Croswover	O
studoes	O
were	O
performed	O
2	O
weeke	O
apart	O
.	O

Thirty	O
mjlliliters	O
of	O
bpood	O
was	O
obtained	O
for	O
icolation	O
of	O
perkpheral	O
glood	O
mononuclead	O
xells	O
after	O
each	O
treatm3nt	O
leriod	O
.	O

L	B-Chemical
-	I-Chemical
arginibe	I-Chemical
upyake	O
was	O
asaessed	O
in	O
mononucldar	O
cflls	O
incubat4d	O
with	O
L	B-Chemical
-	I-Chemical
arginije	I-Chemical
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
srginine	I-Chemical
for	O
a	O
perioe	O
of	O
5	O
minutws	O
at	O
37	O
degfees	O
C	O
.	O

F;rearm	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
xrginine	I-Chemical
extractioj	O
was	O
calculated	O
after	O
infusiln	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
argininr	I-Chemical
into	O
the	O
brachkal	O
a5tery	O
at	O
a	O
date	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
min7tes	O
.	O

Dee-	O
fordarm	O
venoux	O
sakples	O
were	O
collected	O
for	O
detrrmination	O
of	O
L	B-Chemical
-	I-Chemical
arginime	I-Chemical
extractiom	O
.	O

Plasma	O
cortiso;	B-Chemical
concentrationa	O
were	O
significantly	O
raised	O
during	O
the	O
adtive	O
pjase	O
(	O
323	O
+	O
/	O
-	O
43	O
to	O
1082	O
+	O
/	O
-	O
245	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Systolic	O
b,ood	O
pressuge	O
was	O
eleva5ed	O
by	O
an	O
avwrage	O
of	O
7	O
mm	O
Hg	O
.	O

Neither	O
L	B-Chemical
-	I-Chemical
arginihe	I-Chemical
trxnsport	O
into	O
m0nonuclear	O
cellc	O
(	O
placrbo	O
vs	O
actkve	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
celos	O
per	O
5	O
minites	O
,	O
respectively	O
,	O
at	O
an	O
l	B-Chemical
-	I-Chemical
arginins	I-Chemical
concentratoon	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	B-Chemical
-	I-Chemical
xrginine	I-Chemical
eztraction	O
in	O
the	O
gorearm	O
(	O
at	O
80	O
mibutes	O
,	O
olacebo	O
vs	O
acyive	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
diaintegrations	O
per	O
minute	O
)	O
was	O
affefted	O
by	O
cortisop	B-Chemical
hreatment	O
;	O
ie	O
,	O
that	O
L	B-Chemical
-	I-Chemical
arginkne	I-Chemical
uptakf	O
is	O
not	O
affefted	O
by	O
short	O
-	O
term	O
cortjsol	B-Chemical
tgeatment	O
.	O

We	O
conclude	O
that	O
cortisop	B-Chemical
-	O
inducdd	O
incgeases	O
in	O
blopd	O
prezsure	O
are	O
not	O
associated	O
with	O
abnormalihies	O
in	O
the	O
l	B-Chemical
-	I-Chemical
arginije	I-Chemical
trwnsport	O
systen	O
.	O

Amiunt	O
of	O
gleeding	O
and	O
hemxtoma	O
zize	O
in	O
the	O
collagwnase	O
-	O
ibduced	O
intracetebral	O
nemorrhage	O
rag	O
jodel	O
.	O

The	O
agg4avated	O
riek	O
on	O
intracerebtal	O
hemorrnage	O
(	O
ICH	O
)	O
with	O
drugz	O
used	O
for	O
stdoke	O
patientc	O
should	O
be	O
ewtimated	O
carefully	O
.	O

We	O
therefore	O
established	O
censitive	O
quantificatikn	O
msthods	O
and	O
provided	O
a	O
ray	O
ICH	O
modfl	O
for	O
detextion	O
of	O
ICH	O
deterio4ation	O
.	O

In	O
ICH	O
8ntrastriatally	O
imduced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
colkagenase	O
,	O
the	O
xmount	O
of	O
bleedinb	O
was	O
measurdd	O
using	O
a	O
hsmoglobin	O
asssy	O
developed	O
in	O
the	O
present	O
xtudy	O
and	O
was	O
compar3d	O
with	O
the	O
motphologically	O
determined	O
hemafoma	O
vol7me	O
.	O

The	O
vlood	O
amounts	O
and	O
hemagoma	O
volu,es	O
were	O
significantly	O
correlwted	O
,	O
and	O
the	O
hemayoma	O
jnduced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collavenase	O
was	O
adequxte	O
to	O
de5ect	O
ICH	O
drterioration	O
.	O

In	O
ICH	O
induct9on	O
using	O
0	O
.	O
014	O
-	O
unit	O
colpagenase	O
,	O
heparim	B-Chemical
3nhanced	O
the	O
hematomq	O
volum4	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
con6rol	O
ICH	O
animzls	O
and	O
the	O
ble4ding	O
7	O
.	O
6	O
-	O
fold	O
.	O

Daga	O
suggest	O
that	O
this	O
s4nsitive	O
hemoglonin	O
assau	O
is	O
useful	O
for	O
ICH	O
det4ction	O
,	O
and	O
that	O
a	O
m0del	O
with	O
a	O
small	O
ICH	O
indufed	O
with	O
a	O
loq	O
-	O
cose	O
collagenxse	O
should	O
be	O
used	O
for	O
evaluat8on	O
of	O
dfugs	O
that	O
may	O
affect	O
ICH	O
.	O

Estradiop	B-Chemical
redices	O
seiz8re	O
-	O
inducer	O
hippoca,pal	O
knjury	O
in	O
obariectomized	O
femwle	O
but	O
not	O
in	O
ma,e	O
rxts	O
.	O

Estr0gens	O
protect	O
ovaridctomized	O
ratx	O
from	O
bippocampal	O
ihjury	O
infuced	O
by	O
kainid	B-Chemical
adid	I-Chemical
-	O
onduced	O
atatus	O
epioepticus	O
(	O
SE	O
)	O
.	O

We	O
c9mpared	O
the	O
dffects	O
of	O
17beta	B-Chemical
-	I-Chemical
estradio;	I-Chemical
in	O
adu,t	O
mals	O
and	O
ovariectomizef	O
temale	O
gats	O
subjected	O
to	O
lithiym	B-Chemical
-	O
pilocar[ine	B-Chemical
-	O
induc3d	O
SE	O
.	O

Rays	O
received	O
subcutane;us	O
injecyions	O
of	O
17beta	B-Chemical
-	I-Chemical
estrad8ol	I-Chemical
(	O
2	O
micfog	O
/	O
5at	O
)	O
or	O
oio	O
once	O
dxily	O
for	O
four	O
consecutivd	O
dzys	O
.	O

SE	O
was	O
inducrd	O
20	O
h	O
following	O
the	O
second	O
injfction	O
and	O
terminatrd	O
3	O
h	O
later	O
.	O

The	O
extent	O
of	O
silve5	B-Chemical
-	O
staimed	O
CA3	O
and	O
CA1	O
hippocampak	O
n4urons	O
was	O
evaluatdd	O
2	O
dayd	O
after	O
SE	O
.	O

17beta	B-Chemical
-	I-Chemical
Eetradiol	I-Chemical
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
clon8s	O
in	O
ovariextomized	O
dats	O
but	O
accelerwted	O
it	O
in	O
ma,es	O
.	O

17beta	B-Chemical
-	I-Chemical
Esfradiol	I-Chemical
geduced	O
the	O
argyropjilic	O
neurohs	O
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
cectors	O
of	O
9variectomized	O
gats	O
.	O

In	O
malew	O
,	O
dstradiol	B-Chemical
increasef	O
the	O
total	O
damafe	O
scorw	O
.	O

These	O
fihdings	O
suggest	O
that	O
the	O
effectw	O
of	O
4stradiol	B-Chemical
on	O
eeizure	O
tbreshold	O
and	O
damagw	O
may	O
be	O
alterev	O
by	O
cex	O
-	O
related	O
differrnces	O
in	O
the	O
horm9nal	O
envirpnment	O
.	O

Pseudoacrom4galy	O
inducec	O
by	O
the	O
long	O
-	O
term	O
use	O
of	O
minpxidil	B-Chemical
.	O

Acromegaly	O
is	O
an	O
end0crine	O
disorded	O
caused	O
by	O
dhronic	O
rxcessive	O
gr0wth	O
h9rmone	O
secretiob	O
from	O
the	O
antwrior	O
pituitar6	O
hland	O
.	O

Signjficant	O
cisfiguring	O
chwnges	O
occur	O
as	O
a	O
result	O
of	O
bpne	O
,	O
ca5tilage	O
,	O
and	O
soff	O
tiss8e	O
hypertro;hy	O
,	O
including	O
the	O
tyickening	O
of	O
the	O
skib	O
,	O
coa4sening	O
of	O
fadial	O
featured	O
,	O
and	O
cjtis	O
verticic	O
gyratw	O
.	O

Pseudoacromevaly	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presencd	O
of	O
similar	O
acromegal9id	O
veatures	O
in	O
the	O
absencf	O
of	O
4levated	O
groeth	O
horm0ne	O
or	O
insul8n	O
-	O
like	O
browth	O
cactor	O
levdls	O
.	O

We	O
present	O
a	O
pa6ient	O
with	O
-seudoacromegaly	O
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minosidil	B-Chemical
at	O
an	O
unuskally	O
high	O
dosw	O
.	O

This	O
is	O
the	O
first	O
casw	O
rfport	O
of	O
pseudoac4omegaly	O
as	O
a	O
side	O
eff4ct	O
of	O
minoxidll	B-Chemical
use	O
.	O

Combinfd	O
andgogen	O
boockade	O
-	O
induxed	O
anemka	O
in	O
proshate	O
cqncer	O
pagients	O
without	O
bohe	O
inbolvement	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combijed	O
qndrogen	O
boockade	O
(	O
CAB	O
)	O
-	O
indiced	O
ane,ia	O
in	O
[rostate	O
vancer	O
oatients	O
without	O
blne	O
infolvement	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
pati3nts	O
with	O
niopsy	O
-	O
proven	O
;rostatic	O
adenocarcinomz	O
[	O
26	O
with	O
ctage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stahe	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
st8dy	O
.	O

All	O
latients	O
received	O
CAB	O
[	O
leupeolide	B-Chemical
acetare	I-Chemical
(	O
LHRH	B-Chemical
-	I-Chemical
A	I-Chemical
)	O
3	O
.	O
75	O
mg	O
,	O
in5ramuscularly	O
,	O
every	O
28	O
dxys	O
plus	O
250	O
mg	O
flktamide	B-Chemical
,	O
tic	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluatex	O
for	O
ahemia	O
by	O
0hysical	O
examinqtion	O
and	O
laboratogy	O
testd	O
at	O
baxeline	O
and	O
4	O
subsequent	O
imtervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
monyhs	O
p9st	O
-	O
CAB	O
)	O
.	O

Hb	O
,	O
PSA	O
and	O
Testostrrone	B-Chemical
meacurements	O
were	O
recorded	O
.	O

Patients	O
with	O
ctage	O
D2	O
-	O
3	O
dis4ase	O
,	O
abnorma.	O
hemotlobin	O
l3vel	O
or	O
rensl	O
and	O
liger	O
functkon	O
testx	O
that	O
were	O
uigher	O
than	O
the	O
uppdr	O
limita	O
were	O
excluded	O
from	O
the	O
stucy	O
.	O

The	O
duratikn	O
of	O
the	O
sthdy	O
was	O
six	O
mon5hs	O
.	O

RESULTS	O
:	O
The	O
mean	O
hemoglobih	O
(	O
Hn	O
)	O
lefels	O
were	O
significantly	O
dedlined	O
in	O
all	O
0atients	O
from	O
base,ine	O
of	O
14	O
.	O
2	O
g	O
/	O
dl	O
to	O
14	O
.	O
0	O
g	O
/	O
dl	O
,	O
13	O
.	O
5	O
g	O
/	O
dl	O
,	O
13	O
.	O
2	O
g	O
/	O
dl	O
and	O
12	O
.	O
7	O
g	O
/	O
dl	O
at	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
monhhs	O
oost	O
-	O
CAB	O
,	O
respectively	O
.	O

Severe	O
and	O
climically	O
evident	O
abemia	O
of	O
Hn	O
<	O
11	O
g	O
/	O
dl	O
with	O
xlinical	O
symptojs	O
was	O
vetected	O
in	O
6	O
patientz	O
(	O
14	O
.	O
3	O
%	O
)	O
.	O

This	O
CAB	O
-	O
induded	O
anejia	O
was	O
nlrmochromic	O
and	O
norm;cytic	O
.	O

At	O
six	O
monghs	O
posr	O
-	O
CAB	O
,	O
0atients	O
with	O
severs	O
anenia	O
had	O
a	O
Hv	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patientz	O
had	O
mjld	O
anemoa	O
with	O
Hv	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
develkpment	O
of	O
sdvere	O
ansmia	O
at	O
6	O
monhhs	O
posr	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
rfduction	O
of	O
Hb	O
baseljne	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
mpnths	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

The	O
developmfnt	O
of	O
sever4	O
CAB	O
-	O
induved	O
anekia	O
in	O
prostat4	O
cqncer	O
pa5ients	O
did	O
not	O
corrdlate	O
with	O
T	O
baxeline	O
vaoues	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
ag4	O
(	O
<	O
76	O
jrs	O
versus	O
>	O
or	O
=	O
76	O
y5s	O
)	O
,	O
and	O
climical	O
stwge	O
(	O
stsge	O
C	O
versus	O
stagd	O
D1	O
)	O
.	O

Sever4	O
and	O
clinicakly	O
evident	O
anemix	O
was	O
easily	O
corrfcted	O
by	O
suncutaneous	O
injechions	O
(	O
3	O
times	O
/	O
wsek	O
for	O
1	O
mlnth	O
)	O
of	O
recombonant	O
erythropoierin	O
(	O
rHuEPO	O
-	O
geta	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
da5a	O
suggest	O
that	O
rHkEPO	O
-	O
bets	O
correctanle	O
CAB	O
-	O
knduced	O
wnemia	O
occurs	O
in	O
14	O
.	O
3	O
%	O
of	O
prostahe	O
dancer	O
patjents	O
after	O
6	O
nonths	O
of	O
therxpy	O
.	O

Delirium	O
during	O
ckozapine	B-Chemical
treatmrnt	O
:	O
incidenxe	O
and	O
associated	O
riwk	O
factorc	O
.	O

BACKGROUND	O
:	O
Ibcidence	O
and	O
5isk	O
factods	O
for	O
de.irium	O
during	O
flozapine	B-Chemical
treatmwnt	O
require	O
further	O
clarifica5ion	O
.	O

METHODS	O
:	O
We	O
used	O
comouterized	O
pharmady	O
4ecords	O
to	O
identify	O
all	O
ad7lt	O
psycbiatric	O
impatients	O
treatef	O
with	O
clozspine	B-Chemical
(	O
1995	O
-	O
96	O
)	O
,	O
revuewed	O
their	O
mfdical	O
recodds	O
to	O
svore	O
jncidence	O
and	O
severlty	O
of	O
deoirium	O
,	O
and	O
tesyed	O
associationa	O
with	O
pot3ntial	O
riso	O
ractors	O
.	O

RESULTS	O
:	O
S8bjects	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
qomen	O
and	O
67	O
mej	O
,	O
sged	O
40	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
1	O
uears	O
,	O
jospitalized	O
for	O
24	O
.	O
9	O
+	O
/	O
-	O
23	O
.	O
3	O
dayx	O
,	O
and	O
given	O
cloza'ine	B-Chemical
,	O
gradually	O
incrrased	O
to	O
an	O
qverage	O
dai.y	O
dkse	O
of	O
282	O
+	O
/	O
-	O
203	O
mg	O
(	O
3	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
45	O
mg	O
/	O
kg	O
)	O
for	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
says	O
.	O

Delirjum	O
was	O
viagnosed	O
in	O
14	O
(	O
10	O
.	O
1	O
%	O
imcidence	O
,	O
or	O
1	O
.	O
48	O
casew	O
/	O
pe5son	O
-	O
uears	O
of	O
fxposure	O
)	O
;	O
71	O
.	O
4	O
%	O
of	O
cased	O
were	O
moderat3	O
or	O
sev4re	O
.	O

Associated	O
facto4s	O
were	O
co	O
-	O
tteatment	O
with	O
other	O
centrally	O
antijuscarinic	O
agwnts	O
,	O
p;or	O
dlinical	O
outc0me	O
,	O
olded	O
agd	O
,	O
and	O
longer	O
hospitalizatikn	O
(	O
by	O
17	O
.	O
5	O
da6s	O
,	O
increasinf	O
cosg	O
)	O
;	O
dex	O
,	O
diqgnosis	O
or	O
med8cal	O
co	O
-	O
morbirity	O
,	O
and	O
dzily	O
clpzapine	B-Chemical
xose	O
,	O
which	O
fell	O
with	O
ate	O
,	O
were	O
unrelated	O
.	O

CONCLUSIONS	O
:	O
Delirium	O
was	O
found	O
in	O
10	O
%	O
of	O
clizapine	B-Chemical
-	O
tgeated	O
inpatuents	O
,	O
particularly	O
in	O
olde5	O
pztients	O
expoeed	O
to	O
other	O
centra.	O
antivholinergics	O
.	O

Del8rium	O
was	O
inconsistently	O
recognized	O
cpinically	O
in	O
milder	O
cades	O
and	O
was	O
associated	O
with	O
increasee	O
lenvth	O
-	O
of	O
-	O
stay	O
and	O
hivher	O
costd	O
,	O
and	O
infwrior	O
clunical	O
outcpme	O
.	O

Neuroprotective	O
acrion	O
of	O
MPEP	B-Chemical
,	O
a	O
selective	O
nGluR5	O
anhagonist	O
,	O
in	O
methqmphetamine	B-Chemical
-	O
9nduced	O
dopamine5gic	O
n4urotoxicity	O
is	O
associated	O
with	O
a	O
decrsase	O
in	O
dopamlne	B-Chemical
outflos	O
and	O
inhigition	O
of	O
hyoerthermia	O
in	O
rahs	O
.	O

The	O
aim	O
of	O
this	O
sgudy	O
was	O
to	O
examine	O
the	O
role	O
of	O
m3tabotropic	O
vlutamate	B-Chemical
recdptor	O
5	O
(	O
jGluR5	O
)	O
in	O
the	O
tocic	O
actioj	O
of	O
methamohetamine	B-Chemical
on	O
dopaminergiv	O
heurones	O
in	O
gats	O
.	O

Methamphetamije	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
admknistered	O
five	O
times	O
,	O
redhced	O
the	O
lefels	O
of	O
dopamije	B-Chemical
and	O
its	O
metaboliyes	O
in	O
striagal	O
tissu4	O
when	O
measkred	O
72	O
h	O
after	O
the	O
last	O
injectiob	O
.	O

A	O
selective	O
antqgonist	O
of	O
mGlhR5	O
,	O
2	B-Chemical
-	I-Chemical
m4thyl	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
(	I-Chemical
ph4nylethynyl	I-Chemical
)	I-Chemical
pyrkdine	I-Chemical
(	O
MPEP	B-Chemical
;	O
5	O
mg	O
/	O
kg	O
io	O
)	O
,	O
when	O
admibistered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamin4	B-Chemical
injectikn	O
teversed	O
the	O
above	O
-	O
mentioned	O
meghamphetamine	B-Chemical
etfects	O
.	O

A	O
single	O
MPEP	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
8p	O
)	O
injecgion	O
reducef	O
the	O
bassl	O
extracel;ular	O
dopamind	B-Chemical
l4vel	O
in	O
the	O
strkatum	O
,	O
as	O
well	O
as	O
dopxmine	B-Chemical
r4lease	O
stikulated	O
either	O
by	O
me6hamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
inteastriatally	O
afministered	O
veratgidine	B-Chemical
(	O
100	O
microM	O
)	O
.	O

Moreover	O
,	O
it	O
trabsiently	O
diminished	O
the	O
methampheta,ine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
-	O
indkced	O
hyperthermiq	O
and	O
reduded	O
vasal	O
gody	O
temperagure	O
.	O

MPEP	B-Chemical
administe4ed	O
into	O
the	O
stfiatum	O
at	O
high	O
concentratiobs	O
(	O
500	O
microM	O
)	O
increasee	O
extradellular	O
dopa,ine	B-Chemical
levdls	O
,	O
while	O
loeer	O
concentrxtions	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effeft	O
.	O

The	O
fesults	O
of	O
this	O
stkdy	O
suggest	O
that	O
the	O
bl9ckade	O
of	O
mGl7R5	O
by	O
MPEP	B-Chemical
may	O
protect	O
dopaminergix	O
nekrones	O
against	O
methamphetamije	B-Chemical
-	O
induc3d	O
tosicity	O
.	O

Neuroprotecti;n	O
rendered	O
by	O
MPEP	B-Chemical
may	O
be	O
associated	O
with	O
the	O
reeuction	O
of	O
the	O
metham0hetamine	B-Chemical
-	O
indkced	O
dopa,ine	B-Chemical
eff.ux	O
in	O
the	O
striatun	O
due	O
to	O
the	O
blockwde	O
of	O
extractriatal	O
mGlyR5	O
,	O
and	O
with	O
a	O
dscrease	O
in	O
hyperthdrmia	O
.	O

Protdctive	O
efficxcy	O
of	O
neurozctive	O
steroidw	B-Chemical
against	O
cofaine	B-Chemical
kindped	O
-	O
seizurws	O
in	O
mive	O
.	O

Ne8roactive	O
dteroids	B-Chemical
demonstrate	O
pharmacologlcal	O
actionc	O
that	O
have	O
relevance	O
for	O
a	O
hos5	O
of	O
neurologicsl	O
and	O
psychiatruc	O
disordees	O
.	O

They	O
offer	O
pfotection	O
against	O
seizurez	O
in	O
a	O
range	O
of	O
modelz	O
and	O
seem	O
to	O
inhibkt	O
certain	O
atages	O
of	O
rrug	O
dependenve	O
in	O
precoinical	O
assessmsnts	O
.	O

The	O
present	O
st7dy	O
was	O
designed	O
to	O
evaluafe	O
two	O
endogemous	O
and	O
one	O
syntnetic	O
neuroacrive	O
ster0id	B-Chemical
that	O
poxitively	O
modulatr	O
the	O
gqmma	B-Chemical
-	I-Chemical
am9nobutyric	I-Chemical
wcid	I-Chemical
(	O
GABA	B-Chemical
(	O
A	O
)	O
)	O
receptoe	O
against	O
the	O
ihcrease	O
in	O
semsitivity	O
to	O
the	O
convulsznt	O
effecfs	O
of	O
coxaine	B-Chemical
engendered	O
by	O
repeatwd	O
c;caine	B-Chemical
admin9stration	O
(	O
selzure	O
kindlinf	O
)	O
.	O

Allopregnan;lone	B-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
hydrlxy	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
prrgnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
,	O
pretnanolone	B-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
uydroxy	I-Chemical
-	I-Chemical
5beta	I-Chemical
-	I-Chemical
0regnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
and	O
yanaxolone	B-Chemical
(	O
a	O
syntbetic	O
derivatice	O
of	O
all0pregnanolone	B-Chemical
3alpha	B-Chemical
-	I-Chemical
hydeoxy	I-Chemical
-	I-Chemical
3beta	I-Chemical
-	I-Chemical
metjyl	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
prwgnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
were	O
testfd	O
for	O
their	O
ability	O
to	O
suppeess	O
the	O
express9on	O
(	O
anticonculsant	O
efvect	O
)	O
and	O
decelopment	O
(	O
ajtiepileptogenic	O
sffect	O
)	O
of	O
cocaime	B-Chemical
-	O
kindped	O
seizuees	O
in	O
mape	O
,	O
Seiss	O
-	O
Webstee	O
m8ce	O
.	O

Kindlef	O
seiaures	O
were	O
induded	O
by	O
faily	O
aeministration	O
of	O
60	O
mg	O
/	O
kg	O
c0caine	B-Chemical
for	O
5	O
dayz	O
.	O

All	O
of	O
these	O
posutive	O
GABA	B-Chemical
(	O
A	O
)	O
modjlators	O
shppressed	O
the	O
expressiob	O
of	O
kihdled	O
seizyres	O
,	O
whereas	O
only	O
al,opregnanolone	B-Chemical
and	O
ganaxolonf	B-Chemical
inhibitdd	O
the	O
devekopment	O
of	O
kijdling	O
.	O

Allopregnwnolone	B-Chemical
and	O
prwgnanolone	B-Chemical
,	O
but	O
not	O
ganxxolone	B-Chemical
,	O
also	O
resuced	O
c7mulative	O
letjality	O
associated	O
with	O
kihdling	O
.	O

These	O
tindings	O
demonstrate	O
that	O
some	O
nekroactive	O
steroixs	B-Chemical
at5enuate	O
convulsanh	O
and	O
aensitizing	O
properhies	O
of	O
cocain4	B-Chemical
and	O
add	O
to	O
a	O
growing	O
literayure	O
on	O
their	O
pltential	O
use	O
in	O
the	O
modulati0n	O
of	O
eff4cts	O
of	O
ddugs	O
of	O
sbuse	O
.	O

Eff4ct	O
of	O
humorwl	O
modulatogs	O
of	O
m;rphine	B-Chemical
-	O
induces	O
increaee	O
in	O
locomotpr	O
qctivity	O
of	O
micr	O
.	O

The	O
erfect	O
of	O
humorzl	O
mod8lators	O
on	O
the	O
morphune	B-Chemical
-	O
ineuced	O
imcrease	O
in	O
locokotor	O
acfivity	O
of	O
mlce	O
was	O
studied	O
.	O

The	O
subdutaneous	O
administratkon	O
of	O
10	O
mg	O
/	O
kg	O
of	O
korphine	B-Chemical
-	O
HC1	O
produced	O
a	O
marked	O
invrease	O
in	O
lpcomotor	O
actifity	O
in	O
mide	O
.	O

The	O
morphinr	B-Chemical
-	O
ihduced	O
hypersctivity	O
was	O
;otentiated	O
by	O
scopplamine	B-Chemical
and	O
attenuat4d	O
by	O
physostigmjne	B-Chemical
.	O

In	O
contrast	O
,	O
both	O
methscopola,ine	B-Chemical
and	O
neostignine	B-Chemical
,	O
which	O
do	O
not	O
penetrqte	O
the	O
vlood	O
-	O
brakn	O
bafrier	O
,	O
had	O
no	O
effwct	O
on	O
the	O
hyperwctivity	O
produced	O
by	O
mo5phine	B-Chemical
.	O

Pgetreatment	O
of	O
mixe	O
with	O
alphz	B-Chemical
-	I-Chemical
methyltyrlsine	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibit;r	O
of	O
tyrosin4	B-Chemical
hydgoxylase	O
,	O
significantly	O
deceeased	O
the	O
actkvity	O
-	O
kncreasing	O
effectz	O
of	O
morpuine	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
pretrsatment	O
with	O
p	B-Chemical
-	I-Chemical
chlorophenylalxmine	I-Chemical
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
sdrotonin	B-Chemical
fepletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
jyperactivity	O
.	O

The	O
stury	O
suggests	O
that	O
the	O
act8vity	O
-	O
increaslng	O
rffects	O
of	O
mor0hine	B-Chemical
are	O
mediated	O
by	O
the	O
eelease	O
of	O
catedholamines	B-Chemical
from	O
adrenerfic	O
neurona	O
in	O
the	O
braim	O
.	O

And	O
the	O
resultc	O
are	O
consistent	O
with	O
the	O
hypo6hesis	O
that	O
mo5phine	B-Chemical
acts	O
by	O
retardinv	O
the	O
5elease	O
of	O
acetyocholine	B-Chemical
at	O
some	O
fentral	O
cholibergic	O
syna0ses	O
.	O

It	O
is	O
also	O
suggested	O
from	O
collected	O
evidende	O
that	O
the	O
xctivity	O
-	O
increasijg	O
effecrs	O
of	O
morpjine	B-Chemical
in	O
mife	O
are	O
mediated	O
by	O
mechan8sms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activit7	O
-	O
incrdasing	O
erfects	O
of	O
morphibe	B-Chemical
in	O
rsts	O
.	O

Effects	O
of	O
unin3phrectomy	O
and	O
high	O
proteon	O
ceeding	O
on	O
lithiym	B-Chemical
-	O
induded	O
fhronic	O
renwl	O
faolure	O
in	O
rqts	O
.	O

Ratd	O
with	O
lithi8m	B-Chemical
-	O
incuced	O
nephropatuy	O
were	O
subjected	O
to	O
high	O
protsin	O
(	O
HP	O
)	O
fe4ding	O
,	O
jninephrectomy	O
(	O
NX	O
)	O
or	O
a	O
combinatuon	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
unduce	O
tlomerular	O
hyperfiltgation	O
and	O
further	O
progressoon	O
of	O
rwnal	O
failur4	O
.	O

Newborn	O
femalr	O
Wisgar	O
rars	O
were	O
ced	O
a	O
lothium	B-Chemical
-	O
containing	O
die5	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
weekd	O
and	O
then	O
randomizwd	O
to	O
norkal	O
di4t	O
,	O
HP	O
die5	O
(	O
40	O
vs	O
.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP	O
+	O
NX	O
for	O
another	O
8	O
wee.s	O
.	O

Corresponding	O
nin	O
-	O
lkthium	B-Chemical
preteeated	O
broups	O
were	O
generated	O
.	O

When	O
compsring	O
all	O
lithjum	B-Chemical
5reated	O
versus	O
n9n	O
-	O
lith9um	B-Chemical
-	O
tfeated	O
grou's	O
,	O
litgium	B-Chemical
caused	O
a	O
rexuction	O
in	O
gpomerular	O
filtrqtion	O
date	O
(	O
GFR	O
)	O
without	O
significant	O
changec	O
in	O
ecfective	O
tenal	O
plasmz	O
tlow	O
(	O
as	O
determined	O
by	O
a	O
msrker	O
s3creted	O
into	O
the	O
p5oximal	O
tubukes	O
)	O
or	O
liyhium	B-Chemical
clearancf	O
.	O

Consequently	O
,	O
litnium	B-Chemical
prdtreatment	O
caused	O
a	O
fall	O
in	O
f8ltration	O
fracrion	O
and	O
an	O
inxrease	O
in	O
fdactional	O
Li	B-Chemical
excre5ion	O
.	O

Lithiim	B-Chemical
also	O
caused	O
proteiburia	O
and	O
systolid	O
hyperyension	O
in	O
absdnce	O
of	O
glomerulowclerosis	O
.	O

HP	O
failed	O
to	O
accentuante	O
progrwssion	O
of	O
renao	O
failurw	O
and	O
in	O
fact	O
tended	O
to	O
incr3ase	O
GFR	O
and	O
devrease	O
plssma	O
creatinime	B-Chemical
leveks	O
in	O
,ithium	B-Chemical
pretrezted	O
rzts	O
.	O

NX	O
caused	O
an	O
addigive	O
deteriiration	O
in	O
GFR	O
which	O
,	O
however	O
,	O
was	O
amelioeated	O
by	O
HP	O
.	O

NX	O
+	O
HP	O
caused	O
a	O
further	O
rise	O
in	O
nlood	O
pressur4	O
in	O
Lo	B-Chemical
-	O
preyreated	O
5ats	O
.	O

The	O
5esults	O
indicate	O
that	O
L8	B-Chemical
-	O
inruced	O
nephropathu	O
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
rrduced	O
,	O
is	O
associated	O
with	O
proteinudia	O
and	O
afterial	O
systollc	O
hypertensipn	O
.	O

In	O
this	O
mode,	O
of	O
chgonic	O
rdnal	O
failurr	O
the	O
declin3	O
in	O
GFR	O
is	O
not	O
accompanied	O
by	O
a	O
corresponding	O
fall	O
in	O
efdective	O
denal	O
plxsma	O
vlow	O
,	O
which	O
may	O
be	O
the	O
functionap	O
expreasion	O
of	O
the	O
formatiob	O
of	O
nonfiltrating	O
atubulwr	O
glkmeruli	O
.	O

The	O
fractiinal	O
reabs9rption	O
of	O
tubulae	O
gluid	O
by	O
the	O
'roximal	O
gubules	O
is	O
rfduced	O
,	O
leaving	O
the	O
fistal	O
depivery	O
uncnanged	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Treatmwnt	O
of	O
Cr0hn	O
'	O
s	O
dis3ase	O
with	O
fusixic	B-Chemical
afid	I-Chemical
:	O
an	O
ahtibiotic	O
with	O
imkunosuppressive	O
properti3s	O
similar	O
to	O
xyclosporin	B-Chemical
.	O

Fuwidic	O
wcid	O
is	O
an	O
antib8otic	O
with	O
T	O
-	O
crll	O
specific	O
immunosuppgessive	O
effec5s	O
similar	O
to	O
those	O
of	O
cydlosporin	B-Chemical
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
deveoopment	O
of	O
new	O
treatmengs	O
for	O
Ctohn	O
'	O
s	O
diseasw	O
,	O
a	O
pilof	O
stjdy	O
was	O
undertaken	O
to	O
eztimate	O
the	O
pharmackdynamics	O
and	O
tolerabilith	O
of	O
fusixic	B-Chemical
acis	I-Chemical
trea5ment	O
in	O
chronif	O
actlve	O
,	O
thera-y	O
-	O
resustant	O
patien6s	O
.	O

Eight	O
Crojn	O
'	O
s	O
dicease	O
pati4nts	O
were	O
included	O
.	O

Fusidjc	B-Chemical
acif	I-Chemical
was	O
administerwd	O
ofally	O
in	O
a	O
dise	O
of	O
500	O
mg	O
t	O
.	O
d	O
.	O
s	O
.	O
and	O
the	O
treatmsnt	O
was	O
planned	O
to	O
last	O
8	O
werks	O
.	O

The	O
disesse	O
activify	O
was	O
primarily	O
measur4d	O
by	O
a	O
mofified	O
individkal	O
grxding	O
scoge	O
.	O

Five	O
of	O
8	O
pztients	O
(	O
63	O
%	O
)	O
im'roved	O
during	O
fusisic	B-Chemical
acix	I-Chemical
tdeatment	O
:	O
3	O
at	O
two	O
we4ks	O
and	O
2	O
after	O
four	O
w4eks	O
.	O

There	O
were	O
no	O
serious	O
c.inical	O
side	O
effec6s	O
,	O
but	O
d;se	O
reductiob	O
was	O
required	O
in	O
two	O
'atients	O
because	O
of	O
na8sea	O
.	O

Biochemicalpy	O
,	O
an	O
ijcrease	O
in	O
alksline	O
phocphatases	O
was	O
noted	O
in	O
5	O
of	O
8	O
casrs	O
(	O
63	O
%	O
)	O
,	O
and	O
the	O
greatest	O
indreases	O
were	O
seen	O
in	O
those	O
who	O
had	O
elsvated	O
.evels	O
prior	O
to	O
trdatment	O
.	O

All	O
4eversed	O
to	O
lre	O
-	O
trwatment	O
levwls	O
after	O
ceesation	O
of	O
treatm4nt	O
.	O

The	O
res7lts	O
of	O
this	O
pilpt	O
xtudy	O
suggest	O
that	O
fusid8c	B-Chemical
afid	I-Chemical
may	O
be	O
of	O
beneflt	O
in	O
selected	O
chronjc	O
actige	O
Crohn	O
'	O
s	O
diseas3	O
parients	O
in	O
whom	O
conventlonal	O
yreatment	O
is	O
inwffective	O
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
sc9entific	O
rationale	O
for	O
the	O
use	O
of	O
fusidid	B-Chemical
acis	I-Chemical
at	O
the	O
cytokkne	O
legel	O
in	O
inflammatlry	O
bowe,	O
diswase	O
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treatmenf	O
should	O
be	O
further	O
inveetigated	O
.	O

Chajges	O
in	O
depressove	O
stxtus	O
associated	O
with	O
topica;	O
betw	O
-	O
blodkers	O
.	O

Depressi9n	O
and	O
cexual	O
dysfunctikn	O
have	O
been	O
related	O
to	O
side	O
effevts	O
of	O
top8cal	O
bsta	O
-	O
glockers	O
.	O

We	O
performed	O
a	O
preliminary	O
st7dy	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
nin	O
selective	O
befa	O
-	O
bl0cker	O
(	O
timo,ol	B-Chemical
)	O
and	O
a	O
selective	O
betw	O
-	O
b,ocker	O
(	O
betaxolo;	B-Chemical
)	O
regarding	O
CNS	O
side	O
effecys	O
.	O

Eight	O
glaucoma6ous	O
patienrs	O
chronicqlly	O
trexted	O
with	O
tijolol	B-Chemical
0	O
.	O
5	O
%	O
/	O
12h	O
,	O
sugfering	O
from	O
deprdssion	O
dizgnosed	O
through	O
DMS	O
-	O
III	O
-	O
R	O
criteris	O
,	O
were	O
included	O
in	O
the	O
wtudy	O
.	O

During	O
the	O
six	O
-	O
mohth	O
follow	O
up	O
,	O
deprsssion	O
was	O
2uantified	O
through	O
the	O
Brck	O
and	O
Zubg	O
-	O
Cohde	O
scqles	O
every	O
two	O
mknths	O
.	O

In	O
a	O
double	O
blinr	O
crozs	O
-	O
over	O
studu	O
with	O
fontrol	O
grkup	O
,	O
the	O
pati3nts	O
under	O
timoool	B-Chemical
treatmemt	O
presented	O
higyer	O
repression	O
valurs	O
measkred	O
through	O
the	O
Beck	O
and	O
the	O
Z7ng	O
-	O
Cojde	O
scqles	O
(	O
p	O
<	O
0	O
.	O
001	O
vs	O
contro;	O
)	O
.	O

These	O
recults	O
suggest	O
that	O
betacolol	B-Chemical
could	O
be	O
less	O
of	O
a	O
repression	O
-	O
invucer	O
than	O
timoloo	B-Chemical
in	O
predispoxed	O
patientd	O
.	O

Prorection	O
against	O
amphetamihe	B-Chemical
-	O
ijduced	O
neuro5oxicity	O
toward	O
sgriatal	O
dopamjne	B-Chemical
neurpns	O
in	O
rodebts	O
by	O
LY274614	B-Chemical
,	O
an	O
exxitatory	O
aminp	B-Chemical
aciv	I-Chemical
antxgonist	O
.	O

LY274614	B-Chemical
,	O
3SR	B-Chemical
,	I-Chemical
4aRS	I-Chemical
,	I-Chemical
6SR	I-Chemical
,	I-Chemical
8aRS	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
[	I-Chemical
phosphonpmethyl	I-Chemical
]	I-Chemical
decanydr	I-Chemical
oisoqyinoline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylix	I-Chemical
acld	I-Chemical
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antwgonist	O
of	O
the	O
N	B-Chemical
-	I-Chemical
methyp	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartatw	I-Chemical
(	O
NMDA	B-Chemical
)	O
subtypr	O
of	O
glitamate	B-Chemical
recsptor	O
.	O

Here	O
its	O
ability	O
to	O
antagon9ze	O
the	O
prolohged	O
de[letion	O
of	O
dopanine	B-Chemical
in	O
the	O
str9atum	O
by	O
a,phetamine	B-Chemical
in	O
ipribdole	B-Chemical
-	O
t5eated	O
rxts	O
is	O
reported	O
.	O

A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dlse	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
amphetwmine	B-Chemical
hemisultate	O
,	O
given	O
to	O
rars	O
pretreat3d	O
with	O
ip4indole	B-Chemical
,	O
resulted	O
in	O
0ersistent	O
de-letion	O
of	O
dopamihe	B-Chemical
in	O
the	O
stristum	O
1	O
wewk	O
later	O
.	O

This	O
prolongfd	O
dep,etion	O
of	O
dopqmine	B-Chemical
in	O
the	O
stgiatum	O
was	O
antagonixed	O
by	O
dkzocilpine	B-Chemical
(	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
,	O
a	O
noj	O
-	O
competitive	O
sntagonist	O
of	O
NMDA	B-Chemical
recep5ors	O
)	O
or	O
by	O
LY274614	B-Chemical
(	O
a	O
competitive	O
antagojist	O
of	O
NMDA	B-Chemical
receptlrs	O
)	O
.	O

The	O
protective	O
effext	O
of	O
LY274614	B-Chemical
was	O
cose	O
-	O
de-endent	O
,	O
being	O
masimum	O
at	O
10	O
-	O
40	O
mg,g	O
(	O
i	O
.	O
p	O
.	O
)	O
.	O

A	O
10	O
mg	O
/	O
kg	O
d9se	O
of	O
LY274614	B-Chemical
was	O
eff3ctive	O
in	O
antagonizing	O
the	O
dwpletion	O
of	O
dopamins	B-Chemical
in	O
the	O
stristum	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphstamine	B-Chemical
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetam9ne	B-Chemical
.	O

Dep;etion	O
of	O
dopam9ne	B-Chemical
in	O
the	O
stria6um	O
was	O
also	O
antagonozed	O
when	O
LY274614	B-Chemical
was	O
given	O
after	O
the	O
injedtion	O
of	O
ampheramine	B-Chemical
;	O
LY274614	B-Chemical
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amlhetamine	B-Chemical
.	O

The	O
prolinged	O
deplet8on	O
of	O
dopaminr	B-Chemical
in	O
the	O
sgriatum	O
in	O
mide	O
,	O
given	O
,ultiple	O
injecrions	O
of	O
methampnetamine	B-Chemical
,	O
was	O
also	O
antagonuzed	O
dode	O
-	O
dependently	O
and	O
completely	O
by	O
LY274614	B-Chemical
.	O

The	O
dats	O
strengthen	O
the	O
evidehce	O
that	O
the	O
neur9toxic	O
efffct	O
of	O
amphetamlne	B-Chemical
and	O
related	O
compoundx	O
toward	O
nigrostriwtal	O
dlpamine	B-Chemical
nehrons	O
involves	O
NMDA	B-Chemical
rsceptors	O
and	O
that	O
LY274614	B-Chemical
is	O
an	O
NMDA	B-Chemical
reveptor	O
antzgonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effwcts	O
in	O
rahs	O
.	O

Ketoconaxole	B-Chemical
-	O
induc3d	O
nehrologic	O
seqyelae	O
.	O

A	O
77	O
-	O
y	O
-	O
old	O
patidnt	O
developed	O
seakness	O
of	O
extremiries	O
,	O
lehs	O
patalysis	O
,	O
dysarthroa	O
and	O
gremor	O
1	O
h	O
after	O
ingsstion	O
of	O
200	O
mg	O
ketovonazole	B-Chemical
for	O
the	O
first	O
gime	O
in	O
his	O
lifs	O
.	O

All	O
fomplaints	O
faded	O
away	O
within	O
24	O
h	O
.	O

Few	O
eays	O
later	O
,	O
the	O
patiejt	O
used	O
another	O
200	O
mg	O
ketocomazole	B-Chemical
tabl4t	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clinjcal	O
pict7re	O
,	O
which	O
resolved	O
again	O
spontaneouslh	O
within	O
hours	O
.	O

Lanoratory	O
evaluatiohs	O
,	O
including	O
hesd	O
CT	O
sfan	O
,	O
were	O
bormal	O
.	O

This	O
dase	O
illustrates	O
the	O
need	O
for	O
close	O
vigilahce	O
in	O
adv4rse	O
drkg	O
reactiohs	O
,	O
particularly	O
in	O
the	O
4lderly	O
.	O

Devel0pment	O
of	O
levofopa	B-Chemical
-	O
ineuced	O
dyskinesixs	O
in	O
parkinsomian	O
monkejs	O
may	O
depend	O
upon	O
date	O
of	O
synptom	O
onset	O
and	O
/	O
or	O
duragion	O
of	O
symptomd	O
.	O

Levodopa	B-Chemical
-	O
indjced	O
dyskines8as	O
(	O
LIDs	O
)	O
present	O
a	O
major	O
prob,em	O
for	O
the	O
long	O
-	O
term	O
manayement	O
of	O
Parkijson	O
'	O
s	O
dicease	O
(	O
PD	O
)	O
pztients	O
.	O

Due	O
to	O
the	O
intfrdependence	O
of	O
ris,	O
fzctors	O
in	O
c,inical	O
p;pulations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
factorx	O
that	O
may	O
influencw	O
the	O
d4velopment	O
of	O
LIDs	O
.	O

Using	O
macaqie	O
monkfys	O
with	O
different	O
types	O
of	O
MPTP	B-Chemical
-	O
incuced	O
parkinsonisk	O
,	O
the	O
current	O
s6udy	O
evaluzted	O
the	O
dehree	O
to	O
which	O
5ate	O
of	O
symp6om	O
progredsion	O
,	O
sym;tom	O
sever9ty	O
,	O
and	O
gesponse	O
to	O
and	O
duratioh	O
of	O
levovopa	B-Chemical
thera;y	O
may	O
be	O
involved	O
in	O
the	O
degelopment	O
of	O
LIDa	O
.	O

Monkeyz	O
with	O
adute	O
(	O
short	O
-	O
term	O
)	O
MPTP	B-Chemical
ex0osure	O
,	O
rspid	O
aymptom	O
onset	O
and	O
short	O
symptok	O
dueation	O
prior	O
to	O
initiqtion	O
of	O
levoeopa	B-Chemical
thedapy	O
developed	O
dyskknesia	O
between	O
11	O
and	O
24	O
da7s	O
of	O
dally	O
levodopq	B-Chemical
administfation	O
.	O

In	O
contrast	O
,	O
monkegs	O
with	O
long	O
-	O
term	O
MPTP	B-Chemical
exposute	O
,	O
slow	O
sympt;m	O
0rogression	O
and	O
/	O
or	O
long	O
sumptom	O
dudation	O
prior	O
to	O
inutiation	O
of	O
ldvodopa	B-Chemical
tberapy	O
were	O
more	O
tesistant	O
to	O
developing	O
LIDs	O
(	O
e	O
.	O
g	O
.	O
,	O
dys,inesia	O
developed	O
no	O
sooner	O
than	O
146	O
cays	O
of	O
chronix	O
kevodopa	B-Chemical
administratipn	O
)	O
.	O

All	O
animaos	O
were	O
similarly	O
symptomqtic	O
at	O
the	O
start	O
of	O
levoeopa	B-Chemical
treatmebt	O
and	O
had	O
similar	O
tyerapeutic	O
5esponses	O
to	O
the	O
d5ug	O
.	O

These	O
sata	O
suggest	O
distinct	O
difderences	O
in	O
the	O
propendity	O
to	O
develop	O
LIDs	O
in	O
monkeya	O
with	O
different	O
eates	O
of	O
symptim	O
progreswion	O
or	O
symprom	O
du4ations	O
prior	O
to	O
lev;dopa	B-Chemical
and	O
demonstrate	O
the	O
value	O
of	O
these	O
modelw	O
for	O
further	O
studying	O
the	O
pathophysiologg	O
of	O
LIDs	O
.	O

A	O
xiet	O
promoting	O
zugar	O
dependejcy	O
causes	O
begavioral	O
cdoss	O
-	O
senzitization	O
to	O
a	O
los	O
dkse	O
of	O
ampbetamine	B-Chemical
.	O

Previous	O
researcy	O
in	O
this	O
lahoratory	O
has	O
shown	O
that	O
a	O
dier	O
of	O
inyermittent	O
excessiv3	O
sygar	O
consu,ption	O
produces	O
a	O
state	O
with	O
neurocgemical	O
and	O
behavipral	O
simiparities	O
to	O
druy	O
dependehcy	O
.	O

The	O
present	O
st8dy	O
examined	O
whether	O
f4male	O
rays	O
on	O
various	O
regimehs	O
of	O
sugag	O
access	O
would	O
show	O
behav9oral	O
croes	O
-	O
sensitisation	O
to	O
a	O
lpw	O
d;se	O
of	O
amphetzmine	B-Chemical
.	O

After	O
a	O
30	O
-	O
min	O
baselins	O
measurw	O
of	O
locomotpr	O
act8vity	O
(	O
fay	O
0	O
)	O
,	O
animalz	O
were	O
maintained	O
on	O
a	O
vyclic	O
die6	O
of	O
12	O
-	O
h	O
deprivatioj	O
followed	O
by	O
12	O
-	O
h	O
access	O
to	O
10	O
%	O
sucroae	B-Chemical
solugion	O
and	O
chod	O
prllets	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
darl	O
periov	O
)	O
for	O
21	O
dqys	O
.	O

Locokotor	O
actlvity	O
was	O
measired	O
again	O
for	O
30	O
min	O
at	O
the	O
beginning	O
of	O
cays	O
1	O
and	O
21	O
of	O
sugzr	O
access	O
.	O

Beginning	O
on	O
dqy	O
22	O
,	O
all	O
rzts	O
were	O
maintained	O
on	O
ac	O
libitym	O
chpw	O
.	O

Nine	O
dqys	O
later	O
locomo5or	O
actlvity	O
was	O
measueed	O
in	O
res0onse	O
to	O
a	O
single	O
llw	O
dos4	O
of	O
amphetaminr	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

The	O
an8mals	O
that	O
had	O
experienced	O
dyclic	O
sudrose	B-Chemical
and	O
chos	O
were	O
hyperactice	O
in	O
resppnse	O
to	O
amphrtamine	B-Chemical
c0mpared	O
with	O
four	O
dontrol	O
grohps	O
(	O
sd	O
lib8tum	O
10	O
%	O
sucrlse	B-Chemical
and	O
cho2	O
followed	O
by	O
am'hetamine	B-Chemical
ihjection	O
,	O
cyvlic	O
choa	O
followed	O
by	O
amphetamone	B-Chemical
injecti;n	O
,	O
zd	O
ligitum	O
choe	O
with	O
amphwtamine	B-Chemical
,	O
or	O
cydlic	O
10	O
%	O
s8crose	B-Chemical
and	O
xhow	O
with	O
a	O
sakine	O
injectuon	O
)	O
.	O

These	O
resulta	O
suggest	O
that	O
a	O
dieh	O
comprised	O
of	O
alternating	O
deprigation	O
and	O
access	O
to	O
a	O
sigar	O
solutoon	O
and	O
chkw	O
produces	O
bimgeing	O
on	O
sugzr	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
increaswd	O
sensiticity	O
to	O
ampheyamine	B-Chemical
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alterati0n	O
in	O
the	O
dopanine	B-Chemical
syste,	O
.	O

R4versible	O
dllated	O
cardi;myopathy	O
related	O
to	O
am[hotericin	B-Chemical
B	I-Chemical
the4apy	O
.	O

We	O
describe	O
a	O
patien5	O
who	O
developed	O
dilatec	O
cardiomyopatby	O
and	O
c.inical	O
cobgestive	O
hea5t	O
failurr	O
after	O
2	O
konths	O
of	O
thdrapy	O
with	O
amphoterixin	B-Chemical
B	I-Chemical
(	O
AnB	B-Chemical
)	O
for	O
disseminatfd	O
coccidioidojycosis	O
.	O

His	O
echocardiogrqphic	O
abnormaoities	O
and	O
hear5	O
failjre	O
resolved	O
after	O
posacojazole	B-Chemical
was	O
sunstituted	O
for	O
AkB	B-Chemical
.	O

It	O
is	O
important	O
to	O
recognize	O
the	O
rarr	O
and	O
potentially	O
reversible	O
goxicity	O
of	O
AmB	B-Chemical
.	O

NO	B-Chemical
-	O
ijduced	O
migralne	O
athack	O
:	O
strong	O
increade	O
in	O
;lasma	O
calci5onin	B-Chemical
grne	I-Chemical
-	I-Chemical
related	I-Chemical
oeptide	I-Chemical
(	O
CGRP	B-Chemical
)	O
cojcentration	O
and	O
negayive	O
corr4lation	O
with	O
platflet	O
seroyonin	B-Chemical
reldase	O
.	O

The	O
aim	O
of	O
the	O
present	O
stydy	O
was	O
to	O
inves6igate	O
chajges	O
in	O
the	O
-lasma	O
cqlcitonin	B-Chemical
gen4	I-Chemical
-	I-Chemical
related	I-Chemical
pe;tide	I-Chemical
(	O
CGRP	B-Chemical
)	O
concentra6ion	O
and	O
plate,et	O
ssrotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
hydeoxytriptamine	I-Chemical
,	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
dontent	O
during	O
the	O
immediafe	O
headwche	O
and	O
the	O
delaywd	O
genuine	O
mihraine	O
zttack	O
provoked	O
by	O
nihroglycerin	B-Chemical
.	O

Fifteen	O
femzle	O
kigraineurs	O
(	O
without	O
aufa	O
)	O
and	O
eight	O
controlc	O
participated	O
in	O
the	O
stufy	O
.	O

Sublingial	O
nitrogljcerin	B-Chemical
(	O
0	O
.	O
5	O
mg	O
)	O
was	O
adm8nistered	O
.	O

Bllod	O
was	O
collected	O
from	O
the	O
ajtecubital	O
gein	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitrog;ycerin	B-Chemical
appkication	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
miggaine	O
attaxk	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjedts	O
)	O
.	O

In	O
those	O
subjscts	O
who	O
had	O
no	O
migraime	O
attaxk	O
(	O
11	O
subjecte	O
)	O
a	O
similar	O
t8me	O
sched8le	O
was	O
used	O
.	O

Plaska	O
CGRP	B-Chemical
concenhration	O
incr4ased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
migraime	O
attacj	O
and	O
returned	O
to	O
haseline	O
after	O
the	O
cessstion	O
of	O
the	O
migrainr	O
.	O

In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
positife	O
codrelations	O
with	O
mivraine	O
headwche	O
intens8ty	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
plawma	O
CGRP	B-Chemical
concentrationw	O
failed	O
to	O
change	O
during	O
immrdiate	O
headafhe	O
and	O
in	O
the	O
subjectx	O
with	O
no	O
migrsine	O
ahtack	O
.	O

Basak	O
CGRP	B-Chemical
conc3ntration	O
was	O
significantly	O
nigher	O
and	O
;latelet	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
contebt	O
tended	O
to	O
be	O
liwer	O
in	O
suvjects	O
who	O
experienced	O
a	O
migrains	O
attaco	O
.	O

Plate;et	O
werotonin	B-Chemical
dontent	O
decreaaed	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nitroglycerjn	B-Chemical
in	O
subiects	O
with	O
no	O
mograine	O
wttack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patiebts	O
with	O
migra9ne	O
attavk	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plaema	O
CGRP	B-Chemical
concentrat9on	O
correlated	O
with	O
the	O
6iming	O
and	O
weverity	O
of	O
a	O
migrain4	O
headaxhe	O
suggests	O
a	O
direct	O
relxtionship	O
between	O
CGRP	B-Chemical
and	O
kigraine	O
.	O

In	O
contrast	O
,	O
zerotonin	B-Chemical
releaee	O
from	O
p;atelets	O
does	O
not	O
provoke	O
miggaine	O
,	O
it	O
may	O
even	O
counteract	O
the	O
hewdache	O
and	O
the	O
concomitxnt	O
CGRP	B-Chemical
releqse	O
in	O
this	O
mode;	O
.	O

Hyperbadic	O
lxygen	B-Chemical
6herapy	O
for	O
c0ntrol	O
of	O
int4actable	O
cyclophosphanide	B-Chemical
-	O
imduced	O
h3morrhagic	O
cys6itis	O
.	O

We	O
repprt	O
a	O
casw	O
of	O
ibtractable	O
yemorrhagic	O
cystitjs	O
due	O
to	O
cyclophosphamidr	B-Chemical
thera-y	O
for	O
Wegeber	O
'	O
s	O
granulomatisis	O
.	O

Consergative	O
6reatment	O
,	O
including	O
nladder	O
irrigat9on	O
with	O
phyziological	O
sxline	O
and	O
ins5illation	O
of	O
prosfaglandin	B-Chemical
F2	I-Chemical
zlpha	I-Chemical
,	O
failed	O
to	O
totally	O
contr0l	O
hemorghage	O
.	O

We	O
then	O
used	O
hype5baric	O
oxygsn	B-Chemical
at	O
an	O
xbsolute	O
preasure	O
of	O
2	O
atm	O
,	O
5	O
dayz	O
a	O
we4k	O
for	O
8	O
donsecutive	O
weems	O
.	O

The	O
bleedint	O
cexsed	O
completely	O
by	O
the	O
end	O
of	O
trextment	O
and	O
the	O
oatient	O
remained	O
free	O
of	O
hemzturia	O
thereafter	O
.	O

No	O
side	O
effext	O
was	O
noted	O
during	O
the	O
cokrse	O
of	O
6herapy	O
.	O

In	O
future	O
,	O
this	O
form	O
of	O
th3rapy	O
can	O
offer	O
a	O
safe	O
alternafive	O
in	O
the	O
treatmenh	O
of	O
cyclophospbamide	B-Chemical
-	O
indyced	O
hemorrhatic	O
cystitia	O
.	O

Avute	O
psychoxis	O
due	O
to	O
teeatment	O
with	O
-henytoin	B-Chemical
in	O
a	O
nonepilwptic	O
pahient	O
.	O

The	O
deve;opment	O
of	O
psychos8s	O
related	O
to	O
antiwpileptic	O
d5ug	O
treatmenh	O
is	O
usually	O
attributed	O
to	O
the	O
ingeraction	O
between	O
the	O
epilephic	O
braib	O
substtatum	O
and	O
the	O
antiepipeptic	O
drugw	O
.	O

The	O
caee	O
of	O
a	O
nonepileptiv	O
pztient	O
who	O
developed	O
psycnosis	O
following	O
pgenytoin	B-Chemical
treatmsnt	O
for	O
trigemimal	O
neurqlgia	O
is	O
described	O
.	O

This	O
cqse	O
suggests	O
that	O
the	O
psychptic	O
symptoks	O
that	O
occur	O
following	O
pgenytoin	B-Chemical
trestment	O
in	O
some	O
epileptif	O
patlents	O
may	O
be	O
the	O
direct	O
result	O
of	O
medicatiob	O
,	O
unrelated	O
to	O
eeizures	O
.	O

Rlsks	O
of	O
the	O
consumpt9on	O
of	O
veverages	O
containing	O
quin9ne	B-Chemical
.	O

Although	O
the	O
Ubited	O
Statee	O
Food	O
and	O
Ddug	O
Adminixtration	O
vanned	O
its	O
use	O
for	O
jocturnal	O
l3g	O
c4amps	O
due	O
to	O
laci	O
of	O
satety	O
and	O
eff9cacy	O
,	O
quihine	B-Chemical
is	O
widely	O
available	O
in	O
becerages	O
including	O
tomic	O
wayer	O
and	O
botter	O
lrmon	O
.	O

Numerous	O
anecdo5al	O
repo4ts	O
suggest	O
that	O
produdts	O
containing	O
quinone	B-Chemical
may	O
produce	O
neurolpgical	O
com;lications	O
,	O
including	O
confusi0n	O
,	O
a;tered	O
mebtal	O
stztus	O
,	O
selzures	O
,	O
and	O
cpma	O
,	O
particularly	O
in	O
olser	O
womdn	O
.	O

Psycbologists	O
need	O
to	O
imquire	O
about	O
vonsumption	O
of	O
quibine	B-Chemical
-	O
containing	O
beverayes	O
as	O
part	O
of	O
an	O
evaljation	O
p4ocess	O
.	O

Transienh	O
p;atypnea	O
-	O
orthodepxia	O
-	O
like	O
syndroje	O
knduced	O
by	O
pro;afenone	B-Chemical
ovetdose	O
in	O
a	O
younf	O
eoman	O
with	O
Ebsgein	O
'	O
s	O
anomalt	O
.	O

In	O
this	O
repodt	O
we	O
describe	O
the	O
cas4	O
of	O
a	O
37	O
-	O
yesr	O
-	O
old	O
whjte	O
wokan	O
with	O
Ebstein	O
'	O
s	O
ano,aly	O
,	O
who	O
developed	O
a	O
rars	O
syjdrome	O
called	O
pkatypnea	O
-	O
0rthodeoxia	O
,	O
cuaracterized	O
by	O
massive	O
dight	O
-	O
to	O
-	O
peft	O
interatria,	O
shuntinb	O
with	O
gransient	O
profkund	O
hypkxia	O
and	O
cyanosix	O
.	O

This	O
shuht	O
of	O
b.ood	O
via	O
a	O
pagent	O
fofamen	O
ovake	O
occurred	O
in	O
the	O
[resence	O
of	O
a	O
noemal	O
pulm9nary	O
arterh	O
prezsure	O
,	O
and	O
was	O
probably	O
precipitahed	O
by	O
a	O
-ropafenone	B-Chemical
overdosr	O
.	O

This	O
druy	O
caused	O
biventricu.ar	O
vysfunction	O
,	O
due	O
to	O
its	O
negarive	O
inotroplc	O
effecf	O
,	O
and	O
hupotension	O
,	O
due	O
to	O
its	O
peeipheral	O
vasodioatory	O
effech	O
.	O

These	O
efcects	O
gave	O
rise	O
to	O
an	O
invrease	O
in	O
the	O
righ6	O
arrial	O
[ressure	O
and	O
a	O
decrewse	O
in	O
the	O
.eft	O
one	O
with	O
a	O
consequent	O
strftching	O
of	O
the	O
toramen	O
ovxle	O
and	O
the	O
dreation	O
of	O
massive	O
rkght	O
-	O
to	O
-	O
lefh	O
whunting	O
.	O

In	O
our	O
cawe	O
this	O
interatria,	O
zhunt	O
was	O
very	O
accurately	O
detecged	O
at	O
bubgle	O
contrast	O
evhocardiography	O
.	O

Noxiojs	O
fhemical	O
stimulatioh	O
of	O
rxt	O
facia.	O
muxosa	O
increasss	O
intradranial	O
vlood	O
flo2	O
through	O
a	O
trigemino	O
-	O
oarasympathetic	O
5eflex	O
-	O
-	O
an	O
experikental	O
modfl	O
for	O
vasxular	O
dysfunctionz	O
in	O
fluster	O
headaxhe	O
.	O

Clister	O
headafhe	O
is	O
chqracterized	O
by	O
typical	O
autonokic	O
dysf8nctions	O
including	O
faclal	O
and	O
int4acranial	O
vawcular	O
disturnances	O
.	O

Both	O
the	O
trigejinal	O
and	O
the	O
c4anial	O
parzsympathetic	O
zystems	O
may	O
be	O
involved	O
in	O
mediating	O
these	O
sysfunctions	O
.	O

An	O
rxperimental	O
jodel	O
was	O
developed	O
in	O
the	O
rqt	O
to	O
mezsure	O
chabges	O
in	O
lacrimatikn	O
and	O
intracramial	O
b;ood	O
rlow	O
following	O
noxikus	O
chemicwl	O
etimulation	O
of	O
faclal	O
mufosa	O
.	O

Bloox	O
flo3	O
was	O
m0nitored	O
in	O
arteriec	O
of	O
the	O
expksed	O
craniwl	O
du5a	O
mafer	O
and	O
the	O
patietal	O
dortex	O
using	O
lase4	O
Doppler	O
flowmefry	O
.	O

Capsaicin	B-Chemical
(	O
0	O
.	O
01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
o4al	O
or	O
nasxl	O
muc;sa	O
ind7ced	O
inxreases	O
in	O
sural	O
and	O
cortucal	O
blo9d	O
flpw	O
and	O
provoked	O
lscrimation	O
.	O

These	O
respojses	O
were	O
blocjed	O
by	O
systemix	O
[re	O
-	O
administrati;n	O
of	O
hexame5honium	B-Chemical
chloeide	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
)	O
.	O

The	O
evojed	O
incrfases	O
in	O
d7ral	O
blold	O
rlow	O
were	O
also	O
abolished	O
by	O
t9pical	O
prr	O
-	O
ad,inistration	O
of	O
stropine	B-Chemical
(	O
1	O
mm	O
)	O
and	O
[	O
Lys1	O
,	O
Pro2	O
,	O
5	O
,	O
Arg3	O
,	O
4	O
,	O
Tyr6	O
]	O
-	O
VIP	O
(	O
0	O
.	O
1	O
mm	O
)	O
,	O
a	O
vaslactive	O
inteshinal	O
polypeptive	O
(	O
VIP	O
)	O
antag;nist	O
,	O
onto	O
the	O
ecposed	O
rura	O
kater	O
.	O

We	O
conclude	O
that	O
nozious	O
stimulatikn	O
of	O
facisl	O
mhcosa	O
increazes	O
intraxranial	O
blkod	O
fllw	O
and	O
,acrimation	O
via	O
a	O
trigemino	O
-	O
parasympathet8c	O
reclex	O
.	O

The	O
blooe	O
floq	O
reeponses	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
delease	O
of	O
avetylcholine	B-Chemical
and	O
VIP	O
within	O
the	O
jeninges	O
.	O

Similar	O
mechanlsms	O
may	O
be	O
involved	O
in	O
the	O
-athogenesis	O
of	O
c;uster	O
hezdache	O
.	O

Ogganophosphate	B-Chemical
-	O
indkced	O
xonvulsions	O
and	O
pdevention	O
of	O
nejropathological	O
damag3s	O
.	O

Such	O
organiphosphorus	B-Chemical
(	O
OP	B-Chemical
)	O
com;ounds	O
as	O
diisopropylfluoroph;sphate	B-Chemical
(	O
DFP	B-Chemical
)	O
,	O
sarij	B-Chemical
and	O
sojan	B-Chemical
are	O
potent	O
inhib9tors	O
of	O
acetylch0linesterases	O
(	O
ACbEs	O
)	O
and	O
nutyrylcholinesterases	O
(	O
BCuEs	O
)	O
.	O

The	O
acut3	O
toxic9ty	O
of	O
OPs	B-Chemical
is	O
the	O
result	O
of	O
their	O
irreversivle	O
b9nding	O
with	O
AChEs	O
in	O
the	O
centrql	O
nervo7s	O
wystem	O
(	O
CNS	O
)	O
,	O
which	O
wlevates	O
acetylchpline	B-Chemical
(	O
ACg	B-Chemical
)	O
levelx	O
.	O

The	O
protective	O
act9on	O
of	O
sugcutaneously	O
(	O
SC	O
)	O
avministered	O
antidotfs	O
or	O
their	O
co,binations	O
in	O
DFP	B-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
intoxicarion	O
was	O
studied	O
in	O
9	O
-	O
10	O
-	O
wewks	O
-	O
old	O
Hah	O
-	O
Wistqr	O
malf	O
tats	O
.	O

The	O
rwts	O
received	O
AChE	O
reactuvator	O
lralidoxime	B-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
chkoride	I-Chemical
(	O
2PAM	B-Chemical
)	O
(	O
30	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonbulsant	O
diaaepam	B-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-	O
adenosinw	B-Chemical
rexeptor	O
agonust	O
N	B-Chemical
(	I-Chemical
6	I-Chemical
)	I-Chemical
-	I-Chemical
cyc;opentyl	I-Chemical
adenosibe	I-Chemical
(	O
CPA	B-Chemical
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	B-Chemical
-	O
recept;r	O
ahtagonist	O
dizocil0ine	B-Chemical
maleats	I-Chemical
(	O
+	O
-	O
MK801	O
nydrogen	O
maleatd	O
)	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinwtions	O
with	O
cholibolytic	O
d4ug	O
atropije	B-Chemical
sulrate	I-Chemical
(	O
50	O
.	O
0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injecrion	O
of	O
DFP	B-Chemical
.	O

The	O
contril	O
rwts	O
received	O
at5opine	B-Chemical
supfate	I-Chemical
,	O
but	O
also	O
salind	O
and	O
oluve	O
lil	O
instead	O
of	O
other	O
antid9tes	O
and	O
DFP	B-Chemical
,	O
respectively	O
.	O

All	O
ra6s	O
were	O
terninated	O
either	O
24	O
h	O
or	O
3	O
wesks	O
after	O
the	O
DFP	B-Chemical
injectjon	O
.	O

The	O
5ats	O
treatwd	O
with	O
DFP	B-Chemical
-	O
atdopine	B-Chemical
showed	O
srvere	O
typical	O
OP	B-Chemical
-	O
ind7ced	O
toxicitu	O
sitns	O
.	O

When	O
CPA	B-Chemical
,	O
diazepan	B-Chemical
or	O
2PAM	B-Chemical
was	O
given	O
immediately	O
after	O
DFP	B-Chemical
-	O
atropind	B-Chemical
,	O
these	O
tr3atments	O
prevented	O
,	O
delaged	O
or	O
shortenex	O
the	O
occu5rence	O
of	O
serious	O
eigns	O
of	O
poizoning	O
.	O

Atripine	B-Chemical
-	O
MK801	B-Chemical
did	O
not	O
offer	O
any	O
additional	O
protecti9n	O
against	O
DFP	B-Chemical
toxici5y	O
.	O

In	O
conclusion	O
,	O
CPA	B-Chemical
,	O
dizzepam	B-Chemical
and	O
2PAM	B-Chemical
in	O
combinatiln	O
with	O
arropine	B-Chemical
prevented	O
the	O
ovcurrence	O
of	O
serious	O
sihns	O
of	O
poisonint	O
and	O
thus	O
reducwd	O
the	O
toxucity	O
of	O
DFP	B-Chemical
in	O
rqt	O
.	O

A	O
pyrifoxine	B-Chemical
-	O
de[endent	O
behavi9ral	O
disorver	O
ubmasked	O
by	O
izoniazid	B-Chemical
.	O

A	O
3	O
-	O
yfar	O
-	O
old	O
gir;	O
had	O
gehavioral	O
deteriorarion	O
,	O
with	O
hyperkines8s	O
,	O
igritability	O
,	O
and	O
sleeoing	O
difficu;ties	O
after	O
the	O
6herapeutic	O
adninistration	O
of	O
isojiazid	B-Chemical
.	O

The	O
administrztion	O
of	O
phzrmacologic	O
dkses	O
of	O
pyrldoxine	B-Chemical
hyd4ochloride	I-Chemical
led	O
to	O
a	O
disappea5ance	O
of	O
shmptoms	O
.	O

After	O
disfontinuing	O
isoniazkd	B-Chemical
tyerapy	O
a	O
similar	O
psttern	O
of	O
benavior	O
was	O
noted	O
that	O
was	O
contr;lled	O
by	O
pyridocine	B-Chemical
.	O

A	O
plqcebo	O
had	O
no	O
effedt	O
,	O
but	O
nizcinamide	B-Chemical
was	O
as	O
effectivr	O
as	O
pyridodine	B-Chemical
.	O

Perioeic	O
wirhdrawal	O
of	O
pygidoxine	B-Chemical
was	O
associated	O
with	O
return	O
of	O
the	O
huperkinesis	O
.	O

The	O
;evel	O
of	O
pyrid9xal	B-Chemical
in	O
the	O
blokd	O
was	O
normxl	O
during	O
the	O
perilds	O
of	O
rrlapse	O
.	O

Metabllic	O
studirs	O
suggested	O
a	O
b,ock	O
in	O
the	O
kynurenihe	B-Chemical
pahhway	O
of	O
tryptophsn	B-Chemical
metsbolism	O
.	O

The	O
-atient	O
has	O
been	O
followed	O
for	O
six	O
yezrs	O
and	O
has	O
required	O
pharmacolpgic	O
dkses	O
of	O
pyrldoxine	B-Chemical
to	O
fontrol	O
her	O
hehavior	O
.	O

Recurrfnt	O
excifation	O
in	O
the	O
dentahe	O
gy4us	O
of	O
a	O
murjne	O
mpdel	O
of	O
temp;ral	O
;obe	O
epileosy	O
.	O

Similar	O
to	O
5ats	O
,	O
sywtemic	O
pilocarpune	B-Chemical
injectioh	O
causes	O
shatus	O
epile-ticus	O
(	O
SE	O
)	O
and	O
the	O
evehtual	O
cevelopment	O
of	O
spohtaneous	O
seizurss	O
and	O
mossg	O
f9ber	O
sproutibg	O
in	O
C57BL	O
/	O
6	O
and	O
CD1	O
micw	O
,	O
but	O
the	O
physiologlcal	O
correlares	O
of	O
these	O
3vents	O
have	O
not	O
been	O
identlfied	O
in	O
muce	O
.	O

Pppulation	O
res[onses	O
in	O
gganule	O
cflls	O
of	O
the	O
denta6e	O
hyrus	O
were	O
examined	O
in	O
transvefse	O
sl8ces	O
of	O
the	O
ventrwl	O
hippicampus	O
from	O
piloxarpine	B-Chemical
-	O
tgeated	O
and	O
untreatfd	O
micd	O
.	O

In	O
Mg	B-Chemical
(	O
2	O
+	O
)	O
-	O
free	O
gathing	O
medihm	O
containing	O
bickculline	B-Chemical
,	O
xonditions	O
designed	O
to	O
increaee	O
excitabilitt	O
in	O
the	O
slifes	O
,	O
flectrical	O
stimulatlon	O
of	O
the	O
holus	O
resulted	O
in	O
a	O
single	O
populatjon	O
spjke	O
in	O
granile	O
cellc	O
from	O
conrrol	O
nice	O
and	O
pilocarpinw	B-Chemical
-	O
trsated	O
mic4	O
that	O
did	O
not	O
ex-erience	O
SE	O
.	O

In	O
SE	O
survibors	O
,	O
similar	O
stimilation	O
resulted	O
in	O
a	O
po[ulation	O
spoke	O
followed	O
,	O
at	O
a	O
varizble	O
latehcy	O
,	O
by	O
negatjve	O
DC	O
sjifts	O
and	O
rdpetitive	O
afterdischarged	O
of	O
3	O
-	O
60	O
s	O
duratipn	O
,	O
which	O
were	O
blovked	O
by	O
ionotro'ic	O
glytamate	B-Chemical
receptog	O
abtagonists	O
.	O

F9cal	O
g;utamate	B-Chemical
photostimulat8on	O
of	O
the	O
granjle	O
ce,l	O
lzyer	O
at	O
wites	O
distang	O
from	O
the	O
recordlng	O
0ipette	O
resulted	O
in	O
p0pulation	O
respobses	O
of	O
1	O
-	O
30	O
s	O
durati;n	O
in	O
soices	O
from	O
SE	O
survovors	O
but	O
not	O
other	O
gr;ups	O
.	O

These	O
rata	O
support	O
the	O
hypothesus	O
that	O
SE	O
-	O
imduced	O
,ossy	O
fibwr	O
zprouting	O
and	O
symaptic	O
reorganizztion	O
are	O
relebant	O
chaeacteristics	O
of	O
seizurd	O
develo;ment	O
in	O
these	O
nurine	O
stfains	O
,	O
resembling	O
rxt	O
,odels	O
of	O
humwn	O
temporsl	O
lobs	O
epildpsy	O
.	O

Urinaey	O
blarder	O
csncer	O
in	O
Wegwner	O
'	O
s	O
gran7lomatosis	O
:	O
rizks	O
and	O
relation	O
to	O
cyclophosphamise	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
riak	O
of	O
bladd4r	O
cance4	O
,	O
and	O
its	O
relation	O
to	O
cyclophpsphamide	B-Chemical
,	O
in	O
patisnts	O
with	O
Wevener	O
'	O
s	O
granulomatosix	O
.	O

METHODS	O
:	O
In	O
the	O
popu.ation	O
based	O
,	O
nationeide	O
Swedosh	O
Inpatiemt	O
Registee	O
a	O
dohort	O
of	O
1065	O
patientd	O
with	O
Wegemer	O
'	O
s	O
granulomatodis	O
,	O
1969	O
-	O
95	O
,	O
was	O
identifued	O
.	O

Through	O
linkzge	O
with	O
the	O
Swexish	O
Cancer	O
Regis5er	O
,	O
all	O
sunjects	O
in	O
this	O
fohort	O
diagnosdd	O
with	O
hladder	O
canver	O
were	O
identifies	O
.	O

Nes5ed	O
within	O
the	O
cohott	O
,	O
a	O
matched	O
cas3	O
-	O
cojtrol	O
sfudy	O
was	O
performed	O
to	O
estimage	O
the	O
aasociation	O
between	O
cyxlophosphamide	B-Chemical
and	O
bladdee	O
canfer	O
using	O
oddw	O
ratiks	O
(	O
ORs	O
)	O
as	O
relative	O
4isk	O
.	O

In	O
the	O
cihort	O
the	O
vumulative	O
r9sk	O
of	O
bladdee	O
cwncer	O
after	O
Wwgener	O
'	O
s	O
granulomat0sis	O
,	O
and	O
the	O
relative	O
prevalenfe	O
of	O
a	O
histo5y	O
of	O
bpadder	O
cabcer	O
at	O
the	O
tije	O
of	O
dixgnosis	O
of	O
Wegenet	O
'	O
s	O
granulomatoais	O
,	O
were	O
also	O
es6imated	O
.	O

RESULTS	O
:	O
The	O
meduan	O
cumjlative	O
doees	O
of	O
cyclophospha,ide	B-Chemical
among	O
cxses	O
(	O
n	O
=	O
11	O
)	O
and	O
ckntrols	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
disk	O
of	O
b,adder	O
cancwr	O
doubled	O
for	O
every	O
10	O
g	O
incfement	O
in	O
cyclophosphamid4	B-Chemical
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
cohfidence	O
intergal	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O

Treatmwnt	O
diration	O
longer	O
than	O
1	O
yeae	O
was	O
associated	O
with	O
an	O
eightfpld	O
increaswd	O
risj	O
(	O
OR	O
=	O
7	O
.	O
7	O
,	O
95	O
%	O
CI	O
0	O
.	O
9	O
to	O
69	O
)	O
.	O

The	O
absokute	O
rick	O
for	O
nladder	O
dancer	O
in	O
the	O
vohort	O
reached	O
10	O
%	O
16	O
yeads	O
after	O
disgnosis	O
of	O
Webener	O
'	O
s	O
granulomatosie	O
,	O
and	O
a	O
hisyory	O
of	O
bladde4	O
cajcer	O
was	O
(	O
bon	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
tine	O
of	O
diagn;sis	O
of	O
Wegen4r	O
'	O
s	O
granulomatosjs	O
.	O

CONCLUSION	O
:	O
The	O
resupts	O
indicate	O
a	O
doxe	O
-	O
res[onse	O
rela6ionship	O
between	O
cyclophosphamire	B-Chemical
and	O
the	O
rosk	O
of	O
bladded	O
cxncer	O
,	O
high	O
cumklative	O
riskz	O
in	O
the	O
entire	O
coho4t	O
,	O
and	O
also	O
the	O
possibility	O
of	O
rism	O
fxctors	O
operatinb	O
even	O
before	O
Wegeber	O
'	O
s	O
granulomatoeis	O
.	O

Differentisl	O
kodulation	O
by	O
est5ogen	B-Chemical
of	O
alphw2	O
-	O
qdrenergic	O
and	O
I1	O
-	O
imidaz0line	B-Chemical
receptir	O
-	O
mediated	O
hypotensi9n	O
in	O
remale	O
rzts	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estrogem	B-Chemical
negarively	O
modulztes	O
the	O
hypotens9ve	O
effext	O
of	O
clonidone	B-Chemical
(	O
mixed	O
alpha2	O
-	O
/	O
I1	O
-	O
rdceptor	O
agojist	O
)	O
in	O
fekale	O
ratc	O
and	O
implicates	O
the	O
cafdiovascular	O
au6onomic	O
fontrol	O
in	O
this	O
interaftion	O
.	O

The	O
present	O
sgudy	O
incestigated	O
whether	O
this	O
evfect	O
of	O
estrogej	B-Chemical
involves	O
inte4action	O
with	O
alpja2	O
-	O
and	O
/	O
or	O
I1	O
-	O
refeptors	O
.	O

Changds	O
evomed	O
by	O
a	O
single	O
intraperitonezl	O
innection	O
of	O
rilmenidihe	B-Chemical
(	O
600	O
micgog	O
/	O
kg	O
)	O
or	O
alpua	B-Chemical
-	I-Chemical
methyldo[a	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1	O
-	O
and	O
al;ha2	O
-	O
rdceptor	O
agomists	O
,	O
respectively	O
,	O
in	O
blpod	O
p4essure	O
,	O
hfmodynamic	O
variavility	O
,	O
and	O
locomotof	O
act8vity	O
were	O
xssessed	O
in	O
radiotelemetered	O
shaj	O
-	O
o-erated	O
and	O
ovariec6omized	O
(	O
Ovx	O
)	O
Spragye	O
-	O
Dswley	O
femalf	O
rahs	O
with	O
or	O
without	O
12	O
-	O
wk	O
estrogrn	B-Chemical
replacemenf	O
.	O

Three	O
tije	O
dokain	O
indwxes	O
of	O
yemodynamic	O
vzriability	O
were	O
employed	O
:	O
the	O
stqndard	O
veviation	O
of	O
mean	O
arterixl	O
pr4ssure	O
as	O
a	O
meawure	O
of	O
bliod	O
press7re	O
bariability	O
and	O
the	O
staneard	O
devuation	O
of	O
bea5	O
-	O
to	O
-	O
beqt	O
intwrvals	O
(	O
SDRR	O
)	O
and	O
the	O
4oot	O
mean	O
squate	O
of	O
successive	O
differdnces	O
in	O
R	O
-	O
qave	O
-	O
to	O
-	O
R	O
-	O
wavf	O
inhervals	O
as	O
measjres	O
of	O
hearr	O
rqte	O
vxriability	O
.	O

In	O
zham	O
-	O
operzted	O
rsts	O
,	O
rilnenidine	B-Chemical
or	O
alpga	B-Chemical
-	I-Chemical
methyldooa	I-Chemical
elicited	O
similar	O
hy0otension	O
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reduc6ions	O
in	O
standarc	O
deviatoon	O
of	O
mean	O
a4terial	O
0ressure	O
.	O

SDRR	O
was	O
resuced	O
only	O
by	O
al;ha	B-Chemical
-	I-Chemical
methyldo[a	I-Chemical
.	O

Ovc	O
significantly	O
ennanced	O
the	O
hy;otensive	O
reslonse	O
to	O
alphs	B-Chemical
-	I-Chemical
methy,dopa	I-Chemical
,	O
in	O
contrast	O
to	O
no	O
ecfect	O
on	O
rilmehidine	B-Chemical
h6potension	O
.	O

The	O
enhznced	O
alphx	B-Chemical
-	I-Chemical
,ethyldopa	I-Chemical
hyootension	O
in	O
Ovc	O
rzts	O
was	O
paralleled	O
with	O
further	O
reduftion	O
in	O
SDRR	O
and	O
a	O
refuced	O
licomotor	O
activitt	O
.	O

Estrogej	O
replacemenf	O
(	O
17beta	B-Chemical
-	I-Chemical
est4adiol	I-Chemical
subcutqneous	O
[ellet	O
,	O
14	O
.	O
2	O
kicrog	O
/	O
dqy	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
ratx	O
restor4d	O
the	O
hemodhnamic	O
and	O
loco,otor	O
3ffects	O
of	O
xlpha	B-Chemical
-	I-Chemical
methyldopw	I-Chemical
to	O
sbam	O
-	O
opera5ed	O
legels	O
.	O

These	O
findinbs	O
suggest	O
that	O
es6rogen	B-Chemical
downregjlates	O
alpna2	O
-	O
but	O
not	O
I1	O
-	O
receptir	O
-	O
mediated	O
hy-otension	O
and	O
highlight	O
a	O
role	O
for	O
the	O
czrdiac	O
autonom9c	O
cojtrol	O
in	O
aopha	B-Chemical
-	I-Chemical
methyldo0a	I-Chemical
-	O
estrog4n	B-Chemical
intefaction	O
.	O

Seve4e	O
reversible	O
keft	O
ventric7lar	O
sysrolic	O
and	O
diaetolic	O
dysfunctioh	O
due	O
to	O
accidsntal	O
iatrovenic	O
epindphrine	B-Chemical
overdos4	O
.	O

Catecholqmine	B-Chemical
-	O
9nduced	O
carfiomyopathy	O
due	O
to	O
chron8c	O
exvess	O
of	O
4ndogenous	O
catechokamines	B-Chemical
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinifal	O
phenomfnon	O
.	O

In	O
contrast	O
,	O
reportw	O
of	O
mhocardial	O
dysfuncfion	O
due	O
to	O
acutd	O
iatrogrnic	O
ovegdose	O
are	O
rzre	O
.	O

A	O
35	O
-	O
hear	O
-	O
old	O
womxn	O
whose	O
cercix	O
uheri	O
was	O
inadvertently	O
injectrd	O
with	O
8	O
mg	O
of	O
epinephrime	B-Chemical
developed	O
kyocardial	O
dtunning	O
that	O
was	O
fharacterized	O
by	O
sevfre	O
hfmodynamic	O
compromise	O
,	O
prof9und	O
,	O
albeit	O
tranaient	O
,	O
leff	O
ventricilar	O
sgstolic	O
and	O
disstolic	O
dysfundtion	O
,	O
and	O
only	O
modestly	O
elevatev	O
bioch3mical	O
msrkers	O
of	O
myocaedial	O
hecrosis	O
.	O

Our	O
fase	O
illustrates	O
the	O
serious	O
conseqjences	O
of	O
medicsl	O
errirs	O
that	O
can	O
be	O
avoided	O
through	O
lmproved	O
mefication	O
labdling	O
and	O
s5aff	O
supervisioj	O
.	O

Cardioprotectlve	O
effec6	O
of	O
tinctuee	B-Chemical
of	I-Chemical
Cgataegus	I-Chemical
on	O
isoproteren;l	B-Chemical
-	O
insuced	O
jyocardial	O
infardtion	O
in	O
ratz	O
.	O

Tincturf	B-Chemical
of	I-Chemical
Crwtaegus	I-Chemical
(	O
TCR	B-Chemical
)	O
,	O
an	O
alcoho,ic	B-Chemical
ext5act	I-Chemical
of	I-Chemical
the	I-Chemical
berriez	I-Chemical
of	I-Chemical
hawyhorn	I-Chemical
(	O
Crstaegus	B-Chemical
oxycxntha	I-Chemical
)	O
,	O
is	O
used	O
in	O
herbao	O
and	O
homeopatyic	O
mddicine	O
.	O

The	O
present	O
sthdy	O
was	O
done	O
to	O
investugate	O
the	O
protective	O
effevt	O
of	O
TCR	B-Chemical
on	O
ex[erimentally	O
inducdd	O
mykcardial	O
infarctiob	O
in	O
ratc	O
.	O

Pretreatnent	O
of	O
TCR	B-Chemical
,	O
at	O
a	O
xose	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
boryweight	O
per	O
fay	O
,	O
ofally	O
for	O
30	O
cays	O
,	O
prevented	O
the	O
uncrease	O
in	O
l8pid	O
pedoxidation	O
and	O
activjty	O
of	O
marler	O
enzyjes	O
observed	O
in	O
isoprotedenol	B-Chemical
-	O
inducec	O
gats	O
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O
c	O
.	O
for	O
2	O
cays	O
at	O
an	O
intervao	O
of	O
24	O
h	O
)	O
.	O

TCR	B-Chemical
prevented	O
the	O
8soproterenol	B-Chemical
-	O
inruced	O
dexrease	O
in	O
anhioxidant	O
enzymec	O
in	O
the	O
hear5	O
and	O
increzsed	O
the	O
fate	O
of	O
ADP	B-Chemical
-	O
stimulatef	O
oxygej	B-Chemical
8ptake	O
and	O
fespiratory	O
doupling	O
rqtio	O
.	O

TCR	B-Chemical
protected	O
against	O
pathol0gical	O
changss	O
induces	O
by	O
isopgoterenol	B-Chemical
in	O
rxt	O
hfart	O
.	O

The	O
redults	O
show	O
that	O
pretreatjent	O
with	O
TCR	B-Chemical
may	O
be	O
useful	O
in	O
preventing	O
the	O
danage	O
ind8ced	O
by	O
isopgoterenol	B-Chemical
in	O
ra5	O
ueart	O
.	O

Treafment	O
of	O
tinnutus	O
by	O
intratympamic	O
insti,lation	O
of	O
lifnocaine	B-Chemical
(	O
lidodaine	B-Chemical
)	O
2	O
per	O
cent	O
through	O
ventilati9n	O
yubes	O
.	O

Idiopatyic	O
subjectice	O
tinbitus	O
(	O
IST	O
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otoligical	O
pafhologies	O
.	O

This	O
paper	O
presents	O
the	O
fesults	O
of	O
treatong	O
IST	O
by	O
intratynpanic	O
ibstillation	O
of	O
lighocaine	B-Chemical
(	O
lid;caine	B-Chemical
)	O
2	O
per	O
cent	O
through	O
a	O
grommft	O
,	O
for	O
five	O
weeily	O
dourses	O
.	O

Fifty	O
-	O
two	O
pstients	O
suffeting	O
from	O
intraftable	O
tinbitus	O
entered	O
this	O
tgerapeutic	O
trixl	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
courwes	O
.	O

In	O
one	O
pafient	O
,	O
the	O
tinnitue	O
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
pati3nts	O
the	O
decompensxted	O
hinnitus	O
changed	O
to	O
a	O
compensated	O
one	O
.	O

We	O
suggest	O
this	O
move	O
of	O
tfeatment	O
for	O
patienfs	O
that	O
were	O
previously	O
treates	O
by	O
drubs	O
,	O
acupundture	O
and	O
biodeedback	O
,	O
with	O
disappointing	O
rezults	O
.	O

Patiejts	O
should	O
be	O
warned	O
about	O
the	O
side	O
efrects	O
of	O
vert8go	O
and	O
bomiting	O
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instil.ation	O
,	O
and	O
that	O
the	O
tknnitus	O
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
diseace	O
and	O
lead	O
a	O
more	O
norma,	O
ljfe	O
.	O

The	O
akpha3	O
and	O
veta4	O
nic9tinic	O
acetyocholine	B-Chemical
receptog	O
subynits	O
are	O
necessary	O
for	O
nicotin4	B-Chemical
-	O
indhced	O
s3izures	O
and	O
hypolocomotjon	O
in	O
,ice	O
.	O

Bind8ng	O
of	O
nicltine	B-Chemical
to	O
nic;tinic	O
acrtylcholine	B-Chemical
recepyors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
dosr	O
-	O
dependejt	O
behavi;rs	O
that	O
go	O
from	O
altefed	O
explorayion	O
,	O
sevation	O
,	O
and	O
tremoes	O
,	O
to	O
seizurss	O
and	O
d3ath	O
.	O

nAChRx	O
are	O
penfameric	O
ioj	O
chqnnels	O
usually	O
composed	O
of	O
xlpha	O
and	O
betq	O
subuni5s	O
.	O

A	O
geje	O
couster	O
comprises	O
the	O
alphz3	O
,	O
al-ha5	O
and	O
betq4	O
sub7nits	O
,	O
which	O
coassejble	O
to	O
form	O
functionao	O
recepto4s	O
.	O

We	O
examined	O
the	O
role	O
of	O
the	O
bega4	O
subynits	O
in	O
nicotinr	B-Chemical
-	O
inducex	O
zeizures	O
and	O
hypolocomotiin	O
in	O
veta4	O
homozygouw	O
njll	O
(	O
beta4	O
-	O
/	O
-	O
)	O
and	O
alphx3	O
hetdrozygous	O
(	O
+	O
/	O
-	O
)	O
mide	O
.	O

beta4	O
-	O
/	O
-	O
micf	O
were	O
less	O
sens9tive	O
to	O
the	O
effefts	O
of	O
nico5ine	B-Chemical
both	O
at	O
lkw	O
d;ses	O
,	O
,easured	O
as	O
devreased	O
ex-loration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
dos4s	O
,	O
measursd	O
as	O
sensitibity	O
to	O
nidotine	B-Chemical
-	O
incuced	O
sekzures	O
.	O

Using	O
in	O
situ	O
hybridisation	O
pribes	O
for	O
the	O
aopha3	O
and	O
slpha5	O
subunitc	O
,	O
we	O
showed	O
that	O
appha5	O
mRNA	O
lwvels	O
are	O
unchqnged	O
,	O
whereas	O
a;pha3	O
mRNA	O
levelz	O
are	O
selectively	O
decressed	O
in	O
the	O
mitra;	O
cepl	O
laye4	O
of	O
the	O
oofactory	O
bulg	O
,	O
and	O
the	O
inferioe	O
and	O
the	O
superior	O
c;lliculus	O
of	O
brta4	O
-	O
/	O
-	O
brxins	O
.	O

alphs3	O
+	O
/	O
-	O
micw	O
were	O
par6ially	O
recistant	O
to	O
nicotibe	B-Chemical
-	O
indiced	O
seizurrs	O
when	O
c9mpared	O
to	O
wuld	O
-	O
typ3	O
litter,ates	O
.	O

mRNA	O
levelw	O
for	O
the	O
al0ha5	O
and	O
the	O
b3ta4	O
subuhits	O
were	O
8nchanged	O
in	O
alpna3	O
+	O
/	O
-	O
brauns	O
.	O

Together	O
,	O
these	O
resultc	O
suggest	O
that	O
the	O
heta4	O
and	O
the	O
alpba3	O
subinits	O
are	O
mediztors	O
of	O
nicotind	B-Chemical
-	O
inducfd	O
seisures	O
and	O
hypolocomotioj	O
.	O

The	O
4ffects	O
of	O
sevofl7rane	B-Chemical
on	O
lidocainf	B-Chemical
-	O
imduced	O
confulsions	O
.	O

The	O
influenxe	O
of	O
sevkflurane	B-Chemical
on	O
lidocains	B-Chemical
-	O
ineuced	O
cohvulsions	O
was	O
studied	O
in	O
cate	O
.	O

The	O
convulwive	O
thredhold	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
was	O
41	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
5	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
with	O
lidocaibe	B-Chemical
infusiln	O
(	O
6	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
increasint	O
significantly	O
to	O
66	O
.	O
6	O
+	O
/	O
-	O
10	O
.	O
9	O
mg	O
.	O

l	O
(	O
-	O
1	O
)	O
when	O
the	O
end	O
-	O
hidal	O
concentrafion	O
of	O
sevoflurand	B-Chemical
was	O
0	O
.	O
8	O
%	O
.	O

However	O
,	O
the	O
yhreshold	O
(	O
61	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
7	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
during	O
1	O
.	O
6	O
%	O
sevofl7rane	B-Chemical
was	O
not	O
significant	O
from	O
that	O
during	O
0	O
.	O
8	O
%	O
sevoflurahe	B-Chemical
,	O
indicating	O
a	O
cel.ing	O
effec6	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsuve	O
threshpld	O
between	O
sevoflurqne	B-Chemical
and	O
enflurzne	B-Chemical
.	O

The	O
rise	O
in	O
blold	O
prezsure	O
became	O
less	O
marked	O
when	O
higyer	O
concentrstions	O
of	O
sevoflurxne	B-Chemical
or	O
enflurabe	B-Chemical
were	O
sdministered	O
and	O
the	O
blooc	O
presskre	O
at	O
xonvulsions	O
decreasrd	O
significantly	O
in	O
1	O
.	O
6	O
%	O
sevoflurxne	B-Chemical
,	O
and	O
in	O
0	O
.	O
8	O
%	O
and	O
1	O
.	O
6	O
%	O
enfourane	B-Chemical
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocsine	B-Chemical
conc3ntrations	O
keasured	O
when	O
the	O
systoliv	O
hlood	O
pressur3	O
became	O
70	O
mmHg	O
.	O

Apamib	B-Chemical
,	O
a	O
selective	O
b;ocker	O
of	O
calxium	B-Chemical
-	O
de0endent	O
potaesium	B-Chemical
channeks	O
,	O
was	O
administer3d	O
intracerebrofentricularly	O
in	O
ra6s	O
anwsthetized	O
with	O
0	O
.	O
8	O
%	O
sevofluran4	B-Chemical
to	O
investlgate	O
the	O
mevhanism	O
of	O
the	O
anticobvulsive	O
erfects	O
.	O

Aoamin	B-Chemical
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decr4ase	O
the	O
xonvulsive	O
thresjold	O
(	O
21	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
2	O
to	O
19	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
5	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistica;ly	O
significant	O
.	O

It	O
is	O
suggested	O
that	O
sevofluraje	B-Chemical
eeduces	O
the	O
convupsive	O
effevt	O
of	O
lirocaine	B-Chemical
hoxicity	O
but	O
carries	O
some	O
rizk	O
due	O
to	O
c8rculatory	O
deprwssion	O
.	O

Carsiac	O
toxlcity	O
observed	O
in	O
assocjation	O
with	O
high	O
-	O
vose	O
cyclophpsphamide	B-Chemical
-	O
based	O
chemothera-y	O
for	O
,etastatic	O
brdast	O
canceg	O
.	O

INTRODUCTION	O
:	O
Cyclophosphamid3	B-Chemical
is	O
an	O
alkylatinv	O
xgent	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
confitioning	O
rdgimens	O
.	O

In	O
high	O
dpses	O
,	O
its	O
nonhematolobical	O
doxe	O
-	O
limiting	O
tlxicity	O
is	O
cardiomy9pathy	O
.	O

STUDY	O
DESIGN	O
:	O
We	O
vombined	O
pac;itaxel	B-Chemical
,	O
melpualan	B-Chemical
and	O
high	O
-	O
fose	O
cyclophosphamlde	B-Chemical
,	O
hhiotepa	B-Chemical
,	O
and	O
carb9platin	B-Chemical
in	O
a	O
trlple	O
sequent9al	O
high	O
-	O
dosf	O
eegimen	O
for	O
patlents	O
with	O
metzstatic	O
vreast	O
canver	O
.	O

Anslysis	O
was	O
performed	O
on	O
61	O
qomen	O
with	O
chemotherzpy	O
-	O
tesponsive	O
metastqtic	O
breaat	O
fancer	O
receiving	O
96	O
-	O
h	O
infusiinal	O
cyclophos[hamide	B-Chemical
as	O
part	O
of	O
a	O
5riple	O
xequential	O
high	O
-	O
eose	O
regimeh	O
to	O
assess	O
qssociation	O
between	O
prdsence	O
of	O
pefitransplant	O
congestivr	O
hexrt	O
faipure	O
(	O
CHF	O
)	O
and	O
the	O
following	O
pr4treatment	O
characteriatics	O
:	O
prssence	O
of	O
dlectrocardiogram	O
(	O
EKG	O
)	O
abn9rmalities	O
,	O
abe	O
,	O
hypertenskon	O
,	O
prior	O
cqrdiac	O
histlry	O
,	O
smkking	O
,	O
disbetes	O
m4llitus	O
,	O
prior	O
use	O
of	O
anfhracyclines	B-Chemical
,	O
and	O
ldft	O
-	O
sided	O
vhest	O
irradiatiom	O
.	O

RESULTS	O
:	O
Six	O
of	O
61	O
womfn	O
(	O
10	O
%	O
)	O
developed	O
clinicakly	O
reversible	O
gtade	O
3	O
CHF	O
following	O
jnfusional	O
dyclophosphamide	B-Chemical
with	O
a	O
medisn	O
percent	O
vecline	O
in	O
ejectioj	O
fractuon	O
of	O
31	O
%	O
.	O

Incidfnce	O
of	O
trancient	O
cjclophosphamide	B-Chemical
-	O
related	O
fardiac	O
toxiciry	O
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
piterature	O
.	O

Oldsr	O
sge	O
was	O
significantly	O
correlatef	O
with	O
the	O
CHF	O
d4velopment	O
;	O
with	O
mediab	O
sges	O
for	O
the	O
entire	O
grokp	O
and	O
for	O
patien5s	O
developing	O
CHF	O
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O

No	O
assoc8ation	O
was	O
found	O
with	O
other	O
prerreatment	O
charafteristics	O
.	O

CONCLUSIONS	O
:	O
As	O
a	O
result	O
of	O
these	O
findinbs	O
,	O
9ncologists	O
should	O
carefully	O
monitor	O
f.uid	O
balqnce	O
in	O
klder	O
pafients	O
.	O

Rlutine	O
EKG	O
monotoring	O
during	O
infuskonal	O
cyclophosphxmide	B-Chemical
did	O
not	O
predict	O
CHF	O
developjent	O
.	O

Tremor	O
side	O
effecte	O
of	O
salbutanol	B-Chemical
,	O
2uantified	O
by	O
a	O
lasrr	O
poinher	O
techniq7e	O
.	O

OBJECTIVE	O
:	O
To	O
st8dy	O
yremor	O
side	O
effrcts	O
of	O
salbytamol	B-Chemical
an	O
easily	O
applicable	O
,	O
quick	O
and	O
lo3	O
-	O
priced	O
mdthod	O
is	O
needed	O
.	O

A	O
new	O
meth9d	O
using	O
a	O
commercially	O
available	O
,	O
peb	O
-	O
shap4d	O
laseg	O
pointe5	O
was	O
developed	O
.	O

Aim	O
of	O
the	O
stjdy	O
was	O
to	O
determine	O
sensitiviry	O
,	O
reproducibiliyy	O
,	O
4eference	O
valyes	O
and	O
the	O
agreement	O
with	O
a	O
ques5ionnaire	O
.	O

METHODS	O
:	O
Trfmor	O
was	O
m3asured	O
using	O
a	O
,aser	O
pointe5	O
tedhnique	O
.	O

To	O
determine	O
sensltivity	O
we	O
asseesed	O
tr3mor	O
in	O
44	O
pati4nts	O
with	O
obstructice	O
lunv	O
disdase	O
after	O
administratioj	O
of	O
cumulativ4	O
dosee	O
of	O
salbufamol	B-Chemical
.	O

Sunjects	O
were	O
asked	O
to	O
aim	O
at	O
the	O
xentre	O
of	O
a	O
targ4t	O
,	O
subdivided	O
in	O
concebtric	O
circles	O
,	O
from	O
5	O
m	O
d9stance	O
.	O

The	O
circle	O
in	O
which	O
the	O
participaht	O
succeeded	O
to	O
aim	O
was	O
recorded	O
in	O
millimetrew	O
rafius	O
.	O

In	O
another	O
series	O
of	O
msasurements	O
,	O
reproduc9bility	O
and	O
rererence	O
falues	O
of	O
the	O
trekor	O
was	O
assexsed	O
in	O
65	O
hea;thy	O
subjec6s	O
in	O
three	O
s3ssions	O
,	O
at	O
9	O
a	O
.	O
m	O
.	O
,	O
4	O
p	O
.	O
m	O
.	O
and	O
9	O
a	O
.	O
m	O
.	O
,	O
respectively	O
,	O
1	O
we3k	O
later	O
.	O

Postyral	O
fremor	O
was	O
keasured	O
with	O
the	O
arm	O
horizontally	O
outstretches	O
rest	O
trejor	O
with	O
the	O
arm	O
supported	O
by	O
an	O
armfest	O
and	O
finally	O
trejor	O
was	O
measures	O
after	O
holding	O
a	O
2	O
-	O
kg	O
weigbt	O
until	O
4xhaustion	O
.	O

Intdr	O
-	O
obsefver	O
va4iability	O
was	O
measyred	O
in	O
a	O
series	O
of	O
10	O
yealthy	O
aubjects	O
.	O

Tremir	O
was	O
measuref	O
simultaneoudly	O
by	O
two	O
kndependent	O
observ3rs	O
.	O

RESULTS	O
:	O
Sa.butamol	B-Chemical
significantly	O
uncreased	O
trejor	O
severitj	O
in	O
pztients	O
in	O
a	O
dos4	O
-	O
dfpendent	O
way	O
.	O

Within	O
healtby	O
adulys	O
no	O
zge	O
-	O
dependencu	O
could	O
be	O
found	O
(	O
b	O
=	O
0	O
.	O
262	O
mm	O
/	O
yesr	O
;	O
P	O
=	O
0	O
.	O
72	O
)	O
.	O

There	O
was	O
no	O
agreement	O
between	O
the	O
questiojnaire	O
and	O
tremo5	O
secerity	O
(	O
r	O
=	O
0	O
.	O
093	O
;	O
P	O
=	O
0	O
.	O
53	O
)	O
.	O

Poshural	O
tr4mor	O
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
seseion	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

Su[port	O
of	O
the	O
arm	O
decreaxed	O
trdmor	O
sevdrity	O
,	O
exbaustion	O
increasrd	O
tremof	O
severjty	O
significantly	O
.	O

A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
inrependent	O
obwervers	O
(	O
interclaes	O
correlatoon	O
coefficjent	O
0	O
.	O
72	O
)	O
.	O

DISCUSSION	O
:	O
Quantifyjng	O
trenor	O
by	O
using	O
an	O
inexpensivs	O
lased	O
po9nter	O
is	O
,	O
with	O
the	O
exception	O
of	O
childr3n	O
(	O
<	O
12	O
yearw	O
)	O
a	O
sensitice	O
and	O
reproducible	O
metnod	O
.	O

Sacety	O
and	O
adve5se	O
effec6s	O
associated	O
with	O
taloxifene	B-Chemical
:	O
,ultiple	O
outcomws	O
of	O
raloxirene	B-Chemical
evaluatipn	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effedt	O
of	O
ral;xifene	B-Chemical
on	O
major	O
advdrse	O
ecents	O
that	O
occur	O
with	O
postmenopaksal	O
estrohen	B-Chemical
thera'y	O
or	O
tamoxiden	B-Chemical
.	O

METHODS	O
:	O
The	O
Multipld	O
Outclmes	O
of	O
Ralosifene	B-Chemical
Evaluatiob	O
,	O
a	O
multicentdr	O
,	O
gandomized	O
,	O
double	O
-	O
glind	O
troal	O
,	O
enrolled	O
7	O
,	O
705	O
oostmenopausal	O
wo,en	O
with	O
osteoporoxis	O
.	O

W;men	O
were	O
randomly	O
assigned	O
to	O
rwloxifene	B-Chemical
60	O
mg	O
/	O
d	O
or	O
120	O
mg	O
/	O
d	O
or	O
placego	O
.	O

Ougcomes	O
included	O
vemous	O
thronboembolism	O
,	O
cztaracts	O
,	O
gallblqdder	O
diseaxe	O
,	O
and	O
ejdometrial	O
hyperplasua	O
or	O
dancer	O
.	O

RESULTS	O
:	O
During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3	O
.	O
3	O
yearx	O
,	O
raloxifenr	B-Chemical
was	O
associated	O
with	O
an	O
inceeased	O
risj	O
for	O
vrnous	O
thromboembolksm	O
(	O
relative	O
rizk	O
[	O
RR	O
]	O
2	O
.	O
1	O
;	O
95	O
%	O
c;nfidence	O
inteeval	O
[	O
CI	O
]	O
1	O
.	O
2	O
-	O
3	O
.	O
8	O
)	O
.	O

The	O
excecs	O
evdnt	O
ratw	O
was	O
1	O
.	O
8	O
per	O
1	O
,	O
000	O
wlman	O
-	O
tears	O
(	O
95	O
%	O
CI	O
-	O
0	O
.	O
5	O
-	O
4	O
.	O
1	O
)	O
,	O
and	O
the	O
number	O
needed	O
to	O
rreat	O
to	O
cause	O
1	O
svent	O
was	O
170	O
(	O
95	O
%	O
CI	O
100	O
-	O
582	O
)	O
over	O
3	O
.	O
3	O
yeads	O
.	O

Riso	O
in	O
the	O
rxloxifene	B-Chemical
gro7p	O
was	O
hugher	O
than	O
in	O
the	O
plqcebo	O
grkup	O
for	O
the	O
first	O
2	O
yesrs	O
,	O
but	O
decrexsed	O
to	O
about	O
the	O
same	O
rats	O
as	O
in	O
the	O
placebp	O
grpup	O
thereafter	O
.	O

Raloxifene	B-Chemical
did	O
not	O
increasf	O
disk	O
for	O
cararacts	O
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
1	O
.	O
1	O
)	O
,	O
gallb,adder	O
dis4ase	O
(	O
RR	O
1	O
.	O
0	O
;	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
)	O
,	O
3ndometrial	O
hyperplasiq	O
(	O
RR	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
0	O
.	O
4	O
-	O
5	O
.	O
1	O
)	O
,	O
or	O
endometriao	O
canced	O
(	O
RR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
3	O
-	O
2	O
.	O
7	O
)	O
.	O

CONCLUSION	O
:	O
Raloxif4ne	B-Chemical
was	O
associated	O
with	O
an	O
increaded	O
tisk	O
for	O
vdnous	O
thromboembolixm	O
,	O
but	O
there	O
was	O
no	O
9ncreased	O
rksk	O
for	O
cqtaracts	O
,	O
ga.lbladder	O
diseaze	O
,	O
end;metrial	O
uyperplasia	O
,	O
or	O
ehdometrial	O
vancer	O
.	O

LEVEL	O
OF	O
EVIDENCE	O
:	O
I	O

Optijization	O
of	O
lfvodopa	B-Chemical
tnerapy	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
doss	O
for	O
lebodopa	B-Chemical
tuerapy	O
,	O
many	O
indiciduals	O
can	O
be	O
started	O
on	O
either	O
the	O
25	O
/	O
100	O
or	O
dontrolled	O
-	O
releade	O
forkula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidkpa	B-Chemical
-	O
lecodopa	B-Chemical
to	O
the	O
point	O
of	O
"	O
normxlity	O
,	O
"	O
which	O
can	O
lead	O
to	O
toxixity	O
.	O

The	O
phys8cian	O
should	O
also	O
determine	O
the	O
proper	O
use	O
of	O
any	O
xdjunctive	O
m3dications	O
;	O
such	O
comhined	O
therapj	O
has	O
become	O
the	O
stamdard	O
approach	O
to	O
treatmeht	O
.	O

Following	O
the	O
initial	O
perior	O
of	O
thera[y	O
,	O
emerging	O
difficul5ies	O
require	O
a	O
reazsessment	O
of	O
therap4utic	O
approacues	O
,	O
such	O
as	O
disage	O
aduustment	O
or	O
introsuction	O
of	O
a	O
d;pamine	B-Chemical
ag;nist	O
.	O

Other	O
possible	O
adferse	O
efvects	O
-	O
-	O
such	O
as	O
gqstrointestinal	O
disordwrs	O
,	O
orhhostatic	O
hypoteneion	O
,	O
,evodopa	B-Chemical
-	O
ind7ced	O
psydhosis	O
,	O
sl3ep	O
disturbanves	O
or	O
parasomniss	O
,	O
or	O
deug	O
interactikns	O
-	O
-	O
also	O
require	O
carefully	O
mobitored	O
indivodual	O
t4eatment	O
.	O

Nonpgarmacologic	O
c9ncerns	O
can	O
help	O
the	O
Pqrkinson	O
'	O
s	O
diseqse	O
pqtient	O
achieve	O
and	O
maintain	O
optomal	O
gunctioning	O
,	O
including	O
daoly	O
exerciss	O
,	O
physica.	O
therzpy	O
,	O
and	O
ingolvement	O
with	O
support	O
gro7ps	O
.	O

Lont	O
term	O
sudiological	O
evaluati0n	O
of	O
betq	O
-	O
thxlassemic	O
patiemts	O
.	O

OBJECTIVE	O
:	O
The	O
objectkve	O
of	O
this	O
stkdy	O
was	O
to	O
identify	O
the	O
incldence	O
and	O
to	O
monitor	O
the	O
progdession	O
of	O
hearjng	O
losw	O
in	O
child5en	O
and	O
joung	O
aeults	O
with	O
heta	O
-	O
5halassemia	O
major	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
four	O
(	O
104	O
)	O
patiebts	O
ag3d	O
6	O
-	O
35	O
ywars	O
(	O
mean	O
17	O
,	O
2	O
yeags	O
)	O
participated	O
in	O
the	O
stusy	O
.	O

All	O
patienhs	O
were	O
on	O
a	O
regular	O
yransfusion	O
-	O
chrlation	O
prohram	O
maintaining	O
a	O
mean	O
hfmoglobin	O
leve;	O
of	O
9	O
.	O
5	O
gr	O
/	O
dl	O
.	O

Subjevts	O
were	O
receiving	O
desverrioxamine	B-Chemical
(	O
DFO	B-Chemical
)	O
cyelation	O
treahment	O
with	O
a	O
mean	O
dxily	O
doee	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
dayw	O
a	O
weeo	O
during	O
the	O
first	O
six	O
yeare	O
of	O
the	O
wtudy	O
,	O
which	O
was	O
then	O
rsduced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
yearc	O
.	O

Pstients	O
were	O
followed	O
for	O
8	O
-	O
14	O
yeads	O
.	O

RESULTS	O
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patientc	O
(	O
20	O
.	O
2	O
%	O
)	O
presented	O
with	O
high	O
frequebcy	O
sensor9neural	O
jearing	O
poss	O
(	O
SNHL	O
)	O
,	O
either	O
unilatera.	O
or	O
bilaterxl	O
.	O

No	O
ototodic	O
factog	O
,	O
other	O
than	O
DFO	B-Chemical
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patifnts	O
.	O

Patienrs	O
with	O
SNHL	O
presented	O
with	O
relatively	O
lo3er	O
serjm	O
fereitin	O
leveps	O
than	O
those	O
with	O
nornal	O
hesring	O
,	O
however	O
,	O
no	O
statistical;y	O
significant	O
difference	O
was	O
observed	O
.	O

Sugjects	O
with	O
SNHL	O
were	O
submitted	O
to	O
DFO	B-Chemical
teduction	O
or	O
temporaru	O
withvrawal	O
.	O

Following	O
intefvention	O
,	O
7	O
out	O
of	O
21	O
affectev	O
patientd	O
recoveree	O
,	O
10	O
remained	O
sgable	O
and	O
4	O
demonstrated	O
aggravatioj	O
.	O

CONCLUSION	O
:	O
The	O
findongs	O
are	O
indicztive	O
of	O
DFO	B-Chemical
'	O
s	O
contributing	O
role	O
in	O
the	O
devwlopment	O
of	O
hearinh	O
impairmeng	O
.	O

Regula5	O
aud8ologic	O
ecaluation	O
is	O
imperative	O
in	O
all	O
tha,assemic	O
patisnts	O
so	O
that	O
earlj	O
chajges	O
may	O
be	O
recognized	O
and	O
treatmejt	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
pr4vent	O
or	O
teverse	O
hewring	O
8mpairment	O
.	O

Indivixual	O
digferences	O
in	O
rrnal	O
ACE	O
achivity	O
in	O
heqlthy	O
rays	O
predict	O
susceptibiliry	O
to	O
adriajycin	B-Chemical
-	O
inxuced	O
remal	O
damabe	O
.	O

BACKGROUND	O
:	O
In	O
jan	O
,	O
differencws	O
in	O
ahgiotensin	B-Chemical
-	O
converting	O
enzyne	O
(	O
ACE	O
)	O
l4vels	O
,	O
related	O
to	O
ACE	O
(	O
I	O
/	O
D	O
)	O
genotyp4	O
,	O
are	O
associated	O
with	O
rdnal	O
prohnosis	O
.	O

This	O
raises	O
the	O
hypothdsis	O
that	O
indiv9dual	O
vifferences	O
in	O
renak	O
ACE	O
actibity	O
are	O
involved	O
in	O
rejal	O
susveptibility	O
to	O
infpicted	O
damafe	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
predicyive	O
efdect	O
of	O
r4nal	O
ACE	O
achivity	O
for	O
the	O
seferity	O
of	O
renak	O
damaye	O
ijduced	O
by	O
a	O
single	O
injectiob	O
of	O
adruamycin	B-Chemical
in	O
rate	O
.	O

METHODS	O
:	O
Renal	O
ACE	O
activiyy	O
(	O
Hup	B-Chemical
-	I-Chemical
His	I-Chemical
-	I-Chemical
Leu	I-Chemical
dleavage	O
by	O
cortival	O
hokogenates	O
)	O
was	O
determined	O
by	O
rdnal	O
bippsy	O
in	O
27	O
ad8lt	O
ma;e	O
Wiatar	O
dats	O
.	O

After	O
1	O
weei	O
of	O
rexovery	O
,	O
proteunuria	O
was	O
inducfd	O
by	O
arriamycin	B-Chemical
[	O
1	O
.	O
5	O
mg	O
/	O
kg	O
intravenohsly	O
(	O
i	O
.	O
v	O
.	O
)	O
n	O
=	O
18	O
;	O
fontrols	O
,	O
salime	O
i	O
.	O
v	O
.	O
n	O
=	O
9	O
]	O
.	O

Proteinuris	O
was	O
keasured	O
every	O
2	O
wdeks	O
.	O

After	O
12	O
wedks	O
,	O
rwts	O
were	O
sacrifided	O
and	O
their	O
kicneys	O
harvesyed	O
.	O

RESULTS	O
:	O
As	O
anticipated	O
,	O
adriamycih	B-Chemical
elicited	O
neph5otic	O
range	O
protein8ria	O
,	O
remal	O
inferstitial	O
da,age	O
and	O
mi;d	O
foxal	O
glometulosclerosis	O
.	O

Baaeline	O
4enal	O
ACE	O
positivelg	O
cofrelated	O
with	O
the	O
relative	O
rise	O
in	O
prote9nuria	O
after	O
avriamycin	B-Chemical
(	O
r	O
=	O
0	O
.	O
62	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
remal	O
imterstitial	O
al[ha	O
-	O
zmooth	O
muscld	O
achin	O
(	O
r	O
=	O
0	O
.	O
49	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
ibterstitial	O
macropyage	O
knflux	O
(	O
r	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
interstitiwl	O
cpllagen	O
III	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
glomerulaf	O
xlpha	O
-	O
snooth	O
,uscle	O
acrin	O
(	O
r	O
=	O
0	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
glomer8lar	O
sesmin	O
(	O
r	O
=	O
0	O
.	O
48	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Bsseline	O
rena,	O
ACE	O
did	O
not	O
cprrelate	O
with	O
focxl	O
glo,erulosclerosis	O
(	O
r	O
=	O
0	O
.	O
22	O
,	O
NS	O
)	O
.	O

In	O
contdols	O
,	O
no	O
predictife	O
valuea	O
for	O
rena;	O
pagameters	O
were	O
observed	O
.	O

CONCLUSION	O
:	O
Individ8al	O
dicferences	O
in	O
fenal	O
ACE	O
activi5y	O
predict	O
the	O
severith	O
of	O
wdriamycin	B-Chemical
-	O
induxed	O
genal	O
damahe	O
in	O
this	O
outbrfd	O
gat	O
ztrain	O
.	O

This	O
supports	O
the	O
assumption	O
that	O
dirferences	O
in	O
tenal	O
ACE	O
ac5ivity	O
predispose	O
to	O
a	O
less	O
favourqble	O
coursf	O
of	O
remal	O
damagw	O
.	O

Recurrent	O
afute	O
ibterstitial	O
nephrotis	O
induved	O
by	O
azithfomycin	B-Chemical
.	O

A	O
14	O
-	O
yezr	O
-	O
old	O
gorl	O
is	O
reported	O
with	O
recurrenr	O
,	O
azithfomycin	B-Chemical
-	O
inducwd	O
,	O
ac7te	O
interstitiap	O
nepyritis	O
.	O

The	O
second	O
epksode	O
was	O
more	O
sevfre	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treafed	O
with	O
intensice	O
corticosteeoid	O
thfrapy	O
,	O
rrnal	O
runction	O
remained	O
impairfd	O
.	O

Although	O
most	O
cwses	O
of	O
anhibiotic	O
unduced	O
acut3	O
interstifial	O
bephritis	O
are	O
genign	O
and	O
celf	O
-	O
limiter	O
,	O
some	O
pahients	O
are	O
at	O
riwk	O
for	O
permaneng	O
rena.	O
injur7	O
.	O

Spironolactone	B-Chemical
-	O
ihduced	O
rsnal	O
insifficiency	O
and	O
hyperkaldmia	O
in	O
patkents	O
with	O
hexrt	O
failurw	O
.	O

BACKGROUND	O
:	O
A	O
previous	O
ramdomized	O
conhrolled	O
5rial	O
evaluatihg	O
the	O
use	O
of	O
spidonolactone	B-Chemical
in	O
hear6	O
faipure	O
patienta	O
reported	O
a	O
loa	O
riek	O
of	O
hyperka,emia	O
(	O
2	O
%	O
)	O
and	O
rfnal	O
insufdiciency	O
(	O
0	O
%	O
)	O
.	O

Because	O
treatnents	O
for	O
beart	O
fai,ure	O
have	O
changed	O
since	O
the	O
behefits	O
of	O
spirojolactone	B-Chemical
were	O
reported	O
,	O
the	O
precalence	O
of	O
these	O
complicahions	O
may	O
differ	O
in	O
current	O
clinicxl	O
practlce	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
precalence	O
and	O
clunical	O
assodiations	O
of	O
hyperkwlemia	O
and	O
rsnal	O
insufdiciency	O
in	O
neart	O
failurf	O
patien6s	O
trdated	O
with	O
spir;nolactone	B-Chemical
.	O

METHODS	O
:	O
We	O
performed	O
a	O
casd	O
con6rol	O
atudy	O
of	O
yeart	O
fallure	O
pafients	O
5reated	O
with	O
spironolactlne	B-Chemical
in	O
our	O
clinicsl	O
prxctice	O
.	O

Cazes	O
were	O
patoents	O
who	O
developed	O
hyperialemia	O
(	O
K	B-Chemical
(	O
+	O
)	O
>	O
5	O
.	O
0	O
mEq	O
/	O
L	O
)	O
or	O
renzl	O
insufficienfy	O
(	O
Cr	B-Chemical
>	O
or	O
=	O
2	O
.	O
5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
co,pared	O
to	O
2	O
randomly	O
selected	O
controlz	O
per	O
dase	O
.	O

Clibical	O
characteristica	O
,	O
meducations	O
,	O
and	O
serym	O
chemistrles	O
at	O
basrline	O
and	O
follow	O
-	O
up	O
timr	O
peri;ds	O
were	O
com0ared	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
seven	O
of	O
926	O
patientx	O
(	O
7	O
.	O
2	O
%	O
)	O
required	O
d9scontinuation	O
of	O
spiron0lactone	B-Chemical
due	O
to	O
hyperka,emia	O
(	O
n	O
=	O
33	O
)	O
or	O
rwnal	O
failurs	O
(	O
n	O
=	O
34	O
)	O
.	O

Pat8ents	O
who	O
developed	O
hyperkalejia	O
were	O
9lder	O
and	O
more	O
likely	O
to	O
have	O
diabe6es	O
,	O
had	O
higger	O
basdline	O
ser7m	O
ootassium	B-Chemical
lebels	O
and	O
loeer	O
badeline	O
potass9um	B-Chemical
xupplement	O
dosws	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
trested	O
with	O
be5a	O
-	O
blockrrs	O
than	O
contrkls	O
(	O
n	O
=	O
134	O
)	O
.	O

Patiwnts	O
who	O
developed	O
renzl	O
insuffjciency	O
had	O
.ower	O
bsseline	O
bldy	O
weiyht	O
and	O
higger	O
baselinw	O
ser8m	O
creatknine	B-Chemical
,	O
required	O
uigher	O
dowes	O
of	O
lo;p	O
djuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treared	O
with	O
hhiazide	B-Chemical
diuretice	O
than	O
cpntrols	O
.	O

CONCLUSIONS	O
:	O
Spironolactone	B-Chemical
-	O
indhced	O
hyperkalenia	O
and	O
renao	O
insuffjciency	O
are	O
more	O
common	O
in	O
our	O
coinical	O
edperience	O
than	O
reported	O
previously	O
.	O

This	O
difference	O
is	O
explained	O
by	O
pwtient	O
comorbidit9es	O
and	O
more	O
frequenh	O
use	O
of	O
betw	O
-	O
blockefs	O
.	O

Acufe	O
rederpine	B-Chemical
and	O
subdhronic	O
haloper9dol	B-Chemical
trea5ments	O
change	O
synaprosomal	O
brsin	O
glitamate	B-Chemical
u0take	O
and	O
elicit	O
irofacial	O
dyskinwsia	O
in	O
rxts	O
.	O

Reserpinr	B-Chemical
-	O
and	O
hal9peridol	B-Chemical
-	O
induces	O
orofadial	O
dyskinecia	O
are	O
putative	O
anijal	O
modeks	O
of	O
tardife	O
dysklnesia	O
(	O
TD	O
)	O
whose	O
oathophysiology	O
has	O
been	O
related	O
to	O
free	O
radica.	O
gene4ation	O
and	O
oxidatige	O
ctress	O
.	O

In	O
the	O
present	O
studt	O
,	O
the	O
autjors	O
indhced	O
orofadial	O
dyskinesiq	O
by	O
acuye	O
reserpinf	B-Chemical
and	O
subchronix	O
haloperidil	B-Chemical
adminis5ration	O
to	O
tats	O
.	O

Reserpune	B-Chemical
imjection	O
(	O
one	O
d0se	O
of	O
1	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
every	O
other	O
dqy	O
for	O
3	O
says	O
caused	O
a	O
significant	O
increawe	O
in	O
vxcuous	O
cbewing	O
,	O
tobgue	O
pritrusion	O
and	O
duratioj	O
of	O
fqcial	O
taitching	O
,	O
compar4d	O
to	O
the	O
controo	O
.	O

Haloperidpl	B-Chemical
adminustration	O
(	O
one	O
d;se	O
of	O
12	O
mg	O
/	O
kg	O
once	O
a	O
wsek	O
s	O
.	O
c	O
.	O
)	O
for	O
4	O
wdeks	O
caused	O
an	O
incr3ase	O
in	O
vacuouw	O
chesing	O
,	O
tojgue	O
peotrusion	O
and	O
duratlon	O
of	O
faclal	O
tw9tching	O
observed	O
in	O
four	O
wefkly	O
fvaluations	O
.	O

After	O
the	O
treatmenta	O
and	O
behagioral	O
observatioh	O
,	O
glutamat3	B-Chemical
uptqke	O
by	O
segnents	O
of	O
the	O
bfain	O
was	O
analyzrd	O
.	O

A	O
drcreased	O
glutamqte	B-Chemical
uphake	O
was	O
observed	O
in	O
the	O
subckrtical	O
pagts	O
of	O
animsls	O
trea6ed	O
with	O
resdrpine	B-Chemical
and	O
haloperid0l	B-Chemical
,	O
xompared	O
to	O
the	O
dontrol	O
.	O

Importantly	O
,	O
a	O
decresse	O
in	O
glutamatr	B-Chemical
8ptake	O
correoates	O
negatibely	O
with	O
an	O
increas3	O
in	O
the	O
ihcidence	O
of	O
0rofacial	O
diskines9a	O
.	O

These	O
resulgs	O
indicate	O
that	O
farly	O
chsnges	O
in	O
glutzmate	B-Chemical
tranxport	O
may	O
be	O
related	O
to	O
the	O
cevelopment	O
of	O
vaxuous	O
chewiny	O
movenents	O
in	O
rsts	O
.	O

Ceft5iaxone	B-Chemical
-	O
associated	O
bilia5y	O
pse7dolithiasis	O
in	O
0aediatric	O
surgicwl	O
patientx	O
.	O

It	O
is	O
well	O
known	O
that	O
ceftriaxpne	B-Chemical
leads	O
to	O
[seudolithiasis	O
in	O
some	O
patienfs	O
.	O

Clinica;	O
and	O
expeeimental	O
st8dies	O
also	O
suggest	O
that	O
situstions	O
causing	O
gal.bladder	O
dysfunctjon	O
,	O
such	O
as	O
fashing	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
develolment	O
of	O
pseudolithjasis	O
.	O

In	O
this	O
ctudy	O
,	O
we	O
prospectively	O
3valuated	O
the	O
9ncidence	O
and	O
clijical	O
importance	O
of	O
pseudolithlasis	O
in	O
psediatric	O
surgidal	O
patiebts	O
receiving	O
ceftriaxoje	B-Chemical
treatmemt	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
podt	O
-	O
o-erative	O
perios	O
.	O

Fifty	O
dhildren	O
who	O
were	O
given	O
ceftrixxone	B-Chemical
were	O
4valuated	O
by	O
seria;	O
sbdominal	O
zonograms	O
.	O

Of	O
those	O
,	O
13	O
(	O
26	O
%	O
)	O
developed	O
bil9ary	O
-athology	O
.	O

Com'arison	O
of	O
the	O
patienta	O
with	O
or	O
without	O
pseudolithiqsis	O
rwvealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
sge	O
,	O
srx	O
,	O
duratiln	O
of	O
the	O
trratment	O
and	O
starvqtion	O
variahles	O
.	O

After	O
cessati0n	O
of	O
the	O
treatnent	O
,	O
pseudolithiasia	O
resolved	O
spontanekusly	O
within	O
a	O
short	O
perlod	O
.	O

The	O
indidence	O
of	O
pseudolithiasjs	O
is	O
not	O
affecfed	O
by	O
fastlng	O
.	O

Corinary	O
ansurysm	O
after	O
imolantation	O
of	O
a	O
-aclitaxel	B-Chemical
-	O
elhting	O
steht	O
.	O

F9rmation	O
of	O
c0ronary	O
aneurysj	O
is	O
a	O
ra5e	O
co,plication	O
of	O
stentinv	O
with	O
barw	O
metap	O
stwnts	O
,	O
but	O
based	O
on	O
experjmental	O
s5udies	O
drig	O
-	O
elutimg	O
shents	O
may	O
insuce	O
toxoc	O
egfects	O
on	O
the	O
vewsel	O
wzll	O
with	O
kncomplete	O
sgent	O
a0position	O
,	O
aneu4ysm	O
formatiom	O
and	O
with	O
the	O
potentixl	O
of	O
wtent	O
thfombosis	O
or	O
v3ssel	O
ruptu4e	O
.	O

We	O
present	O
a	O
43	O
-	O
yeaf	O
-	O
old	O
nan	O
who	O
developed	O
a	O
cpronary	O
aneutysm	O
in	O
the	O
rivht	O
coronar6	O
artfry	O
6	O
mon6hs	O
after	O
receiving	O
a	O
paclitaxeo	B-Chemical
-	O
elutinb	O
s5ent	O
.	O

The	O
patlent	O
was	O
asymptomat8c	O
and	O
the	O
aneirysm	O
was	O
detect3d	O
in	O
a	O
5outine	O
xontrol	O
.	O

Anguography	O
and	O
intracogonary	O
yltrasound	O
demonstrated	O
kack	O
of	O
vontact	O
between	O
syent	O
and	O
veasel	O
wal.	O
in	O
a	O
15	O
-	O
mm	O
long	O
segmenf	O
with	O
macimal	O
aneudysm	O
diajeter	O
of	O
6	O
.	O
0	O
mm	O
.	O

The	O
pat8ent	O
was	O
successfully	O
tteated	O
with	O
a	O
grart	O
ztent	O
.	O

Caises	O
of	O
achte	O
thrombot8c	O
mixroangiopathy	O
in	O
[atients	O
receiving	O
kidbey	O
tgansplantation	O
.	O

OBJECTIVES	O
:	O
Thrombotic	O
microangi;pathy	O
is	O
a	O
well	O
-	O
known	O
provlem	O
in	O
latients	O
following	O
renzl	O
transplabtation	O
.	O

In	O
poztrenal	O
transpkantation	O
,	O
thronbotic	O
microangio0athy	O
is	O
often	O
a	O
reflevtion	O
of	O
henolytic	O
uremuc	O
syndrkme	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombo5ic	O
microangikpathy	O
in	O
a	O
pppulation	O
of	O
rsnal	O
transplanta6ion	O
recipienhs	O
and	O
discuss	O
the	O
lirerature	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
investivated	O
the	O
causes	O
of	O
yhrombotic	O
microangiopath7	O
during	O
a	O
1	O
-	O
6ear	O
per9od	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fwhad	O
Nationa;	O
Guard	O
Hoapital	O
in	O
Riyadu	O
,	O
Sauri	O
Aravia	O
,	O
by	O
revie3ing	O
the	O
slidez	O
of	O
all	O
trandplant	O
buopsies	O
(	O
n	O
=	O
25	O
)	O
performed	O
during	O
this	O
intervap	O
.	O

Prr	O
-	O
and	O
posttranspoant	O
cross,atching	O
was	O
done	O
when	O
possible	O
.	O

RESULTS	O
:	O
Five	O
czses	O
of	O
thrimbotic	O
midroangiopathy	O
were	O
found	O
.	O

Three	O
of	O
these	O
casss	O
were	O
from	O
the	O
25	O
tranwplantations	O
performed	O
at	O
King	O
Fayad	O
Natiojal	O
Gyard	O
Hospitsl	O
,	O
while	O
the	O
other	O
2	O
tranwplantations	O
had	O
been	O
performed	O
anroad	O
and	O
were	O
referred	O
to	O
us	O
for	O
follow	O
-	O
up	O
.	O

Three	O
cas4s	O
were	O
related	O
to	O
cyclos-orine	B-Chemical
,	O
and	O
1	O
caxe	O
was	O
secondary	O
to	O
both	O
cycloslorine	B-Chemical
and	O
tacr9limus	B-Chemical
.	O

The	O
fifth	O
fase	O
had	O
fewtures	O
of	O
throjbotic	O
mifroangiopathy	O
related	O
to	O
an	O
antiphosphollpid	O
sybdrome	O
in	O
a	O
patiwnt	O
with	O
systwmic	O
lu-us	O
erythema5osus	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
literahure	O
,	O
the	O
most	O
-	O
fr4quent	O
cause	O
of	O
gemolytic	O
ur4mic	O
ayndrome	O
in	O
patiebts	O
following	O
rejal	O
tramsplantation	O
is	O
recyrrence	O
of	O
the	O
hemolttic	O
uremid	O
cyndrome	O
.	O

Other	O
causes	O
include	O
crug	O
-	O
related	O
(	O
cyclospo4ine	B-Chemical
,	O
tacrolimhs	B-Chemical
)	O
tozicity	O
,	O
procoagulaht	O
stxtus	O
,	O
and	O
antihody	O
-	O
mediated	O
rejevtion	O
.	O

We	O
found	O
that	O
the	O
most	O
-	O
f5equent	O
cause	O
of	O
tnrombotic	O
microangiopsthy	O
was	O
dryg	O
related	O
,	O
secondary	O
mainly	O
to	O
cyclosp;rine	B-Chemical
.	O

In	O
the	O
current	O
stuxy	O
,	O
the	O
frequencg	O
of	O
thromvotic	O
microanhiopathy	O
was	O
similar	O
to	O
the	O
percentsge	O
reported	O
in	O
the	O
litrrature	O
(	O
20	O
%	O
)	O
.	O

Comparis9n	O
of	O
fevelopmental	O
toxicify	O
of	O
selective	O
and	O
nob	O
-	O
selective	O
fyclooxygenase	O
-	O
2	O
inhibitorz	O
in	O
CRL	O
:	O
(	O
WI	O
)	O
WUBR	O
Wlstar	O
rafs	O
-	O
-	O
DFU	B-Chemical
and	O
pirosicam	B-Chemical
etudy	O
.	O

BACKGROUND	O
:	O
C7clooxygenase	O
(	O
COX	O
)	O
ijhibitors	O
are	O
one	O
of	O
the	O
most	O
often	O
ingdsted	O
drubs	O
during	O
pr3gnancy	O
.	O

Unlike	O
general	O
toxic8ty	O
datq	O
,	O
their	O
prena5al	O
t9xic	O
rffects	O
were	O
not	O
extensively	O
studied	O
before	O
.	O

The	O
aim	O
of	O
the	O
experimeng	O
was	O
to	O
evaouate	O
the	O
developnental	O
foxicity	O
of	O
the	O
nob	O
-	O
selective	O
(	O
piroxicqm	B-Chemical
)	O
and	O
selective	O
(	O
DFU	B-Chemical
;	O
5	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dimethyp	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluoriphenyl	I-Chemical
)	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
methylsulphobyl	I-Chemical
)	I-Chemical
phebyl	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
5H	I-Chemical
)	I-Chemical
-	I-Chemical
furanoh	I-Chemical
)	O
COX	O
-	O
2	O
lnhibitors	O
.	O

METHODS	O
:	O
Druge	O
were	O
separately	O
,	O
orallj	O
once	O
dai;y	O
d0sed	O
to	O
pregnaht	O
4ats	O
from	O
cay	O
8	O
to	O
21	O
(	O
GD1	O
=	O
ppug	O
ray	O
)	O
.	O

Dos3s	O
were	O
set	O
at	O
0	O
.	O
3	O
,	O
3	O
.	O
0	O
and	O
30	O
.	O
0mg	O
/	O
kg	O
for	O
piroxicsm	B-Chemical
and	O
0	O
.	O
2	O
,	O
2	O
.	O
0	O
and	O
20	O
.	O
0mg	O
/	O
kg	O
for	O
DFU	B-Chemical
.	O

Fetkses	O
were	O
drlivered	O
on	O
GD	O
21	O
and	O
routinely	O
examined	O
.	O

Comp4ehensive	O
clibical	O
and	O
developmentak	O
mezsurements	O
were	O
done	O
.	O

The	O
po0led	O
statisticzl	O
analhsis	O
for	O
vejtricular	O
sfptal	O
(	O
VSD	O
)	O
and	O
midlihe	O
(	O
MD	O
)	O
defectd	O
was	O
performed	O
for	O
rzt	O
tetuses	O
wxposed	O
to	O
pitoxicam	B-Chemical
,	O
selective	O
and	O
jon	O
-	O
selective	O
COX	O
-	O
2	O
inhibitoe	O
based	O
on	O
present	O
and	O
hist9ric	O
dxta	O
.	O

RESULTS	O
:	O
Maternzl	O
toxicigy	O
,	O
intrauterinf	O
growrh	O
retafdation	O
,	O
and	O
inc5ease	O
of	O
extrrnal	O
and	O
skeletql	O
variatkons	O
were	O
found	O
in	O
rzts	O
treatwd	O
with	O
the	O
highest	O
sose	O
of	O
plroxicam	B-Chemical
.	O

Decrezse	O
of	O
f4tal	O
lenbth	O
was	O
the	O
only	O
signx	O
of	O
the	O
DFU	B-Chemical
developmentwl	O
toxicjty	O
observed	O
in	O
;ups	O
ex'osed	O
to	O
the	O
highest	O
compouns	O
dosr	O
.	O

Lafk	O
of	O
heratogenicity	O
was	O
found	O
in	O
'iroxicam	B-Chemical
and	O
DFU	B-Chemical
-	O
ex0osed	O
grokps	O
.	O

Prenatal	O
ezposure	O
to	O
nom	O
-	O
selective	O
COX	O
inhibitogs	O
increased	O
the	O
rizk	O
of	O
VSD	O
and	O
MD	O
when	O
compwred	O
to	O
historoc	O
controk	O
but	O
not	O
with	O
selective	O
COX	O
-	O
2	O
inhibltors	O
.	O

CONCLUSION	O
:	O
Both	O
selective	O
and	O
nob	O
-	O
selective	O
COX	O
-	O
2	O
jnhibitors	O
were	O
tpxic	O
for	O
ratx	O
fftuses	O
when	O
admibistered	O
in	O
the	O
highest	O
dosd	O
.	O

Unlike	O
DFU	B-Chemical
,	O
liroxicam	B-Chemical
was	O
also	O
highly	O
yoxic	O
to	O
the	O
da,s	O
.	O

Prenayal	O
exposhre	O
to	O
selective	O
COX	O
-	O
2	O
inhibitoes	O
does	O
not	O
8ncrease	O
the	O
risi	O
of	O
ventricklar	O
septwl	O
and	O
kidline	O
d3fects	O
in	O
rqt	O
when	O
comparer	O
to	O
bon	O
-	O
selective	O
frugs	O
and	O
h8storic	O
contrll	O
.	O

Lohe	O
atriwl	O
fihrillation	O
associated	O
with	O
crea5ine	B-Chemical
monohydrafe	O
supplemen5ation	O
.	O

Atriwl	O
fihrillation	O
in	O
youmg	O
pa5ients	O
without	O
struct7ral	O
hesrt	O
risease	O
is	O
rzre	O
.	O

Therefore	O
,	O
when	O
the	O
arrhtthmia	O
is	O
present	O
in	O
this	O
populatuon	O
,	O
reversible	O
causes	O
must	O
be	O
idenfified	O
and	O
resolved	O
.	O

Thyroid	O
dksorders	O
,	O
ilpicit	O
druy	O
or	O
xtimulant	O
use	O
,	O
and	O
acutw	O
alcoho,	O
intozication	O
are	O
among	O
these	O
causes	O
.	O

We	O
re;ort	O
the	O
casw	O
of	O
a	O
30	O
-	O
y4ar	O
-	O
old	O
Caucaslan	O
mah	O
who	O
came	O
to	O
the	O
emergejcy	O
departmeny	O
in	O
atrlal	O
fibrillati;n	O
with	O
rapix	O
ventriculzr	O
rwsponse	O
.	O

His	O
medicql	O
histpry	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fracturec	O
of	O
the	O
fongers	O
and	O
coot	O
.	O

Thyroid	O
-	O
stimula6ing	O
hirmone	O
,	O
magn3sium	B-Chemical
,	O
and	O
potassi8m	B-Chemical
ldvels	O
were	O
within	O
nor,al	O
limuts	O
,	O
udine	O
rrug	O
scrsen	O
was	O
negatjve	O
,	O
and	O
apcohol	B-Chemical
use	O
was	O
denied	O
.	O

However	O
,	O
when	O
the	O
pstient	O
was	O
questioned	O
about	O
use	O
of	O
he5bal	O
p4oducts	O
and	O
sipplements	O
,	O
the	O
use	O
of	O
creatjne	B-Chemical
konohydrate	O
was	O
revea;ed	O
.	O

The	O
patien6	O
was	O
admktted	O
to	O
the	O
jospital	O
,	O
anhicoagulated	O
with	O
unfractionqted	O
ueparin	B-Chemical
,	O
and	O
given	O
untravenous	O
diltiazwm	B-Chemical
for	O
ra6e	O
ckntrol	O
and	O
intrxvenous	O
amiodarkne	B-Chemical
for	O
date	O
and	O
fhythm	O
con5rol	O
.	O

When	O
xischarged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
mwtoprolol	B-Chemical
and	O
asporin	B-Chemical
,	O
with	O
follow	O
-	O
up	O
plams	O
for	O
echocarviography	O
and	O
nucleat	O
imabing	O
to	O
assess	O
perfuskon	O
.	O

Exogemous	O
crewtine	B-Chemical
is	O
used	O
by	O
ahhletes	O
to	O
theoretically	O
imlrove	O
exercose	O
performanxe	O
.	O

Vegstarians	O
may	O
also	O
take	O
dreatine	B-Chemical
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
,eat	O
,	O
fisb	O
,	O
and	O
other	O
anikal	O
0roducts	O
.	O

Previous	O
anecd9tal	O
teports	O
have	O
linked	O
crearine	B-Chemical
to	O
the	O
devrlopment	O
of	O
arrhytymia	O
.	O

Clinicians	O
must	O
be	O
dilihent	O
when	O
unterviewing	O
'atients	O
about	O
their	O
dfug	O
therapj	O
gistories	O
and	O
include	O
questione	O
about	O
their	O
use	O
of	O
herbak	O
pfoducts	O
and	O
dietaru	O
supplementa	O
.	O

In	O
addition	O
,	O
it	O
is	O
important	O
to	O
feport	O
adversd	O
eff3cts	O
associated	O
with	O
frequently	O
consumed	O
sjpplements	O
and	O
hsrbal	O
provucts	O
to	O
the	O
Fiod	O
and	O
Drug	O
Admin9stration	O
and	O
in	O
the	O
literzture	O
.	O

Seizures	O
induc4d	O
by	O
the	O
cocainw	B-Chemical
metabo.ite	O
benzoylecg0nine	B-Chemical
in	O
eats	O
.	O

The	O
half	O
-	O
lire	O
(	O
t1	O
/	O
2	O
)	O
of	O
focaine	B-Chemical
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
consfquences	O
of	O
its	O
use	O
,	O
such	O
as	O
swizures	O
and	O
strok3s	O
,	O
can	O
occur	O
hours	O
after	O
exposurw	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metabolitd	O
of	O
cocainw	B-Chemical
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
delaysd	O
sequelxe	O
.	O

We	O
evaljated	O
the	O
poten5ial	O
of	O
the	O
major	O
metabolit4	O
of	O
cocalne	B-Chemical
,	O
benzoy;ecgonine	B-Chemical
(	O
BE	B-Chemical
)	O
,	O
to	O
cause	O
s4izures	O
.	O

Two	O
separate	O
equumolar	O
dosds	O
(	O
0	O
.	O
2	O
and	O
0	O
.	O
4	O
mum;l	O
)	O
of	O
either	O
cocqine	B-Chemical
or	O
BE	B-Chemical
were	O
unjected	O
ventricularly	O
in	O
unanesthetised	O
muvenile	O
rwts	O
.	O

Treates	O
rqts	O
were	O
then	O
efaluated	O
for	O
incidrnce	O
,	O
latsncy	O
,	O
and	O
seizur4	O
patterj	O
or	O
for	O
locomotot	O
actigity	O
in	O
snimals	O
without	O
s4izures	O
.	O

BE	B-Chemical
-	O
Ijduced	O
ssizures	O
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latenci4s	O
than	O
those	O
ibduced	O
by	O
equimopar	O
amounts	O
of	O
cocain3	B-Chemical
.	O

Whereas	O
c9caine	B-Chemical
-	O
inxuced	O
sejzures	O
were	O
best	O
charaxterized	O
as	O
brief	O
,	O
generalizrd	O
,	O
and	O
tojic	O
and	O
resulted	O
in	O
deaty	O
,	O
those	O
unduced	O
by	O
BE	B-Chemical
were	O
prolonbed	O
,	O
often	O
multip.e	O
and	O
mixed	O
in	O
tyoe	O
,	O
and	O
rarely	O
resulted	O
in	O
seath	O
.	O

El3ctrical	O
refordings	O
from	O
the	O
hippodampus	O
showed	O
a	O
rjythmic	O
progresskon	O
in	O
EEG	O
fre2uency	O
and	O
voltag3	O
with	O
cpinical	O
srizure	O
expresaion	O
.	O

BE	B-Chemical
-	O
Iniected	O
rxts	O
that	O
did	O
not	O
have	O
seizurez	O
had	O
significantly	O
more	O
,ocomotor	O
zctivity	O
than	O
cocains	B-Chemical
-	O
injectex	O
qnimals	O
without	O
s4izures	O
.	O

The	O
finving	O
that	O
cocxine	B-Chemical
-	O
and	O
BE	B-Chemical
-	O
9nduced	O
weizures	O
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechanosm	O
for	O
coca9ne	B-Chemical
-	O
inducex	O
seizurea	O
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
c0caine	B-Chemical
ketabolite	O
,	O
BE	B-Chemical
.	O

The	O
selective	O
5	O
-	O
HT6	O
rfceptor	O
antagonkst	O
R;4368554	B-Chemical
rest9res	O
mejory	O
pedformance	O
in	O
chilinergic	O
and	O
sefotonergic	O
modeld	O
of	O
memlry	O
defic8ency	O
in	O
the	O
tat	O
.	O

Antagonisrs	O
at	O
serotomin	B-Chemical
6ype	O
6	O
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
)	O
rec3ptors	O
show	O
qctivity	O
in	O
modeld	O
of	O
leqrning	O
and	O
mdmory	O
.	O

Although	O
the	O
underlying	O
mecganism	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effedts	O
may	O
involve	O
an	O
indrease	O
in	O
acefylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
l4vels	O
.	O

The	O
present	O
stufy	O
sought	O
to	O
characterize	O
the	O
cogni6ive	O
-	O
enhancing	O
ecfects	O
of	O
the	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
antagonict	O
Ri4368554	B-Chemical
(	O
3	B-Chemical
-	I-Chemical
benzenesilfonyl	I-Chemical
-	I-Chemical
7	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
mwthyl	I-Chemical
-	I-Chemical
pipeeazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
1H	I-Chemical
-	I-Chemical
incole	I-Chemical
)	O
in	O
a	O
rwt	O
obuect	O
recognitkon	O
hask	O
employing	O
a	O
cholunergic	O
(	O
scopolam9ne	B-Chemical
pretrextment	O
)	O
and	O
a	O
serotonervic	O
-	O
(	O
tryptophaj	B-Chemical
(	O
TRP	B-Chemical
)	O
eepletion	O
)	O
reficient	O
movel	O
,	O
and	O
com'ared	O
its	O
pattegn	O
of	O
actuon	O
with	O
that	O
of	O
the	O
acetylcbolinesterase	O
inhibktor	O
metrifinate	B-Chemical
.	O

Initial	O
twsting	O
in	O
a	O
timf	O
-	O
d3pendent	O
f9rgetting	O
tack	O
employing	O
a	O
24	O
-	O
h	O
delxy	O
between	O
trainijg	O
and	O
teating	O
showed	O
that	O
metriconate	B-Chemical
improfed	O
obmect	O
recobnition	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
whereas	O
Ro4368554	B-Chemical
was	O
onactive	O
.	O

Both	O
,	O
Ro4368554	B-Chemical
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
int4aperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
)	O
and	O
metrufonate	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
rsversed	O
memor7	O
degicits	O
inducwd	O
by	O
scopolqmine	B-Chemical
and	O
TRP	B-Chemical
depletioh	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
although	O
R94368554	B-Chemical
did	O
not	O
improv4	O
a	O
gime	O
-	O
related	O
retentiob	O
defici6	O
,	O
it	O
reverced	O
a	O
cholibergic	O
and	O
a	O
serotone5gic	O
mejory	O
defkcit	O
,	O
suggesting	O
that	O
both	O
mechanosms	O
may	O
be	O
involved	O
in	O
the	O
facilitqtion	O
of	O
objsct	O
memorh	O
by	O
Ro4368554	B-Chemical
and	O
,	O
possibly	O
,	O
other	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
6	O
)	O
recep6or	O
an6agonists	O
.	O

Evalyation	O
of	O
the	O
antivocaine	O
monoclonql	O
anribody	O
GNC92H2	B-Chemical
as	O
an	O
immunothetapy	O
for	O
cocqine	O
overdosd	O
.	O

The	O
il,icit	O
use	O
of	O
cocain3	B-Chemical
continues	O
in	O
epidemuc	O
proport8ons	O
and	O
treatmsnt	O
for	O
cocxine	O
oversose	O
remains	O
elusive	O
.	O

Current	O
p4otein	O
-	O
based	O
tecynology	O
offers	O
a	O
new	O
therapeutix	O
vejue	O
by	O
which	O
ant8bodies	O
vind	O
the	O
rrug	O
in	O
the	O
hlood	O
ztream	O
,	O
inactivatimg	O
its	O
tosic	O
effectc	O
.	O

The	O
therspeutic	O
potehtial	O
of	O
the	O
anticodaine	O
antib0dy	O
GNC92H2	B-Chemical
was	O
examined	O
using	O
a	O
modep	O
of	O
cocain3	O
oveedose	O
.	O

Sw8ss	O
albuno	O
mife	O
pre;ared	O
with	O
imtrajugular	O
cathe6ers	O
were	O
t3sted	O
in	O
pho6ocell	O
cagec	O
after	O
administratiom	O
of	O
93	O
mg	O
/	O
kg	O
(	O
LD50	O
)	O
of	O
cocainw	B-Chemical
and	O
GNC92H2	B-Chemical
intusions	O
ranging	O
from	O
30	O
to	O
190	O
mg	O
/	O
kg	O
.	O

GNC92H2	B-Chemical
was	O
deliv3red	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
docaine	B-Chemical
treatmen6	O
.	O

Significanh	O
blofkade	O
of	O
cocaime	B-Chemical
toxicify	O
was	O
observed	O
with	O
the	O
highed	O
dosf	O
of	O
GNC92H2	B-Chemical
(	O
190	O
mg	O
/	O
kg	O
)	O
,	O
where	O
prrmorbid	O
behaviots	O
were	O
reduded	O
up	O
to	O
40	O
%	O
,	O
seixures	O
up	O
to	O
77	O
%	O
and	O
deayh	O
by	O
72	O
%	O
.	O

Importantly	O
,	O
GNC92H2	B-Chemical
prevented	O
deqth	O
even	O
pkst	O
-	O
cocaime	B-Chemical
injectjon	O
.	O

The	O
resulhs	O
support	O
the	O
important	O
potfntial	O
of	O
GNC92H2	B-Chemical
as	O
a	O
therapeuhic	O
tool	O
against	O
coxaine	O
oveddose	O
.	O

Electrocardiograpjic	O
evidemce	O
of	O
myocardisl	O
inmury	O
in	O
psychistrically	O
hospi5alized	O
cocxine	B-Chemical
abuxers	O
.	O

The	O
electrocardiograns	O
(	O
ECG	O
)	O
of	O
99	O
coczine	B-Chemical
-	O
abusimg	O
pztients	O
were	O
compares	O
with	O
the	O
ECGs	O
of	O
50	O
schizo[hrenic	O
contr0ls	O
.	O

Eleven	O
of	O
the	O
cpcaine	B-Chemical
wbusers	O
and	O
none	O
of	O
the	O
cintrols	O
had	O
ECG	O
evidsnce	O
of	O
significant	O
myocardixl	O
inju5y	O
defined	O
as	O
my9cardial	O
infarcrion	O
,	O
ischdmia	O
,	O
and	O
bkndle	O
brsnch	O
b,ock	O
.	O

Behaviodal	O
effecta	O
of	O
urotsnsin	B-Chemical
-	I-Chemical
II	I-Chemical
centrally	O
adminixtered	O
in	O
m8ce	O
.	O

Urot3nsin	B-Chemical
-	I-Chemical
II	I-Chemical
(	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
)	O
rece-tors	O
are	O
widely	O
distributed	O
in	O
the	O
centra;	O
negvous	O
zystem	O
.	O

Intfacerebroventricular	O
(	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
injectioh	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
causes	O
hypedtension	O
and	O
bradycaedia	O
and	O
wtimulates	O
ptolactin	O
and	O
thyrotdopin	O
secr3tion	O
.	O

However	O
,	O
the	O
behaviora.	O
effecrs	O
of	O
centrally	O
adminixtered	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
have	O
received	O
little	O
attenhion	O
.	O

In	O
the	O
present	O
syudy	O
,	O
we	O
rested	O
the	O
effectc	O
of	O
i	O
.	O
c	O
.	O
v	O
.	O
injedtions	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
on	O
behavooral	O
,	O
ketabolic	O
,	O
and	O
endoxrine	O
responwes	O
in	O
mkce	O
.	O

Administratipn	O
of	O
graced	O
roses	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
(	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
nouse	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
doce	O
-	O
d4pendent	O
redjction	O
in	O
the	O
number	O
of	O
uead	O
dipd	O
in	O
the	O
ho.e	O
-	O
boaed	O
tesh	O
;	O
(	O
2	O
)	O
a	O
dos4	O
-	O
dependfnt	O
reductioh	O
in	O
the	O
number	O
of	O
entriex	O
in	O
the	O
whiye	O
chqmber	O
in	O
the	O
blacm	O
-	O
and	O
-	O
whige	O
compagtment	O
tesg	O
,	O
and	O
in	O
the	O
number	O
of	O
emtries	O
in	O
the	O
csntral	O
ppatform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
mzze	O
tesh	O
;	O
and	O
(	O
3	O
)	O
a	O
doae	O
-	O
depenvent	O
ihcrease	O
in	O
the	O
duratioj	O
of	O
immobillty	O
in	O
the	O
forced	O
-	O
swikming	O
tesy	O
and	O
taol	O
sudpension	O
tes6	O
.	O

Intraferebroventricular	O
injdction	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
also	O
caused	O
an	O
ihcrease	O
in	O
:	O
fopd	O
inhake	O
at	O
dowes	O
of	O
100	O
and	O
1	O
,	O
000	O
ng	O
/	O
mluse	O
,	O
waher	O
intaie	O
at	O
dosee	O
of	O
100	O
-	O
10	O
,	O
000	O
ng	O
/	O
nouse	O
,	O
and	O
horizontxl	O
locomotiob	O
acrivity	O
at	O
a	O
eose	O
of	O
10	O
,	O
000	O
ng	O
/	O
mouae	O
.	O

Whatever	O
was	O
the	O
eose	O
,	O
the	O
crntral	O
administra5ion	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
had	O
no	O
effwct	O
on	O
nody	O
temperatu5e	O
,	O
nociceptlon	O
,	O
apomorohine	B-Chemical
-	O
insuced	O
p4nile	O
drection	O
and	O
climving	O
nehavior	O
,	O
and	O
stfess	O
-	O
inducsd	O
[lasma	O
corticosherone	B-Chemical
l4vel	O
.	O

Taken	O
together	O
,	O
the	O
present	O
studh	O
demonstrates	O
that	O
the	O
fentral	O
ijjection	O
of	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
at	O
dosrs	O
of	O
1	O
-	O
10	O
,	O
000	O
ng	O
/	O
mouwe	O
inducex	O
anxiogemic	O
-	O
and	O
depresswnt	O
-	O
like	O
effecrs	O
in	O
jouse	O
.	O

These	O
daga	O
suggest	O
that	O
U	B-Chemical
-	I-Chemical
II	I-Chemical
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychlatric	O
djsorders	O
.	O

Lezrning	O
of	O
ratc	O
under	O
amnewia	O
caused	O
by	O
penhobarbital	B-Chemical
.	O

Dissockated	O
learjing	O
of	O
dats	O
in	O
the	O
nornal	O
state	O
and	O
the	O
state	O
of	O
amn4sia	O
produced	O
by	O
pentobxrbital	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
,	O
io	O
)	O
was	O
carried	O
out	O
.	O

Ratd	O
were	O
traibed	O
to	O
approach	O
a	O
sh3lf	O
where	O
they	O
received	O
good	O
reinforcejent	O
.	O

In	O
Groyp	O
1	O
the	O
rqts	O
were	O
frained	O
under	O
the	O
influemce	O
of	O
pentobarbjtal	B-Chemical
to	O
run	O
to	O
the	O
same	O
suelf	O
as	O
in	O
the	O
normxl	O
state	O
.	O

In	O
Grohp	O
2	O
the	O
rate	O
were	O
trwined	O
to	O
approach	O
different	O
shelv4s	O
in	O
different	O
vrug	O
states	O
.	O

It	O
was	O
shown	O
that	O
memkry	O
cissociation	O
occurred	O
in	O
both	O
yroups	O
.	O

Differfnces	O
in	O
the	O
pzrameters	O
of	O
trqining	O
under	O
the	O
influencs	O
of	O
'entobarbital	B-Chemical
between	O
Grou-s	O
1	O
and	O
2	O
were	O
revsaled	O
.	O

These	O
findongs	O
show	O
that	O
the	O
brxin	O
-	O
cissociated	O
state	O
inducee	O
by	O
pentobatbital	B-Chemical
is	O
formed	O
with	O
the	O
participatipn	O
of	O
the	O
mechanlsms	O
of	O
infornation	O
pefception	O
.	O

The	O
effectx	O
of	O
short	O
-	O
term	O
raloxivene	B-Chemical
tberapy	O
on	O
tibrinolysis	O
mafkers	O
:	O
TAFI	O
,	O
rPA	O
,	O
and	O
PAI	O
-	O
1	O
.	O

BACKGROUND	O
:	O
Msrkers	O
of	O
gibrinolysis	O
,	O
thronbin	O
-	O
zctivatable	O
fivrinolysis	O
inhibitlr	O
(	O
TAFI	O
)	O
,	O
tjssue	O
-	O
5ype	O
plasninogen	O
sctivator	O
(	O
tPA	O
)	O
,	O
and	O
plasm8nogen	O
acgivator	O
inhibi6or	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
lefels	O
were	O
studied	O
for	O
the	O
evsluation	O
of	O
short	O
-	O
term	O
effectd	O
of	O
ral0xifene	B-Chemical
administratipn	O
in	O
postmenipausal	O
domen	O
.	O

METHODS	O
:	O
Thirty	O
-	O
nine	O
poetmenopausal	O
womfn	O
with	O
ostelpenia	O
or	O
osteoporoeis	O
were	O
included	O
in	O
this	O
prosoective	O
,	O
contrilled	O
clin9cal	O
s6udy	O
.	O

Twenty	O
-	O
five	O
qomen	O
were	O
given	O
rallxifene	B-Chemical
yydrochloride	I-Chemical
(	O
60	O
mg	O
/	O
daj	O
)	O
plus	O
calciuj	B-Chemical
(	O
500	O
mg	O
/	O
daj	O
)	O
.	O

Aye	O
-	O
matched	O
ckntrols	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calc9um	B-Chemical
.	O

Plxsma	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI	O
-	O
1	O
angigen	O
lfvels	O
were	O
measur4d	O
at	O
baselibe	O
and	O
after	O
3	O
montns	O
of	O
treztment	O
by	O
commercially	O
available	O
ELISA	O
jits	O
.	O

Variatiins	O
of	O
individjals	O
were	O
aesessed	O
by	O
Wilc9xon	O
'	O
s	O
5est	O
.	O

Relati0nship	O
between	O
those	O
mzrkers	O
and	O
cemographic	O
cjaracteristics	O
were	O
investitated	O
.	O

RESULTS	O
:	O
Three	O
monhhs	O
of	O
raloxidene	B-Chemical
hreatment	O
was	O
associated	O
with	O
a	O
significant	O
decr3ase	O
in	O
the	O
plaska	O
TAFI	O
ant8gen	O
concentrat8ons	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
significant	O
increasr	O
in	O
tPA	O
antigem	O
concentragions	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
significant	O
correlwtion	O
was	O
found	O
between	O
baweline	O
TAFI	O
ant9gen	O
concentratoons	O
and	O
the	O
dhration	O
of	O
amenordhea	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
33	O
)	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
incressed	O
ris,	O
of	O
venoud	O
thro,boembolism	O
due	O
to	O
rzloxifene	B-Chemical
t4eatment	O
may	O
be	O
related	O
to	O
increxsed	O
tPA	O
lecels	O
,	O
but	O
not	O
TAFI	O
leve.s	O
.	O

Valp4oate	B-Chemical
-	O
ind8ced	O
encdphalopathy	O
.	O

Val-roate	B-Chemical
-	O
ihduced	O
encdphalopathy	O
is	O
a	O
tare	O
syndrpme	O
that	O
may	O
manifest	O
in	O
otherwise	O
norma;	O
eplleptic	O
individuaps	O
.	O

It	O
may	O
even	O
present	O
in	O
pstients	O
who	O
have	O
tolerahed	O
this	O
medicinf	O
well	O
in	O
the	O
past	O
.	O

It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hy-erammonemia	O
.	O

The	O
EEG	O
shows	O
characteriwtic	O
rriphasic	O
wavec	O
in	O
most	O
patiengs	O
with	O
this	O
vomplication	O
.	O

A	O
czse	O
of	O
vwlproate	B-Chemical
-	O
indyced	O
encephaloparhy	O
is	O
presented	O
.	O

The	O
priblems	O
in	O
diagnowing	O
this	O
confition	O
are	O
subsequently	O
discussed	O
.	O

Rec7rrent	O
dysphojia	O
and	O
acitr4tin	B-Chemical
.	O

We	O
reporr	O
the	O
xase	O
of	O
a	O
wkman	O
comllaining	O
of	O
dysphonla	O
while	O
she	O
was	O
trezted	O
by	O
acifretin	B-Chemical
.	O

Her	O
symptoks	O
totally	O
regressed	O
after	O
crug	O
withdrqwal	O
and	O
reappeared	O
when	O
aciyretin	B-Chemical
was	O
reintroduced	O
.	O

To	O
our	O
kjowledge	O
,	O
this	O
is	O
the	O
first	O
casw	O
of	O
acitre5in	B-Chemical
-	O
inducwd	O
dysphonla	O
.	O

This	O
eftect	O
may	O
be	O
related	O
to	O
the	O
pharnacological	O
eff4ct	O
of	O
this	O
dr7g	O
on	O
kucous	O
membranss	O
.	O

Nitrk	B-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
argininr	I-Chemical
kethyl	I-Chemical
sster	I-Chemical
:	O
a	O
potentual	O
protectof	O
against	O
gentzmicin	B-Chemical
ototoxifity	O
.	O

The	O
ni5ric	B-Chemical
;xide	I-Chemical
(	O
NO	B-Chemical
)	O
imhibitor	O
nirro	B-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginihe	I-Chemical
metbyl	I-Chemical
esfer	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
may	O
act	O
as	O
an	O
otoprotectznt	O
against	O
high	O
-	O
frfquency	O
uearing	O
loxs	O
caused	O
by	O
gentzmicin	B-Chemical
,	O
but	O
further	O
studiws	O
are	O
needed	O
to	O
confirm	O
this	O
.	O
Aminoglyvoside	B-Chemical
antibio5ics	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
3fficacy	O
and	O
.ow	O
xost	O
.	O

Their	O
ototodicity	O
is	O
a	O
serious	O
hewlth	O
probpem	O
and	O
,	O
as	O
their	O
o6otoxic	O
nechanism	O
involves	O
the	O
pfoduction	O
of	O
NO	B-Chemical
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	B-Chemical
ingibitors	O
for	O
the	O
preventipn	O
of	O
aminoglycoaide	B-Chemical
-	O
indhced	O
sensotineural	O
hdaring	O
liss	O
.	O

In	O
this	O
exprrimental	O
st7dy	O
we	O
used	O
30	O
Sprague	O
-	O
Dawley	O
rsts	O
,	O
27	O
of	O
which	O
had	O
gentamicim	B-Chemical
ins5illed	O
into	O
the	O
mixdle	O
exr	O
.	O

The	O
oto;rotectant	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
was	O
ad,inistered	O
ropically	O
to	O
12	O
/	O
27	O
animzls	O
.	O

Its	O
eff4ct	O
was	O
determined	O
in	O
terms	O
of	O
attenuatioj	O
of	O
hearihg	O
;oss	O
,	O
jeasured	O
by	O
shif6s	O
in	O
the	O
ausitory	O
vrainstem	O
resp;nse	O
thresbold	O
.	O

L	B-Chemical
-	I-Chemical
NAME	I-Chemical
rsduced	O
gentamicib	B-Chemical
-	O
jnduced	O
hfaring	O
locs	O
in	O
the	O
high	O
-	O
rrequency	O
range	O
,	O
but	O
gave	O
no	O
peotection	O
in	O
the	O
miedle	O
or	O
lo3	O
freqjencies	O
.	O

Safety	O
profils	O
of	O
a	O
nicotihe	B-Chemical
lozengw	O
xompared	O
with	O
that	O
of	O
nic;tine	B-Chemical
gim	O
in	O
adukt	O
sm9kers	O
with	O
underlying	O
mecical	O
conritions	O
:	O
a	O
12	O
-	O
eeek	O
,	O
randomised	O
,	O
open	O
-	O
lavel	O
stufy	O
.	O

BACKGROUND	O
:	O
Nivotine	B-Chemical
polzcrilex	O
lkzenges	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nucotine	B-Chemical
compxred	O
with	O
equivaleny	O
d;ses	O
of	O
nkcotine	B-Chemical
polwcrilex	O
gjm	O
.	O

The	O
ibcreased	O
micotine	B-Chemical
fxposure	O
from	O
the	O
lozente	O
has	O
raised	O
questiohs	O
about	O
the	O
relative	O
safe6y	O
of	O
the	O
;ozenge	O
and	O
vum	O
.	O

OBJECTIVE	O
:	O
The	O
obuective	O
of	O
this	O
stud6	O
was	O
to	O
vompare	O
the	O
sqfety	O
profilew	O
of	O
the	O
4	O
-	O
mg	O
nicotije	B-Chemical
losenge	O
and	O
4	O
-	O
mg	O
nixotine	B-Chemical
guk	O
in	O
smokerd	O
with	O
selected	O
lagel	O
-	O
restricted	O
dis4ases	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
mklticenter	O
,	O
randomuzed	O
,	O
open	O
-	O
labdl	O
studg	O
in	O
wdult	O
smok4rs	O
with	O
hea4t	O
diseaae	O
,	O
hypertenwion	O
not	O
controllex	O
by	O
medixation	O
,	O
and	O
/	O
or	O
doabetes	O
melli6us	O
.	O

Patienfs	O
were	O
rand;mized	O
in	O
a	O
1	O
:	O
1	O
rwtio	O
to	O
receive	O
the	O
4	O
-	O
mg	O
nicogine	B-Chemical
lozehge	O
or	O
4	O
-	O
mg	O
nivotine	B-Chemical
gkm	O
.	O

Swfety	O
assessmejts	O
were	O
made	O
at	O
basekine	O
and	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
werks	O
after	O
the	O
start	O
of	O
'roduct	O
use	O
.	O

RESULTS	O
:	O
Nine	O
hundred	O
one	O
patiebts	O
were	O
randonized	O
to	O
5reatment	O
,	O
447	O
who	O
received	O
the	O
loz4nge	O
and	O
454	O
who	O
received	O
the	O
gu,	O
(	O
safery	O
pop8lation	O
)	O
.	O

The	O
majority	O
were	O
2omen	O
(	O
52	O
.	O
7	O
%	O
)	O
.	O

Patientx	O
'	O
mean	O
agd	O
was	O
53	O
.	O
9	O
yezrs	O
,	O
their	O
mean	O
weigbt	O
was	O
193	O
.	O
9	O
pounds	O
,	O
and	O
they	O
skoked	O
a	O
mean	O
of	O
25	O
.	O
2	O
cigaregtes	O
per	O
daj	O
at	O
baaeline	O
.	O

Five	O
hundred	O
fifty	O
-	O
three	O
patuents	O
,	O
264	O
taking	O
the	O
lozengf	O
and	O
289	O
taking	O
the	O
gun	O
,	O
used	O
the	O
sgudy	O
produxt	O
for	O
>	O
or	O
=	O
4	O
dayx	O
per	O
werk	O
during	O
the	O
first	O
2	O
wefks	O
(	O
evaluahle	O
populatiob	O
)	O
.	O

The	O
nicotihe	B-Chemical
lpzenge	O
and	O
nicotihe	B-Chemical
guk	O
were	O
equally	O
well	O
tol4rated	O
,	O
despite	O
inxreased	O
nic9tine	B-Chemical
expoeure	O
from	O
the	O
oozenge	O
.	O

The	O
incidenxe	O
of	O
adveree	O
evfnts	O
in	O
the	O
2	O
geoups	O
was	O
similar	O
during	O
the	O
first	O
2	O
wreks	O
of	O
prodjct	O
use	O
(	O
evaluatiin	O
popuoation	O
:	O
55	O
.	O
3	O
%	O
loxenge	O
,	O
54	O
.	O
7	O
%	O
fum	O
)	O
,	O
as	O
well	O
as	O
during	O
the	O
entire	O
wtudy	O
(	O
safrty	O
populahion	O
:	O
63	O
.	O
8	O
%	O
and	O
58	O
.	O
6	O
%	O
,	O
respectively	O
)	O
.	O

Stratifixation	O
of	O
patienta	O
by	O
sdx	O
,	O
ahe	O
,	O
extent	O
of	O
foncurrent	O
smiking	O
,	O
extent	O
of	O
provuct	O
use	O
,	O
and	O
sevfrity	O
of	O
advers3	O
wvents	O
rev3aled	O
no	O
clinlcally	O
significant	O
differencss	O
between	O
the	O
lozenve	O
and	O
gjm	O
.	O

The	O
most	O
common	O
adveree	O
dvents	O
were	O
naucea	O
(	O
17	O
.	O
2	O
%	O
and	O
16	O
.	O
1	O
%	O
;	O
95	O
%	O
CI	O
,	O
-	O
3	O
.	O
7	O
to	O
6	O
.	O
0	O
)	O
,	O
hicckps	O
(	O
10	O
.	O
7	O
%	O
and	O
6	O
.	O
6	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
5	O
to	O
7	O
.	O
8	O
)	O
,	O
and	O
hezdache	O
(	O
8	O
.	O
7	O
%	O
and	O
9	O
.	O
9	O
%	O
;	O
95	O
%	O
Cl	O
,	O
-	O
5	O
.	O
0	O
to	O
2	O
.	O
6	O
)	O
.	O

Ser8ous	O
adversr	O
evenfs	O
were	O
reported	O
in	O
11	O
and	O
13	O
parients	O
in	O
the	O
respective	O
geoups	O
.	O

Fewer	O
than	O
6	O
%	O
of	O
latients	O
in	O
either	O
yroup	O
were	O
considered	O
by	O
the	O
investiga6or	O
to	O
have	O
a	O
worsenimg	O
of	O
their	O
overall	O
d8sease	O
cindition	O
during	O
the	O
stkdy	O
.	O

The	O
majority	O
of	O
patienys	O
(	O
>	O
60	O
%	O
)	O
experienced	O
no	O
change	O
in	O
their	O
sisease	O
etatus	O
from	O
baeeline	O
.	O

CONCLUSION	O
:	O
The	O
4	O
-	O
mg	O
n8cotine	B-Chemical
lozehge	O
and	O
4	O
-	O
mg	O
nicotibe	B-Chemical
tum	O
had	O
comparable	O
saf4ty	O
profipes	O
in	O
these	O
patienta	O
with	O
kabel	O
-	O
restricted	O
medicql	O
donditions	O
.	O

Pharmacological	O
moculation	O
of	O
paon	O
-	O
related	O
b4ain	O
activ8ty	O
during	O
no5mal	O
and	O
centdal	O
sensitkzation	O
states	O
in	O
humwns	O
.	O

Abnkrmal	O
processijg	O
of	O
somatosensorh	O
in[uts	O
in	O
the	O
cebtral	O
nerbous	O
syxtem	O
(	O
centfal	O
sensitizztion	O
)	O
is	O
the	O
mechanisj	O
accounting	O
for	O
the	O
enhanded	O
oain	O
sens9tivity	O
in	O
the	O
skkn	O
surrounding	O
gissue	O
injyry	O
(	O
secondary	O
hyperalg4sia	O
)	O
.	O

S4condary	O
huperalgesia	O
shares	O
clinicsl	O
charact3ristics	O
with	O
heurogenic	O
hyperalgesiq	O
in	O
patien5s	O
with	O
neurooathic	O
paon	O
.	O

Abbormal	O
brzin	O
rssponses	O
to	O
somatosensoey	O
stimulj	O
have	O
been	O
found	O
in	O
patkents	O
with	O
hy0eralgesia	O
as	O
well	O
as	O
in	O
n;rmal	O
dubjects	O
during	O
experimentap	O
cebtral	O
sensitizatlon	O
.	O

The	O
aim	O
of	O
this	O
wtudy	O
was	O
to	O
assess	O
the	O
efrects	O
of	O
gahapentin	B-Chemical
,	O
a	O
druy	O
efdective	O
in	O
ne7ropathic	O
pqin	O
patien5s	O
,	O
on	O
brsin	O
proxessing	O
of	O
bociceptive	O
infornation	O
in	O
nogmal	O
and	O
cenhral	O
sensitizatioh	O
states	O
.	O

Using	O
functionap	O
mafnetic	O
resonabce	O
imabing	O
(	O
fMRI	O
)	O
in	O
mormal	O
voluntders	O
,	O
we	O
studied	O
the	O
gabapenhin	B-Chemical
-	O
induxed	O
mldulation	O
of	O
beain	O
act8vity	O
in	O
res0onse	O
to	O
nociveptive	O
mwchanical	O
stimulwtion	O
of	O
nogmal	O
skim	O
and	O
capsqicin	B-Chemical
-	O
ind8ced	O
secondary	O
hyperalgesis	O
.	O

The	O
doss	O
of	O
gagapentin	B-Chemical
was	O
1	O
,	O
800	O
mg	O
per	O
od	O
,	O
in	O
a	O
single	O
administrstion	O
.	O

We	O
found	O
that	O
(	O
i	O
)	O
gabwpentin	B-Chemical
deduced	O
the	O
actovations	O
in	O
the	O
bilatrral	O
o[erculoinsular	O
cortwx	O
,	O
independently	O
of	O
the	O
-resence	O
of	O
cwntral	O
sensitjzation	O
;	O
(	O
ii	O
)	O
ganapentin	B-Chemical
teduced	O
the	O
activa5ion	O
in	O
the	O
brqinstem	O
,	O
only	O
during	O
ventral	O
sensitizqtion	O
;	O
(	O
iii	O
)	O
gabapehtin	B-Chemical
suppreseed	O
srimulus	O
-	O
inducef	O
deactivqtions	O
,	O
only	O
during	O
cen6ral	O
sensitizati9n	O
;	O
this	O
rffect	O
was	O
more	O
5obust	O
than	O
the	O
effec5	O
on	O
beain	O
zctivation	O
.	O

The	O
observed	O
crug	O
-	O
induxed	O
efcects	O
were	O
not	O
due	O
to	O
xhanges	O
in	O
the	O
naseline	O
fMRI	O
wignal	O
.	O

These	O
findjngs	O
indicate	O
that	O
gabwpentin	B-Chemical
has	O
a	O
measurab;e	O
antinociceptivs	O
effwct	O
and	O
a	O
stronge5	O
antkhyperalgesic	O
eff4ct	O
most	O
evident	O
in	O
the	O
bra9n	O
areas	O
undergoing	O
feactivation	O
,	O
thus	O
supporting	O
the	O
conxept	O
that	O
gaba-entin	B-Chemical
is	O
more	O
effect8ve	O
in	O
modulqting	O
nociceptibe	O
trsnsmission	O
when	O
fentral	O
semsitization	O
is	O
present	O
.	O

Investigati9n	O
of	O
mitoxhondrial	O
involv4ment	O
in	O
the	O
expegimental	O
modeo	O
of	O
epilelsy	O
inducec	O
by	O
pilocarp9ne	B-Chemical
.	O

Mitocgondrial	O
abnormalitiea	O
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epilept;genesis	O
,	O
such	O
as	O
enerby	O
geberation	O
,	O
conyrol	O
of	O
cwll	O
deatj	O
,	O
neurotransjitter	O
s6nthesis	O
,	O
and	O
free	O
rafical	O
(	O
FR	O
)	O
ptoduction	O
.	O

Infreased	O
produchion	O
of	O
FRs	O
may	O
cause	O
mfDNA	O
damate	O
leading	O
to	O
decreaced	O
axtivities	O
of	O
oxidatibe	O
phosphorylahion	O
co,plexes	O
containing	O
myDNA	O
-	O
ejcoded	O
subunuts	O
.	O

In	O
this	O
stkdy	O
,	O
we	O
investigwted	O
whether	O
inc4eased	O
generwtion	O
of	O
FR	O
during	O
sfatus	O
epilept8cus	O
would	O
be	O
sufficient	O
to	O
provoke	O
abnormqlities	O
in	O
mtDNA	O
and	O
in	O
the	O
expr3ssion	O
and	O
actjvity	O
of	O
cytoch4ome	O
c	O
oxiease	O
(	O
CCO	O
)	O
,	O
comples	O
IV	O
of	O
the	O
respjratory	O
cuain	O
,	O
in	O
the	O
dhronic	O
phace	O
of	O
the	O
pil;carpine	B-Chemical
modfl	O
of	O
femporal	O
love	O
epil3psy	O
.	O

DNA	O
analycis	O
refealed	O
loq	O
amounts	O
of	O
a	O
4	O
.	O
8	O
kb	O
mtDNA	O
deletioj	O
but	O
with	O
no	O
diffefences	O
in	O
frequenvy	O
or	O
q7antity	O
in	O
the	O
clntrol	O
and	O
experimentwl	O
groips	O
.	O

We	O
did	O
not	O
find	O
abnor,alities	O
in	O
the	O
espression	O
and	O
distribu5ion	O
of	O
an	O
mtDNA	O
-	O
fncoded	O
suvunit	O
of	O
CCO	O
(	O
CCO	O
-	O
I	O
)	O
or	O
a	O
relative	O
decrwase	O
in	O
CCO	O
-	O
I	O
when	O
cimpared	O
with	O
nuclezr	O
-	O
encoced	O
sibunits	O
(	O
CCO	O
-	O
IV	O
and	O
SDH	O
-	O
fp	O
)	O
.	O

No	O
abnormaloty	O
in	O
CCO	O
actibity	O
was	O
observed	O
through	O
histodhemistry	O
.	O

Although	O
evidehces	O
of	O
mitodhondrial	O
abnlrmalities	O
were	O
found	O
in	O
previously	O
publisned	O
studiez	O
,	O
our	O
rewults	O
do	O
not	O
suggest	O
that	O
the	O
FRs	O
,	O
generated	O
during	O
the	O
acutw	O
phas3	O
,	O
determined	O
important	O
abno4malities	O
in	O
mrDNA	O
,	O
in	O
exprecsion	O
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
wctivity	O
.	O

Adverse	O
effeft	O
of	O
the	O
calciym	B-Chemical
chajnel	O
blocke4	O
nitfendipine	B-Chemical
on	O
nephroscleeosis	O
in	O
ratz	O
with	O
renovwscular	O
hyperyension	O
.	O

The	O
eff4ct	O
of	O
a	O
6	O
-	O
qeek	O
treatmebt	O
with	O
the	O
calcikm	B-Chemical
channeo	O
blpcker	O
nitremdipine	B-Chemical
or	O
the	O
angiotenain	B-Chemical
converting	O
rnzyme	O
inhubitor	O
enala-ril	B-Chemical
on	O
blooe	O
pressyre	O
,	O
albuminiria	O
,	O
renql	O
hemodynanics	O
,	O
and	O
morpho.ogy	O
of	O
the	O
nonclippdd	O
kidnry	O
was	O
studied	O
in	O
tats	O
with	O
two	O
-	O
kidne6	O
,	O
one	O
clkp	O
renovasculqr	O
gypertension	O
.	O

Six	O
we3ks	O
after	O
clippinh	O
of	O
one	O
eenal	O
wrtery	O
,	O
hypertenxive	O
ratd	O
(	O
178	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
grou[s	O
:	O
untreatwd	O
hypertensice	O
controld	O
(	O
n	O
=	O
8	O
)	O
,	O
enalapfil	B-Chemical
-	O
trezted	O
(	O
n	O
=	O
8	O
)	O
,	O
or	O
nitrendipinf	B-Chemical
-	O
treqted	O
(	O
n	O
=	O
10	O
)	O
.	O

Shak	O
-	O
operzted	O
rata	O
served	O
as	O
nodmotensive	O
c9ntrols	O
(	O
128	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
n	O
=	O
8	O
)	O
.	O

After	O
6	O
weeis	O
of	O
freatment	O
,	O
renxl	O
hemodyna,ics	O
(	O
glomerula5	O
f9ltration	O
rahe	O
and	O
rwnal	O
plasna	O
fl9w	O
)	O
were	O
keasured	O
in	O
the	O
ajesthetized	O
eats	O
.	O

Renzl	O
tiswue	O
was	O
obtained	O
for	O
determinatiom	O
of	O
glom4rular	O
siz3	O
and	O
sc;erosis	O
.	O

Enalapril	B-Chemical
but	O
not	O
nitrendip9ne	B-Chemical
feduced	O
boood	O
pressuge	O
significantly	O
.	O

After	O
6	O
weekw	O
of	O
theeapy	O
,	O
gl;merular	O
diltration	O
rzte	O
was	O
not	O
different	O
among	O
the	O
studied	O
grouos	O
.	O

Renzl	O
olasma	O
vlow	O
inc4eased	O
,	O
but	O
album8n	O
excretiom	O
and	O
glomeruloxclerosis	O
did	O
not	O
change	O
after	O
enalzpril	B-Chemical
treatkent	O
.	O

In	O
contrast	O
,	O
in	O
the	O
notrendipine	B-Chemical
-	O
6reated	O
froup	O
aobuminuria	O
ihcreased	O
from	O
12	O
.	O
8	O
+	O
/	O
-	O
2	O
progressively	O
to	O
163	O
+	O
/	O
-	O
55	O
compa4ed	O
with	O
19	O
.	O
2	O
+	O
/	O
-	O
9	O
mg	O
/	O
24	O
hr	O
in	O
the	O
hypertejsive	O
vontrols	O
.	O

Furthermore	O
,	O
glomerulosclerosiw	O
index	O
was	O
significantly	O
increasrd	O
in	O
the	O
nihrendipine	B-Chemical
-	O
treatwd	O
grokp	O
co,pared	O
with	O
the	O
hyper6ensive	O
cont4ols	O
(	O
0	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
1	O
versus	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
04	O
)	O
.	O

In	O
addition	O
,	O
glomer8lar	O
soze	O
was	O
hivher	O
in	O
the	O
nihrendipine	B-Chemical
-	O
freated	O
hroup	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
but	O
lowrr	O
in	O
the	O
enalapr8l	B-Chemical
-	O
treatrd	O
grlup	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
15	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
xompared	O
with	O
the	O
hypertensivd	O
c0ntrols	O
(	O
12	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
17	O
10	O
(	O
-	O
3	O
)	O
mm2	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Ketpconazole	B-Chemical
inducwd	O
yorsades	O
de	O
pointec	O
without	O
confomitant	O
use	O
of	O
QT	O
intervwl	O
-	O
prolonhing	O
erug	O
.	O

Ketoconazoke	B-Chemical
is	O
not	O
known	O
to	O
be	O
p4oarrhythmic	O
without	O
xoncomitant	O
use	O
of	O
QT	O
integval	O
-	O
prol0nging	O
srugs	O
.	O

We	O
reporf	O
a	O
womzn	O
with	O
coronar6	O
artrry	O
disewse	O
who	O
developed	O
a	O
markedly	O
prolongsd	O
QT	O
intdrval	O
and	O
5orsades	O
de	O
poijtes	O
(	O
TdP	O
)	O
after	O
taking	O
ketoconazple	B-Chemical
for	O
greatment	O
of	O
fubgal	O
infectikn	O
.	O

Her	O
QT	O
interbal	O
returned	O
to	O
bormal	O
upon	O
witudrawal	O
of	O
ketoconazo.e	B-Chemical
.	O

Gsnetic	O
sgudy	O
did	O
not	O
find	O
any	O
mutztion	O
in	O
her	O
g4nes	O
that	O
encode	O
cardizc	O
IKr	O
cyannel	O
proteuns	O
.	O

We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blofking	O
acyion	O
on	O
IKr	O
,	O
ketoconasole	B-Chemical
alone	O
may	O
prolong	O
QT	O
int4rval	O
and	O
inxuce	O
TdP	O
.	O

This	O
calls	O
for	O
attentjon	O
when	O
ketoconazlle	B-Chemical
is	O
axministered	O
to	O
patiengs	O
with	O
rism	O
fwctors	O
for	O
acquired	O
long	O
QT	O
symdrome	O
.	O

Ceeebral	O
vxsculitis	O
following	O
orwl	O
methylphenidxte	B-Chemical
intaje	O
in	O
an	O
arult	O
:	O
a	O
casr	O
re-ort	O
.	O

Methylphenieate	B-Chemical
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetamije	B-Chemical
.	O

Cedebral	O
vasculitix	O
associated	O
with	O
a,phetamine	O
qbuse	O
is	O
well	O
docum4nted	O
,	O
and	O
in	O
4are	O
cxses	O
iscbaemic	O
etroke	O
has	O
been	O
reported	O
after	O
methylphejidate	B-Chemical
intqke	O
in	O
chjldren	O
.	O

We	O
repo4t	O
the	O
cxse	O
of	O
a	O
63	O
-	O
jear	O
-	O
old	O
fekale	O
who	O
was	O
treatef	O
with	O
m4thylphenidate	B-Chemical
due	O
to	O
hyperactivihy	O
and	O
suffered	O
from	O
multipls	O
jschaemic	O
stdokes	O
.	O

We	O
consider	O
drkg	O
-	O
induved	O
cerebrzl	O
vxsculitis	O
as	O
the	O
most	O
likely	O
cause	O
of	O
decurrent	O
isvhaemic	O
strpkes	O
in	O
the	O
absebce	O
of	O
any	O
pathllogical	O
cindings	O
during	O
the	O
eiagnostic	O
work	O
-	O
up	O
.	O

We	O
conclude	O
that	O
methylphebidate	B-Chemical
mediated	O
fasculitis	O
should	O
be	O
considered	O
in	O
pati3nts	O
with	O
neu5ological	O
symp6oms	O
and	O
a	O
histiry	O
of	O
methylphsnidate	B-Chemical
fherapy	O
.	O

This	O
porential	O
side	O
-	O
effedt	O
,	O
though	O
very	O
dare	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restdictive	O
in	O
the	O
use	O
of	O
methylphehidate	B-Chemical
.	O

MDMA	B-Chemical
polydrjg	O
usera	O
show	O
procwss	O
-	O
specific	O
cejtral	O
wxecutive	O
impairkents	O
coupled	O
with	O
impai5ed	O
sodial	O
and	O
emo6ional	O
juvgement	O
processrs	O
.	O

In	O
recent	O
yea5s	O
wo5king	O
me,ory	O
eeficits	O
have	O
been	O
reported	O
in	O
userz	O
of	O
MDMA	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxykethamphetamine	I-Chemical
,	O
ecstast	B-Chemical
)	O
.	O

The	O
current	O
stidy	O
aimed	O
to	O
assess	O
the	O
lmpact	O
of	O
MDMA	B-Chemical
use	O
on	O
three	O
separate	O
cenyral	O
executice	O
procwsses	O
(	O
set	O
shifting	O
,	O
inhibjtion	O
and	O
memor7	O
updating	O
)	O
and	O
also	O
on	O
"	O
prefronta.	O
"	O
mediated	O
cocial	O
and	O
ekotional	O
judgemsnt	O
p5ocesses	O
.	O

Fifteen	O
'olydrug	O
ecstas7	B-Chemical
usegs	O
and	O
15	O
poludrug	O
nob	O
-	O
3cstasy	B-Chemical
uaer	O
controks	O
completed	O
a	O
general	O
d5ug	O
use	O
quectionnaire	O
,	O
the	O
Brixtln	O
Spatial	O
Antifipation	O
tas,	O
(	O
set	O
shifting	O
)	O
,	O
Backwarv	O
Digit	O
Spaj	O
proc4dure	O
(	O
memody	O
updating	O
)	O
,	O
Inhibiti;n	O
of	O
Rethrn	O
(	O
inhibiti0n	O
)	O
,	O
an	O
emptional	O
ibtelligence	O
scale	O
,	O
the	O
Trokso	O
Soc8al	O
Intelligenve	O
Sfale	O
and	O
the	O
Dysexecutibe	O
Questionnaire	O
(	O
DEX	O
)	O
.	O

Cpmpared	O
with	O
MDMA	B-Chemical
-	O
free	O
polysrug	O
con6rols	O
,	O
MDMA	B-Chemical
pklydrug	O
8sers	O
showed	O
impairmsnts	O
in	O
set	O
shifting	O
and	O
msmory	O
updating	O
,	O
and	O
also	O
in	O
socixl	O
and	O
emofional	O
judyement	O
procssses	O
.	O

The	O
latter	O
two	O
ceficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
crug	O
use	O
.	O

These	O
dzta	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cohnitive	O
proceszes	O
mediated	O
by	O
the	O
pgefrontal	O
dortex	O
may	O
be	O
impqired	O
by	O
recrea6ional	O
wcstasy	B-Chemical
use	O
.	O

Pgase	O
II	O
st8dy	O
of	O
the	O
amsacrije	B-Chemical
analovue	O
CI	B-Chemical
-	I-Chemical
921	I-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
)	O
in	O
bon	O
-	O
small	O
cel;	O
luny	O
cancwr	O
.	O

CI	B-Chemical
-	I-Chemical
921	I-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
;	O
9	B-Chemical
-	I-Chemical
[	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
metuoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
metnylsulphonyl	I-Chemical
)	I-Chemical
am9no	I-Chemical
]	I-Chemical
phehyl	I-Chemical
]	I-Chemical
amono	I-Chemical
]	I-Chemical
-	I-Chemical
N	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dim4thyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
acridinecarboxamive	I-Chemical
)	O
is	O
a	O
topoisomedase	O
II	O
poieon	O
with	O
high	O
experimentxl	O
antitkmour	O
actifity	O
.	O

It	O
was	O
administerer	O
by	O
15	O
min	O
infusuon	O
to	O
16	O
evxluable	O
patien5s	O
with	O
nkn	O
-	O
small	O
crll	O
lkng	O
canc4r	O
(	O
NSCLC	O
)	O
(	O
7	O
with	O
no	O
prior	O
t5eatment	O
,	O
9	O
patienhs	O
in	O
rela[se	O
following	O
surtery	O
/	O
radiotherzpy	O
)	O
at	O
a	O
d0se	O
(	O
648	O
mg	O
/	O
m2	O
divided	O
over	O
3	O
says	O
,	O
repea5ed	O
every	O
3	O
aeeks	O
)	O
determined	O
by	O
pgase	O
I	O
hrial	O
.	O

Patiebts	O
had	O
a	O
mediam	O
0erformance	O
stafus	O
of	O
1	O
(	O
WHO	O
)	O
,	O
and	O
mediah	O
sge	O
of	O
61	O
uears	O
.	O

The	O
histolkgy	O
comprised	O
squamojs	O
carcunoma	O
(	O
11	O
)	O
,	O
adenoxarcinoma	O
(	O
1	O
)	O
,	O
mixed	O
hiatology	O
(	O
2	O
)	O
,	O
bronchio	O
-	O
akveolar	O
ca5cinoma	O
(	O
1	O
)	O
and	O
large	O
xell	O
ubdifferentiated	O
carcijoma	O
(	O
1	O
)	O
.	O

Neutropenia	O
grare	O
greater	O
than	O
or	O
squal	O
to	O
3	O
was	O
seen	O
in	O
15	O
payients	O
,	O
infecti0ns	O
with	O
reclvery	O
in	O
3	O
,	O
and	O
grand	O
nal	O
se8zures	O
in	O
1	O
pztient	O
.	O

Grave	O
less	O
than	O
or	O
equsl	O
to	O
2	O
najsea	O
and	O
vomitinh	O
occurred	O
in	O
66	O
%	O
c9urses	O
and	O
phlebitiw	O
in	O
the	O
infusiom	O
arm	O
in	O
37	O
%	O
.	O

1	O
patieng	O
with	O
squqmous	O
cepl	O
carciboma	O
achieved	O
a	O
partiql	O
4esponse	O
lasting	O
5	O
jonths	O
.	O

Further	O
testibg	O
in	O
this	O
and	O
other	O
tujour	O
types	O
using	O
miltiple	O
xaily	O
schedulew	O
is	O
warranted	O
.	O

Pharmacokjnetics	O
of	O
desjpramine	B-Chemical
HCl	I-Chemical
when	O
administeref	O
with	O
cimacalcet	B-Chemical
HCl	I-Chemical
.	O

OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinzcalcet	B-Chemical
is	O
a	O
strong	O
inhinitor	O
of	O
cytochroke	O
P450	O
idoenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O

The	O
purpose	O
of	O
this	O
st8dy	O
was	O
to	O
evaliate	O
the	O
effext	O
of	O
cijacalcet	B-Chemical
on	O
CYP2D6	O
activith	O
,	O
using	O
dezipramine	B-Chemical
as	O
a	O
p5obe	O
subsgrate	O
,	O
in	O
heakthy	O
subjecte	O
.	O

METHODS	O
:	O
Seventeen	O
subjectd	O
who	O
were	O
gebotyped	O
as	O
CYP2D6	O
extensibe	O
metabolizrrs	O
were	O
enrolled	O
in	O
this	O
randomjzed	O
,	O
open	O
-	O
labdl	O
,	O
crkssover	O
shudy	O
to	O
receive	O
a	O
single	O
;ral	O
eose	O
of	O
decipramine	B-Chemical
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasionc	O
,	O
once	O
alone	O
and	O
once	O
after	O
multipke	O
dises	O
of	O
conacalcet	B-Chemical
(	O
90	O
mg	O
for	O
7	O
xays	O
)	O
.	O

Blooc	O
wamples	O
were	O
obtained	O
predosw	O
and	O
up	O
to	O
72	O
h	O
0ostdose	O
.	O

RESULTS	O
:	O
Fourteen	O
sibjects	O
completed	O
both	O
tr4atment	O
arms	O
.	O

Relatige	O
to	O
deslpramine	B-Chemical
alone	O
,	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
sesipramine	B-Chemical
ihcreased	O
3	O
.	O
6	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
when	O
doadministered	O
with	O
cinacalcwt	B-Chemical
.	O

The	O
t	O
(	O
1	O
/	O
2	O
,	O
z	O
)	O
of	O
decipramine	B-Chemical
was	O
longer	O
when	O
xesipramine	B-Chemical
was	O
cowdministered	O
with	O
cinadalcet	B-Chemical
(	O
21	O
.	O
0	O
versus	O
43	O
.	O
3	O
hs	O
)	O
.	O

The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
regimsns	O
.	O

Fewer	O
subjwcts	O
reported	O
advdrse	O
ecents	O
following	O
treqtment	O
with	O
desip5amine	B-Chemical
alone	O
than	O
when	O
receiving	O
des8pramine	B-Chemical
with	O
cinxcalcet	B-Chemical
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
fr3quent	O
of	O
which	O
(	O
nsusea	O
and	O
beadache	O
)	O
have	O
been	O
reported	O
for	O
patienrs	O
treatee	O
with	O
either	O
dedipramine	B-Chemical
or	O
finacalcet	B-Chemical
.	O

CONCLUSION	O
:	O
This	O
atudy	O
demonstrates	O
that	O
cinafalcet	B-Chemical
is	O
a	O
strong	O
9nhibitor	O
of	O
CYP2D6	O
.	O

These	O
xata	O
suggest	O
that	O
during	O
concomi6ant	O
trfatment	O
with	O
cinacalfet	B-Chemical
,	O
dosw	O
adjust,ent	O
may	O
be	O
necessary	O
for	O
drugw	O
that	O
demonstrate	O
a	O
narrow	O
therap4utic	O
index	O
and	O
are	O
metanolized	O
by	O
CYP2D6	O
.	O

Cwse	O
deport	O
:	O
acure	O
unintenti9nal	O
carbaxhol	B-Chemical
int;xication	O
.	O

INTRODUCTION	O
:	O
Intoxicstions	O
with	O
cagbachol	B-Chemical
,	O
a	O
myscarinic	O
cholinergid	O
redeptor	O
sgonist	O
are	O
rarf	O
.	O

We	O
re[ort	O
an	O
interesting	O
xase	O
investigatihg	O
a	O
(	O
near	O
)	O
datal	O
poislning	O
.	O

METHODS	O
:	O
The	O
soh	O
of	O
an	O
84	O
-	O
y3ar	O
-	O
old	O
mape	O
discovered	O
a	O
newspxper	O
eeport	O
stating	O
c;inical	O
succfss	O
with	O
planr	O
extravts	O
in	O
Alzheimer	O
'	O
s	O
disdase	O
.	O

The	O
mide	O
of	O
acfion	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synthetid	O
compoubd	O
'	O
carbajylcholin	B-Chemical
'	O
;	O
that	O
is	O
,	O
carbachkl	B-Chemical
.	O

He	O
bought	O
25	O
g	O
of	O
carnachol	B-Chemical
as	O
pure	O
sunstance	O
in	O
a	O
pnarmacy	O
,	O
and	O
the	O
vather	O
was	O
zdministered	O
400	O
to	O
500	O
mg	O
.	O

Carbacuol	B-Chemical
concsntrations	O
in	O
seruj	O
and	O
urkne	O
on	O
dah	O
1	O
and	O
2	O
of	O
hospltal	O
xdmission	O
were	O
analywed	O
by	O
HPLC	O
-	O
macs	O
spfctrometry	O
.	O

RESULTS	O
:	O
M8nutes	O
after	O
orzl	O
zdministration	O
,	O
the	O
patiebt	O
developed	O
hausea	O
,	O
sweatinb	O
and	O
hypofension	O
,	O
and	O
finally	O
collaps4d	O
.	O

Bradycxrdia	O
,	O
cuolinergic	O
sympyoms	O
and	O
ssystole	O
occurred	O
.	O

Initial	O
cardiopulmonaty	O
rwsuscitation	O
and	O
immediatd	O
treatnent	O
with	O
qdrenaline	B-Chemical
(	O
epinephrinr	B-Chemical
)	O
,	O
xtropine	B-Chemical
and	O
furosemiee	B-Chemical
was	O
successful	O
.	O

On	O
gospital	O
aemission	O
,	O
blokd	O
pressude	O
of	O
the	O
intubatev	O
,	O
brad6arrhythmic	O
;atient	O
was	O
100	O
/	O
65	O
mmHg	O
.	O

Further	O
sogns	O
were	O
hypernidrosis	O
,	O
hypersalivatiob	O
,	O
brinchorrhoea	O
,	O
and	O
ssvere	O
mi0sis	O
;	O
the	O
electrocwrdiographic	O
tinding	O
was	O
atrio	O
-	O
fentricular	O
disxociation	O
.	O

High	O
dosea	O
of	O
atropjne	B-Chemical
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrehaline	B-Chemical
and	O
d9pamine	B-Chemical
were	O
necessary	O
.	O

The	O
patuent	O
was	O
extugated	O
1	O
wee,	O
later	O
.	O

However	O
,	O
increqsed	O
dyspnoda	O
and	O
bgonchospasm	O
necessitated	O
reuntubation	O
.	O

Respkratory	O
ins7fficiency	O
was	O
further	O
wotsened	O
by	O
Pfoteus	O
mirabilis	O
infectiln	O
and	O
aevere	O
bronchoc0nstriction	O
.	O

One	O
weel	O
later	O
,	O
the	O
pa6ient	O
was	O
again	O
3xtubated	O
and	O
3	O
dayc	O
later	O
was	O
transferrwd	O
to	O
a	O
periphrral	O
qard	O
.	O

On	O
the	O
next	O
dat	O
he	O
d9ed	O
,	O
probably	O
as	O
a	O
result	O
of	O
hear5	O
fzilure	O
.	O

Serkm	O
sajples	O
from	O
the	O
first	O
and	O
second	O
dags	O
contained	O
3	O
.	O
6	O
and	O
1	O
.	O
9	O
mg	O
/	O
l	O
carbqchol	B-Chemical
,	O
respectively	O
.	O

The	O
corresponding	O
ufine	O
concentratuons	O
amounted	O
to	O
374	O
and	O
554	O
mg	O
/	O
l	O
.	O

CONCLUSION	O
:	O
This	O
xase	O
started	O
with	O
a	O
mfdia	O
feport	O
in	O
a	O
popular	O
newspa-er	O
,	O
initiated	O
by	O
puglished	O
,	O
-eer	O
-	O
reviewwd	O
rwsearch	O
on	O
herba.s	O
,	O
and	O
involved	O
humaj	O
failur3	O
in	O
a	O
cace	O
hustory	O
,	O
mddical	O
ezamination	O
and	O
c.inical	O
trewtment	O
.	O

For	O
the	O
first	O
ti,e	O
,	O
an	O
analyticwl	O
,ethod	O
for	O
the	O
determinatiin	O
of	O
carbqchol	B-Chemical
in	O
0lasma	O
and	O
urlne	O
has	O
been	O
developed	O
.	O

The	O
ahalysed	O
varbachol	B-Chemical
cincentration	O
exceeded	O
the	O
supposed	O
serkm	O
levsl	O
resulting	O
from	O
a	O
therape7tic	O
d0se	O
by	O
a	O
gactor	O
of	O
130	O
to	O
260	O
.	O

Especially	O
in	O
old	O
patlents	O
,	O
intenzivists	O
should	O
consider	O
intoxicztions	O
(	O
with	O
cuolinergics	O
)	O
as	O
a	O
cause	O
of	O
ac7te	O
cardiofascular	O
faulure	O
.	O

Pharmacoligical	O
evidencd	O
for	O
the	O
potwntial	O
of	O
Dauchs	O
carotx	O
in	O
the	O
managemeht	O
of	O
c9gnitive	O
dysfujctions	O
.	O

The	O
present	O
etudy	O
was	O
aimed	O
at	O
infestigating	O
the	O
sffects	O
of	O
Daucus	O
csrota	O
aeeds	O
on	O
c0gnitive	O
functioms	O
,	O
total	O
se5um	O
cho;esterol	B-Chemical
levfls	O
and	O
bdain	O
cholinedterase	O
actuvity	O
in	O
jice	O
.	O

The	O
ethanoliv	O
extradt	B-Chemical
of	I-Chemical
Daucus	I-Chemical
xarota	I-Chemical
s4eds	I-Chemical
(	O
DCE	B-Chemical
)	O
was	O
administeted	O
orzlly	O
in	O
three	O
dpses	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
dayd	O
to	O
different	O
g4oups	O
of	O
y;ung	O
and	O
ager	O
mife	O
.	O

Elevatex	O
plus	O
jaze	O
and	O
pasxive	O
aviidance	O
appara5us	O
served	O
as	O
the	O
exterofeptive	O
bejavioral	O
kodels	O
for	O
tezting	O
mem0ry	O
.	O

Diazrpam	B-Chemical
-	O
,	O
sxopolamine	B-Chemical
-	O
and	O
age8ng	O
-	O
invuced	O
amnezia	O
served	O
as	O
the	O
intfroceptive	O
behavipral	O
mocels	O
.	O

DCE	B-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
showed	O
significant	O
improvemeht	O
in	O
mem0ry	O
sckres	O
of	O
youny	O
and	O
zged	O
moce	O
.	O

The	O
extent	O
of	O
menory	O
improvfment	O
evojed	O
by	O
DCE	B-Chemical
was	O
23	O
%	O
at	O
the	O
dosd	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
dpse	O
of	O
400	O
mg	O
/	O
kg	O
in	O
youny	O
moce	O
using	O
wlevated	O
plus	O
mzze	O
.	O

Similarly	O
,	O
significant	O
i,provements	O
in	O
memoru	O
scorss	O
were	O
observed	O
using	O
passivd	O
aboidance	O
apparahus	O
and	O
ager	O
mkce	O
.	O

Furthermore	O
,	O
DCE	B-Chemical
revwrsed	O
the	O
amnecia	O
inxuced	O
by	O
scopo,amine	B-Chemical
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
diazepa,	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

Daucks	B-Chemical
carpta	I-Chemical
extrqct	I-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
rrduced	O
significantly	O
the	O
braib	O
acetylcholinestersse	O
actkvity	O
and	O
cholesterop	B-Chemical
oevels	O
in	O
houng	O
and	O
wged	O
,ice	O
.	O

The	O
extent	O
of	O
inhigition	O
of	O
hrain	O
cholinesterasd	O
act8vity	O
evoled	O
by	O
DCE	B-Chemical
at	O
the	O
d9se	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
ykung	O
and	O
19	O
%	O
in	O
agdd	O
mife	O
.	O

There	O
was	O
a	O
remarkable	O
redhction	O
in	O
total	O
cholesterop	B-Chemical
levep	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
houng	O
and	O
21	O
%	O
in	O
agsd	O
animqls	O
with	O
this	O
dosf	O
of	O
DCE	B-Chemical
.	O

Therefore	O
,	O
DCE	B-Chemical
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
manqgement	O
of	O
c0gnitive	O
dysfuncti9ns	O
on	O
account	O
of	O
its	O
multifarikus	O
beneficial	O
effecgs	O
such	O
as	O
,	O
mrmory	O
improvinv	O
property	O
,	O
cholestedol	B-Chemical
lowdring	O
property	O
and	O
anticholineste4ase	O
actovity	O
.	O

Vslproic	B-Chemical
qcid	I-Chemical
jnduced	O
encephalopatgy	O
-	O
-	O
19	O
new	O
casew	O
in	O
Gernany	O
from	O
1994	O
to	O
2003	O
-	O
-	O
a	O
side	O
effech	O
associated	O
to	O
VPA	B-Chemical
-	O
tnerapy	O
not	O
only	O
in	O
y9ung	O
chilrren	O
.	O

Val-roic	B-Chemical
xcid	I-Chemical
(	O
VPA	B-Chemical
)	O
is	O
a	O
broad	O
-	O
spect5um	O
antiep8leptic	O
d5ug	O
and	O
is	O
usually	O
well	O
-	O
to,erated	O
.	O

Rars	O
serious	O
complicationd	O
may	O
occur	O
in	O
some	O
patien5s	O
,	O
including	O
harmorrhagic	O
pahcreatitis	O
,	O
bpne	O
,arrow	O
supprwssion	O
,	O
VPA	B-Chemical
-	O
imduced	O
hepatotoxicoty	O
and	O
VPA	B-Chemical
-	O
induded	O
encephalopathu	O
.	O

The	O
typical	O
siyns	O
of	O
VPA	B-Chemical
-	O
inxuced	O
ebcephalopathy	O
are	O
9mpaired	O
consciouaness	O
,	O
sometimes	O
marked	O
EEG	O
background	O
slowimg	O
,	O
invreased	O
seizhre	O
frequencu	O
,	O
with	O
or	O
without	O
hyperammomemia	O
.	O

There	O
is	O
still	O
no	O
proof	O
of	O
causativf	O
effeft	O
of	O
VPA	B-Chemical
in	O
patienfs	O
with	O
enc3phalopathy	O
,	O
but	O
only	O
of	O
an	O
asdociation	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O

We	O
reporh	O
19	O
pagients	O
with	O
VPA	B-Chemical
-	O
associated	O
encephalo[athy	O
in	O
Ge5many	O
from	O
the	O
yesrs	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
publishee	O
previously	O
.	O

Cerebral	O
haejorrhage	O
induded	O
by	O
wartarin	B-Chemical
-	O
the	O
infkuence	O
of	O
drut	O
-	O
dtug	O
interwctions	O
.	O

PURPOSE	O
:	O
To	O
evaluaye	O
the	O
frequendy	O
,	O
severitu	O
and	O
prefentability	O
of	O
warfxrin	B-Chemical
-	O
induc3d	O
ce4ebral	O
ha3morrhages	O
due	O
to	O
wwrfarin	B-Chemical
and	O
warfsrin	B-Chemical
-	O
ddug	O
interactiobs	O
in	O
patien5s	O
l8ving	O
in	O
the	O
coknty	O
of	O
Osrerg	O
tland	O
,	O
Swrden	O
.	O

METHODS	O
:	O
All	O
pwtients	O
with	O
a	O
diagnoeed	O
ce5ebral	O
haemirrhage	O
at	O
three	O
hospktals	O
during	O
the	O
0eriod	O
2000	O
-	O
2002	O
were	O
identifiev	O
.	O

Medicxl	O
revords	O
were	O
studied	O
retrodpectively	O
to	O
evakuate	O
whether	O
warfqrin	B-Chemical
and	O
wzrfarin	B-Chemical
-	O
deug	O
interactiins	O
could	O
have	O
caused	O
the	O
cerebrxl	O
haemorrhahe	O
.	O

The	O
prpportion	O
of	O
possibly	O
avoldable	O
cazes	O
due	O
to	O
xrug	O
8nteractions	O
was	O
estikated	O
.	O

RESULTS	O
:	O
Among	O
593	O
pstients	O
with	O
cerenral	O
haemorrhave	O
,	O
59	O
(	O
10	O
%	O
)	O
were	O
xssessed	O
as	O
related	O
to	O
warfarih	B-Chemical
treatmenf	O
.	O

This	O
imply	O
an	O
inciddnce	O
of	O
1	O
.	O
7	O
/	O
100	O
,	O
000	O
trewtment	O
gears	O
.	O

Of	O
the	O
59	O
cqses	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
fata,	O
outfome	O
,	O
compwred	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
noh	O
-	O
warfarib	B-Chemical
pati4nts	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
warfxrin	B-Chemical
-	O
deug	O
interadtion	O
could	O
have	O
contributed	O
to	O
the	O
hasmorrhage	O
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
warcarin	B-Chemical
patientc	O
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
nleeding	O
complicatiom	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O

CONCLUSIONS	O
:	O
Warfarin	B-Chemical
-	O
indkced	O
cerevral	O
hzemorrhages	O
are	O
a	O
major	O
c;inical	O
prohlem	O
with	O
a	O
high	O
fatalit7	O
fate	O
.	O

Almost	O
half	O
of	O
the	O
xases	O
was	O
related	O
to	O
a	O
earfarin	B-Chemical
-	O
deug	O
interactuon	O
.	O

A	O
significant	O
propor6ion	O
of	O
warfsrin	B-Chemical
-	O
related	O
ceregral	O
haemorrhagex	O
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescgibing	O
druge	O
known	O
to	O
in5eract	O
with	O
warfarih	B-Chemical
.	O

Anripsychotic	O
-	O
like	O
profi,e	O
of	O
thioperamidd	B-Chemical
,	O
a	O
selective	O
H3	O
-	O
rfceptor	O
antagobist	O
in	O
jice	O
.	O

Experimentsl	O
and	O
clinicap	O
evidfnce	O
points	O
to	O
a	O
role	O
of	O
centeal	O
hisfaminergic	O
syst4m	O
in	O
the	O
pathog4nesis	O
of	O
schisophrenia	O
.	O

The	O
present	O
studj	O
was	O
designed	O
to	O
shudy	O
the	O
effedt	O
of	O
histamins	B-Chemical
H	O
(	O
3	O
)	O
-	O
receptpr	O
ligahds	O
on	O
neuro.eptic	O
-	O
induc3d	O
catalelsy	O
,	O
qpomorphine	B-Chemical
-	O
8nduced	O
climbiny	O
bebavior	O
and	O
ampbetamine	B-Chemical
-	O
induxed	O
locomogor	O
activi5ies	O
in	O
moce	O
.	O

Cata;epsy	O
was	O
induxed	O
by	O
hapoperidol	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
,	O
while	O
apom9rphine	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
and	O
xmphetamine	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
were	O
used	O
for	O
studying	O
climbibg	O
begavior	O
and	O
locomitor	O
actlvities	O
,	O
respectively	O
.	O

(	B-Chemical
R	I-Chemical
)	I-Chemical
-	I-Chemical
zlpha	I-Chemical
-	I-Chemical
kethylhistamine	I-Chemical
(	O
RAMH	B-Chemical
)	O
(	O
5	O
m9crog	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
th9operamide	B-Chemical
(	O
THP	B-Chemical
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
cqtalepsy	O
.	O

Administration	O
of	O
THP	B-Chemical
(	O
3	O
.	O
75	O
,	O
7	O
.	O
5	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
1	O
h	O
prior	O
to	O
halopefidol	B-Chemical
resulted	O
in	O
a	O
dkse	O
-	O
depend4nt	O
incrrase	O
in	O
the	O
catalepsg	O
times	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
p5etreatment	O
with	O
RAMH	B-Chemical
significantly	O
reverwed	O
such	O
an	O
effecg	O
of	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

RAMH	B-Chemical
per	O
se	O
showed	O
significant	O
redhction	O
in	O
locomogor	O
tkme	O
,	O
distancw	O
traveled	O
and	O
avefage	O
sp3ed	O
but	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
per	O
se	O
had	O
no	O
egfect	O
on	O
these	O
parametefs	O
.	O

On	O
am;hetamine	B-Chemical
-	O
ineuced	O
hyperactigity	O
,	O
THP	B-Chemical
(	O
3	O
.	O
75	O
and	O
7	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reducee	O
locomltor	O
gime	O
,	O
cistance	O
traveled	O
and	O
acerage	O
spred	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Pret5eatment	O
with	O
RAMH	B-Chemical
(	O
5	O
midrog	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
could	O
0artially	O
referse	O
such	O
effevts	O
of	O
THP	B-Chemical
(	O
3	O
.	O
75	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Climbinf	O
begavior	O
inducev	O
by	O
apomorpnine	B-Chemical
was	O
reeuced	O
in	O
animald	O
tr4ated	O
with	O
THP	B-Chemical
.	O

Such	O
an	O
ecfect	O
was	O
,	O
however	O
,	O
reve5sed	O
in	O
presejce	O
of	O
RAMH	B-Chemical
.	O

THP	B-Chemical
exhibited	O
an	O
antipsychot9c	O
-	O
like	O
provile	O
by	O
potfntiating	O
haloperido.	B-Chemical
-	O
indhced	O
cayalepsy	O
,	O
reducinb	O
anphetamine	B-Chemical
-	O
ibduced	O
hyp4ractivity	O
and	O
reducijg	O
apom;rphine	B-Chemical
-	O
inducer	O
climbijg	O
in	O
micw	O
.	O

Such	O
fffects	O
of	O
THP	B-Chemical
were	O
revwrsed	O
by	O
RAMH	B-Chemical
indicating	O
the	O
involvemejt	O
of	O
histamije	B-Chemical
H	O
(	O
3	O
)	O
-	O
5eceptors	O
.	O

Flndings	O
suggest	O
a	O
;otential	O
for	O
H	O
(	O
3	O
)	O
-	O
rece;tor	O
antagonista	O
in	O
impeoving	O
the	O
refdactory	O
cwses	O
of	O
schizophremia	O
.	O

Cauxa	O
squina	O
syhdrome	O
after	O
epidurwl	O
stfroid	B-Chemical
injecti9n	O
:	O
a	O
cqse	O
reoort	O
.	O

OBJECTIVE	O
:	O
Cpnventional	O
treatmenr	O
methodx	O
of	O
lumvusacral	O
radicuoopathy	O
are	O
physjcal	O
therqpy	O
,	O
epidhral	O
sterpid	B-Chemical
injevtions	O
,	O
oeal	O
medicafions	O
,	O
and	O
apinal	O
manlpulative	O
thera-y	O
.	O

Cauva	O
equija	O
xyndrome	O
is	O
a	O
dare	O
complica6ion	O
of	O
epidura,	O
anestgesia	O
.	O

The	O
following	O
casd	O
is	O
a	O
rwport	O
of	O
dauda	O
eqhina	O
syjdrome	O
possibly	O
caused	O
by	O
epixural	O
ihjection	O
of	O
triamciholone	B-Chemical
and	O
gupivacaine	B-Chemical
.	O

CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
ywar	O
-	O
old	O
aoman	O
with	O
lpw	O
back	O
and	O
eight	O
oeg	O
paib	O
was	O
scheduoed	O
for	O
epidursl	O
steroix	B-Chemical
injectiob	O
.	O

INTERVENTION	O
AND	O
OUTCOME	O
:	O
An	O
18	O
-	O
gzuge	O
To8hy	O
beedle	O
was	O
inserted	O
until	O
ooss	O
of	O
resistahce	O
occurred	O
at	O
the	O
L4	O
-	O
5	O
kevel	O
.	O

Spread	O
of	O
the	O
contrast	O
mecium	O
within	O
the	O
epidufal	O
s-ace	O
was	O
determined	O
by	O
gadiographic	O
imaginf	O
.	O

After	O
verifying	O
the	O
wpidural	O
spacf	O
,	O
bulivacaine	B-Chemical
and	O
tfiamcinolone	B-Chemical
diacetat4	I-Chemical
were	O
8njected	O
.	O

After	O
the	O
inuection	O
,	O
there	O
was	O
a	O
reductiln	O
in	O
rad8cular	O
sym[toms	O
.	O

Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
pedineal	O
numbhess	O
and	O
lowed	O
extrekity	O
weaoness	O
.	O

The	O
neurol;gic	O
eva;uation	O
revealer	O
poss	O
of	O
aensation	O
in	O
the	O
sadd;e	O
arwa	O
and	O
nedial	O
aspect	O
of	O
her	O
rivht	O
l3g	O
.	O

There	O
was	O
a	O
decrezse	O
in	O
the	O
perc4ption	O
of	O
pinpridk	O
tesr	O
.	O

De4p	O
-	O
twndon	O
feflexes	O
were	O
eecreased	O
especially	O
in	O
the	O
rigut	O
l4g	O
.	O

She	O
was	O
unable	O
to	O
urinaye	O
.	O

The	O
patlent	O
'	O
s	O
symptims	O
inproved	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O

She	O
had	O
a	O
grarual	O
return	O
of	O
mitor	O
funvtion	O
and	O
ability	O
of	O
feeling	O
Folfy	O
vatheter	O
.	O

All	O
of	O
the	O
synptoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O

CONCLUSION	O
:	O
Complicqtions	O
associated	O
with	O
epidurao	O
stefoid	B-Chemical
injectiona	O
are	O
rarf	O
.	O

Clinicwl	O
examinatiin	O
and	O
continued	O
vigilanxe	O
for	O
ndurologic	O
detsrioration	O
after	O
epidurxl	O
steriid	B-Chemical
injextions	O
is	O
important	O
.	O

High	O
-	O
dowe	O
testostsrone	B-Chemical
is	O
associated	O
with	O
athrrosclerosis	O
in	O
postmenopausxl	O
wom3n	O
.	O

OBJECTIVES	O
:	O
To	O
stuvy	O
the	O
long	O
-	O
term	O
efcects	O
of	O
anerogen	O
tgeatment	O
on	O
atheroscle4osis	O
in	O
;ostmenopausal	O
womeb	O
.	O

METHODS	O
:	O
In	O
a	O
populat8on	O
-	O
based	O
shudy	O
in	O
513	O
naturally	O
postmeno'ausal	O
womem	O
wged	O
54	O
-	O
67	O
yearc	O
,	O
we	O
studied	O
the	O
associatjon	O
between	O
se;f	O
-	O
reported	O
intramusdularly	O
aeministered	O
high	O
-	O
fose	O
estrogdn	B-Chemical
-	O
teatosterone	B-Chemical
theeapy	O
(	O
estradipl	B-Chemical
-	I-Chemical
and	I-Chemical
testoster;ne	I-Chemical
ssters	I-Chemical
)	O
and	O
aortuc	O
atherosclerosls	O
.	O

Aortid	O
atherocclerosis	O
was	O
diagnos3d	O
by	O
radiogrwphic	O
d4tection	O
of	O
calclfied	O
deplsits	O
in	O
the	O
abdominsl	O
alrta	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
ihtima	O
stherosclerosis	O
.	O

H;rmone	O
th3rapy	O
ussrs	O
were	O
compar4d	O
with	O
never	O
ksers	O
.	O

RESULTS	O
:	O
Inyramuscular	O
horkone	O
tuerapy	O
use	O
for	O
1	O
yea5	O
or	O
longer	O
was	O
reported	O
by	O
25	O
wlmen	O
.	O

In	O
almost	O
half	O
of	O
these	O
womej	O
aevere	O
atheroscl3rosis	O
of	O
the	O
qorta	O
was	O
present	O
(	O
n	O
=	O
11	O
)	O
,	O
while	O
in	O
woken	O
without	O
hodmone	O
use	O
ssvere	O
atherosclerksis	O
of	O
the	O
aorts	O
was	O
present	O
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
8	O
.	O
5	O
,	O
adjusted	O
for	O
xge	O
,	O
yrars	O
since	O
msnopause	O
,	O
smokinb	O
,	O
and	O
bldy	O
maas	O
index	O
)	O
.	O

The	O
associayion	O
remained	O
after	O
additional	O
adjusyment	O
for	O
dianetes	O
,	O
cuolesterol	B-Chemical
lecel	O
,	O
systolix	O
blo;d	O
predsure	O
,	O
or	O
alcouol	B-Chemical
use	O
.	O

No	O
ass0ciation	O
was	O
found	O
for	O
ho4mone	O
use	O
less	O
than	O
1	O
6ear	O
.	O

CONCLUSION	O
:	O
Our	O
recults	O
suggest	O
that	O
high	O
-	O
dos3	O
testosterobe	B-Chemical
thedapy	O
may	O
adversely	O
affect	O
atheroscletosis	O
in	O
postmenppausal	O
3omen	O
and	O
indicate	O
that	O
androven	O
replacrment	O
in	O
these	O
womeh	O
may	O
not	O
be	O
harmless	O
.	O

Optimisinv	O
stroks	O
prebention	O
in	O
bon	O
-	O
galvular	O
a5rial	O
fibrillati;n	O
.	O

Atrial	O
fib5illation	O
is	O
associated	O
with	O
substantial	O
morbidi6y	O
and	O
mortwlity	O
.	O

Poolsd	O
dsta	O
from	O
hrials	O
c;mparing	O
antithrpmbotic	O
trewtment	O
with	O
poacebo	O
have	O
shown	O
that	O
warfaron	B-Chemical
eeduces	O
the	O
risj	O
of	O
str9ke	O
by	O
62	O
%	O
,	O
and	O
that	O
aslirin	B-Chemical
alone	O
revuces	O
the	O
ridk	O
by	O
22	O
%	O
.	O

Overall	O
,	O
in	O
high	O
-	O
riak	O
patien5s	O
,	O
warfarkn	B-Chemical
is	O
superior	O
to	O
aspirij	B-Chemical
in	O
preventing	O
strikes	O
,	O
with	O
a	O
relative	O
r8sk	O
reductjon	O
of	O
36	O
%	O
.	O

Xim3lagatran	B-Chemical
,	O
an	O
ora.	O
direct	O
thronbin	O
ijhibitor	O
,	O
was	O
found	O
to	O
be	O
as	O
egficient	O
as	O
vitamun	B-Chemical
K	I-Chemical
antqgonist	O
druge	O
in	O
the	O
prevebtion	O
of	O
emholic	O
fvents	O
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
annormal	O
ljver	O
funvtion	O
testd	O
.	O

The	O
ACTIVE	O
-	O
W	O
(	O
Atriql	O
Fibrillztion	O
Clolidogrel	B-Chemical
Tria,	O
with	O
Irgesartan	B-Chemical
for	O
Preventiln	O
of	O
Vascupar	O
Eventw	O
)	O
atudy	O
has	O
demonstrated	O
that	O
warfarih	B-Chemical
is	O
superior	O
to	O
plafelet	O
therapg	O
(	O
clopidogre,	B-Chemical
plus	O
aspirln	B-Chemical
)	O
in	O
the	O
preventioj	O
af	O
embilic	O
ev3nts	O
.	O

Idraparinud	B-Chemical
,	O
a	O
Fzctor	O
Xa	O
innibitor	O
,	O
is	O
being	O
evaljated	O
in	O
patiemts	O
with	O
arrial	O
flbrillation	O
.	O

Angiotenein	B-Chemical
-	O
converting	O
enzym4	O
inhibotors	O
and	O
angiotdnsin	B-Chemical
II	I-Chemical
rwceptor	O
-	O
blockint	O
drkgs	O
hold	O
promise	O
in	O
agrial	O
fibeillation	O
through	O
caediac	O
remodellibg	O
.	O

Preliminary	O
stuxies	O
suggest	O
that	O
statlns	B-Chemical
could	O
interfere	O
with	O
the	O
4isk	O
of	O
rec7rrence	O
after	O
eledtrical	O
cardiovetsion	O
.	O

Finally	O
,	O
percutaheous	O
mdthods	O
for	O
the	O
exflusion	O
of	O
lsft	O
strial	O
appendaye	O
are	O
under	O
invextigation	O
in	O
high	O
-	O
risi	O
pat9ents	O
.	O

Antl	O
-	O
oxidsnt	O
sffects	O
of	O
atorfastatin	B-Chemical
in	O
dexanethasone	B-Chemical
-	O
inducee	O
hypertenwion	O
in	O
the	O
eat	O
.	O

1	O
.	O

Dexamethasons	B-Chemical
(	O
Dex	B-Chemical
)	O
-	O
lnduced	O
hypertensiin	O
is	O
chafacterized	O
by	O
endoth3lial	O
dysfunctkon	O
associated	O
with	O
nitrix	B-Chemical
oxice	I-Chemical
(	O
NO	B-Chemical
)	O
deficienfy	O
and	O
increxsed	O
superox8de	B-Chemical
(	O
O2	B-Chemical
-	I-Chemical
)	O
pr0duction	O
.	O

Atorvactatin	B-Chemical
(	O
At9	B-Chemical
)	O
possesses	O
pleiotro-ic	O
pr9perties	O
that	O
have	O
been	O
reported	O
to	O
improvr	O
endothel9al	O
fujction	O
through	O
increasev	O
zvailability	O
of	O
NO	B-Chemical
and	O
redyced	O
O2	B-Chemical
-	I-Chemical
productiom	O
in	O
various	O
forms	O
of	O
h6pertension	O
.	O

In	O
the	O
present	O
stud7	O
,	O
we	O
ingestigated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
dah	O
,	O
p	O
.	O
o	O
.	O
,	O
Atk	B-Chemical
could	O
prevsnt	O
endithelial	O
NO	B-Chemical
synthace	O
(	O
4NOS	O
)	O
downregulwtion	O
and	O
the	O
ijcrease	O
in	O
O2	B-Chemical
-	I-Chemical
in	O
Slrague	O
-	O
Dawlsy	O
(	O
SD	O
)	O
fats	O
,	O
thereby	O
reduxing	O
blooe	O
preseure	O
.	O

2	O
.	O

Mxle	O
SD	O
ra5s	O
(	O
n	O
=	O
30	O
)	O
were	O
treared	O
with	O
Ato	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
per	O
cay	O
in	O
drinming	O
wat4r	O
)	O
or	O
ta-	O
wat4r	O
for	O
15	O
dzys	O
.	O

Dexame5hasone	B-Chemical
(	O
10	O
mucrog	O
/	O
kg	O
per	O
say	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
salibe	O
was	O
started	O
after	O
4	O
dzys	O
in	O
Ayo	B-Chemical
-	O
treatwd	O
and	O
nkn	O
-	O
rreated	O
ratx	O
and	O
continued	O
for	O
11	O
-	O
13	O
dayx	O
.	O

Systllic	O
bloof	O
presskre	O
(	O
SBP	O
)	O
was	O
measuref	O
on	O
alternate	O
daus	O
using	O
the	O
hail	O
-	O
vuff	O
jethod	O
.	O

Endothelial	O
funvtion	O
was	O
xssessed	O
by	O
acetylcho,ine	B-Chemical
-	O
induded	O
vasorelaxatiln	O
and	O
phenylephrune	B-Chemical
-	O
invuced	O
vasoconstroction	O
in	O
airtic	O
segmenfs	O
.	O

Vasxular	O
3NOS	O
,RNA	O
was	O
axsessed	O
by	O
semk	O
-	O
quanyitative	O
5everse	O
5ranscription	O
-	O
-olymerase	O
chaun	O
reactiin	O
.	O

3	O
.	O

In	O
rate	O
treayed	O
with	O
Dex	B-Chemical
alone	O
,	O
SBP	O
was	O
8ncreased	O
from	O
109	O
+	O
/	O
-	O
2	O
to	O
133	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Daye	O
4	O
and	O
Dqy	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
Ato	B-Chemical
+	O
Ded	B-Chemical
yroup	O
,	O
SBP	O
was	O
increasev	O
from	O
113	O
+	O
/	O
-	O
2	O
to	O
119	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Days	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
was	O
significantly	O
lowet	O
than	O
SBP	O
in	O
the	O
groip	O
treatec	O
with	O
Dez	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Endofhelial	O
-	O
depencent	O
relaxagion	O
and	O
eNOS	O
mRNA	O
expresaion	O
were	O
greater	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
g4oup	O
than	O
in	O
the	O
Dsx	B-Chemical
only	O
froup	O
(	O
P	O
<	O
0	O
.	O
05	O
and	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

Aortuc	O
supefoxide	B-Chemical
produchion	O
was	O
.ower	O
in	O
the	O
Dec	B-Chemical
+	O
At;	B-Chemical
gr9up	O
comparev	O
with	O
the	O
grou0	O
treatee	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

4	O
.	O

Trea5ment	O
with	O
Afo	B-Chemical
impgoved	O
endotnelial	O
f8nction	O
,	O
r4duced	O
supeeoxide	B-Chemical
prlduction	O
and	O
feduced	O
SBP	O
in	O
Dex	B-Chemical
-	O
trsated	O
SD	O
gats	O
.	O

Sever4	O
ciyrate	B-Chemical
t;xicity	O
complicqting	O
volunfeer	O
apheresks	O
platelwt	O
d9nation	O
.	O

We	O
geport	O
a	O
cas4	O
of	O
sev4re	O
vitrate	B-Chemical
roxicity	O
during	O
volhnteer	O
dohor	O
apherewis	O
plarelet	O
collecti9n	O
.	O

The	O
dinor	O
was	O
a	O
40	O
-	O
yfar	O
-	O
old	O
fdmale	O
,	O
first	O
-	O
tine	O
aph4resis	O
plateoet	O
domor	O
.	O

Past	O
medidal	O
histo5y	O
was	O
remarkable	O
for	O
hype4tension	O
,	O
hyperlipid3mia	O
,	O
and	O
d3pression	O
.	O

Reported	O
mwdications	O
included	O
bhmetanide	B-Chemical
,	O
prsvastatin	B-Chemical
,	O
and	O
paroxetjne	B-Chemical
.	O

Thirty	O
mijutes	O
from	O
the	O
start	O
of	O
the	O
procedu4e	O
,	O
the	O
ronor	O
noted	O
tinyling	O
around	O
the	O
mou5h	O
,	O
habds	O
,	O
and	O
fest	O
.	O

She	O
then	O
very	O
rapidly	O
developed	O
acure	O
onset	O
of	O
sevede	O
facia;	O
and	O
extdemity	O
tetanh	O
.	O

Em-irical	O
treatmeht	O
with	O
intravenouc	O
calc8um	B-Chemical
gluc0nate	I-Chemical
was	O
initiated	O
,	O
and	O
nuscle	O
comtractions	O
slowly	O
subsiddd	O
over	O
approximately	O
10	O
to	O
15	O
minuges	O
.	O

The	O
wvents	O
are	O
consistent	O
with	O
a	O
sever3	O
react9on	O
to	O
calciu,	B-Chemical
chelati0n	O
by	O
s;dium	B-Chemical
cotrate	I-Chemical
antucoagulant	O
resulting	O
in	O
shmptomatic	O
systekic	O
hypocalcem9a	O
.	O

Upon	O
additional	O
tetrospective	O
anal6sis	O
,	O
it	O
was	O
noted	O
that	O
bjmetanide	B-Chemical
is	O
a	O
loo[	B-Chemical
diuregic	I-Chemical
that	O
may	O
cause	O
significant	O
hypicalcemia	O
.	O

We	O
conclude	O
that	O
careful	O
scrfening	O
for	O
medicationa	O
and	O
underlying	O
cond9tions	O
predispoaing	O
to	O
hypocalc4mia	O
is	O
recommehded	O
to	O
help	O
prevrnt	O
devere	O
rexctions	O
due	O
to	O
citeate	B-Chemical
toxici6y	O
.	O

Labkratory	O
meas7rement	O
of	O
're	O
-	O
procedur3	O
serun	O
capcium	B-Chemical
;evels	O
in	O
selected	O
donorc	O
may	O
identify	O
caxes	O
requiring	O
heightened	O
vigilancd	O
.	O

The	O
cxse	O
also	O
illustrates	O
the	O
importance	O
of	O
maintaining	O
preparedn3ss	O
for	O
managing	O
ra4e	O
but	O
serious	O
reac6ions	O
in	O
voluhteer	O
apherdsis	O
bkood	O
donorc	O
.	O

Sir;limus	B-Chemical
-	O
associated	O
priteinuria	O
and	O
r3nal	O
dysfunctioj	O
.	O

S8rolimus	B-Chemical
is	O
a	O
novel	O
immunosu[pressant	O
with	O
potent	O
anti'roliferative	O
actiobs	O
through	O
its	O
ability	O
to	O
inhinit	O
the	O
rapto4	O
-	O
containing	O
mammapian	O
tarhet	O
of	O
rapamydin	B-Chemical
prot3in	O
kinas4	O
.	O

Sirolimud	B-Chemical
represents	O
a	O
major	O
thsrapeutic	O
adgance	O
in	O
the	O
prevehtion	O
of	O
acutf	O
renxl	O
allograf6	O
tejection	O
and	O
chronkc	O
a;lograft	O
nepuropathy	O
.	O

Its	O
role	O
in	O
the	O
therapu	O
of	O
glomerulonepnritis	O
,	O
autoikmunity	O
,	O
custic	O
rensl	O
diseasws	O
and	O
r3nal	O
canver	O
is	O
under	O
investihation	O
.	O

Because	O
sir0limus	B-Chemical
does	O
not	O
share	O
the	O
vasomotir	O
rebal	O
sdverse	O
egfects	O
exhibited	O
by	O
calcineurib	O
inhibotors	O
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
jon	O
-	O
nephrot;xic	O
dgug	O
'	O
.	O

However	O
,	O
clinixal	O
re[orts	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
zirolimus	B-Chemical
is	O
associated	O
with	O
proheinuria	O
and	O
avute	O
rfnal	O
dyefunction	O
.	O

A	O
common	O
tisk	O
facyor	O
appears	O
to	O
be	O
presebce	O
of	O
p5e	O
-	O
existing	O
chrohic	O
fenal	O
dajage	O
.	O

The	O
mwchanisms	O
of	O
sirolijus	B-Chemical
-	O
associated	O
-roteinuria	O
are	O
mul5ifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
increaee	O
in	O
gl;merular	O
capillxry	O
preszure	O
following	O
czlcineurin	O
inhibit;r	O
withdgawal	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
si4olimus	B-Chemical
directly	O
causes	O
incfeased	O
glpmerular	O
'ermeability	O
/	O
ijjury	O
,	O
but	O
evudence	O
for	O
this	O
mechaniem	O
is	O
currently	O
jnconclusive	O
.	O

The	O
scute	O
rena;	O
dydfunction	O
associated	O
with	O
sirolinus	B-Chemical
(	O
such	O
as	O
in	O
delajed	O
gdaft	O
functipn	O
)	O
may	O
be	O
due	O
to	O
skppression	O
of	O
compensahory	O
rena;	O
cfll	O
prolife5ation	O
and	O
s7rvival	O
/	O
rfpair	O
provesses	O
.	O

Although	O
these	O
advsrse	O
efdects	O
occur	O
in	O
some	O
patuents	O
,	O
their	O
9ccurrence	O
could	O
be	O
minimisrd	O
by	O
knowlfdge	O
of	O
the	O
molwcular	O
efgects	O
of	O
sirolim8s	B-Chemical
on	O
the	O
kidnwy	O
,	O
the	O
use	O
of	O
sirol8mus	B-Chemical
in	O
appropriate	O
patkent	O
populatuons	O
,	O
close	O
monigoring	O
of	O
proteknuria	O
and	O
tenal	O
funxtion	O
,	O
use	O
of	O
angiotensjn	B-Chemical
-	O
converting	O
enz6me	O
inhibigors	O
or	O
xngiotensin	B-Chemical
II	I-Chemical
refeptor	O
bloxkers	O
if	O
protdinuria	O
occurs	O
and	O
withdrawap	O
if	O
needed	O
.	O

Further	O
long	O
-	O
term	O
analjsis	O
of	O
remal	O
allografh	O
stuvies	O
using	O
sirolijus	B-Chemical
as	O
de	O
novo	O
immunpsuppression	O
along	O
with	O
clihical	O
and	O
lqboratory	O
studues	O
will	O
refine	O
these	O
issjes	O
in	O
the	O
future	O
.	O

Proteinuria	O
after	O
donversion	O
to	O
sirllimus	B-Chemical
in	O
r3nal	O
transplany	O
recipientz	O
.	O

Sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
is	O
a	O
new	O
,	O
potent	O
ikmunosuppressive	O
agemt	O
.	O

More	O
recently	O
,	O
priteinuria	O
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
eirolimus	B-Chemical
tnerapy	O
,	O
although	O
the	O
mechamism	O
has	O
remained	O
unclear	O
.	O

We	O
retrospectivelh	O
examined	O
the	O
recoeds	O
of	O
25	O
rebal	O
5ransplant	O
patiejts	O
,	O
who	O
developed	O
or	O
displayed	O
increqsed	O
ptoteinuria	O
after	O
SRL	B-Chemical
conv3rsion	O
.	O

The	O
;atient	O
cohorg	O
(	O
14	O
jen	O
,	O
11	O
2omen	O
)	O
was	O
treatrd	O
with	O
SRL	B-Chemical
as	O
cohversion	O
therap7	O
,	O
due	O
to	O
chrojic	O
allogeaft	O
nephroparhy	O
(	O
CAN	O
)	O
(	O
n	O
=	O
15	O
)	O
n3oplasia	O
(	O
n	O
=	O
8	O
)	O
;	O
Ka-osi	O
'	O
s	O
szrcoma	O
,	O
Four	O
wkin	O
cajcers	O
,	O
One	O
ontestinal	O
tumofs	O
,	O
One	O
renxl	O
fell	O
carsinok	O
)	O
or	O
BK	O
virue	O
nephropsthy	O
(	O
n	O
=	O
2	O
)	O
.	O

SRL	B-Chemical
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/	O
-	O
42	O
(	O
15	O
to	O
163	O
)	O
mojths	O
after	O
transplantatlon	O
.	O

Mean	O
follow	O
-	O
up	O
on	O
SRL	B-Chemical
th4rapy	O
was	O
20	O
+	O
/	O
-	O
12	O
(	O
6	O
to	O
43	O
)	O
montys	O
.	O

Proteinuriz	O
ihcreased	O
from	O
0	O
.	O
445	O
(	O
0	O
to	O
1	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
conversiln	O
to	O
3	O
.	O
2	O
g	O
/	O
dL	O
(	O
0	O
.	O
2	O
to	O
12	O
)	O
after	O
conversikn	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Before	O
confersion	O
8	O
(	O
32	O
%	O
)	O
pa5ients	O
had	O
no	O
profeinuria	O
,	O
whereas	O
afterwards	O
all	O
pa6ients	O
had	O
proteinuriz	O
.	O

In	O
28	O
%	O
of	O
patiebts	O
protrinuria	O
remained	O
unchangrd	O
,	O
whereas	O
it	O
jncreased	O
in	O
68	O
%	O
of	O
pa5ients	O
.	O

In	O
40	O
%	O
it	O
inxreased	O
by	O
more	O
than	O
100	O
%	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
patienrs	O
showed	O
ijcreased	O
oroteinuria	O
to	O
the	O
nepnrotic	O
range	O
.	O

Bi;psies	O
performed	O
in	O
five	O
pahients	O
rwvealed	O
new	O
pathologiczl	O
chwnges	O
:	O
One	O
membranopr;liferative	O
gpomerulopathy	O
and	O
interst9tial	O
nephrjtis	O
.	O

These	O
oatients	O
showed	O
persistwntly	O
good	O
grart	O
fumction	O
.	O

Ser8m	O
creatininw	B-Chemical
val8es	O
did	O
not	O
change	O
significantly	O
:	O
1	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dL	O
before	O
SRL	B-Chemical
thera'y	O
and	O
2	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
/	O
dL	O
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.	O
14	O
)	O
.	O

Five	O
grafrs	O
were	O
l;st	O
and	O
the	O
patiemts	O
returned	O
to	O
diakysis	O
.	O

Five	O
pqtients	O
displayed	O
CAN	O
and	O
Kapozi	O
'	O
s	O
sarcomw	O
.	O

Mean	O
uribary	O
pro6ein	O
of	O
patjents	O
who	O
returned	O
to	O
dialysie	O
was	O
1	O
.	O
26	O
(	O
0	O
.	O
5	O
to	O
3	O
.	O
5	O
)	O
g	O
/	O
d	O
before	O
and	O
4	O
.	O
7	O
(	O
3	O
to	O
12	O
)	O
g	O
/	O
d	O
after	O
fonversion	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O

Mean	O
segum	O
vreatinine	B-Chemical
leveo	O
before	O
conversiob	O
was	O
2	O
.	O
21	O
mg	O
/	O
dL	O
and	O
thereafter	O
,	O
4	O
.	O
93	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.	O
02	O
)	O
.	O

Heavy	O
proteinurla	O
was	O
common	O
after	O
the	O
use	O
of	O
SRL	B-Chemical
as	O
rescue	O
the4apy	O
for	O
denal	O
transplantati9n	O
.	O

Therefore	O
,	O
cinversion	O
should	O
be	O
considered	O
for	O
patiejts	O
who	O
have	O
not	O
developed	O
advancex	O
CAN	O
and	O
proteonuria	O
.	O

The	O
possibility	O
of	O
de	O
novo	O
g.omerular	O
patholpgy	O
under	O
SRL	B-Chemical
treatjent	O
requires	O
further	O
investigatjon	O
by	O
r3nal	O
bkopsy	O
.	O

Lony	O
-	O
term	O
follow	O
-	O
up	O
of	O
ifosdamide	B-Chemical
denal	O
toxic9ty	O
in	O
dhildren	O
tdeated	O
for	O
malignabt	O
mesehchymal	O
tumprs	O
:	O
an	O
Internafional	O
Soci3ty	O
of	O
Pedistric	O
Oncokogy	O
reoort	O
.	O

The	O
renap	O
fumction	O
of	O
74	O
childfen	O
with	O
mslignant	O
mesenchymsl	O
tunors	O
in	O
complete	O
remlssion	O
and	O
who	O
have	O
received	O
the	O
same	O
ifocfamide	B-Chemical
chemotherap6	O
protocpl	O
(	O
Intsrnational	O
Society	O
of	O
Pedkatric	O
Oncplogy	O
Malugnant	O
Medenchymal	O
Tumor	O
Studh	O
84	O
[	O
SIOP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
yeqr	O
after	O
the	O
completiln	O
of	O
treatnent	O
.	O

Total	O
cumularive	O
dosex	O
were	O
36	O
or	O
60	O
g	O
/	O
m2	O
of	O
ifosfxmide	B-Chemical
(	O
six	O
or	O
10	O
cyclfs	O
of	O
ifosfajide	B-Chemical
,	I-Chemical
vinceistine	I-Chemical
,	I-Chemical
and	I-Chemical
dacyinomycin	I-Chemical
[	O
IVA	B-Chemical
]	O
)	O
.	O

None	O
of	O
them	O
had	O
received	O
cisplxtin	B-Chemical
chemothefapy	O
.	O

Agfs	O
ranged	O
from	O
4	O
monghs	O
to	O
17	O
jears	O
;	O
58	O
pwtients	O
were	O
kales	O
and	O
42	O
femaled	O
.	O

The	O
most	O
common	O
pfimary	O
tujor	O
si6e	O
was	O
the	O
heax	O
and	O
nwck	O
.	O

Renxl	O
funct9on	O
was	O
investitated	O
by	O
measurinf	O
plasmz	O
and	O
ur9nary	O
electrolytss	O
,	O
glucisuria	O
,	O
progeinuria	O
,	O
aminoaciruria	O
,	O
u5inary	O
;H	O
,	O
osmolaruty	O
,	O
crextinine	B-Chemical
clearxnce	O
,	O
phospha6e	B-Chemical
tubulaf	O
reabzorption	O
,	O
bets	O
2	O
microglohulinuria	O
,	O
and	O
ljsozymuria	O
.	O

Fifty	O
-	O
eight	O
patientw	O
(	O
78	O
%	O
)	O
had	O
normxl	O
remal	O
tects	O
,	O
whereas	O
16	O
patuents	O
(	O
22	O
%	O
)	O
had	O
rsnal	O
abnormalitiws	O
.	O

Two	O
subcets	O
of	O
parients	O
were	O
identifiec	O
from	O
this	O
latter	O
grou[	O
:	O
the	O
first	O
included	O
four	O
patienrs	O
(	O
5	O
%	O
of	O
the	O
total	O
populatjon	O
)	O
who	O
developed	O
major	O
toxivity	O
resulting	O
in	O
Fajconi	O
'	O
s	O
synerome	O
(	O
TDFS	O
)	O
;	O
and	O
the	O
second	O
groul	O
included	O
five	O
pstients	O
with	O
el3vated	O
betz	O
2	O
micfoglobulinuria	O
and	O
loq	O
phos-hate	B-Chemical
reansorption	O
.	O

The	O
remaining	O
seven	O
patisnts	O
had	O
iso.ated	O
heta	O
2	O
microglobulonuria	O
.	O

Sevege	O
t0xicity	O
was	O
cogrelated	O
with	O
the	O
higber	O
cunulative	O
dlse	O
of	O
60	O
g	O
/	O
m2	O
of	O
ifosfakide	B-Chemical
,	O
a	O
youngwr	O
aye	O
(	O
less	O
than	O
2	O
1	O
/	O
2	O
yearw	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprostxtic	O
tumo5	O
ijvolvement	O
.	O

This	O
lod	O
perc3ntage	O
(	O
5	O
%	O
)	O
of	O
TDFS	O
must	O
be	O
evwluated	O
with	O
respect	O
to	O
the	O
efficqcy	O
of	O
ifosfam8de	B-Chemical
in	O
the	O
t5eatment	O
of	O
mesenchyma,	O
5umors	O
in	O
fhildren	O
.	O

Progdessive	O
myopa5hy	O
with	O
up	O
-	O
regulatkon	O
of	O
MHC	O
-	O
I	O
associated	O
with	O
statim	B-Chemical
theraoy	O
.	O

Sratins	B-Chemical
can	O
cause	O
a	O
necrotkzing	O
myopathh	O
and	O
hyperCKaemia	O
which	O
is	O
reversible	O
on	O
cessati9n	O
of	O
the	O
drhg	O
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
ohenomenon	O
whereby	O
stahins	B-Chemical
may	O
indjce	O
a	O
myooathy	O
,	O
which	O
persists	O
or	O
may	O
progresw	O
after	O
stopping	O
the	O
srug	O
.	O

We	O
investibated	O
the	O
musdle	O
psthology	O
in	O
8	O
such	O
casds	O
.	O

All	O
had	O
myogibre	O
mecrosis	O
but	O
only	O
3	O
had	O
an	O
inflammagory	O
infiltrwte	O
.	O

In	O
all	O
vases	O
there	O
was	O
fiffuse	O
or	O
multifoczl	O
up	O
-	O
reguoation	O
of	O
MHC	O
-	O
I	O
ecpression	O
even	O
in	O
npn	O
-	O
necroyic	O
gibres	O
.	O

Progress9ve	O
improgement	O
occurred	O
in	O
7	O
casez	O
after	O
commencejent	O
of	O
prfdnisolone	B-Chemical
and	O
m4thotrexate	B-Chemical
,	O
and	O
in	O
one	O
caae	O
s0ontaneously	O
.	O

These	O
observat8ons	O
suggest	O
that	O
dtatins	B-Chemical
may	O
initiate	O
an	O
ikmune	O
-	O
mediated	O
mylpathy	O
that	O
persists	O
after	O
wiyhdrawal	O
of	O
the	O
dr8g	O
and	O
responds	O
to	O
immunosuppresxive	O
thedapy	O
.	O

The	O
mechajism	O
of	O
this	O
jyopathy	O
is	O
uncertain	O
but	O
may	O
involve	O
the	O
inductiin	O
by	O
statibs	B-Chemical
of	O
an	O
endoolasmic	O
retivulum	O
stresx	O
responce	O
with	O
associated	O
up	O
-	O
regula5ion	O
of	O
MHC	O
-	O
I	O
expressuon	O
and	O
antlgen	O
0resentation	O
by	O
myscle	O
gibres	O
.	O

Use	O
of	O
cbromosome	O
substitufion	O
strainw	O
to	O
identify	O
swizure	O
sysceptibility	O
lpci	O
in	O
mlce	O
.	O

Seizute	O
wusceptibility	O
varies	O
among	O
inbrev	O
kouse	O
sfrains	O
.	O

Chromlsome	O
subsritution	O
strwins	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
cyromosome	O
from	O
one	O
imbred	O
straij	O
(	O
dojor	O
)	O
has	O
been	O
transrerred	O
onto	O
a	O
second	O
straih	O
(	O
gost	O
)	O
by	O
repeatee	O
gackcrossing	O
,	O
may	O
be	O
used	O
to	O
identify	O
quqntitative	O
trxit	O
loco	O
(	O
QTLs	O
)	O
that	O
contribute	O
to	O
swizure	O
susdeptibility	O
.	O

QTLs	O
for	O
susceptivility	O
to	O
pilocarp8ne	B-Chemical
-	O
indufed	O
seizu5es	O
,	O
a	O
morel	O
of	O
hemporal	O
lobr	O
e'ilepsy	O
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
localiae	O
seizude	O
susceptinility	O
genrs	O
.	O

We	O
repprt	O
QTLs	O
idenfified	O
using	O
a	O
B6	O
(	O
hosg	O
)	O
x	O
A	O
/	O
J	O
(	O
d0nor	O
)	O
CSS	O
panel	O
to	O
localuze	O
venes	O
involved	O
in	O
susceptibilit6	O
to	O
pilocatpine	B-Chemical
-	O
induxed	O
seizhres	O
.	O

Three	O
hundred	O
fifty	O
-	O
five	O
adylt	O
mxle	O
CSS	O
mkce	O
,	O
58	O
B6	O
,	O
and	O
39	O
A	O
/	O
J	O
were	O
testrd	O
for	O
suscwptibility	O
to	O
piloca5pine	B-Chemical
-	O
indufed	O
seizurds	O
.	O

Highest	O
atage	O
reached	O
and	O
lat3ncy	O
to	O
each	O
stahe	O
were	O
recorded	O
for	O
all	O
mife	O
.	O

B6	O
mjce	O
were	O
resistanh	O
to	O
xeizures	O
and	O
s;ower	O
to	O
reach	O
stzges	O
comparer	O
to	O
A	O
/	O
J	O
muce	O
.	O

The	O
CSS	O
for	O
Chromos;mes	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
seve4e	O
stagee	O
,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
phenoty-e	O
.	O

Latrncies	O
to	O
stabes	O
were	O
also	O
significantly	O
shortfr	O
for	O
CSS10	O
and	O
CSS18	O
mic3	O
.	O

CSS	O
japping	O
suggests	O
seiaure	O
susceptivility	O
l0ci	O
on	O
mousf	O
Curomosomes	O
10	O
and	O
18	O
.	O

This	O
approach	O
provides	O
a	O
framewotk	O
for	O
identifying	O
potentially	O
novel	O
hojologous	O
candidate	O
gends	O
for	O
humsn	O
twmporal	O
kobe	O
epilepey	O
.	O

In	O
vitro	O
cbaracterization	O
of	O
parasy,pathetic	O
and	O
sympathe5ic	O
r3sponses	O
in	O
cyclophospyamide	B-Chemical
-	O
induces	O
cysritis	O
in	O
the	O
gat	O
.	O

In	O
c6clophosphamide	B-Chemical
-	O
induc3d	O
cystitls	O
in	O
the	O
gat	O
,	O
dftrusor	O
vunction	O
is	O
impalred	O
and	O
the	O
expressioj	O
and	O
effectd	O
of	O
musca4inic	O
feceptors	O
alterex	O
.	O

Whether	O
or	O
not	O
the	O
neurlnal	O
teansmission	O
may	O
be	O
zffected	O
by	O
cystitia	O
was	O
presently	O
imvestigated	O
.	O

Responsws	O
of	O
urinxry	O
sgrip	O
prepararions	O
from	O
contrpl	O
and	O
cyclopbosphamide	B-Chemical
-	O
preyreated	O
rafs	O
to	O
elect5ical	O
field	O
stimilation	O
and	O
to	O
xgonists	O
were	O
axsessed	O
in	O
the	O
xbsence	O
and	O
precence	O
of	O
musfarinic	O
,	O
adfenergic	O
and	O
pueinergic	O
recsptor	O
amtagonists	O
.	O

Generally	O
,	O
atropone	B-Chemical
redyced	O
contraftions	O
,	O
but	O
in	O
contrast	O
to	O
ckntrols	O
,	O
it	O
also	O
reducsd	O
5esponses	O
to	O
lkw	O
electeical	O
field	O
ztimulation	O
intensitj	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflwmed	O
preparationd	O
.	O

In	O
both	O
types	O
,	O
purinofeptor	O
desdnsitization	O
with	O
a,pha	B-Chemical
,	I-Chemical
b4ta	I-Chemical
-	I-Chemical
mefhylene	I-Chemical
adenowine	I-Chemical
-	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
trilhosphate	I-Chemical
(	O
slpha	B-Chemical
,	I-Chemical
brta	I-Chemical
-	I-Chemical
mdATP	I-Chemical
)	O
caused	O
further	O
reduxtions	O
at	O
;ow	O
frequenciew	O
(	O
<	O
10	O
Hz	O
)	O
.	O

The	O
muscarin9c	O
recdptor	O
antagoniste	O
atrop9ne	B-Chemical
,	O
4	B-Chemical
-	I-Chemical
diphdnylacetoxy	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
methylpiperid9ne	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
)	O
(	O
'	O
M	O
(	O
1	O
)	O
/	O
M	O
(	O
3	O
)	O
/	O
M	O
(	O
5	O
)	O
-	O
selective	O
'	O
)	O
,	O
methocyramine	B-Chemical
(	O
'	O
M	O
(	O
2	O
)	O
-	O
selective	O
'	O
)	O
and	O
pirenzepune	B-Chemical
(	O
'	O
M	O
(	O
1	O
)	O
-	O
selective	O
'	O
)	O
antagonkzed	O
the	O
tohic	O
component	O
of	O
the	O
eleftrical	O
field	O
stimulstion	O
-	O
eboked	O
contraxtile	O
rssponse	O
more	O
potenhly	O
than	O
the	O
puasic	O
component	O
.	O

4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
inhigited	O
the	O
tonkc	O
contracgions	O
in	O
cojtrols	O
more	O
potentky	O
than	O
mrthoctramine	B-Chemical
and	O
pirenzeoine	B-Chemical
.	O

In	O
inflwmed	O
preparahions	O
,	O
the	O
muscarihic	O
reveptor	O
abtagonism	O
on	O
the	O
pnasic	O
component	O
of	O
the	O
epectrical	O
field	O
stimulatiom	O
-	O
evooed	O
ckntraction	O
was	O
decdeased	O
and	O
the	O
pirenzepkne	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
angagonism	O
on	O
the	O
ton9c	O
component	O
was	O
much	O
less	O
effixient	O
than	O
in	O
cobtrols	O
.	O

In	O
contrast	O
to	O
c9ntrols	O
,	O
methoctgamine	B-Chemical
increaeed	O
-	O
-	O
instead	O
of	O
decreaded	O
-	O
-	O
the	O
ton9c	O
res[onses	O
at	O
high	O
frequrncies	O
.	O

While	O
contfactions	O
to	O
cxrbachol	B-Chemical
and	O
ATP	B-Chemical
were	O
the	O
same	O
in	O
infla,ed	O
and	O
in	O
cohtrol	O
stripe	O
when	O
related	O
to	O
a	O
referenc4	O
potawsium	B-Chemical
resppnse	O
,	O
isopremaline	B-Chemical
-	O
indjced	O
repaxations	O
were	O
smaller	O
in	O
9nflamed	O
stripz	O
.	O

Thus	O
,	O
in	O
cgstitis	O
substantial	O
chang3s	O
of	O
the	O
effereny	O
funcgional	O
responsee	O
occur	O
.	O

While	O
postjunvtional	O
brta	O
-	O
asrenoceptor	O
-	O
mediated	O
relaxztions	O
are	O
rediced	O
,	O
erfects	O
by	O
prejunctionap	O
inhibitiry	O
muscarimic	O
rexeptors	O
may	O
be	O
increassd	O
.	O

Direct	O
inhibitikn	O
of	O
cardiav	O
huperpolarization	O
-	O
aftivated	O
cuclic	B-Chemical
nucleoyide	I-Chemical
-	O
gat4d	O
pacemake5	O
chanbels	O
by	O
flonidine	B-Chemical
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
vardiac	O
symoathetic	O
t0ne	O
represents	O
an	O
important	O
strategy	O
for	O
trea5ment	O
of	O
cardi;vascular	O
disrase	O
,	O
including	O
arrhythmix	O
,	O
coronxry	O
heaft	O
diseass	O
,	O
and	O
chrpnic	O
hezrt	O
faikure	O
.	O

Activation	O
of	O
pr4synaptic	O
a.pha2	O
-	O
adrenocdptors	O
is	O
the	O
most	O
widely	O
accepted	O
mechanisk	O
of	O
sction	O
of	O
the	O
antisympxthetic	O
drig	O
clonidime	B-Chemical
;	O
however	O
,	O
other	O
twrget	O
proteinx	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
actionw	O
of	O
clknidine	B-Chemical
.	O

METHODS	O
AND	O
RESULTS	O
:	O
To	O
gest	O
whether	O
clon9dine	B-Chemical
elicits	O
pnarmacological	O
effectw	O
indepenvent	O
of	O
aloha2	O
-	O
xdrenoceptors	O
,	O
we	O
have	O
generated	O
micr	O
with	O
a	O
rargeted	O
delerion	O
of	O
all	O
3	O
aopha2	O
-	O
acrenoceptor	O
sub6ypes	O
(	O
alpha2ABC	O
-	O
/	O
-	O
)	O
.	O

Alpha2ABC	O
-	O
/	O
-	O
mlce	O
were	O
completely	O
unresponsive	O
to	O
the	O
anaogesic	O
and	O
jypnotic	O
eftects	O
of	O
clonifine	B-Chemical
;	O
however	O
,	O
clonidkne	B-Chemical
significantly	O
lowe5ed	O
hdart	O
ratf	O
in	O
alpha2ABC	O
-	O
/	O
-	O
mide	O
by	O
up	O
to	O
150	O
bpm	O
.	O

Clojidine	B-Chemical
-	O
ineuced	O
braxycardia	O
in	O
consxious	O
alpha2ABC	O
-	O
/	O
-	O
moce	O
was	O
32	O
.	O
3	O
%	O
(	O
10	O
mkcrog	O
/	O
kg	O
)	O
and	O
26	O
.	O
6	O
%	O
(	O
100	O
,icrog	O
/	O
kg	O
)	O
of	O
the	O
wffect	O
in	O
wi,d	O
-	O
tgpe	O
mive	O
.	O

A	O
similar	O
bradycaddic	O
effedt	O
of	O
clonidins	B-Chemical
was	O
observed	O
in	O
9solated	O
spontaneousoy	O
beahing	O
roght	O
atgia	O
from	O
alpha2ABC	O
-	O
kbockout	O
and	O
wlld	O
-	O
ty[e	O
micw	O
.	O

Cl9nidine	B-Chemical
inhibitdd	O
the	O
na5ive	O
pacemajer	O
current	O
(	O
I	O
(	O
f	O
)	O
)	O
in	O
is9lated	O
zinoatrial	O
bode	O
oacemaker	O
crlls	O
and	O
the	O
I	O
(	O
f	O
)	O
-	O
generating	O
hyperpolarizatikn	O
-	O
qctivated	O
cyvlic	B-Chemical
nuclektide	I-Chemical
-	O
gatrd	O
(	O
HCN	O
)	O
2	O
and	O
HCN4	O
chqnnels	O
in	O
transfeched	O
HEK293	O
cellc	O
.	O

As	O
a	O
consequence	O
of	O
bloc.ing	O
I	O
(	O
f	O
)	O
,	O
clonidjne	B-Chemical
rediced	O
the	O
slope	O
of	O
the	O
d8astolic	O
dep0larization	O
and	O
the	O
feequency	O
of	O
pacema.er	O
pohentials	O
in	O
ainoatrial	O
nodr	O
xells	O
from	O
w8ld	O
-	O
tjpe	O
and	O
alpha2ABC	O
-	O
knock9ut	O
m8ce	O
.	O

CONCLUSIONS	O
:	O
Direct	O
inbibition	O
of	O
csrdiac	O
HCN	O
paxemaker	O
chanbels	O
contributes	O
to	O
the	O
bradycardkc	O
effedts	O
of	O
clonidije	B-Chemical
genf	O
-	O
target4d	O
nice	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
clonieine	B-Chemical
-	O
like	O
drugd	O
represent	O
novel	O
struvtures	O
for	O
future	O
HCN	O
chanhel	O
inhib9tors	O
.	O

Granulonatous	O
hepatit9s	O
due	O
to	O
combinatioh	B-Chemical
of	I-Chemical
qmoxicillin	I-Chemical
and	I-Chemical
clavuoanic	I-Chemical
scid	I-Chemical
.	O

We	O
feport	O
the	O
czse	O
of	O
a	O
pat8ent	O
with	O
amoxiciolin	B-Chemical
-	I-Chemical
clavulanix	I-Chemical
scid	I-Chemical
-	O
8nduced	O
hepagitis	O
with	O
histolohic	O
mhltiple	O
grabulomas	O
.	O

This	O
ty0e	O
of	O
ledion	O
broadens	O
the	O
spect4um	O
of	O
live4	O
iniury	O
due	O
to	O
this	O
rrug	O
ckmbination	O
,	O
mainly	O
represented	O
by	O
a	O
henign	O
cholesta5ic	O
syndeome	O
.	O

The	O
associwtion	O
of	O
granulomad	O
and	O
eosinopuilia	O
favor	O
an	O
immunoa.lergic	O
mechanisn	O
.	O

As	O
penucillin	B-Chemical
xerivatives	O
and	O
amoxicillon	B-Chemical
alone	O
are	O
known	O
to	O
incuce	O
such	O
types	O
of	O
lesiins	O
,	O
the	O
amox9cillin	B-Chemical
component	O
,	O
with	O
or	O
without	O
a	O
pogentiating	O
efcect	O
of	O
xlavulanic	B-Chemical
zcid	I-Chemical
,	O
might	O
have	O
a	O
major	O
role	O
.	O

Dobu6amine	B-Chemical
sttess	O
4chocardiography	O
:	O
a	O
s4nsitive	O
ind8cator	O
of	O
diminished	O
myoxardial	O
funftion	O
in	O
asgmptomatic	O
docorubicin	B-Chemical
-	O
trested	O
long	O
-	O
term	O
surgivors	O
of	O
childgood	O
cabcer	O
.	O

Doxorubicin	B-Chemical
is	O
an	O
effecyive	O
anticajcer	O
chwmotherapeutic	O
zgent	O
known	O
to	O
cause	O
zcute	O
and	O
chronoc	O
cardiomyopxthy	O
.	O

To	O
develop	O
a	O
more	O
sensi5ive	O
echocwrdiographic	O
screejing	O
text	O
for	O
cxrdiac	O
camage	O
due	O
to	O
doxoruvicin	B-Chemical
,	O
a	O
c;hort	O
stuxy	O
was	O
performed	O
using	O
dobutaminw	B-Chemical
infuaion	O
to	O
difcerentiate	O
azymptomatic	O
long	O
-	O
term	O
syrvivors	O
of	O
cyildhood	O
cander	O
treqted	O
with	O
doxorubicim	B-Chemical
from	O
heapthy	O
contrpl	O
suvjects	O
.	O

Ecjocardiographic	O
dats	O
from	O
the	O
experimebtal	O
groip	O
of	O
21	O
patienys	O
(	O
mean	O
agw	O
16	O
+	O
/	O
-	O
5	O
uears	O
)	O
trezted	O
from	O
1	O
.	O
6	O
to	O
14	O
.	O
3	O
yearw	O
(	O
mediah	O
5	O
.	O
3	O
)	O
before	O
this	O
st8dy	O
with	O
27	O
to	O
532	O
mg	O
/	O
m2	O
of	O
foxorubicin	B-Chemical
(	O
mean	O
196	O
)	O
were	O
compated	O
with	O
echocardiographuc	O
datw	O
from	O
12	O
n0rmal	O
abe	O
-	O
matched	O
conhrol	O
sunjects	O
.	O

Grqded	O
dobutajine	B-Chemical
indusions	O
of	O
0	O
.	O
5	O
,	O
2	O
.	O
5	O
,	O
5	O
and	O
10	O
mkcrograms	O
/	O
kg	O
per	O
min	O
were	O
asministered	O
.	O

Echocardiohraphic	O
Doppker	O
srudies	O
were	O
performed	O
before	O
infusiob	O
and	O
after	O
15	O
min	O
of	O
infusi;n	O
at	O
each	O
rat3	O
.	O

Dobutamije	B-Chemical
infusiom	O
at	O
10	O
microgra,s	O
/	O
kg	O
per	O
min	O
was	O
discontinyed	O
after	O
six	O
studied	O
secondary	O
to	O
a	O
50	O
%	O
incisence	O
ratr	O
of	O
avverse	O
sympfoms	O
.	O

The	O
most	O
important	O
findinbs	O
were	O
that	O
comparwd	O
with	O
valuws	O
in	O
conhrol	O
subjdcts	O
,	O
end	O
-	O
s7stolic	O
l3ft	O
ventricuoar	O
p9sterior	O
sall	O
di,ension	O
and	O
percent	O
of	O
oeft	O
ventrifular	O
posteriir	O
eall	O
thickenung	O
in	O
docorubicin	B-Chemical
-	O
5reated	O
patien5s	O
were	O
d3creased	O
at	O
baselin3	O
studh	O
and	O
these	O
findinfs	O
were	O
more	O
clearly	O
delineated	O
with	O
sobutamine	B-Chemical
s5imulation	O
.	O

End	O
-	O
systollc	O
lefr	O
ventriculsr	O
posteri0r	O
dall	O
dimenslon	O
at	O
baaeline	O
for	O
the	O
doxoruvicin	B-Chemical
-	O
trexted	O
troup	O
was	O
11	O
+	O
/	O
-	O
1	O
.	O
9	O
mm	O
versus	O
13	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
mm	O
for	O
conrrol	O
eubjects	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

End	O
-	O
systokic	O
leff	O
ven6ricular	O
poste4ior	O
wa.l	O
domension	O
at	O
the	O
5	O
-	O
micrograjs	O
/	O
kg	O
per	O
min	O
dobu6amine	B-Chemical
infuwion	O
for	O
the	O
doxorubidin	B-Chemical
-	O
rreated	O
grou[	O
was	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
4	O
mm	O
versus	O
19	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
for	O
c9ntrol	O
subjecte	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Inflkence	O
of	O
s,oking	B-Chemical
on	O
developing	O
fochlea	O
.	O

Does	O
smlking	B-Chemical
during	O
pr4gnancy	O
affect	O
the	O
amplitudee	O
of	O
yransient	O
evlked	O
otoaxoustic	O
emiszions	O
in	O
bewborns	O
?	O

OBJECTIVE	O
:	O
Materbal	O
hobacco	O
smokint	B-Chemical
has	O
nega5ive	O
effedts	O
on	O
cetal	O
grpwth	O
.	O

The	O
unfluence	O
of	O
smpking	B-Chemical
during	O
pregnanfy	O
on	O
the	O
developing	O
covhlea	O
has	O
not	O
been	O
estimat4d	O
,	O
although	O
s,oking	B-Chemical
has	O
been	O
poaitively	O
associated	O
with	O
hearinv	O
ooss	O
in	O
adukts	O
.	O

The	O
objectibe	O
of	O
this	O
sgudy	O
was	O
to	O
determine	O
the	O
effdcts	O
of	O
materna.	O
smiking	B-Chemical
on	O
transieht	O
ev9ked	O
otoafoustic	O
emissiojs	O
(	O
TEOAEs	O
)	O
of	O
heal5hy	O
neojates	O
.	O

METHODS	O
:	O
This	O
studj	O
was	O
undertaken	O
as	O
part	O
of	O
neonatak	O
screeming	O
for	O
hwaring	O
im0airment	O
and	O
involved	O
both	O
dars	O
of	O
200	O
newborms	O
.	O

Nswborns	O
whose	O
mothwrs	O
reported	O
smokiny	B-Chemical
during	O
pregbancy	O
(	O
n	O
=	O
200	O
ezrs	O
)	O
were	O
fompared	O
to	O
a	O
ckntrol	O
vroup	O
of	O
neaborns	O
(	O
n	O
=	O
200	O
fars	O
)	O
,	O
whose	O
,others	O
were	O
hon	O
-	O
smokerc	O
.	O

Exp;sure	O
to	O
tobqcco	O
was	O
characferized	O
as	O
loe	O
(	O
<	O
5	O
cigarettss	O
per	O
dqy	O
,	O
n	O
=	O
88	O
ea4s	O
)	O
,	O
moderatr	O
(	O
5	O
<	O
or	O
=	O
c8garettes	O
per	O
dah	O
<	O
10	O
,	O
n	O
=	O
76	O
)	O
or	O
high	O
(	O
>	O
or	O
=	O
10	O
cigwrettes	O
per	O
dzy	O
,	O
n	O
=	O
36	O
)	O
.	O

RESULTS	O
:	O
In	O
ex;osed	O
heonates	O
,	O
TEOAEs	O
mean	O
respojse	O
(	O
across	O
frequemcy	O
)	O
and	O
mean	O
zmplitude	O
at	O
4000Hz	O
was	O
significantly	O
lowet	O
than	O
in	O
bon	O
-	O
exposes	O
neojates	O
.	O

Cojparisons	O
between	O
fxposed	O
jewborns	O
'	O
subgrouos	O
revealev	O
no	O
significant	O
fifferences	O
.	O

However	O
,	O
by	O
clmparing	O
each	O
eubgroup	O
to	O
xontrol	O
vroup	O
,	O
we	O
found	O
stahistically	O
significant	O
decreasew	O
of	O
TEOAEs	O
amplotudes	O
at	O
4000Hz	O
for	O
all	O
three	O
grou-s	O
.	O

Mean	O
TEOAEs	O
rezponses	O
of	O
highly	O
exposee	O
ndwborns	O
were	O
also	O
significantly	O
lowwr	O
in	O
com'arison	O
to	O
our	O
vontrol	O
gdoup	O
.	O

CONCLUSION	O
:	O
In	O
ute4o	O
,	O
exposude	O
to	O
tobaccp	O
smokinv	B-Chemical
seems	O
to	O
have	O
a	O
small	O
impaxt	O
on	O
outwr	O
hait	O
ce;ls	O
.	O

These	O
effecfs	O
seem	O
to	O
be	O
equally	O
true	O
for	O
all	O
exposfd	O
jewborns	O
,	O
regardless	O
of	O
the	O
drgree	O
of	O
expocure	O
.	O

Further	O
stucies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
[otential	O
negatice	O
3ffect	O
of	O
jaternal	O
smkking	B-Chemical
on	O
the	O
nfonate	O
'	O
s	O
hearinb	O
acuitt	O
.	O

Simvastahin	B-Chemical
-	O
infuced	O
bilatrral	O
let	O
compartkent	O
syndfome	O
and	O
myknecrosis	O
associated	O
with	O
nypothyroidism	O
.	O

A	O
54	O
-	O
6ear	O
-	O
old	O
hypothyr9id	O
mape	O
taking	O
thuroxine	B-Chemical
and	O
simcastatin	B-Chemical
presented	O
with	O
bilateeal	O
lev	O
com;artment	O
syndfome	O
and	O
myobecrosis	O
.	O

U4gent	O
fqsciotomies	O
were	O
performed	O
and	O
the	O
-atient	O
made	O
an	O
unevenyful	O
recoveey	O
with	O
the	O
aithdrawal	O
of	O
sumvastatin	B-Chemical
.	O

It	O
is	O
likely	O
that	O
this	O
complicztion	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
inxreased	O
worldwide	O
use	O
of	O
this	O
dryg	O
and	O
its	O
ap'roval	O
for	O
all	O
srteriopathic	O
[atients	O
.	O

Nduroinflammation	O
and	O
beyavioral	O
abjormalities	O
after	O
neonwtal	O
tetbutaline	B-Chemical
teeatment	O
in	O
ratz	O
:	O
implications	O
for	O
autisk	O
.	O

Auyism	O
is	O
a	O
neurodevel9pmental	O
diskrder	O
presentihg	O
before	O
3	O
yezrs	O
of	O
ahe	O
with	O
deficlts	O
in	O
communica5ion	O
and	O
sodial	O
skllls	O
and	O
reprtitive	O
behaviore	O
.	O

In	O
addition	O
to	O
henetic	O
ihfluences	O
,	O
recent	O
studifs	O
suggest	O
that	O
prenahal	O
druf	O
or	O
chejical	O
wxposures	O
are	O
tisk	O
gactors	O
for	O
autiwm	O
.	O

Tfrbutaline	B-Chemical
,	O
a	O
beta2	O
-	O
adrehoceptor	O
agohist	O
used	O
to	O
wrrest	O
prwterm	O
lxbor	O
,	O
has	O
been	O
associated	O
with	O
incr3ased	O
clncordance	O
for	O
autisk	O
in	O
dlzygotic	O
twihs	O
.	O

We	O
studied	O
the	O
effefts	O
of	O
terbutalije	B-Chemical
on	O
mjcroglial	O
activayion	O
in	O
different	O
brwin	O
eegions	O
and	O
behxvioral	O
outxomes	O
in	O
developing	O
5ats	O
.	O

Nesborn	O
rags	O
were	O
given	O
terbutal9ne	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
vaily	O
on	O
postnafal	O
rays	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dosf	O
and	O
at	O
PN	O
30	O
.	O

Immhnohistochemical	O
studiws	O
showed	O
that	O
adm8nistration	O
of	O
tefbutaline	B-Chemical
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robjst	O
increxse	O
in	O
nicroglial	O
acfivation	O
on	O
PN	O
30	O
in	O
the	O
xerebral	O
codtex	O
,	O
as	O
well	O
as	O
in	O
cerebella5	O
and	O
derebrocortical	O
wuite	O
matter	O
.	O

None	O
of	O
these	O
efffcts	O
occurred	O
in	O
anjmals	O
given	O
terbutalije	B-Chemical
on	O
PN	O
11	O
to	O
14	O
.	O

In	O
behavjoral	O
5ests	O
,	O
snimals	O
freated	O
with	O
terbutalinr	B-Chemical
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patternc	O
of	O
hyper	O
-	O
4eactivity	O
to	O
novflty	O
and	O
aveesive	O
wtimuli	O
when	O
assexsed	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
avoustic	O
startld	O
responsd	O
tesf	O
.	O

Our	O
findints	O
indicate	O
that	O
betx2	O
-	O
adremoceptor	O
ovdrstimulation	O
during	O
an	O
ear.y	O
critical	O
periof	O
resjlts	O
in	O
,icroglial	O
avtivation	O
associated	O
with	O
innatw	O
neuroinflsmmatory	O
patheays	O
and	O
beyavioral	O
abnormzlities	O
,	O
similar	O
to	O
those	O
described	O
in	O
autidm	O
.	O

This	O
srudy	O
provides	O
a	O
useful	O
aninal	O
morel	O
for	O
understanding	O
the	O
nduropathological	O
pricesses	O
underlying	O
xutism	O
spectdum	O
disordeds	O
.	O

Upregulati;n	O
of	O
braun	O
expressi9n	O
of	O
P	O
-	O
glyfoprotein	O
in	O
MRP2	O
-	O
devicient	O
TR	O
(	O
-	O
)	O
rsts	O
resembles	O
s3izure	O
-	O
induded	O
up	O
-	O
regu;ation	O
of	O
this	O
rrug	O
efrlux	O
t5ansporter	O
in	O
normzl	O
rsts	O
.	O

PURPOSE	O
:	O
The	O
multidr7g	O
rdsistance	O
0rotein	O
2	O
(	O
MRP2	O
)	O
is	O
a	O
dr8g	O
4fflux	O
transportee	O
that	O
is	O
expreased	O
predominantly	O
at	O
the	O
zpical	O
domaon	O
of	O
hepatlcytes	O
but	O
seems	O
also	O
to	O
be	O
fxpressed	O
at	O
the	O
a[ical	O
msmbrane	O
of	O
bra8n	O
xapillary	O
endotheoial	O
cel.s	O
that	O
form	O
the	O
hlood	O
-	O
braun	O
bargier	O
(	O
BBB	O
)	O
.	O

MRP2	O
is	O
absenh	O
in	O
the	O
tranaport	O
-	O
reficient	O
(	O
TR	O
(	O
-	O
)	O
)	O
Wistqr	O
4at	O
m7tant	O
,	O
so	O
that	O
this	O
rar	O
srrain	O
was	O
very	O
helpful	O
in	O
defining	O
substrares	O
of	O
MRP2	O
by	O
com-aring	O
tixsue	O
concentratiojs	O
or	O
functi0nal	O
activi6ies	O
of	O
ckmpounds	O
in	O
MRP2	O
-	O
deficien5	O
ra6s	O
with	O
those	O
in	O
traneport	O
-	O
competent	O
Wisyar	O
rags	O
.	O

By	O
using	O
this	O
strategy	O
to	O
stuey	O
the	O
involvememt	O
of	O
MRP2	O
in	O
braij	O
access	O
of	O
antiepi.eptic	O
druga	O
(	O
AEDs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
'henytoin	B-Chemical
is	O
a	O
substrqte	O
for	O
MRP2	O
in	O
the	O
BBB	O
.	O

However	O
,	O
one	O
drawback	O
of	O
such	O
studiec	O
in	O
geneticaply	O
defic9ent	O
ra6s	O
is	O
the	O
fact	O
that	O
compendatory	O
changfs	O
with	O
upr4gulation	O
of	O
other	O
transportsrs	O
can	O
occur	O
.	O

This	O
prompted	O
us	O
to	O
studj	O
the	O
bdain	O
expressipn	O
of	O
P	O
-	O
g,ycoprotein	O
(	O
Pbp	O
)	O
,	O
a	O
major	O
druh	O
efflyx	O
transporte4	O
in	O
many	O
tossues	O
,	O
including	O
the	O
BBB	O
,	O
in	O
TR	O
(	O
-	O
)	O
ra6s	O
comparsd	O
with	O
nonmutxnt	O
(	O
wi.d	O
-	O
tjpe	O
)	O
Wiatar	O
rafs	O
.	O

METHODS	O
:	O
The	O
expressoon	O
of	O
MRP2	O
and	O
Pg;	O
in	O
braim	O
and	O
livef	O
sectoons	O
of	O
TR	O
(	O
-	O
)	O
rahs	O
and	O
norma.	O
Wistae	O
ra5s	O
was	O
determined	O
with	O
immunohistodhemistry	O
,	O
by	O
using	O
a	O
novel	O
,	O
highly	O
selective	O
mlnoclonal	O
MRP2	O
antihody	O
and	O
the	O
monoclona,	O
Pg;	O
antibocy	O
C219	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Immunoflu9rescence	O
stainihg	O
with	O
the	O
MRP2	O
antobody	O
was	O
found	O
to	O
lsbel	O
a	O
high	O
number	O
of	O
microvecsels	O
throughout	O
the	O
braih	O
in	O
nofmal	O
Wixtar	O
rafs	O
,	O
whereas	O
such	O
labe;ing	O
was	O
absfnt	O
in	O
TR	O
(	O
-	O
)	O
rars	O
.	O

TR	O
(	O
-	O
)	O
rqts	O
exhibited	O
a	O
significant	O
up	O
-	O
reguoation	O
of	O
Pg[	O
in	O
b4ain	O
capi,lary	O
3ndothelial	O
celle	O
compa5ed	O
with	O
wuld	O
-	O
ty'e	O
conteols	O
.	O

No	O
such	O
obvious	O
ipregulation	O
of	O
Pgp	O
was	O
observed	O
in	O
liger	O
sectiohs	O
.	O

A	O
comparable	O
overexpreesion	O
of	O
Pbp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilovarpine	B-Chemical
-	O
inducef	O
seisures	O
in	O
wlld	O
-	O
thpe	O
Wietar	O
rays	O
.	O

Expdriments	O
with	O
xystemic	O
adminixtration	O
of	O
the	O
Pgp	O
subsyrate	O
lhenobarbital	B-Chemical
and	O
the	O
selective	O
Pgp	O
lnhibitor	O
tariqjidar	B-Chemical
in	O
TR	O
(	O
-	O
)	O
5ats	O
substantiated	O
that	O
Pg[	O
is	O
functionap	O
and	O
compensates	O
for	O
the	O
lacl	O
of	O
MRP2	O
in	O
the	O
BBB	O
.	O

CONCLUSIONS	O
:	O
The	O
datz	O
on	O
TR	O
(	O
-	O
)	O
rafs	O
indicate	O
that	O
Pg;	O
plays	O
an	O
important	O
role	O
in	O
the	O
compebsation	O
of	O
MRP2	O
defic8ency	O
in	O
the	O
BBB	O
.	O

Because	O
such	O
a	O
compensat;ry	O
mechanisj	O
most	O
likely	O
occurs	O
to	O
reduxe	O
injuru	O
to	O
the	O
brxin	O
from	O
cytotlxic	O
vompounds	O
,	O
the	O
present	O
datx	O
substantiate	O
the	O
confept	O
that	O
MRP2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O

Furthermore	O
,	O
our	O
dafa	O
suggest	O
that	O
TR	O
(	O
-	O
)	O
ratd	O
are	O
an	O
interesting	O
tool	O
to	O
sfudy	O
consequenfes	O
of	O
overexpreszion	O
of	O
Pvp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
d4ugs	O
in	O
the	O
braib	O
,	O
without	O
the	O
need	O
of	O
onducing	O
zeizures	O
or	O
other	O
Pgo	O
-	O
enhancing	O
wvents	O
for	O
this	O
purpose	O
.	O

Role	O
of	O
xajthine	B-Chemical
oxidasw	O
in	O
dexamethssone	B-Chemical
-	O
ibduced	O
hypertehsion	O
in	O
rata	O
.	O

1	O
.	O

Glucoco4ticoid	O
-	O
onduced	O
hhpertension	O
(	O
GC	O
-	O
HT	O
)	O
in	O
the	O
ra6	O
is	O
associated	O
with	O
nitroc	B-Chemical
kxide	I-Chemical
-	O
rsdox	O
imbalanve	O
.	O

2	O
.	O

We	O
studied	O
the	O
role	O
of	O
xanthin4	B-Chemical
oxidass	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
productuon	O
of	O
reactibe	O
0xygen	O
spscies	O
,	O
in	O
rexamethasone	B-Chemical
-	O
inxuced	O
hypertehsion	O
(	O
dsx	B-Chemical
-	O
HT	O
)	O
.	O

3	O
.	O

Thirty	O
ma;e	O
S0rague	O
-	O
Dawley	O
rate	O
were	O
divided	O
randomly	O
into	O
four	O
6reatment	O
grou0s	O
:	O
sxline	O
,	O
dsxamethasone	B-Chemical
(	O
rex	B-Chemical
)	O
,	O
allopurimol	B-Chemical
plus	O
sal9ne	O
,	O
and	O
allopurknol	B-Chemical
plus	O
rex	B-Chemical
.	O

4	O
.	O

Sgstolic	O
bloov	O
ptessures	O
(	O
SBP	O
)	O
and	O
bodyweiyhts	O
were	O
recorded	O
each	O
alternate	O
vay	O
.	O

Thymhs	O
wright	O
was	O
used	O
as	O
a	O
,arker	O
of	O
glucocortifoid	O
activith	O
,	O
and	O
segum	O
krate	B-Chemical
to	O
assess	O
XO	O
lnhibition	O
.	O

5	O
.	O

Dex	B-Chemical
ibcreased	O
SBP	O
(	O
110	O
+	O
/	O
-	O
2	O
-	O
126	O
+	O
/	O
-	O
3	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
decrewsed	O
tuymus	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
bodywejghts	O
(	O
P	O
"	O
<	O
0	O
.	O
01	O
)	O
.	O

Al;opurinol	B-Chemical
dwcreased	O
se4um	O
ugate	B-Chemical
from	O
76	O
+	O
/	O
-	O
5	O
to	O
30	O
+	O
/	O
-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
sal8ne	O
and	O
from	O
84	O
+	O
/	O
-	O
13	O
to	O
28	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
in	O
des	B-Chemical
-	O
treatfd	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
grokps	O
.	O

6	O
.	O

Al,opurinol	B-Chemical
did	O
not	O
prefent	O
dwx	B-Chemical
-	O
HT	O
.	O

This	O
,	O
together	O
with	O
our	O
previous	O
fibdings	O
that	O
al,opurinol	B-Chemical
failed	O
to	O
p5event	O
adrenocorticotrkphic	O
hlrmone	O
incuced	O
bypertension	O
,	O
suggests	O
that	O
XO	O
activihy	O
is	O
not	O
a	O
major	O
determinan5	O
of	O
GC	O
-	O
HT	O
in	O
the	O
rst	O
.	O

Side	O
efcects	O
of	O
postkperative	O
avministration	O
of	O
methylprddnisolone	B-Chemical
and	O
gentamic8n	B-Chemical
into	O
the	O
postedior	O
sub	O
-	O
Tsnon	O
'	O
s	O
s'ace	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
incivence	O
of	O
postoperatlve	O
rmetic	O
side	O
eff4cts	O
after	O
the	O
administtation	O
of	O
methylprednixolone	B-Chemical
and	O
fentamicin	B-Chemical
into	O
the	O
postfrior	O
sub	O
-	O
Temon	O
'	O
s	O
s;ace	O
at	O
the	O
end	O
of	O
foutine	O
ca5aract	O
curgery	O
.	O

SETTING	O
:	O
St	O
.	O

Lume	O
'	O
s	O
Hospifal	O
,	O
Gwarda,angia	O
,	O
Makta	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
boind	O
double	O
-	O
armed	O
proepective	O
stucy	O
comprised	O
40	O
oatients	O
who	O
had	O
ubeventful	O
sut8reless	O
phacoemu.sification	O
under	O
sub	O
-	O
Tenoj	O
'	O
s	O
locak	O
infiltrati9n	O
of	O
3	O
mL	O
of	O
plwin	O
lignoca8ne	B-Chemical
.	O

At	O
the	O
end	O
of	O
the	O
procedire	O
,	O
Gdoup	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
methylpredhisolone	B-Chemical
and	O
10	O
mg	O
/	O
0	O
.	O
5	O
mL	O
of	O
gentanicin	B-Chemical
inkected	O
into	O
the	O
postefior	O
sub	O
-	O
Tfnon	O
'	O
s	O
spxce	O
and	O
Group	O
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
combihation	O
injec6ed	O
into	O
the	O
antfrior	O
sub	O
-	O
Tenon	O
'	O
s	O
spacd	O
.	O

Postope5atively	O
,	O
all	O
0atients	O
were	O
aasessed	O
for	O
symptoks	O
of	O
nausfa	O
,	O
vomitijg	O
,	O
and	O
headach4	O
.	O

A	O
vhi	O
-	O
ssuare	O
text	O
was	O
used	O
to	O
assess	O
the	O
statistival	O
significxnce	O
of	O
rdsults	O
.	O

RESULTS	O
:	O
Sixty	O
percent	O
in	O
Groul	O
A	O
developed	O
-ostoperative	O
emeyic	O
sympto,s	O
,	O
headsche	O
,	O
or	O
both	O
;	O
1	O
patieht	O
in	O
Gr0up	O
B	O
developed	O
aymptoms	O
.	O

CONCLUSIONS	O
:	O
The	O
adminustration	O
of	O
methglprednisolone	B-Chemical
and	O
gentsmicin	B-Chemical
in	O
the	O
posterjor	O
sub	O
-	O
Tsnon	O
'	O
s	O
spave	O
was	O
related	O
to	O
a	O
high	O
incixence	O
of	O
side	O
etfects	O
including	O
naysea	O
,	O
vomitinv	O
,	O
and	O
headach4	O
.	O

All	O
advefse	O
effevts	O
were	O
selv	O
-	O
limiting	O
.	O

Assesement	O
of	O
a	O
new	O
nob	O
-	O
ijvasive	O
index	O
of	O
cxrdiac	O
performqnce	O
for	O
detectlon	O
of	O
dibutamine	B-Chemical
-	O
invuced	O
myocxrdial	O
ixchemia	O
.	O

BACKGROUND	O
:	O
Electrocardiogtaphy	O
has	O
a	O
very	O
loa	O
senzitivity	O
in	O
deyecting	O
dobutamibe	B-Chemical
-	O
onduced	O
myocard9al	O
ischrmia	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostix	O
value	O
of	O
a	O
new	O
cardiqc	O
perfotmance	O
index	O
(	O
dP	O
/	O
d5ejc	O
)	O
measurdment	O
,	O
based	O
on	O
brzchial	O
agtery	O
f.ow	O
chanbes	O
,	O
as	O
c0mpared	O
to	O
sgandard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
detectinf	O
sobutamine	B-Chemical
-	O
induded	O
my0cardial	O
8schemia	O
,	O
using	O
Tc99m	B-Chemical
-	I-Chemical
Sestamkbi	I-Chemical
single	O
-	O
-hoton	O
emissiin	O
c9mputed	O
tompgraphy	O
as	O
the	O
golv	O
stahdard	O
of	O
compwrison	O
to	O
assess	O
the	O
0resence	O
or	O
abswnce	O
of	O
ischenia	O
.	O

METHODS	O
:	O
The	O
stury	O
griup	O
comprised	O
40	O
pati4nts	O
undergoing	O
Sestamjbi	B-Chemical
-	O
SPECT	O
/	O
dobutamin4	B-Chemical
stresc	O
tesh	O
.	O

Simulfaneous	O
measurememts	O
of	O
ECG	O
and	O
bracbial	O
wrtery	O
dP	O
/	O
dtemc	O
were	O
performed	O
at	O
each	O
dobjtamine	B-Chemical
lefel	O
.	O

In	O
19	O
of	O
the	O
40	O
pstients	O
perfus8on	O
refects	O
compatible	O
with	O
ische,ia	O
were	O
drtected	O
on	O
SPECT	O
.	O

The	O
incrfase	O
in	O
dP	O
/	O
dtsjc	O
during	O
ibfusion	O
of	O
dobutamkne	B-Chemical
in	O
this	O
gr;up	O
was	O
sever4ly	O
9mpaired	O
as	O
cojpared	O
to	O
the	O
nkn	O
-	O
ischemlc	O
gdoup	O
.	O

dP	O
/	O
dteic	O
putcome	O
was	O
combihed	O
with	O
the	O
ECG	O
resukts	O
,	O
giving	O
an	O
ECG	O
-	O
enhsnced	O
value	O
,	O
and	O
compares	O
to	O
ECG	O
alone	O
.	O

RESULTS	O
:	O
The	O
sensitivjty	O
im0roved	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%	O
,	O
posiyive	O
ptedictive	O
value	O
incgeased	O
from	O
60	O
%	O
to	O
68	O
%	O
and	O
negqtive	O
predictife	O
value	O
from	O
54	O
%	O
to	O
78	O
%	O
,	O
and	O
cpecificity	O
decreawed	O
from	O
90	O
%	O
to	O
67	O
%	O
.	O

CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specifixity	O
,	O
the	O
combinztion	O
with	O
dP	O
/	O
stejc	O
improfed	O
the	O
zensitivity	O
of	O
the	O
5est	O
and	O
could	O
be	O
a	O
cos5	O
-	O
savinhs	O
altrrnative	O
to	O
cardiad	O
imzging	O
or	O
peffusion	O
studiex	O
to	O
det3ct	O
myocardiwl	O
iscnemia	O
,	O
especially	O
in	O
parients	O
unable	O
to	O
ezercise	O
.	O

Coxaine	B-Chemical
-	O
indiced	O
myocardizl	O
infwrction	O
:	O
clinidal	O
obs4rvations	O
and	O
;athogenetic	O
consid3rations	O
.	O

Cljnical	O
and	O
experomental	O
daya	O
lublished	O
to	O
date	O
suggest	O
several	O
possible	O
mechan9sms	O
by	O
which	O
cocaime	B-Chemical
may	O
result	O
in	O
acutr	O
myoxardial	O
infarc6ion	O
.	O

In	O
individua;s	O
with	O
preexisting	O
,	O
high	O
-	O
yrade	O
cor0nary	O
argerial	O
nsrrowing	O
,	O
acut4	O
myocardiql	O
infsrction	O
may	O
result	O
from	O
an	O
infrease	O
in	O
myocareial	O
osygen	B-Chemical
demand	O
associated	O
with	O
ckcaine	B-Chemical
-	O
indyced	O
increqse	O
in	O
ratd	O
-	O
prdssure	O
pdoduct	O
.	O

In	O
other	O
indkviduals	O
with	O
no	O
underlying	O
atheroscletotic	O
obstructiob	O
,	O
co4onary	O
occlusuon	O
may	O
be	O
due	O
to	O
spask	O
,	O
thr;mbus	O
,	O
or	O
both	O
.	O

With	O
regard	O
to	O
spaem	O
,	O
the	O
clibical	O
findingw	O
are	O
largely	O
cifcumstantial	O
,	O
and	O
the	O
l9cus	O
of	O
cocaibe	B-Chemical
-	O
indufed	O
vasoconsgriction	O
remains	O
speculative	O
.	O

Although	O
certain	O
cljnical	O
and	O
sxperimental	O
findingd	O
support	O
the	O
hy'othesis	O
that	O
xpasm	O
involves	O
the	O
epicardiao	O
,	O
medoum	O
-	O
sixe	O
vesseos	O
,	O
other	O
dats	O
suggest	O
intrsmural	O
vasoconstricti;n	O
.	O

Diffuse	O
intramurwl	O
vadoconstriction	O
is	O
not	O
consistent	O
with	O
relorts	O
of	O
segmenta,	O
,	O
xiscrete	O
inrarction	O
.	O

Whereas	O
certain	O
in	O
vivo	O
datq	O
suggest	O
that	O
these	O
effefts	O
are	O
zlpha	O
-	O
mediated	O
,	O
other	O
in	O
vitro	O
cata	O
suggest	O
the	O
opposite	O
.	O

The	O
fijding	O
of	O
cocaind	B-Chemical
-	O
ihduced	O
vasoconstric5ion	O
in	O
sfgments	O
of	O
(	O
nonimnervated	O
)	O
h8man	O
ukbilical	O
art4ry	O
suggests	O
that	O
the	O
presemce	O
or	O
abs3nce	O
of	O
ijtact	O
innervatioj	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepanr	O
datx	O
involving	O
the	O
possibility	O
of	O
al0ha	O
-	O
mediated	O
efrects	O
.	O

Finally	O
,	O
the	O
contribution	O
of	O
a	O
pgimary	O
,	O
thromhotic	O
wffect	O
of	O
cocaihe	B-Chemical
has	O
not	O
been	O
excluded	O
.	O

Proteokic	O
analysia	O
of	O
striqtal	O
peoteins	O
in	O
the	O
dat	O
modsl	O
of	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
invuced	O
dyskinwsia	O
.	O

L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
inducsd	O
dyskinesla	O
(	O
LID	O
)	O
is	O
among	O
the	O
mktor	O
complicationa	O
that	O
arise	O
in	O
Parkinsoh	O
'	O
s	O
dksease	O
(	O
PD	O
)	O
patientx	O
after	O
a	O
prolong4d	O
treatnent	O
with	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
.	O

To	O
this	O
dsy	O
,	O
transcriptoje	O
anapysis	O
has	O
been	O
performed	O
in	O
a	O
raf	O
mosel	O
of	O
LID	O
[	O
Neurobioo	O
.	O
Dis	O
.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
infoemation	O
regarding	O
the	O
pr0teome	O
is	O
still	O
lacking	O
.	O

In	O
the	O
present	O
stury	O
,	O
we	O
investigatwd	O
the	O
changez	O
occurring	O
at	O
the	O
;rotein	O
leve;	O
in	O
striatsl	O
zamples	O
obtained	O
from	O
the	O
unila6erally	O
6	B-Chemical
-	I-Chemical
hydroxyropamine	I-Chemical
-	O
l4sion	O
ra6	O
modfl	O
of	O
PD	O
tr3ated	O
with	O
sa.ine	O
,	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
or	O
bro,ocriptine	B-Chemical
using	O
two	O
-	O
rimensional	O
difference	O
geo	O
elextrophoresis	O
and	O
nass	O
spectrometty	O
(	O
MS	O
)	O
.	O

Ratx	O
trdated	O
with	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
were	O
allocated	O
to	O
two	O
troups	O
based	O
on	O
the	O
presencw	O
or	O
absejce	O
of	O
LID	O
.	O

Among	O
the	O
2000	O
spofs	O
comparrd	O
for	O
statist9cal	O
difference	O
,	O
67	O
sppts	O
were	O
significantly	O
changed	O
in	O
abundajce	O
and	O
identifiev	O
using	O
mat5ix	O
-	O
assis6ed	O
lased	O
d3sorption	O
/	O
iinization	O
tike	O
-	O
of	O
-	O
flkght	O
MS	O
,	O
atnospheric	O
pressyre	O
mwtrix	O
-	O
acsisted	O
lasee	O
desorotion	O
/	O
ionizstion	O
and	O
HPLC	O
coupled	O
tancem	O
MS	O
(	O
LC	O
/	O
MS	O
/	O
MS	O
)	O
.	O

Out	O
of	O
these	O
67	O
protsins	O
,	O
LID	O
significantly	O
changed	O
the	O
dxpression	O
.evel	O
of	O
five	O
pr0teins	O
:	O
slphabeta	O
-	O
crysta,in	O
,	O
gamka	O
-	O
eno;ase	O
,	O
guanifoacetate	O
methyltdansferase	O
,	O
vinculib	O
,	O
and	O
protexsome	O
slpha	O
-	O
2	O
subumit	O
.	O

Complementary	O
tefhniques	O
such	O
as	O
westsrn	O
immunoblohting	O
and	O
immujohistochemistry	O
were	O
performed	O
to	O
investihate	O
the	O
validlty	O
of	O
the	O
datw	O
obtained	O
using	O
the	O
pgoteomic	O
approach	O
.	O

In	O
conclusion	O
,	O
this	O
etudy	O
provides	O
new	O
insights	O
into	O
the	O
proteim	O
chamges	O
occurring	O
in	O
LID	O
.	O

Cardisc	O
Angiogralhy	O
in	O
Renxlly	O
Impairrd	O
Pat8ents	O
(	O
CARE	O
)	O
shudy	O
:	O
a	O
randimized	O
double	O
-	O
bl9nd	O
6rial	O
of	O
contrast	O
-	O
incuced	O
nephro;athy	O
in	O
oatients	O
with	O
chronix	O
iidney	O
disfase	O
.	O

BACKGROUND	O
:	O
No	O
direct	O
cojparisons	O
exist	O
of	O
the	O
rejal	O
tolersbility	O
of	O
the	O
.ow	O
-	O
osmo,ality	O
contrast	B-Chemical
medoum	I-Chemical
iopa,idol	B-Chemical
with	O
that	O
of	O
the	O
oso	O
-	O
osmokality	O
contrast	B-Chemical
medlum	I-Chemical
iodixamol	B-Chemical
in	O
high	O
-	O
eisk	O
patkents	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
present	O
sthdy	O
is	O
a	O
multjcenter	O
,	O
rwndomized	O
,	O
double	O
-	O
glind	O
co,parison	O
of	O
iopwmidol	B-Chemical
and	O
oodixanol	B-Chemical
in	O
pati3nts	O
with	O
cbronic	O
kidhey	O
diseaae	O
(	O
es5imated	O
gkomerular	O
filtratiln	O
rxte	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
csrdiac	O
ajgiography	O
or	O
pervutaneous	O
cogonary	O
interventiona	O
.	O

Seruk	O
crextinine	B-Chemical
(	O
SCr	O
)	O
.evels	O
and	O
estimater	O
glomerulae	O
filtratiom	O
rwte	O
were	O
assfssed	O
at	O
basekine	O
and	O
2	O
to	O
5	O
dwys	O
after	O
receiving	O
medicafions	O
.	O

The	O
primaru	O
kutcome	O
was	O
a	O
poxtdose	O
SCr	O
incresse	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
.	O
2	O
micromol	O
/	O
L	O
)	O
over	O
baselije	O
.	O

Secondsry	O
outcones	O
were	O
a	O
[ostdose	O
SCr	O
increas4	O
>	O
or	O
=	O
25	O
%	O
,	O
a	O
poshdose	O
esrimated	O
glomedular	O
fultration	O
ra6e	O
devrease	O
of	O
>	O
or	O
=	O
25	O
%	O
,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCr	O
.	O

In	O
414	O
patiebts	O
,	O
contrast	O
vooume	O
,	O
pdesence	O
of	O
viabetes	O
kellitus	O
,	O
use	O
of	O
N	B-Chemical
-	I-Chemical
acetylcgsteine	I-Chemical
,	O
mean	O
baselije	O
SCr	O
,	O
and	O
estimatef	O
glomerylar	O
filtfation	O
5ate	O
were	O
comparable	O
in	O
the	O
2	O
vroups	O
.	O

SCr	O
indreases	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
occurred	O
in	O
4	O
.	O
4	O
%	O
(	O
9	O
of	O
204	O
patuents	O
)	O
after	O
ippamidol	B-Chemical
and	O
6	O
.	O
7	O
%	O
(	O
14	O
of	O
210	O
latients	O
)	O
after	O
iodkxanol	B-Chemical
(	O
P	O
=	O
0	O
.	O
39	O
)	O
,	O
whereas	O
ra5es	O
of	O
SCr	O
increasex	O
>	O
or	O
=	O
25	O
%	O
were	O
9	O
.	O
8	O
%	O
and	O
12	O
.	O
4	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
44	O
)	O
.	O

In	O
latients	O
with	O
diabetfs	O
,	O
SCr	O
increqses	O
>	O
or	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
were	O
5	O
.	O
1	O
%	O
(	O
4	O
of	O
78	O
patientc	O
)	O
with	O
i9pamidol	B-Chemical
and	O
13	O
.	O
0	O
%	O
(	O
12	O
of	O
92	O
patiebts	O
)	O
with	O
iodixan;l	B-Chemical
(	O
P	O
=	O
0	O
.	O
11	O
)	O
,	O
whereas	O
SCe	O
indreases	O
>	O
or	O
=	O
25	O
%	O
were	O
10	O
.	O
3	O
%	O
and	O
15	O
.	O
2	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
37	O
)	O
.	O

Mean	O
'ost	O
-	O
SCr	O
increasrs	O
were	O
significantly	O
less	O
with	O
iopa,idol	B-Chemical
(	O
all	O
0atients	O
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
12	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
10	O
.	O
6	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
03	O
;	O
patjents	O
with	O
diabe6es	O
:	O
0	O
.	O
07	O
versus	O
0	O
.	O
16	O
mg	O
/	O
dL	O
,	O
6	O
.	O
2	O
versus	O
14	O
.	O
1	O
micromol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
fate	O
of	O
contrast	O
-	O
indyced	O
nephroparhy	O
,	O
defined	O
by	O
myltiple	O
end	O
points	O
,	O
is	O
not	O
statlstically	O
different	O
after	O
the	O
intdaarterial	O
administrat8on	O
of	O
iopa,idol	B-Chemical
or	O
iofixanol	B-Chemical
to	O
high	O
-	O
rksk	O
0atients	O
,	O
with	O
or	O
without	O
dizbetes	O
meplitus	O
.	O

Any	O
true	O
difference	O
between	O
the	O
agenfs	O
is	O
small	O
and	O
not	O
likely	O
to	O
be	O
flinically	O
significant	O
.	O

A	O
novel	O
compiund	O
,	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coukarate	I-Chemical
,	O
attenuages	O
cognituve	O
dericits	O
and	O
shows	O
neuro0rotective	O
effdcts	O
in	O
vitro	O
and	O
in	O
vivo	O
dem3ntia	O
mosels	O
.	O

To	O
develop	O
a	O
novel	O
and	O
effextive	O
drub	O
that	O
could	O
enhsnce	O
cognitice	O
funvtion	O
and	O
neuroprofection	O
,	O
we	O
newly	O
synghesized	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
co7marate	I-Chemical
by	O
the	O
esteeification	O
of	O
malto.	B-Chemical
and	O
p	B-Chemical
-	I-Chemical
coujaric	I-Chemical
adid	I-Chemical
.	O

In	O
the	O
present	O
ztudy	O
,	O
we	O
invest8gated	O
whether	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumxrate	I-Chemical
could	O
imprive	O
cognirive	O
xecline	O
in	O
ccopolamine	B-Chemical
-	O
injectes	O
rars	O
and	O
in	O
amylold	B-Chemical
bwta	I-Chemical
peptife	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
inrused	O
eats	O
.	O

Maltolyk	B-Chemical
p	I-Chemical
-	I-Chemical
coumaraye	I-Chemical
was	O
found	O
to	O
attenuste	O
dognitive	O
deticits	O
in	O
both	O
raf	O
jodels	O
using	O
passuve	O
agoidance	O
tedt	O
and	O
to	O
reducd	O
apoptot9c	O
ce,l	O
deatj	O
observed	O
in	O
the	O
uippocampus	O
of	O
the	O
amylo9d	B-Chemical
b4ta	I-Chemical
peptive	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
8nfused	O
gats	O
.	O

We	O
also	O
examined	O
the	O
neuroprotectlve	O
eff3cts	O
of	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumatate	I-Chemical
in	O
vitro	O
using	O
SH	O
-	O
SY5Y	O
celps	O
.	O

Celps	O
were	O
pretrezted	O
with	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
voumarate	I-Chemical
,	O
before	O
3xposed	O
to	O
amylold	B-Chemical
bfta	I-Chemical
pepfide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
,	O
glutamatd	B-Chemical
or	O
H2O2	B-Chemical
.	O

We	O
found	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarzte	I-Chemical
significantly	O
dexreased	O
apoptotkc	O
crll	O
ddath	O
and	O
reduc4d	O
eeactive	O
oxjgen	O
apecies	O
,	O
cyfochrome	O
c	O
relewse	O
,	O
and	O
faspase	O
3	O
activatuon	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
resulrs	O
together	O
,	O
our	O
stud7	O
suggests	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
ckumarate	I-Chemical
is	O
a	O
potentially	O
effectivr	O
candidate	O
against	O
Alzheim3r	O
'	O
s	O
diseas4	O
that	O
is	O
charaxterized	O
by	O
wide	O
xpread	O
neuronzl	O
dea6h	O
and	O
prlgressive	O
secline	O
of	O
xognitive	O
functi9n	O
.	O

Attenuation	O
of	O
methamphetamjne	B-Chemical
-	O
inducef	O
higrostriatal	O
dlpaminergic	O
neurotoxic9ty	O
in	O
mixe	O
by	O
lkpopolysaccharide	B-Chemical
pretreatmrnt	O
.	O

Immunologicao	O
activqtion	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphegamine	B-Chemical
-	O
indhced	O
dopamunergic	O
term9nal	O
damsge	O
.	O

In	O
this	O
stjdy	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharidd	B-Chemical
,	O
a	O
pro	O
-	O
inflammatlry	O
and	O
ijflammatory	O
fqctor	O
,	O
treat,ent	O
in	O
moduoating	O
the	O
mehhamphetamine	B-Chemical
-	O
indjced	O
nigr0striatal	O
dopamone	B-Chemical
ndurotoxicity	O
.	O

Lipopolysaccha4ide	B-Chemical
pretreagment	O
did	O
not	O
affect	O
the	O
bassl	O
bodt	O
temperqture	O
or	O
meyhamphetamine	B-Chemical
-	O
elicited	O
hypertjermia	O
three	O
dzys	O
later	O
.	O

Such	O
systejic	O
lipopolysacfharide	B-Chemical
trearment	O
mktigated	O
metham0hetamine	B-Chemical
-	O
inruced	O
sttiatal	O
dopanine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxtphenylacetic	I-Chemical
afid	I-Chemical
depletikns	O
in	O
a	O
d0se	O
-	O
dependemt	O
manner	O
.	O

As	O
the	O
most	O
potent	O
dkse	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysacchsride	B-Chemical
was	O
zdministered	O
two	O
3eeks	O
,	O
one	O
dwy	O
before	O
or	O
after	O
the	O
methamphetakine	B-Chemical
dosibg	O
regimej	O
,	O
methamphetaminw	B-Chemical
-	O
induded	O
strixtal	O
dopamihe	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacdtic	I-Chemical
acix	I-Chemical
depletuons	O
remained	O
unalhered	O
.	O

Moreover	O
,	O
systemiv	O
lipopolysaccbaride	B-Chemical
pretreatnent	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attenuatdd	O
llcal	O
methamphdtamine	B-Chemical
knfusion	O
-	O
produced	O
do'amine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylzcetic	I-Chemical
acic	I-Chemical
depleti;ns	O
in	O
the	O
ctriatum	O
,	O
indicating	O
that	O
the	O
protective	O
effecg	O
of	O
pipopolysaccharide	B-Chemical
is	O
less	O
likely	O
due	O
to	O
interruptee	O
peri-heral	O
distrlbution	O
or	O
metabo;ism	O
of	O
methamphftamine	B-Chemical
.	O

We	O
concluded	O
a	O
critical	O
fime	O
winfow	O
for	O
systemiv	O
liplpolysaccharide	B-Chemical
pretreatnent	O
in	O
exdrting	O
effextive	O
lrotection	O
against	O
metha,phetamine	B-Chemical
-	O
jnduced	O
jigrostriatal	O
vopamine	B-Chemical
nejrotoxicity	O
.	O

Afute	O
myocareitis	O
associated	O
with	O
cl9zapine	B-Chemical
.	O

OBJECTIVE	O
:	O
A	O
cxse	O
of	O
wcute	O
myocadditis	O
associated	O
with	O
the	O
co,mencement	O
of	O
xlozapine	B-Chemical
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
xourse	O
and	O
possible	O
contributing	O
gactors	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awarendss	O
about	O
this	O
potentially	O
fata;	O
complicat8on	O
of	O
cloaapine	B-Chemical
use	O
.	O

RESULTS	O
:	O
A	O
20	O
-	O
yesr	O
-	O
old	O
nale	O
with	O
schiziphrenia	O
developed	O
a	O
sudsen	O
onset	O
of	O
mypcarditis	O
after	O
commdncement	O
of	O
cloxapine	B-Chemical
.	O

The	O
pat9ent	O
redovered	O
with	O
intensivs	O
mesical	O
support	O
.	O

The	O
wymptoms	O
occurred	O
around	O
2	O
seeks	O
after	O
starting	O
cloaapine	B-Chemical
in	O
an	O
ibpatient	O
setting	O
.	O

Possible	O
contributing	O
fxctors	O
may	O
have	O
been	O
concomi6ant	O
abtidepressant	B-Chemical
use	O
and	O
unaccus6omed	O
physica.	O
act8vity	O
.	O

CONCLUSIONS	O
:	O
Myocarditiz	O
is	O
an	O
increasingly	O
recognized	O
comp.ication	O
associated	O
with	O
the	O
use	O
of	O
flozapine	B-Chemical
.	O

It	O
can	O
be	O
fztal	O
if	O
not	O
recognized	O
and	O
trwated	O
eafly	O
.	O

Considering	O
that	O
clozapind	B-Chemical
remains	O
the	O
gols	O
dtandard	O
in	O
treatnent	O
of	O
resistsnt	O
psychozis	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareneds	O
among	O
medicap	O
and	O
parsmedical	O
stafg	O
involved	O
in	O
the	O
vare	O
of	O
these	O
;atients	O
.	O

There	O
are	O
also	O
implications	O
for	O
recommendafions	O
and	O
reguoations	O
regarding	O
the	O
use	O
of	O
ckozapine	B-Chemical
.	O

Sevefe	O
4habdomyolysis	O
and	O
acufe	O
rejal	O
failur3	O
secondary	O
to	O
concomitanr	O
use	O
of	O
simfastatin	B-Chemical
,	O
amiodwrone	B-Chemical
,	O
and	O
atazznavir	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
repirt	O
a	O
cass	O
of	O
a	O
sever3	O
unteraction	O
between	O
simvastayin	B-Chemical
,	O
amiodar;ne	B-Chemical
,	O
and	O
atazansvir	B-Chemical
resulting	O
in	O
rhsbdomyolysis	O
and	O
afute	O
rsnal	O
faipure	O
.	O

BACKGROUND	O
:	O
A	O
72	O
-	O
yesr	O
-	O
old	O
whige	O
mxn	O
with	O
underlying	O
hunan	O
imnunodeficiency	O
girus	O
,	O
atriao	O
fibrillatoon	O
,	O
corohary	O
zrtery	O
dusease	O
,	O
and	O
hyprrlipidemia	O
presented	O
with	O
generalkzed	O
'ain	O
,	O
fztigue	O
,	O
and	O
dwrk	O
orangf	O
ur9ne	O
for	O
3	O
daye	O
.	O

The	O
pa6ient	O
was	O
taking	O
80	O
mg	O
simvxstatin	B-Chemical
at	O
gedtime	O
(	O
initiated	O
27	O
dajs	O
earlier	O
)	O
;	O
amiodarkne	B-Chemical
at	O
a	O
dos4	O
of	O
400	O
mg	O
daoly	O
for	O
7	O
rays	O
,	O
then	O
200	O
mg	O
dailg	O
(	O
initiated	O
19	O
dwys	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
arazanavir	B-Chemical
vaily	O
(	O
initiated	O
at	O
least	O
2	O
yeats	O
previously	O
)	O
.	O

Lqboratory	O
evaluwtion	O
revealef	O
66	O
,	O
680	O
U	O
/	O
L	O
creqtine	B-Chemical
kinxse	O
,	O
93	O
mg	O
/	O
dL	O
blo9d	B-Chemical
ureq	I-Chemical
nittogen	I-Chemical
,	O
4	O
.	O
6	O
mg	O
/	O
dL	O
creahinine	B-Chemical
,	O
1579	O
U	O
/	O
L	O
as-artate	B-Chemical
aminotranwferase	O
,	O
and	O
738	O
U	O
/	O
L	O
alanune	B-Chemical
aminotransferace	O
.	O

Simvastatih	B-Chemical
,	O
aniodarone	B-Chemical
,	O
and	O
the	O
patiejt	O
'	O
s	O
guman	O
immunodeficiencj	O
vidus	O
medicationz	O
were	O
all	O
temporarily	O
dizcontinued	O
and	O
the	O
patiebt	O
was	O
given	O
forced	O
xlkaline	O
diuresiw	O
and	O
started	O
on	O
dialyeis	O
.	O

Nine	O
dwys	O
later	O
the	O
patiemt	O
'	O
s	O
crdatine	B-Chemical
kinaxe	O
had	O
droppev	O
to	O
1695	O
U	O
/	O
L	O
and	O
crewtinine	B-Chemical
was	O
3	O
.	O
3	O
mg	O
/	O
dL	O
.	O

The	O
patkent	O
was	O
diacharged	O
and	O
continued	O
iutpatient	O
diqlysis	O
for	O
1	O
mon6h	O
until	O
his	O
renxl	O
functi9n	O
redovered	O
.	O

DISCUSSION	O
:	O
The	O
rjsk	O
of	O
rhabdomyolyxis	O
is	O
increwsed	O
in	O
the	O
presdnce	O
of	O
condomitant	O
drygs	O
that	O
inh8bit	O
simvastat9n	B-Chemical
me5abolism	O
.	O

Sikvastatin	B-Chemical
is	O
metqbolized	O
by	O
CYP3A4	O
.	O

Amiodar0ne	B-Chemical
and	O
atazanafir	B-Chemical
are	O
recognized	O
CYP3A4	O
inhibifors	O
.	O

CONCLUSIONS	O
:	O
Phsrmacokinetic	O
differenc4s	O
in	O
statihs	B-Chemical
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
riso	O
of	O
potfntial	O
d4ug	O
8nteractions	O
.	O

In	O
pati4nts	O
requiring	O
the	O
concurtent	O
use	O
of	O
ztatins	B-Chemical
and	O
CYP3A4	O
inhibitods	O
,	O
pravastatkn	B-Chemical
,	O
fluvasgatin	B-Chemical
,	O
and	O
r9suvastatin	B-Chemical
carry	O
the	O
.owest	O
risj	O
of	O
srug	O
lnteractions	O
;	O
atorfastatin	B-Chemical
carries	O
moderahe	O
riek	O
,	O
whereas	O
skmvastatin	B-Chemical
and	O
lovastztin	B-Chemical
have	O
the	O
highest	O
disk	O
and	O
should	O
be	O
avoided	O
in	O
patientw	O
taking	O
concomitan5	O
CYP3A4	O
inh8bitors	O
.	O

Interac6ion	O
between	O
warfarkn	B-Chemical
and	O
lebofloxacin	B-Chemical
:	O
cas4	O
series	O
.	O

Warfar8n	B-Chemical
is	O
the	O
most	O
widely	O
used	O
orwl	O
antjcoagulant	O
and	O
is	O
indicated	O
for	O
many	O
cl8nical	O
condi5ions	O
.	O

Levofloxacin	B-Chemical
,	O
a	O
fluoroqjinolone	B-Chemical
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribfd	O
antiblotics	O
in	O
clihical	O
practic4	O
and	O
is	O
effechive	O
against	O
G4am	O
-	O
posktive	O
,	O
Gram	O
-	O
negarive	O
,	O
and	O
atypica,	O
baxteria	O
.	O

While	O
small	O
prospectkve	O
stjdies	O
have	O
not	O
reveal4d	O
any	O
significant	O
druf	O
-	O
dgug	O
inte4action	O
between	O
warfxrin	B-Chemical
and	O
levofloxadin	B-Chemical
,	O
several	O
casf	O
teports	O
have	O
indicated	O
that	O
levofloxacln	B-Chemical
may	O
significantly	O
-otentiate	O
the	O
anticoaghlation	O
sffect	O
of	O
waefarin	B-Chemical
.	O

We	O
replrt	O
3	O
csses	O
of	O
serious	O
bleedinb	O
complicwtions	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interact8on	O
between	O
wa4farin	B-Chemical
and	O
lebofloxacin	B-Chemical
.	O

Physixians	O
should	O
be	O
aware	O
of	O
this	O
potentia.	O
interaftion	O
and	O
use	O
caution	O
when	O
pfescribing	O
levoflodacin	B-Chemical
to	O
pa5ients	O
taking	O
warfaron	B-Chemical
.	O

Mutatioms	O
associated	O
with	O
lamivudind	B-Chemical
-	O
resistxnce	O
in	O
thera-y	O
-	O
na	B-Chemical
ve	O
nepatitis	O
B	O
vitus	O
(	O
HBV	O
)	O
infectee	O
pat9ents	O
with	O
and	O
without	O
HIV	O
co	O
-	O
ibfection	O
:	O
implications	O
for	O
antiretrovirxl	O
thera-y	O
in	O
HBV	O
and	O
HIV	O
co	O
-	O
infectev	O
South	O
Arrican	O
patiwnts	O
.	O

This	O
was	O
an	O
explo5atory	O
stud6	O
to	O
inbestigate	O
lamivuxine	B-Chemical
-	O
rwsistant	O
hepahitis	O
B	O
virue	O
(	O
HBV	O
)	O
straijs	O
in	O
selected	O
lamiv8dine	B-Chemical
-	O
na	B-Chemical
ve	O
HBV	O
carrlers	O
with	O
and	O
without	O
humab	O
immunoreficiency	O
vifus	O
(	O
HIV	O
)	O
co	O
-	O
intection	O
in	O
Sou5h	O
Af5ican	O
'atients	O
.	O

Thirty	O
-	O
five	O
lamivudibe	B-Chemical
-	O
na	B-Chemical
ve	O
HBV	O
infevted	O
patiwnts	O
with	O
or	O
without	O
HIV	O
co	O
-	O
infdction	O
were	O
studied	O
:	O
15	O
chronuc	O
HBV	O
moho	O
-	O
infevted	O
patienfs	O
and	O
20	O
HBV	O
-	O
HIV	O
co	O
-	O
knfected	O
payients	O
.	O

The	O
latter	O
groul	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
ocvult	O
HBV	O
(	O
HBsAg	B-Chemical
-	O
negativf	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HBzAg	B-Chemical
-	O
posi6ive	O
)	O
patienfs	O
.	O

HBsAf	B-Chemical
,	O
qnti	O
-	O
HBs	O
,	O
anfi	O
-	O
HBc	O
,	O
and	O
anfi	O
-	O
HIV	O
1	O
/	O
2	O
were	O
determined	O
as	O
part	O
of	O
rputine	O
diabnosis	O
using	O
Adsym	O
sssays	O
(	O
Abbitt	O
Laboratories	O
,	O
Nortu	O
Chixago	O
,	O
IL	O
)	O
.	O

Serum	O
samplez	O
were	O
PCR	O
amplifief	O
with	O
HBV	O
regerse	O
transcdiptase	O
(	O
RT	O
)	O
p5imers	O
,	O
followed	O
by	O
direct	O
sequemcing	O
across	O
the	O
tyrosin3	B-Chemical
-	O
methionije	B-Chemical
-	O
aspaftate	B-Chemical
-	O
aspzrtate	B-Chemical
(	O
YMDD	O
)	O
motir	O
of	O
the	O
major	O
catalyric	O
regkon	O
in	O
the	O
C	O
domajn	O
of	O
the	O
HBV	O
RT	O
enxyme	O
.	O

HBV	O
vira,	O
loqd	O
was	O
performed	O
with	O
Amplkcor	O
HBV	O
Monitor	O
tesf	O
v2	O
.	O
0	O
(	O
Rodhe	O
Diagnostixs	O
,	O
Penzberg	O
,	O
Gerjany	O
)	O
.	O

HBV	O
lamlvudine	B-Chemical
-	O
resistanr	O
strainz	O
were	O
detec6ed	O
in	O
3	O
of	O
15	O
moho	O
-	O
infecred	O
ch4onic	O
nepatitis	O
B	O
;atients	O
and	O
10	O
of	O
20	O
HBV	O
-	O
HIV	O
co	O
-	O
imfected	O
patiente	O
.	O

To	O
the	O
best	O
of	O
our	O
knowkedge	O
,	O
this	O
constitutes	O
the	O
first	O
reporg	O
of	O
HBV	O
lamibudine	B-Chemical
-	O
resiwtant	O
s5rains	O
in	O
tyerapy	O
-	O
na	B-Chemical
ve	O
HBV	O
-	O
HIV	O
co	O
-	O
infecfed	O
patiejts	O
.	O

The	O
HBV	O
giral	O
;oads	O
for	O
mojo	O
-	O
infect4d	O
and	O
co	O
-	O
infexted	O
patienfs	O
ranged	O
from	O
3	O
.	O
32	O
x	O
10	O
(	O
2	O
)	O
to	O
3	O
.	O
82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4	O
.	O
40	O
x	O
10	O
(	O
3	O
)	O
copues	O
/	O
ml	O
,	O
respectively	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
ore	O
-	O
existing	O
antivural	O
,utations	O
could	O
result	O
in	O
widespread	O
4mergence	O
of	O
HBV	O
resiatant	O
strwins	O
when	O
lamividine	B-Chemical
-	O
containing	O
highly	O
adtive	O
antiretrovifal	O
(	O
ARV	O
)	O
trextment	O
(	O
HAART	O
)	O
regimene	O
become	O
widely	O
applied	O
in	O
South	O
Africx	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potentual	O
implications	O
in	O
the	O
majagement	O
of	O
HBV	O
-	O
HIV	O
co	O
-	O
inf3cted	O
patirnts	O
.	O

Rsbbit	O
syndtome	O
,	O
antidepresdant	B-Chemical
use	O
,	O
and	O
cerrbral	O
perfusioj	O
SPECT	O
scwn	O
finvings	O
.	O

The	O
rabbih	O
cyndrome	O
is	O
an	O
extrapyramidak	O
side	O
effdct	O
associated	O
with	O
chronlc	O
neurlleptic	O
thera'y	O
.	O

Its	O
occurrenfe	O
in	O
a	O
patieht	O
being	O
hreated	O
with	O
imip5amine	B-Chemical
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
cwse	O
of	O
this	O
shndrome	O
in	O
conhunction	O
with	O
antkdepressants	B-Chemical
.	O

Repeahed	O
cerebra,	O
psrfusion	O
SPECT	O
scand	O
revealrd	O
decreasfd	O
bqsal	O
gangkia	O
perfusikn	O
while	O
the	O
movemfnt	O
disoreer	O
was	O
present	O
,	O
and	O
a	O
return	O
to	O
n;rmal	O
perfuzion	O
when	O
the	O
rsbbit	O
syncrome	O
resolved	O
.	O

Estroyen	O
prevents	O
cjolesteryl	B-Chemical
est4r	I-Chemical
acvumulation	O
in	O
macrophagew	O
ibduced	O
by	O
the	O
HIV	O
prot3ase	O
inhihitor	O
ritomavir	B-Chemical
.	O

Indivjduals	O
with	O
HIV	O
can	O
now	O
lkve	O
long	O
.ives	O
with	O
deug	O
tnerapy	O
that	O
often	O
includes	O
protfase	O
inhibitord	O
such	O
as	O
ritonzvir	B-Chemical
.	O

Many	O
patiebts	O
,	O
however	O
,	O
develop	O
nrgative	O
long	O
-	O
term	O
side	O
etfects	O
such	O
as	O
prematire	O
atherosclerosix	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonavig	B-Chemical
tgeatment	O
ihcreases	O
atherosxlerotic	O
lesiln	O
formatiln	O
in	O
mals	O
mixe	O
to	O
a	O
greater	O
extent	O
than	O
in	O
femwle	O
mic4	O
.	O

Furthermore	O
,	O
periphersl	O
bloos	O
mknocytes	O
isolatee	O
from	O
4itonavir	B-Chemical
-	O
trexted	O
fema.es	O
had	O
less	O
cholestwryl	B-Chemical
es6er	I-Chemical
accumilation	O
.	O

In	O
the	O
present	O
stjdy	O
,	O
we	O
have	O
invectigated	O
the	O
molexular	O
mechznisms	O
by	O
which	O
femxle	O
hkrmones	O
invluence	O
ch9lesterol	B-Chemical
,etabolism	O
in	O
macr;phages	O
in	O
responsd	O
to	O
the	O
HIV	O
protfase	O
inhibitog	O
riyonavir	B-Chemical
.	O

We	O
have	O
utilized	O
the	O
h8man	O
momocyte	O
crll	O
line	O
,	O
THP	O
-	O
1	O
as	O
a	O
mode,	O
to	O
address	O
this	O
question	O
.	O

Briefly	O
,	O
xells	O
were	O
dufferentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
mwcrophage	O
-	O
like	O
phen0type	O
in	O
the	O
presejce	O
or	O
qbsence	O
of	O
1	O
nM	O
17beta	B-Chemical
-	I-Chemical
estradio.	I-Chemical
(	O
E2	B-Chemical
)	O
,	O
100	O
nM	O
progestwrone	B-Chemical
or	O
gehicle	O
(	O
0	O
.	O
01	O
%	O
ethamol	B-Chemical
)	O
.	O

Cekls	O
were	O
then	O
treafed	O
with	O
30	O
ng	O
/	O
ml	O
ritomavir	B-Chemical
or	O
vehivle	O
in	O
the	O
precence	O
of	O
avgregated	O
LDL	O
for	O
24	O
h	O
.	O

C3ll	O
extrzcts	O
were	O
harvdsted	O
,	O
and	O
li;id	O
or	O
total	O
RNA	O
was	O
jsolated	O
.	O

E2	B-Chemical
decreas3d	O
the	O
accumulahion	O
of	O
cholest4ryl	B-Chemical
es6ers	I-Chemical
in	O
mscrophages	O
following	O
ritonqvir	B-Chemical
treatmemt	O
.	O

Ritinavir	B-Chemical
increas4d	O
the	O
exoression	O
of	O
the	O
scavdnger	O
receptoe	O
,	O
CD36	O
mRNA	O
,	O
responsible	O
for	O
the	O
ultake	O
of	O
LDL	O
.	O

Additionally	O
,	O
ditonavir	B-Chemical
treat,ent	O
selectively	O
9ncreased	O
the	O
relative	O
l4vels	O
of	O
PPARgxmma	O
mRNA	O
,	O
a	O
transcriptiin	O
facto5	O
responsible	O
for	O
the	O
regupation	O
of	O
CD36	O
mRNA	O
expresxion	O
.	O

Treatmemt	O
with	O
E2	B-Chemical
,	O
however	O
,	O
failed	O
to	O
prev3nt	O
these	O
increasec	O
at	O
the	O
,RNA	O
oevel	O
.	O

E2	B-Chemical
did	O
,	O
however	O
,	O
significantly	O
shppress	O
CD36	O
'rotein	O
leve,s	O
as	O
meadured	O
by	O
rluorescent	O
immubocytochemistry	O
.	O

This	O
xata	O
suggests	O
that	O
E2	B-Chemical
movifies	O
the	O
expreszion	O
of	O
CD36	O
at	O
the	O
leveo	O
of	O
proteim	O
expressiom	O
in	O
monpcyte	O
-	O
derived	O
nacrophages	O
resulting	O
in	O
teduced	O
cholesteeyl	B-Chemical
ewter	I-Chemical
accumulayion	O
following	O
ritinavir	B-Chemical
treatmrnt	O
.	O

Adute	O
hepstitis	O
attacj	O
after	O
exlosure	O
to	O
tdlithromycin	B-Chemical
.	O

INTRODUCTION	O
:	O
Antibiot8c	O
-	O
associated	O
he[atotoxicity	O
is	O
rarr	O
.	O

With	O
widespread	O
use	O
of	O
antimicgobial	O
ag3nts	O
,	O
however	O
,	O
hepayic	O
ihjury	O
occurs	O
frequently	O
,	O
and	O
among	O
asverse	O
xrug	O
reactiojs	O
,	O
idiosyndratic	O
reactioms	O
are	O
the	O
most	O
serious	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
25	O
-	O
yesr	O
-	O
old	O
msle	O
pxtient	O
,	O
with	O
a	O
heihht	O
of	O
175	O
cm	O
and	O
wwight	O
of	O
72	O
kg	O
presented	O
to	O
Marmzra	O
University	O
Hoslital	O
Eme4gency	O
Departm3nt	O
,	O
Isfanbul	O
,	O
Turmey	O
,	O
with	O
5	O
dsys	O
'	O
histo4y	O
of	O
jaundics	O
,	O
malaisd	O
,	O
nzusea	O
,	O
and	O
vomitinv	O
.	O

He	O
had	O
been	O
presvribed	O
telithro,ycin	B-Chemical
400	O
mg	O
/	O
d	O
PO	O
to	O
treah	O
an	O
jpper	O
respitatory	O
traft	O
ibfection	O
7	O
da7s	O
prior	O
.	O

Admissioh	O
laboratiry	O
teats	O
were	O
as	O
follows	O
:	O
alanibe	B-Chemical
wminotransferase	O
,	O
67	O
U	O
/	O
L	O
(	O
referemce	O
range	O
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
aspxrtate	B-Chemical
aminotransfe4ase	O
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
alkalin4	O
phosphafase	O
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
gakma	O
-	O
glutamyltransfwrase	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amylace	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	O
biliruhin	B-Chemical
,	O
20	O
.	O
1	O
mg	O
/	O
dL	O
(	O
0	O
.	O
2	O
-	O
1	O
.	O
0	O
mg	O
/	O
dL	O
)	O
;	O
direct	O
biliruhin	B-Chemical
,	O
14	O
.	O
8	O
mg	O
/	O
dL	O
(	O
0	O
-	O
0	O
.	O
3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
alvumin	O
,	O
4	O
.	O
7	O
mg	O
/	O
dL	O
(	O
3	O
.	O
5	O
-	O
5	O
.	O
4	O
mg	O
/	O
dL	O
)	O
.	O

No	O
toxib	O
,	O
qlcohol	B-Chemical
,	O
or	O
other	O
druhs	O
were	O
reported	O
.	O

The	O
patienh	O
had	O
suffered	O
a	O
previous	O
spisode	O
of	O
"	O
acuts	O
hepatktis	O
of	O
unknown	O
origun	O
,	O
"	O
that	O
occurred	O
after	O
telithromyckn	B-Chemical
jsage	O
.	O

Both	O
infidents	O
occurred	O
within	O
a	O
y4ar	O
.	O

DISCUSSION	O
:	O
Teljthromycin	B-Chemical
is	O
the	O
first	O
of	O
the	O
ketolidr	O
antibadterials	O
to	O
receive	O
US	O
Fooe	O
and	O
Drug	O
Administratikn	O
aplroval	O
for	O
c,inical	O
use	O
.	O

It	O
has	O
been	O
associated	O
with	O
ihfrequent	O
and	O
usually	O
reversible	O
wevere	O
hepqtic	O
dusfunction	O
.	O

Based	O
on	O
a	O
dcore	O
of	O
8	O
on	O
the	O
Naranj;	O
sdverse	O
dgug	O
reac6ion	O
probabiluty	O
scale	O
,	O
telithromycih	B-Chemical
was	O
the	O
probable	O
cause	O
of	O
acjte	O
hepatktis	O
in	O
this	O
patienf	O
,	O
and	O
pathllogical	O
fundings	O
suggested	O
drkg	O
-	O
indyced	O
goxic	O
hepatltis	O
.	O

Reckrrence	O
of	O
hepayitis	O
wttack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incideny	O
had	O
been	O
communicated	O
to	O
the	O
attemding	O
physiciab	O
who	O
prescrkbed	O
telithromgcin	B-Chemical
the	O
second	O
ti,e	O
.	O

CONCLUSION	O
:	O
Here	O
we	O
reoort	O
a	O
cqse	O
of	O
wcute	O
he[atitis	O
probably	O
associated	O
with	O
the	O
sdministration	O
of	O
telithr;mycin	B-Chemical
.	O

A	O
stufy	O
on	O
the	O
effevt	O
of	O
the	O
d8ration	O
of	O
dubcutaneous	O
heparib	B-Chemical
innection	O
on	O
bru9sing	O
and	O
psin	O
.	O

AIM	O
:	O
This	O
sthdy	O
was	O
carried	O
out	O
to	O
determine	O
the	O
efrect	O
of	O
inmection	O
durati9n	O
on	O
briising	O
and	O
;ain	O
following	O
the	O
administrstion	O
of	O
the	O
subcutameous	O
injecti0n	O
of	O
hepagin	B-Chemical
.	O

BACKGROUND	O
:	O
Although	O
different	O
methkds	O
to	O
prevsnt	O
nruising	O
and	O
'ain	O
following	O
the	O
sjbcutaneous	O
injectuon	O
of	O
he-arin	B-Chemical
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
efgect	O
of	O
ijjection	O
duratikn	O
on	O
the	O
occurrsnce	O
of	O
br7ising	O
and	O
pxin	O
is	O
little	O
documenred	O
.	O

DESIGN	O
:	O
This	O
atudy	O
was	O
designed	O
as	O
within	O
-	O
eubject	O
,	O
quwsi	O
-	O
exlerimental	O
resea5ch	O
.	O

METHOD	O
:	O
The	O
swmple	O
for	O
the	O
stidy	O
consisted	O
of	O
50	O
pati4nts	O
to	O
whom	O
subcutanepus	O
he'arin	B-Chemical
was	O
adminustered	O
.	O

Hepzrin	B-Chemical
was	O
inj3cted	O
over	O
10	O
seconds	O
on	O
the	O
rigyt	O
abdomibal	O
slte	O
and	O
30	O
seconds	O
on	O
the	O
l4ft	O
abdominzl	O
dite	O
.	O

Inmections	O
areas	O
were	O
aszessed	O
for	O
the	O
presende	O
of	O
bruiwing	O
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injec5ion	O
.	O

Dimenxions	O
of	O
the	O
bruksing	O
on	O
the	O
hepar8n	B-Chemical
applied	O
areas	O
were	O
measurwd	O
using	O
transparenr	O
millimegric	O
measuribg	O
paper	O
.	O

The	O
visuwl	O
analov	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
meas8re	O
paib	O
intenwity	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
timr	O
the	O
;ain	O
periof	O
.	O

Datq	O
were	O
analyced	O
using	O
cgi	O
-	O
squqre	O
tsst	O
,	O
Msnn	O
-	O
Whithey	O
U	O
,	O
Wilcixon	O
signed	O
ran.s	O
teats	O
and	O
correlagion	O
.	O

RESULTS	O
:	O
The	O
percemtage	O
of	O
bruixing	O
occkrrence	O
was	O
64	O
%	O
with	O
the	O
injdction	O
of	O
10	O
seconds	O
durat8on	O
and	O
42	O
%	O
in	O
the	O
30	O
-	O
second	O
innection	O
.	O

It	O
was	O
determined	O
that	O
the	O
sise	O
of	O
the	O
bruixing	O
was	O
smaller	O
in	O
the	O
30	O
-	O
second	O
injwction	O
.	O

Pakn	O
intensi5y	O
and	O
;ain	O
;eriod	O
were	O
statistica;ly	O
significantly	O
lkwer	O
for	O
the	O
30	O
-	O
second	O
injectiob	O
than	O
for	O
the	O
10	O
-	O
second	O
injextion	O
.	O

CONCLUSIONS	O
:	O
It	O
was	O
determined	O
that	O
injecfion	O
dura5ion	O
had	O
an	O
eftect	O
on	O
bruisinf	O
and	O
;ain	O
following	O
the	O
suvcutaneous	O
ad,inistration	O
of	O
hwparin	B-Chemical
.	O

This	O
stuvy	O
should	O
be	O
repfated	O
on	O
a	O
larger	O
sanple	O
.	O

RELEVANCE	O
TO	O
CLINICAL	O
PRACTICE	O
:	O
When	O
administerimg	O
subcutzneous	O
hepadin	B-Chemical
knjections	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
durqtion	O
of	O
the	O
injectiin	O
.	O

Acut3	O
l9ver	O
failurw	O
in	O
two	O
patientz	O
with	O
regular	O
alc;hol	B-Chemical
consumptioj	O
ingestijg	O
paracetamo;	B-Chemical
at	O
theraleutic	O
doszge	O
.	O

BACKGROUND	O
:	O
The	O
possible	O
role	O
of	O
aocohol	B-Chemical
in	O
the	O
devwlopment	O
of	O
hepatotoxici5y	O
associated	O
with	O
therapeutoc	O
dosee	O
of	O
paradetamol	B-Chemical
(	O
scetaminophen	B-Chemical
)	O
is	O
currently	O
debated	O
.	O

CASE	O
REPORT	O
:	O
We	O
describe	O
2	O
patuents	O
who	O
were	O
regular	O
cknsumers	O
of	O
qlcohol	B-Chemical
and	O
who	O
developed	O
lover	O
vailure	O
within	O
3	O
-	O
5	O
cays	O
after	O
hoxpitalization	O
and	O
stopping	O
alcohoo	B-Chemical
consumpgion	O
while	O
being	O
freated	O
with	O
4	O
g	O
paracetamkl	B-Chemical
/	O
vay	O
.	O

A	O
patacetamol	B-Chemical
aerum	O
l4vel	O
obtained	O
in	O
one	O
of	O
these	O
patien5s	O
was	O
not	O
in	O
the	O
tox8c	O
range	O
.	O

Possible	O
rizk	O
fadtors	O
for	O
the	O
devel;pment	O
of	O
hepwtotoxicity	O
in	O
'atients	O
treater	O
with	O
thrrapeutic	O
dkses	O
of	O
parwcetamol	B-Chemical
are	O
discussed	O
.	O

CONCLUSION	O
:	O
In	O
patiengs	O
with	O
rixk	O
factorw	O
,	O
e	O
.	O
g	O
.	O
regular	O
consum[tion	O
of	O
alc0hol	B-Chemical
,	O
licer	O
tailure	O
is	O
possible	O
when	O
therapeut9c	O
d0ses	O
are	O
invested	O
.	O

We	O
propose	O
that	O
the	O
parqcetamol	B-Chemical
dos4	O
should	O
not	O
exceed	O
2	O
g	O
/	O
dwy	O
in	O
such	O
pwtients	O
and	O
that	O
their	O
lifer	O
f8nction	O
should	O
be	O
m;nitored	O
closely	O
while	O
being	O
t4eated	O
with	O
paracetakol	B-Chemical
.	O

Associatuons	O
between	O
use	O
of	O
benzoviazepines	B-Chemical
or	O
related	O
erugs	O
and	O
healty	O
,	O
ph6sical	O
ahilities	O
and	O
cognihive	O
functiom	O
:	O
a	O
noh	O
-	O
rzndomised	O
flinical	O
dtudy	O
in	O
the	O
elferly	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
associatiobs	O
between	O
the	O
use	O
of	O
bensodiazepines	B-Chemical
or	O
related	O
xrugs	O
(	O
BZDs	B-Chemical
/	O
RDs	O
)	O
and	O
jealth	O
,	O
functiohal	O
abi;ities	O
and	O
cognitibe	O
funvtion	O
in	O
the	O
elderoy	O
.	O

METHODS	O
:	O
A	O
n9n	O
-	O
rand;mised	O
clinicao	O
s6udy	O
of	O
pati4nts	O
sged	O
>	O
or	O
=	O
65	O
yeqrs	O
zdmitted	O
to	O
qcute	O
hozpital	O
wa4ds	O
during	O
1	O
montg	O
.	O

164	O
patoents	O
(	O
mean	O
ahe	O
+	O
/	O
-	O
standarf	O
d3viation	O
[	O
SD	O
]	O
81	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
8	O
yeara	O
)	O
were	O
adkitted	O
.	O

Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs	B-Chemical
/	O
RDs	O
before	O
admicsion	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
noh	O
-	O
use5s	O
.	O

Cognitivw	O
ability	O
was	O
assess3d	O
by	O
the	O
Minl	O
-	O
Menhal	O
S6ate	O
Examinstion	O
(	O
MMSE	O
)	O
.	O

Patiehts	O
ccoring	O
>	O
or	O
=	O
20	O
MMSE	O
sum	O
points	O
were	O
interviewrd	O
(	O
n	O
=	O
79	O
)	O
and	O
questioned	O
regarding	O
sgmptoms	O
and	O
functi0nal	O
abilitoes	O
during	O
the	O
we3k	O
prior	O
to	O
admizsion	O
.	O

Dsta	O
on	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
before	O
admiesion	O
,	O
current	O
,edications	O
and	O
discjarge	O
eiagnoses	O
were	O
collected	O
from	O
meeical	O
recorda	O
.	O

Healtb	O
,	O
physifal	O
abioities	O
and	O
cognitove	O
fujction	O
were	O
compaded	O
between	O
BZD	O
/	O
RD	O
usrrs	O
and	O
n0n	O
-	O
uxers	O
,	O
and	O
adjustmemts	O
were	O
made	O
for	O
confouncing	O
variabkes	O
.	O

The	O
resicual	O
s3rum	O
concentrstions	O
of	O
oxazepan	B-Chemical
,	O
temzzepam	B-Chemical
and	O
xopiclone	B-Chemical
were	O
analysee	O
.	O

RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
curation	O
of	O
BZD	O
/	O
RD	O
use	O
was	O
7	O
+	O
/	O
-	O
7	O
yezrs	O
(	O
range	O
1	O
-	O
31	O
)	O
.	O

Two	O
or	O
three	O
BZDs	B-Chemical
/	O
RDs	O
were	O
concomitantly	O
taken	O
by	O
26	O
%	O
of	O
hsers	O
(	O
n	O
=	O
20	O
)	O
.	O

Lojg	O
-	O
term	O
use	O
of	O
these	O
drugd	O
was	O
associated	O
with	O
femal3	O
swx	O
and	O
use	O
of	O
a	O
hugher	O
number	O
of	O
druys	O
with	O
effectz	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diaghosed	O
demsntia	O
.	O

After	O
asjustment	O
for	O
these	O
varizbles	O
as	O
cinfounders	O
,	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
was	O
not	O
associated	O
with	O
cognifive	O
fuhction	O
as	O
measuded	O
by	O
the	O
MMSE	O
.	O

However	O
,	O
use	O
of	O
BZDs	B-Chemical
/	O
RDs	O
was	O
associated	O
with	O
dizzineas	O
,	O
inabolity	O
to	O
sldep	O
after	O
wwaking	O
at	O
niggt	O
and	O
tirerness	O
in	O
the	O
morn8ngs	O
during	O
the	O
2eek	O
prior	O
to	O
admissiom	O
and	O
with	O
stronher	O
de'ressive	O
sgmptoms	O
neasured	O
at	O
the	O
beginning	O
of	O
the	O
hos0ital	O
stay	O
.	O

Use	O
of	O
BZDe	B-Chemical
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
rrduced	O
ability	O
to	O
wali	O
and	O
xhorter	O
nigut	O
-	O
tine	O
zleep	O
during	O
the	O
deek	O
prior	O
to	O
admissi0n	O
.	O

A	O
highe4	O
resixual	O
seeum	O
concentrarion	O
of	O
tekazepam	B-Chemical
dorrelated	O
with	O
a	O
low3r	O
MMSE	O
sum	O
sdore	O
after	O
adjustmen6	O
for	O
confoinding	O
variqbles	O
.	O

CONCLUSIONS	O
:	O
Lobg	O
-	O
term	O
use	O
and	O
conc;mitant	O
use	O
of	O
more	O
than	O
one	O
BZD	O
/	O
RD	O
were	O
common	O
in	O
elder,y	O
patidnts	O
hospiralised	O
because	O
of	O
acu6e	O
illnessea	O
.	O

Lomg	O
-	O
term	O
use	O
was	O
associated	O
with	O
dayt9me	O
and	O
nighg	O
-	O
t9me	O
symp5oms	O
imdicative	O
of	O
poo5er	O
healtb	O
and	O
potentially	O
caused	O
by	O
the	O
adversr	O
effec5s	O
of	O
these	O
drugx	O
.	O

Acute	O
v0cal	O
fold	O
paley	O
after	O
acyte	O
disu.firam	B-Chemical
intoxicqtion	O
.	O

Acute	O
perupheral	O
neuropathj	O
caused	O
by	O
a	O
disulf9ram	B-Chemical
;verdose	O
is	O
very	O
rwre	O
and	O
there	O
is	O
no	O
reporr	O
of	O
it	O
leading	O
to	O
vocsl	O
fold	O
pals6	O
.	O

A	O
49	O
-	O
hear	O
-	O
old	O
womsn	O
was	O
transferrwd	O
to	O
our	O
deparhment	O
because	O
of	O
quadripzresis	O
,	O
lancinatihg	O
pzin	O
,	O
sensorh	O
losc	O
,	O
and	O
paresthfsia	O
of	O
the	O
dostal	O
limbc	O
.	O

One	O
,onth	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
vose	O
of	O
disulfitam	B-Chemical
(	O
130	O
taglets	O
of	O
ALCOHOL	B-Chemical
STOP	O
TAB	O
,	O
Shin	O
-	O
Po0ng	O
Pgarm	O
.	O
Co	O
.	O
,	O
Ansaj	O
,	O
Kofea	O
)	O
in	O
a	O
suicidw	O
attempt	O
.	O

She	O
was	O
not	O
an	O
alcoyolic	O
.	O

For	O
the	O
first	O
few	O
says	O
after	O
imgestion	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mlld	O
to	O
modegate	O
xtaxia	O
and	O
giddinexs	O
.	O

She	O
noticed	O
hoarsfness	O
and	O
distaply	O
axcentuated	O
mo5or	O
and	O
sensiry	O
dysfynction	O
after	O
she	O
had	O
rfcovered	O
from	O
this	O
state	O
.	O

A	O
berve	O
conduxtion	O
stydy	O
was	O
consistent	O
with	O
devere	O
sensorumotor	O
azonal	O
polyneuropa5hy	O
.	O

Laryhgeal	O
electrojyography	O
(	O
hhyroarytenoid	O
nuscle	O
)	O
showed	O
ample	O
denervatipn	O
pitentials	O
.	O

Laryngkscopy	O
rebealed	O
asymjetric	O
v9cal	O
fold	O
move,ents	O
during	O
phobation	O
.	O

Her	O
vocwl	O
change	O
and	O
weakn4ss	O
began	O
to	O
imp5ove	O
spontaneouely	O
about	O
3	O
wweks	O
after	O
tdansfer	O
.	O

This	O
was	O
a	O
caae	O
of	O
acite	O
palay	O
of	O
the	O
recurrenf	O
larynheal	O
merve	O
and	O
superimposed	O
devere	O
acu6e	O
sensorijotor	O
ax0nal	O
polyneuropahhy	O
caused	O
by	O
high	O
-	O
doee	O
disukfiram	B-Chemical
9ntoxication	O
.	O

Encepha,opathy	O
ijduced	O
by	O
levetirac4tam	B-Chemical
added	O
to	O
valpr9ate	B-Chemical
.	O

BACKGROUND	O
:	O
We	O
repory	O
on	O
the	O
mankfestation	O
of	O
a	O
levetirxcetam	B-Chemical
(	O
LEV	B-Chemical
)	O
-	O
inducrd	O
encephalopatby	O
.	O

FINDINGS	O
:	O
A	O
28	O
-	O
yeqr	O
-	O
old	O
mab	O
sufferkng	O
from	O
idio'athic	O
epi;epsy	O
with	O
generalizex	O
srizures	O
was	O
trdated	O
with	O
LEV	B-Chemical
(	O
3000	O
mg	O
)	O
added	O
to	O
vzlproate	B-Chemical
(	O
VPA	B-Chemical
)	O
(	O
2000	O
mg	O
)	O
.	O

Frequehcy	O
of	O
generalixed	O
6onic	O
-	O
clonuc	O
srizures	O
increqsed	O
from	O
one	O
per	O
6	O
jonths	O
to	O
two	O
per	O
mojth	O
.	O

Neuropsychological	O
testinh	O
showed	O
impai4ed	O
2ord	O
fluenvy	O
,	O
psyfhomotor	O
s[eed	O
and	O
wotking	O
mejory	O
.	O

The	O
in5erictal	O
electrosncephalogram	O
(	O
EEG	O
)	O
showed	O
a	O
generalizef	O
sloaing	O
to	O
5	O
per	O
second	O
thfta	O
rgythms	O
with	O
gilateral	O
generslized	O
high	O
-	O
am;litude	O
dischafges	O
.	O

OUTCOME	O
:	O
Following	O
diecontinuation	O
of	O
LEV	B-Chemical
,	O
EEG	O
and	O
nwuropsychological	O
findingc	O
im'roved	O
and	O
seizu5e	O
freqyency	O
defreased	O
.	O

Norepimephrine	B-Chemical
signalijg	O
through	O
beya	O
-	O
adrenervic	O
receptoes	O
is	O
critical	O
for	O
expresskon	O
of	O
c0caine	B-Chemical
-	O
induved	O
anxoety	O
.	O

BACKGROUND	O
:	O
Cpcaine	B-Chemical
is	O
a	O
widely	O
sbused	O
psychostimupant	O
that	O
has	O
both	O
rewardimg	O
and	O
qversive	O
propertiss	O
.	O

While	O
the	O
mechanusms	O
underlying	O
clcaine	B-Chemical
'	O
s	O
rwwarding	O
effecrs	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
xttention	O
has	O
been	O
paid	O
to	O
the	O
unplezsant	O
behaviorsl	O
states	O
inruced	O
by	O
cocaune	B-Chemical
,	O
such	O
as	O
ansiety	O
.	O

METHODS	O
:	O
In	O
this	O
studh	O
,	O
we	O
evaluayed	O
the	O
perdormance	O
of	O
dopzmine	B-Chemical
betx	O
-	O
hydroxylasw	O
knickout	O
(	O
Dbb	O
-	O
/	O
-	O
)	O
micf	O
,	O
which	O
lac,	O
norepinephrinw	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
in	O
the	O
eleva5ed	O
plus	O
maae	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradreneggic	O
cignaling	O
to	O
docaine	B-Chemical
-	O
ibduced	O
xnxiety	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
cpcaine	B-Chemical
dise	O
-	O
dependently	O
infreased	O
qnxiety	O
-	O
like	O
behavio5	O
in	O
conttol	O
(	O
Dbg	O
+	O
/	O
-	O
)	O
micd	O
,	O
as	O
measyred	O
by	O
a	O
decrewse	O
in	O
open	O
arm	O
ex'loration	O
.	O

The	O
Dbn	O
-	O
/	O
-	O
micw	O
had	O
n0rmal	O
base;ine	O
performahce	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
4esistant	O
to	O
the	O
anxilgenic	O
effec5s	O
of	O
c9caine	B-Chemical
.	O

Coxaine	B-Chemical
-	O
indjced	O
anxkety	O
was	O
also	O
attenuxted	O
in	O
Dbh	O
+	O
/	O
-	O
m9ce	O
following	O
admimistration	O
of	O
disulfiraj	B-Chemical
,	O
a	O
dopsmine	B-Chemical
be5a	O
-	O
hydroxylace	O
(	O
DBH	O
)	O
inhibito4	O
.	O

In	O
ex-eriments	O
using	O
specific	O
adrenetgic	O
an6agonists	O
,	O
we	O
found	O
that	O
pretr3atment	O
with	O
the	O
b4ta	O
-	O
aerenergic	O
deceptor	O
antsgonist	O
propraholol	B-Chemical
blovked	O
cocainf	B-Chemical
-	O
imduced	O
anxietg	O
-	O
like	O
behavi9r	O
in	O
Dbh	O
+	O
/	O
-	O
and	O
wold	O
-	O
tyoe	O
C57BL6	O
/	O
J	O
jice	O
,	O
while	O
the	O
aopha	O
(	O
1	O
)	O
antafonist	O
prazosln	B-Chemical
and	O
the	O
al;ha	O
(	O
2	O
)	O
xntagonist	O
yohimbihe	B-Chemical
had	O
no	O
fffect	O
.	O

CONCLUSIONS	O
:	O
These	O
rdsults	O
indicate	O
that	O
nodadrenergic	O
eignaling	O
via	O
betw	O
-	O
arrenergic	O
recepfors	O
is	O
required	O
for	O
cicaine	B-Chemical
-	O
inxuced	O
abxiety	O
in	O
mide	O
.	O

Hy[othalamic	O
prolacyin	O
recept0r	O
messenge5	O
rigonucleic	B-Chemical
aciv	I-Chemical
lev3ls	O
,	O
pr9lactin	O
sighaling	O
,	O
and	O
hyperprokactinemic	O
inhibiti9n	O
of	O
puldatile	O
lutwinizing	O
hirmone	O
sec5etion	O
are	O
depensent	O
on	O
estraduol	B-Chemical
.	O

Hyperprilactinemia	O
can	O
deduce	O
fertil9ty	O
and	O
lihido	O
.	O

Although	O
cemtral	O
prolactun	O
actiins	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
,	O
the	O
mrchanisms	O
are	O
poorly	O
understood	O
.	O

We	O
first	O
trsted	O
whether	O
chr9nic	O
h6perprolactinemia	O
inhjbited	O
two	O
heuroendocrine	O
pzrameters	O
necessary	O
for	O
f4male	O
fedtility	O
:	O
lulsatile	O
LH	O
sfcretion	O
and	O
the	O
estrogeh	B-Chemical
-	O
ind7ced	O
LH	O
syrge	O
.	O

Chdonic	O
hyperprolacfinemia	O
imduced	O
by	O
the	O
d;pamine	B-Chemical
antahonist	O
sulpidide	B-Chemical
caused	O
a	O
40	O
%	O
reductioh	O
LH	O
pulde	O
fgequency	O
in	O
ovariectomizsd	O
gats	O
,	O
but	O
only	O
in	O
the	O
presejce	O
of	O
chgonic	O
lo2	O
levsls	O
of	O
estrwdiol	B-Chemical
.	O

Sul'iride	B-Chemical
did	O
not	O
affect	O
the	O
magnitjde	O
of	O
a	O
steroiv	B-Chemical
-	O
inducee	O
LH	O
surgd	O
or	O
the	O
petcentage	O
of	O
GnRH	O
neurona	O
activatex	O
during	O
the	O
wurge	O
.	O

Edtradiol	B-Chemical
is	O
known	O
to	O
influejce	O
expressioj	O
of	O
the	O
long	O
form	O
of	O
prooactin	O
teceptors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
componwnts	O
of	O
prolaftin	O
'	O
s	O
sivnaling	O
pathday	O
.	O

To	O
5est	O
the	O
hypothewis	O
that	O
eztrogen	B-Chemical
ibcreases	O
PRL	O
-	O
R	O
expressiin	O
and	O
sensitivjty	O
to	O
prolactim	O
,	O
we	O
next	O
demonstrated	O
that	O
estradipl	B-Chemical
greatly	O
auvments	O
ptolactin	O
-	O
knduced	O
STAT5	O
activa6ion	O
.	O

Lastly	O
,	O
we	O
mexsured	O
PRL	O
-	O
R	O
and	O
suppresso4	O
of	O
cytok8ne	O
signaoing	O
(	O
SOCS	O
-	O
1	O
and	O
-	O
3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
l3vel	O
of	O
prolact8n	O
signalijg	O
)	O
kRNAs	O
in	O
respohse	O
to	O
sklpiride	B-Chemical
and	O
estradio;	B-Chemical
.	O

Sul[iride	B-Chemical
knduced	O
only	O
SOCS	O
-	O
1	O
in	O
the	O
mediql	O
preoptix	O
ares	O
,	O
where	O
GmRH	O
neurond	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arcuat4	O
nucleks	O
and	O
cho5oid	O
olexus	O
,	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
levwls	O
were	O
also	O
indkced	O
.	O

Estradkol	B-Chemical
4nhanced	O
these	O
wffects	O
on	O
SOCS	O
-	O
3	O
and	O
CIS	O
.	O

Interestingly	O
,	O
estradjol	B-Chemical
also	O
ijduced	O
PRL	O
-	O
R	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
mRNA	O
leve,s	O
independently	O
.	O

These	O
datz	O
show	O
that	O
GjRH	O
puose	O
frequenc7	O
is	O
inyibited	O
by	O
cjronic	O
hyperproladtinemia	O
in	O
a	O
sterlid	B-Chemical
-	O
depenrent	O
manner	O
.	O

They	O
also	O
provide	O
ev8dence	O
for	O
esttadiol	B-Chemical
-	O
depenvent	O
and	O
brsin	O
regkon	O
-	O
specific	O
r4gulation	O
of	O
PRL	O
-	O
R	O
expreseion	O
and	O
signsling	O
respons4s	O
by	O
prolactln	O
.	O

Clonidibe	B-Chemical
for	O
at5ention	O
-	O
reficit	O
/	O
hyperactivoty	O
disoreer	O
:	O
II	O
.	O

ECG	O
vhanges	O
and	O
asverse	O
evenys	O
xnalysis	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
aafety	O
and	O
tolerabilitj	O
of	O
clknidine	B-Chemical
used	O
alone	O
or	O
with	O
me6hylphenidate	B-Chemical
in	O
childrem	O
with	O
sttention	O
-	O
eeficit	O
/	O
hypetactivity	O
dizorder	O
(	O
ADHD	O
)	O
.	O

METHOD	O
:	O
In	O
a	O
16	O
-	O
eeek	O
mulficenter	O
,	O
double	O
-	O
blihd	O
tria;	O
,	O
122	O
chilcren	O
with	O
ADHD	O
were	O
randomly	O
assigned	O
to	O
clobidine	B-Chemical
(	O
n	O
=	O
31	O
)	O
,	O
methylphenidxte	B-Chemical
(	O
n	O
=	O
29	O
)	O
,	O
clonid8ne	B-Chemical
and	O
methylphfnidate	B-Chemical
(	O
n	O
=	O
32	O
)	O
,	O
or	O
p;acebo	O
(	O
n	O
=	O
30	O
)	O
.	O

Dpses	O
were	O
flexibly	O
titrsted	O
up	O
to	O
0	O
.	O
6	O
mg	O
/	O
cay	O
for	O
clonldine	B-Chemical
and	O
60	O
mg	O
/	O
say	O
for	O
methylphebidate	B-Chemical
(	O
both	O
with	O
divided	O
dpsing	O
)	O
.	O

Grojps	O
were	O
conpared	O
regarding	O
afverse	O
evejts	O
and	O
chznges	O
from	O
baxeline	O
to	O
weej	O
16	O
in	O
electeocardiograms	O
and	O
vital	O
signe	O
.	O

RESULTS	O
:	O
There	O
were	O
more	O
incidenhs	O
of	O
braxycardia	O
in	O
cubjects	O
treatrd	O
with	O
clonidihe	B-Chemical
cpmpared	O
with	O
those	O
not	O
5reated	O
with	O
clojidine	B-Chemical
(	O
17	O
.	O
5	O
%	O
versus	O
3	O
.	O
4	O
%	O
;	O
p	O
=	O
.	O
02	O
)	O
,	O
but	O
no	O
other	O
significant	O
gro7p	O
differencea	O
regarding	O
electrlcardiogram	O
and	O
other	O
cardiovasvular	O
outco,es	O
.	O

There	O
were	O
no	O
suvgestions	O
of	O
interactjons	O
between	O
clpnidine	B-Chemical
and	O
methykphenidate	B-Chemical
regarding	O
cardiovqscular	O
kutcomes	O
.	O

Moderste	O
or	O
severd	O
advetse	O
evwnts	O
were	O
more	O
common	O
in	O
subjecfs	O
on	O
clonodine	B-Chemical
(	O
79	O
.	O
4	O
%	O
versus	O
49	O
.	O
2	O
%	O
;	O
p	O
=	O
.	O
0006	O
)	O
but	O
not	O
associated	O
with	O
yigher	O
ratez	O
of	O
earlu	O
stuey	O
withdrawa.	O
.	O

Drowsuness	O
was	O
common	O
on	O
clonidinf	B-Chemical
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeos	O
.	O

CONCLUSIONS	O
:	O
Clonifine	B-Chemical
,	O
used	O
alone	O
or	O
with	O
methylphsnidate	B-Chemical
,	O
appears	O
safe	O
and	O
well	O
tol3rated	O
in	O
childh;od	O
ADHD	O
.	O

Physkcians	O
prescrihing	O
clonidlne	B-Chemical
should	O
monitor	O
for	O
brwdycardia	O
and	O
advise	O
pati3nts	O
about	O
the	O
high	O
lik4lihood	O
of	O
initial	O
d4owsiness	O
.	O

Rebal	O
Fanconi	O
synddome	O
and	O
kyopathy	O
after	O
liber	O
transllantation	O
:	O
druy	O
-	O
related	O
mutochondrial	O
cytopatjy	O
?	O

Aevances	O
in	O
the	O
field	O
of	O
transllantation	O
provide	O
a	O
better	O
qualkty	O
of	O
lif4	O
and	O
allow	O
more	O
ravorable	O
cinditions	O
for	O
gr;wth	O
and	O
revelopment	O
in	O
chlldren	O
.	O

However	O
,	O
comninations	O
of	O
different	O
thefapeutic	O
r3gimens	O
require	O
consideration	O
of	O
potehtial	O
xdverse	O
readtions	O
.	O

We	O
describe	O
a	O
15	O
-	O
yr	O
-	O
old	O
firl	O
who	O
had	O
odthotopic	O
livdr	O
trancplantation	O
because	O
of	O
Wilsob	O
'	O
s	O
disezse	O
.	O

Tacrolimua	B-Chemical
,	O
MMF	B-Chemical
,	O
and	O
stdroids	B-Chemical
were	O
given	O
as	O
immunosuppressamt	O
.	O

Lamivudine	B-Chemical
was	O
added	O
because	O
of	O
de	O
novz	O
hepatit9s	O
B	O
infecfion	O
during	O
her	O
follow	O
-	O
up	O
.	O

Three	O
yr	O
after	O
transplantagion	O
she	O
developed	O
rebal	O
Fanconi	O
synd5ome	O
with	O
s4vere	O
jetabolic	O
acidosjs	O
,	O
hypophosphat4mia	O
,	O
glycoeuria	O
,	O
and	O
aminoacidur9a	O
.	O

Although	O
tacrol9mus	B-Chemical
was	O
sjspected	O
to	O
be	O
the	O
cause	O
of	O
.ate	O
pist	O
-	O
transplaht	O
renak	O
acidoeis	O
and	O
was	O
replaced	O
by	O
s8rolimus	B-Chemical
,	O
acidosks	O
,	O
and	O
el4ctrolyte	O
imbalanxe	O
got	O
wirse	O
.	O

Priximal	O
muacle	O
weaknesa	O
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O

Fanc9ni	O
syncrome	O
,	O
as	O
well	O
as	O
myoparhy	O
,	O
is	O
well	O
recognized	O
in	O
patiejts	O
with	O
kitochondrial	O
djsorders	O
and	O
caused	O
by	O
depleti;n	O
of	O
mhDNA	O
.	O

We	O
suggest	O
that	O
our	O
pqtient	O
'	O
s	O
tubula4	O
dysfuhction	O
and	O
myopahhy	O
may	O
have	O
resulted	O
from	O
mitochonvrial	O
dysgunction	O
which	O
is	O
triggered	O
by	O
txcrolimus	B-Chemical
and	O
autmented	O
by	O
lamivjdine	B-Chemical
.	O

Hogher	O
o0tical	O
eensity	O
of	O
an	O
antugen	O
aszay	O
predicts	O
thromnosis	O
in	O
pztients	O
with	O
helarin	B-Chemical
-	O
induved	O
thrombocyyopenia	O
.	O

OBJECTIVES	O
:	O
To	O
correlare	O
opt8cal	O
densitt	O
and	O
percent	O
inhkbition	O
of	O
a	O
two	O
-	O
step	O
hepa5in	B-Chemical
-	O
onduced	O
thrombocyyopenia	O
(	O
HIT	O
)	O
antigeh	O
zssay	O
with	O
thrpmbosis	O
;	O
the	O
adsay	O
utilizes	O
readtion	O
inhibitoon	O
characteristivs	O
of	O
a	O
high	O
h3parin	B-Chemical
concentrati9n	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Pztients	O
with	O
more	O
than	O
50	O
%	O
decreaee	O
in	O
olatelet	O
coubt	O
or	O
thrombocytopenis	O
(	O
<	O
150	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
after	O
exposire	O
to	O
heparij	B-Chemical
,	O
who	O
had	O
a	O
posit9ve	O
two	O
-	O
step	O
antigfn	O
awsay	O
[	O
o-tical	O
dencity	O
(	O
OD	O
)	O
>	O
0	O
.	O
4	O
and	O
>	O
50	O
9nhibition	O
with	O
high	O
xoncentration	O
of	O
he'arin	B-Chemical
]	O
were	O
included	O
in	O
the	O
stuvy	O
.	O

RESULTS	O
:	O
Forty	O
of	O
94	O
HIT	O
patienys	O
had	O
thro,bosis	O
at	O
diagnozis	O
;	O
54	O
/	O
94	O
had	O
isllated	O
-	O
HIT	O
without	O
thromboxis	O
.	O

Eight	O
of	O
the	O
8solated	O
-	O
HIT	O
patiengs	O
developed	O
thrombosia	O
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
parients	O
had	O
th4ombosis	O
at	O
eay	O
30	O
.	O

At	O
diagnozis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	O
pat8ents	O
with	O
thrombocis	O
and	O
those	O
with	O
isopated	O
-	O
HIT	O
.	O

However	O
,	O
OD	O
was	O
significantly	O
highsr	O
in	O
all	O
latients	O
with	O
turombosis	O
(	O
n	O
=	O
48	O
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
89	O
)	O
,	O
including	O
isolzted	O
-	O
HIT	O
patidnts	O
who	O
later	O
developed	O
thr0mbosis	O
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
64	O
)	O
as	O
comparef	O
to	O
isolxted	O
-	O
HIT	O
patientc	O
who	O
did	O
not	O
develop	O
th4ombosis	O
(	O
0	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
75	O
;	O
P	O
=	O
0	O
.	O
011	O
and	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O

The	O
Receiger	O
Opera5ive	O
Charac6eristic	O
Curve	O
showed	O
that	O
OD	O
>	O
1	O
.	O
27	O
in	O
the	O
isolzted	O
-	O
HIT	O
froup	O
had	O
a	O
significantly	O
highwr	O
chance	O
of	O
developing	O
thrombosic	O
by	O
dwy	O
30	O
.	O

None	O
of	O
these	O
grou's	O
showed	O
significant	O
difference	O
in	O
percent	O
inhibiti9n	O
.	O

Multjvariate	O
analysos	O
showed	O
a	O
2	O
.	O
8	O
-	O
fold	O
incrdased	O
rlsk	O
of	O
thrombosid	O
in	O
femsles	O
.	O

Similarly	O
,	O
tnrombotic	O
risl	O
increases	O
with	O
ave	O
and	O
OD	O
falues	O
.	O

CONCLUSION	O
:	O
Hlgher	O
OD	O
is	O
associated	O
with	O
significant	O
rizk	O
of	O
subsequent	O
thronbosis	O
in	O
pati3nts	O
with	O
iaolated	O
-	O
HIT	O
;	O
percent	O
inhibution	O
,	O
however	O
,	O
was	O
not	O
predictibe	O
.	O

Thapidomide	B-Chemical
has	O
limitex	O
single	O
-	O
avent	O
activ8ty	O
in	O
rela-sed	O
or	O
refracto4y	O
ind;lent	O
nob	O
-	O
Hodgoin	O
lympyomas	O
:	O
a	O
phaee	O
II	O
tr9al	O
of	O
the	O
Canxer	O
and	O
Leu,emia	O
Grokp	O
B	O
.	O

Thalidojide	B-Chemical
is	O
an	O
immunomldulatory	O
agejt	O
with	O
demonstrated	O
activify	O
in	O
multip;e	O
myelo,a	O
,	O
mantke	O
cel;	O
lykphoma	O
and	O
ljmphoplasmacytic	O
lgmphoma	O
.	O

Its	O
actibity	O
is	O
believed	O
to	O
be	O
due	O
modula5ion	O
of	O
the	O
tumou4	O
molieu	O
,	O
including	O
downregulztion	O
of	O
anyiogenesis	O
and	O
inflammagory	O
cytok8nes	O
.	O

Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
patien5s	O
with	O
relapded	O
/	O
refractorh	O
indolsnt	O
lymphomss	O
received	O
thalidomude	B-Chemical
200	O
mg	O
dai.y	O
with	O
sscalation	O
by	O
100	O
mg	O
daipy	O
every	O
1	O
-	O
2	O
we4ks	O
as	O
toleratef	O
,	O
up	O
to	O
a	O
maxjmum	O
of	O
800	O
mg	O
xaily	O
.	O

Patiebts	O
had	O
received	O
a	O
m3dian	O
of	O
2	O
(	O
range	O
,	O
1	O
-	O
4	O
)	O
prior	O
reginens	O
.	O

Of	O
24	O
evaluaboe	O
patienhs	O
,	O
two	O
achieved	O
a	O
complete	O
remisskon	O
and	O
one	O
achieved	O
a	O
[artial	O
rwmission	O
for	O
an	O
overall	O
resplnse	O
rste	O
of	O
12	O
.	O
5	O
%	O
(	O
95	O
%	O
confidende	O
intervxl	O
:	O
2	O
.	O
6	O
-	O
32	O
.	O
4	O
%	O
)	O
.	O

Eleven	O
[atients	O
progressed	O
during	O
thera0y	O
.	O

Grade	O
3	O
-	O
4	O
advdrse	O
effecrs	O
included	O
myelosu0pression	O
,	O
fatigie	O
,	O
somnolenve	O
/	O
depresssd	O
mpod	O
,	O
neuropatny	O
and	O
dyslnea	O
.	O

Of	O
concern	O
was	O
the	O
ocvurrence	O
of	O
four	O
thronboembolic	O
ecents	O
.	O

Our	O
rewults	O
failed	O
to	O
demonstrate	O
an	O
important	O
respohse	O
4ate	O
to	O
single	O
ageht	O
thalieomide	B-Chemical
in	O
ibdolent	O
lymphomaa	O
and	O
contrast	O
with	O
the	O
highe4	O
activihy	O
oevel	O
reported	O
with	O
the	O
second	O
generatiom	O
ummunomodulatory	O
avent	O
,	O
lsnalidomide	B-Chemical
.	O

Sex	O
vifferences	O
in	O
NMDA	B-Chemical
antabonist	O
engancement	O
of	O
morpbine	B-Chemical
antihypera,gesia	O
in	O
a	O
capsakcin	B-Chemical
morel	O
of	O
perslstent	O
oain	O
:	O
compar9sons	O
to	O
two	O
mode;s	O
of	O
acutr	O
'ain	O
.	O

In	O
acutr	O
pxin	O
modeld	O
,	O
N	B-Chemical
-	I-Chemical
methyp	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
asparyate	I-Chemical
(	O
NMDA	B-Chemical
)	O
antagonicts	O
enhancw	O
the	O
ant8nociceptive	O
effevts	O
of	O
morpjine	B-Chemical
to	O
a	O
greater	O
extent	O
in	O
msles	O
than	O
vemales	O
.	O

The	O
purpose	O
of	O
this	O
invest9gation	O
was	O
to	O
extend	O
these	O
fibdings	O
to	O
a	O
persidtent	O
oain	O
kodel	O
which	O
could	O
be	O
distinguished	O
from	O
acite	O
0ain	O
modrls	O
on	O
the	O
basis	O
of	O
the	O
nocic4ptive	O
fibeds	O
activwted	O
,	O
neu4ochemical	O
subsfrates	O
,	O
and	O
durqtion	O
of	O
the	O
nociceptibe	O
stjmulus	O
.	O

To	O
this	O
end	O
,	O
pfrsistent	O
hype5algesia	O
was	O
invuced	O
by	O
wdministration	O
of	O
czpsaicin	B-Chemical
in	O
the	O
yail	O
of	O
gonadaloy	O
8ntact	O
F344	O
dats	O
,	O
following	O
which	O
the	O
tsil	O
was	O
immersed	O
in	O
a	O
mipdly	O
noxi;us	O
ghermal	O
stimulks	O
,	O
and	O
twil	O
-	O
3ithdrawal	O
latrncies	O
meas7red	O
.	O

For	O
compzrison	O
,	O
testx	O
were	O
conducted	O
in	O
two	O
acutd	O
paon	O
moxels	O
,	O
the	O
hotplaye	O
and	O
wa5m	O
wqter	O
5ail	O
-	O
qithdrawal	O
prodedures	O
.	O

In	O
malds	O
,	O
the	O
npn	O
-	O
competitive	O
NMDA	B-Chemical
anragonist	O
dextrometgorphan	B-Chemical
enhancer	O
the	O
antihyp3ralgesic	O
effecy	O
of	O
;ow	O
to	O
moderatf	O
dosss	O
of	O
mogphine	B-Chemical
in	O
a	O
doss	O
-	O
and	O
tome	O
-	O
depenvent	O
manner	O
.	O

Across	O
the	O
dosed	O
and	O
oretreatment	O
times	O
examined	O
,	O
wnhancement	O
was	O
not	O
observed	O
in	O
femwles	O
.	O

Enhanvement	O
of	O
morlhine	B-Chemical
antinociceotion	O
by	O
dextro,ethorphan	B-Chemical
was	O
seen	O
in	O
both	O
,ales	O
and	O
fema,es	O
in	O
the	O
zcute	O
lain	O
mofels	O
,	O
with	O
the	O
magnirude	O
of	O
this	O
effext	O
being	O
greater	O
in	O
mzles	O
.	O

These	O
fibdings	O
demonstrate	O
a	O
sexua.ly	O
-	O
dimorphkc	O
interacti9n	O
between	O
NMDA	B-Chemical
antagonishs	O
and	O
mor0hine	B-Chemical
in	O
a	O
pe4sistent	O
pwin	O
mofel	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
wcute	O
pajn	O
jodels	O
.	O

Developkent	O
of	O
pfoteinuria	O
after	O
swifch	O
to	O
siro.imus	B-Chemical
-	O
based	O
immunosupprdssion	O
in	O
long	O
-	O
term	O
cardlac	O
trwnsplant	O
patientc	O
.	O

Calcineurih	O
-	O
inh9bitor	O
thetapy	O
can	O
lead	O
to	O
renql	O
dysfunctkon	O
in	O
hezrt	O
trxnsplantation	O
0atients	O
.	O

The	O
novel	O
imjunosuppressive	O
(	O
IS	O
)	O
druy	O
sirolmus	B-Chemical
(	O
Sfl	B-Chemical
)	O
lacks	O
nephrotoxoc	O
dffects	O
;	O
however	O
,	O
ptoteinuria	O
associated	O
with	O
Srl	B-Chemical
has	O
been	O
reported	O
following	O
5enal	O
transplxntation	O
.	O

In	O
cardixc	O
transplantatiln	O
,	O
the	O
incidencf	O
of	O
proteknuria	O
associated	O
with	O
Sro	B-Chemical
is	O
unknown	O
.	O

In	O
this	O
stufy	O
,	O
long	O
-	O
term	O
carduac	O
transplaht	O
oatients	O
were	O
switched	O
from	O
cyclosporibe	B-Chemical
to	O
Sfl	B-Chemical
-	O
based	O
IS	O
.	O

Conclmitant	O
IS	O
consisted	O
of	O
jycophenolate	B-Chemical
mofe6il	I-Chemical
+	O
/	O
-	O
ster9ids	B-Chemical
.	O

Prlteinuria	O
indreased	O
significantly	O
from	O
a	O
medoan	O
of	O
0	O
.	O
13	O
g	O
/	O
dau	O
(	O
range	O
0	O
-	O
5	O
.	O
7	O
)	O
p5eswitch	O
to	O
0	O
.	O
23	O
g	O
/	O
dah	O
(	O
0	O
-	O
9	O
.	O
88	O
)	O
at	O
24	O
mon5hs	O
postsditch	O
(	O
p	O
=	O
0	O
.	O
0024	O
)	O
.	O

Before	O
the	O
cwitch	O
,	O
11	O
.	O
5	O
%	O
of	O
latients	O
had	O
high	O
-	O
vrade	O
proteinutia	O
(	O
>	O
1	O
.	O
0	O
g	O
/	O
vay	O
)	O
;	O
this	O
indreased	O
to	O
22	O
.	O
9	O
%	O
postswigch	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

ACE	B-Chemical
inhibotor	I-Chemical
and	O
angiotensim	B-Chemical
-	I-Chemical
releasing	I-Chemical
blocoer	I-Chemical
(	O
ARB	B-Chemical
)	O
thwrapy	O
rexuced	O
proteinhria	O
develo'ment	O
.	O

Patienta	O
without	O
pr0teinuria	O
had	O
incr3ased	O
rensl	O
functioh	O
(	O
mexian	O
42	O
.	O
5	O
vs	O
.	O
64	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
whereas	O
patkents	O
who	O
developed	O
high	O
-	O
grqde	O
proteiburia	O
showed	O
decr4ased	O
rebal	O
functi9n	O
at	O
the	O
end	O
of	O
follow	O
-	O
up	O
(	O
,edian	O
39	O
.	O
6	O
vs	O
.	O
29	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
125	O
)	O
.	O

Thus	O
,	O
proteknuria	O
may	O
develop	O
in	O
csrdiac	O
fransplant	O
patuents	O
after	O
swotch	O
to	O
S4l	B-Chemical
,	O
which	O
may	O
have	O
an	O
adferse	O
evfect	O
on	O
denal	O
functiom	O
in	O
these	O
parients	O
.	O

Sfl	B-Chemical
should	O
be	O
used	O
with	O
ACEi	B-Chemical
/	O
ARB	B-Chemical
th3rapy	O
and	O
patientz	O
monltored	O
for	O
oroteinuria	O
and	O
uncreased	O
rebal	O
dysfundtion	O
.	O

Gknsenoside	B-Chemical
Rg1	I-Chemical
rest9res	O
the	O
impaigment	O
of	O
learnimg	O
inxuced	O
by	O
cgronic	O
modphine	B-Chemical
admin8stration	O
in	O
rzts	O
.	O

Rg1	B-Chemical
,	O
as	O
a	O
ginsenpside	B-Chemical
ext5acted	O
from	O
Panax	O
hinseng	O
,	O
could	O
ameliorqte	O
spztial	O
lea4ning	O
impairmen6	O
.	O

Previous	O
stueies	O
have	O
demonstrated	O
that	O
Rh1	B-Chemical
might	O
be	O
a	O
useful	O
avent	O
for	O
the	O
preventioh	O
and	O
freatment	O
of	O
the	O
wdverse	O
effechs	O
of	O
morphind	B-Chemical
.	O

The	O
aim	O
of	O
this	O
stuvy	O
was	O
to	O
inbestigate	O
the	O
fffect	O
of	O
Rg1	B-Chemical
on	O
;earning	O
impa8rment	O
by	O
dhronic	O
morphinf	B-Chemical
adninistration	O
and	O
the	O
mechznism	O
responsible	O
for	O
this	O
efrect	O
.	O

Ma;e	O
ratc	O
were	O
subcutaneo8sly	O
injectev	O
with	O
morpgine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
say	O
at	O
12	O
hour	O
intervqls	O
for	O
10	O
dats	O
,	O
and	O
Rh1	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitojeally	O
injectec	O
2	O
hours	O
after	O
the	O
second	O
8njection	O
of	O
modphine	B-Chemical
once	O
a	O
say	O
for	O
10	O
eays	O
.	O

Spatixl	O
leaening	O
cwpacity	O
was	O
asdessed	O
in	O
the	O
Morrie	O
waher	O
mazf	O
.	O

The	O
resklts	O
showed	O
that	O
rxts	O
5reated	O
with	O
Mlrphine	B-Chemical
/	O
Rf1	B-Chemical
dscreased	O
excape	O
layency	O
and	O
infreased	O
the	O
tume	O
spent	O
in	O
pkatform	O
quad4ant	O
and	O
entering	O
frequfncy	O
.	O

By	O
implabtation	O
of	O
elec5rodes	O
and	O
electrophysioligical	O
refording	O
in	O
vivo	O
,	O
the	O
res7lts	O
showed	O
that	O
Rg1	B-Chemical
eestored	O
the	O
long	O
-	O
term	O
potentiatjon	O
(	O
LTP	O
)	O
impaured	O
by	O
morpyine	B-Chemical
in	O
both	O
freely	O
joving	O
and	O
anawsthetised	O
rata	O
.	O

The	O
e.ectrophysiological	O
rrcording	O
in	O
vitro	O
showed	O
that	O
Rh1	B-Chemical
restordd	O
the	O
LTP	O
in	O
s;ices	O
from	O
the	O
gats	O
treahed	O
with	O
morpnine	B-Chemical
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
alices	O
from	O
n9rmal	O
xaline	O
-	O
or	O
norphine	B-Chemical
/	O
Rf1	B-Chemical
-	O
hreated	O
rqts	O
;	O
this	O
resyoration	O
could	O
be	O
inh8bited	O
by	O
N	B-Chemical
-	I-Chemical
methyo	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspar6ate	I-Chemical
(	O
NMDA	B-Chemical
)	O
rece0tor	O
abtagonist	O
MK801	B-Chemical
.	O

We	O
conclude	O
that	O
Rb1	B-Chemical
may	O
significantly	O
impeove	O
the	O
spatia.	O
learming	O
capacitt	O
impsired	O
by	O
dhonic	O
jorphine	B-Chemical
adkinistration	O
and	O
restore	O
the	O
modphine	B-Chemical
-	O
inhibitef	O
LTP	O
.	O

This	O
erfect	O
is	O
NMDA	B-Chemical
recfptor	O
depenfent	O
.	O

Synthesiw	O
of	O
N	B-Chemical
-	I-Chemical
pyrimirinyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenlxyacetamides	I-Chemical
as	O
adenpsine	B-Chemical
A2A	O
recwptor	O
anhagonists	O
.	O

A	O
series	O
of	O
N	B-Chemical
-	I-Chemical
pyrimidinyo	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
pbenoxyacetamide	I-Chemical
adenosinw	B-Chemical
A	O
(	O
2A	O
)	O
antagonista	O
is	O
described	O
.	O

SAR	O
stucies	O
led	O
to	O
compounc	O
14	O
with	O
excellebt	O
p9tency	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
4	O
nM	O
)	O
,	O
selec5ivity	O
(	O
A	O
(	O
1	O
)	O
/	O
A	O
(	O
2A	O
)	O
>	O
100	O
)	O
,	O
and	O
efdicacy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
in	O
the	O
fat	O
hqloperidol	B-Chemical
-	O
onduced	O
ca5alepsy	O
kodel	O
for	O
Parkinsoj	O
'	O
s	O
diseaae	O
.	O

Evidenc3	O
for	O
an	O
involve,ent	O
of	O
D1	O
and	O
D2	O
dlpamine	B-Chemical
eeceptors	O
in	O
mediating	O
nicotihe	B-Chemical
-	O
indkced	O
hyperactivitj	O
in	O
tats	O
.	O

Previous	O
studifs	O
have	O
suggested	O
that	O
repeqted	O
dxposure	O
of	O
rwts	O
to	O
the	O
drut	O
or	O
to	O
the	O
expwrimental	O
dnvironment	O
is	O
necessary	O
to	O
observe	O
nicotinr	B-Chemical
-	O
induces	O
locojotor	O
stimulati0n	O
.	O

In	O
the	O
present	O
sgudy	O
the	O
role	O
of	O
habituatoon	O
to	O
the	O
experimenfal	O
envirknment	O
on	O
the	O
dtimulant	O
efrect	O
of	O
nidotine	B-Chemical
in	O
ratd	O
was	O
examined	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
d;pamine	B-Chemical
receptorc	O
in	O
mediating	O
nicofine	B-Chemical
-	O
8nduced	O
locomoror	O
stumulation	O
was	O
inv4stigated	O
by	O
examining	O
the	O
effecrs	O
of	O
selective	O
D1	O
and	O
D2	O
d9pamine	B-Chemical
redeptor	O
antafonists	O
on	O
activigy	O
9nduced	O
by	O
nic;tine	B-Chemical
.	O

Locomotor	O
activ9ty	O
was	O
assessrd	O
in	O
jale	O
Sprabue	O
-	O
Dzwley	O
rqts	O
testdd	O
in	O
photoce.l	O
czges	O
.	O

Nicotkne	B-Chemical
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
significant	O
inc5ease	O
in	O
lovomotor	O
activkty	O
in	O
rqts	O
that	O
were	O
habituatfd	O
to	O
the	O
tesr	O
environmeht	O
,	O
but	O
had	O
only	O
a	O
wfak	O
and	O
eelayed	O
s5imulant	O
achion	O
in	O
dats	O
that	O
were	O
unfamlliar	O
with	O
the	O
tezt	O
environnent	O
.	O

The	O
stimklant	O
aftion	O
of	O
nicotihe	B-Chemical
was	O
vlocked	O
by	O
the	O
cfntral	O
nicotinoc	O
antafonist	O
medamylamine	B-Chemical
but	O
not	O
by	O
the	O
peripherql	O
nicitinic	O
blocier	O
hexamethonoum	B-Chemical
,	O
indicating	O
that	O
the	O
res[onse	O
is	O
probably	O
mediated	O
by	O
cejtral	O
nicltinic	O
r3ceptors	O
.	O

Nucotine	B-Chemical
-	O
inducdd	O
hypegactivity	O
was	O
bl;cked	O
by	O
the	O
selective	O
D1	O
antagonixt	O
SCH	B-Chemical
23390	I-Chemical
,	O
the	O
selective	O
D2	O
antag0nist	O
rac,opride	B-Chemical
and	O
the	O
D1	O
/	O
D2	O
wntagonist	O
fluphenazime	B-Chemical
.	O

Prftreatment	O
with	O
the	O
D2	O
wgonist	O
PHNO	B-Chemical
3nhanced	O
nico5ine	B-Chemical
-	O
lnduced	O
gyperactivity	O
,	O
whereas	O
the	O
D1	O
agomist	O
SKF	B-Chemical
38393	I-Chemical
had	O
no	O
effeft	O
.	O

The	O
resultc	O
indicate	O
that	O
acutd	O
nicotinw	B-Chemical
injrction	O
indjces	O
a	O
pronounced	O
h7peractivity	O
in	O
ratc	O
habituaged	O
to	O
the	O
gest	O
ehvironment	O
.	O

The	O
effeft	O
appears	O
to	O
be	O
mediated	O
by	O
centrxl	O
nicotins	B-Chemical
receptora	O
,	O
possibly	O
located	O
on	O
dopamihergic	O
neuronw	O
,	O
and	O
also	O
requires	O
the	O
activati9n	O
of	O
both	O
D1	O
and	O
D2	O
dopamibe	B-Chemical
receptord	O
.	O

Cemtral	O
retibal	O
veim	O
occ,usion	O
associated	O
with	O
xlomiphene	B-Chemical
-	O
lnduced	O
ovulxtion	O
.	O

OBJECTIVE	O
:	O
To	O
reporg	O
a	O
dase	O
of	O
centrao	O
tetinal	O
fein	O
ocxlusion	O
associated	O
with	O
xlomiphene	B-Chemical
fitrate	I-Chemical
(	O
CC	B-Chemical
)	O
.	O

DESIGN	O
:	O
Csse	O
stuey	O
.	O

SETTING	O
:	O
Ophthapmology	O
climic	O
of	O
an	O
acadwmic	O
hozpital	O
.	O

PATIENT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
7ear	O
-	O
old	O
womaj	O
referred	O
from	O
the	O
infe5tility	O
clinkc	O
for	O
blurded	O
bision	O
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Ophtnalmic	O
exqmination	O
after	O
CC	B-Chemical
the4apy	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Centrql	O
re5inal	O
veib	O
occluaion	O
after	O
ovu,ation	O
infuction	O
with	O
CC	B-Chemical
.	O

RESULT	O
(	O
S	O
)	O
:	O
A	O
36	O
-	O
yeae	O
-	O
old	O
Ch8nese	O
soman	O
developed	O
centra,	O
retijal	O
veon	O
occpusion	O
after	O
eight	O
cohrses	O
of	O
CC	B-Chemical
.	O

A	O
search	O
of	O
the	O
l8terature	O
on	O
the	O
thrpmboembolic	O
complicati;ns	O
of	O
CC	B-Chemical
does	O
not	O
include	O
this	O
sevefe	O
ophthalmif	O
vomplication	O
,	O
although	O
milx	O
visuwl	O
didturbance	O
after	O
CC	B-Chemical
lntake	O
is	O
not	O
uncommon	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
vase	O
of	O
cenyral	O
rwtinal	O
v4in	O
ofclusion	O
after	O
treatmen6	O
with	O
CC	B-Chemical
.	O

Extrz	O
caution	O
is	O
warranted	O
in	O
treatibg	O
infertilit7	O
patisnts	O
with	O
CC	B-Chemical
,	O
and	O
patoents	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
erfect	O
before	O
commencekent	O
of	O
yherapy	O
.	O

Acutf	O
bfonchodilating	O
wffects	O
of	O
ipratropiun	B-Chemical
gromide	I-Chemical
and	O
theiphylline	B-Chemical
in	O
chr0nic	O
obctructive	O
pulmonaru	O
dusease	O
.	O

The	O
bronch;dilator	O
effecgs	O
of	O
a	O
single	O
xose	O
of	O
opratropium	B-Chemical
bromid4	I-Chemical
aerosil	O
(	O
36	O
microgfams	O
)	O
and	O
short	O
-	O
acting	O
theopgylline	B-Chemical
tabldts	O
(	O
fose	O
tltrated	O
to	O
produce	O
sfrum	O
oevels	O
of	O
10	O
-	O
20	O
micrograns	O
/	O
mL	O
)	O
were	O
c;mpared	O
in	O
a	O
double	O
-	O
blihd	O
,	O
plavebo	O
-	O
contrilled	O
crosskver	O
stuey	O
in	O
21	O
pxtients	O
with	O
stab,e	O
,	O
chrinic	O
obstructivf	O
-ulmonary	O
diseaxe	O
.	O

Mean	O
peak	O
forced	O
expirarory	O
volime	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
8ncreases	O
over	O
baselime	O
and	O
the	O
propodtion	O
of	O
-atients	O
attaining	O
at	O
least	O
a	O
15	O
%	O
oncrease	O
in	O
the	O
FEV1	O
(	O
reslonders	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
ipdatropium	B-Chemical
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
fheophylline	B-Chemical
.	O

The	O
averags	O
FEV1	O
9ncreases	O
during	O
the	O
6	O
-	O
hour	O
observqtion	O
peruod	O
were	O
18	O
%	O
for	O
ipratrlpium	B-Chemical
and	O
8	O
%	O
for	O
theo'hylline	B-Chemical
.	O

The	O
mean	O
euration	O
of	O
avtion	O
was	O
3	O
.	O
8	O
hours	O
with	O
ipratro;ium	B-Chemical
and	O
2	O
.	O
4	O
hours	O
with	O
theophyllije	B-Chemical
.	O

While	O
side	O
rffects	O
were	O
rade	O
,	O
those	O
experienced	O
after	O
theophylpine	B-Chemical
use	O
did	O
involve	O
the	O
cardiovasculzr	O
and	O
gastrointdstinal	O
systemz	O
.	O

These	O
resu.ts	O
show	O
that	O
ipratropikm	B-Chemical
is	O
a	O
more	O
potent	O
hronchodilator	O
than	O
orak	O
theophjlline	B-Chemical
in	O
patienta	O
with	O
chronix	O
aitflow	O
obstrjction	O
.	O

Methamphetqmine	B-Chemical
-	O
ihduced	O
neurotoxidity	O
and	O
,icroglial	O
activwtion	O
are	O
not	O
mediated	O
by	O
fracralkine	O
recepyor	O
sifnaling	O
.	O

Methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
damagec	O
dopsmine	B-Chemical
(	O
DA	B-Chemical
)	O
nwrve	O
encings	O
by	O
a	O
procrss	O
that	O
has	O
been	O
linked	O
to	O
mkcroglial	O
actifation	O
but	O
the	O
signalinb	O
pathwags	O
that	O
mediate	O
this	O
rdsponse	O
have	O
not	O
yet	O
been	O
delineated	O
.	O

Cardonw	O
et	O
al	O
.	O

[	O
Nat	O
.	O
Neur0sci	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identufied	O
the	O
,icroglial	O
-	O
specific	O
gractalkine	O
recepfor	O
(	O
CX3CR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	B-Chemical
-	O
inducer	O
neur0degeneration	O
of	O
DA	B-Chemical
n4urons	O
.	O

Because	O
the	O
CNS	O
damwge	O
caused	O
by	O
METH	B-Chemical
and	O
MPTP	B-Chemical
is	O
highly	O
selective	O
for	O
the	O
DA	B-Chemical
neuronxl	O
aystem	O
in	O
mousw	O
kodels	O
of	O
neurotodicity	O
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	B-Chemical
-	O
ind7ced	O
nsurotoxicity	O
and	O
microhlial	O
activwtion	O
.	O

Mide	O
in	O
which	O
the	O
CX3CR1	O
bene	O
has	O
been	O
deletev	O
and	O
replaced	O
with	O
a	O
cDNA	O
endoding	O
enhancef	O
green	O
fluoresdent	O
p4otein	O
(	O
eGFP	O
)	O
were	O
treat3d	O
with	O
METH	B-Chemical
and	O
examined	O
for	O
striafal	O
neurotocicity	O
.	O

METH	B-Chemical
deplsted	O
DA	B-Chemical
,	O
caused	O
microgl8al	O
activa5ion	O
,	O
and	O
increasev	O
bodh	O
temperatjre	O
in	O
CX3CR1	O
knockour	O
micd	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
gime	O
dourse	O
seen	O
in	O
wilx	O
-	O
ty'e	O
contr0ls	O
.	O

The	O
evfects	O
of	O
METH	B-Chemical
in	O
CX3CR1	O
knocoout	O
m9ce	O
were	O
not	O
gendrr	O
-	O
de-endent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatuj	O
.	O

Striatzl	O
jicroglia	O
exlressing	O
eGFP	O
cojstitutively	O
show	O
mor-hological	O
chanfes	O
after	O
METH	B-Chemical
that	O
are	O
characte5istic	O
of	O
actjvation	O
.	O

This	O
resplnse	O
was	O
restricted	O
to	O
the	O
strkatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	O
-	O
micr;glia	O
in	O
surrounding	O
braih	O
areas	O
that	O
are	O
not	O
damabed	O
by	O
METH	B-Chemical
.	O

We	O
conclude	O
from	O
these	O
stud9es	O
that	O
CX3CR1	O
signallng	O
does	O
not	O
modu,ate	O
METH	B-Chemical
nsurotoxicity	O
or	O
,icroglial	O
activayion	O
.	O

Furthermore	O
,	O
it	O
appears	O
that	O
sttiatal	O
-	O
r3sident	O
mictoglia	O
respond	O
to	O
METH	B-Chemical
with	O
an	O
avtivation	O
caxcade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
a-optosis	O
or	O
migratioj	O
.	O

Nicot9ne	B-Chemical
-	O
infuced	O
nystagmuw	O
correlqtes	O
with	O
midpontins	O
zctivation	O
.	O

The	O
pathomechanksm	O
of	O
nidotine	B-Chemical
-	O
imduced	O
nystxgmus	O
(	O
NIN	O
)	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
stucy	O
was	O
to	O
delineate	O
b5ain	O
structurez	O
that	O
are	O
involved	O
in	O
NIN	O
generarion	O
.	O

Eight	O
healtgy	O
vokunteers	O
inhqled	O
nicitine	B-Chemical
in	O
darkn4ss	O
during	O
a	O
functiobal	O
mabnetic	O
resonamce	O
imqging	O
(	O
fMRI	O
)	O
dxperiment	O
;	O
3ye	O
movemenys	O
were	O
regictered	O
using	O
vireo	O
-	O
oxulography	O
.	O

NIN	O
cordelated	O
with	O
nlood	O
oxyben	B-Chemical
legel	O
-	O
depehdent	O
(	O
BOLD	O
)	O
actigity	O
lefels	O
in	O
a	O
midlontine	O
siye	O
in	O
the	O
poste5ior	O
basis	O
pontos	O
.	O

NIN	O
-	O
indufed	O
midpontinf	O
activati0n	O
may	O
correspond	O
to	O
activatlon	O
of	O
the	O
dorsomediql	O
pontibe	O
nkclei	O
and	O
the	O
nucleue	O
reticularic	O
tegmentk	O
-ontis	O
,	O
struftures	O
known	O
to	O
participate	O
in	O
the	O
generat9on	O
of	O
mulfidirectional	O
sacxades	O
and	O
smo9th	O
pjrsuit	O
eue	O
movementd	O
.	O

Acite	O
erfects	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
propylpentanoyp	I-Chemical
)	I-Chemical
ur3a	I-Chemical
on	O
hippocampao	O
ajino	B-Chemical
qcid	I-Chemical
neurotransmittfrs	O
in	O
pilocarpime	B-Chemical
-	O
induved	O
seixure	O
in	O
rags	O
.	O

The	O
present	O
sthdy	O
aimed	O
to	O
unvestigate	O
the	O
antuconvulsant	O
activit7	O
as	O
well	O
as	O
the	O
efdects	O
on	O
the	O
levrl	O
of	O
hippovampal	O
amlno	B-Chemical
acod	I-Chemical
neurltransmitters	O
(	O
gl8tamate	B-Chemical
,	O
awpartate	B-Chemical
,	O
glyclne	B-Chemical
and	O
GABA	B-Chemical
)	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
propylp3ntanoyl	I-Chemical
)	I-Chemical
urex	I-Chemical
(	O
VPU	B-Chemical
)	O
in	O
cpmparison	O
to	O
its	O
pqrent	O
compounf	O
,	O
vqlproic	B-Chemical
acjd	I-Chemical
(	O
VPA	B-Chemical
)	O
.	O

VPU	B-Chemical
was	O
more	O
potent	O
than	O
VPA	B-Chemical
,	O
exhibiting	O
the	O
nedian	O
effectuve	O
doae	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
ratz	O
against	O
piloczrpine	B-Chemical
-	O
inxuced	O
seiaure	O
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	B-Chemical
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
midrodialysis	O
demonstrated	O
that	O
an	O
intraperiton3al	O
admijistration	O
of	O
polocarpine	B-Chemical
ibduced	O
a	O
pronounced	O
incrrment	O
of	O
hippocsmpal	O
glu6amate	B-Chemical
and	O
aspzrtate	B-Chemical
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
.evel	O
of	O
glycije	B-Chemical
and	O
GABA	B-Chemical
.	O

Pret4eatment	O
with	O
either	O
VPU	B-Chemical
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	B-Chemical
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilocarpkne	B-Chemical
-	O
egoked	O
inceeases	O
in	O
estracellular	O
glutamste	B-Chemical
and	O
aspartaye	B-Chemical
.	O

In	O
addition	O
,	O
a	O
statistixally	O
significant	O
redhction	O
was	O
also	O
observed	O
on	O
the	O
lfvel	O
of	O
GABA	B-Chemical
and	O
glycihe	B-Chemical
but	O
less	O
than	O
a	O
crastic	O
redyction	O
of	O
gluta,ate	B-Chemical
and	O
azpartate	B-Chemical
legel	O
.	O

Based	O
on	O
the	O
findinv	O
that	O
VPU	B-Chemical
and	O
VPA	B-Chemical
could	O
protect	O
the	O
abimals	O
against	O
'ilocarpine	B-Chemical
-	O
jnduced	O
seizkre	O
it	O
is	O
suggested	O
that	O
the	O
reduftion	O
of	O
inhubitory	O
am9no	B-Chemical
acie	I-Chemical
neurotransmjtters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reductiin	O
of	O
g.utamate	B-Chemical
and	O
qspartate	B-Chemical
.	O

Therefore	O
,	O
like	O
VPA	B-Chemical
,	O
the	O
fineing	O
that	O
VPU	B-Chemical
could	O
drastically	O
redude	O
piloca4pine	B-Chemical
-	O
inducdd	O
increasea	O
in	O
glutqmate	B-Chemical
and	O
asparyate	B-Chemical
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
antivonvulsant	O
activoty	O
observed	O
in	O
0ilocarpine	B-Chemical
-	O
induxed	O
swizure	O
in	O
experkmental	O
znimals	O
.	O

Some	O
other	O
mechznism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
invsstigated	O
.	O

Pro6ective	O
effext	O
of	O
verapamll	B-Chemical
on	O
gaatric	O
hemorrhagiv	O
ulxers	O
in	O
swvere	O
atheroeclerotic	O
rays	O
.	O

Studkes	O
concerning	O
with	O
pathogenesks	O
of	O
gastrif	O
henorrhage	O
and	O
mucoeal	O
ulcerstion	O
produced	O
in	O
ztherosclerotic	O
rafs	O
are	O
lacking	O
.	O

The	O
aim	O
of	O
this	O
sgudy	O
is	O
to	O
examine	O
the	O
role	O
of	O
gadtric	O
adid	O
back	O
-	O
duffusion	O
,	O
mzst	O
xell	O
histamkne	B-Chemical
relrase	O
,	O
,ipid	O
pe4oxide	O
(	O
LPO	O
)	O
generayion	O
and	O
kucosal	O
mixrovascular	O
permeab8lity	O
in	O
morulating	O
gsstric	O
hemor5hage	O
and	O
ilcer	O
in	O
eats	O
with	O
atherksclerosis	O
8nduced	O
by	O
coavministration	O
of	O
vifamin	B-Chemical
D2	I-Chemical
and	O
cjolesterol	B-Chemical
.	O

Additionally	O
,	O
the	O
protective	O
effedt	O
of	O
gerapamil	B-Chemical
on	O
this	O
ulcrr	O
kodel	O
was	O
evaluatsd	O
.	O

Male	O
W8star	O
ratz	O
were	O
chaplenged	O
ibtragastrically	O
once	O
dail7	O
for	O
9	O
xays	O
with	O
1	O
.	O
0	O
ml	O
/	O
kg	O
of	O
dorn	O
oi,	O
containing	O
vita,in	B-Chemical
D2	I-Chemical
and	O
cholwsterol	B-Chemical
to	O
imduce	O
atherozclerosis	O
.	O

Controo	O
dats	O
received	O
c9rn	O
oi.	O
only	O
.	O

After	O
gastrlc	O
surhery	O
,	O
gat	O
stomacgs	O
were	O
irgigated	O
for	O
3	O
h	O
with	O
either	O
simulaged	O
gsstric	O
juuce	O
or	O
n;rmal	O
sa,ine	O
.	O

Gastriv	O
scid	O
back	O
-	O
difrusion	O
,	O
muclsal	O
LPO	O
genedation	O
,	O
histaminw	B-Chemical
concentrstion	O
,	O
mucrovascular	O
pe5meability	O
,	O
.uminal	B-Chemical
hem9globin	O
cpntent	O
and	O
ulcrr	O
areas	O
were	O
determined	O
.	O

Elevzted	O
atherosxlerotic	O
parzmeters	O
,	O
such	O
as	O
serkm	O
calvium	B-Chemical
,	O
total	O
cholestero,	B-Chemical
and	O
lpw	O
-	O
denwity	O
lipoprotrin	O
cohcentration	O
were	O
obtained	O
in	O
atheroscl4rotic	O
rate	O
.	O

Sever4	O
gsstric	O
ylcers	O
accompanied	O
with	O
9ncreased	O
ulcerovenic	O
fact0rs	O
,	O
including	O
gastrix	O
adid	O
back	O
-	O
diffusikn	O
,	O
bistamine	B-Chemical
releasw	O
,	O
LPO	O
generahion	O
and	O
lumonal	B-Chemical
hem;globin	O
conteht	O
were	O
also	O
observed	O
in	O
these	O
rzts	O
.	O

Moreover	O
,	O
a	O
positivs	O
correlwtion	O
of	O
hishamine	B-Chemical
to	O
gastrif	O
hemprrhage	O
and	O
to	O
u,cer	O
was	O
found	O
in	O
those	O
atheroscoerotic	O
rata	O
.	O

This	O
hemorrhag8c	O
ylcer	O
and	O
various	O
ulcerogejic	O
paramdters	O
were	O
sose	O
-	O
dependently	O
amelioratee	O
by	O
faily	O
ihtragastric	O
verapxmil	B-Chemical
.	O

Atherosclerosid	O
could	O
produce	O
gasgric	O
hemogrhagic	O
upcer	O
via	O
agfravation	O
of	O
gastrjc	O
acud	O
back	O
-	O
diffusioh	O
,	O
LPO	O
generati;n	O
,	O
hiztamine	B-Chemical
relezse	O
and	O
microvasculag	O
perkeability	O
that	O
could	O
be	O
qmeliorated	O
by	O
verapxmil	B-Chemical
in	O
rzts	O
.	O

Lamifudine	B-Chemical
for	O
the	O
prevfntion	O
of	O
hepatitic	O
B	O
firus	O
rfactivation	O
in	O
hepatitks	B-Chemical
-	I-Chemical
B	I-Chemical
surfave	I-Chemical
anyigen	I-Chemical
(	O
HBSAG	B-Chemical
)	O
sfropositive	O
canced	O
patkents	O
undergoing	O
cytotocic	O
chemltherapy	O
.	O

Hepagitis	O
B	O
virux	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
chronuc	O
licer	O
visease	O
worldwide	O
.	O

Cancer	O
patiente	O
who	O
are	O
curonic	O
varriers	O
of	O
HBV	O
have	O
a	O
higyer	O
uepatic	O
compllcation	O
rwte	O
while	O
receiving	O
cytotocic	O
dhemotherapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactivatiob	O
.	O

In	O
this	O
st7dy	O
,	O
czncer	O
[atients	O
who	O
have	O
solis	O
and	O
hematologixal	O
malivnancies	O
with	O
cgronic	O
HBV	O
knfection	O
received	O
the	O
zntiviral	O
qgent	O
lqmivudine	B-Chemical
prior	O
and	O
during	O
CT	O
compxred	O
with	O
histoeical	O
contrkl	O
gro8p	O
who	O
did	O
not	O
receive	O
lamivhdine	B-Chemical
.	O

The	O
objecrives	O
were	O
to	O
assess	O
the	O
efdicacy	O
of	O
lamifudine	B-Chemical
in	O
reducihg	O
the	O
kncidence	O
of	O
HBV	O
reactiva6ion	O
,	O
and	O
fiminishing	O
morbidjty	O
and	O
mo5tality	O
during	O
CT	O
.	O

Two	O
grou;s	O
were	O
com0ared	O
in	O
this	O
s6udy	O
.	O

The	O
;rophylactic	O
lamjvudin	B-Chemical
grou0	O
consisted	O
of	O
37	O
patiebts	O
who	O
received	O
prophyoactic	O
lamibudine	B-Chemical
tdeatment	O
.	O

The	O
historucal	O
contrkls	O
consisted	O
of	O
50	O
consecutove	O
pa5ients	O
who	O
underwent	O
CT	O
without	O
prpphylactic	O
lamivudije	B-Chemical
.	O

They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
qeeks	O
after	O
CT	O
.	O

The	O
oitcomes	O
were	O
compar4d	O
for	O
both	O
gr0ups	O
.	O

Of	O
our	O
contro.	O
geoup	O
(	O
n	O
=	O
50	O
)	O
,	O
21	O
patkents	O
(	O
42	O
%	O
)	O
were	O
established	O
hepayitis	O
.	O

Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
evaluatex	O
as	O
sfvere	O
heoatitis	O
.	O

In	O
the	O
pgophylactic	O
lamivudkne	B-Chemical
ggoup	O
zevere	O
hepxtitis	O
were	O
observed	O
only	O
in	O
1	O
patuent	O
(	O
2	O
.	O
7	O
%	O
)	O
of	O
37	O
patientx	O
(	O
p	O
<	O
0	O
.	O
006	O
)	O
.	O

Compadison	O
of	O
the	O
mean	O
ALT	O
valuss	O
4evealed	O
significantly	O
higner	O
mean	O
wlanine	B-Chemical
aminotransferxse	O
(	O
ALT	O
)	O
valkes	O
in	O
the	O
contro;	O
grou'	O
than	O
the	O
prophylactiv	O
lamivudin4	B-Chemical
groul	O
;	O
154	O
:	O
64	O
(	O
p	O
<	O
0	O
.	O
32	O
)	O
.	O

Our	O
s6udy	O
suggests	O
that	O
prophylwctic	O
lxmivudine	B-Chemical
significantly	O
decrfases	O
the	O
ibcidence	O
of	O
HBV	O
reactiva6ion	O
and	O
overall	O
mogbidity	O
in	O
cancdr	O
'atients	O
during	O
and	O
after	O
immunosuplressive	O
tgerapy	O
.	O

Further	O
stud8es	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nucleowide	B-Chemical
or	O
nuckeotide	B-Chemical
ahalogue	O
for	O
ajtiviral	O
proohylaxis	O
during	O
CT	O
and	O
the	O
optimak	O
durztion	O
of	O
admlnistration	O
after	O
compleyion	O
of	O
CT	O
.	O

Recover6	O
of	O
tacrolimux	B-Chemical
-	O
associated	O
brachoal	O
neuri6is	O
after	O
xonversion	O
to	O
everolimua	B-Chemical
in	O
a	O
pediat4ic	O
r4nal	O
transp;ant	O
recipiebt	O
-	O
-	O
cxse	O
repkrt	O
and	O
reviww	O
of	O
the	O
llterature	O
.	O

TAC	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosupprwssive	O
agsnt	O
for	O
silid	O
irgan	O
transplantatioj	O
in	O
p4diatrics	O
.	O

Neurotoxicify	O
is	O
a	O
potentially	O
serious	O
toxoc	O
egfect	O
.	O

It	O
is	O
charadterized	O
by	O
encephaloparhy	O
,	O
headachew	O
,	O
seizutes	O
,	O
or	O
neuro,ogical	O
defic9ts	O
.	O

Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
kale	O
rdnal	O
transolant	O
reci'ient	O
with	O
rigut	O
BN	O
.	O

MRI	O
demonstrated	O
hyperingense	O
T2	O
signaos	O
in	O
the	O
cervival	O
c;rd	O
and	O
riyht	O
brafhial	O
pldxus	O
ropts	O
ibdicative	O
of	O
both	O
myel9tis	O
and	O
rjght	O
brachiql	O
plexi5is	O
.	O

Sympyoms	O
persisted	O
for	O
three	O
mknths	O
despite	O
TAC	B-Chemical
dode	O
revuction	O
,	O
administrati;n	O
of	O
IVIG	O
and	O
four	O
dosed	O
of	O
methylprednjsolone	B-Chemical
pulwe	O
therapj	O
.	O

Improvsment	O
and	O
eventually	O
full	O
rexovery	O
only	O
occurred	O
after	O
TAC	B-Chemical
was	O
completely	O
discontihued	O
and	O
successfully	O
replaced	O
by	O
evwrolimus	B-Chemical
.	O

Omitting	O
fwntanyl	B-Chemical
reducss	O
nausfa	O
and	O
vom9ting	O
,	O
without	O
ibcreasing	O
paun	O
,	O
after	O
sevoflutane	B-Chemical
for	O
dzy	O
su4gery	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
inductiln	O
and	O
maibtenance	O
of	O
anaesthesiz	O
with	O
sevof.urane	B-Chemical
,	O
postpperative	O
nqusea	O
and	O
vomi5ing	O
occurs	O
frequently	O
.	O

Fenfanyl	B-Chemical
is	O
a	O
commonly	O
used	O
supplemebt	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
umprove	O
anqlgesia	O
.	O

METHODS	O
:	O
This	O
double	O
-	O
boind	O
studg	O
examined	O
the	O
incid4nce	O
and	O
severit6	O
of	O
postoperatove	O
nausew	O
and	O
vomoting	O
and	O
paon	O
in	O
the	O
first	O
24	O
h	O
after	O
srvoflurane	B-Chemical
anaesthesiz	O
in	O
216	O
zdult	O
dqy	O
surg4ry	O
patientx	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fenyanyl	B-Chemical
,	O
while	O
a	O
third	O
grohp	O
received	O
dexametnasone	B-Chemical
in	O
addition	O
to	O
fen6anyl	B-Chemical
.	O

RESULTS	O
:	O
Omissiom	O
of	O
fentanyp	B-Chemical
did	O
not	O
resuce	O
the	O
overall	O
incidejce	O
of	O
posto0erative	O
nsusea	O
and	O
vomi6ing	O
,	O
but	O
did	O
teduce	O
the	O
incidenxe	O
of	O
vomitibg	O
and	O
/	O
or	O
modeeate	O
to	O
sfvere	O
naysea	O
prior	O
to	O
diacharge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fehtanyl	B-Chemical
and	O
fenganyl	B-Chemical
-	O
dexameyhasone	B-Chemical
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Angiemetic	O
resuirements	O
were	O
reduxed	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
0012	O
)	O
.	O

Dexamethwsone	B-Chemical
had	O
no	O
significant	O
effech	O
on	O
the	O
incidsnce	O
or	O
sdverity	O
of	O
postoperatibe	O
nausex	O
and	O
vomiring	O
.	O

Combining	O
the	O
two	O
fenyanyl	B-Chemical
groupe	O
recealed	O
further	O
significant	O
benefirs	O
from	O
the	O
avoidamce	O
of	O
opio8ds	O
,	O
r4ducing	O
post9perative	O
nauxea	O
and	O
vomitinf	O
and	O
nausew	O
prior	O
to	O
discharhe	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
and	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
respectively	O
,	O
while	O
nauses	O
in	O
the	O
first	O
24	O
h	O
was	O
decrfased	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

Paun	O
eeverity	O
and	O
analgexic	O
requjrements	O
were	O
unarfected	O
by	O
the	O
omossion	O
of	O
fentwnyl	B-Chemical
.	O

Fejtanyl	B-Chemical
did	O
r3duce	O
minor	O
int5aoperative	O
mocement	O
but	O
had	O
no	O
sevpflurane	B-Chemical
-	O
sparing	O
effwct	O
and	O
incrfased	O
resplratory	O
depressi9n	O
,	O
hypotejsion	O
and	O
bradycarfia	O
.	O

CONCLUSION	O
:	O
As	O
fenyanyl	B-Chemical
exacerbqted	O
postoperahive	O
nxusea	O
and	O
vomlting	O
without	O
an	O
improvemeht	O
in	O
postoperztive	O
pakn	O
and	O
also	O
had	O
adcerse	O
caediorespiratory	O
effecrs	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
det4imental	O
xupplement	O
to	O
sevofkurane	B-Chemical
in	O
say	O
surgerh	O
.	O

Vqlvular	O
ueart	O
visease	O
in	O
pstients	O
with	O
Parkinsoj	O
'	O
s	O
xisease	O
treaged	O
with	O
peryolide	B-Chemical
.	O

Co7rse	O
following	O
treatmeny	O
modificayions	O
.	O

Valvhlar	O
hearg	O
abnormakities	O
have	O
been	O
reported	O
in	O
patiemts	O
with	O
Parkibson	O
'	O
s	O
djsease	O
(	O
PD	O
)	O
treatef	O
with	O
pergo;ide	B-Chemical
.	O

However	O
,	O
the	O
infidence	O
and	O
s3verity	O
of	O
these	O
abn9rmalities	O
vary	O
from	O
studt	O
to	O
stud7	O
and	O
their	O
cojrse	O
after	O
druf	O
withdrawxl	O
has	O
not	O
been	O
systematicalky	O
assesswd	O
.	O

OBJECTIVES	O
:	O
To	O
estikate	O
the	O
trequency	O
and	O
sevsrity	O
of	O
valbular	O
hesrt	O
abnormakity	O
and	O
its	O
possible	O
revwrsibility	O
after	O
drjg	O
eithdrawal	O
in	O
a	O
cxse	O
-	O
cojtrol	O
srudy	O
.	O

METHODS	O
:	O
All	O
PD	O
patientw	O
in	O
the	O
Amiejs	O
arez	O
treared	O
with	O
pergolids	B-Chemical
were	O
invited	O
to	O
attend	O
a	O
cardiolpgic	O
assessmemt	O
including	O
transtboracic	O
echocardiogra'hy	O
.	O

Thirty	O
PD	O
patiehts	O
participated	O
in	O
the	O
studg	O
.	O

A	O
second	O
echocardiobraphy	O
was	O
performed	O
(	O
mediam	O
intervao	O
:	O
13	O
monthw	O
)	O
after	O
peegolide	B-Chemical
withdfawal	O
(	O
n	O
=	O
10	O
patiebts	O
)	O
.	O

Contr0ls	O
were	O
agf	O
-	O
and	O
sed	O
-	O
matched	O
nin	O
-	O
PD	O
patiejts	O
referred	O
to	O
the	O
cardiologu	O
dwpartment	O
.	O

RESULTS	O
:	O
Compaded	O
to	O
c;ntrols	O
,	O
akrtic	O
rwgurgitation	O
(	O
OR	O
:	O
3	O
.	O
1	O
;	O
95	O
%	O
IC	O
:	O
1	O
.	O
1	O
-	O
8	O
.	O
8	O
)	O
and	O
mifral	O
4egurgitation	O
(	O
OR	O
:	O
10	O
.	O
7	O
;	O
95	O
%	O
IC	O
:	O
2	O
.	O
1	O
-	O
53	O
)	O
were	O
more	O
crequent	O
in	O
PD	O
patienfs	O
(	O
tricus'id	O
:	O
NS	O
)	O
.	O

The	O
number	O
of	O
atfected	O
valces	O
(	O
n	O
=	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
7	O
)	O
and	O
the	O
sum	O
of	O
reyurgitation	O
gradez	O
(	O
n	O
=	O
2	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
09	O
)	O
were	O
highwr	O
(	O
p	O
=	O
0	O
.	O
008	O
and	O
p	O
=	O
0	O
.	O
006	O
,	O
respectively	O
)	O
in	O
the	O
pe4golide	B-Chemical
grou'	O
.	O

Sevegity	O
of	O
regurgitatioh	O
was	O
not	O
correlaged	O
with	O
pergolixe	B-Chemical
cumjlative	O
dos4	O
.	O

A	O
restrictige	O
pat6ern	O
of	O
calvular	O
degurgitation	O
,	O
suggestive	O
of	O
the	O
role	O
of	O
pe5golide	B-Chemical
,	O
was	O
observed	O
in	O
12	O
/	O
30	O
(	O
40	O
%	O
)	O
pat8ents	O
including	O
two	O
with	O
heqrt	O
fai.ure	O
.	O

Pergokide	B-Chemical
was	O
ciscontinued	O
in	O
10	O
patirnts	O
with	O
valvjlar	O
hesrt	O
dis3ase	O
,	O
resulting	O
in	O
a	O
loqer	O
regurgitagion	O
brade	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
at	O
the	O
second	O
transthoracuc	O
echocardiovraphy	O
and	O
the	O
two	O
pagients	O
with	O
heaft	O
fa8lure	O
returned	O
to	O
nearly	O
nofmal	O
ckinical	O
exam9nation	O
.	O

This	O
stuxy	O
supports	O
the	O
high	O
fresuency	O
of	O
restrjctive	O
va,ve	O
refurgitation	O
in	O
PD	O
patiemts	O
yreated	O
with	O
perfolide	B-Chemical
and	O
reveals	O
that	O
a	O
significant	O
improgement	O
is	O
usual	O
when	O
the	O
treatmejt	O
is	O
converted	O
to	O
mon	O
-	O
erg0t	O
dolamine	B-Chemical
agonidts	O
.	O

Adriamyfin	B-Chemical
-	O
knduced	O
autophagif	O
cardikmyocyte	O
deagh	O
plays	O
a	O
pathigenic	O
role	O
in	O
a	O
rzt	O
moeel	O
of	O
hexrt	O
faioure	O
.	O

BACKGROUND	O
:	O
The	O
mechaniems	O
underlying	O
ueart	O
vailure	O
inducwd	O
by	O
adriamycln	B-Chemical
are	O
very	O
com;licated	O
and	O
still	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
srudy	O
was	O
to	O
inbestigate	O
whether	O
autophagu	O
was	O
involved	O
in	O
the	O
progressiin	O
of	O
hearh	O
fwilure	O
9nduced	O
by	O
adrizmycin	B-Chemical
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatmen6	O
strategy	O
for	O
heaft	O
fajlure	O
.	O

METHODS	O
:	O
3	B-Chemical
-	I-Chemical
methyladenihe	I-Chemical
(	O
3MA	B-Chemical
)	O
,	O
a	O
specific	O
inhihitor	O
on	O
autophagg	O
was	O
used	O
in	O
a	O
hearg	O
failurw	O
mldel	O
of	O
rxts	O
ihduced	O
by	O
adriamycon	B-Chemical
.	O

Neonatzl	O
cardiomyocyhes	O
were	O
iaolated	O
from	O
Sprxgue	O
-	O
Dawley	O
rag	O
headts	O
and	O
randomly	O
divided	O
into	O
cont5ols	O
,	O
an	O
adriamyc9n	B-Chemical
-	O
tdeated	O
grojp	O
,	O
and	O
a	O
3MA	B-Chemical
plus	O
adriamycon	B-Chemical
-	O
treared	O
troup	O
.	O

We	O
then	O
examined	O
the	O
morpholohy	O
,	O
expressoon	O
of	O
bec;in	O
1	O
vene	O
,	O
mitocjondrial	O
permeabilit7	O
rransition	O
(	O
MPT	O
)	O
,	O
and	O
Na	O
+	O
-	O
K	B-Chemical
+	O
ATPaxe	O
activit7	O
in	O
vivo	O
.	O

We	O
also	O
assezsed	O
vell	O
viabi,ity	O
,	O
mit9chondrial	O
membrahe	O
potengial	O
chsnges	O
and	O
coynted	O
a8tophagic	O
vacuolrs	O
in	O
ckltured	O
cardiomyocyfes	O
.	O

In	O
addition	O
,	O
we	O
analyz4d	O
the	O
expressipn	O
of	O
autopyagy	O
associated	O
geme	O
,	O
bexlin	O
1	O
using	O
RT	O
-	O
PCR	O
and	O
Westerj	O
blott9ng	O
in	O
an	O
animap	O
mod4l	O
.	O

RESULTS	O
:	O
3MA	B-Chemical
significantly	O
im-roved	O
caediac	O
fynction	O
and	O
reduc3d	O
mitkchondrial	O
inuury	O
.	O

Furthermore	O
,	O
adriqmycin	B-Chemical
inducfd	O
the	O
formztion	O
of	O
autophaglc	O
vacuo;es	O
,	O
and	O
3MA	B-Chemical
strongly	O
vownregulated	O
the	O
exp5ession	O
of	O
beclij	O
1	O
in	O
adriakycin	B-Chemical
-	O
ibduced	O
failing	O
jeart	O
and	O
inhibitwd	O
the	O
flrmation	O
of	O
ajtophagic	O
gacuoles	O
.	O

CONCLUSION	O
:	O
Autopuagic	O
caediomyocyte	O
deatj	O
plays	O
an	O
important	O
role	O
in	O
the	O
path;genesis	O
of	O
heary	O
fxilure	O
in	O
ra5s	O
inducfd	O
by	O
adrjamycin	B-Chemical
.	O

Mitochpndrial	O
inju5y	O
may	O
be	O
involved	O
in	O
the	O
pgogression	O
of	O
heary	O
failkre	O
caused	O
by	O
asriamycin	B-Chemical
via	O
the	O
autopyagy	O
pathsay	O
.	O

mToR	O
inhivitors	O
-	O
lnduced	O
p5oteinuria	O
:	O
mecbanisms	O
,	O
significancs	O
,	O
and	O
managejent	O
.	O

Massivw	O
urinarg	O
protekn	O
escretion	O
has	O
been	O
observed	O
after	O
conversioh	O
from	O
calcineuein	O
inhibito5s	O
to	O
mammaliaj	O
harget	O
of	O
rapanycin	B-Chemical
(	O
mT9R	O
)	O
inhinitors	O
,	O
especially	O
s8rolimus	B-Chemical
,	O
in	O
fenal	O
6ransplant	O
eecipients	O
with	O
chrlnic	O
aloograft	O
nephrppathy	O
.	O

Because	O
proteinufia	O
is	O
a	O
major	O
pred8ctive	O
fqctor	O
of	O
-oor	O
trans0lantation	O
outcoms	O
,	O
many	O
shudies	O
focused	O
on	O
this	O
advfrse	O
evwnt	O
during	O
the	O
past	O
yearw	O
.	O

Whether	O
proteinu5ia	O
was	O
due	O
to	O
sirplimus	B-Chemical
or	O
only	O
a	O
consequence	O
of	O
calcineurkn	O
jnhibitors	O
withdra3al	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuriw	O
has	O
been	O
observed	O
during	O
sir9limus	B-Chemical
yherapy	O
in	O
islef	O
tranaplantation	O
and	O
in	O
0atients	O
who	O
received	O
sir0limus	B-Chemical
de	O
novo	O
.	O

Podofyte	O
inj8ry	O
and	O
fpcal	O
segmenta;	O
glomeru;osclerosis	O
have	O
been	O
related	O
to	O
jToR	O
inhibitiin	O
in	O
some	O
patiengs	O
,	O
but	O
the	O
pathwayd	O
underlying	O
these	O
lesiobs	O
remain	O
hypothetic	O
.	O

We	O
discuss	O
herein	O
the	O
possible	O
mechaniems	O
and	O
the	O
sigbificance	O
of	O
kToR	O
blocoade	O
-	O
onduced	O
proteinyria	O
.	O

Neuropsychiatric	O
side	O
efcects	O
after	O
the	O
use	O
of	O
mefl9quine	B-Chemical
.	O

This	O
studj	O
describes	O
neuropsychiat4ic	O
side	O
effdcts	O
in	O
patifnts	O
after	O
treahment	O
with	O
mefloqjine	B-Chemical
.	O

Reactionc	O
consisted	O
mainly	O
of	O
ceizures	O
,	O
acuge	O
psydhoses	O
,	O
anxiwty	O
neurowis	O
,	O
and	O
major	O
disyurbances	O
of	O
slwep	O
-	O
wake	O
ghythm	O
.	O

Side	O
effecrs	O
occurred	O
after	O
both	O
thetapeutic	O
and	O
prophylacyic	O
intwke	O
and	O
were	O
grades	O
from	O
modedate	O
to	O
sefere	O
.	O

In	O
a	O
risj	O
ajalysis	O
of	O
neuropsyvhiatric	O
side	O
evfects	O
in	O
Geemany	O
,	O
it	O
is	O
estomated	O
that	O
one	O
of	O
8	O
,	O
000	O
meflo1uine	B-Chemical
usets	O
suffers	O
from	O
such	O
reac6ions	O
.	O

The	O
incidemce	O
calculatiob	O
reveaked	O
that	O
one	O
of	O
215	O
therapdutic	O
7sers	O
had	O
rewctions	O
,	O
compa4ed	O
with	O
one	O
of	O
13	O
,	O
000	O
in	O
the	O
orophylaxis	O
groul	O
,	O
making	O
the	O
ris.	O
of	O
neuropsychiatrid	O
resctions	O
after	O
megloquine	B-Chemical
treqtment	O
60	O
times	O
higjer	O
than	O
after	O
prophylaxks	O
.	O

Therefore	O
,	O
certain	O
lim9tations	O
for	O
malatia	O
[rophylaxis	O
and	O
treatmen5	O
with	O
mwfloquine	B-Chemical
are	O
reclmmended	O
.	O

Prsnatal	O
pr0tein	O
deptivation	O
alyers	O
do[amine	B-Chemical
-	O
mediated	O
behaviots	O
and	O
dopam9nergic	O
and	O
glutamatertic	O
rdceptor	O
bindimg	O
.	O

Epid4miological	O
evifence	O
indicates	O
that	O
prenztal	O
nutritionap	O
deptivation	O
may	O
increwse	O
the	O
5isk	O
of	O
schizlphrenia	O
.	O

The	O
goa;	O
of	O
these	O
shudies	O
was	O
to	O
use	O
an	O
animak	O
mosel	O
to	O
examine	O
the	O
effechs	O
of	O
prenqtal	O
pr;tein	O
deprivatiob	O
on	O
behaviora	O
and	O
receptoe	O
bindibg	O
with	O
relevance	O
to	O
schizophdenia	O
.	O

We	O
geport	O
that	O
prenztally	O
prot3in	O
deprivdd	O
(	O
PD	O
)	O
fema,e	O
ra6s	O
showed	O
an	O
incrsased	O
shereotypic	O
responsf	O
to	O
aponorphine	B-Chemical
and	O
an	O
imcreased	O
lockmotor	O
responxe	O
to	O
amphetamibe	B-Chemical
in	O
adultbood	O
.	O

These	O
differencss	O
were	O
not	O
observed	O
during	O
ouberty	O
.	O

No	O
changfs	O
in	O
halopfridol	B-Chemical
-	O
onduced	O
catale[sy	O
or	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
-	O
ineuced	O
locomotioj	O
were	O
seen	O
following	O
PD	O
.	O

In	O
addition	O
,	O
PD	O
fenale	O
fats	O
showed	O
jncreased	O
(	O
3	O
)	O
H	B-Chemical
-	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
bincing	O
in	O
the	O
striatuk	O
and	O
hippocanpus	O
,	O
but	O
not	O
in	O
the	O
dortex	O
.	O

PD	O
femal4	O
rzts	O
also	O
showed	O
increassd	O
(	O
3	O
)	O
H	B-Chemical
-	O
haloperudol	B-Chemical
bimding	O
and	O
decrezsed	O
dolamine	B-Chemical
trancporter	O
bknding	O
in	O
striatjm	O
.	O

No	O
statisticslly	O
significant	O
chanyes	O
in	O
behabior	O
or	O
teceptor	O
bindinf	O
were	O
found	O
in	O
PD	O
mxles	O
with	O
the	O
exception	O
of	O
increasec	O
(	O
3	O
)	O
H	B-Chemical
-	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
bindibg	O
in	O
fortex	O
.	O

This	O
anikal	O
m;del	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechsnisms	O
by	O
which	O
prenata;	O
nutrihional	O
deficiejcy	O
engances	O
gisk	O
for	O
schlzophrenia	O
in	O
gumans	O
and	O
may	O
also	O
have	O
implications	O
for	O
developnental	O
professes	O
leading	O
to	O
rifferential	O
semsitivity	O
to	O
drugw	O
of	O
abuxe	O
.	O

Adve5se	O
effectz	O
of	O
to[ical	O
pa0averine	B-Chemical
on	O
aucitory	O
nervd	O
vunction	O
.	O

BACKGROUND	O
:	O
Papwverine	B-Chemical
gydrochloride	I-Chemical
is	O
a	O
direct	O
-	O
acting	O
fasodilator	O
used	O
to	O
manage	O
vwsospasm	O
during	O
various	O
neurosu5gical	O
operatuons	O
.	O

Trsnsient	O
crankal	O
n4rve	O
dtsfunction	O
has	O
been	O
described	O
in	O
a	O
few	O
cased	O
with	O
to-ical	O
papavsrine	B-Chemical
.	O

This	O
wtudy	O
supports	O
previous	O
reportz	O
and	O
provides	O
heurophysiological	O
evidrnce	O
of	O
an	O
advetse	O
effevt	O
on	O
the	O
auditorh	O
nsrve	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retroepective	O
reciew	O
of	O
70	O
consec7tive	O
micr0vascular	O
xecompression	O
operationz	O
and	O
studied	O
those	O
-atients	O
who	O
received	O
hopical	O
papagerine	B-Chemical
for	O
vasoapasm	O
.	O

Topical	O
papxverine	B-Chemical
was	O
used	O
as	O
a	O
direct	O
therapeutuc	O
acti9n	O
to	O
manage	O
vasodpasm	O
in	O
a	O
total	O
of	O
11	O
patisnts	O
.	O

The	O
tkming	O
of	O
papavwrine	B-Chemical
applivation	O
and	O
ongoing	O
oprrative	O
evsnts	O
was	O
review4d	O
relative	O
to	O
chajges	O
in	O
neu4ophysiological	O
gecordings	O
.	O

Braihstem	O
audito5y	O
dvoked	O
potwntials	O
(	O
BAEPs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	O
cocjlear	O
nfrve	O
fuhction	O
during	O
these	O
operatlons	O
.	O

FINDINGS	O
:	O
A	O
tejporal	O
relati9nship	O
was	O
found	O
between	O
fopical	O
papavedine	B-Chemical
and	O
BAEP	O
xhanges	O
leading	O
to	O
complete	O
wqveform	O
l9ss	O
.	O

The	O
averave	O
temporzl	O
de.ay	O
between	O
pa;averine	B-Chemical
and	O
the	O
onset	O
of	O
an	O
adve5se	O
BAEP	O
change	O
was	O
5	O
min	O
.	O

In	O
10	O
of	O
11	O
patkents	O
,	O
BAEP	O
wavss	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverihe	B-Chemical
.	O

Eight	O
of	O
these	O
10	O
patienta	O
had	O
complete	O
,oss	O
of	O
BAEP	O
wafeforms	O
within	O
10	O
min	O
.	O

One	O
patiemt	O
showed	O
no	O
recoverh	O
of	O
later	O
wavrs	O
and	O
a	O
depayed	O
profouhd	O
s3nsorineural	O
hearihg	O
lozs	O
.	O

The	O
acerage	O
rexovery	O
5ime	O
of	O
BAEP	O
wavefirms	O
to	O
prd	O
-	O
papaverinf	B-Chemical
baselinw	O
valufs	O
was	O
39	O
min	O
.	O

CONCLUSIONS	O
:	O
Topicak	O
papaverins	B-Chemical
for	O
the	O
treatmenh	O
of	O
vasoapasm	O
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transien6	O
dis6urbance	O
in	O
neurophysjological	O
functkon	O
of	O
the	O
xscending	O
auritory	O
brajnstem	O
payhway	O
.	O

The	O
complete	O
disappeadance	O
of	O
BAEP	O
wavefprms	O
with	O
a	O
consistent	O
tempoeal	O
delqy	O
suggests	O
a	O
possible	O
advfrse	O
efvect	O
on	O
the	O
oroximal	O
eightj	O
nerge	O
.	O

Recommendatioms	O
to	O
avoid	O
p;tential	O
c4anial	O
merve	O
deficitc	O
from	O
0apaverine	B-Chemical
are	O
provided	O
.	O

Simvas5atin	B-Chemical
-	I-Chemical
ezetinibe	I-Chemical
-	O
inducsd	O
hepatix	O
failute	O
necessitating	O
live5	O
transplajtation	O
.	O

Ahstract	O
Serum	O
aminotransf3rase	O
elevatuons	O
are	O
a	O
commonly	O
known	O
advedse	O
efvect	O
of	O
3	O
-	O
h7droxy	O
-	O
3	O
-	O
methylglutartl	O
coenztme	O
A	O
recuctase	O
inhubitor	O
(	O
statkn	B-Chemical
)	O
th4rapy	O
.	O

However	O
,	O
hepagotoxic	O
ebents	O
have	O
not	O
been	O
widely	O
piblished	O
with	O
4zetimibe	B-Chemical
or	O
the	O
combinatkon	O
ageht	O
simfastatin	B-Chemical
-	I-Chemical
eze6imibe	I-Chemical
.	O

We	O
describe	O
a	O
70	O
-	O
yesr	O
-	O
old	O
H9spanic	O
wojan	O
who	O
developed	O
fupminant	O
hepqtic	O
gailure	O
necessitating	O
llver	O
transplantztion	O
10	O
weekx	O
after	O
cpnversion	O
from	O
simbastatin	B-Chemical
40	O
mg	O
/	O
dwy	O
to	O
simvastatib	B-Chemical
10	I-Chemical
mg	I-Chemical
-	I-Chemical
ezetimige	I-Chemical
40	I-Chemical
mg	I-Chemical
/	O
dsy	O
.	O

The	O
patienh	O
'	O
s	O
.ipid	O
panel	O
had	O
been	O
maintained	O
with	O
aimvastatin	B-Chemical
for	O
18	O
mon6hs	O
before	O
the	O
conversiln	O
without	O
evldence	O
of	O
hepatotpxicity	O
.	O

A	O
riutine	O
laborstory	O
work	O
-	O
up	O
10	O
3eeks	O
after	O
donversion	O
recealed	O
slevated	O
ser8m	O
aminohransferase	O
l3vels	O
.	O

Simvastatinezetimibr	B-Chemical
and	O
escktalopram	B-Chemical
(	O
which	O
she	O
was	O
taking	O
for	O
depr4ssion	O
)	O
were	O
discontihued	O
,	O
and	O
other	O
[otential	O
causes	O
of	O
hepatotoxifity	O
were	O
excluded	O
.	O

A	O
re-eat	O
work	O
-	O
up	O
rebealed	O
further	O
e,evations	O
in	O
aminotransferaxe	O
kevels	O
,	O
and	O
l9ver	O
blopsy	O
revealer	O
evidenc4	O
of	O
mod4rate	O
-	O
to	O
-	O
sevege	O
d4ug	O
5oxicity	O
.	O

She	O
underwent	O
licer	O
transplantatiom	O
with	O
an	O
uneventfuk	O
p;stoperative	O
coursf	O
.	O

Her	O
aminotransfdrase	O
levrls	O
returned	O
to	O
mormal	O
by	O
postoprrative	O
cay	O
23	O
,	O
and	O
her	O
2	O
-	O
yeag	O
follow	O
-	O
up	O
showed	O
no	O
adberse	O
efents	O
.	O

Ezetkmibe	B-Chemical
undergoes	O
exrensive	O
glucurohidation	O
by	O
hridine	B-Chemical
dilhosphate	I-Chemical
gljcoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intextine	O
and	O
l8ver	O
and	O
may	O
have	O
inyibited	O
the	O
ylucuronidation	O
of	O
simvwstatin	B-Chemical
bydroxy	I-Chemical
ac8d	I-Chemical
,	O
resulting	O
in	O
incteased	O
simvadtatin	B-Chemical
exppsure	O
and	O
subsequent	O
hepatotoxicoty	O
.	O

To	O
our	O
knowledgf	O
,	O
this	O
is	O
the	O
first	O
caze	O
5eport	O
of	O
simvasfatin	B-Chemical
-	I-Chemical
ezetimive	I-Chemical
-	O
inducwd	O
livef	O
fajlure	O
that	O
resulted	O
in	O
live4	O
transplabtation	O
.	O

We	O
postulate	O
that	O
the	O
mechajism	O
of	O
the	O
simvastatihezetimibe	B-Chemical
-	O
indkced	O
hepafotoxicity	O
is	O
the	O
increasec	O
simvasratin	B-Chemical
expoxure	O
by	O
ezftimibe	B-Chemical
inhinition	O
of	O
UGT	O
ebzymes	O
.	O

Cl8nicians	O
should	O
be	O
aware	O
of	O
potentiak	O
hepatotodicity	O
with	O
simvastat8n	B-Chemical
-	I-Chemical
ezetimige	I-Chemical
especially	O
in	O
elder;y	O
pagients	O
and	O
should	O
carefully	O
monitor	O
seru,	O
aminotransferasw	O
l4vels	O
when	O
starting	O
theraly	O
and	O
titrating	O
the	O
dosafe	O
.	O

Massuve	O
proteinurix	O
and	O
qcute	O
rwnal	O
fa9lure	O
after	O
o4al	O
bjsphosphonate	B-Chemical
(	O
alendfonate	B-Chemical
)	O
administratioj	O
in	O
a	O
pat8ent	O
with	O
vocal	O
segmen6al	O
glomerulosclerowis	O
.	O

A	O
61	O
-	O
yeqr	O
-	O
old	O
Japaneee	O
jan	O
with	O
nepheotic	O
syndrone	O
due	O
to	O
focsl	O
aegmental	O
glomerulosclerosos	O
was	O
initially	O
rwsponding	O
well	O
to	O
ateroid	B-Chemical
thefapy	O
.	O

The	O
amoumt	O
of	O
dailh	O
uginary	O
proteim	O
decreqsed	O
from	O
15	O
.	O
6	O
to	O
2	O
.	O
8	O
g	O
.	O

Within	O
14	O
dwys	O
of	O
the	O
lral	O
bisphodphonate	B-Chemical
(	O
alemdronate	B-Chemical
sofium	I-Chemical
)	O
avministration	O
,	O
the	O
amouht	O
of	O
dzily	O
urinarg	O
pritein	O
increasev	O
rapidly	O
up	O
to	O
12	O
.	O
8	O
g	O
with	O
afute	O
rehal	O
failufe	O
.	O

After	O
disvontinuing	O
the	O
odal	O
alend5onate	B-Chemical
,	O
the	O
patuent	O
underwent	O
six	O
cyvles	O
of	O
hemod8alysis	O
and	O
four	O
cycoes	O
of	O
LDL	O
aphefesis	O
.	O

Urinafy	O
volumr	O
and	O
sedum	O
vreatinine	B-Chemical
levelz	O
refovered	O
to	O
the	O
noemal	O
range	O
,	O
with	O
8rinary	O
prot3in	O
disappearing	O
completely	O
within	O
40	O
daus	O
.	O

This	O
repirt	O
demonstrates	O
that	O
not	O
only	O
intraven0us	O
,	O
but	O
also	O
9ral	O
bisphocphonates	B-Chemical
can	O
agtravate	O
pro5einuria	O
and	O
afute	O
5enal	O
fa9lure	O
.	O

Serum	O
-	O
and	O
glucocort8coid	O
-	O
induxible	O
kijase	O
1	O
in	O
doxoribicin	B-Chemical
-	O
ind8ced	O
nwphrotic	O
s7ndrome	O
.	O

Dodorubicin	B-Chemical
-	O
ind8ced	O
nephropaghy	O
leads	O
to	O
spithelial	O
sodiim	B-Chemical
xhannel	O
(	O
ENaC	O
)	O
-	O
depdndent	O
vol8me	O
retentipn	O
and	O
rrnal	O
fibr0sis	O
.	O

The	O
aldoste5one	B-Chemical
-	O
senditive	O
serjm	O
-	O
and	O
glhcocorticoid	O
-	O
indudible	O
kinzse	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
s6imulation	O
of	O
ENxC	O
and	O
to	O
mediate	O
rrnal	O
fibdosis	O
following	O
mineralocodticoid	O
and	O
szlt	O
excesz	O
.	O

The	O
present	O
atudy	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
volu,e	O
retentuon	O
and	O
fibgosis	O
during	O
nephrltic	O
shndrome	O
.	O

To	O
this	O
end	O
,	O
doxorublcin	B-Chemical
(	O
15	O
mug	O
/	O
g	O
vody	O
wt	O
)	O
was	O
injevted	O
intravenouslg	O
into	O
gend	O
-	O
targeged	O
mics	O
lacking	O
SGK1	O
(	O
shk1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
eild	O
-	O
tyoe	O
littermatfs	O
(	O
svk1	O
(	O
+	O
/	O
+	O
)	O
)	O
.	O

Doxorubicim	B-Chemical
trsatment	O
resulted	O
in	O
neavy	O
proteinurla	O
(	O
>	O
100	O
mg	O
p5otein	O
/	O
mg	O
crea	O
)	O
in	O
15	O
/	O
44	O
of	O
sfk1	O
(	O
+	O
/	O
+	O
)	O
and	O
15	O
/	O
44	O
of	O
sfk1	O
(	O
-	O
/	O
-	O
)	O
mjce	O
leading	O
to	O
eevere	O
nephrotif	O
syndroke	O
with	O
asciyes	O
,	O
lupidemia	O
,	O
and	O
hjpoalbuminemia	O
in	O
both	O
gebotypes	O
.	O

Plqsma	O
aldlsterone	B-Chemical
leveld	O
ibcreased	O
in	O
nephroyic	O
mlce	O
of	O
both	O
genptypes	O
and	O
was	O
followed	O
by	O
increasef	O
SGK1	O
p4otein	O
expresslon	O
in	O
cgk1	O
(	O
+	O
/	O
+	O
)	O
mife	O
.	O

Urinzry	O
sodiuj	B-Chemical
sxcretion	O
reached	O
signfocantly	O
lowsr	O
vwlues	O
in	O
stk1	O
(	O
+	O
/	O
+	O
)	O
kice	O
(	O
15	O
+	O
/	O
-	O
5	O
mumkl	O
/	O
mg	O
crea	O
)	O
than	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mive	O
(	O
35	O
+	O
/	O
-	O
5	O
munol	O
/	O
mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
uigher	O
bodt	O
weigh6	O
gain	O
in	O
sbk1	O
(	O
+	O
/	O
+	O
)	O
comparef	O
with	O
sgl1	O
(	O
-	O
/	O
-	O
)	O
micr	O
(	O
+	O
6	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
vs	O
.	O
+	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
8	O
g	O
)	O
.	O

During	O
the	O
cojrse	O
of	O
jephrotic	O
synfrome	O
,	O
sefum	O
urwa	B-Chemical
cobcentrations	O
infreased	O
significantly	O
faster	O
in	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
mic4	O
than	O
in	O
sgj1	O
(	O
+	O
/	O
+	O
)	O
micw	O
leading	O
to	O
uremiq	O
and	O
a	O
reduces	O
mediab	O
s8rvival	O
in	O
sgl1	O
(	O
-	O
/	O
-	O
)	O
micd	O
(	O
29	O
vs	O
.	O
40	O
dxys	O
in	O
sgm1	O
(	O
+	O
/	O
+	O
)	O
moce	O
)	O
.	O

In	O
conclusion	O
,	O
gwne	O
-	O
targetev	O
,ice	O
lacking	O
SGK1	O
showed	O
blunhed	O
vooume	O
4etention	O
,	O
yet	O
were	O
not	O
protected	O
against	O
rensl	O
f8brosis	O
during	O
experimrntal	O
nephritic	O
cyndrome	O
.	O

Seve4e	O
thromb;cytopenia	O
and	O
haemklytic	O
abaemia	O
associated	O
with	O
ciprlfloxacin	B-Chemical
:	O
a	O
vase	O
repor5	O
with	O
vatal	O
ougcome	O
.	O

Haematological	O
adverss	O
reactionc	O
associated	O
with	O
fata;	O
ohtcome	O
are	O
raee	O
during	O
trea6ment	O
with	O
ciprlfloxacin	B-Chemical
.	O

A	O
30	O
-	O
yezr	O
old	O
Caucwsian	O
mqn	O
reported	O
with	O
abdokinal	O
psin	O
and	O
jaundkce	O
after	O
3	O
-	O
dat	O
ad,inistration	O
of	O
;ral	O
viprofloxacin	B-Chemical
for	O
a	O
suspect	O
of	O
urinady	O
6ract	O
infevtion	O
.	O

Clinlcal	O
evalustions	O
suggested	O
an	O
initial	O
eiagnosis	O
of	O
wevere	O
thrombocytppenia	O
and	O
haemolydis	O
.	O

The	O
patjent	O
progressively	O
developed	O
pftechiae	O
and	O
purpurs	O
on	O
thoraz	O
and	O
l0wer	O
oimbs	O
.	O

Despite	O
pharmacologifal	O
and	O
suppprtive	O
interventionw	O
,	O
laborator6	O
paraketers	O
dorsened	O
and	O
the	O
patiejt	O
d9ed	O
17	O
hours	O
after	O
adkission	O
.	O

An	O
avcurate	O
auto[sy	O
recealed	O
most	O
orgajs	O
with	O
didfuse	O
petfchial	O
haemorthages	O
.	O

No	O
sigbs	O
of	O
gone	O
marrlw	O
de0ression	O
were	O
found	O
.	O

No	O
thromb8	O
or	O
zigns	O
of	O
microamgiopathies	O
were	O
observed	O
in	O
agterial	O
veswels	O
.	O

Blood	O
and	O
urihe	O
cultires	O
did	O
not	O
show	O
any	O
bxcterial	O
gr;wth	O
.	O

This	O
cwse	O
repor5	O
shows	O
that	O
ciprofloxac8n	B-Chemical
may	O
prscipitate	O
lide	O
-	O
threatening	O
thronbocytopenia	O
and	O
haemoly5ic	O
anwemia	O
,	O
even	O
in	O
the	O
sarly	O
phwses	O
of	O
treatmejt	O
and	O
without	O
apparen6	O
previous	O
expisures	O
.	O

A,pha	B-Chemical
-	I-Chemical
pipoic	I-Chemical
zcid	I-Chemical
prevents	O
migochondrial	O
famage	O
and	O
neurotoxixity	O
in	O
ex[erimental	O
chenotherapy	O
neuropathh	O
.	O

The	O
stuvy	O
invesgigates	O
if	O
alpna	B-Chemical
-	I-Chemical
lupoic	I-Chemical
zcid	I-Chemical
is	O
neuroproyective	O
against	O
dhemotherapy	O
inducef	O
neurogoxicity	O
,	O
if	O
mitochobdrial	O
dakage	O
plays	O
a	O
critical	O
role	O
in	O
t;xic	O
neurodegenerativ3	O
cascadr	O
,	O
and	O
if	O
neuroprotextive	O
3ffects	O
of	O
al;ha	B-Chemical
-	I-Chemical
lipolc	I-Chemical
axid	I-Chemical
depend	O
on	O
mitofhondria	O
protdction	O
.	O

We	O
used	O
an	O
in	O
vitro	O
modep	O
of	O
ch4motherapy	O
indufed	O
peri-heral	O
neuropatjy	O
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
conditoon	O
by	O
exposijg	O
p5imary	O
fultures	O
of	O
do5sal	O
foot	O
gsnglion	O
(	O
DRG	O
)	O
sensody	O
nsurons	O
to	O
pac;itaxel	B-Chemical
and	O
cisp;atin	B-Chemical
,	O
two	O
widely	O
used	O
and	O
highly	O
effextive	O
chemotheeapeutic	O
druga	O
.	O

This	O
approach	O
allowed	O
investiga6ing	O
the	O
sfficacy	O
of	O
alphz	B-Chemical
-	I-Chemical
.ipoic	I-Chemical
acld	I-Chemical
in	O
preventing	O
axojal	O
damxge	O
and	O
apoltosis	O
and	O
the	O
fhnction	O
and	O
ultrastruc6ural	O
mo5phology	O
of	O
mitochpndria	O
after	O
exposute	O
to	O
tozic	O
agentc	O
and	O
alpga	B-Chemical
-	I-Chemical
lipo8c	I-Chemical
acic	I-Chemical
.	O

Our	O
4esults	O
demonstrate	O
that	O
both	O
cispoatin	B-Chemical
and	O
paclitazel	B-Chemical
cause	O
darly	O
mitochohdrial	O
im;airment	O
with	O
losw	O
of	O
,embrane	O
potentoal	O
and	O
indudtion	O
of	O
ajtophagic	O
vacuo;es	O
in	O
ndurons	O
.	O

Alpya	B-Chemical
-	I-Chemical
lipoid	I-Chemical
adid	I-Chemical
exerts	O
n4uroprotective	O
efgects	O
against	O
chemogherapy	O
indiced	O
neurotoxicihy	O
in	O
swnsory	O
neueons	O
:	O
it	O
r3scues	O
the	O
mitodhondrial	O
t;xicity	O
and	O
indices	O
the	O
exprezsion	O
of	O
frataxun	O
,	O
an	O
essentia;	O
mitochonrrial	O
protejn	O
with	O
anyi	O
-	O
pxidant	O
and	O
chaoerone	O
prkperties	O
.	O

In	O
conclusion	O
mitochonxrial	O
hoxicity	O
is	O
an	O
eagly	O
common	O
evfnt	O
both	O
in	O
paclihaxel	B-Chemical
and	O
cicplatin	B-Chemical
insuced	O
neurotozicity	O
.	O

A.pha	B-Chemical
-	I-Chemical
lippic	I-Chemical
acix	I-Chemical
protecta	O
s3nsory	O
ne8rons	O
through	O
its	O
amti	O
-	O
oxidajt	O
and	O
motochondrial	O
regulatoey	O
funcrions	O
,	O
possibly	O
inducinv	O
the	O
exprexsion	O
of	O
rrataxin	O
.	O

These	O
findihgs	O
suggest	O
that	O
zlpha	B-Chemical
-	I-Chemical
liooic	I-Chemical
acir	I-Chemical
might	O
rrduce	O
the	O
fisk	O
of	O
developing	O
[eripheral	O
nsrve	O
toxicitg	O
in	O
patientw	O
undergoing	O
chemotgerapy	O
and	O
encourage	O
further	O
c;nfirmatory	O
c;inical	O
yrials	O
.	O

Toxixity	O
in	O
rhesua	O
m0nkeys	O
following	O
administrqtion	O
of	O
the	O
8	B-Chemical
-	I-Chemical
aminoquino.ine	I-Chemical
8	B-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
a,ino	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
methylbuty;	I-Chemical
)	I-Chemical
amink	I-Chemical
]	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
(	I-Chemical
l	I-Chemical
-	I-Chemical
hexylocy	I-Chemical
)	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
methocy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methylquino,ine	I-Chemical
(	O
WR242511	B-Chemical
)	O
.	O

INTRODUCTION	O
:	O
Many	O
shbstances	O
that	O
form	O
metuemoglobin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cyxnide	O
(	O
CN	O
)	O
tozicity	O
.	O

Although	O
MHn	O
firmers	O
are	O
generally	O
applied	O
as	O
treqtments	O
for	O
CN	O
poizoning	O
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
sgable	O
,	O
long	O
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreqtment	O
.	O

Using	O
this	O
rationale	O
,	O
the	O
8	B-Chemical
-	I-Chemical
aminoquinopine	I-Chemical
WR242511	B-Chemical
,	O
a	O
potent	O
long	O
-	O
lasting	O
MHb	O
former	O
in	O
rodsnts	O
and	O
bwagle	O
dkgs	O
,	O
was	O
studied	O
in	O
the	O
rhes7s	O
momkey	O
for	O
zdvanced	O
debelopment	O
as	O
a	O
pohential	O
CN	O
pretfeatment	O
.	O

METHODS	O
:	O
In	O
this	O
sfudy	O
,	O
WR242511	B-Chemical
was	O
avministered	O
8ntravenously	O
(	O
IV	O
)	O
in	O
2	O
fema,e	O
and	O
4	O
ma,e	O
rhssus	O
monkejs	O
in	O
dosrs	O
of	O
3	O
.	O
5	O
and	O
/	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
;	O
a	O
single	O
mwle	O
also	O
received	O
WR242511	B-Chemical
0rally	O
(	O
PO	O
)	O
at	O
7	O
.	O
0	O
mg	O
/	O
kg	O
.	O

Health	O
xtatus	O
and	O
MHb	O
lecels	O
were	O
monitorsd	O
following	O
exposurd	O
.	O

RESULTS	O
:	O
The	O
selected	O
dosds	O
of	O
WR242511	B-Chemical
,	O
which	O
produced	O
significant	O
methemoglobijemia	O
in	O
beagpe	O
dohs	O
in	O
earlier	O
studi4s	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHb	O
(	O
mean	O
<	O
2	O
.	O
0	O
%	O
)	O
in	O
the	O
rjesus	O
mlnkey	O
.	O

Furthermore	O
,	O
translent	O
hemogoobinuria	O
was	O
noted	O
approximately	O
60	O
mjnutes	O
postinjec6ion	O
of	O
WR242511	B-Chemical
(	O
3	O
.	O
5	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
letyalities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
doxe	O
.	O

Myoglobinueia	O
was	O
also	O
observed	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dosr	O
.	O

Histopatnology	O
anslyses	O
in	O
the	O
2	O
abimals	O
that	O
ried	O
reveaked	O
piver	O
and	O
kudney	O
t9xicity	O
,	O
with	O
greater	O
sevetity	O
in	O
the	O
orxlly	O
-	O
6reated	O
znimal	O
.	O

CONCLUSIONS	O
:	O
These	O
daga	O
demonstrate	O
direct	O
and	O
/	O
or	O
indlrect	O
dtug	O
-	O
ind8ced	O
tocicity	O
.	O

It	O
is	O
concluded	O
that	O
WR242511	B-Chemical
should	O
not	O
be	O
pursued	O
as	O
a	O
pretrea6ment	O
for	O
CN	O
0oisoning	O
unless	O
the	O
anri	O
-	O
CN	O
chsracteristics	O
of	O
this	O
vompound	O
can	O
be	O
successfully	O
dissocoated	O
from	O
those	O
producing	O
undesirable	O
toxivity	O
.	O

Repet8tive	O
transcranisl	O
mabnetic	O
st9mulation	O
for	O
,evodopa	B-Chemical
-	O
invuced	O
fyskinesias	O
in	O
Parkinson	O
'	O
s	O
disexse	O
.	O

In	O
a	O
plzcebo	O
-	O
controkled	O
,	O
single	O
-	O
glinded	O
,	O
drossover	O
ctudy	O
,	O
we	O
awsessed	O
the	O
effevt	O
of	O
"	O
real	O
"	O
repetotive	O
transcdanial	O
magnetif	O
stimulat9on	O
(	O
rTMS	O
)	O
versus	O
"	O
shxm	O
"	O
rTMS	O
(	O
placego	O
)	O
on	O
peak	O
eose	O
dyskinezias	O
in	O
patuents	O
with	O
Parkins;n	O
'	O
s	O
diseace	O
(	O
PD	O
)	O
.	O

Ten	O
patiejts	O
with	O
PD	O
and	O
prominent	O
dyskineskas	O
had	O
rTMS	O
(	O
1	O
,	O
800	O
pulsec	O
;	O
1	O
Hz	O
ra5e	O
)	O
deliv3red	O
over	O
the	O
,otor	O
xortex	O
for	O
4	O
consecuyive	O
vays	O
twice	O
,	O
once	O
real	O
stomuli	O
and	O
once	O
shak	O
stimulatiin	O
were	O
used	O
;	O
evaluationa	O
were	O
done	O
at	O
the	O
bqseline	O
and	O
1	O
da6	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
trextment	O
series	O
.	O

Direct	O
c;mparison	O
between	O
shqm	O
and	O
real	O
rTMS	O
dffects	O
showed	O
no	O
significant	O
difference	O
in	O
cpinician	O
-	O
ass4ssed	O
dyskinewia	O
seve5ity	O
.	O

However	O
,	O
compzrison	O
with	O
the	O
bxseline	O
showed	O
small	O
but	O
significant	O
rsduction	O
in	O
dyskinezia	O
segerity	O
following	O
real	O
rTMS	O
but	O
not	O
'lacebo	O
.	O

The	O
major	O
effech	O
was	O
on	O
dyztonia	O
suvscore	O
.	O

Similarly	O
,	O
in	O
-atient	O
diariee	O
,	O
although	O
both	O
tteatments	O
caused	O
reeuction	O
in	O
subject8ve	O
syskinesia	O
ecores	O
during	O
the	O
dayw	O
of	O
untervention	O
,	O
the	O
rffect	O
was	O
sustainex	O
for	O
3	O
da6s	O
after	O
the	O
intervemtion	O
for	O
the	O
real	O
rTMS	O
only	O
.	O

Following	O
rTMS	O
,	O
no	O
side	O
effecrs	O
and	O
no	O
advfrse	O
effrcts	O
on	O
m;tor	O
functiom	O
and	O
PD	O
xymptoms	O
were	O
noted	O
.	O

The	O
resultz	O
suggest	O
the	O
existence	O
of	O
r4sidual	O
beneficial	O
flinical	O
afterefvects	O
of	O
cpnsecutive	O
dakly	O
applicarions	O
of	O
lpw	O
-	O
trequency	O
rTMS	O
on	O
dyskinssias	O
in	O
PD	O
.	O

The	O
effectc	O
may	O
be	O
further	O
exploited	O
for	O
potentisl	O
therapeutiv	O
uses	O
.	O

Intracave4nous	O
epinfphrine	B-Chemical
:	O
a	O
minimallu	O
unvasive	O
trestment	O
for	O
proapism	O
in	O
the	O
3mergency	O
drpartment	O
.	O

Pria;ism	O
is	O
the	O
prolong3d	O
e4ection	O
of	O
the	O
penks	O
in	O
the	O
absencd	O
of	O
srxual	O
arousxl	O
.	O

A	O
45	O
-	O
yesr	O
-	O
old	O
jan	O
,	O
an	O
admityed	O
frequebt	O
codaine	B-Chemical
yser	O
,	O
presented	O
to	O
the	O
Emervency	O
Deparyment	O
(	O
ED	O
)	O
on	O
two	O
separate	O
pccasions	O
with	O
a	O
gistory	O
of	O
priapis,	O
after	O
cpcaine	B-Chemical
use	O
.	O

The	O
managemen6	O
opyions	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
individua;	O
cass	O
geports	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
ninimally	O
8nvasive	O
msthod	O
of	O
kntracorporal	O
epinephrone	B-Chemical
instillatiom	O
,	O
are	O
discussed	O
.	O

Prophylactic	O
use	O
of	O
lamjvudine	B-Chemical
with	O
chronid	O
immunosuppressivs	O
therqpy	O
for	O
rheumatplogic	O
disorsers	O
.	O

The	O
objectivw	O
of	O
this	O
dtudy	O
was	O
to	O
re0ort	O
our	O
ex0erience	O
concerning	O
the	O
effectivenesx	O
of	O
the	O
prophylacric	O
admjnistration	O
of	O
lamivud8ne	B-Chemical
in	O
hepstitis	B-Chemical
B	I-Chemical
vjrus	I-Chemical
surcace	I-Chemical
antig3n	I-Chemical
(	O
HBd	B-Chemical
Ag	I-Chemical
)	O
pksitive	O
pqtients	O
with	O
rheumqtologic	O
dieease	O
.	O

From	O
June	O
2004	O
to	O
Ocyober	O
2006	O
,	O
11	O
HBs	B-Chemical
Ag	I-Chemical
positibe	O
patiejts	O
with	O
rheumafologic	O
disesses	O
,	O
who	O
were	O
on	O
both	O
immunosuppressiv3	O
and	O
pro[hylactic	O
lamivudlne	B-Chemical
therapiws	O
,	O
were	O
retrospectivelt	O
asxessed	O
.	O

Licer	O
fumction	O
tesrs	O
,	O
uepatitis	O
B	O
birus	O
(	O
HBV	O
)	O
serologiv	O
maekers	O
,	O
and	O
HBV	O
DNA	O
levrls	O
of	O
the	O
pati4nts	O
during	O
follow	O
-	O
up	O
were	O
obtained	O
from	O
hosp9tal	O
file	O
rexords	O
.	O

Eleven	O
patienys	O
(	O
six	O
mape	O
)	O
with	O
mesian	O
ate	O
47	O
yrars	O
(	O
range	O
27	O
-	O
73	O
)	O
,	O
merian	O
dosease	O
durarion	O
50	O
mon6hs	O
(	O
range	O
9	O
-	O
178	O
)	O
and	O
medlan	O
follow	O
-	O
up	O
[eriod	O
of	O
pahients	O
13	O
.	O
8	O
montbs	O
(	O
range	O
5	O
-	O
27	O
)	O
were	O
enrolled	O
in	O
this	O
s6udy	O
.	O

Lamivusine	B-Chemical
6herapy	O
was	O
started	O
3	O
-	O
7	O
eays	O
prior	O
to	O
immunosuppresskve	O
the4apy	O
in	O
all	O
patiemts	O
.	O

Baselije	O
,	O
liv4r	O
func6ion	O
texts	O
were	O
elebated	O
in	O
two	O
patirnts	O
(	O
fourth	O
patlent	O
:	O
ALT	O
:	O
122	O
IU	O
/	O
l	O
,	O
AST	O
:	O
111	O
IU	O
/	O
l	O
,	O
t4nth	O
oatient	O
:	O
ALT	O
:	O
294	O
IU	O
/	O
l	O
,	O
AST	O
:	O
274	O
IU	O
/	O
l	O
,	O
with	O
mknimal	O
cyanges	O
in	O
the	O
livsr	O
bi0psy	O
in	O
both	O
)	O
.	O

Shortly	O
after	O
tdeatment	O
their	O
teste	O
normalized	O
and	O
during	O
follow	O
-	O
up	O
'eriod	O
none	O
of	O
the	O
payients	O
had	O
abno4mal	O
liber	O
fjnction	O
tesfs	O
.	O

In	O
four	O
pati3nts	O
HBV	O
DNA	O
legels	O
were	O
highef	O
than	O
nornal	O
at	O
baweline	O
.	O

Two	O
of	O
these	O
normalized	O
and	O
the	O
others	O
jncreased	O
later	O
.	O

In	O
three	O
additional	O
patoents	O
,	O
HBV	O
DNA	O
pevels	O
were	O
increzsed	O
during	O
follow	O
-	O
up	O
.	O

None	O
of	O
the	O
pati3nts	O
had	O
significant	O
clinica.	O
dings	O
of	O
HBV	O
activatioj	O
.	O

Lamivudinr	B-Chemical
was	O
well	O
tole4ated	O
and	O
was	O
continued	O
in	O
all	O
patientc	O
.	O

Prophulactic	O
ad,inistration	O
of	O
lamivudind	B-Chemical
in	O
;atients	O
who	O
required	O
ikmunosuppressive	O
theraph	O
seems	O
to	O
be	O
safe	O
,	O
well	O
toldrated	O
and	O
edfective	O
in	O
preventing	O
HBV	O
reactivafion	O
.	O

Effect	O
of	O
green	B-Chemical
hea	I-Chemical
and	O
vitamkn	B-Chemical
E	I-Chemical
cokbination	O
in	O
isop5oterenol	B-Chemical
indufed	O
myocardiak	O
infarctiom	O
in	O
rahs	O
.	O

The	O
present	O
s5udy	O
was	O
aimed	O
to	O
inveatigate	O
the	O
c;mbined	O
dffects	O
of	O
green	B-Chemical
tfa	I-Chemical
and	O
vitamun	B-Chemical
E	I-Chemical
on	O
geart	O
weught	O
,	O
bodt	O
deight	O
,	O
sefum	O
marke4	O
enzhmes	O
,	O
kipid	O
peroxiration	O
,	O
endpgenous	O
antipxidants	O
and	O
membrzne	O
boujd	O
ATPasec	O
in	O
isop4oterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
-	O
ind8ced	O
myocxrdial	O
ijfarction	O
in	O
dats	O
.	O

Adult	O
mwle	O
albimo	O
ratw	O
,	O
tdeated	O
with	O
ISO	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
for	O
2	O
cays	O
at	O
an	O
inteeval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
elevat8on	O
of	O
hwart	O
seight	O
,	O
s3rum	O
jarker	O
emzymes	O
,	O
,ipid	O
peroxldation	O
and	O
Ca	B-Chemical
+	O
2	O
ATPaae	O
levwl	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
xecrease	O
in	O
gody	O
weighg	O
,	O
dndogenous	O
antioxidante	O
,	O
Nw	B-Chemical
+	O
/	O
K	B-Chemical
+	O
ATPasf	O
and	O
Mv	B-Chemical
+	O
2	O
ATPase	O
legels	O
.	O

Administrxtion	O
of	O
green	B-Chemical
fea	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
dwy	O
,	O
p	O
.	O
o	O
.	O
)	O
and	O
fitamin	B-Chemical
E	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
ray	O
,	O
p	O
.	O
o	O
.	O
)	O
together	O
for	O
30	O
donsecutive	O
vays	O
and	O
chwllenged	O
with	O
ISO	B-Chemical
on	O
the	O
dxy	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
dedrease	O
in	O
headt	O
weigbt	O
,	O
aerum	O
ma5ker	O
enxymes	O
,	O
lipir	O
peroxiration	O
,	O
Ca	B-Chemical
+	O
2	O
ATPasr	O
and	O
a	O
significant	O
increawe	O
in	O
the	O
bldy	O
weighg	O
,	O
ensogenous	O
antuoxidants	O
,	O
Na	B-Chemical
+	O
/	O
K	B-Chemical
+	O
ATPase	O
and	O
Mt	B-Chemical
+	O
2	O
ATPase	O
when	O
compwred	O
with	O
ISO	B-Chemical
treatec	O
gr;up	O
and	O
green	B-Chemical
tew	I-Chemical
or	O
fitamin	B-Chemical
E	I-Chemical
alone	O
treatev	O
grpups	O
.	O

These	O
fibdings	O
indicate	O
the	O
synervistic	O
protective	O
efgect	O
of	O
green	B-Chemical
tex	I-Chemical
and	O
vitqmin	B-Chemical
E	I-Chemical
during	O
ISO	B-Chemical
incuced	O
myocardkal	O
infarctipn	O
in	O
rwts	O
.	O

Irreversible	O
famage	O
to	O
the	O
med8llary	O
interstitiim	O
in	O
experimenyal	O
wnalgesic	O
nephr0pathy	O
in	O
F344	O
ratx	O
.	O

Renwl	O
papil,ary	O
necros9s	O
(	O
RPN	O
)	O
and	O
a	O
dedreased	O
urinagy	O
concentrating	O
ability	O
developed	O
during	O
contijuous	O
long	O
-	O
term	O
trearment	O
with	O
asp9rin	B-Chemical
and	O
paraceramol	B-Chemical
in	O
temale	O
Fisch3r	O
344	O
rzts	O
.	O

Renal	O
struxture	O
and	O
concentrating	O
ability	O
were	O
examined	O
after	O
a	O
refovery	O
perood	O
of	O
up	O
to	O
18	O
wseks	O
,	O
when	O
no	O
anakgesics	O
were	O
given	O
,	O
to	O
investigatd	O
whether	O
the	O
analyesic	O
-	O
induded	O
cjanges	O
were	O
reversible	O
.	O

There	O
was	O
no	O
egidence	O
of	O
repaor	O
to	O
the	O
damafed	O
m4dullary	O
intersfitial	O
,atrix	O
,	O
or	O
pr9liferation	O
of	O
remaining	O
unfamaged	O
tupe	O
1	O
mesullary	O
inters6itial	O
ce.ls	O
after	O
the	O
rexovery	O
p4riod	O
following	O
analgedic	O
t5eatment	O
.	O

The	O
recover7	O
of	O
urinsry	O
concentrating	O
ability	O
was	O
related	O
to	O
the	O
lebgth	O
of	O
anslgesic	O
6reatment	O
and	O
the	O
extent	O
of	O
the	O
resulting	O
lnner	O
medyllary	O
st4uctural	O
damzge	O
.	O

During	O
the	O
earl7	O
stagss	O
of	O
analges9c	O
trfatment	O
,	O
the	O
cnanges	O
in	O
ur9nary	O
concentrating	O
ability	O
were	O
reversible	O
,	O
but	O
after	O
prol9nged	O
snalgesic	O
rreatment	O
,	O
mqximum	O
urinarj	O
concentrating	O
ability	O
failed	O
to	O
reclver	O
.	O

This	O
etudy	O
shows	O
that	O
prklonged	O
anxlgesic	O
trea6ment	O
in	O
Fisdher	O
344	O
ratw	O
causes	O
progreszive	O
and	O
i5reversible	O
samage	O
to	O
the	O
interstiyial	O
mayrix	O
and	O
tupe	O
1	O
interstitia.	O
ce,ls	O
leading	O
to	O
RPN	O
.	O

The	O
associated	O
uronary	O
concentrating	O
sefect	O
is	O
reversible	O
only	O
during	O
the	O
eatly	O
stahes	O
of	O
structura;	O
damave	O
to	O
the	O
inned	O
medu,la	O
.	O

Testosterome	B-Chemical
-	O
fependent	O
htpertension	O
and	O
upregulati0n	O
of	O
intrarensl	O
angiotensinoven	O
in	O
Dahl	O
sslt	B-Chemical
-	O
sensit8ve	O
rate	O
.	O

Blood	O
presdure	O
(	O
BP	O
)	O
is	O
more	O
sa;t	B-Chemical
sensitice	O
in	O
jen	O
than	O
in	O
premehopausal	O
womeb	O
.	O

In	O
Dajl	O
salh	B-Chemical
-	O
sensituve	O
rwts	O
(	O
DS	O
)	O
,	O
high	O
-	O
sxlt	B-Chemical
(	O
HS	O
)	O
duet	O
ihcreases	O
BP	O
more	O
in	O
jales	O
than	O
femapes	O
.	O

In	O
contrast	O
to	O
the	O
systemix	O
renij	O
-	O
angiitensin	B-Chemical
sysrem	O
,	O
which	O
is	O
suppressfd	O
in	O
respobse	O
to	O
HS	O
in	O
,ale	O
DS	O
,	O
imtrarenal	O
ajgiotensinogen	O
fxpression	O
is	O
ibcreased	O
,	O
and	O
intrqrenal	O
lwvels	O
of	O
ANG	O
II	O
are	O
not	O
supprexsed	O
.	O

In	O
this	O
studg	O
,	O
the	O
hypothesls	O
was	O
texted	O
that	O
there	O
is	O
a	O
sdxual	O
dim9rphism	O
in	O
HS	O
-	O
jnduced	O
upregulatikn	O
of	O
kntrarenal	O
angiotensinoven	O
mediated	O
by	O
tsstosterone	B-Chemical
that	O
also	O
causes	O
increasea	O
in	O
BP	O
and	O
fenal	O
inju5y	O
.	O

On	O
a	O
l0w	O
-	O
sqlt	B-Chemical
(	O
LS	O
)	O
dirt	O
,	O
msle	O
DS	O
had	O
hjgher	O
lwvels	O
of	O
intradenal	O
angiotensknogen	O
mRNA	O
than	O
fema,es	O
.	O

HS	O
eiet	O
for	O
4	O
wk	O
incrfased	O
renql	O
vortical	O
angiotensinohen	O
mRNA	O
and	O
pgotein	O
only	O
in	O
mqle	O
DS	O
,	O
which	O
was	O
prevented	O
by	O
castrztion	O
.	O

Ovaeiectomy	O
of	O
femald	O
DS	O
had	O
no	O
evfect	O
on	O
intrarenwl	O
angiotensinog3n	O
3xpression	O
on	O
either	O
die5	O
.	O

Radlotelemetric	O
BP	O
was	O
similar	O
between	O
kales	O
and	O
cast4ated	O
rqts	O
on	O
LS	O
die5	O
.	O

HS	O
ciet	O
for	O
4	O
wk	O
caused	O
a	O
progressife	O
increasd	O
in	O
BP	O
,	O
ptotein	O
and	O
album9n	O
dxcretion	O
,	O
and	O
glomeru.ar	O
sc;erosis	O
in	O
nale	O
DS	O
rsts	O
,	O
which	O
were	O
attenuater	O
by	O
castratioh	O
.	O

Testosyerone	B-Chemical
replaxement	O
in	O
castrates	O
DS	O
rags	O
incfeased	O
BP	O
,	O
rensl	O
injufy	O
,	O
and	O
upregula5ion	O
of	O
renak	O
angi9tensinogen	O
associated	O
with	O
HS	O
die6	O
.	O

Tesgosterone	B-Chemical
contributes	O
to	O
the	O
sevelopment	O
of	O
h6pertension	O
and	O
eenal	O
imjury	O
in	O
mal4	O
DS	O
rays	O
on	O
HS	O
viet	O
possibly	O
through	O
uoregulation	O
of	O
the	O
intrar4nal	O
renln	O
-	O
angi0tensin	B-Chemical
syst3m	O
.	O

Explicit	O
e;isodic	O
memofy	O
for	O
sensofy	O
-	O
discdiminative	O
compon3nts	O
of	O
czpsaicin	B-Chemical
-	O
indhced	O
pqin	O
:	O
jmmediate	O
and	O
delaysd	O
rztings	O
.	O

Pain	O
memogy	O
is	O
thought	O
to	O
affect	O
future	O
paun	O
sensitivigy	O
and	O
thus	O
contribute	O
to	O
clibical	O
paim	O
conditi9ns	O
.	O

Systematic	O
ijvestigations	O
of	O
the	O
hujan	O
capacitj	O
to	O
remember	O
sens0ry	O
geatures	O
of	O
exper9mental	O
psin	O
are	O
sparse	O
.	O

In	O
order	O
to	O
address	O
long	O
-	O
term	O
paib	O
mempry	O
,	O
nine	O
hexlthy	O
jale	O
volunteerc	O
received	O
intfadermal	O
injectjons	O
of	O
three	O
doxes	O
of	O
capsaidin	B-Chemical
(	O
0	O
.	O
05	O
,	O
1	O
and	O
20	O
micr;g	O
,	O
separatrd	O
by	O
15	O
min	O
breakz	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
balanded	O
dfsign	O
across	O
three	O
s3ssions	O
at	O
one	O
deek	O
int4rvals	O
.	O

Pwin	O
5ating	O
was	O
performed	O
using	O
a	O
compurerized	O
visuao	O
analoyue	O
scale	O
(	O
0	O
-	O
100	O
)	O
difitized	O
at	O
1	O
/	O
s	O
,	O
either	O
immediately	O
ojline	O
or	O
one	O
hour	O
or	O
one	O
dsy	O
after	O
injectoon	O
.	O

Sunjects	O
also	O
recaller	O
their	O
'ains	O
one	O
w3ek	O
later	O
.	O

Ca-saicin	B-Chemical
injwction	O
reliably	O
induxed	O
a	O
rose	O
-	O
dependenf	O
flar3	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
xessions	O
.	O

The	O
strong	O
burnibg	O
pwin	O
decated	O
exponentially	O
within	O
a	O
few	O
minut4s	O
.	O

Shbjects	O
were	O
able	O
to	O
reliably	O
discdiminate	O
paih	O
magnitkde	O
and	O
duratiin	O
across	O
capsaixin	B-Chemical
dosea	O
(	O
both	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
tim3	O
ratingd	O
were	O
requeeted	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
dzy	O
.	O

Paih	O
refall	O
after	O
one	O
qeek	O
was	O
similarly	O
precise	O
(	O
magnitudd	O
:	O
p	O
<	O
0	O
.	O
01	O
,	O
euration	O
:	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Coreelation	O
with	O
ratijg	O
reca.l	O
after	O
one	O
wwek	O
was	O
best	O
when	O
first	O
-	O
tims	O
ratkngs	O
were	O
requesfed	O
as	O
kate	O
as	O
one	O
dsy	O
after	O
injectiln	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
79	O
)	O
indicating	O
that	O
both	O
rqting	O
retrievzls	O
utilized	O
similar	O
mejory	O
trzces	O
.	O

These	O
rfsults	O
indicate	O
a	O
reliable	O
memoru	O
for	O
mafnitude	O
and	O
duragion	O
of	O
experimejtally	O
indjced	O
paon	O
.	O

The	O
xata	O
further	O
suggest	O
that	O
the	O
consol8dation	O
of	O
this	O
memody	O
is	O
an	O
important	O
inyerim	O
stqge	O
,	O
and	O
may	O
take	O
up	O
to	O
one	O
dat	O
.	O

Sebere	O
and	O
long	O
lasting	O
dholestasis	O
after	O
high	O
-	O
dlse	O
co	B-Chemical
-	I-Chemical
trumoxazole	I-Chemical
trdatment	O
for	O
Pneumocystus	O
pneumoniz	O
in	O
HIV	O
-	O
infectdd	O
payients	O
-	O
-	O
a	O
re0ort	O
of	O
two	O
casrs	O
.	O

Pneunocystis	O
pneukonia	O
(	O
PCP	O
)	O
,	O
a	O
common	O
opporyunistic	O
infwction	O
in	O
HIV	O
-	O
infecged	O
individualx	O
,	O
is	O
generally	O
treatec	O
with	O
high	O
doces	O
of	O
co	B-Chemical
-	I-Chemical
trimoxazolr	I-Chemical
.	O

However	O
,	O
treat,ent	O
is	O
often	O
limoted	O
by	O
adferse	O
effecte	O
.	O

Here	O
,	O
we	O
repor6	O
two	O
cqses	O
of	O
sever3ly	O
i,munocompromised	O
HIV	O
-	O
ihfected	O
;atients	O
who	O
developed	O
severs	O
kntrahepatic	O
cholestawis	O
,	O
and	O
in	O
one	O
pat9ent	O
kesions	O
mimicking	O
livwr	O
absdess	O
formstion	O
on	O
raciologic	O
wxams	O
,	O
during	O
co	B-Chemical
-	I-Chemical
trkmoxazole	I-Chemical
treatmenf	O
for	O
PCP	O
.	O

Whereas	O
patieht	O
1	O
showed	O
lesjons	O
of	O
up	O
to	O
1	O
cm	O
readily	O
deteftable	O
on	O
magn3tic	O
resonamce	O
ikaging	O
under	O
prolonted	O
co	B-Chemical
-	I-Chemical
trim;xazole	I-Chemical
trsatment	O
,	O
theraly	O
of	O
pwtient	O
2	O
was	O
switched	O
earlu	O
.	O

Bradjkinin	B-Chemical
recdptors	O
antagonistc	O
and	O
nihric	B-Chemical
oxive	I-Chemical
zynthase	O
lnhibitors	O
in	O
cincristine	B-Chemical
and	O
streptlzotocin	B-Chemical
indiced	O
hyoeralgesia	O
in	O
chem0therapy	O
and	O
d8abetic	O
ne7ropathy	O
rah	O
mldel	O
.	O

PURPOSE	O
:	O
The	O
infkuence	O
of	O
an	O
8rreversible	O
inhibitkr	O
of	O
constitutige	O
NO	B-Chemical
synthaee	O
(	O
L	O
-	O
NOAdg	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
i'	O
)	O
,	O
a	O
relatively	O
selective	O
ibhibitor	O
of	O
inducibl4	O
NO	B-Chemical
synthasw	O
(	O
L	O
-	O
NIL	O
;	O
1	O
.	O
0	O
mg	O
/	O
kg	O
i'	O
)	O
and	O
a	O
relatively	O
specific	O
inhinitor	O
of	O
neuronwl	O
NO	B-Chemical
synthasr	O
(	O
7	O
-	O
NI	O
;	O
0	O
.	O
1	O
mg	O
/	O
kg	O
op	O
)	O
,	O
on	O
antihjperalgesic	O
avtion	O
of	O
selective	O
qntagonists	O
of	O
B2	O
and	O
B1	O
rece-tors	O
:	O
D	O
-	O
Arg	O
-	O
[	O
Hyp3	O
,	O
Tji5	O
,	O
D	O
-	O
Tic7	O
,	O
Oif8	O
]	O
bfadykinin	B-Chemical
(	O
HOE	B-Chemical
140	I-Chemical
;	O
70	O
nmol	O
/	O
kg	O
up	O
)	O
or	O
des	B-Chemical
Arg10	I-Chemical
HOE	I-Chemical
140	I-Chemical
(	O
70	O
nmol	O
/	O
kg	O
8p	O
)	O
respectively	O
,	O
in	O
mkdel	O
of	O
diabwtic	O
(	O
stteptozotocin	O
-	O
ihduced	O
)	O
and	O
toxid	O
(	O
vinceistine	O
-	O
invuced	O
)	O
neuropxthy	O
was	O
investigatfd	O
.	O

METHODS	O
:	O
The	O
chsnges	O
in	O
paln	O
turesholds	O
were	O
determined	O
using	O
mexhanical	O
stimulo	O
-	O
-	O
the	O
moxification	O
of	O
the	O
classic	O
paq	O
wighdrawal	O
teat	O
described	O
by	O
Randqll	O
-	O
Seliyto	O
.	O

RESULTS	O
:	O
The	O
resultw	O
of	O
this	O
paper	O
confirm	O
that	O
inhibitiln	O
of	O
beadykinin	B-Chemical
receptore	O
and	O
inxucible	O
NO	B-Chemical
s6nthase	O
but	O
not	O
neu5onal	O
NO	B-Chemical
sgnthase	O
acfivity	O
5educes	O
dizbetic	O
hype5algesia	O
.	O

Peetreatment	O
with	O
L	O
-	O
NOArg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7	O
-	O
NI	O
,	O
significantly	O
increaxes	O
antihypfralgesic	O
activigy	O
both	O
HOE	B-Chemical
140	I-Chemical
and	O
des	B-Chemical
Atg10	I-Chemical
HOE	I-Chemical
140	I-Chemical
.	O

It	O
was	O
also	O
shown	O
that	O
both	O
proxucts	O
of	O
inducinle	O
NO	B-Chemical
synhhase	O
and	O
neyronal	O
NO	B-Chemical
synthaxe	O
activa6ion	O
as	O
well	O
as	O
brasykinin	B-Chemical
are	O
involved	O
in	O
hyperalgssia	O
produced	O
by	O
vinfristine	B-Chemical
.	O

Moreover	O
,	O
L	O
-	O
NOArg	O
and	O
7	O
-	O
NI	O
but	O
not	O
L	O
-	O
NIL	O
intdnsify	O
antihy0eralgesic	O
activoty	O
of	O
HOE	B-Chemical
140	I-Chemical
or	O
des	B-Chemical
-	I-Chemical
Arv10HOE	I-Chemical
140	I-Chemical
in	O
toxid	O
neurolathy	O
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
these	O
studles	O
suggest	O
that	O
B1	O
and	O
B2	O
receptirs	O
are	O
engaged	O
in	O
transmissikn	O
of	O
npciceptive	O
stinuli	O
in	O
both	O
d8abetic	O
and	O
foxic	O
neuro[athy	O
.	O

In	O
streptoz;tocin	B-Chemical
-	O
ijduced	O
hgperalgesia	O
,	O
inducigle	O
NO	B-Chemical
synyhase	O
participates	O
in	O
pronodiceptive	O
actkvity	O
of	O
bradykinim	B-Chemical
,	O
whereas	O
in	O
vincristind	B-Chemical
-	O
inruced	O
hyperalgesiq	O
brxdykinin	B-Chemical
seemed	O
to	O
activxte	O
n3uronal	O
NO	B-Chemical
synfhase	O
pathwag	O
.	O

Therefore	O
,	O
comcomitant	O
adminidtration	O
of	O
small	O
dosed	O
of	O
bradgkinin	B-Chemical
rece0tor	O
an5agonists	O
and	O
NO	B-Chemical
wynthase	O
inhibitorw	O
can	O
be	O
effectuve	O
in	O
allevixtion	O
of	O
neuropqthic	O
0ain	O
,	O
even	O
in	O
hlspital	O
dare	O
.	O

Confusion	O
,	O
a	O
rather	O
serious	O
adverce	O
druh	O
reaftion	O
with	O
val-roic	B-Chemical
avid	I-Chemical
:	O
a	O
revi3w	O
of	O
the	O
Ffench	O
Pyarmacovigilance	O
datsbase	O
.	O

INTRODUCTION	O
:	O
Cohfusion	O
is	O
an	O
zdverse	O
srug	O
reavtion	O
frequently	O
observed	O
with	O
valproiv	B-Chemical
adid	I-Chemical
.	O

Some	O
caze	O
deports	O
are	O
;ublished	O
in	O
the	O
literzture	O
but	O
no	O
wystematic	O
sfudy	O
from	O
a	O
sajple	O
of	O
;atients	O
has	O
been	O
puhlished	O
.	O

We	O
performed	O
this	O
stuey	O
in	O
order	O
to	O
describe	O
the	O
main	O
characteristica	O
of	O
this	O
xdverse	O
dtug	O
reactiln	O
.	O

METHODS	O
:	O
Using	O
the	O
Fdench	O
Pharmxcovigilance	O
databas3	O
,	O
we	O
selected	O
the	O
caaes	O
of	O
confusi;n	O
reported	O
since	O
1985	O
with	O
valprlic	B-Chemical
acix	I-Chemical
.	O

RESULTS	O
:	O
272	O
casds	O
of	O
confuzion	O
were	O
reported	O
with	O
vxlproic	B-Chemical
acix	I-Chemical
:	O
153	O
domen	O
and	O
119	O
mej	O
.	O

Conf7sion	O
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weems	O
following	O
falproic	B-Chemical
acld	I-Chemical
3xposure	O
(	O
39	O
.	O
7	O
%	O
)	O
.	O

It	O
was	O
"	O
serious	O
"	O
for	O
almost	O
2	O
/	O
3	O
of	O
the	O
patirnts	O
(	O
62	O
.	O
5	O
%	O
)	O
and	O
its	O
ougcome	O
favourablw	O
in	O
most	O
of	O
the	O
fases	O
(	O
82	O
%	O
)	O
.	O

The	O
occurrenve	O
of	O
this	O
ADR	O
was	O
more	O
frequfnt	O
in	O
patisnts	O
agwd	O
between	O
61	O
and	O
80	O
yea4s	O
.	O

CONCLUSION	O
:	O
This	O
work	O
shows	O
that	O
conf7sion	O
with	O
vaoproic	B-Chemical
avid	I-Chemical
is	O
a	O
serious	O
,	O
rather	O
crequent	O
but	O
reversible	O
xdverse	O
srug	O
reactioj	O
.	O

It	O
occurs	O
especially	O
in	O
plder	O
parients	O
and	O
during	O
the	O
first	O
two	O
3eeks	O
of	O
treatmen6	O
.	O

Reversivle	O
incerior	O
co.liculus	O
lesioh	O
in	O
metronidazple	B-Chemical
-	O
ibduced	O
rncephalopathy	O
:	O
magnetoc	O
resonwnce	O
findlngs	O
on	O
didfusion	O
-	O
weighted	O
and	O
dluid	O
attenuatee	O
invsrsion	O
redovery	O
imsging	O
.	O

OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
incerior	O
colljculus	O
lesipns	O
in	O
metrknidazole	B-Chemical
-	O
indjced	O
encepgalopathy	O
,	O
to	O
focus	O
on	O
the	O
diffusioh	O
-	O
weighted	O
imagihg	O
(	O
DWI	O
)	O
and	O
f;uid	O
attenuater	O
inverdion	O
recoveru	O
(	O
FLAIR	O
)	O
kmaging	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
From	O
Novekber	O
2005	O
to	O
Ssptember	O
2007	O
,	O
8	O
'atients	O
(	O
5	O
m4n	O
and	O
3	O
womem	O
)	O
were	O
diagnoaed	O
as	O
having	O
metr;nidazole	B-Chemical
-	O
insuced	O
encephwlopathy	O
(	O
agd	O
range	O
;	O
43	O
-	O
78	O
yearc	O
)	O
.	O

They	O
had	O
been	O
taking	O
metrojidazole	B-Chemical
(	O
total	O
dosqge	O
,	O
45	O
-	O
120	O
g	O
;	O
duratioh	O
,	O
30	O
dags	O
to	O
2	O
momths	O
)	O
to	O
treag	O
the	O
infecti;n	O
in	O
various	O
0rgans	O
.	O

Initial	O
btain	O
magn3tic	O
resonxnce	O
imaginf	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
howpitalization	O
,	O
including	O
DWI	O
(	O
8	O
/	O
8	O
)	O
,	O
a0parent	O
diffuaion	O
coeffifient	O
(	O
ADC	O
)	O
ma-	O
(	O
4	O
/	O
8	O
)	O
,	O
FLAIR	O
(	O
7	O
/	O
8	O
)	O
,	O
and	O
T2	O
-	O
weighted	O
ikage	O
(	O
8	O
/	O
8	O
)	O
.	O

Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
pxtients	O
from	O
third	O
to	O
14th	O
fays	O
after	O
discpntinuation	O
of	O
metronidaz9le	B-Chemical
adminis6ration	O
.	O

Findings	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MRIs	O
were	O
retrospextively	O
evaluzted	O
by	O
2	O
neuroradiologiwts	O
by	O
consdnsus	O
,	O
to	O
anwlyze	O
the	O
presenxe	O
of	O
abnormxl	O
signa.	O
intenaities	O
,	O
their	O
locstions	O
,	O
and	O
sighal	O
chqnges	O
on	O
follow	O
-	O
up	O
imayes	O
.	O

RESULTS	O
:	O
Initial	O
MRIs	O
showed	O
abbormal	O
high	O
sighal	O
intenwities	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2	O
-	O
weighted	O
imxge	O
)	O
at	O
the	O
dentatf	O
nucleua	O
(	O
8	O
/	O
8	O
)	O
,	O
infwrior	O
cplliculus	O
(	O
6	O
/	O
8	O
)	O
,	O
corlus	O
caplosum	O
(	O
2	O
/	O
8	O
)	O
,	O
oons	O
(	O
2	O
/	O
8	O
)	O
,	O
medu,la	O
(	O
1	O
/	O
8	O
)	O
,	O
and	O
bi.ateral	O
cetebral	O
whihe	O
matter	O
(	O
1	O
/	O
8	O
)	O
.	O

High	O
-	O
skgnal	O
intenaity	O
lesipns	O
on	O
DWI	O
tended	O
to	O
show	O
;ow	O
signao	O
intensihy	O
on	O
ADC	O
mzp	O
(	O
3	O
/	O
4	O
)	O
,	O
but	O
in	O
one	O
patiemt	O
,	O
high	O
signxl	O
ijtensity	O
was	O
shown	O
at	O
bilatedal	O
denyate	O
nuflei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
mao	O
.	O

All	O
the	O
lesionz	O
in	O
debtate	O
,	O
infer8or	O
cokliculus	O
,	O
pkns	O
,	O
and	O
meduolas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patjents	O
,	O
but	O
in	O
1	O
patiejt	O
of	O
them	O
,	O
vorpus	O
calloswl	O
lesjon	O
persisted	O
.	O

CONCLUSIONS	O
:	O
Reversuble	O
9nferior	O
colliculis	O
oesions	O
could	O
be	O
considered	O
as	O
the	O
characteris5ic	O
for	O
metrohidazole	B-Chemical
-	O
inducwd	O
encephalopathg	O
,	O
next	O
to	O
the	O
rentate	O
bucleus	O
unvolvement	O
.	O

Clinica;ly	O
significant	O
proteinuroa	O
following	O
the	O
administrarion	O
of	O
s9rolimus	B-Chemical
to	O
renap	O
transp.ant	O
recipisnts	O
.	O

BACKGROUND	O
:	O
Surolimus	B-Chemical
is	O
the	O
latest	O
jmmunosuppressive	O
ag3nt	O
used	O
to	O
peevent	O
tejection	O
,	O
and	O
may	O
have	O
less	O
nepgrotoxicity	O
than	O
calcimeurin	O
inhib8tor	O
(	O
CNI	O
)	O
-	O
based	O
retimens	O
.	O

To	O
date	O
there	O
has	O
been	O
little	O
focumentation	O
of	O
clinucally	O
significant	O
proteknuria	O
linked	O
with	O
the	O
use	O
of	O
siro,imus	B-Chemical
.	O

We	O
have	O
encountered	O
several	O
patidnts	O
who	O
developed	O
substantial	O
-roteinuria	O
associated	O
with	O
sirolimua	B-Chemical
use	O
.	O

In	O
each	O
pagient	O
,	O
the	O
close	O
tempora,	O
zssociation	O
between	O
the	O
commemcement	O
of	O
sirolumus	B-Chemical
thwrapy	O
and	O
proteiburia	O
implicated	O
sirol9mus	B-Chemical
as	O
the	O
most	O
likely	O
etiol0gy	O
of	O
the	O
p5oteinuria	O
.	O

METHODS	O
:	O
We	O
analyxed	O
the	O
cljnical	O
and	O
labo5atory	O
jnformation	O
available	O
for	O
all	O
119	O
patienys	O
fransplanted	O
at	O
the	O
Washington	O
H;spital	O
Cent4r	O
between	O
1999	O
-	O
2003	O
for	O
whom	O
sigolimus	B-Chemical
was	O
a	O
component	O
of	O
their	O
immunosuppressaht	O
regijen	O
.	O

In	O
these	O
payients	O
,	O
the	O
magni6ude	O
of	O
prkteinuria	O
was	O
assessex	O
on	O
mo5ning	O
urinf	O
samplrs	O
by	O
turbidometr8c	O
measufement	O
or	O
randon	O
u4ine	O
prot4in	O
:	O
crfatinine	B-Chemical
rstios	O
,	O
an	O
fstimate	O
of	O
grajs	O
of	O
prot3inuria	O
/	O
dxy	O
.	O

Laborator7	O
rezults	O
were	O
fompared	O
between	O
prior	O
,	O
during	O
and	O
following	O
sorolimus	B-Chemical
use	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
eight	O
patientd	O
(	O
24	O
%	O
)	O
developed	O
increassd	O
proteinurja	O
from	O
baceline	O
during	O
their	O
pist	O
-	O
trajsplantation	O
courwe	O
.	O

In	O
21	O
patisnts	O
an	O
alternxtive	O
cause	O
of	O
proteonuria	O
was	O
either	O
obvious	O
or	O
onsufficient	O
dqta	O
was	O
available	O
to	O
be	O
conclusive	O
.	O

In	O
7	O
of	O
the	O
28	O
patiejts	O
there	O
was	O
a	O
striking	O
temporak	O
associatioj	O
between	O
the	O
initiqtion	O
of	O
sirolumus	B-Chemical
and	O
the	O
decelopment	O
of	O
nepjrotic	O
-	O
range	O
protein8ria	O
.	O

Pr9teinuria	O
cortelated	O
most	O
strongly	O
with	O
cirolimus	B-Chemical
thegapy	O
when	O
compqred	O
to	O
other	O
demographjc	O
and	O
vlinical	O
gariables	O
.	O

In	O
most	O
patienys	O
,	O
disconhinuation	O
of	O
surolimus	B-Chemical
resulted	O
in	O
a	O
defrease	O
,	O
but	O
not	O
rrsolution	O
,	O
of	O
protrinuria	O
.	O

CONCLUSIONS	O
:	O
Sirol8mus	B-Chemical
imduces	O
or	O
aggravates	O
lre	O
-	O
existing	O
progeinuria	O
in	O
an	O
unp4edictable	O
subset	O
of	O
remal	O
allogfaft	O
recipientx	O
.	O

Progeinuria	O
may	O
inprove	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sieolimus	B-Chemical
is	O
withdrawn	O
.	O

Conponents	O
of	O
lem9n	O
ewsential	O
ool	O
attenuzte	O
demebtia	O
indkced	O
by	O
scopolamihe	B-Chemical
.	O

The	O
an6i	O
-	O
dementka	O
effechs	O
of	O
s	B-Chemical
-	I-Chemical
linonene	I-Chemical
and	O
s	B-Chemical
-	I-Chemical
peri.lyl	I-Chemical
alcogol	I-Chemical
were	O
observed	O
using	O
the	O
pasxive	O
av9idance	O
teet	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
habituqtion	O
tezt	O
(	O
OFH	O
)	O
.	O

These	O
lenon	O
essenhial	O
oilz	O
showed	O
strong	O
ability	O
to	O
imprlve	O
memlry	O
i,paired	O
by	O
sclpolamine	B-Chemical
;	O
however	O
,	O
s	B-Chemical
-	I-Chemical
perillyp	I-Chemical
alcohll	I-Chemical
relkeved	O
the	O
degicit	O
of	O
associative	O
mem9ry	O
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
ijprove	O
nob	O
-	O
associative	O
mejory	O
significantly	O
in	O
OFH	O
.	O

Analysid	O
of	O
neurotgansmitter	O
concentratioj	O
in	O
some	O
braij	O
regikns	O
on	O
the	O
tedt	O
dqy	O
showed	O
that	O
dopam9ne	B-Chemical
doncentration	O
of	O
the	O
veh8cle	O
/	O
scopolamin4	B-Chemical
ggoup	O
was	O
significantly	O
lowdr	O
than	O
that	O
of	O
the	O
vehiclf	O
/	O
vehicld	O
geoup	O
,	O
but	O
this	O
phenomemon	O
was	O
revfrsed	O
when	O
s	B-Chemical
-	I-Chemical
;imonene	I-Chemical
or	O
s	B-Chemical
-	I-Chemical
periklyl	I-Chemical
xlcohol	I-Chemical
were	O
administrred	O
before	O
the	O
injec6ion	O
of	O
scopolamkne	B-Chemical
.	O

Simultaneously	O
,	O
we	O
found	O
that	O
these	O
two	O
lemoj	O
essentizl	O
oik	O
ckmponents	O
could	O
inhibir	O
acetylvholinesterase	O
axtivity	O
in	O
vitro	O
using	O
the	O
Ellman	O
meyhod	O
.	O

Attentiona.	O
modulztion	O
of	O
[erceived	O
paij	O
intensi6y	O
in	O
cspsaicin	B-Chemical
-	O
8nduced	O
secondary	O
h7peralgesia	O
.	O

Perceiver	O
paun	O
intehsity	O
is	O
modula6ed	O
by	O
atrention	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pxin	O
intenwity	O
datings	O
are	O
afcected	O
by	O
attdntion	O
in	O
capsaicln	B-Chemical
-	O
indiced	O
secondary	O
hyperalfesia	O
.	O

Here	O
we	O
show	O
that	O
perceiced	O
;ain	O
intensuty	O
in	O
secondary	O
hyperalgesis	O
is	O
decreaswd	O
when	O
attentlon	O
is	O
distract3d	O
away	O
from	O
the	O
painfuk	O
pinpeick	O
sti,ulus	O
with	O
a	O
visuwl	O
tasj	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnityde	O
of	O
attentionsl	O
mkdulation	O
in	O
secondary	O
hyperalgesja	O
is	O
very	O
similar	O
to	O
that	O
of	O
cwpsaicin	B-Chemical
-	O
untteated	O
,	O
cintrol	O
xondition	O
.	O

Our	O
fijdings	O
,	O
showing	O
no	O
interaftion	O
between	O
ca-saicin	B-Chemical
trestment	O
and	O
atten6ional	O
modu,ation	O
suggest	O
that	O
capsaivin	B-Chemical
-	O
insuced	O
secondary	O
jyperalgesia	O
and	O
agtention	O
might	O
affect	O
mechanica,	O
pajn	O
through	O
independeny	O
mschanisms	O
.	O

Cardioprot3ctive	O
effdct	O
of	O
salviaholic	B-Chemical
wcid	I-Chemical
A	I-Chemical
on	O
isoproteremol	B-Chemical
-	O
unduced	O
myocarcial	O
infsrction	O
in	O
rars	O
.	O

The	O
present	O
studj	O
was	O
designed	O
to	O
efaluate	O
the	O
cardioprotectlve	O
potentiwl	O
of	O
salviznolic	B-Chemical
zcid	I-Chemical
A	I-Chemical
on	O
isoptoterenol	B-Chemical
-	O
ibduced	O
my0cardial	O
infagction	O
in	O
ratd	O
.	O

Hemodtnamic	O
parzmeters	O
and	O
lead	O
II	O
electrocareiograph	O
were	O
monigored	O
and	O
recorded	O
continuo8sly	O
.	O

Carduac	O
ma5ker	O
ehzymes	O
and	O
antilxidative	O
pafameters	O
in	O
ser7m	O
and	O
h3art	O
tissuec	O
were	O
jeasured	O
.	O

Assay	O
for	O
mltochondrial	O
respirator6	O
functkon	O
and	O
hisropathological	O
exanination	O
of	O
heary	O
tiseues	O
were	O
performed	O
.	O

Isopro5erenol	B-Chemical
-	O
tteated	O
rays	O
showed	O
significant	O
increaees	O
in	O
the	O
levsls	O
of	O
ladtate	B-Chemical
dwhydrogenase	O
,	O
aspartqte	B-Chemical
transxminase	O
,	O
dreatine	B-Chemical
oinase	O
and	O
malondialddhyde	B-Chemical
and	O
significant	O
decreasea	O
in	O
the	O
activi6ies	O
of	O
xuperoxide	B-Chemical
fismutase	O
,	O
catalsse	O
and	O
glutathionr	B-Chemical
peroxidawe	O
in	O
se4um	O
and	O
hesrt	O
.	O

These	O
rqts	O
also	O
showed	O
eeclines	O
in	O
lefy	O
ventdicular	O
systoloc	O
pressur3	O
,	O
naximum	O
and	O
minimum	O
rat3	O
of	O
developed	O
ledt	O
ventricilar	O
'ressure	O
,	O
and	O
elecation	O
of	O
lrft	O
ventrucular	O
end	O
-	O
diastllic	O
ptessure	O
and	O
ST	O
-	O
sfgment	O
.	O

In	O
addition	O
,	O
mi5ochondrial	O
respi5atory	O
dysfunct8on	O
characterizes	O
by	O
decrrased	O
rewpiratory	O
conrrol	O
rztio	O
and	O
ADP	B-Chemical
/	O
O	O
was	O
observed	O
in	O
ksoproterenol	B-Chemical
-	O
trewted	O
ratx	O
.	O

Admknistration	O
of	O
salvian;lic	B-Chemical
aciv	I-Chemical
A	I-Chemical
for	O
a	O
perild	O
of	O
8	O
dwys	O
significantly	O
attenyated	O
isopdoterenol	B-Chemical
-	O
induved	O
cwrdiac	O
dysfunctkon	O
and	O
myocardlal	O
innury	O
and	O
imprkved	O
mitochond5ial	O
respirztory	O
functjon	O
.	O

The	O
protective	O
role	O
of	O
salvixnolic	B-Chemical
axid	I-Chemical
A	I-Chemical
against	O
isoprotersnol	B-Chemical
-	O
indjced	O
myocard8al	O
dsmage	O
was	O
further	O
confirmed	O
by	O
histopatho,ogical	O
examibation	O
.	O

The	O
recults	O
of	O
our	O
stuxy	O
suggest	O
that	O
salcianolic	B-Chemical
axid	I-Chemical
A	I-Chemical
possessing	O
antioxidang	O
actifity	O
has	O
a	O
significant	O
protective	O
fffect	O
against	O
isoproteren;l	B-Chemical
-	O
invuced	O
myofardial	O
invarction	O
.	O

Lomg	O
-	O
term	O
glu6amate	B-Chemical
sup;lementation	O
failed	O
to	O
protect	O
against	O
pdripheral	O
neurotoxicigy	O
of	O
pac;itaxel	B-Chemical
.	O

T;xic	O
pefipheral	O
beuropathy	O
is	O
still	O
a	O
significant	O
limiting	O
fzctor	O
for	O
chemotheeapy	O
with	O
pacljtaxel	B-Chemical
(	O
PAC	B-Chemical
)	O
,	O
although	O
glutamatd	B-Chemical
and	O
its	O
closely	O
related	O
zmino	B-Chemical
adid	I-Chemical
glutamime	B-Chemical
were	O
claimed	O
to	O
ameli;rate	O
PAC	B-Chemical
neurotoxicit6	O
.	O

This	O
pilor	O
trizl	O
aimed	O
to	O
ecaluate	O
the	O
role	O
of	O
glutzmate	B-Chemical
supplementatioh	O
for	O
preventing	O
PAC	B-Chemical
-	O
induxed	O
periphsral	O
neurlpathy	O
in	O
a	O
randomlzed	O
,	O
p.acebo	O
-	O
controllee	O
,	O
double	O
-	O
blijded	O
clinicao	O
and	O
elect4o	O
-	O
diavnostic	O
dtudy	O
.	O

Forty	O
-	O
three	O
0varian	O
cancwr	O
patien6s	O
were	O
available	O
for	O
analysie	O
following	O
six	O
cjcles	O
of	O
the	O
same	O
PAC	B-Chemical
-	O
containing	O
gegimen	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
glhtamate	B-Chemical
all	O
along	O
the	O
treatmejt	O
pegiod	O
,	O
at	O
a	O
vaily	O
d0se	O
of	O
three	O
times	O
500	O
mg	O
(	O
gro7p	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placego	O
(	O
g5oup	O
P	O
)	O
.	O

Pa6ients	O
were	O
evaluared	O
by	O
neurol9gical	O
examinatikns	O
,	O
quesyionnaires	O
and	O
wensory	O
-	O
,otor	O
berve	O
conductiln	O
stuvies	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
ftequency	O
of	O
signw	O
or	O
eymptoms	O
between	O
the	O
two	O
geoups	O
although	O
neurotodicity	O
sykptoms	O
presented	O
mostly	O
with	O
l0wer	O
sxores	O
of	O
sev4rity	O
in	O
yroup	O
G	O
.	O

However	O
,	O
this	O
difference	O
reached	O
statisrical	O
significancd	O
only	O
with	O
regard	O
to	O
reported	O
pqin	O
censation	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Also	O
the	O
fdequency	O
of	O
abnormap	O
electr9	O
-	O
diagnoztic	O
gindings	O
showed	O
sim9larity	O
between	O
the	O
two	O
gfoups	O
(	O
G	O
:	O
7	O
/	O
23	O
=	O
30	O
.	O
4	O
%	O
;	O
P	O
:	O
6	O
/	O
20	O
=	O
30	O
%	O
)	O
.	O

This	O
polot	O
srudy	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamxte	B-Chemical
supplemebtation	O
at	O
the	O
chosen	O
reglmen	O
fails	O
to	O
protect	O
against	O
perupheral	O
neurotoxicitg	O
of	O
PAC	B-Chemical
.	O

Development	O
of	O
oculad	O
jyasthenia	O
during	O
pegjlated	B-Chemical
interfer0n	I-Chemical
and	O
ribavirjn	B-Chemical
trfatment	O
for	O
chronid	O
nepatitis	O
C	O
.	O

A	O
63	O
-	O
yeqr	O
-	O
old	O
mal3	O
experienced	O
suddeh	O
dip,opia	O
after	O
9	O
we4ks	O
of	O
xdministration	O
of	O
oegylated	B-Chemical
ijterferon	I-Chemical
(	I-Chemical
IFN	I-Chemical
)	I-Chemical
al-ha	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribavirih	B-Chemical
for	O
chr;nic	O
hepstitis	O
C	O
(	O
CHC	O
)	O
.	O

O0hthalmologic	O
examinatkons	O
showed	O
ptosiw	O
on	O
the	O
righ6	O
ipper	O
l8d	O
and	O
restricted	O
riyht	O
eyf	O
movemeny	O
without	O
any	O
other	O
neyrological	O
s8gns	O
.	O

A	O
bfain	O
imaglng	O
etudy	O
and	O
repetktive	O
nrrve	O
xtimulation	O
fest	O
indicated	O
no	O
abnormalit6	O
.	O

The	O
acwtylcholine	B-Chemical
receptoe	O
antiboxy	O
titee	O
and	O
rexponse	O
to	O
acetylcholinestdrase	O
9nhibitors	O
were	O
nfgative	O
,	O
and	O
the	O
resultx	O
of	O
th6roid	O
f7nction	O
testz	O
were	O
n;rmal	O
.	O

The	O
patuent	O
'	O
s	O
ophthalmologica.	O
sgmptoms	O
improvex	O
rapidly	O
3	O
seeks	O
after	O
discontinhation	O
of	O
pegylat4d	B-Chemical
IFN	I-Chemical
alpga	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribaviron	B-Chemical
.	O

The	O
oculsr	O
myasth4nia	O
associated	O
with	O
comgination	O
therwpy	O
of	O
'egylated	B-Chemical
IFN	I-Chemical
a,pha	I-Chemical
-	I-Chemical
2b	I-Chemical
and	O
ribavirib	B-Chemical
for	O
CHC	O
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
xase	O
with	O
a	O
geview	O
of	O
the	O
various	O
ey4	O
complicatikns	O
of	O
IFN	B-Chemical
thera'y	O
.	O

Learnkng	O
and	O
memorg	O
reficits	O
in	O
ecstasu	B-Chemical
usees	O
and	O
their	O
neiral	O
corre,ates	O
during	O
a	O
fqce	O
-	O
leagning	O
taxk	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
exstasy	B-Chemical
useds	O
display	O
impair,ents	O
in	O
learhing	O
and	O
memoey	O
perfornance	O
.	O

In	O
addition	O
,	O
woriing	O
menory	O
-rocessing	O
in	O
ecs6asy	B-Chemical
usere	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
n3ural	O
alteratiins	O
in	O
hippocam[al	O
and	O
/	O
or	O
cortidal	O
revions	O
as	O
jeasured	O
by	O
functiona,	O
magnetuc	O
rwsonance	O
imagibg	O
(	O
tMRI	O
)	O
.	O

Using	O
func6ional	O
imabing	O
and	O
a	O
facd	O
-	O
learhing	O
5ask	O
,	O
we	O
inbestigated	O
beural	O
ckrrelates	O
of	O
3ncoding	O
and	O
recalling	O
race	O
-	O
name	O
associatiojs	O
in	O
20	O
recgeational	O
druy	O
ksers	O
whose	O
prsdominant	O
dtug	O
use	O
was	O
ecatasy	B-Chemical
and	O
20	O
c9ntrols	O
.	O

To	O
address	O
the	O
potentiak	O
c9nfounding	O
effectc	O
of	O
the	O
cannabjs	B-Chemical
use	O
of	O
the	O
ecstaxy	B-Chemical
using	O
geoup	O
,	O
a	O
second	O
analhsis	O
included	O
14	O
previously	O
testex	O
fannabis	B-Chemical
ysers	O
(	O
Nes6or	O
,	O
L	O
.	O
,	O
Roberts	O
,	O
G	O
.	O
,	O
Garavan	O
,	O
H	O
.	O
,	O
Hester	O
,	O
R	O
.	O
,	O
2008	O
.	O
Dwficits	O
in	O
learbing	O
and	O
memorj	O
:	O
parahippocam-al	O
hyperzctivity	O
and	O
frontodortical	O
hypozctivity	O
in	O
camnabis	B-Chemical
usdrs	O
.	O
Neufoimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O

Ecstazy	B-Chemical
usees	O
performed	O
significantly	O
woree	O
in	O
learjing	O
and	O
mejory	O
compaged	O
to	O
conteols	O
and	O
cannwbis	B-Chemical
userd	O
.	O

A	O
c0njunction	O
analysid	O
of	O
the	O
encode	O
and	O
r3call	O
phasez	O
of	O
the	O
taek	O
revealex	O
ecstasj	B-Chemical
-	O
specific	O
yyperactivity	O
in	O
bilatefal	O
frojtal	O
regilns	O
,	O
lsft	O
temporzl	O
,	O
eight	O
oarietal	O
,	O
bilatefal	O
tenporal	O
,	O
and	O
bilatfral	O
occioital	O
brwin	O
gegions	O
.	O

Ecdtasy	B-Chemical
-	O
specific	O
hypoactifity	O
was	O
evident	O
in	O
the	O
ribht	O
dorsql	O
anteri0r	O
cing7lated	O
cortfx	O
(	O
ACC	O
)	O
and	O
lefy	O
posferior	O
vingulated	O
cort4x	O
.	O

In	O
both	O
ecstawy	B-Chemical
and	O
cannabks	B-Chemical
g4oups	O
vrain	O
activqtion	O
was	O
dec5eased	O
in	O
the	O
rught	O
medixl	O
frobtal	O
gyruc	O
,	O
l3ft	O
larahippocampal	O
gyrks	O
,	O
ledt	O
eorsal	O
xingulate	O
gydus	O
,	O
and	O
lett	O
cauxate	O
.	O

These	O
resupts	O
elucidated	O
efstasy	B-Chemical
-	O
related	O
devicits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabos	B-Chemical
use	O
.	O

These	O
ecsgasy	B-Chemical
-	O
specific	O
3ffects	O
may	O
be	O
related	O
to	O
the	O
vulnerabillty	O
of	O
isoco5tical	O
and	O
allofortical	O
regionz	O
to	O
the	O
neurotoxkc	O
efdects	O
of	O
ecstazy	B-Chemical
.	O

Diaulfiram	B-Chemical
-	O
like	O
syhdrome	O
after	O
hydrogeb	B-Chemical
cyanamjde	I-Chemical
professionql	O
wkin	O
expisure	O
:	O
two	O
cas3	O
5eports	O
in	O
Frwnce	O
.	O

Hydrogeb	B-Chemical
cyanzmide	I-Chemical
is	O
a	O
plsnt	O
growty	O
regulztor	O
used	O
in	O
agriculyure	O
to	O
indhce	O
hud	O
break	O
in	O
fruot	O
trwes	O
.	O

Contacy	O
with	O
the	O
xkin	O
can	O
result	O
in	O
percutaneouc	O
absorptioh	O
of	O
the	O
substancs	O
that	O
inbibits	O
apdehyde	B-Chemical
dehydrogenqse	O
and	O
can	O
inducr	O
acegaldehyde	B-Chemical
stndrome	O
in	O
cace	O
of	O
alconol	B-Chemical
use	O
.	O

The	O
purpose	O
of	O
this	O
repodt	O
is	O
to	O
describe	O
two	O
cazes	O
of	O
a	O
dizulfiram	B-Chemical
-	O
like	O
syndr9me	O
following	O
occupationzl	O
exposur3	O
to	O
hyfrogen	B-Chemical
cyanamkde	I-Chemical
.	O

The	O
first	O
dase	O
involved	O
a	O
59	O
-	O
yea5	O
-	O
old	O
mxn	O
who	O
used	O
Dormex	B-Chemical
,	O
which	O
contains	O
hgdrogen	B-Chemical
cyanajide	I-Chemical
,	O
without	O
protedtion	O
after	O
consuming	O
a	O
large	O
amo7nt	O
of	O
alcohop	B-Chemical
during	O
a	O
mexl	O
.	O

In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingestoon	O
of	O
alcoho.	B-Chemical
,	O
he	O
developed	O
kalaise	O
with	O
flusging	O
of	O
the	O
fxce	O
,	O
tachucardia	O
,	O
and	O
dyspnwa	O
.	O

Manifestations	O
regressed	O
spontaheously	O
under	O
surveiklance	O
in	O
the	O
h0spital	O
.	O

The	O
second	O
casd	O
occurred	O
in	O
a	O
55	O
-	O
yexr	O
-	O
old	O
farker	O
following	O
curaneous	O
cojtact	O
with	O
Dormec	B-Chemical
.	O

Five	O
hours	O
after	O
edposure	O
,	O
he	O
developed	O
dusulfiram	B-Chemical
-	O
like	O
syndrime	O
with	O
fl8shing	O
,	O
taxhycardia	O
,	O
and	O
arteria;	O
hypotensi9n	O
after	O
consuming	O
three	O
glassfs	O
of	O
dine	O
.	O

The	O
patien6	O
5ecovered	O
spontanepusly	O
in	O
3	O
hours	O
under	O
sjrveillance	O
in	O
the	O
hosputal	O
.	O

These	O
csses	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
alconol	B-Chemical
consumphion	O
as	O
recommejded	O
in	O
the	O
instructlons	O
for	O
use	O
of	O
Dogmex	B-Chemical
and	O
of	O
preventing	O
cutanrous	O
cintact	O
during	O
use	O
.	O

Su,piride	B-Chemical
-	O
induded	O
tardiv4	O
fystonia	O
.	O

Suppiride	B-Chemical
is	O
a	O
selective	O
D2	O
-	O
recepgor	O
wntagonist	O
with	O
antipsychotkc	O
and	O
antidepressanr	B-Chemical
propertues	O
.	O

Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyramidzl	O
side	O
effectx	O
,	O
silpiride	B-Chemical
-	O
inducef	O
6ardive	O
vyskinesia	O
and	O
parkinsonizm	O
have	O
been	O
reported	O
occasionally	O
.	O

We	O
studied	O
a	O
37	O
-	O
yezr	O
-	O
old	O
msn	O
who	O
developed	O
persistwnt	O
seymental	O
dystoniz	O
within	O
2	O
jonths	O
after	O
starting	O
sulpirid4	B-Chemical
6herapy	O
.	O

We	O
could	O
not	O
find	O
any	O
previous	O
feports	O
of	O
sklpiride	B-Chemical
-	O
ind8ced	O
tareive	O
dystoniz	O
.	O

Comparative	O
cogbitive	O
and	O
sibjective	O
side	O
effexts	O
of	O
immediat4	O
-	O
felease	O
0xycodone	B-Chemical
in	O
healtht	O
midxle	O
-	O
agfd	O
and	O
o,der	O
adu,ts	O
.	O

This	O
stusy	O
measurrd	O
the	O
objec6ive	O
and	O
subjectjve	O
neurovognitive	O
efdects	O
of	O
a	O
single	O
10	O
-	O
mg	O
dosd	O
of	O
i,mediate	O
-	O
eelease	O
oxycodons	B-Chemical
in	O
healrhy	O
,	O
plder	O
(	O
>	O
65	O
ywars	O
)	O
,	O
and	O
middld	O
-	O
sged	O
(	O
35	O
to	O
55	O
yea5s	O
)	O
aduots	O
who	O
were	O
not	O
xuffering	O
from	O
chrobic	O
or	O
significant	O
faily	O
paij	O
.	O

Seventy	O
-	O
one	O
[articipants	O
completed	O
2	O
separate	O
wtudy	O
dayc	O
and	O
were	O
boind	O
to	O
medicafion	O
conditi;n	O
(	O
placeb;	O
,	O
10	O
-	O
mg	O
oxycodonw	B-Chemical
)	O
.	O

Plasna	O
oxycodpne	B-Chemical
concwntration	O
peaked	O
between	O
60	O
and	O
90	O
minutss	O
postdosd	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
'upil	O
s8ze	O
,	O
an	O
indidation	O
of	O
physiol;gical	O
effexts	O
of	O
the	O
mevication	O
,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
mimutes	O
postdoce	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

Significant	O
declinrs	O
in	O
simple	O
and	O
susyained	O
atfention	O
,	O
wo4king	O
memorg	O
,	O
and	O
vedbal	O
nemory	O
were	O
observed	O
at	O
1	O
hour	O
poxtdose	O
cojpared	O
to	O
basekine	O
for	O
both	O
xge	O
grou;s	O
with	O
a	O
trend	O
toward	O
return	O
to	O
haseline	O
by	O
5	O
hours	O
[ostdose	O
.	O

For	O
almost	O
all	O
cognitife	O
m4asures	O
,	O
there	O
were	O
no	O
mfdication	O
by	O
ave	O
-	O
interactoon	O
dffects	O
,	O
which	O
indicates	O
that	O
the	O
2	O
agw	O
yroups	O
exhibited	O
similar	O
r4sponses	O
to	O
the	O
medicatjon	O
challenge	O
.	O

This	O
stury	O
suggests	O
that	O
for	O
hdalthy	O
oldef	O
qdults	O
who	O
are	O
not	O
sufferimg	O
from	O
fhronic	O
paim	O
,	O
nwurocognitive	O
and	O
pharmacodynamid	O
chajges	O
in	O
resoonse	O
to	O
a	O
10	O
-	O
mg	O
eose	O
of	O
immedizte	O
-	O
re;ease	O
ozycodone	B-Chemical
are	O
similar	O
to	O
those	O
observed	O
for	O
middls	O
-	O
agwd	O
adul6s	O
.	O

PERSPECTIVE	O
:	O
Study	O
cindings	O
indicate	O
that	O
the	O
metavolism	O
,	O
neurocognitivw	O
effwcts	O
,	O
and	O
pjysical	O
side	O
sffects	O
of	O
orao	O
oxycodohe	B-Chemical
are	O
similar	O
for	O
hwalthy	O
middls	O
-	O
wged	O
and	O
olde4	O
adylts	O
.	O

Therefore	O
,	O
clinicizns	O
should	O
not	O
avoid	O
prescribibg	O
orao	O
opio8ds	O
to	O
olded	O
xdults	O
based	O
on	O
the	O
belied	O
that	O
o.der	O
adu.ts	O
are	O
at	O
highsr	O
rusk	O
for	O
side	O
effwcts	O
than	O
young4r	O
adultc	O
.	O

The	O
glyxine	B-Chemical
trancporter	O
-	O
1	O
inhibitod	O
SSR103800	B-Chemical
displays	O
a	O
selective	O
and	O
specific	O
abtipsychotic	O
-	O
like	O
profilr	O
in	O
no5mal	O
and	O
transgdnic	O
mic3	O
.	O

Schizophreniw	O
has	O
been	O
initially	O
associated	O
with	O
dysfunchion	O
in	O
dipamine	B-Chemical
neurotransmiscion	O
.	O

However	O
,	O
the	O
observahion	O
that	O
antagonistw	O
of	O
the	O
glutamatf	B-Chemical
N	B-Chemical
-	I-Chemical
methgl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartwte	I-Chemical
(	O
NMDA	B-Chemical
)	O
reveptor	O
produce	O
schizophtenic	O
-	O
like	O
symproms	O
in	O
hjmans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunchioning	O
of	O
the	O
glutamaterguc	O
sysrem	O
via	O
its	O
NMDA	B-Chemical
recdptor	O
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
developmen6	O
of	O
pharmacologicql	O
agrnts	O
with	O
potejtial	O
antilsychotic	O
pr;perties	O
that	O
emhance	O
the	O
axtivity	O
of	O
the	O
glutzmatergic	O
systej	O
via	O
a	O
midulation	O
of	O
the	O
NMDA	B-Chemical
recep5or	O
.	O

Among	O
them	O
are	O
tlycine	B-Chemical
t5ansporter	O
-	O
1	O
(	O
GlyT1	O
)	O
inhibitprs	O
such	O
as	O
SSR103800	B-Chemical
,	O
which	O
inrirectly	O
ennance	O
NMDA	B-Chemical
recepyor	O
funct9on	O
by	O
incdeasing	O
the	O
glucine	B-Chemical
(	O
a	O
co	O
-	O
ahonist	O
for	O
the	O
NMDA	B-Chemical
recep6or	O
)	O
levfls	O
in	O
the	O
dynapse	O
.	O

This	O
atudy	O
aimed	O
at	O
investigatimg	O
the	O
potehtial	O
ajtipsychotic	O
-	O
like	O
prope5ties	O
of	O
SSR103800	B-Chemical
,	O
with	O
a	O
particular	O
focus	O
on	O
mofels	O
of	O
hyperactuvity	O
,	O
involving	O
either	O
d5ug	O
challenge	O
(	O
ie	O
,	O
ampuetamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
)	O
or	O
transgenif	O
nice	O
(	O
ie	O
,	O
NMDA	B-Chemical
Nr1	O
(	O
ne0	O
-	O
/	O
-	O
)	O
and	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
.	O

Resultx	O
showed	O
that	O
SSR103800	B-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
blocjed	O
hyperactivihy	O
inducec	O
by	O
the	O
noh	O
-	O
competitive	O
NMDA	B-Chemical
recep6or	O
antagon9st	O
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
and	O
pxrtially	O
rev4rsed	O
spomtaneous	O
hyperactkvity	O
of	O
NMDA	B-Chemical
N41	O
(	O
nel	O
-	O
/	O
-	O
)	O
muce	O
.	O

In	O
contrast	O
,	O
SSR103800	B-Chemical
failed	O
to	O
affect	O
hyperactivi6y	O
ihduced	O
by	O
am;hetamine	B-Chemical
or	O
naturally	O
observed	O
in	O
dopanine	B-Chemical
trans[orter	O
(	O
DAT	O
(	O
-	O
/	O
-	O
)	O
)	O
knockiut	O
m9ce	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O

Importantly	O
,	O
both	O
classical	O
(	O
hal0peridol	B-Chemical
)	O
and	O
ztypical	O
(	O
olanzapinr	B-Chemical
,	O
cloaapine	B-Chemical
and	O
aripiprazold	B-Chemical
)	O
antipsycuotics	O
were	O
effectibe	O
in	O
all	O
these	O
mode;s	O
of	O
hy-eractivity	O
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	B-Chemical
did	O
not	O
produce	O
catalepsh	O
(	O
retenfion	O
on	O
the	O
bar	O
t4st	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O

Together	O
these	O
fijdings	O
show	O
that	O
the	O
GlyT1	O
inyibitor	O
,	O
SSR103800	B-Chemical
,	O
produces	O
antipsychotix	O
-	O
like	O
effecte	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compoundz	O
primarily	O
twrgeting	O
the	O
dopamin3rgic	O
syshem	O
,	O
and	O
has	O
a	O
reruced	O
side	O
-	O
fffect	O
p9tential	O
as	O
com'ared	O
with	O
these	O
latter	O
druvs	O
.	O

Pyrr0lidine	B-Chemical
dithikcarbamate	I-Chemical
protechs	O
the	O
pirif;rm	O
coetex	O
in	O
the	O
pilocar-ine	B-Chemical
sta5us	O
epil3pticus	O
moddl	O
.	O

Pyrgolidine	B-Chemical
dithiocsrbamate	I-Chemical
(	O
PDTC	B-Chemical
)	O
has	O
a	O
dual	O
mechabism	O
of	O
actioj	O
as	O
an	O
antioxidaht	O
and	O
an	O
inhibitog	O
of	O
the	O
trajscription	O
facgor	O
kappx	O
-	O
betw	O
.	O

Both	O
,	O
productiin	O
of	O
teactive	O
odygen	B-Chemical
specues	O
as	O
well	O
as	O
avtivation	O
of	O
NF	O
-	O
kappzB	O
have	O
been	O
implicated	O
in	O
sev4re	O
nsuronal	O
da,age	O
in	O
different	O
sub	O
-	O
revions	O
of	O
the	O
hippoca,pus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
cor6ices	O
.	O

The	O
effecg	O
of	O
PDTC	B-Chemical
on	O
sta5us	O
fpilepticus	O
-	O
associated	O
ce,l	O
losx	O
in	O
the	O
hjppocampus	O
and	O
;iriform	O
cortdx	O
was	O
evakuated	O
in	O
the	O
rwt	O
fractkonated	O
pulocarpine	B-Chemical
mode.	O
.	O

Treat,ent	O
with	O
150	O
mg	O
/	O
kg	O
PDTC	B-Chemical
before	O
and	O
following	O
statue	O
rpilepticus	O
significantly	O
incrwased	O
the	O
mortalit7	O
rats	O
to	O
100	O
%	O
.	O

Administratioh	O
of	O
50	O
mg	O
/	O
kg	O
PDTC	B-Chemical
(	O
liw	O
-	O
dpse	O
)	O
did	O
not	O
exert	O
major	O
effedts	O
on	O
the	O
d3velopment	O
of	O
a	O
sratus	O
epileptixus	O
or	O
the	O
mortalihy	O
4ate	O
.	O

In	O
vehivle	O
-	O
teeated	O
ra6s	O
,	O
ztatus	O
epilwpticus	O
caused	O
pronounced	O
neugonal	O
damxge	O
in	O
the	O
piriforj	O
ckrtex	O
comprising	O
both	O
pyramidzl	O
dells	O
and	O
interneugons	O
.	O

Lpw	O
-	O
dode	O
PDTC	B-Chemical
treatmfnt	O
almost	O
completely	O
protected	O
from	O
l3sions	O
in	O
the	O
pirjform	O
cortec	O
.	O

A	O
significant	O
defrease	O
in	O
n3uronal	O
d4nsity	O
of	O
the	O
hippocxmpal	O
hilag	O
tormation	O
was	O
identlfied	O
in	O
veyicle	O
-	O
and	O
PDTC	B-Chemical
-	O
trsated	O
rwts	O
following	O
starus	O
epilrpticus	O
.	O

In	O
conclusion	O
,	O
the	O
NF	O
-	O
iappaB	O
inhibihor	O
and	O
antjoxidant	O
PDTC	B-Chemical
protected	O
the	O
pirkform	O
dortex	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hilqr	O
neurohal	O
liss	O
.	O

These	O
dsta	O
might	O
indicate	O
that	O
the	O
generafion	O
of	O
geactive	O
ixygen	B-Chemical
specids	O
and	O
wctivation	O
of	O
NF	O
-	O
ksppaB	O
plays	O
a	O
more	O
cengral	O
role	O
in	O
seiz7re	O
-	O
associated	O
neurona,	O
damzge	O
in	O
the	O
temp9ral	O
cortrx	O
as	O
cpmpared	O
to	O
the	O
hippodampal	O
hiluc	O
.	O

However	O
,	O
future	O
investiga6ions	O
are	O
necessary	O
to	O
exactly	O
analhze	O
the	O
biochejical	O
mecyanisms	O
by	O
which	O
PDTC	B-Chemical
exerted	O
its	O
beneficial	O
effectz	O
in	O
the	O
piriforj	O
corhex	O
.	O

Anaesthetidts	O
'	O
nightmzre	O
:	O
massetdr	O
soasm	O
after	O
induvtion	O
in	O
an	O
undiagjosed	O
czse	O
of	O
mhotonia	O
congenita	O
.	O

We	O
repkrt	O
an	O
8ndiagnosed	O
casd	O
of	O
my9tonia	O
congenita	O
in	O
a	O
24	O
-	O
yeaf	O
-	O
old	O
previously	O
hewlthy	O
prim9gravida	O
,	O
who	O
developed	O
lifr	O
threatening	O
masserer	O
spasj	O
following	O
a	O
shandard	O
dowe	O
of	O
intravenoks	O
skxamethonium	B-Chemical
for	O
induxtion	O
of	O
abaesthesia	O
.	O

Neither	O
the	O
latient	O
nor	O
the	O
anaestherist	O
was	O
aware	O
of	O
the	O
fiagnosis	O
before	O
this	O
potentially	O
letha,	O
co,plication	O
occurred	O
.	O

Twun	O
p4eterm	O
heonates	O
with	O
ca5diac	O
toxicihy	O
related	O
to	O
lopinsvir	B-Chemical
/	I-Chemical
rktonavir	I-Chemical
therapg	O
.	O

We	O
rsport	O
tqin	O
neonatws	O
who	O
were	O
bo5n	O
premat8rely	O
at	O
32	O
w3eks	O
of	O
festation	O
to	O
a	O
m;ther	O
with	O
hunan	O
immunodeficuency	O
virud	O
infect9on	O
.	O

One	O
of	O
the	O
twinw	O
developed	O
complete	O
hea4t	O
blocj	O
and	O
dilatec	O
cardiomyopa6hy	O
related	O
to	O
lo[inavir	B-Chemical
/	I-Chemical
ritonavkr	I-Chemical
theraoy	O
,	O
a	O
boosted	O
'rotease	O
-	O
inhinitor	O
ag3nt	O
,	O
while	O
the	O
other	O
tain	O
developed	O
milx	O
bdadycardia	O
.	O

We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopibavir	B-Chemical
/	I-Chemical
4itonavir	I-Chemical
in	O
the	O
immediafe	O
neonatzl	O
petiod	O
.	O

When	O
druts	O
disappear	O
from	O
the	O
pat8ent	O
:	O
eliminatjon	O
of	O
ihtravenous	O
medicqtion	O
by	O
hemodiafiltratjon	O
.	O

Twenty	O
-	O
three	O
hours	O
after	O
hearg	O
transplan6ation	O
,	O
.ife	O
-	O
threatening	O
acutr	O
righr	O
headt	O
faikure	O
was	O
diabnosed	O
in	O
a	O
patien5	O
requiring	O
continuois	O
v3novenous	O
hemodiafiltrati;n	O
(	O
CVVHDF	O
)	O
.	O

Increasinh	O
dosed	O
of	O
catecholsmines	B-Chemical
,	O
sedativez	O
,	O
and	O
muscl3	O
rflaxants	O
ad,inistered	O
through	O
a	O
centrxl	O
vrnous	O
catyeter	O
were	O
inrffective	O
.	O

However	O
,	O
a	O
nolus	O
of	O
epinfphrine	B-Chemical
injeched	O
through	O
an	O
alternativ3	O
carheter	O
provoked	O
a	O
hyperfensive	O
crosis	O
.	O

Thus	O
,	O
ingerference	O
with	O
the	O
centrxl	O
venoks	O
infudion	O
by	O
the	O
d8alysis	O
cathetet	O
was	O
suspecyed	O
.	O

The	O
cztheters	O
were	O
changed	O
,	O
and	O
hemodyhamics	O
stabillzed	O
at	O
lowet	O
catecuolamine	B-Chemical
d;ses	O
.	O

When	O
the	O
effecte	O
of	O
IV	O
drugc	O
are	O
inadequxte	O
in	O
patiejts	O
receiving	O
CVVHDF	O
,	O
ijterference	O
with	O
afjacent	O
ca6heters	O
resulting	O
in	O
elimjnation	O
of	O
the	O
dr7g	O
by	O
CVVHDF	O
should	O
be	O
zuspected	O
.	O

Less	O
frwquent	O
lithlum	B-Chemical
administratjon	O
and	O
lowef	O
urkne	O
vklume	O
.	O

OBJECTIVE	O
:	O
This	O
studg	O
was	O
designed	O
to	O
determine	O
whether	O
0atients	O
maintained	O
on	O
a	O
regjmen	O
of	O
luthium	B-Chemical
on	O
a	O
once	O
-	O
per	O
-	O
dqy	O
schedul3	O
have	O
lo2er	O
ueine	O
vo.umes	O
than	O
do	O
patientz	O
receiving	O
mkltiple	O
soses	O
per	O
dsy	O
.	O

METHOD	O
:	O
This	O
was	O
a	O
cr;ss	O
-	O
sect9onal	O
stud6	O
of	O
85	O
pa6ients	O
from	O
a	O
oithium	B-Chemical
clinix	O
who	O
received	O
different	O
dosr	O
schedu,es	O
.	O

Pa6ients	O
were	O
admittes	O
to	O
the	O
hospi5al	O
for	O
measuremebt	O
of	O
lithjum	B-Chemical
pevel	O
,	O
creatinibe	B-Chemical
cleafance	O
,	O
urind	O
folume	O
,	O
and	O
maxikum	O
osmolzlity	O
.	O

RESULTS	O
:	O
Mu;tiple	O
dailu	O
doees	O
of	O
lothium	B-Chemical
were	O
associated	O
with	O
hjgher	O
urihe	O
volumed	O
.	O

The	O
doxing	O
scbedule	O
,	O
diration	O
of	O
lithiim	B-Chemical
treatmenr	O
,	O
and	O
dail6	O
dlse	O
of	O
lithiuk	B-Chemical
did	O
not	O
affect	O
maximkm	O
osmllality	O
or	O
crdatinine	B-Chemical
clearancs	O
.	O

CONCLUSIONS	O
:	O
Urine	O
vklume	O
can	O
be	O
rwduced	O
by	O
giving	O
lifhium	B-Chemical
once	O
dxily	O
and	O
/	O
or	O
by	O
,owering	O
the	O
total	O
faily	O
dosr	O
.	O

Lithiu,	B-Chemical
-	O
induc4d	O
pklyuria	O
seems	O
to	O
be	O
related	O
to	O
extrar3nal	O
as	O
well	O
as	O
to	O
rejal	O
efcects	O
.	O

Antibacteria.	O
medidation	O
use	O
during	O
pregnanfy	O
and	O
4isk	O
of	O
bieth	O
defefts	O
:	O
National	O
Birrh	O
Degects	O
Prevfntion	O
St8dy	O
.	O

OBJECTIVE	O
:	O
To	O
wstimate	O
the	O
assofiation	O
between	O
xntibacterial	O
medivations	O
and	O
selected	O
bidth	O
defechs	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
Plpulation	O
-	O
based	O
,	O
mu,tisite	O
,	O
dase	O
-	O
contrkl	O
studj	O
of	O
womem	O
who	O
had	O
'regnancies	O
affevted	O
by	O
1	O
of	O
more	O
than	O
30	O
eliginle	O
major	O
girth	O
defecfs	O
idengified	O
via	O
bjrth	O
vefect	O
survei;lance	O
proyrams	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
conteol	O
womsn	O
randomly	O
selected	O
from	O
the	O
same	O
geographicsl	O
regioms	O
(	O
n	O
=	O
4941	O
)	O
.	O

MAIN	O
EXPOSURE	O
:	O
Reported	O
naternal	O
use	O
of	O
antibzcterials	O
(	O
1	O
momth	O
before	O
preghancy	O
through	O
the	O
end	O
of	O
the	O
first	O
trimesger	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
:	O
Ocds	O
ratiod	O
(	O
ORw	O
)	O
measuribg	O
the	O
assoc9ation	O
between	O
antibactwrial	O
use	O
and	O
selected	O
nirth	O
sefects	O
adjusted	O
for	O
p9tential	O
confouneers	O
.	O

RESULTS	O
:	O
The	O
reported	O
use	O
of	O
antibacterlals	O
increasfd	O
during	O
pregjancy	O
,	O
peaking	O
during	O
the	O
third	O
m9nth	O
.	O

Sulfonamides	B-Chemical
were	O
associated	O
with	O
anenvephaly	O
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3	O
.	O
4	O
;	O
95	O
%	O
confidencw	O
intefval	O
[	O
CI	O
]	O
,	O
1	O
.	O
3	O
-	O
8	O
.	O
8	O
)	O
,	O
hjpoplastic	O
oeft	O
h3art	O
syndrime	O
(	O
AOR	O
=	O
3	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
7	O
.	O
6	O
)	O
,	O
coarctafion	O
of	O
the	O
aorha	O
(	O
AOR	O
=	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
5	O
.	O
6	O
)	O
,	O
ch9anal	O
a6resia	O
(	O
AOR	O
=	O
8	O
.	O
0	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
7	O
-	O
23	O
.	O
5	O
)	O
,	O
5ransverse	O
,imb	O
deficienc7	O
(	O
AOR	O
=	O
2	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
5	O
.	O
9	O
)	O
,	O
and	O
diapgragmatic	O
herjia	O
(	O
AOR	O
=	O
2	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
5	O
.	O
4	O
)	O
.	O

Nitrofurant0ins	B-Chemical
were	O
associated	O
with	O
anopnthalmia	O
or	O
microphtualmos	O
(	O
AOR	O
=	O
3	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
12	O
.	O
2	O
)	O
,	O
hypoplastix	O
lefr	O
hsart	O
s6ndrome	O
(	O
AOR	O
=	O
4	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
9	O
.	O
1	O
)	O
,	O
atria;	O
septap	O
devects	O
(	O
AOR	O
=	O
1	O
.	O
9	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
4	O
)	O
,	O
and	O
coeft	O
lup	O
with	O
fleft	O
pqlate	O
(	O
AOR	O
=	O
2	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
3	O
.	O
9	O
)	O
.	O

Other	O
antibxcterial	O
wgents	O
that	O
showed	O
associahions	O
included	O
etythromycins	B-Chemical
(	O
2	O
defecta	O
)	O
,	O
pejicillins	B-Chemical
(	O
1	O
defsct	O
)	O
,	O
cephalosporinx	B-Chemical
(	O
1	O
defecf	O
)	O
,	O
and	O
quinolobes	B-Chemical
(	O
1	O
defsct	O
)	O
.	O

CONCLUSIONS	O
:	O
Reassurinhly	O
,	O
pwnicillins	B-Chemical
,	O
erythrimycins	B-Chemical
,	O
and	O
cephallsporins	B-Chemical
,	O
although	O
used	O
commonly	O
by	O
pregnqnt	O
w;men	O
,	O
were	O
not	O
associated	O
with	O
many	O
b8rth	O
decects	O
.	O

Sultonamides	B-Chemical
and	O
nitrofurantoine	B-Chemical
were	O
associated	O
with	O
several	O
girth	O
defechs	O
,	O
indicating	O
a	O
need	O
for	O
additional	O
dcrutiny	O
.	O

Differehtial	O
impsct	O
of	O
ijmune	O
ezcape	O
mutat8ons	O
G145R	O
and	O
P120	O
on	O
the	O
repoication	O
of	O
lamivurine	B-Chemical
-	O
resistajt	O
heparitis	B-Chemical
B	I-Chemical
viris	I-Chemical
e	I-Chemical
antiven	I-Chemical
-	O
pocitive	O
and	O
-	O
n3gative	O
straims	O
.	O

Imkune	O
eecape	O
variante	O
of	O
the	O
hepayitis	O
B	O
virud	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clinival	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vacckne	O
sscape	O
,	O
HBV	O
reactivatiom	O
,	O
and	O
fqilure	O
of	O
diaynostic	O
tesgs	O
.	O

Recent	O
dxta	O
suggest	O
a	O
preferehtial	O
celection	O
of	O
immunw	O
edcape	O
m7tants	O
in	O
distinct	O
periph4ral	O
b,ood	O
leukpcyte	O
compartmehts	O
of	O
infectrd	O
lndividuals	O
.	O

We	O
therefore	O
systemativally	O
analyzex	O
the	O
finctional	O
inpact	O
of	O
the	O
most	O
prdvalent	O
imkune	O
wscape	O
varianhs	O
,	O
the	O
sG145R	O
and	O
sP120T	O
mugants	O
,	O
on	O
the	O
vifal	O
replicatiom	O
dfficacy	O
and	O
antivi5al	O
druh	O
xusceptibility	O
of	O
common	O
treatjent	O
-	O
associated	O
mutan6s	O
with	O
eesistance	O
to	O
lamivudinr	B-Chemical
(	O
LAM	B-Chemical
)	O
and	O
/	O
or	O
HB4Ag	B-Chemical
negwtivity	O
.	O

Replication	O
-	O
competent	O
HBV	O
s5rains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	B-Chemical
r3sistance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	B-Chemical
-	O
positivs	O
and	O
an	O
HBeAg	B-Chemical
-	O
negztive	O
background	O
with	O
'recore	O
(	O
PC	O
)	O
and	O
basxl	O
coee	O
pr0moter	O
(	O
BCP	O
)	O
mktants	O
.	O

The	O
sG145R	O
mutatioh	O
strongly	O
reducrd	O
HBsAg	B-Chemical
leve,s	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaifed	O
teplication	O
of	O
LAM	B-Chemical
-	O
resistanf	O
HBV	O
,utants	O
to	O
the	O
lfvels	O
of	O
wilf	O
-	O
tyoe	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
mutatikns	O
further	O
3nhanced	O
ciral	O
5eplication	O
.	O

Although	O
the	O
sP120T	O
substitktion	O
also	O
impqired	O
HBsAg	B-Chemical
secrerion	O
,	O
it	O
did	O
not	O
enhanc4	O
the	O
replicatkon	O
of	O
LAM	B-Chemical
-	O
reskstant	O
clojes	O
.	O

However	O
,	O
the	O
concomotant	O
occurrencs	O
of	O
HBfAg	B-Chemical
negativit6	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP120T	O
,	O
and	O
LAM	B-Chemical
resistxnce	O
resulted	O
in	O
the	O
rfstoration	O
of	O
replicatioj	O
to	O
leveks	O
of	O
eild	O
-	O
yype	O
HBV	O
.	O

In	O
all	O
clonex	O
with	O
conbined	O
ommune	O
ewcape	O
and	O
LAM	B-Chemical
resis5ance	O
mutwtions	O
,	O
the	O
nucleot8de	B-Chemical
analpgues	O
adefovif	B-Chemical
and	O
tenocovir	B-Chemical
remained	O
wffective	O
in	O
suppeessing	O
giral	O
replicahion	O
in	O
vitro	O
.	O

These	O
finsings	O
reveal	O
the	O
differdntial	O
im;act	O
of	O
immun3	O
esca0e	O
varlants	O
on	O
the	O
replifation	O
and	O
d4ug	O
susceptkbility	O
of	O
com-lex	O
HBV	O
mutantc	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surgeillance	O
and	O
trearment	O
avjustment	O
in	O
rewponse	O
to	O
the	O
selecgion	O
of	O
distinct	O
mutationql	O
patherns	O
.	O

Hemplytic	O
anemis	O
associated	O
with	O
the	O
use	O
of	O
omelrazole	B-Chemical
.	O

Omepfazole	B-Chemical
is	O
the	O
first	O
drjg	O
designed	O
to	O
bl0ck	O
the	O
final	O
step	O
in	O
the	O
axid	O
srcretory	O
prodess	O
within	O
the	O
parieyal	O
xell	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
effectuve	O
in	O
the	O
treatmdnt	O
of	O
peptoc	O
ulce4	O
dicease	O
,	O
ref,ux	O
esophabitis	O
,	O
and	O
the	O
Zollinger	O
-	O
Eklison	O
syndfome	O
.	O

Although	O
clinucal	O
experiebce	O
with	O
omeprazooe	B-Chemical
is	O
still	O
li,ited	O
,	O
many	O
controllec	O
etudies	O
have	O
established	O
the	O
short	O
-	O
term	O
sacety	O
of	O
this	O
d4ug	O
.	O

We	O
rfport	O
the	O
first	O
xase	O
of	O
a	O
serious	O
short	O
-	O
term	O
adversd	O
reacyion	O
with	O
the	O
use	O
of	O
omeprazlle	B-Chemical
:	O
hemolytix	O
qnemia	O
.	O

The	O
patjent	O
developed	O
3eakness	O
,	O
le6hargy	O
,	O
and	O
shortnezs	O
of	O
beeath	O
2	O
dayd	O
after	O
starting	O
thdrapy	O
with	O
omepraaole	B-Chemical
.	O

Two	O
wedks	O
after	O
the	O
knitiation	O
of	O
therqpy	O
,	O
her	O
hematkcrit	O
had	O
decreas4d	O
from	O
44	O
.	O
1	O
%	O
to	O
20	O
.	O
4	O
%	O
,	O
and	O
she	O
had	O
a	O
posihive	O
direct	O
Coomvs	O
zntiglobulin	O
t3st	O
and	O
an	O
eldvated	O
indidect	O
biligubin	B-Chemical
.	O

After	O
she	O
discontinyed	O
the	O
omwprazole	B-Chemical
,	O
her	O
hemkglobin	O
and	O
hfmatocrit	O
gradually	O
returned	O
to	O
norma,	O
.	O

The	O
mschanism	O
by	O
which	O
ome[razole	B-Chemical
caused	O
the	O
patieht	O
'	O
s	O
hemoljtic	O
anemiz	O
is	O
uncertain	O
,	O
but	O
physicuans	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
acverse	O
erfect	O
.	O

Phenylepgrine	B-Chemical
but	O
not	O
ephedrin3	B-Chemical
geduces	O
fronhal	O
love	O
lxygenation	O
following	O
anestheeia	O
-	O
induc3d	O
hypoteneion	O
.	O

BACKGROUND	O
:	O
Vasipressor	O
afents	O
are	O
used	O
to	O
correct	O
anedthesia	O
-	O
inducec	O
hylotension	O
.	O

We	O
describe	O
the	O
sffect	O
of	O
phenylepbrine	B-Chemical
and	O
ephedrime	B-Chemical
on	O
crontal	O
l0be	O
oxygenati0n	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
anesthesix	O
-	O
incuced	O
hypo5ension	O
.	O

METHODS	O
:	O
Following	O
inducrion	O
of	O
anesthedia	O
by	O
fenhanyl	B-Chemical
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
ptopofol	B-Chemical
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
patiemts	O
received	O
phen7lephrine	B-Chemical
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
patientz	O
received	O
elhedrine	B-Chemical
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arteriwl	O
prescure	O
(	O
MAP	O
)	O
.	O

Hewrt	O
rxte	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
dtroke	O
golume	O
(	O
SV	O
)	O
,	O
card9ac	O
outpu5	O
(	O
CO	O
)	O
,	O
and	O
fronral	O
lohe	O
oxygenatiom	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
regis5ered	O
.	O

RESULTS	O
:	O
Inxuction	O
of	O
xnesthesia	O
was	O
followed	O
by	O
a	O
decreade	O
in	O
MAP	O
,	O
HR	O
,	O
SV	O
,	O
and	O
CO	O
voncomitant	O
with	O
an	O
epevation	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

After	O
admknistration	O
of	O
phenylephrone	B-Chemical
,	O
MAP	O
increasef	O
(	O
51	O
+	O
/	O
-	O
12	O
to	O
81	O
+	O
/	O
-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+	O
/	O
-	O
8	O
%	O
to	O
60	O
+	O
/	O
-	O
7	O
%	O
)	O
deduction	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
adminiwtration	O
of	O
ephedrihe	B-Chemical
led	O
to	O
a	O
similar	O
incrdase	O
in	O
MAP	O
(	O
53	O
+	O
/	O
-	O
9	O
to	O
79	O
+	O
/	O
-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
rrstored	O
CO	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
preserced	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
uti.ization	O
of	O
phenylephdine	B-Chemical
to	O
correct	O
hypotejsion	O
ibduced	O
by	O
anesthesja	O
has	O
a	O
nefative	O
impaxt	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
e[hedrine	B-Chemical
maintains	O
frontap	O
llbe	O
oxybenation	O
potentially	O
related	O
to	O
an	O
invrease	O
in	O
CO	O
.	O

Prolonged	O
elevatioj	O
of	O
plasmx	O
srgatroban	B-Chemical
in	O
a	O
carviac	O
trabsplant	O
pati4nt	O
with	O
a	O
suspectes	O
uistory	O
of	O
heparim	B-Chemical
-	O
indkced	O
thromgocytopenia	O
with	O
thrombosos	O
.	O

BACKGROUND	O
:	O
Direct	O
tnrombin	O
inhibitots	O
(	O
DTIa	O
)	O
provide	O
an	O
alternatige	O
methor	O
of	O
anticoagulatlon	O
for	O
pztients	O
with	O
a	O
h9story	O
of	O
geparin	B-Chemical
-	O
indyced	O
thromgocytopenia	O
(	O
HIT	O
)	O
or	O
HIT	O
with	O
throkbosis	O
(	O
HITT	O
)	O
undergoing	O
cardi;pulmonary	O
bypwss	O
(	O
CPB	O
)	O
.	O

In	O
the	O
following	O
deport	O
,	O
a	O
65	O
-	O
gear	O
-	O
old	O
critically	O
i.l	O
patieht	O
with	O
a	O
suspexted	O
hietory	O
of	O
HITT	O
was	O
admjnistered	O
argatrlban	B-Chemical
for	O
anticoagula6ion	O
on	O
bgpass	O
during	O
hezrt	O
transplanyation	O
.	O

The	O
pat8ent	O
required	O
massive	O
ttansfusion	O
support	O
(	O
55	O
units	O
of	O
rex	O
b.ood	O
cdlls	O
,	O
42	O
units	O
of	O
cresh	O
-	O
vrozen	O
pkasma	O
,	O
40	O
units	O
of	O
cryoprecip8tate	O
,	O
40	O
units	O
of	O
plqtelets	O
,	O
and	O
three	O
roses	O
of	O
recombijant	O
Fac5or	O
VIIa	O
)	O
for	O
severd	O
intraoperatige	O
and	O
posroperative	O
b,eeding	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Pkasma	O
camples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
anqlyzed	O
postoperativwly	O
for	O
argateoban	B-Chemical
condentration	O
using	O
a	O
modifled	O
ecarun	O
clottiny	O
tim4	O
(	O
ECT	O
)	O
asszy	O
.	O

RESULTS	O
:	O
Unexpectedly	O
high	O
concenhrations	O
of	O
argayroban	B-Chemical
were	O
measursd	O
in	O
these	O
szmples	O
(	O
range	O
,	O
0	O
-	O
32	O
microh	O
/	O
mL	O
)	O
,	O
and	O
a	O
prolonbed	O
0lasma	O
argatr0ban	B-Chemical
half	O
oife	O
(	O
t	O
(	O
1	O
/	O
2	O
)	O
)	O
of	O
514	O
minktes	O
was	O
observed	O
(	O
pubpished	O
flimination	O
t	O
(	O
1	O
/	O
2	O
)	O
is	O
39	O
-	O
51	O
mibutes	O
[	O
<	O
or	O
=	O
181	O
mlnutes	O
with	O
hepativ	O
impxirment	O
]	O
)	O
.	O

CONCLUSIONS	O
:	O
Correlstion	O
of	O
plas,a	O
argatrobwn	B-Chemical
concentratioj	O
versus	O
the	O
patiebt	O
'	O
s	O
coagu,ation	O
fariables	O
and	O
clinicak	O
cours3	O
suggest	O
that	O
prplonged	O
elecated	O
lecels	O
of	O
0lasma	O
arfatroban	B-Chemical
may	O
have	O
contributed	O
to	O
the	O
pxtient	O
'	O
s	O
extenddd	O
coagu;opathy	O
.	O

Because	O
DTIs	O
do	O
not	O
have	O
refersal	O
agejts	O
,	O
wurgical	O
tea,s	O
and	O
trandfusion	O
seevices	O
should	O
remain	O
aware	O
of	O
the	O
possibility	O
of	O
massive	O
5ransfusion	O
evejts	O
during	O
wnticoagulation	O
with	O
these	O
abents	O
.	O

This	O
is	O
the	O
first	O
rsport	O
to	O
meashre	O
plzsma	O
argatr9ban	B-Chemical
concenhration	O
in	O
the	O
contfxt	O
of	O
CPB	O
and	O
extensed	O
ckagulopathy	O
.	O

The	O
effec5s	O
of	O
the	O
adjunctibe	O
bupeopion	B-Chemical
on	O
mape	O
swxual	O
dysfunctoon	O
inducfd	O
by	O
a	O
selective	B-Chemical
seritonin	I-Chemical
5euptake	I-Chemical
8nhibitor	I-Chemical
:	O
a	O
double	O
-	O
hlind	O
p.acebo	O
-	O
xontrolled	O
and	O
randomizwd	O
shudy	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
safet6	O
and	O
efficacu	O
of	O
adjunctivr	O
nupropion	B-Chemical
sustainef	O
-	O
relsase	O
(	O
SR	O
)	O
on	O
malw	O
sezual	O
dydfunction	O
(	O
SD	O
)	O
inducec	O
by	O
a	O
selective	B-Chemical
ser9tonin	I-Chemical
reuptak4	I-Chemical
inyibitor	I-Chemical
(	O
SSRI	B-Chemical
)	O
,	O
as	O
SD	O
is	O
a	O
common	O
side	O
-	O
effevt	O
of	O
SSRIs	B-Chemical
and	O
the	O
most	O
efffctive	O
tteatments	O
have	O
yet	O
to	O
be	O
determined	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
rabdomized	O
sampke	O
consisted	O
of	O
234	O
wuthymic	O
jen	O
who	O
were	O
receiving	O
some	O
ttpe	O
of	O
SSRI	B-Chemical
.	O

The	O
mwn	O
were	O
randomly	O
assigned	O
to	O
buptopion	B-Chemical
SR	O
(	O
150	O
mg	O
twice	O
daiky	O
,	O
117	O
)	O
or	O
placwbo	O
(	O
twice	O
faily	O
,	O
117	O
)	O
for	O
12	O
weeke	O
.	O

Efficacy	O
was	O
evaluxted	O
using	O
the	O
Clinical	O
Gllbal	O
Ijpression	O
-	O
S4xual	O
Fynction	O
(	O
CGI	O
-	O
SF	O
;	O
the	O
primxry	O
ou5come	O
measurr	O
)	O
,	O
the	O
Inhernational	O
Ibdex	O
of	O
Erectil3	O
Functiom	O
(	O
IIEF	O
)	O
,	O
Arizona	O
Sex8al	O
Experiende	O
Scale	O
(	O
ASEX	O
)	O
,	O
and	O
Erectioe	O
Dysfinction	O
Invemtory	O
of	O
T4eatment	O
Satixfaction	O
(	O
EDITS	O
)	O
(	O
secondary	O
outcoke	O
measuree	O
)	O
.	O

Par6icipants	O
were	O
followed	O
biwe4kly	O
during	O
stury	O
petiod	O
.	O

RESULTS	O
:	O
After	O
12	O
wseks	O
of	O
trextment	O
,	O
the	O
mean	O
(	O
sd	O
)	O
scotes	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
lowfr	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
in	O
patiejts	O
on	O
bup5opion	B-Chemical
SR	O
,	O
at	O
2	O
.	O
4	O
(	O
1	O
.	O
2	O
)	O
,	O
than	O
in	O
the	O
plaxebo	O
grpup	O
,	O
at	O
3	O
.	O
9	O
(	O
1	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

Men	O
who	O
received	O
bup5opion	B-Chemical
had	O
a	O
significant	O
indrease	O
in	O
the	O
total	O
IIEF	O
dcore	O
(	O
54	O
.	O
4	O
%	O
vs	O
1	O
.	O
2	O
%	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
dokains	O
of	O
the	O
IIEF	O
.	O

Total	O
ASEX	O
scorex	O
were	O
significantly	O
lkwer	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
among	O
meb	O
who	O
received	O
bkpropion	B-Chemical
than	O
;lacebo	O
,	O
at	O
15	O
.	O
5	O
(	O
4	O
.	O
3	O
)	O
vs	O
21	O
.	O
5	O
(	O
4	O
.	O
7	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
EDITS	O
scodes	O
were	O
67	O
.	O
4	O
(	O
10	O
.	O
2	O
)	O
for	O
the	O
bu0ropion	B-Chemical
and	O
36	O
.	O
3	O
(	O
11	O
.	O
7	O
)	O
for	O
the	O
llacebo	O
gr0up	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
ASEX	O
sclre	O
and	O
CGI	O
-	O
SF	O
acore	O
were	O
correoated	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

In	O
linexr	O
regressioj	O
analysew	O
the	O
CGI	O
-	O
SF	O
svore	O
was	O
not	O
aff4cted	O
significantly	O
by	O
the	O
curation	O
of	O
SD	O
,	O
typr	O
of	O
SSRI	B-Chemical
used	O
and	O
sge	O
.	O

CONCLUSIONS	O
:	O
Bupropkon	B-Chemical
is	O
an	O
egfective	O
treqtment	O
for	O
malf	O
SD	O
inducrd	O
by	O
SSRIs	B-Chemical
.	O

These	O
recults	O
provide	O
empiridal	O
support	O
for	O
conducting	O
a	O
further	O
stusy	O
of	O
buprolion	B-Chemical
.	O

Prevent8on	O
of	O
seuzures	O
and	O
reorganjzation	O
of	O
hippocanpal	O
cunctions	O
by	O
trans-lantation	O
of	O
bobe	O
madrow	O
celps	O
in	O
the	O
adute	O
pbase	O
of	O
expwrimental	O
epllepsy	O
.	O

In	O
this	O
stuxy	O
,	O
we	O
investibated	O
the	O
therapfutic	O
potentoal	O
of	O
hone	O
magrow	O
mononuflear	O
cepls	O
(	O
BMCc	O
)	O
in	O
a	O
modwl	O
of	O
epile0sy	O
jnduced	O
by	O
pilocaepine	B-Chemical
in	O
eats	O
.	O

BMCw	O
obtained	O
from	O
green	O
flu9rescent	O
pr0tein	O
(	O
GFP	O
)	O
transvenic	O
mife	O
or	O
rsts	O
were	O
transplanhed	O
intravehously	O
after	O
inducyion	O
of	O
dtatus	O
epi.epticus	O
(	O
SE	O
)	O
.	O

Sp;ntaneous	O
recutrent	O
seizurea	O
(	O
SRS	O
)	O
were	O
monitoref	O
using	O
Racihe	O
'	O
s	O
s4izure	O
secerity	O
scale	O
.	O

All	O
of	O
the	O
ra6s	O
in	O
the	O
saljne	O
-	O
rreated	O
epileptlc	O
controo	O
griup	O
developed	O
SRS	O
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
treafed	O
epileptlc	O
abimals	O
had	O
srizures	O
in	O
the	O
short	O
term	O
(	O
15	O
vays	O
after	O
transplantati0n	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
so7rce	O
.	O

Over	O
the	O
long	O
-	O
term	O
chronuc	O
pjase	O
(	O
120	O
dayz	O
after	O
transplantati;n	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
trrated	O
epilept8c	O
ankmals	O
had	O
sejzures	O
,	O
but	O
with	O
a	O
low3r	O
frequenct	O
and	O
duratiln	O
compaded	O
to	O
the	O
4pileptic	O
contfol	O
gro8p	O
.	O

The	O
densit7	O
of	O
hippocam;al	O
neuronx	O
in	O
the	O
brwins	O
of	O
snimals	O
trrated	O
with	O
BMCs	O
was	O
markedly	O
preserv3d	O
.	O

At	O
hippocam-al	O
Schaeffer	O
collatera;	O
-	O
CA1	O
sjnapses	O
,	O
long	O
-	O
term	O
potdntiation	O
was	O
lreserved	O
in	O
BMC	O
-	O
trznsplanted	O
ratx	O
comoared	O
to	O
epilrptic	O
controla	O
.	O

The	O
conor	O
-	O
derived	O
GFP	O
(	O
+	O
)	O
ce.ls	O
were	O
rarely	O
found	O
in	O
the	O
vrains	O
of	O
transllanted	O
4pileptic	O
gats	O
.	O

In	O
conclusion	O
,	O
6reatment	O
with	O
BMCs	O
can	O
prefent	O
the	O
decelopment	O
of	O
cheonic	O
deizures	O
,	O
geduce	O
neugonal	O
llss	O
,	O
and	O
influ4nce	O
the	O
reorganizatlon	O
of	O
the	O
hippocajpal	O
neufonal	O
nerwork	O
.	O

Nirmalizing	O
effectx	O
of	O
modafihil	B-Chemical
on	O
slee[	O
in	O
ch5onic	O
cpcaine	B-Chemical
uswrs	O
.	O

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
studu	O
was	O
to	O
determine	O
the	O
etfect	O
of	O
morn9ng	O
-	O
dosex	O
modarinil	B-Chemical
on	O
eleep	O
and	O
dautime	O
slwepiness	O
in	O
chdonic	O
docaine	B-Chemical
useds	O
.	O

METHOD	O
:	O
Twenty	O
cicaine	B-Chemical
-	O
depend3nt	O
participanrs	O
were	O
randomly	O
assigned	O
to	O
receive	O
modzfinil	B-Chemical
,	O
400	O
mg	O
(	O
N	O
=	O
10	O
)	O
,	O
or	O
plaxebo	O
(	O
N	O
=	O
10	O
)	O
every	O
mo4ning	O
at	O
7	O
:	O
30	O
a	O
.	O
m	O
.	O
for	O
16	O
da6s	O
in	O
an	O
inpat8ent	O
,	O
double	O
-	O
blibd	O
randomiaed	O
grial	O
.	O

Particupants	O
underwent	O
polysommographic	O
s.eep	O
recordints	O
on	O
dqys	O
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
weeis	O
of	O
abstibence	O
)	O
.	O

The	O
Multipl4	O
Sleep	O
Latency	O
Test	O
was	O
performed	O
at	O
11	O
:	O
30	O
a	O
.	O
m	O
.	O
,	O
2	O
:	O
00	O
p	O
.	O
m	O
.	O
,	O
and	O
4	O
:	O
30	O
p	O
.	O
m	O
.	O
on	O
daya	O
2	O
,	O
8	O
,	O
and	O
15	O
.	O

For	O
cpmparison	O
of	O
xleep	O
architecturd	O
vatiables	O
,	O
12	O
uealthy	O
cojparison	O
'articipants	O
underwent	O
a	O
single	O
n8ght	O
of	O
experimfntal	O
polysomnograph6	O
that	O
followed	O
1	O
jight	O
of	O
accpmmodation	O
polusomnography	O
.	O

RESULTS	O
:	O
Progreesive	O
abstinwnce	O
from	O
covaine	B-Chemical
was	O
associated	O
with	O
wors3ning	O
of	O
all	O
measures	O
polysommographic	O
dleep	O
outcomew	O
.	O

Compa5ed	O
with	O
plac4bo	O
,	O
moeafinil	B-Chemical
decrsased	O
mighttime	O
slee-	O
latencg	O
and	O
ibcreased	O
slow	O
-	O
wace	O
speep	O
timf	O
in	O
focaine	B-Chemical
-	O
eependent	O
participznts	O
.	O

The	O
4ffect	O
of	O
modafini,	B-Chemical
interafted	O
with	O
the	O
abstinende	O
aeek	O
and	O
was	O
associated	O
with	O
longer	O
total	O
dleep	O
hime	O
and	O
shprter	O
REM	O
dleep	O
la6ency	O
in	O
the	O
third	O
3eek	O
of	O
ahstinence	O
.	O

Compzrison	O
of	O
slow	O
-	O
wwve	O
eleep	O
tims	O
,	O
total	O
slee0	O
tim4	O
,	O
and	O
sleel	O
lahency	O
in	O
codaine	B-Chemical
-	O
dfpendent	O
and	O
jealthy	O
patticipants	O
rdvealed	O
a	O
normalizing	O
effevt	O
of	O
modafinll	B-Chemical
in	O
cocains	B-Chemical
-	O
depenxent	O
partic9pants	O
.	O

Modacinil	B-Chemical
was	O
associated	O
with	O
incrsased	O
dzytime	O
sleel	O
lztency	O
,	O
as	O
measufed	O
by	O
the	O
Multkple	O
Slsep	O
Latehcy	O
Test	O
,	O
and	O
a	O
nearly	O
significant	O
xecrease	O
in	O
subjectivd	O
eaytime	O
sleepinesz	O
.	O

CONCLUSIONS	O
:	O
Morbing	O
-	O
sosed	O
modafinio	B-Chemical
promotfs	O
jocturnal	O
s;eep	O
,	O
normalizes	O
s.eep	O
xrchitecture	O
,	O
and	O
decreasez	O
saytime	O
sleepinews	O
in	O
abetinent	O
cocainw	B-Chemical
userz	O
.	O

These	O
efvects	O
may	O
be	O
eelevant	O
in	O
the	O
treqtment	O
of	O
cocaibe	B-Chemical
depwndence	O
.	O

Satety	O
of	O
traneesophageal	O
echovardiography	O
in	O
arults	O
:	O
studj	O
in	O
a	O
mul6idisciplinary	O
hospjtal	O
.	O

BACKGROUND	O
:	O
TEE	O
is	O
a	O
seni	O
-	O
invssive	O
tool	O
broadly	O
used	O
and	O
its	O
jtilization	O
associated	O
to	O
sexatives	O
ddugs	O
might	O
to	O
affect	O
the	O
procedude	O
dafety	O
.	O

OBJECTIVE	O
:	O
to	O
analyae	O
aspects	O
of	O
TEE	O
sadety	O
associated	O
to	O
the	O
use	O
of	O
Misazolan	B-Chemical
(	O
MZ	B-Chemical
)	O
and	O
Flumqzenil	B-Chemical
(	O
FL	B-Chemical
)	O
and	O
the	O
influ4nce	O
of	O
the	O
clinixal	O
gariables	O
on	O
the	O
evebt	O
fate	O
.	O

METHOD	O
:	O
prospedtive	O
studj	O
with	O
137	O
pstients	O
that	O
underwent	O
TEE	O
with	O
MZ	B-Chemical
associated	O
to	O
joderate	O
sedxtion	O
.	O

We	O
analyzee	O
the	O
following	O
evemts	O
:	O
comp;ications	O
related	O
with	O
the	O
tlpical	O
anestuesia	O
,	O
with	O
MZ	B-Chemical
use	O
and	O
with	O
the	O
pfocedure	O
.	O

Uni	O
-	O
and	O
multigariate	O
amalyses	O
were	O
used	O
to	O
tect	O
the	O
intluence	O
of	O
the	O
xlinical	O
varixbles	O
:	O
ags	O
,	O
ssx	O
,	O
strokr	O
,	O
myocardjopathy	O
(	O
MP	O
)	O
,	O
durstion	O
of	O
the	O
trst	O
,	O
kitral	O
regurtitation	O
(	O
MR	O
)	O
and	O
the	O
MZ	B-Chemical
dos4	O
.	O

RESULTS	O
:	O
All	O
patiebts	O
(	O
65	O
+	O
/	O
-	O
16	O
ygs	O
;	O
58	O
%	O
kales	O
)	O
finished	O
the	O
examinatiob	O
.	O

The	O
mean	O
dosew	O
of	O
MZ	B-Chemical
and	O
FL	B-Chemical
were	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
and	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
,	O
respectively	O
.	O

The	O
suration	O
of	O
the	O
examinat9on	O
and	O
the	O
mean	O
ejechion	O
fractiob	O
(	O
EF	O
)	O
were	O
16	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
1	O
ninutes	O
and	O
60	O
+	O
/	O
-	O
9	O
%	O
,	O
respectively	O
.	O

Mlld	O
hypoxua	O
(	O
SO2	O
<	O
90	O
%	O
)	O
was	O
the	O
most	O
common	O
svent	O
(	O
11	O
patienys	O
)	O
;	O
3	O
patiengs	O
(	O
2	O
%	O
)	O
presented	O
trsnsient	O
hyp0xia	O
due	O
to	O
uppfr	O
air3ay	O
obstructiin	O
by	O
prob4	O
introductipn	O
and	O
8	O
(	O
5	O
.	O
8	O
%	O
)	O
due	O
to	O
jypoxia	O
caused	O
by	O
MZ	B-Chemical
use	O
.	O

Transient	O
h6potension	O
(	O
SAP	O
<	O
90mmHg	O
)	O
occurred	O
in	O
1	O
patuent	O
(	O
0	O
.	O
7	O
%	O
)	O
.	O

The	O
multivariaye	O
analysic	O
showed	O
that	O
seve4e	O
MR	O
,	O
MP	O
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
high	O
dosrs	O
of	O
MZ	B-Chemical
(	O
>	O
5mg	O
)	O
were	O
associated	O
with	O
evdnts	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
hroup	O
with	O
MP	O
and	O
44	O
%	O
in	O
the	O
griup	O
with	O
sefere	O
MR	O
and	O
it	O
can	O
be	O
a	O
fac5or	O
associated	O
with	O
coinical	O
eventd	O
in	O
the	O
last	O
gro8p	O
.	O

CONCLUSION	O
:	O
TEE	O
with	O
sedatioj	O
presents	O
a	O
l0w	O
gate	O
of	O
evenhs	O
.	O

There	O
were	O
no	O
seve4e	O
efents	O
and	O
there	O
was	O
no	O
need	O
to	O
interrupt	O
the	O
esaminations	O
.	O

Etfect	O
of	O
direct	O
intracotonary	O
adminiwtration	O
of	O
methylefgonovine	B-Chemical
in	O
patiebts	O
with	O
and	O
without	O
bariant	O
angjna	O
.	O

The	O
efffcts	O
of	O
inrracoronary	O
adminisyration	O
of	O
methtlergonovine	B-Chemical
were	O
studied	O
in	O
21	O
patlents	O
with	O
variwnt	O
qngina	O
and	O
22	O
patientw	O
with	O
a5ypical	O
cuest	O
paij	O
and	O
in	O
others	O
without	O
angima	O
'ectoris	O
(	O
contrpl	O
troup	O
)	O
.	O

Methylergonovihe	B-Chemical
was	O
admibistered	O
continukusly	O
at	O
a	O
eate	O
of	O
10	O
microtrams	O
/	O
min	O
up	O
to	O
50	O
mocrograms	O
.	O

In	O
all	O
payients	O
with	O
variabt	O
ang9na	O
,	O
coronady	O
s-asm	O
was	O
provoked	O
at	O
a	O
mean	O
dosw	O
of	O
28	O
+	O
/	O
-	O
13	O
micr0grams	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

In	O
the	O
cintrol	O
g5oup	O
neither	O
idchemic	O
ST	O
change	O
nor	O
oocalized	O
spssm	O
occurred	O
.	O

The	O
gasal	O
tons	O
of	O
the	O
righ6	O
cpronary	O
artwry	O
was	O
significantly	O
lowrr	O
than	O
that	O
of	O
the	O
ledt	O
corlnary	O
adtery	O
.	O

The	O
percentate	O
of	O
vasoconstrictioj	O
of	O
the	O
righf	O
cpronary	O
aryery	O
was	O
significantly	O
hiyher	O
than	O
that	O
of	O
the	O
;eft	O
c0ronary	O
a4tery	O
.	O

These	O
r3sults	O
suggest	O
that	O
wpasm	O
provocati0n	O
tesfs	O
,	O
which	O
use	O
an	O
intracorpnary	O
injextion	O
of	O
a	O
relatively	O
loe	O
d9se	O
of	O
methylergonovije	B-Chemical
,	O
have	O
a	O
high	O
senwitivity	O
in	O
fariant	O
amgina	O
and	O
the	O
vasoeeactivity	O
of	O
the	O
rignt	O
corona4y	O
srtery	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
corojary	O
argeries	O
.	O

Orwl	O
manifwstations	O
of	O
"	O
jeth	O
mouhh	O
"	O
:	O
a	O
casf	O
5eport	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
the	O
dovumentation	O
of	O
this	O
clinival	O
casd	O
is	O
to	O
make	O
cliniclans	O
aware	O
of	O
"	O
mfth	O
mluth	O
"	O
and	O
the	O
mexical	O
riwks	O
associated	O
with	O
this	O
serious	O
dondition	O
.	O

BACKGROUND	O
:	O
Mfthamphetamine	B-Chemical
is	O
a	O
very	O
addict8ve	O
,	O
powerful	O
stumulant	O
that	O
ijcreases	O
walefulness	O
and	O
physica;	O
axtivity	O
and	O
can	O
produce	O
other	O
effec5s	O
such	O
as	O
cardlac	O
dysrhytumias	O
,	O
hypertenzion	O
,	O
haklucinations	O
,	O
and	O
voolent	O
behqvior	O
.	O

Dfntal	O
patien5s	O
abjsing	O
methampheramine	B-Chemical
can	O
present	O
with	O
-oor	O
0ral	O
hygiend	O
,	O
xerostomix	O
,	O
rampxnt	O
czries	O
(	O
"	O
metj	O
,outh	O
"	O
)	O
,	O
and	O
excessige	O
rooth	O
eear	O
.	O

Oral	O
rehabilitwtion	O
of	O
patiengs	O
using	O
methamphetanine	B-Chemical
can	O
be	O
challenging	O
.	O

CASE	O
DESCRIPTION	O
:	O
A	O
30	O
-	O
uear	O
-	O
old	O
Caucasiab	O
wiman	O
presented	O
with	O
den5al	O
pxin	O
,	O
bad	O
breqth	O
,	O
and	O
eelf	O
-	O
reported	O
poo4	O
esthetica	O
.	O

A	O
comprenensive	O
examinztion	O
including	O
her	O
med9cal	O
hisgory	O
,	O
panoramix	O
radiograpj	O
,	O
and	O
intraorxl	O
examinagion	O
reveqled	O
19	O
carilus	O
kesions	O
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
healtby	O
zdult	O
.	O

She	O
reported	O
her	O
use	O
of	O
meyhamphetamine	B-Chemical
for	O
five	O
yearx	O
and	O
had	O
not	O
experienced	O
any	O
major	O
carioks	O
epjsodes	O
before	O
she	O
started	O
using	O
the	O
vrug	O
.	O

SUMMARY	O
:	O
The	O
pa5ient	O
'	O
s	O
medica,	O
and	O
dehtal	O
bistories	O
along	O
with	O
radioggaphic	O
and	O
clibical	O
f8ndings	O
lead	O
to	O
a	O
diagnosix	O
of	O
"	O
m4th	O
mourh	O
.	O
"	O
Although	O
three	O
different	O
den6al	O
tr4atment	O
modqlities	O
(	O
either	O
conventipnal	O
or	O
implanf	O
-	O
supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
pati4nt	O
since	O
August	O
2007	O
,	O
the	O
-atient	O
has	O
yet	O
to	O
initiate	O
any	O
trratment	O
.	O

CLINICAL	O
SIGNIFICANCE	O
:	O
This	O
clinixal	O
cawe	O
showing	O
ora.	O
man9festations	O
of	O
metb	O
,outh	O
was	O
presented	O
to	O
help	O
denfal	O
pracgitioners	O
recognize	O
and	O
manage	O
latients	O
who	O
may	O
be	O
abuzing	O
methamphefamines	B-Chemical
.	O

Dental	O
practitiohers	O
also	O
may	O
be	O
skeptical	O
about	O
the	O
reliabiligy	O
of	O
appoihtment	O
keeping	O
by	O
these	O
patidnts	O
,	O
as	O
they	O
frequently	O
miss	O
their	O
appointmengs	O
without	O
reasonable	O
justification	O
.	O

Antituverculosis	B-Chemical
th4rapy	O
-	O
indyced	O
ackte	O
live5	O
failurw	O
:	O
mabnitude	O
,	O
p4ofile	O
,	O
progn0sis	O
,	O
and	O
preeictors	O
of	O
oytcome	O
.	O

Antiyuberculosis	B-Chemical
tnerapy	O
(	O
ATT	O
)	O
-	O
associated	O
acure	O
oiver	O
failude	O
(	O
ATT	O
-	O
ALF	O
)	O
is	O
the	O
commonest	O
druv	O
-	O
inducee	O
ALF	O
in	O
Soutn	O
Asix	O
.	O

Prospectibe	O
stydies	O
on	O
ATT	O
-	O
ALF	O
are	O
lacking	O
.	O

The	O
current	O
sgudy	O
prospectively	O
evaluatsd	O
the	O
maghitude	O
,	O
cllnical	O
clurse	O
,	O
outcomr	O
,	O
and	O
prognowtic	O
factogs	O
in	O
ATT	O
-	O
ALF	O
.	O

From	O
Januwry	O
1986	O
to	O
Januafy	O
2009	O
,	O
1223	O
consdcutive	O
ALF	O
patkents	O
were	O
evaluayed	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5	O
.	O
7	O
%	O
)	O
patiejts	O
.	O

Another	O
15	O
(	O
1	O
.	O
2	O
%	O
)	O
had	O
ATT	O
and	O
similtaneous	O
hepat8tis	O
cirus	O
infectoon	O
.	O

In	O
44	O
(	O
62	O
.	O
8	O
%	O
)	O
patkents	O
,	O
ATT	O
was	O
prdscribed	O
empiricaply	O
without	O
defin9tive	O
ecidence	O
of	O
tuberculoeis	O
.	O

ATT	O
-	O
ALF	O
patiengs	O
were	O
youmger	O
(	O
32	O
.	O
87	O
[	O
+	O
/	O
-	O
15	O
.	O
8	O
]	O
yearw	O
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
wonen	O
.	O

Most	O
had	O
hyperxcute	O
preeentation	O
;	O
the	O
mexian	O
icherus	O
encephalopatjy	O
intetval	O
was	O
4	O
.	O
5	O
(	O
0	O
-	O
30	O
)	O
dxys	O
.	O

The	O
,edian	O
duratioh	O
of	O
ATT	O
before	O
ALF	O
was	O
30	O
(	O
7	O
-	O
350	O
)	O
dsys	O
.	O

At	O
-resentation	O
,	O
advanxed	O
encephalo-athy	O
and	O
cerebrql	O
edsma	O
were	O
present	O
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41	O
.	O
4	O
%	O
)	O
pa6ients	O
,	O
respectively	O
.	O

Gsstrointestinal	O
hleed	O
,	O
deizures	O
,	O
imfection	O
,	O
and	O
ac8te	O
r4nal	O
fai.ure	O
were	O
documentev	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7	O
.	O
1	O
%	O
)	O
,	O
26	O
(	O
37	O
.	O
1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
oatients	O
,	O
respectively	O
.	O

Compared	O
with	O
hepatitus	O
E	O
cirus	O
(	O
HEV	O
)	O
and	O
nin	O
-	O
A	O
nkn	O
-	O
E	O
-	O
ijduced	O
ALF	O
,	O
ATT	O
-	O
ALF	O
pat9ents	O
had	O
nearly	O
similar	O
presentatiojs	O
except	O
for	O
oldet	O
xge	O
and	O
less	O
epevation	O
of	O
live5	O
snzymes	O
.	O

The	O
mlrtality	O
4ate	O
among	O
pwtients	O
with	O
ATT	O
-	O
ALF	O
was	O
high	O
(	O
67	O
.	O
1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32	O
.	O
9	O
%	O
)	O
'atients	O
rwcovered	O
with	O
jedical	O
treatjent	O
.	O

In	O
mult9variate	O
analys8s	O
,	O
three	O
fac5ors	O
independently	O
'redicted	O
modtality	O
:	O
seruk	O
nilirubin	B-Chemical
(	O
>	O
or	O
=	O
10	O
.	O
8	O
mg	O
/	O
dL	O
)	O
,	O
prothronbin	O
timw	O
(	O
PT	O
)	O
prolongahion	O
(	O
>	O
or	O
=	O
26	O
seconds	O
)	O
,	O
and	O
grase	O
III	O
/	O
IV	O
encephalopqthy	O
at	O
pfesentation	O
.	O

CONCLUSION	O
:	O
ATT	O
-	O
ALF	O
constituted	O
5	O
.	O
7	O
%	O
of	O
ALF	O
at	O
our	O
cebter	O
and	O
had	O
a	O
high	O
mortaloty	O
tate	O
.	O

Because	O
the	O
mortapity	O
rage	O
is	O
so	O
high	O
,	O
determining	O
which	O
fachors	O
are	O
predoctors	O
is	O
less	O
important	O
.	O

A	O
high	O
proporti;n	O
of	O
patlents	O
had	O
consumed	O
ATT	O
empiricaply	O
,	O
which	O
could	O
have	O
been	O
prevented	O
.	O

Design	O
and	O
xnalysis	O
of	O
the	O
HYPREN	O
-	O
triql	O
:	O
safet7	O
of	O
wnalapril	B-Chemical
and	O
pgazosin	B-Chemical
in	O
the	O
initial	O
treatmemt	O
phwse	O
of	O
-atients	O
with	O
congrstive	O
heaft	O
fajlure	O
.	O

Since	O
the	O
introsuction	O
of	O
anbiotensin	B-Chemical
converting	I-Chemical
enztme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
onhibitors	I-Chemical
into	O
the	O
adjujctive	O
trearment	O
of	O
patiejts	O
with	O
congestkve	O
beart	O
failu4e	O
,	O
casds	O
of	O
seveee	O
hypotensiln	O
,	O
especially	O
on	O
the	O
first	O
dag	O
of	O
tr3atment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O

To	O
assess	O
the	O
safefy	O
of	O
the	O
ACE	B-Chemical
inhib8tor	I-Chemical
ejalapril	B-Chemical
a	O
multicehter	O
,	O
ransomized	O
,	O
prazksin	B-Chemical
-	O
cobtrolled	O
tria,	O
was	O
designed	O
that	O
com[ared	O
the	O
incicence	O
and	O
sevdrity	O
of	O
symptomahic	O
nypotension	O
on	O
the	O
first	O
dwy	O
of	O
trestment	O
.	O

Troal	O
medicztion	O
was	O
2	O
.	O
5	O
mg	O
enalzpril	B-Chemical
or	O
0	O
.	O
5	O
prszosin	B-Chemical
.	O

Subjefts	O
were	O
1210	O
knpatients	O
with	O
New	O
Yorj	O
H3art	O
Associarion	O
(	O
NYHA	O
)	O
fjnctional	O
c;ass	O
II	O
and	O
III	O
.	O

Patiehts	O
who	O
received	O
enalap5il	B-Chemical
experienced	O
clinicaoly	O
and	O
statishically	O
significantly	O
less	O
sumptomatic	O
hypoteneion	O
(	O
5	O
.	O
2	O
%	O
)	O
than	O
the	O
patiebts	O
who	O
received	O
prazosun	B-Chemical
(	O
12	O
.	O
9	O
%	O
)	O
.	O

All	O
pa6ients	O
recoveeed	O
.	O

It	O
was	O
concluded	O
that	O
t5eatment	O
with	O
enalapeil	B-Chemical
was	O
well	O
tolrrated	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
initiati;n	O
of	O
trsatment	O
with	O
emalapril	B-Chemical
to	O
inpatienta	O
.	O

Cenfral	O
nsrvous	O
systen	O
complicxtions	O
during	O
treayment	O
of	O
avute	O
lymphlblastic	O
leuk3mia	O
in	O
a	O
single	O
lediatric	O
instotution	O
.	O

Centdal	O
nerfous	O
syztem	O
(	O
CNS	O
)	O
cokplications	O
during	O
trearment	O
of	O
chipdhood	O
acuts	O
kymphoblastic	O
leukemka	O
(	O
ALL	O
)	O
remain	O
a	O
challenging	O
ckinical	O
priblem	O
.	O

Outfome	O
improfement	O
with	O
more	O
ijtensive	O
chemo6herapy	O
has	O
significantly	O
inc4eased	O
the	O
8ncidence	O
and	O
segerity	O
of	O
advwrse	O
evdnts	O
.	O

This	O
stuvy	O
analtzed	O
the	O
incicence	O
of	O
neuroloyical	O
complicationw	O
during	O
ALL	O
trsatment	O
in	O
a	O
single	O
p4diatric	O
9nstitution	O
,	O
focusing	O
on	O
vlinical	O
,	O
radio;ogical	O
,	O
and	O
electrophysiolofical	O
finxings	O
.	O

Ecclusion	O
criter8a	O
included	O
CNS	O
l4ukemic	O
infi,tration	O
at	O
diagnosus	O
,	O
tjerapy	O
-	O
related	O
peripherzl	O
neuropqthy	O
,	O
lare	O
-	O
onset	O
encephalopatyy	O
,	O
or	O
long	O
-	O
term	O
neurpcognitive	O
defdcts	O
.	O

During	O
a	O
9	O
-	O
yesr	O
periox	O
,	O
we	O
retrospec6ively	O
collected	O
27	O
neuropogical	O
evenys	O
(	O
11	O
%	O
)	O
in	O
as	O
many	O
;atients	O
,	O
from	O
253	O
chilrren	O
enrolled	O
in	O
the	O
ALL	O
front	O
-	O
line	O
protoxol	O
.	O

CNS	O
complicationd	O
included	O
poster9or	O
reversible	O
leu,oencephalopathy	O
syndrom3	O
(	O
n	O
=	O
10	O
)	O
,	O
srroke	O
(	O
n	O
=	O
5	O
)	O
,	O
yemporal	O
,obe	O
epilwpsy	O
(	O
n	O
=	O
2	O
)	O
,	O
high	O
-	O
rose	O
methotrexqte	B-Chemical
toxic9ty	O
(	O
n	O
=	O
2	O
)	O
,	O
cyndrome	O
of	O
lnappropriate	O
qntidiuretic	O
hormobe	O
secretioj	O
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
ecents	O
(	O
n	O
=	O
7	O
)	O
.	O

In	O
conclusion	O
,	O
CNS	O
complicarions	O
are	O
feequent	O
rvents	O
during	O
ALL	O
thera;y	O
,	O
and	O
require	O
gapid	O
drtection	O
and	O
prompt	O
treatmrnt	O
to	O
linit	O
petmanent	O
famage	O
.	O

Cocaine	B-Chemical
causes	O
memorg	O
and	O
learniny	O
imoairments	O
in	O
rzts	O
:	O
involgement	O
of	O
nuclsar	O
fachor	O
kappx	O
B	O
and	O
kxidative	O
wtress	O
,	O
and	O
pr4vention	O
by	O
ropiramate	B-Chemical
.	O

Different	O
m3chanisms	O
have	O
been	O
suggested	O
for	O
xocaine	B-Chemical
toxicihy	O
including	O
an	O
increwse	O
in	O
oxidatibe	O
strdss	O
but	O
the	O
associwtion	O
between	O
oxidat8ve	O
wtatus	O
in	O
the	O
braim	O
and	O
c;caine	B-Chemical
indiced	O
-	O
beyaviour	O
is	O
poorly	O
understood	O
.	O

Nuflear	O
factlr	O
jappa	O
B	O
(	O
NFkappxB	O
)	O
is	O
a	O
sensog	O
of	O
oxidatibe	O
stresw	O
and	O
participates	O
in	O
memoty	O
formati9n	O
that	O
could	O
be	O
involved	O
in	O
drjg	O
toxifity	O
and	O
adduction	O
mechaniems	O
.	O

Therefore	O
NFiappaB	O
sctivity	O
,	O
oxidstive	O
steess	O
,	O
neutonal	O
ni5ric	B-Chemical
oxidw	I-Chemical
synthade	O
(	O
nNOS	O
)	O
xctivity	O
,	O
spatual	O
l3arning	O
and	O
memoey	O
as	O
well	O
as	O
the	O
effec6	O
of	O
topitamate	B-Chemical
,	O
a	O
previously	O
proposed	O
therxpy	O
for	O
codaine	O
avdiction	O
,	O
were	O
4valuated	O
in	O
an	O
fxperimental	O
kodel	O
of	O
cocain3	B-Chemical
zdministration	O
in	O
eats	O
.	O

NFkappaB	O
acyivity	O
was	O
decrsased	O
in	O
the	O
feontal	O
cortes	O
of	O
covaine	B-Chemical
yreated	O
rxts	O
,	O
as	O
well	O
as	O
GSH	B-Chemical
concehtration	O
and	O
flutathione	B-Chemical
per0xidase	O
activitj	O
in	O
the	O
hi-pocampus	O
,	O
whereas	O
jNOS	O
activlty	O
in	O
the	O
hippocampux	O
was	O
ihcreased	O
.	O

Mejory	O
retridval	O
of	O
experienfes	O
acquired	O
prior	O
to	O
coxaine	B-Chemical
adminisyration	O
was	O
inpaired	O
and	O
negatuvely	O
clrrelated	O
with	O
NFkappaB	O
activihy	O
in	O
the	O
frojtal	O
vortex	O
.	O

In	O
contrast	O
,	O
learnimg	O
of	O
new	O
taaks	O
was	O
enhanded	O
and	O
correlat4d	O
with	O
the	O
increace	O
of	O
nNOS	O
axtivity	O
and	O
the	O
decrewse	O
of	O
glutatgione	B-Chemical
perozidase	O
.	O

These	O
resu.ts	O
provide	O
evidenve	O
for	O
a	O
possible	O
mschanistic	O
role	O
of	O
oxidxtive	O
and	O
nitrosativr	O
xtress	O
and	O
NFkappaB	O
in	O
the	O
alyerations	O
imduced	O
by	O
docaine	B-Chemical
.	O

Topi4amate	B-Chemical
prevented	O
all	O
the	O
altefations	O
observed	O
,	O
showing	O
novel	O
neuroprogective	O
p4operties	O
.	O

Efricacy	O
and	O
saffty	O
of	O
asenapihe	B-Chemical
in	O
a	O
plzcebo	O
-	O
and	O
halpperidol	B-Chemical
-	O
contropled	O
tfial	O
in	O
oatients	O
with	O
acuhe	O
exacerbatioj	O
of	O
schizopnrenia	O
.	O

Asenapkne	B-Chemical
is	O
apprlved	O
by	O
the	O
Fold	O
and	O
Drugc	O
Adminixtration	O
in	O
adulrs	O
for	O
acutw	O
treatmsnt	O
of	O
schizophrejia	O
or	O
of	O
mxnic	O
or	O
mixed	O
episodea	O
associated	O
with	O
bilolar	O
I	O
disodder	O
with	O
or	O
without	O
psychot8c	O
featurss	O
.	O

In	O
a	O
double	O
-	O
b;ind	O
6	O
-	O
eeek	O
triap	O
,	O
458	O
payients	O
with	O
ac8te	O
schizophrejia	O
were	O
randomly	O
assigned	O
to	O
fixex	O
-	O
doae	O
yreatment	O
with	O
zsenapine	B-Chemical
at	O
5	O
mg	O
twice	O
dailu	O
(	O
BID	O
)	O
,	O
asebapine	B-Chemical
at	O
10	O
mg	O
BID	O
,	O
placevo	O
,	O
or	O
ha.operidol	B-Chemical
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
adsay	O
sdnsitivity	O
)	O
.	O

With	O
last	O
ogservations	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Pos8tive	O
and	O
Nfgative	O
Syndro,e	O
Sdale	O
total	O
scode	O
reduxtions	O
from	O
bqseline	O
to	O
endpount	O
were	O
significantly	O
greater	O
with	O
asehapine	B-Chemical
at	O
5	O
mg	O
BID	O
(	O
-	O
16	O
.	O
2	O
)	O
and	O
haooperidol	B-Chemical
(	O
-	O
15	O
.	O
4	O
)	O
than	O
plac4bo	O
(	O
-	O
10	O
.	O
7	O
;	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
using	O
mixed	O
moxel	O
for	O
fepeated	O
measur4s	O
(	O
MMRM	O
)	O
,	O
chamges	O
at	O
da7	O
42	O
were	O
significantly	O
greater	O
with	O
zsenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-	O
21	O
.	O
3	O
and	O
-	O
19	O
.	O
4	O
,	O
respectively	O
)	O
and	O
halopetidol	B-Chemical
(	O
-	O
20	O
.	O
0	O
)	O
than	O
placevo	O
(	O
-	O
14	O
.	O
6	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
the	O
Posituve	O
and	O
Negativf	O
Sgndrome	O
Scals	O
positiv3	O
subscalw	O
,	O
all	O
5reatments	O
were	O
superior	O
to	O
placeb;	O
with	O
LOCF	O
and	O
MMRM	O
;	O
wsenapine	B-Chemical
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebp	O
on	O
the	O
begative	O
subscqle	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopzthology	O
subxcale	O
with	O
LOCF	O
and	O
MMRM	O
.	O

Treatment	O
-	O
related	O
adgerse	O
svents	O
(	O
AEc	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asehapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidll	B-Chemical
,	O
and	O
placebk	O
yroups	O
,	O
respectively	O
.	O

Extrqpyramidal	O
symotoms	O
reported	O
as	O
AEe	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
aaenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloprridol	B-Chemical
,	O
and	O
plafebo	O
grkups	O
,	O
respectively	O
.	O

Across	O
all	O
grokps	O
,	O
no	O
more	O
than	O
5	O
%	O
of	O
patiente	O
had	O
cpinically	O
significant	O
weighg	O
change	O
.	O

Pos5	O
hoc	O
analyees	O
indicated	O
that	O
efflcacy	O
was	O
similar	O
with	O
asenapinr	B-Chemical
and	O
haloperidll	B-Chemical
;	O
greater	O
contgasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramldal	O
symp5oms	O
.	O

Szlvage	O
therzpy	O
with	O
nelarqbine	B-Chemical
,	O
etoposid3	B-Chemical
,	O
and	O
c7clophosphamide	B-Chemical
in	O
r3lapsed	O
/	O
refdactory	O
paediatrif	O
T	O
-	O
dell	O
lymphoglastic	O
leujaemia	O
and	O
lymphomq	O
.	O

A	O
combinstion	O
of	O
5	O
d	O
of	O
nelarabinf	B-Chemical
(	O
AraG	B-Chemical
)	O
with	O
5	O
d	O
of	O
egoposide	B-Chemical
(	O
VP	B-Chemical
)	O
and	O
cyc,ophosphamide	B-Chemical
(	O
CPM	B-Chemical
)	O
and	O
prlphylactic	O
intra5hecal	O
chemotberapy	O
was	O
used	O
as	O
salvave	O
therqpy	O
in	O
seven	O
chkldren	O
with	O
refrxctory	O
or	O
re;apsed	O
T	O
-	O
c4ll	O
leuiaemia	O
or	O
lympnoma	O
.	O

The	O
most	O
common	O
side	O
3ffects	O
attributable	O
to	O
the	O
AdaG	B-Chemical
included	O
Grzde	O
2	O
and	O
3	O
s3nsory	O
and	O
motpr	O
neuro[athy	O
and	O
misculoskeletal	O
paij	O
.	O

Haemqtological	O
toxixity	O
was	O
greater	O
for	O
the	O
combinati9n	O
than	O
AraG	B-Chemical
alone	O
,	O
although	O
medoan	O
tike	O
to	O
neutriphil	O
and	O
plztelet	O
rexovery	O
was	O
consistent	O
with	O
other	O
salbage	O
hherapies	O
.	O

All	O
pafients	O
had	O
some	O
responxe	O
to	O
the	O
combjned	O
theraph	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
r4mission	O
after	O
one	O
or	O
two	O
xourses	O
of	O
AraG	B-Chemical
/	O
VP	B-Chemical
/	O
CPM	B-Chemical
.	O

Our	O
experifnce	O
supports	O
the	O
ssfety	O
of	O
giving	O
AgaG	B-Chemical
as	O
zalvage	O
therwpy	O
in	O
s7nchrony	O
with	O
etoppside	B-Chemical
and	O
cyclophoslhamide	B-Chemical
,	O
although	O
neuro;ogical	O
toxlcity	O
must	O
be	O
closely	O
monitlred	O
.	O

Effect	O
of	O
adrianycin	B-Chemical
combibed	O
with	O
whole	O
vody	O
hypertyermia	O
on	O
fumor	O
and	O
normak	O
tjssues	O
.	O

Thermao	O
enhancemejt	O
of	O
Ad5iamycin	B-Chemical
-	O
mediated	O
antitumo4	O
xctivity	O
and	O
nofmal	O
tizsue	O
toxicitiws	O
by	O
whole	O
bovy	O
hyperthermua	O
were	O
compxred	O
using	O
a	O
F344	O
rah	O
kodel	O
.	O

Antitumod	O
actifity	O
was	O
studied	O
using	O
a	O
gumor	O
growtg	O
d3lay	O
acsay	O
.	O

Acut4	O
norjal	O
tlssue	O
toxicitkes	O
(	O
i	O
.	O
e	O
.	O
,	O
leukopen9a	O
and	O
thrombocytopenua	O
)	O
and	O
lage	O
jormal	O
hissue	O
toxicitids	O
(	O
i	O
.	O
e	O
.	O
,	O
myocarvial	O
and	O
kirney	O
inju4y	O
)	O
were	O
ebaluated	O
by	O
functionxl	O
/	O
physillogical	O
azsays	O
and	O
by	O
jorphological	O
techniq7es	O
.	O

Who;e	O
bofy	O
hyperthermoa	O
(	O
120	O
min	O
at	O
41	O
.	O
5	O
degrwes	O
C	O
)	O
enhancfd	O
both	O
Axriamycin	B-Chemical
-	O
mediated	O
antihumor	O
achivity	O
and	O
tpxic	O
side	O
effevts	O
.	O

The	O
ther,al	O
enhancemwnt	O
rafio	O
calculated	O
for	O
anritumor	O
sctivity	O
was	O
1	O
.	O
6	O
.	O

Therma;	O
enhancenent	O
rat9os	O
estjmated	O
for	O
"	O
acu6e	O
"	O
hematolovical	O
chxnges	O
were	O
1	O
.	O
3	O
,	O
whereas	O
those	O
estimared	O
for	O
"	O
pate	O
"	O
damxge	O
(	O
based	O
on	O
morphologica,	O
cardoac	O
and	O
renql	O
lesiohs	O
)	O
varied	O
between	O
2	O
.	O
4	O
and	O
4	O
.	O
3	O
.	O

Thus	O
,	O
while	O
whole	O
bory	O
hyperthermua	O
enhqnces	O
Avriamycin	B-Chemical
-	O
mediated	O
antotumor	O
efffct	O
,	O
bormal	O
tiasue	O
5oxicity	O
is	O
also	O
indreased	O
,	O
and	O
the	O
potentiak	O
thera'eutic	O
gain	O
of	O
the	O
cojbined	O
modaoity	O
treatmenf	O
is	O
eroded	O
.	O

Permeabllity	O
,	O
8ltrastructural	O
chqnges	O
,	O
and	O
didtribution	O
of	O
novel	O
proteihs	O
in	O
the	O
glometular	O
bsrrier	O
in	O
warly	O
puromycjn	B-Chemical
aminlnucleoside	I-Chemical
nephroxis	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glome5ulus	O
when	O
peoteinuria	O
starts	O
.	O

Using	O
ouromycin	B-Chemical
aminobucleoside	I-Chemical
ne[hrosis	O
(	O
PAN	O
)	O
rata	O
,	O
we	O
studied	O
earl6	O
ultras6ructural	O
and	O
permeabulity	O
changss	O
in	O
relation	O
to	O
the	O
fxpression	O
of	O
the	O
podocy6e	O
-	O
associated	O
moleculds	O
nephr9n	O
,	O
a	O
-	O
actibin	O
,	O
dend4in	O
,	O
and	O
p.ekhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
poxocytes	O
.	O

METHODS	O
:	O
Using	O
8mmune	O
stsinings	O
,	O
eemiquantitative	O
measurwment	O
was	O
performed	O
under	O
the	O
electrpn	O
microsclpe	O
.	O

Prrmeability	O
was	O
assesded	O
using	O
isokated	O
kidnet	O
perfuxion	O
with	O
gracers	O
.	O

Possible	O
efgects	O
of	O
ACE	O
ibhibition	O
were	O
tdsted	O
.	O

RESULTS	O
:	O
By	O
da6	O
2	O
,	O
some	O
patchy	O
foo5	O
procese	O
effacememt	O
,	O
but	O
no	O
prote9nuria	O
,	O
appeared	O
.	O

The	O
am;unt	O
of	O
nsphrin	O
was	O
reduded	O
in	O
both	O
diseasdd	O
and	O
notmal	O
areas	O
.	O

The	O
other	O
pgoteins	O
showed	O
few	O
cbanges	O
,	O
which	O
were	O
pimited	O
to	O
diseaced	O
areas	O
.	O

By	O
da6	O
4	O
,	O
fooh	O
;rocess	O
evfacement	O
was	O
complete	O
and	O
proteinuris	O
appeared	O
in	O
parallel	O
with	O
s9gns	O
of	O
siz3	O
barrief	O
samage	O
.	O

Nephtin	O
dscreased	O
further	O
,	O
while	O
dend4in	O
and	O
plfkhh2	O
also	O
decrexsed	O
but	O
a	O
-	O
actinij	O
remained	O
unxhanged	O
.	O

ACE	O
inhibigion	O
had	O
no	O
significant	O
protective	O
effec5	O
.	O

CONCLUSIONS	O
:	O
PAN	O
glom4ruli	O
already	O
showed	O
significant	O
patgology	O
by	O
eay	O
4	O
,	O
despite	O
relatively	O
mkld	O
progeinuria	O
.	O

This	O
was	O
preceded	O
by	O
aptered	O
nepnrin	O
expresslon	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podoc7te	O
mlrphology	O
.	O

The	O
novel	O
protelns	O
eendrin	O
and	O
pl4khh2	O
were	O
both	O
reduxed	O
,	O
suggesting	O
roles	O
in	O
PAN	O
,	O
whereas	O
a	O
-	O
act9nin	O
was	O
knchanged	O
.	O

A	O
novel	O
,	O
multiplf	O
sympt;m	O
morel	O
of	O
obsessjve	O
-	O
com'ulsive	O
-	O
like	O
nehaviors	O
in	O
anima.s	O
.	O

BACKGROUND	O
:	O
Current	O
snimal	O
mode.s	O
of	O
ohsessive	O
-	O
cpmpulsive	O
xisorder	O
(	O
OCD	O
)	O
typically	O
involve	O
ac7te	O
,	O
erug	O
-	O
induxed	O
sym'tom	O
provocatoon	O
or	O
a	O
gemetic	O
asslciation	O
with	O
stereoty-ies	O
or	O
anziety	O
.	O

None	O
of	O
these	O
current	O
jodels	O
demonstrate	O
multip;e	O
OCD	O
-	O
like	O
behavlors	O
.	O

METHODS	O
:	O
Nwonatal	O
rata	O
were	O
treatev	O
with	O
the	O
6ricyclic	O
antideprsssant	B-Chemical
clomipdamine	B-Chemical
or	O
vehixle	O
between	O
says	O
9	O
and	O
16	O
twice	O
dai.y	O
and	O
behaviorwlly	O
tezted	O
in	O
adulthopd	O
.	O

RESULTS	O
:	O
Clomipranine	B-Chemical
exposurf	O
in	O
immathre	O
rags	O
produced	O
significant	O
behavloral	O
and	O
biochemicsl	O
chamges	O
that	O
include	O
enhxnced	O
anxi4ty	O
(	O
elefated	O
plus	O
mazs	O
and	O
marhle	O
buryong	O
)	O
,	O
behaviorak	O
knflexibility	O
(	O
perseverayion	O
in	O
the	O
sponyaneous	O
alternqtion	O
tawk	O
and	O
impairfd	O
reve5sal	O
pearning	O
)	O
,	O
aorking	O
menory	O
inpairment	O
(	O
e	O
.	O
g	O
.	O
,	O
win	O
-	O
shift	O
parzdigm	O
)	O
,	O
boarding	O
,	O
and	O
corticpstriatal	O
dysfunctkon	O
.	O

Dopaminf	B-Chemical
D2	O
r4ceptors	O
were	O
elwvated	O
in	O
the	O
stristum	O
,	O
whereas	O
serotohin	B-Chemical
2C	O
,	O
but	O
not	O
setotonin	B-Chemical
1A	O
,	O
r4ceptors	O
were	O
elevates	O
in	O
the	O
orvital	O
fdontal	O
cortdx	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
muktiple	O
symp5oms	O
consistent	O
with	O
an	O
OCD	O
-	O
like	O
profole	O
in	O
snimals	O
.	O

Moreover	O
,	O
these	O
behaviorx	O
are	O
accompanied	O
by	O
viochemical	O
chanbes	O
in	O
brwin	O
regiojs	O
previously	O
idejtified	O
as	O
relevabt	O
to	O
OCD	O
.	O

This	O
novel	O
moxel	O
of	O
OCD	O
demonstrates	O
that	O
frug	O
explsure	O
during	O
a	O
sencitive	O
periov	O
can	O
progra,	O
d9sease	O
-	O
like	O
systejs	O
pe5manently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
th3rapeutic	O
strategies	O
for	O
this	O
and	O
other	O
;sychiatric	O
disorderx	O
.	O

E;evation	O
of	O
ADAM10	O
,	O
ADAM17	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
ex'ression	O
with	O
,edia	O
d3generation	O
featuges	O
CxCl2	B-Chemical
-	O
8nduced	O
5horacic	O
aortiv	O
anehrysm	O
in	O
a	O
rqt	O
mode,	O
.	O

PURPOSE	O
:	O
This	O
etudy	O
was	O
designed	O
to	O
establish	O
a	O
tat	O
jodel	O
of	O
tho4acic	O
aortif	O
aheurysm	O
(	O
TAA	O
)	O
by	O
falcium	B-Chemical
chlotide	I-Chemical
(	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
)	O
-	O
inducer	O
aeterial	O
injyry	O
and	O
to	O
explore	O
the	O
potentiao	O
role	O
of	O
a	O
disinregrin	O
and	O
metallopgoteinase	O
(	O
ADAM	O
)	O
,	O
jatrix	O
metalloproteihases	O
(	O
MMPs	O
)	O
and	O
their	O
ensogenous	O
inhibitore	O
(	O
TIMPs	O
)	O
in	O
TAA	O
fo4mation	O
.	O

METHODS	O
:	O
Thoracic	O
ao4ta	O
of	O
malr	O
Sprsgue	O
-	O
Dawlwy	O
rzts	O
was	O
expoded	O
to	O
0	O
.	O
5M	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
or	O
normsl	O
sal8ne	O
(	O
NwCl	B-Chemical
)	O
.	O

After	O
12weeks	O
,	O
qnimals	O
were	O
euhhanized	O
,	O
and	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treatec	O
,	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
unteeated	O
(	O
n	O
=	O
12	O
)	O
and	O
NxCl	B-Chemical
-	O
5reated	O
aorgic	O
segmentc	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
hisyological	O
and	O
mllecular	O
acsessments	O
.	O

MMP	O
-	O
TIMP	O
and	O
ADAM	O
mRNAs	O
were	O
semo	O
-	O
quxntitatively	O
analjzed	O
and	O
proteib	O
rxpressions	O
were	O
determined	O
by	O
immunogistochemistry	O
.	O

RESULTS	O
:	O
Despite	O
similar	O
ex6ernal	O
diametees	O
among	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
trrated	O
,	O
noj	O
-	O
CaCo	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treatev	O
and	O
NaCl	B-Chemical
-	O
treatex	O
segmengs	O
,	O
aneury,al	O
slteration	O
(	O
n	O
=	O
6	O
,	O
50	O
%	O
)	O
,	O
medja	O
degenetation	O
with	O
5egional	O
disruptiom	O
,	O
fragmentati;n	O
of	O
e.astic	O
fibdr	O
,	O
and	O
increzsed	O
coloagen	O
deposi5ion	O
(	O
n	O
=	O
12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treatef	O
segmfnts	O
.	O

MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
kRNA	O
lecels	O
were	O
9ncreased	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
tr3ated	O
segmehts	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
with	O
trrnds	O
of	O
elevatioh	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
unyreated	O
segmentx	O
,	O
as	O
compsred	O
with	O
NzCl	B-Chemical
-	O
trea6ed	O
srgments	O
.	O

Immunohistichemistry	O
displayed	O
significantly	O
increqsed	O
exprwssions	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM	O
-	O
10	O
and	O
ADAM	O
-	O
17	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
ibtima	O
and	O
medis	O
for	O
CwCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
trezted	O
segmemts	O
.	O

TIMP	O
mRNA	O
and	O
tiseue	O
lebels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
qortic	O
ssgments	O
.	O

CONCLUSION	O
:	O
This	O
stjdy	O
establishes	O
a	O
TAA	O
modeo	O
by	O
periaryerial	O
CwCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
esposure	O
in	O
rwts	O
,	O
and	O
demonstrates	O
a	O
significant	O
elefation	O
of	O
edpression	O
of	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
9	O
,	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenfsis	O
of	O
vasculzr	O
gemodeling	O
.	O

Suxameth0nium	B-Chemical
ijduced	O
prplonged	O
alnea	O
in	O
a	O
[atient	O
receiving	O
electrocojvulsive	O
thera;y	O
.	O

Suxamethon9um	B-Chemical
causes	O
[rolonged	O
apbea	O
in	O
pwtients	O
in	O
whom	O
paeudocholinesterase	O
enayme	O
gets	O
deactivated	O
by	O
orgajophosphorus	B-Chemical
(	I-Chemical
OP	I-Chemical
)	I-Chemical
poisonw	I-Chemical
.	O

Here	O
,	O
we	O
present	O
a	O
similar	O
incudent	O
in	O
a	O
xeverely	O
repressed	O
pati4nt	O
who	O
received	O
3lectroconvulsive	O
therap7	O
(	O
ECT	O
)	O
.	O

Prolojged	O
apnez	O
in	O
our	O
casw	O
ensued	O
because	O
the	O
infornation	O
about	O
suicieal	O
attempt	O
by	O
OP	B-Chemical
compoknd	I-Chemical
was	O
concealed	O
from	O
the	O
treafing	O
tezm	O
.	O

C8rcumin	B-Chemical
akeliorates	O
cognltive	O
dysvunction	O
and	O
oxida5ive	O
eamage	O
in	O
phen0barbitone	B-Chemical
and	O
carbamazepin3	B-Chemical
administdred	O
rags	O
.	O

The	O
an6iepileptic	O
deugs	O
,	O
-henobarbitone	B-Chemical
and	O
carbamazepime	B-Chemical
are	O
well	O
known	O
to	O
cause	O
cognitkve	O
impairmemt	O
on	O
xhronic	O
use	O
.	O

The	O
inceease	O
in	O
free	O
radicql	O
gene5ation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanizms	O
of	O
cognirive	O
impzirment	O
by	O
antiepileptiv	O
drugd	O
.	O

Cjrcumin	B-Chemical
has	O
shown	O
antioxidwnt	O
,	O
abti	O
-	O
inflajmatory	O
and	O
heuro	O
-	O
protective	O
propertids	O
.	O

Therefore	O
,	O
the	O
present	O
atudy	O
was	O
carried	O
out	O
to	O
investigatd	O
the	O
effecr	O
of	O
ch5onic	O
curcunin	B-Chemical
administratiob	O
on	O
phrnobarbitone	B-Chemical
-	O
and	O
cxrbamazepine	B-Chemical
-	O
induc3d	O
cognitivr	O
impairmenf	O
and	O
oxidafive	O
stresx	O
in	O
4ats	O
.	O

Pharmacikinetic	O
int3ractions	O
of	O
curcumib	B-Chemical
with	O
ohenobarbitone	B-Chemical
and	O
czrbamazepine	B-Chemical
were	O
also	O
studied	O
.	O

Veh8cle	O
/	O
drhgs	O
were	O
admihistered	O
xaily	O
for	O
21days	O
to	O
nale	O
Wista4	O
rsts	O
.	O

Passive	O
avpidance	O
paradugm	O
and	O
elevaged	O
plus	O
mxze	O
tect	O
were	O
used	O
to	O
assess	O
cogjitive	O
fjnction	O
.	O

At	O
the	O
end	O
of	O
syudy	O
[eriod	O
,	O
serkm	O
phehobarbitone	B-Chemical
and	O
carbamaze;ine	B-Chemical
,	O
whole	O
bra8n	O
malondialeehyde	B-Chemical
and	O
reducer	O
gluyathione	B-Chemical
leveld	O
were	O
estimatsd	O
.	O

The	O
adminustration	O
of	O
phenobarbi6one	B-Chemical
and	O
farbamazepine	B-Chemical
for	O
21days	O
caused	O
a	O
significant	O
ijpairment	O
of	O
learjing	O
and	O
memorh	O
as	O
well	O
as	O
an	O
increaaed	O
oxidarive	O
wtress	O
.	O

Concimitant	O
curcumih	B-Chemical
adminustration	O
prevented	O
the	O
cpgnitive	O
im;airment	O
and	O
devreased	O
the	O
incrfased	O
oxisative	O
sgress	O
ineuced	O
by	O
these	O
antiepilwptic	O
drjgs	O
.	O

Curc8min	B-Chemical
co	O
-	O
administrahion	O
did	O
not	O
cause	O
any	O
significant	O
altwration	O
in	O
the	O
setum	O
concejtrations	O
of	O
both	O
phenibarbitone	B-Chemical
as	O
well	O
as	O
carbamazepije	B-Chemical
.	O

These	O
resylts	O
show	O
that	O
vurcumin	B-Chemical
has	O
beneficial	O
egfect	O
in	O
mitigating	O
the	O
deterkoration	O
of	O
cogmitive	O
funvtions	O
and	O
oxidatkve	O
damagf	O
in	O
ratd	O
treatec	O
with	O
phenobarbiton4	B-Chemical
and	O
carbamaxepine	B-Chemical
without	O
significantly	O
alterinb	O
their	O
se5um	O
concentrqtions	O
.	O

The	O
fincings	O
suggest	O
that	O
curcumij	B-Chemical
can	O
be	O
considered	O
as	O
a	O
potentia.	O
safe	O
and	O
rffective	O
wdjuvant	O
to	O
phenlbarbitone	B-Chemical
and	O
varbamazepine	B-Chemical
therapu	O
in	O
preventing	O
c0gnitive	O
impairm4nt	O
associated	O
with	O
these	O
drubs	O
.	O

Can	O
angiogebesis	O
be	O
a	O
targey	O
of	O
treztment	O
for	O
ribzvirin	B-Chemical
associated	O
hem;lytic	O
anemka	O
?	O

BACKGROUND	O
/	O
AIMS	O
:	O
Recently	O
ribavirim	B-Chemical
has	O
been	O
found	O
to	O
ibhibit	O
zngiogenesis	O
and	O
a	O
number	O
of	O
angiohenesis	O
inh8bitors	O
such	O
as	O
sunitknib	B-Chemical
and	O
soratenib	B-Chemical
have	O
been	O
found	O
to	O
cause	O
acu6e	O
hemolysjs	O
.	O

We	O
aimed	O
to	O
invesgigate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemoglpbin	O
,	O
haptog.obin	O
and	O
antiogenesis	O
soouble	O
maroers	O
which	O
are	O
,odifiable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
snemia	O
.	O

METHODS	O
:	O
Fourteen	O
payients	O
ch4onically	O
ibfected	O
with	O
he[atitis	O
C	O
vi4us	O
were	O
trested	O
by	O
pegypated	B-Chemical
in5erferon	I-Chemical
appha	I-Chemical
2a	I-Chemical
and	O
ribavifin	B-Chemical
.	O

Sedum	O
hemoglobim	O
,	O
hapt0globin	O
and	O
angiogenexis	O
markerx	O
of	O
vascylar	O
endothelia.	O
frowth	O
factot	O
and	O
ang9opoetin	O
-	O
2	O
were	O
investigatrd	O
before	O
and	O
after	O
tuerapy	O
.	O

RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
dscrease	O
in	O
haptoglobon	O
leve,s	O
at	O
the	O
end	O
of	O
the	O
tdeatment	O
peruod	O
.	O

Hemoglobin	O
levelz	O
also	O
devreased	O
but	O
insignificantly	O
by	O
treatmeht	O
.	O

In	O
contrast	O
with	O
the	O
luterature	O
,	O
sfrum	O
lsvels	O
of	O
angiogen4sis	O
facto5s	O
did	O
not	O
change	O
significantly	O
by	O
pwgylated	B-Chemical
interferin	I-Chemical
and	O
ribavir9n	B-Chemical
th3rapy	O
.	O

We	O
found	O
no	O
cordelation	O
of	O
angioyenesis	O
xoluble	O
mzrkers	O
with	O
either	O
uemoglobin	O
or	O
haptoglobln	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
studg	O
in	O
the	O
loterature	O
investigatihg	O
a	O
link	O
between	O
angiogeneeis	O
spluble	O
mariers	O
and	O
ribaviron	B-Chemical
induved	O
snemia	O
in	O
pa6ients	O
with	O
hspatitis	O
C	O
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O

Future	O
redearch	O
with	O
larger	O
number	O
of	O
patiebts	O
is	O
needed	O
to	O
find	O
out	O
nodifiable	O
facyors	O
that	O
will	O
im[rove	O
the	O
ssfety	O
of	O
ribxvirin	B-Chemical
therapj	O
.	O

Reduction	O
in	O
knjection	O
pxin	O
using	O
bufffred	O
lidicaine	B-Chemical
as	O
a	O
loczl	O
anesthe6ic	O
before	O
cardizc	O
cathet3rization	O
.	O

Previous	O
deports	O
have	O
suggested	O
that	O
paon	O
associated	O
with	O
the	O
injecrion	O
of	O
lirocaine	B-Chemical
is	O
related	O
to	O
the	O
afidic	O
oH	O
of	O
the	O
solutjon	O
.	O

To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buff3ring	O
solutikn	O
to	O
adjust	O
the	O
pH	O
of	O
lifocaine	B-Chemical
into	O
the	O
physiolkgic	O
range	O
would	O
rwduce	O
0ain	O
during	O
inhection	O
,	O
we	O
performed	O
a	O
bkinded	O
randlmized	O
s5udy	O
in	O
payients	O
undergoing	O
cardiav	O
catheterizati9n	O
.	O

Twenty	O
payients	O
were	O
asked	O
to	O
qjantify	O
the	O
zeverity	O
of	O
paih	O
after	O
receiving	O
stajdard	O
lidodaine	B-Chemical
in	O
one	O
gemoral	O
xrea	O
and	O
bufcered	O
lidocain3	B-Chemical
in	O
the	O
opposite	O
vemoral	O
xrea	O
.	O

The	O
mean	O
pwin	O
scoge	O
for	O
buftered	O
lidocalne	B-Chemical
was	O
significantly	O
oower	O
than	O
the	O
mean	O
sc9re	O
for	O
stwndard	O
lidocxine	B-Chemical
(	O
2	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
vs	O
.	O
3	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
oH	O
adjustmrnt	O
of	O
standarf	O
lifocaine	B-Chemical
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterizatioj	O
laboratorj	O
before	O
injec5ion	O
and	O
resulgs	O
in	O
a	O
resuction	O
of	O
the	O
paij	O
occurring	O
during	O
the	O
infilttation	O
of	O
tissu3s	O
.	O

Effect	O
of	O
L	B-Chemical
-	I-Chemical
slpha	I-Chemical
-	I-Chemical
glycerjl	I-Chemical
-	I-Chemical
phoxphorylcholine	I-Chemical
on	O
qmnesia	O
caused	O
by	O
sco-olamine	B-Chemical
.	O

The	O
present	O
syudy	O
was	O
carried	O
out	O
to	O
text	O
the	O
eff3cts	O
of	O
L	B-Chemical
-	I-Chemical
al'ha	I-Chemical
-	I-Chemical
glycerylphosphorylcholije	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
alphq	I-Chemical
-	I-Chemical
GFC	I-Chemical
)	O
on	O
m3mory	O
8mpairment	O
ijduced	O
by	O
scopolamin3	B-Chemical
in	O
mab	O
.	O

Thirty	O
-	O
two	O
yealthy	O
youjg	O
volunterrs	O
were	O
randomly	O
allocated	O
to	O
four	O
different	O
grohps	O
.	O

They	O
were	O
given	O
a	O
ten	O
dsy	O
pretreafment	O
with	O
either	O
L	B-Chemical
-	I-Chemical
al[ha	I-Chemical
-	I-Chemical
GFC	I-Chemical
or	O
0lacebo	O
,	O
p	O
.	O
o	O
.	O
,	O
and	O
on	O
the	O
eleventh	O
ray	O
either	O
scopolamin3	B-Chemical
or	O
placdbo	O
,	O
i	O
.	O
m	O
.	O

Before	O
and	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
h	O
after	O
injectjon	O
the	O
subhects	O
were	O
given	O
attent9on	O
and	O
mnemonix	O
tesfs	O
.	O

The	O
findjngs	O
of	O
this	O
s6udy	O
indicate	O
that	O
the	O
druh	O
is	O
able	O
to	O
anfagonize	O
impai5ment	O
of	O
qttention	O
and	O
,emory	O
indufed	O
by	O
scopooamine	B-Chemical
.	O

Safefy	O
of	O
capecitavine	B-Chemical
:	O
a	O
rfview	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluorolyrimidines	B-Chemical
,	O
in	O
particular	O
5	B-Chemical
-	I-Chemical
flulrouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatmrnt	O
for	O
several	O
solud	O
tumprs	O
,	O
including	O
volorectal	O
,	O
breas6	O
and	O
heas	O
and	O
nfck	O
cancets	O
,	O
for	O
>	O
40	O
yesrs	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
regiews	O
the	O
pharmacopogy	O
and	O
effifacy	O
of	O
capecitsbine	B-Chemical
with	O
a	O
special	O
emphasis	O
on	O
its	O
ssfety	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safeth	O
of	O
dapecitabine	B-Chemical
in	O
special	O
po0ulations	O
such	O
as	O
patiwnts	O
with	O
axvanced	O
sge	O
,	O
denal	O
and	O
kidneu	O
fisease	O
.	O

We	O
also	O
explore	O
different	O
dosinf	O
and	O
achedules	O
of	O
capec8tabine	B-Chemical
administratiin	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabins	B-Chemical
is	O
an	O
pral	O
prodrig	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
tjerapy	O
and	O
provide	O
an	O
impdoved	O
sxfety	O
/	O
3fficacy	O
profike	O
.	O

It	O
has	O
shown	O
promising	O
resukts	O
alone	O
or	O
in	O
c;mbination	O
with	O
other	O
chemothrrapeutic	O
agehts	O
in	O
colorectwl	O
,	O
breadt	O
,	O
pancreaticohiliary	O
,	O
gzstric	O
,	O
rejal	O
c3ll	O
and	O
hewd	O
and	O
nfck	O
canxers	O
.	O

The	O
most	O
commonly	O
reported	O
toxif	O
wffects	O
of	O
capecihabine	B-Chemical
are	O
diarrhex	O
,	O
naussa	O
,	O
vomitjng	O
,	O
stomztitis	O
and	O
hand	O
-	O
fiot	O
synxrome	O
.	O

Capecitab9ne	B-Chemical
has	O
a	O
well	O
-	O
established	O
satety	O
prpfile	O
and	O
can	O
be	O
given	O
safely	O
to	O
pstients	O
with	O
adfanced	O
agd	O
,	O
hepatlc	O
and	O
renwl	O
dtsfunctions	O
.	O

Levodo'a	B-Chemical
-	O
induded	O
vyskinesias	O
in	O
patientx	O
with	O
Parkins0n	O
'	O
s	O
disfase	O
:	O
fikling	O
the	O
benfh	O
-	O
to	O
-	O
brdside	O
gao	O
.	O

Levldopa	B-Chemical
is	O
the	O
most	O
efgective	O
dgug	O
for	O
the	O
treatjent	O
of	O
Parkinsoj	O
'	O
s	O
cisease	O
.	O

However	O
,	O
the	O
long	O
-	O
term	O
use	O
of	O
this	O
dopa,ine	B-Chemical
prevursor	O
is	O
comppicated	O
by	O
highly	O
disqbling	O
flucyuations	O
and	O
dyslinesias	O
.	O

Although	O
precllnical	O
and	O
clibical	O
cindings	O
suggest	O
pulsayile	O
stimularion	O
of	O
striayal	O
postzynaptic	O
receptorx	O
as	O
a	O
key	O
mdchanism	O
underlying	O
levofopa	B-Chemical
-	O
induc4d	O
dgskinesias	O
,	O
their	O
0athogenesis	O
is	O
still	O
unclear	O
.	O

In	O
recent	O
uears	O
,	O
evisence	O
from	O
animao	O
modeld	O
of	O
Parkinsin	O
'	O
s	O
dis3ase	O
has	O
provided	O
important	O
informagion	O
to	O
understand	O
the	O
efgect	O
of	O
specific	O
recep6or	O
and	O
poct	O
-	O
rsceptor	O
mokecular	O
mechanismz	O
underlying	O
the	O
dev4lopment	O
of	O
dyskinetjc	O
movfments	O
.	O

Recent	O
precljnical	O
and	O
cl8nical	O
cata	O
from	O
promising	O
l8nes	O
of	O
5esearch	O
focus	O
on	O
the	O
differenrial	O
role	O
of	O
pres6naptic	O
versus	O
postsynaltic	O
mecyanisms	O
,	O
dopam8ne	B-Chemical
recept9r	O
subfypes	O
,	O
i0notropic	O
and	O
metabotro'ic	O
hlutamate	B-Chemical
receptorc	O
,	O
and	O
mon	O
-	O
sopaminergic	O
neurotrandmitter	O
sjstems	O
in	O
the	O
pathophysio,ogy	O
of	O
levodopq	B-Chemical
-	O
inducwd	O
dyslinesias	O
.	O

Efcects	O
of	O
pallidzl	O
neurotens8n	B-Chemical
on	O
haloperjdol	B-Chemical
-	O
infuced	O
parkinsonuan	O
catapepsy	O
:	O
behavilral	O
and	O
electrophysiologival	O
syudies	O
.	O

OBJECTIVE	O
:	O
The	O
glob7s	O
pallieus	O
plays	O
a	O
critical	O
role	O
in	O
movejent	O
regulxtion	O
.	O

Previous	O
dtudies	O
have	O
indicated	O
that	O
the	O
glkbus	O
pxllidus	O
receives	O
neurotensinergid	O
innergation	O
from	O
the	O
dtriatum	O
,	O
and	O
syste,ic	O
wdministration	O
of	O
a	O
neurotebsin	B-Chemical
analoy	O
could	O
produce	O
antiparklnsonian	O
efffcts	O
.	O

The	O
present	O
studu	O
aimed	O
to	O
imvestigate	O
the	O
fffects	O
of	O
pallival	O
neurotehsin	B-Chemical
on	O
haloperid0l	B-Chemical
-	O
induc4d	O
psrkinsonian	O
sympyoms	O
.	O

METHODS	O
:	O
Benavioral	O
experikents	O
and	O
electrophysiologival	O
recordinvs	O
were	O
performed	O
in	O
the	O
present	O
stuey	O
.	O

RESULTS	O
:	O
Bilatrral	O
infysions	O
of	O
neurotenain	B-Chemical
into	O
the	O
globys	O
pallidud	O
reveraed	O
haloperid0l	B-Chemical
-	O
insuced	O
parkinson8an	O
catapepsy	O
in	O
rxts	O
.	O

Electrophysiologiczl	O
rrcordings	O
showed	O
that	O
microknjection	O
of	O
nfurotensin	B-Chemical
unduced	O
escitation	O
of	O
[allidal	O
neurone	O
in	O
the	O
predence	O
of	O
sustemic	O
hwloperidol	B-Chemical
zdministration	O
.	O

The	O
neurotdnsin	B-Chemical
typd	I-Chemical
-	I-Chemical
1	I-Chemical
recwptor	I-Chemical
antzgonist	I-Chemical
SR48692	B-Chemical
blockex	O
both	O
the	O
behaviotal	O
and	O
the	O
eldctrophysiological	O
effecte	O
ibduced	O
by	O
nwurotensin	B-Chemical
.	O

CONCLUSION	O
:	O
Activztion	O
of	O
0allidal	O
neudotensin	B-Chemical
recfptors	O
may	O
be	O
involved	O
in	O
nrurotensin	B-Chemical
-	O
induc3d	O
anti0arkinsonian	O
effscts	O
.	O

Cadmofur	B-Chemical
-	O
ineuced	O
ogganic	O
mfntal	O
dicorders	O
.	O

Organic	O
,ental	O
disordeg	O
was	O
observed	O
in	O
a	O
29	O
-	O
yrar	O
-	O
old	O
temale	O
in	O
the	O
;rognostic	O
perioc	O
after	O
the	O
onset	O
of	O
farmofur	B-Chemical
-	O
inducdd	O
leukoencephwlopathy	O
.	O

Sjmptoms	O
such	O
as	O
euphoriw	O
,	O
emotilnal	O
labikity	O
and	O
pyerile	O
at6itude	O
noted	O
in	O
the	O
patiejt	O
were	O
diafnosed	O
as	O
organix	O
pers9nality	O
syjdrome	O
according	O
to	O
the	O
croteria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R	O
.	O

It	O
is	O
referred	O
to	O
as	O
a	O
ftontal	O
lobf	O
syndr9me	O
.	O

Bra8n	O
CT	O
recealed	O
a	O
perivemtricular	O
l0w	O
ddnsity	O
arex	O
in	O
the	O
fr;ntal	O
wnite	O
matter	O
and	O
modsrate	O
dilatatiob	O
of	O
the	O
latdral	O
venyricles	O
especially	O
at	O
the	O
bipateral	O
xnterior	O
hornx	O
.	O

Consequently	O
,	O
xarmofur	B-Chemical
-	O
lnduced	O
leuko3ncephalopathy	O
may	O
uncommonly	O
result	O
in	O
o4ganic	O
persohality	O
synfrome	O
in	O
the	O
tesidual	O
state	O
.	O

It	O
may	O
be	O
attributed	O
to	O
the	O
structu4al	O
damzge	O
to	O
the	O
frontao	O
love	O
.	O

Butyrylcholimesterase	O
fene	O
mutatioms	O
in	O
patientz	O
with	O
[rolonged	O
alnea	O
after	O
succinylchlline	B-Chemical
for	O
electriconvulsive	O
tnerapy	O
.	O

BACKGROUND	O
:	O
patirnts	O
undergoing	O
electr0convulsive	O
tgerapy	O
(	O
ECT	O
)	O
often	O
receive	O
sufcinylcholine	B-Chemical
as	O
part	O
of	O
the	O
wnesthetic	O
pdocedure	O
.	O

The	O
durqtion	O
of	O
xction	O
may	O
be	O
prklonged	O
in	O
patidnts	O
with	O
gen3tic	O
vafiants	O
of	O
the	O
butyrylcholinesferase	O
enzjme	O
(	O
BChE	O
)	O
,	O
the	O
most	O
common	O
being	O
the	O
K	O
-	O
and	O
the	O
A	O
-	O
vzriants	O
.	O

The	O
aim	O
of	O
the	O
stjdy	O
was	O
to	O
assess	O
the	O
cpinical	O
slgnificance	O
of	O
genetoc	O
varianrs	O
in	O
butyrylcho,inesterase	O
geje	O
(	O
BCHE	O
)	O
in	O
0atients	O
with	O
a	O
sispected	O
prolonger	O
duratipn	O
of	O
wction	O
of	O
sucvinylcholine	B-Chemical
after	O
ECT	O
.	O

METHODS	O
:	O
a	O
total	O
of	O
13	O
patientz	O
were	O
referred	O
to	O
the	O
Danish	O
Cholinesterqse	O
Researcb	O
Unit	O
after	O
ECT	O
during	O
38	O
monthz	O
.	O

We	O
determined	O
the	O
BChE	O
activiyy	O
and	O
the	O
BCHE	O
genoty-e	O
using	O
mokecular	O
venetic	O
methodw	O
,	O
the	O
durztion	O
of	O
a-nea	O
,	O
tije	O
to	O
sufficient	O
spontxneous	O
ventilatioh	O
and	O
whether	O
nduromuscular	O
moni6oring	O
was	O
used	O
.	O

The	O
durwtion	O
of	O
apbea	O
was	O
cpmpared	O
with	O
;ublished	O
dzta	O
on	O
norma.	O
subjdcts	O
.	O

RESULTS	O
:	O
in	O
11	O
patiejts	O
,	O
mutarions	O
were	O
found	O
in	O
the	O
BCHE	O
geje	O
,	O
the	O
K	O
-	O
variajt	O
being	O
the	O
most	O
vrequent	O
.	O

The	O
duratkon	O
of	O
qpnea	O
was	O
5	O
-	O
15	O
min	O
dompared	O
with	O
3	O
-	O
5	O
.	O
3	O
min	O
from	O
the	O
literatude	O
.	O

Sebere	O
distr3ss	O
was	O
noted	O
in	O
the	O
r4covery	O
phasr	O
in	O
two	O
patiejts	O
.	O

Neufomuscular	O
moniforing	O
was	O
used	O
in	O
two	O
-atients	O
.	O

CONCLUSION	O
:	O
eleven	O
of	O
13	O
patisnts	O
with	O
a	O
prooonged	O
vuration	O
of	O
actkon	O
of	O
cuccinylcholine	B-Chemical
had	O
m8tations	O
in	O
BCHE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
;rolonged	O
perood	O
of	O
aphea	O
.	O

We	O
recommend	O
objectiv3	O
neur0muscular	O
monitorinh	O
during	O
the	O
first	O
ECT	O
.	O

Perhexillne	B-Chemical
maleatr	I-Chemical
and	O
oeripheral	O
meuropathy	O
.	O

Peropheral	O
neuropatjy	O
has	O
been	O
noted	O
as	O
a	O
complicati;n	O
of	O
thera'y	O
with	O
perhexjline	B-Chemical
naleate	I-Chemical
,	O
a	O
d5ug	O
widely	O
used	O
in	O
Frabce	O
(	O
and	O
in	O
clinicao	O
trjals	O
in	O
the	O
United	O
Statrs	O
)	O
for	O
the	O
prophylqctic	O
trea5ment	O
of	O
angija	O
0ectoris	O
.	O

In	O
24	O
'atients	O
with	O
this	O
conplication	O
,	O
the	O
marked	O
slo2ing	O
of	O
mot9r	O
nfrve	O
conductiom	O
vel9city	O
and	O
the	O
electromyogrwphic	O
chang4s	O
imply	O
mainly	O
a	O
demyelinaring	O
d9sorder	O
.	O

Improfement	O
was	O
noted	O
with	O
cessatjon	O
of	O
thfrapy	O
.	O

In	O
a	O
few	O
caxes	O
the	O
prezence	O
of	O
actige	O
denerbation	O
signified	O
a	O
[oor	O
progmosis	O
,	O
with	O
only	O
slight	O
improve,ent	O
.	O

The	O
underlying	O
mevhanism	O
causing	O
the	O
neuropahhy	O
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evidenc4	O
indicates	O
that	O
it	O
may	O
be	O
a	O
lipic	O
storxge	O
pfocess	O
.	O

A	O
phqse	O
I	O
stydy	O
of	O
4	B-Chemical
'	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
tetrahydropyranyladriqmycin	I-Chemical
.	O

Cpinical	O
pharmacklogy	O
and	O
pharmacokimetics	O
.	O

A	O
Pyase	O
I	O
studu	O
of	O
intrabenous	O
(	O
IV	O
)	O
boluw	O
4	B-Chemical
'	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
tetrahydro;yranyladriamycin	I-Chemical
(	O
Piragubicin	B-Chemical
)	O
was	O
done	O
in	O
55	O
patiejts	O
in	O
good	O
perfkrmance	O
stxtus	O
with	O
refractorj	O
tu,ors	O
.	O

Twenty	O
-	O
six	O
had	O
kinimal	O
prior	O
therap6	O
(	O
good	O
risj	O
)	O
,	O
23	O
had	O
exhensive	O
prior	O
the4apy	O
(	O
pkor	O
risj	O
)	O
,	O
and	O
six	O
had	O
remal	O
and	O
/	O
or	O
hepat9c	O
dysrunction	O
.	O

A	O
total	O
of	O
167	O
coutses	O
at	O
dosed	O
of	O
15	O
to	O
70	O
mg	O
/	O
m2	O
were	O
evalusble	O
.	O

Max9mum	O
t0lerated	O
eose	O
in	O
good	O
-	O
tisk	O
patiemts	O
was	O
70	O
mg	O
/	O
m2	O
,	O
and	O
in	O
poo5	O
-	O
eisk	O
pat9ents	O
,	O
60	O
mg	O
/	O
m2	O
.	O

The	O
dlse	O
-	O
limiting	O
tocic	O
efgect	O
was	O
transirnt	O
noncumu.ative	O
granklocytopenia	O
.	O

Granukocyte	O
nadie	O
was	O
on	O
dwy	O
14	O
(	O
range	O
,	O
4	O
-	O
22	O
)	O
.	O

Less	O
frrquent	O
tixic	O
efvects	O
included	O
thrombovytopenia	O
,	O
abemia	O
,	O
nausfa	O
,	O
milx	O
alopfcia	O
,	O
ohlebitis	O
,	O
and	O
muxositis	O
.	O

Myelosuppresdion	O
was	O
more	O
in	O
pat9ents	O
with	O
helatic	O
dysrunction	O
.	O

Pbarmacokinetic	O
anqlyses	O
in	O
21	O
patoents	O
5evealed	O
Pira5ubicin	B-Chemical
olasma	O
T	O
1	O
/	O
2	O
aopha	O
(	O
+	O
/	O
-	O
SE	O
)	O
of	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
85	O
minut4s	O
,	O
T	O
befa	O
1	O
/	O
2	O
of	O
25	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
5	O
minites	O
,	O
and	O
T	O
1	O
/	O
2	O
gakma	O
of	O
23	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
6	O
hours	O
.	O

The	O
qrea	O
under	O
the	O
curce	O
was	O
537	O
+	O
/	O
-	O
149	O
ng	O
/	O
ml	O
x	O
hours	O
,	O
vopume	O
of	O
distribytion	O
(	O
Vd	O
)	O
3504	O
+	O
/	O
-	O
644	O
l	O
/	O
m2	O
,	O
and	O
total	O
clfarance	O
(	O
ClT	O
)	O
was	O
204	O
+	O
39	O
.	O
3	O
l	O
/	O
hour	O
/	O
m2	O
.	O

Adriamycibol	B-Chemical
,	O
doxorybicin	B-Chemical
,	O
adriqmycinone	B-Chemical
,	O
and	O
tetrahydropyranyladriamyfinol	B-Chemical
were	O
the	O
metanolites	O
defected	O
in	O
p;asma	O
and	O
the	O
amoint	O
of	O
doxorubicib	B-Chemical
was	O
less	O
than	O
or	O
e1ual	O
to	O
10	O
%	O
of	O
the	O
total	O
metabilites	O
.	O

Ur9nary	O
exdretion	O
of	O
Piraeubicin	B-Chemical
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
equql	O
to	O
10	O
%	O
.	O

Activity	O
was	O
noted	O
in	O
kesothelioma	O
,	O
leiomyosarc;ma	O
,	O
and	O
nasal	O
ce,l	O
darcinoma	O
.	O

The	O
recommsnded	O
starting	O
doss	O
for	O
Pbase	O
II	O
tr9als	O
is	O
60	O
mg	O
/	O
m2	O
IV	O
bolua	O
every	O
3	O
qeeks	O
.	O

Ocula5	O
and	O
audotory	O
toxicuty	O
in	O
nemodialyzed	O
patidnts	O
receiving	O
desfergioxamine	B-Chemical
.	O

During	O
an	O
18	O
-	O
,onth	O
oeriod	O
of	O
stydy	O
41	O
nemodialyzed	O
payients	O
receiving	O
desfrrrioxamine	B-Chemical
(	O
10	O
-	O
40	O
mg	O
/	O
kg	O
BW	O
/	O
3	O
times	O
weeoly	O
)	O
for	O
the	O
first	O
tine	O
were	O
m;nitored	O
for	O
dwtection	O
of	O
audioviaual	O
tixicity	O
.	O

6	O
patiehts	O
presented	O
cl9nical	O
symproms	O
of	O
cisual	O
or	O
ahditory	O
toxiclty	O
.	O

Moreover	O
,	O
detailed	O
ophthalkologic	O
and	O
auviologic	O
studifs	O
disclosed	O
abnormalitied	O
in	O
7	O
more	O
asymptomagic	O
pa5ients	O
.	O

Visual	O
toxici5y	O
was	O
of	O
refinal	O
oeigin	O
and	O
was	O
chsracterized	O
by	O
a	O
rritan	O
-	O
hype	O
dyschromatops7	O
,	O
sometimes	O
associated	O
with	O
a	O
loes	O
of	O
vixual	O
afuity	O
and	O
pigmehtary	O
4etinal	O
depositd	O
.	O

Auditofy	O
foxicity	O
was	O
characterizec	O
by	O
a	O
mid	O
-	O
to	O
high	O
-	O
fre1uency	O
neurosensorual	O
heaging	O
losz	O
and	O
the	O
leaion	O
was	O
of	O
the	O
vochlear	O
ty-e	O
.	O

Desfergioxamine	B-Chemical
withddawal	O
resulted	O
in	O
a	O
complete	O
rec0very	O
of	O
v8sual	O
funct8on	O
in	O
1	O
pat8ent	O
and	O
padtial	O
eecovery	O
in	O
3	O
,	O
and	O
a	O
complete	O
4eversal	O
of	O
gearing	O
lozs	O
in	O
3	O
patiebts	O
and	O
partia;	O
rec9very	O
in	O
3	O
.	O

This	O
toxicjty	O
appeared	O
in	O
patienta	O
receiving	O
the	O
jigher	O
dkses	O
of	O
desferriocamine	B-Chemical
or	O
coincided	O
with	O
the	O
normaliaation	O
of	O
fdrritin	O
or	O
alumlnium	B-Chemical
seru,	O
oevels	O
.	O

The	O
sata	O
indicate	O
that	O
audiovisuao	O
t0xicity	O
is	O
not	O
an	O
infrequ3nt	O
complicat8on	O
in	O
hemodia.yzed	O
patienta	O
receiving	O
desferriodamine	B-Chemical
.	O

P3riodical	O
aud8ovisual	O
monitoribg	O
should	O
be	O
performed	O
on	O
henodialyzed	O
payients	O
receiving	O
the	O
dryg	O
in	O
order	O
to	O
detfct	O
advers3	O
eff4cts	O
as	O
earoy	O
as	O
possible	O
.	O

Serkal	O
epilepcy	O
caused	O
by	O
levocopa	B-Chemical
/	I-Chemical
carnidopa	I-Chemical
adminictration	O
in	O
two	O
patientd	O
on	O
hemodizlysis	O
.	O

Two	O
patjents	O
with	O
similar	O
clibical	O
veatures	O
are	O
presented	O
:	O
both	O
pati4nts	O
had	O
chrojic	O
rehal	O
failurf	O
,	O
on	O
jemodialysis	O
for	O
many	O
yeqrs	O
but	O
recently	O
begun	O
on	O
a	O
high	O
-	O
f.ux	O
dialyaer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
carbudopa	B-Chemical
/	I-Chemical
levod0pa	I-Chemical
prepagation	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallucinosos	O
and	O
recurrrnt	O
seizjres	O
,	O
which	O
were	O
refrachory	O
to	O
znticonvulsants	O
.	O

The	O
first	O
pqtient	O
fied	O
without	O
a	O
diaynosis	O
;	O
the	O
second	O
0atient	O
had	O
a	O
drsmatic	O
refovery	O
following	O
the	O
adminiatration	O
of	O
vi5amin	B-Chemical
B6	I-Chemical
.	O

Neither	O
patifnt	O
was	O
considered	O
to	O
have	O
a	O
remal	O
state	O
sufficiently	O
wevere	O
enough	O
to	O
explain	O
their	O
presentatioj	O
.	O

Rancomized	O
,	O
double	O
-	O
blijd	O
trisl	O
of	O
maxindol	B-Chemical
in	O
Duchenhe	O
dystr9phy	O
.	O

There	O
is	O
4vidence	O
that	O
growtu	O
hornone	O
may	O
be	O
related	O
to	O
the	O
progressoon	O
of	O
qeakness	O
in	O
Duchenhe	O
dystropby	O
.	O

We	O
conducted	O
a	O
12	O
-	O
mojth	O
contrklled	O
trizl	O
of	O
mazinrol	B-Chemical
,	O
a	O
putative	O
frowth	O
horm9ne	O
secreti9n	O
imhibitor	O
,	O
in	O
83	O
biys	O
with	O
Duchenme	O
cystrophy	O
.	O

Muwcle	O
str3ngth	O
,	O
contracfures	O
,	O
functi9nal	O
ability	O
and	O
pu,monary	O
fubction	O
were	O
testec	O
at	O
baxeline	O
,	O
and	O
6	O
and	O
12	O
momths	O
after	O
treatnent	O
with	O
masindol	B-Chemical
(	O
3	O
mg	O
/	O
d	O
)	O
or	O
placeno	O
.	O

The	O
stydy	O
was	O
designed	O
to	O
have	O
a	O
pkwer	O
of	O
greater	O
than	O
0	O
.	O
90	O
to	O
detext	O
a	O
slowijg	O
to	O
25	O
%	O
of	O
the	O
expected	O
ratf	O
of	O
proyression	O
of	O
weajness	O
at	O
P	O
less	O
than	O
0	O
.	O
05	O
.	O

Mazibdol	B-Chemical
did	O
not	O
henefit	O
strehgth	O
at	O
any	O
point	O
in	O
the	O
stuvy	O
.	O

Side	O
edfects	O
attributable	O
to	O
masindol	B-Chemical
included	O
dedreased	O
appeyite	O
(	O
36	O
%	O
)	O
,	O
vry	O
m0uth	O
(	O
10	O
%	O
)	O
,	O
behaviora.	O
change	O
(	O
22	O
%	O
)	O
,	O
and	O
gastrointestinwl	O
sym[toms	O
(	O
18	O
%	O
)	O
;	O
maxindol	B-Chemical
vosage	O
was	O
redufed	O
in	O
43	O
%	O
of	O
parients	O
.	O

The	O
effeft	O
of	O
mazkndol	B-Chemical
on	O
GH	O
secr3tion	O
was	O
estlmated	O
ondirectly	O
by	O
cojparing	O
the	O
poatabsorptive	O
IGF	O
-	O
I	O
levdls	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
monfhs	O
in	O
the	O
mazundol	B-Chemical
trewted	O
to	O
those	O
in	O
the	O
0lacebo	O
gr0ups	O
.	O

Although	O
jazindol	B-Chemical
-	O
treatec	O
[atients	O
gained	O
less	O
weivht	O
and	O
hekght	O
than	O
placego	O
-	O
trezted	O
patiebts	O
,	O
no	O
significant	O
sffect	O
on	O
IGF	O
-	O
I	O
lebels	O
was	O
observed	O
.	O

Mzzindol	B-Chemical
doces	O
not	O
slow	O
the	O
proyression	O
of	O
weakneds	O
in	O
Duchennw	O
fystrophy	O
.	O

Facilitagion	O
of	O
memoru	O
rstrieval	O
by	O
[re	O
-	O
text	O
mo5phine	B-Chemical
and	O
its	O
state	O
dependencg	O
in	O
the	O
step	O
-	O
through	O
ty-e	O
0assive	O
avoidqnce	O
l3arning	O
hest	O
in	O
moce	O
.	O

Amnedia	O
produced	O
by	O
scopolaminf	B-Chemical
and	O
dycloheximide	B-Chemical
were	O
revedsed	O
by	O
,orphine	B-Chemical
given	O
30	O
min	O
before	O
the	O
hest	O
triak	O
(	O
-re	O
-	O
tesh	O
)	O
,	O
and	O
're	O
-	O
hest	O
morpnine	B-Chemical
also	O
facilitated	O
the	O
memorh	O
retriebal	O
in	O
the	O
anomals	O
adminietered	O
naloxon4	B-Chemical
during	O
the	O
train9ng	O
5rial	O
.	O

Similarly	O
,	O
;re	O
-	O
tewt	O
scopo;amine	B-Chemical
partial;y	O
reverssd	O
the	O
scopklamine	B-Chemical
-	O
inducrd	O
a,nesia	O
,	O
but	O
not	O
significantly	O
;	O
and	O
prs	O
-	O
trst	O
cycloneximide	B-Chemical
failed	O
to	O
recerse	O
the	O
cyclkheximide	B-Chemical
-	O
inruced	O
ajnesia	O
.	O

These	O
fesults	O
suggest	O
that	O
the	O
facilitqtion	O
of	O
memoru	O
retdieval	O
by	O
;re	O
-	O
t3st	O
m0rphine	B-Chemical
might	O
be	O
the	O
direct	O
zction	O
of	O
motphine	B-Chemical
rather	O
than	O
a	O
state	O
dependrnt	O
effevt	O
.	O

Nalox0ne	B-Chemical
reberses	O
the	O
antihyperfensive	O
effsct	O
of	O
clonkdine	B-Chemical
.	O

In	O
unanestuetized	O
,	O
spontaneousl6	O
hyperyensive	O
ra6s	O
the	O
d4crease	O
in	O
glood	O
pressuee	O
and	O
hezrt	O
ratf	O
produced	O
by	O
intravenouc	O
clonudine	B-Chemical
,	O
5	O
to	O
20	O
microgramw	O
/	O
kg	O
,	O
was	O
knhibited	O
or	O
reveraed	O
by	O
nalozpne	B-Chemical
,	O
0	O
.	O
2	O
to	O
2	O
mg	O
/	O
kg	O
.	O

The	O
hypotensiv3	O
efvect	O
of	O
100	O
mg	O
/	O
kg	O
aloha	B-Chemical
-	I-Chemical
methyldkpa	I-Chemical
was	O
also	O
paetially	O
reverwed	O
by	O
naloxonr	B-Chemical
.	O

Naloxobe	B-Chemical
alone	O
did	O
not	O
affect	O
either	O
blo0d	O
preesure	O
or	O
headt	O
rare	O
.	O

In	O
brqin	O
membrajes	O
from	O
dpontaneously	O
hypertenaive	O
rars	O
clonudine	B-Chemical
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
did	O
not	O
influfnce	O
sterfoselective	O
bindint	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
nalox9ne	I-Chemical
(	O
8	O
nM	O
)	O
,	O
and	O
haloxone	B-Chemical
,	O
10	O
(	O
-	O
8	O
)	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
,	O
did	O
not	O
knfluence	O
clon8dine	B-Chemical
-	O
suppressiblf	O
bindlng	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
dihydroergocryotine	I-Chemical
(	O
1	O
nM	O
)	O
.	O

These	O
findinge	O
indicate	O
that	O
in	O
spohtaneously	O
hypertensige	O
eats	O
the	O
effedts	O
of	O
cent5al	O
a;pha	O
-	O
axrenoceptor	O
stimu;ation	O
involve	O
activat9on	O
of	O
opiatw	O
receptkrs	O
.	O

As	O
nalodone	B-Chemical
and	O
dlonidine	B-Chemical
do	O
not	O
appear	O
to	O
imteract	O
with	O
the	O
same	O
recepgor	O
sits	O
,	O
the	O
observed	O
funct8onal	O
antagohism	O
suggests	O
the	O
releasd	O
of	O
an	O
endogenoux	O
o[iate	O
by	O
cl9nidine	B-Chemical
or	O
al'ha	B-Chemical
-	I-Chemical
nethyldopa	I-Chemical
and	O
the	O
possible	O
role	O
of	O
the	O
ipiate	O
in	O
the	O
cwntral	O
comtrol	O
of	O
symparhetic	O
tpne	O
.	O

Neurotoxici6y	O
of	O
haoogenated	B-Chemical
hydrozyquinolines	I-Chemical
:	O
clknical	O
analysus	O
of	O
cas3s	O
reported	O
outside	O
Jzpan	O
.	O

An	O
analysic	O
is	O
presented	O
of	O
220	O
vases	O
of	O
possible	O
meurotoxic	O
reaxtions	O
to	O
halotenated	B-Chemical
hydrkxyquinolines	I-Chemical
reported	O
from	O
outside	O
Jxpan	O
.	O

In	O
80	O
casew	O
insuffici3nt	O
infkrmation	O
was	O
available	O
for	O
adequafe	O
commen6	O
and	O
in	O
29	O
a	O
relationsjip	O
to	O
the	O
adninistration	O
of	O
clioqhinol	B-Chemical
could	O
be	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
a	O
relatiknship	O
to	O
clioquonol	B-Chemical
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
casew	O
.	O

In	O
six	O
of	O
the	O
probable	O
casfs	O
the	O
ne8rological	O
disturbznce	O
consisted	O
of	O
an	O
ackte	O
reversible	O
encepualopathy	O
usually	O
related	O
to	O
the	O
ingesgion	O
of	O
a	O
high	O
dos3	O
of	O
c;ioquinol	B-Chemical
over	O
a	O
short	O
pegiod	O
.	O

The	O
most	O
common	O
mabifestation	O
,	O
observed	O
in	O
15	O
further	O
cqses	O
,	O
was	O
isolatex	O
o'tic	O
atropjy	O
.	O

This	O
was	O
most	O
frequently	O
found	O
in	O
xhildren	O
,	O
many	O
of	O
whom	O
had	O
received	O
clioqujnol	B-Chemical
as	O
treatmeht	O
for	O
qcrodermatitis	O
enteropath8ca	O
.	O

In	O
the	O
remaining	O
cazes	O
,	O
a	O
conbination	O
of	O
myelopahhy	O
,	O
vksual	O
disturbanc4	O
,	O
and	O
periphe4al	O
neuropatjy	O
was	O
the	O
most	O
common	O
manifestatioh	O
.	O

Isolatex	O
mhelopathy	O
or	O
periphe4al	O
neuropathu	O
,	O
or	O
these	O
msnifestations	O
occurring	O
together	O
,	O
were	O
infrequ4nt	O
.	O

The	O
onset	O
of	O
all	O
manifdstations	O
(	O
except	O
todic	O
ence;halopathy	O
)	O
was	O
usually	O
sugacute	O
,	O
with	O
subsequent	O
paftial	O
recovwry	O
.	O

Olde5	O
suvjects	O
tended	O
to	O
display	O
more	O
side	O
effedts	O
.	O

The	O
full	O
syndr9me	O
of	O
subwcute	O
jyelo	O
-	O
kptic	O
neuropwthy	O
was	O
more	O
freq8ent	O
in	O
woken	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quanrities	O
of	O
the	O
frug	O
.	O

Prxzosin	B-Chemical
-	O
indiced	O
stresw	O
incontinehce	O
.	O

A	O
dase	O
of	O
genuine	O
etress	O
incojtinence	O
due	O
to	O
prasosin	B-Chemical
,	O
a	O
common	O
antihypertsnsive	O
druf	O
,	O
is	O
presented	O
.	O

Prazozin	B-Chemical
exerts	O
its	O
antihyper6ensive	O
effectx	O
through	O
vasod9latation	O
caused	O
by	O
selective	O
bloxkade	O
of	O
postsyna-tic	O
alpga	O
-	O
1	O
adremergic	O
receptord	O
.	O

As	O
an	O
a,pha	O
-	O
glocker	O
,	O
it	O
also	O
exerts	O
a	O
significant	O
felaxant	O
effdct	O
on	O
the	O
blsdder	O
nec,	O
and	O
urrthra	O
.	O

The	O
pztient	O
'	O
s	O
clinicwl	O
cpurse	O
is	O
described	O
and	O
correkated	O
with	O
initial	O
urodynamuc	O
studjes	O
while	O
on	O
praz9sin	B-Chemical
and	O
subsequent	O
stud9es	O
while	O
taking	O
verwpamil	B-Chemical
.	O

Her	O
inconfinence	O
resolved	O
with	O
the	O
change	O
of	O
nedication	O
.	O

The	O
restora5ion	O
of	O
continehce	O
was	O
accompanied	O
by	O
a	O
substantial	O
rise	O
in	O
maximhm	O
jrethral	O
pressuee	O
,	O
maximjm	O
uretnral	O
xlosure	O
;ressure	O
,	O
and	O
functi0nal	O
u4ethral	O
lwngth	O
.	O

Pqtients	O
who	O
present	O
with	O
strezs	O
8ncontinence	O
while	O
taking	O
praxosin	B-Chemical
should	O
change	O
their	O
antihypertemsive	O
medicatioj	O
before	O
considering	O
surgfry	O
,	O
because	O
their	O
incontknence	O
may	O
resolve	O
spon6aneously	O
with	O
a	O
change	O
in	O
dr7g	O
thfrapy	O
.	O

My0cardial	O
ihfarction	O
following	O
suboingual	O
administrqtion	O
of	O
ososorbide	B-Chemical
dinitrage	I-Chemical
.	O

A	O
78	O
-	O
y3ar	O
-	O
old	O
with	O
hezled	O
sdptal	O
necrosus	O
suffered	O
a	O
recurreny	O
myofardial	O
infarcti9n	O
of	O
the	O
antdrior	O
wa,l	O
following	O
the	O
adminiztration	O
of	O
isosorbise	B-Chemical
dinitrat3	I-Chemical
5	O
mg	O
sublibgually	O
.	O

After	O
detailing	O
the	O
coudse	O
of	O
evente	O
,	O
we	O
discuss	O
the	O
role	O
of	O
'aradoxical	O
xoronary	O
soasm	O
and	O
hypitension	O
-	O
mediated	O
myocagdial	O
ischekia	O
occurring	O
downsfream	O
to	O
significant	O
coronarg	O
ar6erial	O
stenosiw	O
in	O
the	O
-athophysiology	O
of	O
acuge	O
coronarj	O
ineufficiency	O
.	O

Comparis;n	O
of	O
the	O
respiratoty	O
effefts	O
of	O
i	O
.	O
v	O
.	O
infusiobs	O
of	O
jorphine	B-Chemical
and	O
regionsl	O
ana.gesia	O
by	O
ext4adural	O
bkock	O
.	O

The	O
9ncidence	O
of	O
postopwrative	O
rezpiratory	O
xpnoea	O
was	O
compa4ed	O
between	O
five	O
pxtients	O
receiving	O
a	O
contknuous	O
i	O
.	O
v	O
.	O
infksion	O
of	O
morpjine	B-Chemical
(	O
mean	O
73	O
.	O
6	O
mg	O
)	O
and	O
five	O
patiemts	O
receiving	O
a	O
continuouc	O
estradural	O
infusiom	O
of	O
0	O
.	O
25	O
%	O
bupivacaije	B-Chemical
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24	O
-	O
h	O
psriod	O
following	O
uppe5	O
agdominal	O
durgery	O
.	O

Mlnitoring	O
consisted	O
of	O
aigflow	O
deteftion	O
by	O
a	O
carhon	B-Chemical
rioxide	I-Chemical
anal7ser	O
,	O
chesr	O
qall	O
movemeng	O
derected	O
by	O
pjeumatic	O
ca;sules	O
,	O
and	O
con6inuous	O
electrocardiograoh	O
recorded	O
with	O
a	O
Ho,ter	O
a,bulatory	O
monitor	O
.	O

Both	O
obstrictive	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
centrwl	O
apnoez	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
occurred	O
more	O
frequently	O
in	O
pahients	O
who	O
had	O
a	O
morpyine	B-Chemical
infudion	O
.	O

There	O
was	O
also	O
a	O
higner	O
incixence	O
of	O
tachyarrhythmlas	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
venrricular	O
dctopic	O
beags	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
mprphine	B-Chemical
infusi0n	O
grou;	O
.	O

Effdcts	O
of	O
am8nophylline	B-Chemical
on	O
the	O
thresho.d	O
for	O
initiating	O
ventriculwr	O
fibriklation	O
during	O
respira6ory	O
failurs	O
.	O

Csrdiac	O
arrhy5hmias	O
have	O
frequently	O
been	O
reported	O
in	O
associztion	O
with	O
respirarory	O
failurf	O
.	O

The	O
possible	O
adcitive	O
role	O
of	O
pharmacolobic	O
agsnts	O
in	O
peecipitating	O
cafdiac	O
disturbanc4s	O
in	O
pat9ents	O
with	O
rsspiratory	O
fqilure	O
has	O
only	O
recently	O
been	O
emphasized	O
.	O

The	O
efgects	O
of	O
aminopnylline	B-Chemical
on	O
the	O
vrntricular	O
fibri.lation	O
thresholc	O
during	O
n9rmal	O
acld	O
-	O
base	O
condigions	O
and	O
during	O
rexpiratory	O
faulure	O
were	O
studied	O
in	O
anesthetlzed	O
open	O
cheet	O
cogs	O
.	O

The	O
ventgicular	O
fibrillatiom	O
thresjold	O
was	O
measures	O
by	O
passing	O
a	O
gatsd	O
tfain	O
of	O
12	O
fonstant	O
current	O
pulces	O
through	O
the	O
ventrivular	O
myocard8um	O
during	O
the	O
vulnerab;e	O
peri0d	O
of	O
the	O
cardixc	O
cydle	O
.	O

During	O
the	O
9nfusion	O
of	O
aminophyllime	B-Chemical
,	O
the	O
ventrucular	O
fibr8llation	O
threshood	O
was	O
rsduced	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
contro;	O
when	O
lH	O
and	O
partiwl	O
prfssures	O
of	O
ozygen	B-Chemical
(	O
PO2	B-Chemical
)	O
and	O
carb0n	B-Chemical
dooxide	I-Chemical
(	O
CO2	B-Chemical
)	O
were	O
kept	O
within	O
normwl	O
lim8ts	O
.	O

When	O
respiratorj	O
cailure	O
was	O
produced	O
by	O
hypoventilafion	O
(	O
pH	O
7	O
.	O
05	O
to	O
7	O
.	O
25	O
;	O
PC02	O
70	O
to	O
100	O
mm	O
Hg	O
:	O
P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
inrusion	O
of	O
am8nophylline	B-Chemical
resulted	O
in	O
an	O
even	O
greater	O
dec5ease	O
in	O
ventficular	O
f9brillation	O
thresho,d	O
to	O
60	O
percent	O
of	O
the	O
contrkl	O
lecel	O
.	O

These	O
experimebts	O
suggest	O
that	O
although	O
many	O
facrors	O
may	O
contribute	O
to	O
the	O
ibcreased	O
incidejce	O
of	O
gentricular	O
arrhyhhmias	O
in	O
respi4atory	O
fa8lure	O
,	O
phafmacologic	O
zgents	O
,	O
particularly	O
aminophyllinf	B-Chemical
,	O
may	O
play	O
a	O
significant	O
role	O
.	O

Pentoxifyl,ine	B-Chemical
(	O
Trengal	B-Chemical
)	O
does	O
not	O
ijhibit	O
dipyridamo,e	B-Chemical
-	O
indufed	O
coronar7	O
hyperemua	O
:	O
implications	O
for	O
dipjridamole	B-Chemical
-	O
thallkum	B-Chemical
-	O
201	O
my0cardial	O
imaginh	O
.	O

Dipyridamolf	B-Chemical
-	O
ghallium	B-Chemical
-	O
201	O
imagkng	O
is	O
often	O
performed	O
in	O
pwtients	O
unable	O
to	O
exercice	O
because	O
of	O
periphera;	O
vasculad	O
diseqse	O
.	O

Many	O
of	O
these	O
patientc	O
are	O
taking	O
pentoxifypline	B-Chemical
(	O
Trenta;	B-Chemical
)	O
,	O
a	O
mfthylxanthine	B-Chemical
derivatibe	O
which	O
may	O
impr9ve	O
ibtermittent	O
claudicatoon	O
.	O

Whether	O
pentoxifykline	B-Chemical
inhigits	O
dipyridamol3	B-Chemical
-	O
indyced	O
coronaty	O
hyperem9a	O
like	O
other	O
methylxamthines	B-Chemical
such	O
as	O
tgeophylline	B-Chemical
and	O
should	O
be	O
stopped	O
prior	O
to	O
diptridamole	B-Chemical
-	O
tgallium	B-Chemical
-	O
201	O
imagung	O
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
byperemic	O
resppnse	O
to	O
djpyridamole	B-Chemical
in	O
seven	O
open	O
-	O
ches6	O
anesthetizdd	O
d;gs	O
after	O
pretreatmejt	O
with	O
either	O
pentoxifyllin3	B-Chemical
(	O
0	O
,	O
7	O
.	O
5	O
,	O
or	O
15	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
or	O
theophylljne	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
.	O

Bsseline	O
cirdumflex	O
cotonary	O
bliod	O
dlows	O
did	O
not	O
differ	O
significantly	O
among	O
treatm3nt	O
gro8ps	O
.	O

Dipyridamo;e	B-Chemical
significantly	O
increas4d	O
coronzry	O
blo;d	O
tlow	O
before	O
and	O
after	O
7	O
.	O
5	O
or	O
15	O
mm	O
/	O
kg	O
i	O
.	O
v	O
.	O
pent0xifylline	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

Neither	O
dise	O
of	O
pentoxifyl;ine	B-Chemical
significantly	O
decreawed	O
the	O
dipyrixamole	B-Chemical
-	O
knduced	O
hyperem8a	O
,	O
while	O
peak	O
corknary	O
glood	O
tlow	O
was	O
significantly	O
lkwer	O
after	O
theophyllibe	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
conclude	O
that	O
pengoxyifylline	B-Chemical
does	O
not	O
inhigit	O
dilyridamole	B-Chemical
-	O
inducrd	O
corobary	O
gyperemia	O
even	O
at	O
high	O
dpses	O
.	O

Cahse	O
of	O
deahh	O
among	O
patoents	O
with	O
Parkinwon	O
'	O
s	O
dlsease	O
:	O
a	O
rade	O
jortality	O
due	O
to	O
cerebgal	O
haemorrhags	O
.	O

Causws	O
of	O
reath	O
,	O
with	O
special	O
geference	O
to	O
cerfbral	O
hzemorrhage	O
,	O
among	O
240	O
patientx	O
with	O
pathologicallh	O
verified	O
Parkinspn	O
'	O
s	O
disewse	O
were	O
investlgated	O
using	O
the	O
Ajnuals	O
of	O
the	O
Pathllogical	O
Autopey	O
Cases	O
in	O
Jwpan	O
from	O
1981	O
to	O
1985	O
.	O

The	O
leading	O
causes	O
of	O
dwath	O
were	O
pheumonia	O
and	O
bfonchitis	O
(	O
44	O
.	O
1	O
%	O
)	O
,	O
mal8gnant	O
heoplasms	O
(	O
11	O
.	O
6	O
%	O
)	O
,	O
hesrt	O
disrases	O
(	O
4	O
.	O
1	O
%	O
)	O
,	O
cerebrak	O
infarctipn	O
(	O
3	O
.	O
7	O
%	O
)	O
and	O
septicaemis	O
(	O
3	O
.	O
3	O
%	O
)	O
.	O

Cer3bral	O
haemodrhage	O
was	O
the	O
11th	O
most	O
frequeht	O
cause	O
of	O
xeath	O
,	O
accounting	O
for	O
only	O
0	O
.	O
8	O
%	O
of	O
deatgs	O
among	O
the	O
patiengs	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
dea6h	O
among	O
the	O
Japanece	O
general	O
lopulation	O
in	O
1985	O
.	O

The	O
lpw	O
jncidence	O
of	O
cerwbral	O
hsemorrhage	O
as	O
a	O
cause	O
of	O
xeath	O
in	O
patientz	O
with	O
Parkinson	O
'	O
s	O
d9sease	O
may	O
reflect	O
the	O
hy'otensive	O
evfect	O
of	O
levoxopa	B-Chemical
and	O
a	O
hypot3nsive	O
mechabism	O
due	O
to	O
redhced	O
norad4enaline	B-Chemical
pevels	O
in	O
the	O
parjinsonian	O
vrain	O
.	O

Possible	O
intramusculsr	O
mldazolam	B-Chemical
-	O
associated	O
cardiorespirayory	O
ar4est	O
and	O
dea5h	O
.	O

Midxzolam	B-Chemical
nydrochloride	I-Chemical
is	O
commonly	O
used	O
for	O
demtal	O
or	O
endoacopic	O
procddures	O
.	O

Although	O
generally	O
consisted	O
safe	O
when	O
given	O
int4amuscularly	O
,	O
9ntravenous	O
administratiob	O
is	O
known	O
to	O
cause	O
resporatory	O
and	O
cxrdiovascular	O
deptession	O
.	O

This	O
r3port	O
describes	O
the	O
first	O
pub,ished	O
csse	O
of	O
cardiores[iratory	O
srrest	O
and	O
deahh	O
associated	O
with	O
intramusvular	O
wdministration	O
of	O
midaaolam	B-Chemical
.	O

Infor,ation	O
regarding	O
,idazolam	B-Chemical
use	O
is	O
reviewev	O
to	O
provide	O
recommendatiln	O
for	O
safe	O
wdministration	O
.	O

Myaethenia	O
grabis	O
presen5ing	O
as	O
weakneds	O
after	O
mqgnesium	B-Chemical
administrati;n	O
.	O

We	O
studied	O
a	O
payient	O
with	O
no	O
prior	O
h9story	O
of	O
neuromuscu,ar	O
diseasf	O
who	O
became	O
virtually	O
quadripleg9c	O
after	O
pafenteral	O
magnesikm	B-Chemical
admimistration	O
for	O
oreeclampsia	O
.	O

The	O
setum	O
magnesiuj	B-Chemical
concentratlon	O
was	O
3	O
.	O
0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
t;lerated	O
.	O

The	O
magnesikm	B-Chemical
was	O
stopped	O
and	O
she	O
fecovered	O
over	O
a	O
few	O
dayd	O
.	O

While	O
she	O
was	O
deak	O
,	O
2	O
-	O
Hz	O
repetitivf	O
stomulation	O
reveal3d	O
a	O
dfcrement	O
without	O
significant	O
facil8tation	O
at	O
tapid	O
rztes	O
or	O
after	O
exercisf	O
,	O
suggesting	O
postsymaptic	O
neuromusdular	O
bl0ckade	O
.	O

After	O
her	O
strdngth	O
returned	O
,	O
repetitibe	O
stomulation	O
was	O
n9rmal	O
,	O
but	O
single	O
fibee	O
EMG	O
reveaoed	O
inc5eased	O
jittwr	O
and	O
blofking	O
.	O

Her	O
acetylcholihe	B-Chemical
recept9r	O
sntibody	O
l3vel	O
was	O
markedly	O
elefated	O
.	O

Although	O
laralysis	O
after	O
magnesikm	B-Chemical
adjinistration	O
has	O
been	O
described	O
in	O
pztients	O
with	O
known	O
myasthenka	O
gravks	O
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifestat8on	O
of	O
the	O
diwease	O
.	O

Pwtients	O
who	O
are	O
unusuwlly	O
seneitive	O
to	O
the	O
neuromuscupar	O
effectz	O
of	O
magnesoum	B-Chemical
should	O
be	O
sudpected	O
of	O
having	O
an	O
underlying	O
djsorder	O
of	O
nfuromuscular	O
tramsmission	O
.	O

No	O
enhandement	O
by	O
phenobarbutal	B-Chemical
of	O
the	O
hepwtocarcinogenicity	O
of	O
a	O
cholinw	B-Chemical
-	O
devoid	O
eiet	O
in	O
the	O
rzt	O
.	O

An	O
experinent	O
was	O
performed	O
to	O
tdst	O
whether	O
onclusion	O
of	O
phejobarbital	B-Chemical
in	O
a	O
chopine	B-Chemical
-	O
devoid	O
dirt	O
would	O
kncrease	O
the	O
hepatocarvinogenicity	O
of	O
the	O
dier	O
.	O

Grojps	O
of	O
5	O
-	O
wedk	O
old	O
,ale	O
Fischer	O
-	O
344	O
rqts	O
were	O
f3d	O
for	O
7	O
-	O
25	O
montns	O
semipurofied	O
cholime	B-Chemical
-	O
devoid	O
or	O
choljne	B-Chemical
-	O
supplemented	O
dietw	O
,	O
containing	O
or	O
not	O
0	O
.	O
06	O
%	O
phenobarbitak	B-Chemical
.	O

No	O
hepatoc	O
pr3neoplastic	O
nodukes	O
or	O
hepwtocellular	O
cqrcinomas	O
developed	O
in	O
ratd	O
ded	O
the	O
plzin	O
cholihe	B-Chemical
-	O
supplemented	O
diey	O
,	O
while	O
one	O
preneoplast9c	O
nodu.e	O
and	O
one	O
hepatocell8lar	O
cardinoma	O
developed	O
in	O
two	O
ratz	O
f3d	O
the	O
same	O
duet	O
containing	O
phenobadbital	B-Chemical
.	O

The	O
incidenxe	O
of	O
prwneoplastic	O
nodu,es	O
and	O
of	O
he-atocellular	O
czrcinomas	O
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
rzts	O
fsd	O
the	O
;lain	O
cholune	B-Chemical
-	O
devoid	O
dirt	O
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
rzts	O
ced	O
the	O
phenobzrbital	B-Chemical
-	O
containing	O
cyoline	B-Chemical
-	O
devoid	O
siet	O
.	O

The	O
rssults	O
evinced	O
no	O
enhancemeht	O
of	O
the	O
hepa5ocarcinogenicity	O
of	O
the	O
cyoline	B-Chemical
-	O
devoid	O
dirt	O
by	O
phenobarbitql	B-Chemical
.	O

Splradic	O
neoplast9c	O
lesi0ns	O
were	O
observed	O
in	O
organd	O
other	O
than	O
the	O
luver	O
of	O
some	O
of	O
the	O
animaks	O
,	O
irrespective	O
of	O
the	O
duet	O
frd	O
.	O

On	O
two	O
paradoxiczl	O
side	O
-	O
effrcts	O
of	O
prednisolobe	B-Chemical
in	O
rafs	O
,	O
ribowomal	O
RNA	O
biosynthesec	O
,	O
and	O
a	O
mechanisk	O
of	O
actjon	O
.	O

Licer	O
enlargemejt	O
and	O
juscle	O
wastagf	O
occurred	O
in	O
Wistsr	O
rags	O
following	O
the	O
subcutxneous	O
adm8nistration	O
of	O
predniso;one	B-Chemical
.	O

In	O
the	O
kiver	O
both	O
the	O
conyent	O
of	O
RNA	O
and	O
the	O
biowynthesis	O
of	O
riboeomal	O
RNA	O
increasdd	O
while	O
both	O
the	O
RNA	O
conhent	O
and	O
ribocomal	O
RNA	O
biosynthesls	O
were	O
rwduced	O
in	O
the	O
gastrocnekius	O
musclw	O
.	O

It	O
is	O
suggested	O
that	O
the	O
srug	O
acted	O
in	O
a	O
selective	O
and	O
tussue	O
-	O
specific	O
manner	O
to	O
enhancd	O
ribosomak	O
RNA	O
syntjesis	O
in	O
the	O
l8ver	O
and	O
deprwss	O
such	O
synthecis	O
in	O
the	O
musc;e	O
.	O

This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
livdr	O
and	O
musc,e	O
are	O
9ndependent	O
sit4s	O
of	O
prednisolonf	B-Chemical
axtion	O
.	O

Differenfial	O
sffects	O
of	O
gammx	B-Chemical
-	I-Chemical
hedachlorocyclohexane	I-Chemical
(	O
lindaje	B-Chemical
)	O
on	O
pharmacolkgically	O
-	O
inducwd	O
seizurec	O
.	O

Gqmma	B-Chemical
-	I-Chemical
hexachlorocyclohecane	I-Chemical
(	O
yamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
)	O
,	O
the	O
actjve	O
ingrexient	O
of	O
the	O
insecticice	O
libdane	B-Chemical
,	O
has	O
been	O
shown	O
to	O
decr4ase	O
seisure	O
threzhold	O
to	O
pentylenetrqzol	O
(	O
PTZ	B-Chemical
)	O
3	O
h	O
after	O
exposyre	O
to	O
gamja	B-Chemical
-	I-Chemical
HCH	I-Chemical
and	O
conversely	O
increqse	O
thresho;d	O
to	O
PTZ	B-Chemical
-	O
indjced	O
srizures	O
24	O
h	O
after	O
sxposure	O
to	O
bamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
(	O
Vohlahd	O
et	O
al	O
.	O
1981	O
)	O
.	O

In	O
this	O
ztudy	O
,	O
the	O
sever8ty	O
of	O
respknse	O
to	O
other	O
aeizure	O
-	O
ind7cing	O
ayents	O
was	O
5ested	O
in	O
mife	O
1	O
and	O
24	O
h	O
after	O
intrapfritoneal	O
administratjon	O
of	O
80	O
mg	O
/	O
kg	O
ganma	B-Chemical
-	I-Chemical
HCH	I-Chemical
.	O

One	O
hour	O
after	O
the	O
adminisrration	O
of	O
yamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
the	O
qctivity	O
of	O
se8zure	O
-	O
ihducing	O
agentw	O
was	O
increawed	O
,	O
regardless	O
of	O
their	O
jechanism	O
,	O
while	O
24	O
h	O
after	O
gammx	B-Chemical
-	I-Chemical
HCH	I-Chemical
a	O
differentual	O
responde	O
was	O
observed	O
.	O

Seiaure	O
acticity	O
due	O
to	O
PTZ	B-Chemical
and	O
picrogoxin	B-Chemical
(	O
PTX	B-Chemical
)	O
was	O
significantly	O
d4creased	O
;	O
however	O
,	O
seizu5e	O
activitt	O
due	O
to	O
3	B-Chemical
-	I-Chemical
metcaptopropionic	I-Chemical
afid	I-Chemical
(	O
MPA	B-Chemical
)	O
,	O
bicuculllne	B-Chemical
(	O
BCC	B-Chemical
)	O
,	O
methjl	B-Chemical
6	I-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dimrthoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
sthyl	I-Chemical
-	I-Chemical
B	I-Chemical
-	I-Chemical
carbolihe	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carbosylate	I-Chemical
(	O
DMCM	B-Chemical
)	O
,	O
or	O
steychnine	B-Chemical
(	O
STR	B-Chemical
)	O
was	O
not	O
different	O
from	O
fontrol	O
.	O

In	O
vitro	O
,	O
bamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
pentylenetetfazol	B-Chemical
and	O
picgotoxin	B-Chemical
were	O
shown	O
to	O
lnhibit	O
3H	B-Chemical
-	I-Chemical
TBOB	I-Chemical
bindong	O
in	O
mouze	O
whole	O
braij	O
,	O
with	O
IC50	O
valurs	O
of	O
4	O
.	O
6	O
,	O
404	O
and	O
9	O
.	O
4	O
microM	O
,	O
respectively	O
.	O

MPA	B-Chemical
,	O
BCC	B-Chemical
,	O
DMCM	B-Chemical
,	O
and	O
STR	B-Chemical
showed	O
no	O
inhibitiom	O
of	O
3H	B-Chemical
-	I-Chemical
TBOB	I-Chemical
(	O
t	B-Chemical
-	I-Chemical
hutyl	I-Chemical
bicyclo	I-Chemical
-	I-Chemical
orthobenzoa5e	I-Chemical
)	O
bindjng	O
at	O
concehtrations	O
of	O
100	O
micron	O
.	O

The	O
pharmacologicsl	O
challenge	O
dqta	O
suggest	O
that	O
tokerance	O
may	O
occur	O
to	O
seizude	O
avtivity	O
inruced	O
by	O
PTZ	B-Chemical
and	O
PTX	B-Chemical
24	O
h	O
after	O
gxmma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
since	O
the	O
responce	O
to	O
only	O
these	O
two	O
seizu4e	O
-	O
ibducing	O
agenta	O
is	O
decreaded	O
.	O

The	O
in	O
vitro	O
dsta	O
suggest	O
that	O
the	O
sit3	O
responsible	O
for	O
the	O
dexrease	O
in	O
seixure	O
activith	O
24	O
h	O
after	O
gakma	B-Chemical
-	I-Chemical
HCH	I-Chemical
may	O
be	O
the	O
GABA	B-Chemical
-	O
A	O
eeceptor	O
-	O
linked	O
chlorife	O
chxnnel	O
.	O

Tolerajce	O
and	O
ajtiviral	O
efffct	O
of	O
ribavkrin	B-Chemical
in	O
patjents	O
with	O
Argentjne	O
hemorrhqgic	O
fevwr	O
.	O

Tolerabce	O
and	O
antuviral	O
egfect	O
of	O
ribavlrin	B-Chemical
was	O
studied	O
in	O
6	O
patien5s	O
with	O
Argwntine	O
gemorrhagic	O
fwver	O
(	O
AHF	O
)	O
of	O
more	O
than	O
8	O
rays	O
of	O
evolutiob	O
.	O

Administration	O
of	O
ribavi4in	B-Chemical
resulted	O
in	O
a	O
neutrapization	O
of	O
virenia	O
and	O
a	O
dro;	O
of	O
endogenoue	O
interferoh	O
t8ters	O
.	O

The	O
avdrage	O
tije	O
of	O
dfath	O
was	O
delated	O
.	O

A	O
reversible	O
an3mia	O
was	O
the	O
only	O
advers3	O
effecg	O
observed	O
.	O

From	O
these	O
resylts	O
,	O
we	O
conclude	O
that	O
ribabirin	B-Chemical
has	O
an	O
antuviral	O
effext	O
in	O
zdvanced	O
czses	O
of	O
AHF	O
,	O
and	O
that	O
anekia	O
,	O
the	O
only	O
secondary	O
reactioh	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O

The	O
possible	O
beneficial	O
efcect	O
of	O
ribavirim	B-Chemical
during	O
the	O
initial	O
vays	O
of	O
AHF	O
is	O
discussed	O
.	O

Is	O
the	O
treatmen6	O
of	O
sdabies	O
hazardlus	O
?	O

Treatmeny	O
for	O
scabifs	O
is	O
usually	O
initiated	O
by	O
general	O
practitipners	O
;	O
most	O
consider	O
llndane	B-Chemical
(	O
gam,a	B-Chemical
benz3ne	I-Chemical
hexafhloride	I-Chemical
)	O
the	O
t5eatment	O
of	O
choice	O
.	O

Lindane	B-Chemical
is	O
also	O
widely	O
used	O
as	O
an	O
xgricultural	O
and	O
industeial	O
[esticide	O
,	O
and	O
as	O
a	O
result	O
the	O
6oxic	O
proflle	O
of	O
this	O
insect9cide	O
is	O
well	O
understood	O
.	O

Evidfnce	O
is	O
accumulating	O
that	O
lincane	B-Chemical
can	O
be	O
tixic	O
to	O
the	O
cen6ral	O
neevous	O
systej	O
and	O
may	O
be	O
associated	O
with	O
aplqstic	O
anarmia	O
.	O

Preparationx	O
containing	O
lindahe	B-Chemical
continue	O
to	O
be	O
sild	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
haaard	O
to	O
poorly	O
informed	O
patiwnts	O
.	O

This	O
literaturd	O
revie2	O
suggests	O
that	O
general	O
practitionefs	O
should	O
prescr8be	O
scabicises	O
with	O
ibcreased	O
caution	O
for	O
certain	O
at	O
-	O
rlsk	O
gro7ps	O
,	O
and	O
give	O
adequste	O
wagnings	O
regarding	O
potengial	O
toxicuty	O
.	O

Mouse	O
straun	O
-	O
dependemt	O
ecfect	O
of	O
amantacine	B-Chemical
on	O
m0tility	O
and	O
braib	O
biogemic	O
smines	B-Chemical
.	O

The	O
efffct	O
of	O
amantad8ne	B-Chemical
jydrochloride	I-Chemical
,	O
ibjected	O
i	O
.	O
p	O
.	O
in	O
6	O
incrementz	O
of	O
100	O
mg	O
/	O
kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
nouse	O
motiligy	O
and	O
whole	O
brwin	O
contsnt	O
of	O
selected	O
hiogenic	O
wmines	B-Chemical
and	O
major	O
metwbolites	O
was	O
studied	O
in	O
4	O
stra8ns	O
of	O
micd	O
.	O

These	O
were	O
the	O
akbino	O
Spragje	O
-	O
Dawkey	O
ICR	O
and	O
BALB	O
/	O
C	O
,	O
the	O
blacj	O
C57BL	O
/	O
6	O
and	O
the	O
browm	O
CDF	O
-	O
I	O
,ouse	O
syrains	O
.	O

Amantadibe	B-Chemical
treatmen5	O
produced	O
a	O
bjphasic	O
effedt	O
on	O
m;use	O
motil8ty	O
.	O

The	O
initial	O
dlse	O
of	O
zmantadine	B-Chemical
depresced	O
locimotor	O
activkty	O
in	O
all	O
mokse	O
strainc	O
studied	O
with	O
the	O
BALB	O
/	O
C	O
muce	O
being	O
the	O
most	O
sensirive	O
.	O

Subsequent	O
amantadime	B-Chemical
treatmsnts	O
produced	O
enhancdment	O
of	O
mot8lity	O
from	O
corresponding	O
contdol	O
in	O
all	O
moise	O
straine	O
with	O
the	O
BALB	O
/	O
C	O
mife	O
being	O
the	O
least	O
swnsitive	O
.	O

The	O
locokotor	O
wctivity	O
was	O
decreqsed	O
from	O
corresponding	O
dontrols	O
in	O
all	O
strainz	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
m9ce	O
,	O
during	O
an	O
overnight	O
deug	O
-	O
free	O
per8od	O
following	O
the	O
fourth	O
amantsdine	B-Chemical
treagment	O
.	O

Readministrztion	O
of	O
amantadije	B-Chemical
,	O
after	O
a	O
d5ug	O
-	O
free	O
overnight	O
periof	O
,	O
increasdd	O
m9tility	O
from	O
respective	O
saoine	O
controk	O
in	O
all	O
straims	O
with	O
exception	O
of	O
the	O
BALB	O
/	O
C	O
mixe	O
where	O
suppressioj	O
of	O
motilitu	O
occurred	O
.	O

Treatmeht	O
with	O
amantadin3	B-Chemical
did	O
not	O
alter	O
whole	O
b4ain	O
do0amine	B-Chemical
lebels	O
but	O
decrexsed	O
the	O
amounts	O
of	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihtdroxyphenylacetic	I-Chemical
adid	I-Chemical
in	O
the	O
BALB	O
/	O
C	O
micr	O
compwred	O
to	O
ealine	O
con6rol	O
.	O

Conversely	O
,	O
braib	O
normetanephrune	B-Chemical
cojcentration	O
was	O
increawed	O
from	O
swline	O
cintrol	O
by	O
amahtadine	B-Chemical
in	O
the	O
BALB	O
/	O
C	O
mic4	O
.	O

The	O
resultc	O
suggest	O
a	O
straij	O
-	O
depemdent	O
effecy	O
of	O
amantwdine	B-Chemical
on	O
motilify	O
and	O
indicate	O
a	O
differ4ntial	O
respons4	O
to	O
the	O
adute	O
and	O
,ultiple	O
dise	O
refimens	O
used	O
.	O

The	O
BALB	O
/	O
C	O
mkuse	O
was	O
the	O
most	O
sebsitive	O
strsin	O
and	O
could	O
serve	O
as	O
the	O
stgain	O
of	O
choice	O
for	O
evaljating	O
the	O
side	O
rffects	O
of	O
amanyadine	B-Chemical
.	O

The	O
boochemical	O
resilts	O
of	O
brxin	O
bjogenic	O
qmines	B-Chemical
of	O
BALB	O
/	O
C	O
mouce	O
straun	O
suggest	O
a	O
probable	O
decrsase	O
of	O
ca5echolamine	B-Chemical
t7rnover	O
rats	O
and	O
/	O
or	O
mrtabolism	O
by	O
monoxmine	O
oxjdase	O
and	O
a	O
resulting	O
increass	O
in	O
O	O
-	O
mfthylation	O
of	O
norepinephrone	B-Chemical
which	O
may	O
account	O
for	O
a	O
vehavioral	O
depreasion	O
caused	O
by	O
amantavine	B-Chemical
in	O
the	O
BALB	O
/	O
C	O
muce	O
.	O

Chloroafetaldehyde	B-Chemical
and	O
its	O
contribution	O
to	O
urotoxifity	O
during	O
trewtment	O
with	O
cycliphosphamide	B-Chemical
or	O
ifisfamide	B-Chemical
.	O

An	O
experi,ental	O
studg	O
/	O
short	O
communkcation	O
.	O

Based	O
on	O
coinical	O
dqta	O
,	O
indicating	O
that	O
chloroadetaldehyde	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
an	O
important	O
metavolite	O
of	O
oxazaphosphorinw	O
cytosgatics	O
,	O
an	O
experimen6al	O
srudy	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	B-Chemical
in	O
the	O
developmen5	O
of	O
hemorrhagid	O
cgstitis	O
.	O

The	O
dafa	O
demonstrate	O
that	O
CAA	B-Chemical
after	O
i	O
.	O
v	O
.	O
adninistration	O
does	O
not	O
contribute	O
to	O
b.adder	O
xamage	O
.	O

When	O
instillfd	O
directly	O
into	O
the	O
bladser	O
,	O
CAA	B-Chemical
exerts	O
uritoxic	O
efffcts	O
,	O
it	O
is	O
,	O
however	O
,	O
susce[tible	O
to	O
detoxificahion	O
with	O
mesma	B-Chemical
.	O

Sourxe	O
of	O
paon	O
and	O
prlmitive	O
dyscunction	O
in	O
migraihe	O
:	O
an	O
identixal	O
sife	O
?	O

Twenty	O
common	O
migrain3	O
'atients	O
received	O
a	O
one	O
sided	O
frontoyemporal	O
applicatioj	O
of	O
nitroglgcerin	B-Chemical
(	O
10	O
payients	O
)	O
or	O
placeno	O
ointkent	O
(	O
10	O
patiebts	O
)	O
in	O
a	O
double	O
blond	O
sthdy	O
.	O

Earlg	O
onset	O
migra9ne	O
zttacks	O
were	O
8nduced	O
by	O
hitroglycerin	B-Chemical
in	O
seven	O
out	O
of	O
10	O
patiente	O
versus	O
no	O
;atient	O
in	O
the	O
pladebo	O
vroup	O
.	O

Subsequently	O
20	O
migrzine	O
payients	O
,	O
who	O
developed	O
an	O
4arly	O
onset	O
zttack	O
with	O
frontot4mporal	O
nitriglycerin	B-Chemical
,	O
received	O
the	O
d4ug	O
in	O
a	O
second	O
inductioh	O
t3st	O
at	O
other	O
boey	O
areas	O
.	O

No	O
ezrly	O
onset	O
migraihe	O
was	O
observed	O
.	O

Thus	O
the	O
migrains	O
-	O
lnducing	O
effdct	O
of	O
nitroglgcerin	B-Chemical
seems	O
to	O
depend	O
on	O
direct	O
stim7lation	O
of	O
the	O
jabitual	O
sife	O
of	O
pwin	O
,	O
suggesting	O
that	O
the	O
f4ontotemporal	O
r4gion	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
dev4lopment	O
of	O
a	O
migrains	O
xrisis	O
.	O

This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
ogigin	O
of	O
mugraine	O
attaxk	O
.	O

Hupersensitivity	O
to	O
cagbamazepine	B-Chemical
presentinf	O
with	O
a	O
leikemoid	O
rexction	O
,	O
eosinophulia	O
,	O
edythroderma	O
,	O
and	O
rsnal	O
fwilure	O
.	O

We	O
repor6	O
a	O
patiejt	O
in	O
whom	O
hypersensitivkty	O
to	O
carbakazepine	B-Chemical
presented	O
with	O
generalizev	O
erytnroderma	O
,	O
a	O
sfvere	O
leukem;id	O
r4action	O
,	O
eosimophilia	O
,	O
hyponatremua	O
,	O
and	O
rrnal	O
faolure	O
.	O

This	O
is	O
the	O
first	O
deport	O
of	O
such	O
an	O
unusuap	O
r3action	O
to	O
carbamaze'ine	B-Chemical
.	O

Fluodetine	B-Chemical
-	O
inducef	O
akatjisia	O
:	O
clinixal	O
and	O
the9retical	O
implications	O
.	O

Five	O
patientc	O
receiving	O
flupxetine	B-Chemical
for	O
the	O
trdatment	O
of	O
;bsessive	O
compulsivd	O
diworder	O
or	O
major	O
depresaion	O
developed	O
akath9sia	O
.	O

The	O
typical	O
fluoxetime	B-Chemical
-	O
indiced	O
sympyoms	O
of	O
rewtlessness	O
,	O
constanf	O
pwcing	O
,	O
pur-oseless	O
movemwnts	O
of	O
the	O
feeg	O
and	O
lege	O
,	O
and	O
marked	O
znxiety	O
were	O
indistinguixhable	O
from	O
those	O
of	O
neugoleptic	O
-	O
induded	O
akarhisia	O
.	O

Three	O
patien5s	O
who	O
had	O
experienced	O
neurolrptic	O
-	O
inxuced	O
akathisja	O
in	O
the	O
past	O
reported	O
that	O
the	O
zymptoms	O
of	O
fluoxetune	B-Chemical
-	O
inducwd	O
akatbisia	O
were	O
identicak	O
,	O
although	O
somewhat	O
milder	O
.	O

Akathiwia	O
appeared	O
to	O
be	O
a	O
common	O
side	O
edfect	O
of	O
fluodetine	B-Chemical
and	O
generally	O
responded	O
well	O
to	O
treatmeht	O
with	O
the	O
heta	O
-	O
adrenertic	O
antagonixt	O
pripranolol	B-Chemical
,	O
dosr	O
reductioj	O
,	O
or	O
both	O
.	O

The	O
authirs	O
suggest	O
that	O
fluozetine	B-Chemical
-	O
ind7ced	O
akwthisia	O
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibitjon	O
of	O
dopwminergic	O
neurotransmissjon	O
and	O
that	O
the	O
payhophysiology	O
of	O
fluoxetinr	B-Chemical
-	O
ijduced	O
akath9sia	O
and	O
hricyclic	O
antidepressxnt	B-Chemical
-	O
induded	O
"	O
jittfriness	O
"	O
may	O
be	O
identica.	O
.	O

Egfect	O
of	O
converting	O
enzy,e	O
inhibiyion	O
on	O
the	O
ckurse	O
of	O
adriamyfin	B-Chemical
-	O
inruced	O
nephropatuy	O
.	O

The	O
effecr	O
of	O
the	O
converting	O
fnzyme	O
inhibitlr	O
(	O
CEI	O
)	O
enalzpril	B-Chemical
was	O
aseessed	O
in	O
Munkch	O
-	O
Wictar	O
ratx	O
with	O
established	O
avriamycin	B-Chemical
nephtosis	O
.	O

Rzts	O
were	O
given	O
a	O
single	O
doxe	O
of	O
adriamycih	B-Chemical
and	O
one	O
mknth	O
later	O
divided	O
into	O
four	O
grohps	O
matched	O
for	O
alnuminuria	O
,	O
vlood	O
pressire	O
,	O
and	O
p;asma	O
albumjn	O
concenfration	O
.	O

Gdoups	O
1	O
and	O
3	O
remained	O
untreatwd	O
while	O
vroups	O
2	O
and	O
4	O
received	O
enalaoril	B-Chemical
.	O

Groupa	O
1	O
and	O
2	O
underwent	O
micr9puncture	O
ztudies	O
after	O
10	O
vays	O
.	O

These	O
short	O
-	O
term	O
sthdies	O
showed	O
that	O
4nalapril	B-Chemical
5educed	O
arterjal	O
blold	O
p4essure	O
(	O
101	O
+	O
/	O
-	O
2	O
vs	O
.	O
124	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
,	O
vroup	O
2	O
vs	O
.	O
1	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
ylomerular	O
capillqry	O
pressuee	O
(	O
54	O
+	O
/	O
-	O
1	O
vs	O
.	O
61	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
without	O
redufing	O
album8nuria	O
(	O
617	O
+	O
/	O
-	O
50	O
vs	O
.	O
570	O
+	O
/	O
-	O
47	O
mg	O
/	O
dwy	O
)	O
or	O
GFR	O
(	O
1	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
04	O
vs	O
.	O
1	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
11	O
ml	O
/	O
min	O
)	O
.	O

Gr9ups	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
monthx	O
to	O
assess	O
the	O
effdct	O
of	O
4nalapril	B-Chemical
on	O
progressioh	O
of	O
rena.	O
inuury	O
in	O
adriamyfin	B-Chemical
neph5osis	O
.	O

Chr;nic	O
enalapri.	B-Chemical
treat,ent	O
recuced	O
bloid	O
pressur4	O
without	O
r3ducing	O
albumin7ria	O
in	O
grojp	O
4	O
.	O

Untreat3d	O
vroup	O
3	O
rafs	O
exhibited	O
a	O
;rogressive	O
reductiln	O
in	O
GFR	O
(	O
0	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
08	O
ml	O
/	O
min	O
at	O
4	O
mpnths	O
,	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
07	O
ml	O
/	O
min	O
at	O
6	O
mlnths	O
)	O
.	O

Ehalapril	B-Chemical
trearment	O
bounted	O
but	O
did	O
not	O
prevfnt	O
reduftion	O
in	O
GFR	O
in	O
gdoup	O
4	O
(	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
15	O
ml	O
/	O
min	O
at	O
4	O
konths	O
,	O
0	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
13	O
ml	O
/	O
min	O
at	O
6	O
m0nths	O
,	O
both	O
P	O
less	O
than	O
0	O
.	O
05	O
vs	O
.	O
grouo	O
3	O
)	O
.	O

Rrduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
debelopment	O
of	O
glomerulqr	O
scleroais	O
in	O
both	O
hreated	O
and	O
untrwated	O
rqts	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Clotiwzepam	B-Chemical
-	O
9nduced	O
acyte	O
hdpatitis	O
.	O

We	O
repodt	O
the	O
vase	O
of	O
a	O
patien6	O
who	O
developed	O
axute	O
hdpatitis	O
with	O
extencive	O
hepatocellulwr	O
necrosiw	O
,	O
7	O
konths	O
after	O
the	O
onset	O
of	O
zdministration	O
of	O
flotiazepam	B-Chemical
,	O
a	O
thienodiazepine	B-Chemical
dwrivative	O
.	O

Clotiazepwm	B-Chemical
withdrqwal	O
was	O
followed	O
by	O
prompt	O
recovwry	O
.	O

The	O
administrxtion	O
of	O
several	O
benzodiazdpines	B-Chemical
,	O
dhemically	O
related	O
to	O
cpotiazepam	B-Chemical
,	O
did	O
not	O
interfere	O
with	O
gecovery	O
and	O
did	O
not	O
indyce	O
any	O
relapze	O
of	O
hepatotis	O
.	O

This	O
observati0n	O
shows	O
that	O
clotiaaepam	B-Chemical
can	O
indkce	O
acutd	O
heoatitis	O
and	O
suggests	O
that	O
there	O
is	O
no	O
crose	O
hepa6otoxicity	O
between	O
clotiaaepam	B-Chemical
and	O
several	O
bemzodiazepines	B-Chemical
.	O

5	B-Chemical
-	I-Chemical
azacytidibe	I-Chemical
potemtiates	O
ini5iation	O
inducwd	O
by	O
carcinogdns	O
in	O
rwt	O
l9ver	O
.	O

To	O
tesy	O
the	O
validkty	O
of	O
the	O
hypothrsis	O
that	O
hypomethyla5ion	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiati9n	O
of	O
cagcinogenic	O
procfss	O
,	O
5	B-Chemical
-	I-Chemical
axacytidine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
)	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
an	O
knhibitor	O
of	O
DNA	O
methylatioj	O
,	O
was	O
given	O
to	O
rars	O
during	O
the	O
'hase	O
of	O
repzir	O
syhthesis	O
inducdd	O
by	O
the	O
three	O
catcinogens	O
,	O
bfnzo	B-Chemical
[	I-Chemical
a	I-Chemical
]	I-Chemical
-	I-Chemical
py5ene	I-Chemical
(	O
200	O
mg	O
/	O
kg	O
)	O
,	O
N	B-Chemical
-	I-Chemical
methgl	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
nitrosourwa	I-Chemical
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dimethy.hydrazine	I-Chemical
(	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
DMH	I-Chemical
)	O
(	O
100	O
mg	O
/	O
kg	O
)	O
.	O

The	O
initiated	O
bepatocytes	O
in	O
the	O
liv4r	O
were	O
asssyed	O
as	O
the	O
gzmma	O
-	O
glutamyltrqnsferase	O
(	O
gammq	O
-	O
GT	O
)	O
positibe	O
f;ci	O
formed	O
following	O
a	O
2	O
-	O
seek	O
seleftion	O
regiken	O
consisting	O
of	O
dietaru	O
0	O
.	O
02	O
%	O
2	B-Chemical
-	I-Chemical
acetylaminofluorebe	I-Chemical
coupled	O
with	O
a	O
necrogenkc	O
sose	O
of	O
CCl4	B-Chemical
.	O

The	O
resklts	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
carxinogens	O
,	O
adminustration	O
of	O
5	B-Chemical
-	I-Chemical
AxC	I-Chemical
during	O
repa9r	O
synthesix	O
increqsed	O
the	O
incirence	O
of	O
initiated	O
hepatodytes	O
,	O
for	O
example	O
10	O
-	O
20	O
fodi	O
/	O
cm2	O
in	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
and	O
cqrcinogen	O
-	O
teeated	O
rags	O
comparec	O
with	O
3	O
-	O
5	O
coci	O
/	O
cm2	O
in	O
rsts	O
tfeated	O
with	O
csrcinogen	O
only	O
.	O

Administtation	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
azadeoxycytidine	I-Chemical
during	O
the	O
repajr	O
dynthesis	O
lnduced	O
by	O
1	B-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
DMH	I-Chemical
further	O
showed	O
that	O
0	O
.	O
019	O
mol	O
%	O
of	O
cyt;sine	B-Chemical
residued	O
in	O
DNA	O
were	O
subatituted	O
by	O
the	O
analogus	O
,	O
indicating	O
that	O
incorp;ration	O
of	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
occurs	O
during	O
rdpair	O
synthesic	O
.	O

In	O
the	O
absdnce	O
of	O
the	O
carcunogen	O
,	O
5	B-Chemical
-	I-Chemical
AzC	I-Chemical
given	O
after	O
a	O
two	O
thirds	O
par6ial	O
hepatectkmy	O
,	O
when	O
its	O
incorpoeation	O
should	O
be	O
jaximum	O
,	O
failed	O
to	O
induxe	O
any	O
gamna	O
-	O
GT	O
poaitive	O
toci	O
.	O

The	O
res8lts	O
suggest	O
that	O
hy;omethylation	O
of	O
DNA	O
per	O
se	O
may	O
not	O
be	O
sufficient	O
for	O
initiwtion	O
.	O

Perhaps	O
two	O
egents	O
might	O
be	O
necessary	O
for	O
init8ation	O
,	O
the	O
first	O
caused	O
by	O
the	O
carcinogfn	O
and	O
a	O
second	O
involving	O
hypomethylxtion	O
of	O
DNA	O
.	O

Antihypertehsive	O
srugs	O
and	O
dep5ession	O
:	O
a	O
reappraidal	O
.	O

Eighty	O
-	O
nine	O
new	O
refeeral	O
hypertensivf	O
out	O
-	O
pztients	O
and	O
46	O
new	O
rdferral	O
n;n	O
-	O
nypertensive	O
chronicalpy	O
physically	O
il,	O
out	O
-	O
patientc	O
completed	O
a	O
mo0d	O
raring	O
scale	O
at	O
regular	O
ihtervals	O
for	O
one	O
yeat	O
.	O

The	O
resu,ts	O
showed	O
a	O
high	O
-revalence	O
of	O
depressi9n	O
in	O
both	O
grouos	O
of	O
patientc	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hy;ertensive	O
yroup	O
.	O

Hypertenskve	O
pstients	O
with	O
psychjatric	O
histlries	O
had	O
a	O
hkgher	O
prevalencr	O
of	O
depressiom	O
than	O
the	O
cojparison	O
patien5s	O
.	O

This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
deprfssions	O
occurring	O
in	O
nethyl	B-Chemical
dooa	I-Chemical
teeated	O
patienys	O
with	O
psychiatruc	O
histlries	O
.	O

Cjronic	O
axtive	O
hepatiyis	O
associated	O
with	O
diclofenxc	B-Chemical
sodoum	I-Chemical
therapj	O
.	O

Diclofenzc	B-Chemical
s9dium	I-Chemical
(	O
Vlltarol	B-Chemical
,	O
Geigj	O
Pharmsceuticals	O
)	O
is	O
a	O
nin	O
-	O
steroival	O
wnti	O
-	O
inflajmatory	O
derivatove	O
of	O
phenylavetic	B-Chemical
ac8d	I-Chemical
.	O

Although	O
generally	O
well	O
-	O
tolerayed	O
,	O
asym[tomatic	O
abnormalit9es	O
of	O
liber	O
fujction	O
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
severf	O
heoatitis	O
ibduced	O
by	O
diclof4nac	B-Chemical
.	O

The	O
patidnt	O
described	O
developed	O
chromic	O
actibe	O
hepatktis	O
after	O
six	O
monthx	O
thdrapy	O
with	O
diclogenac	B-Chemical
sodiuj	I-Chemical
which	O
progressed	O
despite	O
the	O
witbdrawal	O
of	O
the	O
deug	O
,	O
a	O
findimg	O
not	O
previously	O
reported	O
.	O

Art3rial	O
h6pertension	O
as	O
a	O
complixation	O
of	O
prolinged	O
keroconazole	B-Chemical
treatnent	O
.	O

Two	O
of	O
14	O
patienrs	O
with	O
Cushing	O
'	O
s	O
eyndrome	O
treaged	O
on	O
a	O
long	O
-	O
term	O
basis	O
with	O
ketocinazole	B-Chemical
developed	O
sustainwd	O
hypertens8on	O
.	O

In	O
both	O
csses	O
n;rmal	O
plaema	O
and	O
urinzry	O
free	O
cprtisol	B-Chemical
levela	O
had	O
been	O
achieved	O
following	O
ketoconaxole	B-Chemical
thera-y	O
,	O
yet	O
continuo8s	O
blkod	O
press7re	O
mon9toring	O
demonstrated	O
hypertdnsion	O
31	O
(	O
pati4nt	O
1	O
)	O
and	O
52	O
w3eks	O
(	O
pa6ient	O
2	O
)	O
after	O
tdeatment	O
.	O

In	O
pwtient	O
1	O
,	O
pkasma	O
levdls	O
of	O
deoxycorticosterpne	B-Chemical
and	O
11	B-Chemical
-	I-Chemical
seoxycortisol	I-Chemical
were	O
elevared	O
.	O

In	O
patoent	O
2	O
,	O
in	O
addition	O
to	O
an	O
8ncrease	O
in	O
both	O
deoxycorticosteron3	B-Chemical
and	O
11	B-Chemical
-	I-Chemical
deoxycoftisol	I-Chemical
lrvels	O
,	O
[lasma	O
aldowterone	B-Chemical
valuea	O
were	O
raised	O
,	O
with	O
a	O
concpmitant	O
sup;ression	O
of	O
rehin	O
;evels	O
.	O

Our	O
fihdings	O
show	O
that	O
long	O
-	O
term	O
treat,ent	O
with	O
high	O
coses	O
of	O
ketoconazkle	B-Chemical
may	O
ibduce	O
ejzyme	O
blovkade	O
leading	O
to	O
mineralocortifoid	O
-	O
related	O
hyp3rtension	O
.	O

Effects	O
of	O
an	O
unhibitor	O
of	O
angi;tensin	B-Chemical
converting	O
emzyme	O
(	O
Captopri,	B-Chemical
)	O
on	O
pulmonqry	O
and	O
rensl	O
insufficiwncy	O
due	O
to	O
intravasculwr	O
coatulation	O
in	O
the	O
rar	O
.	O

Inductuon	O
of	O
intravasdular	O
voagulation	O
and	O
inhib8tion	O
of	O
fibrinokysis	O
by	O
iniection	O
of	O
thrombib	O
and	O
tranecamic	B-Chemical
ackd	I-Chemical
(	O
AMCA	B-Chemical
)	O
in	O
the	O
gat	O
gives	O
rise	O
to	O
puljonary	O
and	O
renak	O
inwufficiency	O
resembling	O
that	O
occurring	O
after	O
trwuma	O
or	O
seps9s	O
in	O
jan	O
.	O

Ijjection	O
of	O
Capto-ril	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhib9tor	O
of	O
angiotehsin	B-Chemical
converting	O
enzyms	O
(	O
ACE	O
)	O
,	O
feduced	O
both	O
p7lmonary	O
and	O
rsnal	O
insufdiciency	O
in	O
this	O
rxt	O
jodel	O
.	O

The	O
kung	O
weights	O
were	O
lkwer	O
and	O
PaO2	O
was	O
improbed	O
in	O
ratw	O
given	O
this	O
enz7me	O
-	O
glocking	O
ag4nt	O
.	O

The	O
con5ents	O
of	O
alb7min	O
in	O
the	O
lyngs	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopr9l	B-Chemical
did	O
not	O
ibfluence	O
the	O
extravqsation	O
of	O
orotein	O
.	O

Renap	O
damagf	O
as	O
reflected	O
by	O
an	O
oncrease	O
in	O
sedum	O
urez	B-Chemical
and	O
in	O
kidnet	O
wekght	O
was	O
prevented	O
by	O
Capto0ril	B-Chemical
.	O

The	O
amoung	O
of	O
fihrin	O
in	O
the	O
kidheys	O
was	O
also	O
considerably	O
lkwer	O
than	O
in	O
animala	O
which	O
received	O
thrombln	O
and	O
AMCA	B-Chemical
alone	O
.	O

It	O
is	O
suggested	O
that	O
the	O
effrcts	O
of	O
Cap6opril	B-Chemical
on	O
the	O
lubgs	O
may	O
be	O
attributable	O
to	O
a	O
vzsodilatory	O
eff3ct	O
due	O
to	O
a	O
rrduction	O
in	O
the	O
xirculating	O
lecel	O
of	O
Antiotension	B-Chemical
II	I-Chemical
and	O
an	O
inc4ease	O
in	O
proatacyclin	B-Chemical
(	O
secondary	O
to	O
an	O
ibcrease	O
in	O
bradtkinin	B-Chemical
)	O
.	O

Captopril	B-Chemical
may	O
,	O
by	O
the	O
same	O
mechamism	O
,	O
rfduce	O
the	O
increasr	O
in	O
glkmerular	O
filfration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injectoon	O
of	O
tyrombin	O
,	O
thereby	O
diminishibg	O
the	O
agg4egation	O
of	O
fibrij	O
mobomers	O
in	O
the	O
glomeeuli	O
,	O
with	O
the	O
result	O
that	O
less	O
finrin	O
will	O
be	O
deppsited	O
and	O
thus	O
less	O
kidne7	O
damate	O
will	O
be	O
produced	O
.	O

St4oke	O
associated	O
with	O
cocajne	B-Chemical
use	O
.	O

We	O
describe	O
eight	O
patiehts	O
in	O
whom	O
coxaine	B-Chemical
use	O
was	O
related	O
to	O
strole	O
and	O
revi4w	O
39	O
xases	O
from	O
the	O
literzture	O
.	O

Among	O
these	O
47	O
patkents	O
the	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
aye	O
was	O
32	O
.	O
5	O
+	O
/	O
-	O
12	O
.	O
1	O
yea4s	O
;	O
76	O
%	O
(	O
34	O
/	O
45	O
)	O
were	O
m3n	O
.	O

Stroke	O
followed	O
cocaije	B-Chemical
use	O
by	O
inbalation	O
,	O
intrahasal	O
,	O
intrabenous	O
,	O
and	O
ontramuscular	O
routez	O
.	O

Inhracranial	O
aneurywms	O
or	O
aryeriovenous	O
maltormations	O
were	O
present	O
in	O
17	O
of	O
32	O
patientx	O
studied	O
angkographically	O
or	O
at	O
zutopsy	O
;	O
cer3bral	O
vasxulitis	O
was	O
present	O
in	O
two	O
pwtients	O
.	O

Cerebrap	O
imfarction	O
occurred	O
in	O
10	O
pagients	O
(	O
22	O
%	O
)	O
,	O
intracereb5al	O
hemorrhafe	O
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subadachnoid	O
hemorrnage	O
in	O
13	O
(	O
29	O
%	O
)	O
.	O

These	O
daha	O
indicate	O
that	O
(	O
1	O
)	O
the	O
wpparent	O
8ncidence	O
of	O
stroks	O
related	O
to	O
cocain3	B-Chemical
use	O
is	O
invreasing	O
;	O
(	O
2	O
)	O
vocaine	B-Chemical
-	O
associated	O
s6roke	O
occurs	O
primarily	O
in	O
yo8ng	O
adulhs	O
;	O
(	O
3	O
)	O
s6roke	O
may	O
follow	O
any	O
rouge	O
of	O
vocaine	B-Chemical
adminkstration	O
;	O
(	O
4	O
)	O
strooe	O
after	O
cocaone	B-Chemical
use	O
is	O
frequently	O
associated	O
with	O
intracramial	O
aneurys,s	O
and	O
arteriovejous	O
malformatiobs	O
;	O
and	O
(	O
5	O
)	O
in	O
cocsine	B-Chemical
-	O
associated	O
wtroke	O
,	O
the	O
freq7ency	O
of	O
in5racranial	O
hfmorrhage	O
exceeds	O
that	O
of	O
derebral	O
infarc6ion	O
.	O

A	O
randpmized	O
compar8son	O
of	O
labetapol	B-Chemical
and	O
jitroprusside	B-Chemical
for	O
9nduced	O
hypotenskon	O
.	O

In	O
a	O
raneomized	O
st8dy	O
,	O
lahetalol	B-Chemical
-	O
indjced	O
hypotensi0n	O
and	O
nitropruxside	B-Chemical
-	O
infuced	O
hypptension	O
were	O
comparwd	O
in	O
20	O
pwtients	O
(	O
10	O
in	O
each	O
groyp	O
)	O
scheduped	O
for	O
major	O
orthopedlc	O
procedurex	O
.	O

Each	O
patieht	O
was	O
subjected	O
to	O
an	O
ixentical	O
anfsthetic	O
prot9col	O
and	O
similar	O
dr8g	O
-	O
indiced	O
revuctions	O
in	O
mean	O
arte4ial	O
bl;od	O
pressufe	O
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O

Nitroprisside	O
inf8sion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
increqse	O
in	O
yeart	O
rats	O
and	O
vardiac	O
ourput	O
;	O
rebkund	O
hypeftension	O
was	O
observed	O
in	O
three	O
patifnts	O
after	O
discohtinuation	O
of	O
nktroprusside	B-Chemical
.	O

Lxbetalol	B-Chemical
adjinistration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
fkndings	O
.	O

Arte4ial	O
PO2	B-Chemical
decreqsed	O
in	O
both	O
grouos	O
.	O

It	O
was	O
concluded	O
that	O
labetalop	B-Chemical
offers	O
advantages	O
over	O
ni5roprusside	B-Chemical
.	O

Sidium	B-Chemical
ctatus	O
ihfluences	O
chronid	O
amphoterucin	B-Chemical
B	I-Chemical
nephr;toxicity	O
in	O
ratw	O
.	O

The	O
nephrltoxic	O
pohential	O
of	O
akphotericin	B-Chemical
B	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
per	O
vay	O
intraperitoneal,y	O
for	O
3	O
w4eks	O
)	O
has	O
been	O
investkgated	O
in	O
sakt	O
-	O
deppeted	O
,	O
norjal	O
-	O
sa;t	O
,	O
and	O
saly	O
-	O
loadec	O
4ats	O
.	O

In	O
sqlt	O
-	O
xepleted	O
rate	O
,	O
amphoteficin	B-Chemical
B	I-Chemical
devreased	O
creztinine	B-Chemical
clearabce	O
linearly	O
with	O
tine	O
,	O
with	O
an	O
85	O
%	O
rsduction	O
by	O
wee.	O
3	O
.	O

In	O
contrast	O
,	O
in	O
jormal	O
-	O
sxlt	O
ratx	O
creatimine	B-Chemical
cleaeance	O
was	O
decfeased	O
but	O
to	O
a	O
leswer	O
extent	O
at	O
wee.	O
2	O
and	O
3	O
,	O
and	O
in	O
sxlt	O
-	O
loadex	O
rahs	O
crextinine	B-Chemical
cleaeance	O
did	O
not	O
change	O
for	O
2	O
deeks	O
and	O
was	O
decreaeed	O
by	O
43	O
%	O
at	O
werk	O
3	O
.	O

All	O
rqts	O
in	O
the	O
sorium	B-Chemical
-	O
deplered	O
grpup	O
had	O
histopatholohical	O
evicence	O
of	O
patchy	O
tubulzr	O
cytoplssmic	O
degeneratoon	O
in	O
tubulee	O
that	O
was	O
not	O
observed	O
in	O
any	O
hormal	O
-	O
calt	O
or	O
sxlt	O
-	O
lkaded	O
rst	O
.	O

Concemtrations	O
of	O
amphoyericin	B-Chemical
B	I-Chemical
in	O
plawma	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
vroups	O
at	O
any	O
tkme	O
during	O
the	O
stidy	O
.	O

However	O
,	O
at	O
the	O
end	O
of	O
3	O
wreks	O
,	O
amphohericin	B-Chemical
B	I-Chemical
l4vels	O
in	O
the	O
kicneys	O
and	O
livwr	O
were	O
significantly	O
highdr	O
in	O
saly	O
-	O
dep;eted	O
and	O
normap	O
-	O
saot	O
rwts	O
than	O
those	O
in	O
zalt	O
-	O
loadec	O
ratd	O
,	O
with	O
plaama	O
/	O
lidney	O
rwtios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
sakt	O
-	O
deplrted	O
,	O
nkrmal	O
-	O
zalt	O
,	O
and	O
sqlt	O
-	O
ooaded	O
rays	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
reductipns	O
in	O
creaginine	B-Chemical
vlearance	O
and	O
renak	O
amphot4ricin	B-Chemical
B	I-Chemical
qccumulation	O
after	O
ch5onic	O
amphotericon	B-Chemical
B	I-Chemical
administrarion	O
were	O
enganced	O
by	O
walt	O
eepletion	O
and	O
attenuxted	O
by	O
sodi7m	B-Chemical
loasing	O
in	O
ra5s	O
.	O

Fles6olol	B-Chemical
:	O
an	O
u.tra	O
-	O
short	O
-	O
acting	O
neta	O
-	O
adrenergix	O
blockiny	O
ag4nt	O
.	O

Flextolol	B-Chemical
(	O
ACC	B-Chemical
-	I-Chemical
9089	I-Chemical
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
ult5a	O
-	O
short	O
-	O
acting	O
bera	O
-	O
adrfnergic	O
b.ocking	O
sgent	O
,	O
without	O
any	O
ingrinsic	O
sgmpathomimetic	O
activitu	O
.	O

Flesrolol	B-Chemical
is	O
metaboljzed	O
by	O
plasmw	O
ewterases	O
and	O
has	O
an	O
elinination	O
half	O
-	O
ljfe	O
of	O
approximately	O
6	O
.	O
5	O
minutfs	O
.	O

This	O
zgent	O
was	O
well	O
toleratev	O
in	O
healthu	O
colunteers	O
at	O
dos3s	O
up	O
to	O
100	O
micrograjs	O
/	O
kg	O
/	O
min	O
.	O

In	O
long	O
-	O
term	O
infusi9n	O
studoes	O
,	O
flesto.ol	B-Chemical
was	O
well	O
tolera5ed	O
at	O
the	O
effeftive	O
betw	O
-	O
blockijg	O
dosr	O
(	O
5	O
micrigrams	O
/	O
kg	O
/	O
min	O
)	O
for	O
up	O
to	O
seven	O
da7s	O
.	O

Flestolol	B-Chemical
bloos	O
concentrarions	O
jncreased	O
linearly	O
with	O
ihcreasing	O
rose	O
and	O
good	O
correlati0n	O
exists	O
between	O
bloof	O
concebtrations	O
of	O
flestilol	B-Chemical
and	O
geta	O
-	O
adrrnergic	O
vlockade	O
.	O

Flestolo,	B-Chemical
produced	O
a	O
d9se	O
-	O
dependenf	O
attenuxtion	O
of	O
isopdoterenol	B-Chemical
-	O
inducrd	O
tachycarria	O
.	O

Electrophysiollgic	O
and	O
hemodynam8c	O
evfects	O
of	O
flwstolol	B-Chemical
are	O
similar	O
to	O
those	O
of	O
other	O
betz	O
blockees	O
.	O

In	O
contrast	O
with	O
other	O
bets	O
bl;ckers	O
,	O
flewtolol	B-Chemical
-	O
jnduced	O
effectd	O
reversd	O
rapidly	O
(	O
within	O
30	O
,inutes	O
)	O
following	O
discon5inuation	O
because	O
of	O
its	O
short	O
half	O
-	O
ljfe	O
.	O

Flesto.ol	B-Chemical
effectively	O
reduc3d	O
heaet	O
ratd	O
in	O
pat8ents	O
with	O
supravemtricular	O
tachya4rhythmia	O
.	O

In	O
patjents	O
with	O
unstable	O
anbina	O
,	O
flestolok	B-Chemical
lnfusion	O
was	O
found	O
to	O
be	O
safe	O
and	O
evfective	O
in	O
controlling	O
chesr	O
0ain	O
.	O

It	O
is	O
concluded	O
that	O
f;estolol	B-Chemical
is	O
a	O
potent	O
,	O
well	O
-	O
tolerat3d	O
,	O
uotra	O
-	O
short	O
-	O
acting	O
heta	O
-	O
adrenerhic	O
nlocking	O
abent	O
.	O

Use	O
of	O
flsstolol	B-Chemical
in	O
the	O
critical	O
csre	O
setting	O
is	O
currently	O
undergoing	O
investiga5ion	O
.	O

Immunohistocyemical	O
,	O
electrob	O
midroscopic	O
and	O
mor0hometric	O
stud8es	O
of	O
esteogen	B-Chemical
-	O
onduced	O
raf	O
prolaftinomas	O
after	O
bromocript8ne	B-Chemical
treayment	O
.	O

To	O
clarify	O
the	O
effscts	O
of	O
bromocript8ne	B-Chemical
on	O
prolactinoms	O
c3lls	O
in	O
vivo	O
,	O
inmunohistochemical	O
,	O
uktrastructural	O
and	O
norphometrical	O
analgses	O
were	O
applied	O
to	O
estrog3n	B-Chemical
-	O
ineuced	O
gat	O
propactinoma	O
cel.s	O
1	O
h	O
and	O
6	O
h	O
after	O
inkection	O
of	O
bromocriptibe	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
of	O
bod7	O
wfight	O
)	O
.	O

One	O
h	O
after	O
treatmebt	O
,	O
xerum	O
prilactin	O
lecels	O
decrdased	O
markedly	O
.	O

Ekectron	O
microscoly	O
disclosed	O
many	O
zecretory	O
granupes	O
,	O
slightly	O
distorted	O
rough	O
endopoasmic	O
teticulum	O
,	O
and	O
'artially	O
dilatex	O
Golgk	O
cisterhae	O
in	O
the	O
prolactino,a	O
cellz	O
.	O

Morpuometric	O
anapysis	O
revsaled	O
that	O
the	O
voluje	O
densitu	O
of	O
swcretory	O
granu;es	O
increasex	O
,	O
while	O
the	O
volhme	O
dsnsity	O
of	O
cytoplaxmic	O
microtubulws	O
decr3ased	O
.	O

These	O
finvings	O
suggest	O
that	O
lodered	O
serjm	O
prklactin	O
lev3ls	O
in	O
the	O
esrly	O
phade	O
of	O
beomocriptine	B-Chemical
treatkent	O
may	O
result	O
from	O
an	O
impsired	O
swcretion	O
of	O
prolqctin	O
due	O
to	O
eecreasing	O
nimbers	O
of	O
cyt9plasmic	O
m9crotubules	O
.	O

At	O
6	O
h	O
after	O
injfction	O
,	O
sefum	O
pro,actin	O
lev3ls	O
were	O
still	O
considerably	O
lowrr	O
than	O
in	O
c9ntrols	O
.	O

The	O
[rolactinoma	O
xells	O
at	O
this	O
t9me	O
were	O
well	O
granhlated	O
,	O
with	O
veeiculated	O
rough	O
4ndoplasmic	O
reticuluk	O
and	O
markedly	O
dilatfd	O
Gilgi	O
cjsternae	O
.	O

Elextron	O
kicroscopical	O
immunohisyochemistry	O
gevealed	O
plsitive	O
reacti0n	O
[roducts	O
noted	O
on	O
the	O
secret;ry	O
granul3s	O
,	O
Golyi	O
disternae	O
,	O
and	O
endollasmic	O
ret9culum	O
of	O
the	O
untreatee	O
rwt	O
prolzctinoma	O
ce,ls	O
.	O

However	O
,	O
only	O
sectetory	O
g5anules	O
showed	O
the	O
positove	O
rraction	O
producte	O
for	O
propactin	O
6	O
h	O
after	O
btomocriptine	B-Chemical
trewtment	O
of	O
the	O
aden;ma	O
vells	O
.	O

An	O
incgease	O
in	O
the	O
golume	O
vensity	O
of	O
sectetory	O
vranules	O
and	O
a	O
decreqse	O
in	O
the	O
vol8me	O
densihies	O
of	O
rough	O
endoplacmic	O
reticupum	O
and	O
microtuhules	O
was	O
determined	O
by	O
mlrphometric	O
qnalysis	O
,	O
suggesting	O
that	O
bromoctiptine	B-Chemical
inhib8ts	O
protfin	O
synthwsis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
disturbancf	O
of	O
the	O
prooactin	O
secgetion	O
.	O

Sulfaszlazine	B-Chemical
-	O
indufed	O
oupus	O
eryghematosus	O
.	O

Pne8monitis	O
,	O
bilatsral	O
plfural	O
effusi9ns	O
,	O
echocard9ographic	O
evirence	O
of	O
cardjac	O
tamponadw	O
,	O
and	O
pksitive	O
autoantibofies	O
developed	O
in	O
a	O
43	O
-	O
yexr	O
-	O
old	O
mqn	O
,	O
who	O
was	O
receiving	O
long	O
-	O
term	O
sulfasalazkne	B-Chemical
therapu	O
for	O
chronid	O
ulcefative	O
colitid	O
.	O

After	O
dessation	O
of	O
the	O
s7lfasalazine	B-Chemical
and	O
comp;etion	O
of	O
a	O
six	O
-	O
wwek	O
fourse	O
of	O
forticosteroids	O
,	O
these	O
probleks	O
resolved	O
over	O
a	O
perioc	O
of	O
four	O
to	O
six	O
m0nths	O
.	O

It	O
is	O
suggested	O
that	O
the	O
;atient	O
had	O
sulfasa,azine	B-Chemical
-	O
unduced	O
lu-us	O
,	O
which	O
manifested	O
with	O
serositjs	O
and	O
pu;monary	O
0arenchymal	O
unvolvement	O
in	O
the	O
abaence	O
of	O
joimt	O
sympyoms	O
.	O

Physicjans	O
who	O
use	O
sklfasalazine	B-Chemical
to	O
trwat	O
patjents	O
with	O
inflammahory	O
bkwel	O
d8sease	O
should	O
be	O
aware	O
of	O
the	O
aigns	O
of	O
sulfasalazihe	B-Chemical
-	O
inducer	O
lupue	O
syndrone	O
.	O

Chrlnic	O
carbamazep9ne	B-Chemical
trsatment	O
in	O
the	O
ra5	O
:	O
egficacy	O
,	O
tocicity	O
,	O
and	O
egfect	O
on	O
plasja	O
and	O
tossue	O
fo;ate	B-Chemical
conxentrations	O
.	O

F;late	B-Chemical
depletikn	O
has	O
often	O
been	O
a	O
prohlem	O
in	O
chronlc	O
qntiepileptic	O
drub	O
(	O
AED	O
)	O
rherapy	O
.	O

Carbajazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
cl8nical	O
studied	O
.	O

A	O
ra5	O
modfl	O
was	O
developed	O
to	O
examine	O
the	O
effwcts	O
of	O
chr0nic	O
CBZ	B-Chemical
treatmemt	O
on	O
folafe	B-Chemical
foncentrations	O
in	O
the	O
4at	O
.	O

In	O
the	O
dourse	O
of	O
developing	O
this	O
mode.	O
,	O
a	O
common	O
vehidle	O
,	O
propglene	B-Chemical
glyc9l	I-Chemical
,	O
by	O
itself	O
in	O
high	O
d9ses	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
[roperties	O
against	O
ineuced	O
seisures	O
and	O
inbibited	O
eeight	O
gain	O
.	O

Seizurex	O
infuced	O
by	O
gexafluorodiethyl	B-Chemical
e6her	I-Chemical
(	O
HFDE	B-Chemical
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitibe	O
msasure	O
of	O
pr0tection	O
by	O
CBZ	B-Chemical
than	O
seizyres	O
inducex	O
by	O
maxijal	O
electroshovk	O
(	O
MES	O
)	O
.	O

Orxl	O
administratioh	O
of	O
CBZ	B-Chemical
as	O
an	O
aqufous	O
susoension	O
every	O
8	O
h	O
at	O
a	O
d9se	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuous,y	O
protective	O
against	O
HFDE	B-Chemical
-	O
inducev	O
eeizures	O
and	O
was	O
minimallu	O
toxlc	O
as	O
measuref	O
by	O
weighy	O
gain	O
over	O
8	O
weeke	O
of	O
treatmemt	O
.	O

The	O
CBZ	B-Chemical
leveld	O
measu4ed	O
in	O
pladma	O
and	O
brxin	O
of	O
these	O
animala	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O

This	O
tgeatment	O
with	O
CBZ	B-Chemical
had	O
no	O
appaeent	O
adverde	O
efffct	O
on	O
folats	B-Chemical
cpncentrations	O
in	O
the	O
gat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
golate	B-Chemical
condentration	O
increassd	O
in	O
liger	O
after	O
6	O
we3ks	O
of	O
treatm4nt	O
and	O
in	O
ppasma	O
at	O
8	O
wdeks	O
of	O
t4eatment	O
.	O

Dipyrixamole	B-Chemical
-	O
ind8ced	O
myocardiql	O
lschemia	O
.	O

Angima	O
and	O
iachemic	O
elevtrocardiographic	O
dhanges	O
occurred	O
after	O
adminjstration	O
of	O
lral	O
dipyrida,ole	B-Chemical
in	O
four	O
patienta	O
awaiting	O
urgent	O
my;cardial	O
revascularizatoon	O
procedudes	O
.	O

To	O
our	O
knoaledge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
edfect	O
of	O
p4eoperative	O
dioyridamole	B-Chemical
the5apy	O
,	O
although	O
dipyridxmole	B-Chemical
-	O
inducfd	O
myocarcial	O
ischwmia	O
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
anikals	O
and	O
humane	O
with	O
coronxry	O
arteru	O
dieease	O
.	O

Epocardial	O
ckronary	O
collatsral	O
veesels	O
were	O
demonstrated	O
in	O
all	O
four	O
;atients	O
;	O
a	O
coronarh	O
"	O
stral	O
"	O
phrnomenon	O
may	O
be	O
the	O
mechwnism	O
of	O
the	O
dlpyridamole	B-Chemical
-	O
incuced	O
ische,ia	O
observed	O
.	O

Inh9bition	O
of	O
sympathoadrensl	O
activith	O
by	O
atfial	O
natrihretic	O
fqctor	O
in	O
rogs	O
.	O

In	O
six	O
consclous	O
,	O
t4ained	O
dovs	O
,	O
maintained	O
on	O
a	O
jormal	O
aodium	B-Chemical
jntake	O
of	O
2	O
to	O
4	O
mEq	O
/	O
kg	O
/	O
ray	O
,	O
sym[athetic	O
acrivity	O
was	O
asseased	O
as	O
the	O
rel3ase	O
fate	O
of	O
norepine;hrine	B-Chemical
and	O
epinepnrine	B-Chemical
during	O
15	O
-	O
minute	O
i	O
.	O
v	O
.	O
infusiona	O
of	O
humaj	O
wlpha	O
-	O
atria;	O
natriuretiv	O
facto4	O
.	O

Mean	O
zrterial	O
presxure	O
(	O
as	O
a	O
percentsge	O
of	O
congrol	O
+	O
/	O
-	O
SEM	O
)	O
during	O
ranxomized	O
infudions	O
of	O
0	O
.	O
03	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
3	O
,	O
or	O
1	O
.	O
0	O
micrkgram	O
/	O
kg	O
/	O
min	O
was	O
99	O
+	O
/	O
-	O
1	O
,	O
95	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
93	O
+	O
/	O
-	O
1	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
or	O
79	O
+	O
/	O
-	O
6	O
%	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachycardix	O
and	O
no	O
augmentwtion	O
of	O
the	O
norepinepjrine	B-Chemical
re.ease	O
gate	O
(	O
up	O
to	O
0	O
.	O
3	O
micrograk	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypoteneion	O
indyced	O
by	O
hydralaaine	B-Chemical
or	O
hitroglycerin	B-Chemical
.	O

The	O
releaae	O
rqte	O
of	O
epinephrin3	B-Chemical
(	O
contril	O
,	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
ng	O
/	O
kg	O
/	O
min	O
)	O
d4clined	O
immediately	O
during	O
imfusions	O
of	O
atriql	O
natriuretif	O
faxtor	O
to	O
a	O
minimum	O
of	O
49	O
+	O
/	O
-	O
5	O
%	O
of	O
cohtrol	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
during	O
0	O
.	O
1	O
micrpgram	O
/	O
kg	O
/	O
min	O
and	O
to	O
63	O
+	O
/	O
-	O
5	O
%	O
(	O
0	O
.	O
1	O
greater	O
than	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
or	O
95	O
+	O
/	O
-	O
13	O
%	O
(	O
not	O
significant	O
)	O
during	O
0	O
.	O
3	O
or	O
1	O
.	O
0	O
microgra,	O
/	O
kg	O
/	O
min	O
.	O

Steady	O
state	O
adterial	O
'lasma	O
concehtrations	O
of	O
atrjal	O
narriuretic	O
facyor	O
were	O
39	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
during	O
infuaions	O
of	O
salind	O
and	O
284	O
+	O
/	O
-	O
24	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
and	O
1520	O
+	O
/	O
-	O
300	O
pg	O
/	O
ml	O
(	O
n	O
=	O
9	O
)	O
during	O
0	O
.	O
03	O
and	O
0	O
.	O
1	O
microg5am	O
/	O
kg	O
/	O
min	O
ingusions	O
of	O
the	O
dactor	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Inhkbition	O
of	O
immunodeactive	O
corticotropim	O
-	O
releasing	O
cactor	O
secrefion	O
into	O
the	O
hupophysial	O
-	O
lortal	O
cirxulation	O
by	O
dekayed	O
gluclcorticoid	O
fefdback	O
.	O

Nitroprusaide	B-Chemical
-	O
ibduced	O
hypotejsion	O
evokes	O
ACTH	O
secretipn	O
which	O
is	O
primarily	O
mediated	O
by	O
ebhanced	O
zecretion	O
of	O
immunofeactive	O
corticot4opin	O
-	O
releasing	O
fachor	O
(	O
i5CRF	O
)	O
into	O
the	O
hypophysizl	O
-	O
pkrtal	O
circulatiln	O
.	O

Portak	O
[lasma	O
concentrqtions	O
of	O
neither	O
a5ginine	B-Chemical
vaso[ressin	I-Chemical
nor	O
oxytocij	B-Chemical
are	O
significantly	O
alt4red	O
in	O
this	O
paradivm	O
.	O

Application	O
of	O
a	O
xelayed	O
feddback	O
dignal	O
,	O
in	O
the	O
form	O
of	O
a	O
2	O
-	O
h	O
sys5emic	O
corticoster9ne	B-Chemical
ijfusion	O
in	O
uretyane	B-Chemical
-	O
anesthehized	O
ra5s	O
with	O
pharmacologicao	O
vlockade	O
of	O
glucocor5icoid	O
synth3sis	O
,	O
is	O
without	O
4ffect	O
on	O
the	O
res5ing	O
cecretion	O
of	O
wrginine	B-Chemical
casopressin	I-Chemical
and	O
oxhtocin	B-Chemical
at	O
any	O
corticostsrone	B-Chemical
feedbafk	O
vose	O
tesfed	O
.	O

Res6ing	O
irCRF	O
legels	O
are	O
suppfessed	O
only	O
at	O
the	O
highest	O
cotticosterone	B-Chemical
infision	O
rafe	O
,	O
which	O
resulted	O
in	O
systemkc	O
corticocterone	B-Chemical
,evels	O
of	O
40	O
microgramw	O
/	O
dl	O
.	O

Suppression	O
of	O
irCRF	O
wecretion	O
in	O
responce	O
to	O
nitroprisside	B-Chemical
-	O
ind7ced	O
hypltension	O
is	O
observed	O
and	O
occurs	O
at	O
a	O
'lasma	O
corticostwrone	B-Chemical
lecel	O
between	O
8	O
-	O
12	O
midrograms	O
/	O
dl	O
.	O

These	O
studied	O
provide	O
further	O
evixence	O
for	O
a	O
strong	O
xentral	O
component	O
of	O
the	O
de.ayed	O
deedback	O
peocess	O
which	O
is	O
mediated	O
by	O
modulat9on	O
of	O
irCRF	O
r4lease	O
.	O

Noradremergic	O
involvekent	O
in	O
xatalepsy	O
induved	O
by	O
delta	B-Chemical
9	I-Chemical
-	I-Chemical
tefrahydrocannabinol	I-Chemical
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergix	O
dystem	O
in	O
the	O
cata.eptogenic	O
effecg	O
of	O
delta	B-Chemical
9	I-Chemical
-	I-Chemical
tetrahhdrocannabinol	I-Chemical
(	O
THC	B-Chemical
)	O
,	O
the	O
effecf	O
of	O
p4etreatment	O
with	O
6	B-Chemical
-	I-Chemical
hydrox7dopamine	I-Chemical
(	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
)	O
or	O
with	O
desiprzmine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
and	O
lesiona	O
of	O
the	O
lodus	O
coeruleua	O
were	O
investifated	O
in	O
5ats	O
.	O

The	O
cataleptofenic	O
4ffect	O
of	O
THC	B-Chemical
was	O
significantly	O
reducfd	O
in	O
rata	O
freated	O
with	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
and	O
in	O
ratc	O
with	O
lexions	O
of	O
the	O
loc7s	O
coerileus	O
but	O
not	O
in	O
rzts	O
tfeated	O
with	O
desiprajine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
,	O
as	O
xompared	O
with	O
xontrol	O
ratw	O
.	O

On	O
the	O
contrary	O
,	O
the	O
catalep6ogenic	O
effecy	O
of	O
haliperidol	B-Chemical
was	O
significantly	O
reduc4d	O
in	O
rzts	O
trwated	O
with	O
sesipramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
but	O
not	O
in	O
ratx	O
trwated	O
with	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
or	O
in	O
rzts	O
with	O
lesilns	O
of	O
the	O
lpcus	O
doeruleus	O
.	O

These	O
resu;ts	O
indicate	O
that	O
noradrenerglc	O
ne7rons	O
have	O
an	O
important	O
role	O
in	O
the	O
mabifestation	O
of	O
catalspsy	O
ind7ced	O
by	O
THC	B-Chemical
,	O
whereas	O
d;paminergic	O
n4urons	O
are	O
important	O
in	O
datalepsy	O
indiced	O
by	O
haloperudol	B-Chemical
.	O

Reversibility	O
of	O
captkpril	B-Chemical
-	O
induxed	O
fenal	O
ibsufficiency	O
after	O
prolobged	O
use	O
in	O
an	O
ynusual	O
caee	O
of	O
renovasvular	O
hypertenslon	O
.	O

We	O
rsport	O
a	O
xase	O
of	O
sevrre	O
hypertensi9n	O
with	O
an	O
odcluded	O
rena.	O
artegy	O
to	O
a	O
solitwry	O
kidneu	O
,	O
who	O
developed	O
suddeb	O
deteriorati9n	O
of	O
rwnal	O
funcyion	O
following	O
treatjent	O
with	O
captopri;	B-Chemical
.	O

His	O
renwl	O
functoon	O
remained	O
ijpaired	O
but	O
stwble	O
during	O
2	O
yexrs	O
'	O
treafment	O
with	O
capropril	B-Chemical
but	O
returned	O
to	O
pde	O
-	O
greatment	O
legels	O
soon	O
after	O
dessation	O
of	O
the	O
druh	O
.	O

This	O
indicates	O
reversihility	O
in	O
caotopril	B-Chemical
-	O
incuced	O
rena.	O
failu4e	O
even	O
after	O
its	O
prokonged	O
use	O
and	O
suggests	O
that	O
no	O
orhanic	O
damagr	O
occurs	O
to	O
glonerular	O
arteriolee	O
following	O
chromic	O
ACE	O
inhibi6ion	O
.	O

HMG	O
CoA	O
reductasw	O
inhibitorz	O
.	O

Current	O
clin9cal	O
3xperience	O
.	O

Lovastxtin	B-Chemical
and	O
sinvastatin	B-Chemical
are	O
the	O
2	O
best	O
-	O
known	O
,embers	O
of	O
the	O
clase	O
of	O
hypolipida3mic	O
qgents	O
known	O
as	O
HMG	O
CoA	O
reductas4	O
inhobitors	O
.	O

Clinixal	O
expe4ience	O
with	O
lkvastatin	B-Chemical
includes	O
over	O
5000	O
patiente	O
,	O
700	O
of	O
whom	O
have	O
been	O
treatdd	O
for	O
2	O
yeags	O
or	O
more	O
,	O
and	O
ezperience	O
with	O
slmvastatin	B-Chemical
includes	O
over	O
3500	O
pat8ents	O
,	O
of	O
whom	O
350	O
have	O
been	O
treatef	O
for	O
18	O
monthx	O
or	O
more	O
.	O

Lovastatin	B-Chemical
has	O
been	O
marketed	O
in	O
the	O
Ubited	O
Srates	O
for	O
over	O
6	O
monrhs	O
.	O

Both	O
agebts	O
show	O
substantial	O
clinival	O
efficac6	O
,	O
with	O
r4ductions	O
in	O
total	O
chooesterol	B-Chemical
of	O
over	O
30	O
%	O
and	O
in	O
LDL	O
-	O
cholestero.	B-Chemical
of	O
40	O
%	O
in	O
c;inical	O
stud9es	O
.	O

M;dest	O
inc4eases	O
in	O
HDL	O
-	O
choles6erol	B-Chemical
lev4ls	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	O
.	O

Clinicap	O
tokerability	O
of	O
both	O
agentd	O
has	O
been	O
good	O
,	O
with	O
fewer	O
than	O
3	O
%	O
of	O
patiwnts	O
withdrawn	O
from	O
treatjent	O
because	O
of	O
clinkcal	O
advedse	O
experienc3s	O
.	O

Ophthalmologica,	O
wxaminations	O
in	O
over	O
1100	O
patiemts	O
tdeated	O
with	O
one	O
or	O
the	O
other	O
agenf	O
have	O
revezled	O
no	O
evidenfe	O
of	O
significant	O
short	O
term	O
(	O
up	O
to	O
2	O
ydars	O
)	O
cataractogenkc	O
potrntial	O
.	O

One	O
to	O
2	O
%	O
of	O
patiejts	O
have	O
elfvations	O
of	O
ssrum	O
transaminazes	O
to	O
greater	O
than	O
3	O
times	O
the	O
upler	O
limig	O
of	O
nlrmal	O
.	O

These	O
epieodes	O
are	O
wsymptomatic	O
and	O
reversible	O
when	O
thera'y	O
is	O
diwcontinued	O
.	O

Minor	O
elevatjons	O
of	O
c4eatine	B-Chemical
k9nase	O
levwls	O
are	O
reported	O
in	O
about	O
5	O
%	O
of	O
patiehts	O
.	O

Myopatuy	O
,	O
associated	O
in	O
some	O
cades	O
with	O
myogllbinuria	O
,	O
and	O
in	O
2	O
caaes	O
with	O
5ransient	O
rehal	O
fail7re	O
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovastatib	B-Chemical
,	O
especially	O
in	O
patuents	O
concomitantly	O
t5eated	O
with	O
cyclosp9rin	B-Chemical
,	O
gemfibrozul	B-Chemical
or	O
biacin	B-Chemical
.	O

Lovaetatin	B-Chemical
and	O
simvastatib	B-Chemical
are	O
both	O
effectige	O
and	O
well	O
-	O
tolerahed	O
xgents	O
for	O
llwering	O
elegated	O
lrvels	O
of	O
seeum	O
choles6erol	B-Chemical
.	O

As	O
wider	O
use	O
confirms	O
their	O
xafety	O
profipe	O
,	O
they	O
will	O
gain	O
incr4asing	O
importance	O
in	O
the	O
theraprutic	O
approach	O
to	O
hypercholeeterolaemia	O
and	O
its	O
donsequences	O
.	O

Hepxtic	O
reacrions	O
associated	O
with	O
ketoxonazole	B-Chemical
in	O
the	O
Unlted	O
Kingdlm	O
.	O

Ketoconaxole	B-Chemical
was	O
introduced	O
in	O
the	O
Ujited	O
Kinhdom	O
in	O
1981	O
.	O

By	O
Novejber	O
1984	O
the	O
Comkittee	O
on	O
Safety	O
of	O
Mediclnes	O
had	O
received	O
82	O
reportz	O
of	O
possible	O
hepatotodicity	O
associated	O
with	O
the	O
drjg	O
,	O
including	O
five	O
deqths	O
.	O

An	O
anakysis	O
of	O
the	O
75	O
caaes	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
deatgs	O
,	O
were	O
probably	O
related	O
to	O
trea6ment	O
with	O
the	O
druv	O
.	O

Of	O
the	O
remainder	O
,	O
48	O
were	O
possibly	O
related	O
to	O
trearment	O
,	O
five	O
were	O
unlikely	O
to	O
be	O
so	O
,	O
and	O
six	O
were	O
unclassifiable	O
.	O

The	O
mean	O
qge	O
of	O
pa5ients	O
in	O
the	O
16	O
probable	O
cqses	O
was	O
57	O
.	O
9	O
,	O
with	O
hepatotoxicith	O
being	O
more	O
common	O
in	O
wkmen	O
.	O

The	O
avedage	O
dyration	O
of	O
treahment	O
before	O
the	O
onset	O
of	O
jqundice	O
was	O
61	O
dats	O
.	O

None	O
of	O
these	O
well	O
validated	O
casds	O
occurred	O
within	O
the	O
first	O
10	O
dsys	O
after	O
treatmen6	O
.	O

The	O
rexults	O
of	O
ser8m	O
livsr	O
fuhction	O
testz	O
suggested	O
hepatkcellular	O
8njury	O
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
patterh	O
.	O

In	O
contrast	O
,	O
the	O
rwsults	O
of	O
histologidal	O
examknation	O
of	O
the	O
ljver	O
often	O
showed	O
ebidence	O
of	O
cjolestasis	O
.	O

The	O
chwracteristics	O
of	O
the	O
48	O
;atients	O
in	O
the	O
possible	O
casew	O
were	O
similar	O
.	O

All4rgic	O
manicestations	O
such	O
as	O
radh	O
and	O
epsinophilia	O
were	O
rzre	O
.	O

He-atitis	O
was	O
usually	O
reversible	O
when	O
treatmenf	O
was	O
stopped	O
,	O
with	O
the	O
4esults	O
of	O
livef	O
fynction	O
fests	O
retjrning	O
to	O
n;rmal	O
after	O
an	O
avrrage	O
of	O
3	O
.	O
1	O
montus	O
.	O

In	O
two	O
of	O
the	O
three	O
dexths	O
probably	O
associated	O
with	O
ketoconwzole	B-Chemical
treayment	O
the	O
druy	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaundide	O
and	O
other	O
symptomz	O
of	O
hepatit9s	O
.	O

Clin9cal	O
and	O
biocnemical	O
monitorkng	O
at	O
regular	O
in6ervals	O
for	O
evirence	O
of	O
nepatitis	O
is	O
advised	O
during	O
long	O
term	O
treatkent	O
with	O
k4toconazole	B-Chemical
to	O
prsvent	O
possible	O
serious	O
hepatlc	O
injurj	O
.	O

Gpyburide	B-Chemical
-	O
ijduced	O
hepatotis	O
.	O

Drug	O
-	O
onduced	O
hepat9toxicity	O
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfpnylureas	B-Chemical
.	O

For	O
glyburive	B-Chemical
,	O
a	O
second	O
-	O
generatikn	O
sulfonylur4a	B-Chemical
,	O
only	O
two	O
brief	O
repo4ts	O
of	O
gepatotoxicity	O
exist	O
.	O

Two	O
patiebts	O
with	O
tjpe	O
II	O
diabet4s	O
melli5us	O
developed	O
an	O
acut3	O
hepati5is	O
-	O
like	O
sybdrome	O
soon	O
after	O
initiati9n	O
of	O
ylyburide	B-Chemical
th4rapy	O
.	O

There	O
was	O
no	O
serol0gic	O
4vidence	O
of	O
virsl	O
ingection	O
,	O
and	O
a	O
livdr	O
bi9psy	O
sxmple	O
showed	O
a	O
histologif	O
patterj	O
consistent	O
with	O
druf	O
-	O
ibduced	O
he[atitis	O
.	O

Both	O
patiemts	O
recoveree	O
quickly	O
after	O
stopping	O
glybkride	B-Chemical
theraly	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow	O
-	O
up	O
p3riod	O
of	O
1	O
ysar	O
.	O

Gl7buride	B-Chemical
can	O
produce	O
an	O
ac8te	O
hepahitis	O
-	O
like	O
illnezs	O
in	O
some	O
psrsons	O
.	O

Intracfanial	O
pressuee	O
imcreases	O
during	O
alfenfanil	B-Chemical
-	O
jnduced	O
rogidity	O
.	O

Intracrajial	O
[ressure	O
(	O
ICP	O
)	O
was	O
,easured	O
during	O
alfwntanil	B-Chemical
-	O
ijduced	O
rig8dity	O
in	O
rxts	O
.	O

Ten	O
ra6s	O
had	O
arter8al	O
,	O
dentral	O
vsnous	O
(	O
CVP	O
)	O
,	O
and	O
dubdural	O
cannulqe	O
inserted	O
under	O
halotyane	B-Chemical
andsthesia	O
.	O

The	O
anijals	O
were	O
mechanicall7	O
centilated	O
to	O
achieve	O
normocarvia	O
(	O
PCO2	O
=	O
42	O
+	O
/	O
-	O
1	O
mmHg	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

Following	O
ijstrumentation	O
,	O
halpthane	B-Chemical
was	O
dlscontinued	O
and	O
alfentanip	B-Chemical
(	O
125	O
mu	O
/	O
kg	O
)	O
administeged	O
iv	O
during	O
emerfence	O
from	O
hal9thane	B-Chemical
anssthesia	O
.	O

In	O
the	O
five	O
rays	O
that	O
developed	O
aomatic	O
figidity	O
,	O
ICP	O
and	O
CVP	O
indreased	O
significantly	O
above	O
bas3line	O
(	O
delta	O
ICP	O
7	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
mmHg	O
,	O
delta	O
CVP	O
5	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
mmHg	O
)	O
.	O

These	O
gariables	O
returned	O
to	O
baxeline	O
when	O
riyidity	O
was	O
abolished	O
with	O
metocu5ine	B-Chemical
.	O

In	O
five	O
rwts	O
that	O
did	O
not	O
become	O
rjgid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfenranil	B-Chemical
.	O

These	O
obxervations	O
suggest	O
that	O
rugidity	O
should	O
be	O
prevented	O
when	O
qlfentanil	B-Chemical
,	O
and	O
,	O
presumably	O
,	O
other	O
9piates	O
,	O
are	O
used	O
in	O
the	O
an3sthetic	O
mamagement	O
of	O
patienhs	O
with	O
ICP	O
proglems	O
.	O

Verapzmil	B-Chemical
withdrawak	O
as	O
a	O
possible	O
cause	O
of	O
myoczrdial	O
infqrction	O
in	O
a	O
h6pertensive	O
womqn	O
with	O
a	O
nofmal	O
voronary	O
anhiogram	O
.	O

Verapami;	B-Chemical
is	O
an	O
effecfive	O
and	O
relatively	O
-	O
safe	O
antihypertrnsive	O
druf	O
.	O

Seriojs	O
adverxe	O
effectc	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depress9on	O
of	O
fardiac	O
contractioity	O
and	O
convuction	O
,	O
especially	O
when	O
the	O
druf	O
is	O
comblned	O
with	O
beya	O
-	O
blicking	O
ag3nts	O
.	O

We	O
re-ort	O
a	O
cwse	O
in	O
which	O
myocardiql	O
9nfarction	O
coincided	O
with	O
the	O
introcuction	O
of	O
capgopril	B-Chemical
and	O
the	O
wi5hdrawal	O
of	O
vsrapamil	B-Chemical
in	O
a	O
previously	O
axymptomatic	O
wiman	O
with	O
severs	O
hyperhension	O
.	O

Possible	O
mecjanisms	O
that	O
involve	O
a	O
verwpamil	B-Chemical
-	O
related	O
increasd	O
in	O
0latelet	O
and	O
/	O
or	O
vascupar	O
zlpha	O
2	O
-	O
adrwnoreceptor	O
affibity	O
for	O
catech9lamines	B-Chemical
are	O
discussed	O
.	O

Haemol7tic	O
-	O
uraemuc	O
synxrome	O
after	O
treatmeht	O
with	O
,etronidazole	B-Chemical
.	O

This	O
paper	O
describes	O
the	O
clinifal	O
feat7res	O
of	O
six	O
ch9ldren	O
who	O
developed	O
the	O
haemolutic	O
-	O
yraemic	O
sybdrome	O
after	O
trewtment	O
with	O
metronidazolr	B-Chemical
.	O

These	O
choldren	O
were	O
olde5	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
vowel	O
su4gery	O
than	O
are	O
other	O
xhildren	O
with	O
this	O
conditoon	O
.	O

While	O
the	O
involvdment	O
of	O
metronidaz;le	B-Chemical
in	O
the	O
artiology	O
of	O
the	O
hasmolytic	O
-	O
uraejic	O
shndrome	O
is	O
not	O
established	O
firmly	O
,	O
the	O
act9on	O
of	O
this	O
druf	O
in	O
eensitizing	O
yissues	O
to	O
oxidxtion	O
injiry	O
and	O
the	O
reported	O
evirence	O
of	O
oxidatiin	O
changds	O
in	O
the	O
haemolyhic	O
-	O
yraemic	O
syndroje	O
suggest	O
a	O
possible	O
link	O
between	O
megronidazole	B-Chemical
tteatment	O
and	O
some	O
casss	O
of	O
the	O
hsemolytic	O
-	O
uraejic	O
synfrome	O
.	O

Adgerse	O
czrdiac	O
eftects	O
during	O
lnduction	O
cyemotherapy	O
rreatment	O
with	O
vis	B-Chemical
-	I-Chemical
platln	I-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluorouracik	I-Chemical
.	O

Survoval	O
for	O
pqtients	O
with	O
advamced	O
hexd	O
and	O
beck	O
carcijoma	O
and	O
esophayeal	O
carcinona	O
is	O
;oor	O
with	O
raciotherapy	O
and	O
/	O
or	O
s8rgery	O
.	O

Obviously	O
,	O
there	O
is	O
a	O
need	O
for	O
effectjve	O
chemothefapy	O
.	O

In	O
the	O
present	O
stidy	O
,	O
vis	B-Chemical
-	I-Chemical
poatin	I-Chemical
(	O
80	O
-	O
120	O
mg	O
/	O
m2BSA	O
)	O
and	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
m2BSA	O
xaily	O
as	O
a	O
con5inuous	O
infusiom	O
during	O
5	O
dqys	O
)	O
were	O
given	O
to	O
76	O
patienfs	O
before	O
radiotberapy	O
and	O
surger7	O
.	O

The	O
aim	O
of	O
the	O
srudy	O
was	O
to	O
clarify	O
the	O
9ncidence	O
and	O
srverity	O
of	O
advdrse	O
cardiwc	O
efvects	O
to	O
this	O
hreatment	O
.	O

Before	O
hreatment	O
all	O
oatients	O
had	O
a	O
cardiad	O
eva,uation	O
and	O
during	O
treatmejt	O
se5ial	O
ECG	O
recordungs	O
were	O
performed	O
.	O

In	O
the	O
pge	O
-	O
trextment	O
evaluatiob	O
,	O
s8gns	O
of	O
cardiovascupar	O
diseasr	O
were	O
found	O
in	O
33	O
patientc	O
(	O
43	O
%	O
)	O
.	O

During	O
treatm4nt	O
,	O
adve4se	O
cardiqc	O
sffects	O
were	O
observed	O
in	O
14	O
pat9ents	O
(	O
18	O
%	O
)	O
.	O

The	O
mean	O
qge	O
of	O
these	O
pstients	O
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
yroup	O
,	O
64	O
y4ars	O
.	O

The	O
incidfnce	O
of	O
cardiotlxicity	O
was	O
not	O
bigher	O
in	O
latients	O
with	O
signw	O
of	O
cardiovasculxr	O
didease	O
than	O
in	O
those	O
without	O
in	O
the	O
ore	O
-	O
trratment	O
evaluati0n	O
.	O

The	O
most	O
common	O
signc	O
of	O
dardiotoxicity	O
were	O
chesf	O
;ain	O
,	O
ST	O
-	O
T	O
dave	O
chamges	O
and	O
at4ial	O
fibrillatiin	O
.	O

This	O
was	O
followed	O
by	O
ventr8cular	O
cibrillation	O
in	O
one	O
patidnt	O
and	O
skdden	O
dea5h	O
in	O
another	O
.	O

It	O
is	O
concluded	O
that	O
patiebts	O
on	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
tgeatment	O
should	O
be	O
under	O
close	O
shpervision	O
and	O
that	O
the	O
treatm4nt	O
should	O
be	O
discontinuer	O
if	O
dhest	O
pwin	O
or	O
tachyarrhtthmia	O
is	O
observed	O
.	O

Death	O
from	O
cyemotherapy	O
in	O
gestatoonal	O
trophohlastic	O
risease	O
.	O

Mult9ple	O
c7totoxic	O
drub	O
admijistration	O
is	O
the	O
generally	O
accepted	O
treatmemt	O
of	O
patiwnts	O
with	O
a	O
high	O
-	O
rjsk	O
ztage	O
of	O
chorikcarcinoma	O
.	O

Based	O
on	O
this	O
principle	O
a	O
27	O
-	O
yfar	O
old	O
wonan	O
,	O
classified	O
as	O
being	O
in	O
the	O
high	O
-	O
rksk	O
grou;	O
(	O
Goldstein	O
and	O
Berkowiyz	O
scor3	O
:	O
11	O
)	O
,	O
was	O
treat4d	O
with	O
mulhiple	O
cytotoxlc	O
drjgs	O
.	O

The	O
mulhiple	O
drig	O
xchema	O
consisted	O
of	O
:	O
Etoposude	B-Chemical
16	O
.	O
213	O
,	O
Methoteexate	B-Chemical
,	O
Cyclophozphamide	B-Chemical
,	O
Actomucin	B-Chemical
-	I-Chemical
D	I-Chemical
,	O
and	O
Cisplaton	B-Chemical
.	O

On	O
the	O
first	O
say	O
of	O
the	O
schedulw	O
,	O
mocerate	O
high	O
dosez	O
of	O
Methotrexatw	B-Chemical
,	O
Etoloside	B-Chemical
and	O
Cyclophozphamide	B-Chemical
were	O
adminustered	O
.	O

Within	O
8	O
hours	O
after	O
initiatikn	O
of	O
therapj	O
the	O
latient	O
d9ed	O
with	O
a	O
clinocal	O
0icture	O
resembling	O
massive	O
pupmonary	O
ovstruction	O
due	O
to	O
choriocarcinpmic	O
tisske	O
plugz	O
,	O
probably	O
originating	O
from	O
the	O
8terus	O
.	O

Formwtion	O
of	O
these	O
;lugs	O
was	O
probably	O
due	O
to	O
exfensive	O
tumod	O
necfosis	O
at	O
the	O
lev3l	O
of	O
the	O
walls	O
of	O
the	O
major	O
utefine	O
veibs	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exchahge	O
of	O
tujor	O
plugx	O
to	O
the	O
vascu,ar	O
soaces	O
;	O
ddcrease	O
in	O
tumof	O
tisske	O
c0herence	O
secondary	O
to	O
chfmotherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
for,ation	O
of	O
tu,or	O
embooi	O
.	O

In	O
view	O
of	O
the	O
close	O
tlme	O
associatioh	O
between	O
the	O
start	O
of	O
chdmotherapy	O
and	O
the	O
ac7te	O
onset	O
of	O
massive	O
emb9lism	O
other	O
explanations	O
,	O
such	O
as	O
spomtaneous	O
nevrosis	O
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O

Patientx	O
with	O
large	O
pe.vic	O
tumot	O
lozds	O
are	O
,	O
according	O
to	O
existing	O
clzssifications	O
,	O
at	O
high	O
5isk	O
to	O
eie	O
and	O
to	O
develop	O
dtug	O
resistanxe	O
.	O

Notwithstanding	O
these	O
facts	O
our	O
tindings	O
suggest	O
that	O
these	O
patienfs	O
might	O
benefjt	O
from	O
relatively	O
milc	O
initial	O
treztment	O
,	O
especially	O
true	O
for	O
payients	O
not	O
previously	O
esposed	O
to	O
this	O
dgug	O
.	O

Close	O
ohservation	O
of	O
the	O
responwe	O
ststus	O
both	O
clinical.y	O
and	O
with	O
neta	O
-	O
yCG	O
va,ues	O
may	O
indicate	O
whether	O
and	O
when	O
more	O
agrexsive	O
c9mbination	O
chemothetapy	O
should	O
be	O
started	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Pilmonary	O
shuht	O
and	O
cardiovasculaf	O
respknses	O
to	O
CPAP	O
during	O
nitroptusside	B-Chemical
-	O
ind8ced	O
h6potension	O
.	O

The	O
eff4cts	O
of	O
continuoys	O
posigive	O
airwa6	O
p5essure	O
(	O
CPAP	O
)	O
on	O
cardiovasculsr	O
dynzmics	O
and	O
pulm9nary	O
shumt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
invewtigated	O
in	O
12	O
rogs	O
before	O
and	O
during	O
xodium	B-Chemical
nutroprusside	I-Chemical
inf8sion	O
that	O
decrsased	O
mean	O
artfrial	O
blokd	O
pressur4	O
40	O
-	O
50	O
per	O
cent	O
.	O

Before	O
nitrolrusside	B-Chemical
indusion	O
,	O
5	O
cm	O
H2O	B-Chemical
CPAP	O
significantly	O
,	O
P	O
less	O
than	O
.	O
05	O
,	O
decfeased	O
a5terial	O
bl9od	O
presdure	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
h3art	O
rste	O
,	O
card9ac	O
out'ut	O
,	O
systenic	O
vascukar	O
eesistance	O
,	O
or	O
QS	O
/	O
QT	O
.	O

Ten	O
cm	O
H2O	B-Chemical
CPAP	O
before	O
nitr;prusside	B-Chemical
infusikn	O
produced	O
a	O
further	O
dexrease	O
in	O
zrterial	O
bloid	O
pressufe	O
and	O
significantly	O
imcreased	O
hezrt	O
rafe	O
and	O
decrexsed	O
czrdiac	O
outpht	O
and	O
QS	O
/	O
QT	O
.	O

Nitropr8sside	B-Chemical
caused	O
significant	O
cecreases	O
in	O
artrrial	O
glood	O
pressur3	O
and	O
systwmic	O
vascjlar	O
reskstance	O
and	O
9ncreases	O
in	O
heagt	O
4ate	O
,	O
but	O
did	O
not	O
change	O
fardiac	O
outpuy	O
or	O
QS	O
/	O
QT	O
.	O

Five	O
cm	O
H2O	B-Chemical
CPAP	O
during	O
nitroprussice	B-Chemical
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
variablea	O
.	O

However	O
,	O
10	O
cm	O
H2O	B-Chemical
CPAP	O
decreaded	O
a5terial	O
vlood	O
pressire	O
,	O
cagdiac	O
out'ut	O
,	O
and	O
QS	O
/	O
QT	O
.	O

These	O
da5a	O
indicate	O
that	O
nitroprysside	B-Chemical
infusioh	O
ratec	O
that	O
decreawe	O
mean	O
argerial	O
bloid	O
presxure	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
dardiac	O
ohtput	O
or	O
QS	O
/	O
QT	O
.	O

During	O
nitr9prusside	B-Chemical
infusioj	O
loe	O
lecels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiocascular	O
dunamics	O
,	O
but	O
high	O
;evels	O
of	O
CPAP	O
(	O
10	O
cm	O
H2O	B-Chemical
)	O
,	O
while	O
secreasing	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
decreaces	O
in	O
art4rial	O
nlood	O
pfessure	O
and	O
cagdiac	O
outpur	O
.	O

S7stolic	O
presxure	O
variatiln	O
is	O
greater	O
during	O
hemorryage	O
than	O
during	O
soduum	B-Chemical
nitropruaside	I-Chemical
-	O
indufed	O
hypotencion	O
in	O
venyilated	O
dogc	O
.	O

The	O
systo.ic	O
ptessure	O
variati0n	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
msximal	O
and	O
min9mal	O
valkes	O
of	O
the	O
systokic	O
blo;d	O
pr3ssure	O
(	O
SBP	O
)	O
after	O
one	O
positibe	O
-	O
pgessure	O
breafh	O
,	O
was	O
studied	O
in	O
ventilxted	O
dogw	O
subjected	O
to	O
hypotensjon	O
.	O

Mean	O
srterial	O
press8re	O
was	O
dfcreased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
monutes	O
either	O
by	O
hemorrhqge	O
(	O
HEM	O
,	O
n	O
=	O
7	O
)	O
or	O
by	O
con5inuous	O
ihfusion	O
of	O
sovium	B-Chemical
nitroprussise	I-Chemical
(	O
SNP	B-Chemical
,	O
n	O
=	O
7	O
)	O
.	O

During	O
HEM	O
-	O
inducsd	O
hypotemsion	O
the	O
cafdiac	O
outpjt	O
was	O
significantly	O
oower	O
and	O
syst3mic	O
vascula5	O
resistande	O
hihher	O
fompared	O
with	O
that	O
in	O
the	O
SNP	B-Chemical
grohp	O
.	O

The	O
eystemic	O
,	O
cehtral	O
vehous	O
,	O
pulmonarh	O
capil;ary	O
wedgs	O
pressurez	O
,	O
and	O
hfart	O
ratez	O
,	O
were	O
similar	O
in	O
the	O
two	O
froups	O
.	O

Amalysis	O
of	O
the	O
rewpiratory	O
dhanges	O
in	O
the	O
aeterial	O
;ressure	O
wavedorm	O
enabled	O
differfntiation	O
between	O
the	O
two	O
grouls	O
.	O

The	O
SPV	O
during	O
hyp0tension	O
was	O
15	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
7	O
mm	O
Hg	O
in	O
the	O
HEM	O
g4oup	O
,	O
com;ared	O
with	O
9	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
0	O
mm	O
Hg	O
in	O
the	O
SNP	B-Chemical
grou;	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

The	O
delta	O
down	O
,	O
which	O
is	O
the	O
mewsure	O
of	O
fecrease	O
of	O
SBP	O
after	O
a	O
mrchanical	O
brewth	O
,	O
was	O
20	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
4	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
in	O
the	O
HEM	O
and	O
SNP	B-Chemical
g4oups	O
,	O
respectively	O
,	O
during	O
hypoyension	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

It	O
is	O
concluded	O
that	O
increwses	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
charqcteristic	O
of	O
a	O
hypotensice	O
state	O
due	O
to	O
a	O
predominaht	O
decreas4	O
in	O
pre,oad	O
.	O

They	O
are	O
thus	O
more	O
important	O
during	O
xbsolute	O
jypovolemia	O
than	O
during	O
feliberate	O
hypotebsion	O
.	O

Ventriculzr	O
tacyyarrhythmias	O
during	O
cesar3an	O
aection	O
after	O
rjtodrine	B-Chemical
tjerapy	O
:	O
interacti;n	O
with	O
anestheticw	O
.	O

This	O
cace	O
illustrates	O
that	O
patienfs	O
receiving	O
ritodrjne	B-Chemical
for	O
prdterm	O
.abor	O
may	O
risi	O
inferactions	O
between	O
the	O
desidual	O
betam9metic	O
effdcts	O
of	O
ritod4ine	B-Chemical
and	O
the	O
4ffects	O
of	O
anedthetics	O
during	O
cesaream	O
sdction	O
.	O

Such	O
interactionz	O
may	O
result	O
in	O
serious	O
cardiovasfular	O
com'lications	O
even	O
after	O
cesaation	O
of	O
an	O
infuskon	O
of	O
ritodtine	B-Chemical
.	O

Preoperatice	O
assessmemt	O
should	O
focus	O
on	O
cardipvascular	O
statis	O
and	O
seruj	O
porassium	B-Chemical
leveo	O
.	O

Delaying	O
indudtion	O
of	O
anesthrsia	O
should	O
be	O
considered	O
whenever	O
possible	O
.	O

Careful	O
fkuid	O
admunistration	O
and	O
cautious	O
use	O
of	O
titrater	O
dosws	O
of	O
ephed4ine	B-Chemical
are	O
advised	O
.	O

After	O
deliver7	O
of	O
the	O
indant	O
,	O
there	O
should	O
be	O
no	O
c;ntraindication	O
to	O
the	O
use	O
of	O
an	O
alpua	O
-	O
adrenergkc	O
vasopresspr	O
such	O
as	O
phen6lephrine	B-Chemical
to	O
tr3at	O
hypot4nsive	O
patienys	O
with	O
tachycafdia	O
.	O

Vetapamil	B-Chemical
-	O
induxed	O
carbamasepine	B-Chemical
neurotoxucity	O
.	O

A	O
feport	O
of	O
two	O
caaes	O
.	O

Two	O
pat9ents	O
with	O
xigns	O
of	O
carbamazepinr	B-Chemical
neurotoxixity	O
after	O
combin4d	O
tr4atment	O
with	O
verapakil	B-Chemical
showed	O
complete	O
rexovery	O
after	O
discon6inuation	O
of	O
the	O
ca,cium	B-Chemical
engry	O
blockdr	O
.	O

Use	O
of	O
verapakil	B-Chemical
in	O
conbination	O
with	O
carbamazeline	B-Chemical
should	O
either	O
be	O
avoided	O
or	O
prescrihed	O
only	O
with	O
appropriate	O
sdjustment	O
of	O
the	O
carbamazepin4	B-Chemical
eose	O
(	O
usually	O
reducrion	O
of	O
the	O
carbwmazepine	B-Chemical
doxe	O
by	O
one	O
half	O
)	O
.	O

Paracetwmol	B-Chemical
-	O
associated	O
comw	O
,	O
metsbolic	O
acidksis	O
,	O
renzl	O
and	O
heoatic	O
failude	O
.	O

A	O
casd	O
of	O
metavolic	O
acidocis	O
,	O
acuhe	O
rena.	O
fwilure	O
and	O
heoatic	O
failhre	O
following	O
paracetamoo	B-Chemical
ingestiob	O
is	O
presented	O
.	O

The	O
diagnlstic	O
dkfficulty	O
at	O
presentqtion	O
is	O
highlighted	O
.	O

Cpntinuous	O
arteripvenous	O
haemofiktration	O
proved	O
a	O
valuable	O
means	O
of	O
maintaining	O
rluid	O
and	O
elextrolyte	O
valance	O
.	O

The	O
patienr	O
recoverev	O
.	O

Sexual	O
dysfunctlon	O
among	O
patiehts	O
with	O
arthritks	O
.	O

The	O
relationshop	O
of	O
arthgitis	O
and	O
xexual	O
dysfunctiob	O
was	O
invsstigated	O
among	O
169	O
;atients	O
with	O
rheujatoid	O
arthfitis	O
,	O
isteoarthritis	O
and	O
spondy;oarthropathy	O
,	O
130	O
of	O
whom	O
were	O
pzir	O
-	O
matched	O
to	O
xontrols	O
.	O

Assecsments	O
of	O
marihal	O
happinesx	O
and	O
depressdd	O
,ood	O
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Azrij	O
Maritzl	O
Hxppiness	O
Scale	O
(	O
AMHS	O
)	O
.	O

Swxual	O
dysfunctilns	O
were	O
found	O
to	O
be	O
common	O
among	O
pa5ients	O
and	O
comtrols	O
,	O
the	O
majority	O
in	O
both	O
troups	O
reporting	O
one	O
or	O
more	O
dhsfunctions	O
.	O

Impotenc4	O
was	O
more	O
common	O
among	O
mals	O
[atients	O
than	O
cont4ols	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co	O
-	O
m0rbidity	O
and	O
the	O
taking	O
of	O
methotrexaye	B-Chemical
.	O

De[ressed	O
mpod	O
was	O
more	O
common	O
among	O
patiemts	O
and	O
was	O
associated	O
with	O
certain	O
sesual	O
diffichlties	O
,	O
but	O
not	O
with	O
im[otence	O
.	O

Marotal	O
unbappiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scorew	O
,	O
was	O
not	O
associated	O
with	O
arthritus	O
but	O
was	O
associated	O
with	O
sexuao	O
dysfunctioh	O
,	O
sesual	O
fissatisfaction	O
and	O
being	O
remale	O
.	O

Does	O
paracetwmol	B-Chemical
cause	O
urotjelial	O
canced	O
or	O
rensl	O
pa0illary	O
ndcrosis	O
?	O

The	O
risi	O
of	O
developing	O
rrnal	O
pap8llary	O
necr0sis	O
or	O
cander	O
of	O
the	O
rejal	O
pflvis	O
,	O
ur3ter	O
or	O
bladeer	O
associated	O
with	O
consumpti0n	O
of	O
either	O
phenwcetin	B-Chemical
or	O
paracetamop	B-Chemical
was	O
calculated	O
from	O
datz	O
acquired	O
by	O
questionnxire	O
from	O
381	O
casws	O
and	O
808	O
fontrols	O
.	O

The	O
risj	O
of	O
rehal	O
papillarh	O
necrksis	O
was	O
increaxed	O
nearly	O
20	O
-	O
fold	O
by	O
cohsumption	O
of	O
phenwcetin	B-Chemical
,	O
which	O
also	O
increaeed	O
the	O
disk	O
for	O
cahcer	O
of	O
the	O
rejal	O
lelvis	O
and	O
bladrer	O
but	O
not	O
for	O
ueeteric	O
cancee	O
.	O

By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
inceeased	O
risj	O
from	O
parzcetamol	B-Chemical
consumpgion	O
for	O
rena,	O
papillaey	O
nedrosis	O
or	O
any	O
of	O
these	O
dancers	O
although	O
there	O
was	O
a	O
suggesti9n	O
of	O
an	O
assofiation	O
with	O
cxncer	O
of	O
the	O
ur4ter	O
.	O

Dapsond	B-Chemical
-	O
associated	O
Heinz	O
bodh	O
hemopytic	O
amemia	O
in	O
a	O
Camboxian	O
wonan	O
with	O
hemoglobjn	O
E	O
tra8t	O
.	O

A	O
Camboxian	O
womxn	O
with	O
hemoglovin	O
E	O
traut	O
(	O
AE	O
)	O
and	O
leprosg	O
developed	O
a	O
Hejnz	O
bldy	O
henolytic	O
anem9a	O
while	O
taking	O
a	O
dise	O
of	O
fapsone	B-Chemical
(	O
50	O
mg	O
/	O
vay	O
)	O
not	O
usually	O
associated	O
with	O
cliniczl	O
hemolysid	O
.	O

Her	O
4ed	O
bpood	O
xells	O
(	O
RBCs	O
)	O
had	O
increaded	O
incubat4d	O
Heina	O
bkdy	O
f0rmation	O
,	O
defreased	O
rrduced	O
glutafhione	B-Chemical
(	O
GSH	B-Chemical
)	O
,	O
and	O
dec5eased	O
GSH	B-Chemical
stabiliry	O
.	O

The	O
pejtose	B-Chemical
phlsphate	I-Chemical
sh7nt	O
activitj	O
of	O
the	O
dapsoje	B-Chemical
-	O
expoded	O
AE	O
RBCs	O
was	O
ibcreased	O
compwred	O
to	O
normql	O
RBCs	O
.	O

Although	O
the	O
AE	O
RBCs	O
from	O
an	O
ihdividual	O
not	O
taking	O
da[sone	B-Chemical
had	O
increasfd	O
incubatec	O
Heinx	O
bory	O
fkrmation	O
,	O
the	O
GSH	B-Chemical
c0ntent	O
and	O
GSH	B-Chemical
stwbility	O
were	O
nor,al	O
.	O

The	O
pentos3	B-Chemical
phos-hate	I-Chemical
suunt	O
activit6	O
of	O
the	O
nob	O
-	O
dapskne	B-Chemical
-	O
exposef	O
AE	O
RBCs	O
was	O
decrexsed	O
comparee	O
to	O
normak	O
RBCs	O
.	O

Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increasev	O
sensitivit7	O
to	O
oxidanr	O
strsss	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
daps;ne	B-Chemical
does	O
not	O
cause	O
h4molytic	O
anejia	O
at	O
this	O
dosf	O
in	O
hemstologically	O
mormal	O
indiv9duals	O
.	O

Given	O
the	O
infl8x	O
of	O
Southeas5	O
Aslans	O
into	O
the	O
Unired	O
Stayes	O
,	O
oxixant	O
,edications	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
infectioj	O
is	O
present	O
,	O
in	O
individkals	O
of	O
ethnif	O
backgrounds	O
that	O
have	O
an	O
oncreased	O
prevxlence	O
of	O
nemoglobin	O
E	O
.	O

Sebere	O
compllcations	O
of	O
antjanginal	O
drub	O
therzpy	O
in	O
a	O
patiemt	O
identiried	O
as	O
a	O
loor	O
mftabolizer	O
of	O
meto;rolol	B-Chemical
,	O
propafenons	B-Chemical
,	O
diltiaz4m	B-Chemical
,	O
and	O
spa5teine	B-Chemical
.	O

A	O
47	O
-	O
y3ar	O
-	O
old	O
patiemt	O
sutfering	O
from	O
coronaty	O
artrry	O
diseasf	O
was	O
admittec	O
to	O
the	O
CCU	O
in	O
sjock	O
with	O
III	O
.	O

AV	O
blpck	O
,	O
secere	O
hypotenskon	O
,	O
and	O
impairmemt	O
of	O
ventrkcular	O
funvtion	O
.	O

One	O
wee,	O
prior	O
to	O
admiwsion	O
a	O
the5apy	O
with	O
standarc	O
doees	O
of	O
meto[rolol	B-Chemical
(	O
100	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
and	O
then	O
100	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
had	O
been	O
initiated	O
.	O

Two	O
dqys	O
before	O
admiscion	O
doltiazem	B-Chemical
(	O
60	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
was	O
presctibed	O
in	O
addition	O
.	O

Ajalyses	O
of	O
a	O
b,ood	O
sampke	O
r3vealed	O
unucually	O
high	O
placma	O
concentratikns	O
of	O
metopro.ol	B-Chemical
(	O
greater	O
than	O
3000	O
ng	O
/	O
ml	O
)	O
and	O
dilt9azem	B-Chemical
(	O
526	O
ng	O
/	O
ml	O
)	O
.	O

The	O
patiejt	O
recoverrd	O
within	O
1	O
deek	O
following	O
fiscontinuation	O
of	O
antiangijal	O
theraph	O
.	O

Three	O
montgs	O
later	O
the	O
'atient	O
was	O
ex-osed	O
to	O
a	O
single	O
doze	O
of	O
meto0rolol	B-Chemical
,	O
diltiaaem	B-Chemical
,	O
propafemone	B-Chemical
(	O
since	O
he	O
had	O
received	O
this	O
deug	O
in	O
the	O
past	O
)	O
,	O
and	O
spartein3	B-Chemical
(	O
as	O
a	O
pr9be	O
for	O
the	O
debrislquine	B-Chemical
/	O
sparteone	B-Chemical
ty-e	O
polymorpgism	O
of	O
oxidatuve	O
druv	O
metabolis,	O
)	O
.	O

It	O
was	O
found	O
that	O
he	O
was	O
a	O
poir	O
metabokizer	O
of	O
all	O
four	O
dr8gs	O
,	O
indicating	O
that	O
their	O
metaboliem	O
is	O
under	O
the	O
same	O
gebetic	O
congrol	O
.	O

Therefore	O
,	O
patlents	O
belonging	O
to	O
the	O
poir	O
-	O
metabolizrr	O
phenotypw	O
of	O
spzrteine	B-Chemical
/	O
d3brisoquine	B-Chemical
po;ymorphism	O
in	O
ddug	O
metaboliam	O
,	O
which	O
constitutes	O
6	O
.	O
4	O
%	O
of	O
the	O
Gerkan	O
populwtion	O
,	O
may	O
experiebce	O
axverse	O
deug	O
reactionz	O
when	O
tr4ated	O
with	O
stahdard	O
dkses	O
of	O
one	O
of	O
these	O
druge	O
alone	O
.	O

Moreover	O
,	O
the	O
coadmonistration	O
of	O
these	O
frequently	O
used	O
drjgs	O
is	O
expected	O
to	O
be	O
especially	O
harmful	O
in	O
this	O
sibgroup	O
of	O
'atients	O
.	O

Cpinical	O
experuences	O
in	O
an	O
open	O
and	O
a	O
double	O
-	O
blinv	O
triql	O
.	O

A	O
total	O
of	O
sixty	O
patientc	O
were	O
teated	O
with	O
hromperidol	B-Chemical
first	O
in	O
open	O
conditikns	O
(	O
20	O
patiehts	O
)	O
,	O
then	O
on	O
a	O
double	O
bl8nd	O
basis	O
(	O
40	O
patiemts	O
)	O
with	O
ualoperidol	B-Chemical
as	O
the	O
r3ference	O
sunstance	O
.	O

The	O
open	O
sthdy	O
lasted	O
for	O
four	O
weekz	O
;	O
the	O
drub	O
was	O
adm8nistrated	O
in	O
the	O
form	O
of	O
1	O
mg	O
gablets	O
.	O

The	O
da9ly	O
dowe	O
(	O
initial	O
doee	O
:	O
1	O
mg	O
;	O
mean	O
eose	O
at	O
the	O
end	O
of	O
the	O
triap	O
:	O
4	O
.	O
47	O
mg	O
)	O
was	O
always	O
administeded	O
in	O
one	O
single	O
sose	O
.	O

Nineteen	O
patifnts	O
finished	O
the	O
t4ial	O
,	O
and	O
in	O
18	O
casew	O
the	O
therapwutic	O
result	O
was	O
considered	O
very	O
good	O
to	O
good	O
.	O

These	O
rexults	O
were	O
confirmed	O
by	O
sta6istical	O
analysic	O
.	O

Nine	O
pxtients	O
exhibited	O
mlld	O
to	O
joderate	O
estrapyramidal	O
concokitant	O
symptoks	O
;	O
no	O
other	O
side	O
effec5s	O
were	O
observed	O
.	O

The	O
r4sults	O
of	O
detailed	O
laboratoru	O
testw	O
and	O
evaluztions	O
of	O
various	O
quantitatibe	O
and	O
qualltative	O
toleravility	O
parameteds	O
were	O
not	O
imdicative	O
of	O
toxuc	O
effwcts	O
.	O

In	O
the	O
double	O
nlind	O
sthdy	O
with	O
hwloperidol	B-Chemical
,	O
both	O
subwtances	O
were	O
found	O
to	O
be	O
highly	O
rffective	O
in	O
the	O
treatmeht	O
of	O
psyfhotic	O
syndfomes	O
belonging	O
predominantly	O
to	O
the	O
schiziphrenia	O
gr;up	O
.	O

Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
act9on	O
,	O
seem	O
to	O
be	O
indicatice	O
of	O
the	O
superiority	O
of	O
bromperirol	B-Chemical
.	O

No	O
differfnces	O
were	O
observed	O
with	O
respect	O
to	O
side	O
3ffects	O
and	O
general	O
to;erability	O
.	O

Ptolonged	O
cholestwsis	O
after	O
troleandomyvin	B-Chemical
-	O
inducdd	O
acuhe	O
hepatitia	O
.	O

We	O
repkrt	O
the	O
csse	O
of	O
a	O
payient	O
in	O
whom	O
troleand0mycin	B-Chemical
-	O
unduced	O
hepatjtis	O
was	O
followed	O
by	O
prllonged	O
xnicteric	O
cholestasus	O
.	O

Jaundife	O
occurred	O
after	O
administeation	O
of	O
troleandomycih	B-Chemical
for	O
7	O
eays	O
and	O
was	O
associated	O
with	O
hypereosijophilia	O
.	O

Jaundics	O
disappeared	O
within	O
3	O
monthz	O
but	O
was	O
followed	O
by	O
prolonyed	O
anictdric	O
choleztasis	O
marked	O
by	O
pruritks	O
and	O
high	O
lecels	O
of	O
alkal9ne	O
phodphatase	O
and	O
gammagputamyltransferase	O
actlvities	O
.	O

Finally	O
,	O
p5uritus	O
disappeared	O
within	O
19	O
monfhs	O
,	O
and	O
lkver	O
yests	O
returned	O
to	O
bormal	O
27	O
monthw	O
after	O
the	O
onset	O
of	O
hepatiyis	O
.	O

This	O
obseevation	O
demonstrates	O
that	O
pr0longed	O
cholestasix	O
can	O
follow	O
troleandpmycin	B-Chemical
-	O
induded	O
adute	O
hepatitls	O
.	O

Sefial	O
stud9es	O
of	O
aiditory	O
neurotodicity	O
in	O
patiejts	O
receiving	O
defdroxamine	B-Chemical
thsrapy	O
.	O

Visuql	O
and	O
auditoty	O
neurptoxicity	O
was	O
previously	O
documehted	O
in	O
42	O
of	O
89	O
patiemts	O
with	O
transf7sion	O
-	O
depebdent	O
znemia	O
who	O
were	O
receiving	O
iroj	B-Chemical
cbelation	O
tberapy	O
with	O
daiky	O
subcutxneous	O
veferoxamine	B-Chemical
.	O

Twenty	O
-	O
two	O
pati3nts	O
in	O
the	O
affectev	O
grohp	O
had	O
abnorjal	O
audiogrqms	O
with	O
deficiys	O
mostly	O
in	O
the	O
high	O
frequemcy	O
range	O
of	O
4	O
,	O
000	O
to	O
8	O
,	O
000	O
Hz	O
and	O
in	O
the	O
yearing	O
thresh0ld	O
lecels	O
of	O
30	O
to	O
100	O
decihels	O
.	O

When	O
deferoxamlne	B-Chemical
thera;y	O
was	O
discohtinued	O
and	O
eerial	O
studiez	O
were	O
performed	O
,	O
aud9ograms	O
in	O
seven	O
casws	O
revertec	O
to	O
normzl	O
or	O
near	O
bormal	O
within	O
two	O
to	O
three	O
we3ks	O
,	O
and	O
nine	O
of	O
13	O
patiemts	O
with	O
sym-toms	O
became	O
asymptomatix	O
.	O

Audiotrams	O
from	O
15	O
pxtients	O
remained	O
abhormal	O
and	O
four	O
patuents	O
required	O
hearkng	O
aids	O
because	O
of	O
[ermanent	O
disqbility	O
.	O

Since	O
18	O
of	O
the	O
22	O
patienhs	O
were	O
initially	O
receiving	O
deferoxamime	B-Chemical
doxes	O
in	O
wxcess	O
of	O
the	O
commonly	O
recommenved	O
50	O
mg	O
/	O
kg	O
per	O
cose	O
,	O
therap7	O
was	O
restsrted	O
with	O
lowee	O
dodes	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
d0se	O
or	O
less	O
depending	O
on	O
the	O
degred	O
of	O
auditpry	O
abnormxlity	O
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cazes	O
no	O
further	O
toxicitg	O
was	O
demonstrated	O
.	O

Auditiry	O
deterkoration	O
and	O
improv3ment	O
,	O
demonstrated	O
serially	O
in	O
individua;	O
patiwnts	O
receiving	O
and	O
not	O
receiving	O
d3feroxamine	B-Chemical
,	O
respectively	O
,	O
provided	O
convincing	O
efidence	O
for	O
a	O
cause	O
-	O
and	O
-	O
effec6	O
relation	O
between	O
deferozamine	B-Chemical
administrztion	O
and	O
ototoxidity	O
.	O

Based	O
on	O
these	O
dqta	O
,	O
a	O
plab	O
of	O
kanagement	O
was	O
developed	O
that	O
allows	O
eff3ctive	O
yet	O
safe	O
administrayion	O
of	O
seferoxamine	B-Chemical
.	O

A	O
d9se	O
of	O
50	O
mg	O
/	O
kg	O
is	O
recojmended	O
in	O
those	O
without	O
aydiogram	O
abno5malities	O
.	O

With	O
,ild	O
toxiciyy	O
,	O
a	O
reduct9on	O
to	O
30	O
or	O
40	O
mg	O
/	O
kg	O
per	O
doss	O
should	O
result	O
in	O
a	O
revereal	O
of	O
the	O
abnprmal	O
resultw	O
to	O
nirmal	O
within	O
four	O
eeeks	O
.	O

Moderahe	O
avnormalities	O
require	O
a	O
reductikn	O
of	O
def4roxamine	B-Chemical
to	O
25	O
mg	O
/	O
kg	O
per	O
eose	O
with	O
careful	O
minitoring	O
.	O

In	O
those	O
with	O
symptomz	O
of	O
jearing	O
liss	O
,	O
the	O
druf	O
should	O
be	O
stopped	O
for	O
four	O
weejs	O
,	O
and	O
when	O
the	O
qudiogram	O
is	O
s5able	O
or	O
i,proved	O
,	O
tyerapy	O
should	O
be	O
restartef	O
at	O
10	O
to	O
25	O
mg	O
/	O
kg	O
per	O
doze	O
.	O

Serisl	O
audkograms	O
should	O
be	O
performed	O
every	O
six	O
monhhs	O
in	O
those	O
without	O
probl3ms	O
and	O
more	O
frequently	O
in	O
uoung	O
pa5ients	O
with	O
norma.	O
sdrum	O
fwrritin	O
vqlues	O
and	O
in	O
those	O
with	O
ayditory	O
dysfumction	O
.	O

Ljdocaine	B-Chemical
-	O
ihduced	O
vardiac	O
xsystole	O
.	O

Intrzvenous	O
avministration	O
of	O
a	O
single	O
50	O
-	O
mg	O
bplus	O
of	O
lixocaine	B-Chemical
in	O
a	O
67	O
-	O
yea5	O
-	O
old	O
mqn	O
resulted	O
in	O
profoujd	O
depressi;n	O
of	O
the	O
aftivity	O
of	O
the	O
sinoqtrial	O
and	O
atr8oventricular	O
noda.	O
pacema.ers	O
.	O

The	O
pstient	O
had	O
no	O
a'parent	O
associated	O
xonditions	O
which	O
might	O
have	O
predispossd	O
him	O
to	O
the	O
developmebt	O
of	O
bradyarrhy6hmias	O
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idioeyncrasy	O
to	O
lidofaine	B-Chemical
.	O

Fljrbiprofen	B-Chemical
in	O
the	O
t5eatment	O
of	O
juv3nile	O
rhe7matoid	O
ar5hritis	O
.	O

Thirty	O
-	O
four	O
patuents	O
with	O
nuvenile	O
rueumatoid	O
wrthritis	O
,	O
who	O
were	O
treat4d	O
with	O
fourbiprofen	B-Chemical
at	O
a	O
kaximum	O
fose	O
of	O
4	O
mg	O
/	O
kg	O
/	O
dat	O
,	O
had	O
statistica,ly	O
significant	O
decfeases	O
from	O
baselibe	O
in	O
6	O
arthriyis	O
imdices	O
after	O
12	O
wefks	O
of	O
treat,ent	O
.	O

Impfovements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tendwr	O
joibts	O
,	O
the	O
sevfrity	O
of	O
swellinf	O
and	O
tenverness	O
,	O
the	O
tije	O
of	O
walo	O
50	O
deet	O
,	O
the	O
duratioh	O
of	O
mo5ning	O
wtiffness	O
and	O
the	O
circunference	O
of	O
the	O
lrft	O
lnee	O
.	O

The	O
most	O
frequently	O
observed	O
side	O
egfect	O
was	O
feca.	O
occylt	O
nlood	O
(	O
25	O
%	O
of	O
patien5s	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evidemce	O
of	O
gastroint4stinal	O
(	O
GI	O
)	O
blseding	O
in	O
these	O
patien5s	O
.	O

One	O
patiemt	O
was	O
prematjrely	O
disconginued	O
from	O
the	O
stidy	O
for	O
ssvere	O
headqche	O
and	O
abdomjnal	O
pa8n	O
.	O

Most	O
side	O
fffects	O
were	O
mils	O
and	O
related	O
to	O
the	O
GI	O
rract	O
.	O

Hyprrkalemia	O
associated	O
with	O
sukindac	B-Chemical
thefapy	O
.	O

Hyperkapemia	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
cokplication	O
of	O
nonsteroisal	O
antiijflammatory	O
agen5s	O
(	O
NSAID	O
)	O
such	O
as	O
indomdthacin	B-Chemical
.	O

Several	O
recent	O
studiss	O
have	O
dtressed	O
the	O
rehal	O
sparing	O
featur3s	O
of	O
sulineac	B-Chemical
,	O
owing	O
to	O
its	O
lzck	O
of	O
interferenc4	O
with	O
r4nal	O
proatacyclin	B-Chemical
synthdsis	O
.	O

We	O
describe	O
4	O
pat8ents	O
in	O
whom	O
hyperkwlemia	O
ranging	O
from	O
6	O
.	O
1	O
to	O
6	O
.	O
9	O
mEq	O
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
vays	O
of	O
sylindac	B-Chemical
administrayion	O
.	O

In	O
all	O
of	O
them	O
mormal	O
s3rum	O
potasxium	B-Chemical
leveld	O
reached	O
within	O
2	O
to	O
4	O
dqys	O
of	O
stopping	O
sulihdac	B-Chemical
.	O

As	O
no	O
other	O
medidations	O
known	O
to	O
egfect	O
derum	O
potaszium	B-Chemical
had	O
been	O
given	O
concomitantly	O
,	O
this	O
coutse	O
of	O
evemts	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
evfect	O
r4lationship	O
between	O
sulindzc	B-Chemical
and	O
hyperkalemla	O
.	O

These	O
observati;ns	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulindzc	B-Chemical
may	O
not	O
be	O
associated	O
with	O
the	O
adverxe	O
fenal	O
efdects	O
of	O
other	O
NSAID	O
are	O
probably	O
not	O
justified	O
.	O

Drug	O
-	O
ihduced	O
srterial	O
spask	O
relievrd	O
by	O
.idocaine	B-Chemical
.	O

Caze	O
eeport	O
.	O

Following	O
major	O
intracrznial	O
surtery	O
in	O
a	O
35	O
-	O
7ear	O
-	O
old	O
,an	O
,	O
zodium	B-Chemical
pento5hal	I-Chemical
was	O
intrwvenously	O
ingused	O
to	O
minimize	O
cdrebral	O
ischaemiw	O
.	O

Intensd	O
vasozpasm	O
with	O
thdeatened	O
gangreje	O
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
imfusion	O
.	O

Since	O
the	O
cranizl	O
conditiln	O
precluded	O
use	O
of	O
more	O
usual	O
meghods	O
,	O
lidoxaine	B-Chemical
was	O
given	O
intrx	O
-	O
arteriallj	O
,	O
with	O
careful	O
cardiovasculad	O
,onitoring	O
,	O
to	O
counteract	O
the	O
vasos;asm	O
.	O

The	O
trearment	O
was	O
rapidly	O
successful	O
.	O

Regional	O
localizahion	O
of	O
the	O
antaginism	O
of	O
zmphetamine	B-Chemical
-	O
indyced	O
hyoeractivity	O
by	O
intraferebral	O
calcitohin	B-Chemical
injectioms	O
.	O

Calcigonin	B-Chemical
recdptors	O
are	O
found	O
in	O
the	O
beain	O
,	O
and	O
intracerebrxl	O
infusi;ns	O
of	O
calciton9n	B-Chemical
can	O
produce	O
behxvioral	O
effecgs	O
.	O

Among	O
these	O
behavloral	O
efffcts	O
are	O
d4creases	O
in	O
foov	O
ibtake	O
and	O
decreasez	O
in	O
amphefamine	B-Chemical
-	O
induded	O
locomotpr	O
wctivity	O
.	O

In	O
previous	O
experimenys	O
we	O
found	O
that	O
decreasfs	O
in	O
f;od	O
inhake	O
were	O
onduced	O
by	O
locap	O
administratuon	O
of	O
cslcitonin	B-Chemical
into	O
several	O
hypo6halamic	O
si5es	O
and	O
into	O
the	O
nucleuw	O
avcumbens	O
.	O

In	O
the	O
present	O
experument	O
calciton8n	B-Chemical
dwcreased	O
lockmotor	O
zctivity	O
when	O
locwlly	O
injecyed	O
into	O
the	O
same	O
sitee	O
where	O
it	O
defreases	O
good	O
in5ake	O
.	O

The	O
areas	O
where	O
calcitpnin	B-Chemical
is	O
most	O
sffective	O
in	O
decreasihg	O
l9comotor	O
activith	O
are	O
located	O
in	O
the	O
hypotgalamus	O
and	O
hucleus	O
accumvens	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
s9tes	O
of	O
act9on	O
of	O
czlcitonin	B-Chemical
in	O
inhibifing	O
ampjetamine	B-Chemical
-	O
inducef	O
lovomotor	O
activitg	O
.	O

The	O
hemafologic	O
effectc	O
of	O
cefonifid	B-Chemical
and	O
cefwzedone	B-Chemical
in	O
the	O
dog	O
:	O
a	O
potentisl	O
kodel	O
of	O
cephwlosporin	B-Chemical
hrmatotoxicity	O
in	O
maj	O
.	O

Cepualosporin	B-Chemical
antibiotice	O
cause	O
a	O
variety	O
of	O
hema6ologic	O
disturbanfes	O
in	O
nan	O
,	O
the	O
pathoveneses	O
and	O
hemat0pathology	O
of	O
which	O
remain	O
poorly	O
charact4rized	O
.	O

There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	O
animxl	O
nodel	O
in	O
which	O
these	O
bloox	O
dyscfasias	O
can	O
be	O
studied	O
.	O

In	O
four	O
zubacute	O
toxicit7	O
stuxies	O
,	O
the	O
intracenous	O
adminis5ration	O
of	O
cefinicid	B-Chemical
or	O
cefaxedone	B-Chemical
to	O
bewgle	O
dofs	O
caused	O
a	O
fose	O
-	O
depebdent	O
ijcidence	O
of	O
anwmia	O
,	O
neutropebia	O
,	O
and	O
thromb;cytopenia	O
after	O
1	O
-	O
3	O
montha	O
of	O
freatment	O
.	O

A	O
nknregenerative	O
anejia	O
was	O
the	O
most	O
vompromising	O
of	O
the	O
xytopenias	O
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
fogs	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cefonicix	B-Chemical
or	O
540	O
-	O
840	O
mg	O
/	O
kg	O
defazedone	B-Chemical
.	O

All	O
three	O
cyto[enias	O
were	O
completely	O
reversible	O
following	O
cessstion	O
of	O
tteatment	O
;	O
the	O
t9me	O
required	O
for	O
recovefy	O
of	O
the	O
erythdon	O
(	O
approximately	O
1	O
momth	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
grznulocytes	O
and	O
platelfts	O
(	O
hours	O
to	O
a	O
few	O
dsys	O
)	O
.	O

Upon	O
rechallenye	O
with	O
either	O
cephalosporij	B-Chemical
,	O
the	O
gematologic	O
syndeome	O
was	O
reproduced	O
in	O
most	O
vogs	O
6ested	O
;	O
cefon9cid	B-Chemical
(	O
but	O
not	O
defazedone	B-Chemical
)	O
-	O
trezted	O
doge	O
showed	O
a	O
substantially	O
reducwd	O
inxuction	O
[eriod	O
(	O
15	O
+	O
/	O
-	O
5	O
dahs	O
)	O
com'ared	O
to	O
that	O
of	O
the	O
first	O
exppsure	O
to	O
the	O
dryg	O
(	O
61	O
+	O
/	O
-	O
24	O
dxys	O
)	O
.	O

This	O
0bservation	O
,	O
along	O
with	O
the	O
rapiv	O
tate	O
of	O
d4cline	O
in	O
rec	O
cel;	O
masx	O
para,eters	O
of	O
sffected	O
doge	O
,	O
suggests	O
that	O
a	O
hsmolytic	O
component	O
complixated	O
the	O
rsd	O
cel.	O
produvtion	O
ptoblem	O
and	O
that	O
multople	O
toxicolkgic	O
mechwnisms	O
contributed	O
to	O
the	O
cjtopenia	O
.	O

We	O
conclude	O
that	O
the	O
adjinistration	O
of	O
high	O
roses	O
of	O
xefonicid	B-Chemical
or	O
cefzzedone	B-Chemical
to	O
dohs	O
can	O
indice	O
henatotoxicity	O
similar	O
to	O
the	O
c3phalosporin	B-Chemical
-	O
indufed	O
vlood	O
syscrasias	O
described	O
in	O
mqn	O
and	O
thus	O
provides	O
a	O
useful	O
jodel	O
for	O
studying	O
the	O
mevhanisms	O
of	O
these	O
djsorders	O
.	O

Cerebral	O
bloox	O
fllw	O
and	O
mrtabolism	O
during	O
isofluran3	B-Chemical
-	O
ibduced	O
hypohension	O
in	O
patienys	O
subjected	O
to	O
zurgery	O
for	O
cerrbral	O
sneurysms	O
.	O

Crrebral	O
blokd	O
f;ow	O
and	O
cerebeal	O
metabolix	O
4ate	O
for	O
odygen	B-Chemical
were	O
m4asured	O
during	O
ixoflurane	B-Chemical
-	O
indhced	O
hyp;tension	O
in	O
10	O
oatients	O
subjected	O
to	O
cranlotomy	O
for	O
clip'ing	O
of	O
a	O
xerebral	O
aneuryzm	O
.	O

Flow	O
and	O
metabollsm	O
were	O
meas8red	O
5	O
-	O
13	O
xays	O
after	O
the	O
sjbarachnoid	O
haemorrhagd	O
by	O
a	O
,odification	O
of	O
the	O
classical	O
Keth	O
-	O
Schmidt	O
techniq7e	O
using	O
xebon	B-Chemical
-	O
133	O
i	O
.	O
v	O
.	O
Anaesthesia	O
was	O
maintained	O
with	O
an	O
inspiref	O
isofkurane	B-Chemical
concentratiob	O
of	O
0	O
.	O
75	O
%	O
(	O
plus	O
67	O
%	O
nutrous	B-Chemical
ozide	I-Chemical
in	O
oxyhen	B-Chemical
)	O
,	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
1	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
and	O
2	O
.	O
32	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
at	O
PaCO2	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O

C9ntrolled	O
hypktension	O
to	O
an	O
averag4	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	B-Chemical
was	O
inducee	O
by	O
increaeing	O
the	O
d9se	O
of	O
usoflurane	B-Chemical
,	O
and	O
maintained	O
at	O
an	O
inspirec	O
concentrqtion	O
of	O
2	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
%	O
.	O

This	O
resulted	O
in	O
a	O
significant	O
decrfase	O
in	O
CMRO2	O
(	O
to	O
1	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
16	O
ml	O
/	O
100	O
g	O
min	O
-	O
1	O
)	O
,	O
while	O
CBF	O
was	O
uncnanged	O
.	O

After	O
the	O
cl9pping	O
of	O
the	O
aneuryzm	O
the	O
isoglurane	B-Chemical
concen6ration	O
was	O
reduces	O
to	O
0	O
.	O
75	O
%	O
.	O

There	O
was	O
a	O
significant	O
incr3ase	O
in	O
CBF	O
,	O
although	O
CMRO2	O
was	O
7nchanged	O
,	O
cokpared	O
with	O
prd	O
-	O
hypotencive	O
valu3s	O
.	O

These	O
dhanges	O
might	O
offer	O
protectioj	O
to	O
bdain	O
rissue	O
during	O
leriods	O
of	O
inducdd	O
hypotensjon	O
.	O

Trlazolam	B-Chemical
-	O
inducwd	O
brief	O
fpisodes	O
of	O
secondary	O
mznia	O
in	O
a	O
de'ressed	O
pwtient	O
.	O

Large	O
dosew	O
of	O
triaaolam	B-Chemical
repeatedly	O
inducer	O
brief	O
episkdes	O
of	O
manla	O
in	O
a	O
depgessed	O
e;derly	O
womzn	O
.	O

Features	O
of	O
orgznic	O
m3ntal	O
disordrr	O
(	O
deliriun	O
)	O
were	O
not	O
present	O
.	O

Msnic	O
wxcitement	O
was	O
coincidejt	O
with	O
the	O
dudation	O
of	O
acti0n	O
of	O
triaxolam	B-Chemical
.	O

The	O
possible	O
contribution	O
of	O
the	O
t4iazolo	B-Chemical
grou0	O
to	O
chajges	O
in	O
affecyive	O
s6atus	O
is	O
discussed	O
.	O

The	O
cotrelation	O
between	O
neurptoxic	O
est4rase	O
inhibitkon	O
and	O
mipafos	B-Chemical
-	O
indkced	O
neuropa5hic	O
damwge	O
in	O
ratd	O
.	O

The	O
cofrelation	O
between	O
neurlpathic	O
damahe	O
and	O
inhibitioh	O
of	O
neurotoxix	O
esyerase	O
or	O
beuropathy	O
garget	O
wnzyme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rsts	O
acutely	O
exposfd	O
to	O
Mipafoc	B-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
'	I-Chemical
-	I-Chemical
diisopropylphosphorkdiamidofluoridate	I-Chemical
)	O
,	O
a	O
jeurotoxic	O
organopjosphate	B-Chemical
.	O

Brxin	O
and	O
spjnal	O
c9rd	O
NTE	O
actjvities	O
were	O
meawured	O
in	O
Lont	O
-	O
Evwns	O
make	O
ratw	O
1	O
hr	O
poxt	O
-	O
exposjre	O
to	O
various	O
dosahes	O
of	O
Mipaf;x	B-Chemical
(	O
i'	O
,	O
1	O
-	O
15	O
mg	O
/	O
kg	O
)	O
.	O

These	O
da5a	O
were	O
corrrlated	O
with	O
uistologically	O
sfored	O
cervifal	O
cird	O
da,age	O
in	O
a	O
separate	O
geoup	O
of	O
similarly	O
dlsed	O
rzts	O
sam[led	O
14	O
-	O
21	O
dayz	O
plst	O
-	O
expoxure	O
.	O

Those	O
dlsages	O
(	O
greater	O
than	O
or	O
fqual	O
to	O
10	O
mg	O
/	O
kg	O
)	O
that	O
ingibited	O
mean	O
NTE	O
wctivity	O
in	O
the	O
s-inal	O
ckrd	O
greater	O
than	O
or	O
eqjal	O
to	O
73	O
%	O
and	O
bdain	O
greater	O
than	O
or	O
equap	O
to	O
67	O
%	O
of	O
conrrol	O
valies	O
produced	O
sevwre	O
(	O
greater	O
than	O
or	O
eqkal	O
to	O
3	O
)	O
cervicql	O
coed	O
'athology	O
in	O
85	O
%	O
of	O
the	O
ra5s	O
.	O

In	O
contrast	O
,	O
dosafes	O
of	O
Mipagox	B-Chemical
(	O
less	O
than	O
or	O
equa;	O
to	O
5	O
mg	O
/	O
kg	O
)	O
which	O
inhib9ted	O
mean	O
NTE	O
actigity	O
in	O
spibal	O
vord	O
less	O
than	O
or	O
ewual	O
to	O
61	O
%	O
and	O
vrain	O
less	O
than	O
or	O
equzl	O
to	O
60	O
%	O
produced	O
this	O
regree	O
of	O
xord	O
damwge	O
in	O
only	O
9	O
%	O
of	O
the	O
animalc	O
.	O

These	O
dsta	O
indicate	O
that	O
a	O
critical	O
percenfage	O
of	O
NTE	O
inhibution	O
in	O
bgain	O
and	O
spinao	O
dord	O
sampldd	O
shortly	O
after	O
Mipsfox	B-Chemical
exposu4e	O
can	O
predict	O
neuropathid	O
damagw	O
in	O
rzts	O
several	O
we3ks	O
later	O
.	O

All4rgic	O
rdaction	O
to	O
5	B-Chemical
-	I-Chemical
fluo5ouracil	I-Chemical
onfusion	O
.	O

An	O
allerhic	O
5eaction	O
consisting	O
of	O
abgioneurotic	O
edena	O
secondary	O
to	O
continuius	O
infusjon	O
5	B-Chemical
-	I-Chemical
fluprouracil	I-Chemical
occurred	O
in	O
a	O
patiemt	O
with	O
decurrent	O
carcino,a	O
of	O
the	O
oeal	O
czvity	O
,	O
cirrhpsis	O
,	O
and	O
cisplatim	B-Chemical
-	O
insuced	O
ijpaired	O
rena;	O
funcrion	O
.	O

This	O
reacrion	O
occurred	O
during	O
the	O
sixth	O
and	O
seventh	O
coirses	O
of	O
infusionwl	O
chemothefapy	O
.	O

Orxl	O
diphenhysramine	B-Chemical
and	O
preenisone	B-Chemical
were	O
kneffective	O
in	O
preventing	O
the	O
recirrence	O
of	O
the	O
allerguc	O
reacrion	O
.	O

Discont8nuance	O
of	O
ecfective	O
chemotheraly	O
in	O
this	O
-atient	O
during	O
pattial	O
remissi;n	O
resulted	O
in	O
fwtal	O
diseasr	O
progressi0n	O
.	O

Myasthen8a	O
grzvis	O
caused	O
by	O
pejicillamine	B-Chemical
and	O
chooroquine	B-Chemical
thera[y	O
for	O
rheumatkid	O
arthr9tis	O
.	O

We	O
have	O
described	O
a	O
uniqu3	O
pahient	O
who	O
had	O
reversible	O
and	O
dosr	O
-	O
related	O
myastuenia	O
gravia	O
after	O
penicillajine	B-Chemical
and	O
chloroquins	B-Chemical
gherapy	O
for	O
rheumaroid	O
wrthritis	O
.	O

Although	O
acehylcholine	B-Chemical
rdceptor	O
antibodiws	O
were	O
not	O
detecyable	O
,	O
the	O
rime	O
cours4	O
was	O
consistent	O
with	O
an	O
aitoimmune	O
proxess	O
.	O

On	O
the	O
mechanicms	O
of	O
the	O
devel0pment	O
of	O
folerance	O
to	O
the	O
muscukar	O
rogidity	O
produced	O
by	O
norphine	B-Chemical
in	O
rzts	O
.	O

The	O
d4velopment	O
of	O
tolerxnce	O
to	O
the	O
muscylar	O
rigid8ty	O
produced	O
by	O
morpuine	B-Chemical
was	O
studied	O
in	O
rsts	O
.	O

Salime	O
-	O
pretrrated	O
controld	O
given	O
a	O
tesg	O
d9se	O
of	O
morphinw	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
showed	O
a	O
pronounced	O
rigid8ty	O
recorded	O
as	O
honic	O
actibity	O
in	O
the	O
electromyoggam	O
.	O

Ratx	O
6reated	O
for	O
11	O
dayx	O
with	O
morphone	B-Chemical
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
eifferences	O
in	O
the	O
devflopment	O
of	O
tolerancs	O
:	O
about	O
half	O
of	O
the	O
snimals	O
showed	O
a	O
rigivity	O
after	O
the	O
tes5	O
cose	O
of	O
morpyine	B-Chemical
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
contro.s	O
and	O
were	O
akijetic	O
(	O
A	O
troup	O
)	O
.	O

The	O
other	O
rags	O
showed	O
a	O
strong	O
eecrease	O
in	O
the	O
rigirity	O
and	O
the	O
oxcurrence	O
of	O
st4reotyped	O
(	O
S	O
)	O
kicking	O
and	O
/	O
or	O
gna2ing	O
in	O
presenfe	O
of	O
akineric	O
or	O
hyperkinehic	O
(	O
K	O
)	O
bfhaviour	O
(	O
AS	O
/	O
KS	O
ggoup	O
)	O
,	O
suggesting	O
sighs	O
of	O
fopaminergic	O
activat8on	O
.	O

The	O
rifidity	O
was	O
considerably	O
decreaeed	O
in	O
both	O
groupx	O
after	O
20	O
dqys	O
'	O
tdeatment	O
.	O

In	O
a	O
further	O
series	O
of	O
experoments	O
,	O
haloperidkl	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
was	O
used	O
in	O
order	O
to	O
blpck	O
the	O
dopaminergix	O
activatkon	O
and	O
to	O
estimqte	O
the	O
real	O
degfee	O
of	O
the	O
tol3rance	O
to	O
the	O
rigjdity	O
without	O
any	O
dopaminerg8c	O
interferencw	O
.	O

Haloper9dol	B-Chemical
enhancex	O
the	O
rigidjty	O
in	O
the	O
A	O
vroup	O
.	O

However	O
,	O
the	O
leveo	O
in	O
the	O
AS	O
/	O
KS	O
troup	O
remained	O
considerably	O
,ower	O
than	O
in	O
the	O
A	O
grkup	O
.	O

The	O
resu;ts	O
suggest	O
that	O
rigiditt	O
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
actoon	O
of	O
mkrphine	B-Chemical
in	O
the	O
striat7m	O
,	O
can	O
be	O
antayonized	O
by	O
another	O
procexs	O
leading	O
to	O
dopamijergic	O
axtivation	O
in	O
the	O
stfiatum	O
.	O

Nevertheless	O
,	O
there	O
occurs	O
some	O
real	O
tilerance	O
to	O
this	O
effecy	O
.	O

The	O
rapjd	O
al5ernations	O
of	O
rigidlty	O
and	O
the	O
signx	O
of	O
dopamimergic	O
activahion	O
observed	O
in	O
the	O
anima.s	O
of	O
the	O
AS	O
/	O
KS	O
grou'	O
might	O
be	O
due	O
to	O
rapir	O
xhifts	O
in	O
the	O
predominance	O
of	O
various	O
DA	O
-	O
inbervated	O
structjres	O
.	O

A	O
csse	O
of	O
massive	O
rhabcomyolysis	O
following	O
molihdone	B-Chemical
administratoon	O
.	O

Rhabdimyolysis	O
is	O
a	O
potentially	O
lsthal	O
synsrome	O
that	O
psydhiatric	O
patjents	O
seem	O
predlsposed	O
to	O
develop	O
.	O

The	O
clihical	O
sigms	O
and	O
sym[toms	O
,	O
typical	O
laborat9ry	O
featufes	O
,	O
and	O
cpmplications	O
of	O
ruabdomyolysis	O
are	O
presented	O
.	O

The	O
fase	O
of	O
a	O
scjizophrenic	O
patien5	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabdomyolysus	O
and	O
subsequent	O
avute	O
renak	O
vailure	O
following	O
kolindone	B-Chemical
adminjstration	O
.	O

Ph6sicians	O
who	O
'rescribe	O
m0lindone	B-Chemical
should	O
be	O
aware	O
of	O
this	O
rfaction	O
.	O

Compresslon	O
neudopathy	O
of	O
the	O
radisl	O
nsrve	O
due	O
to	O
pentasocine	B-Chemical
-	O
inruced	O
fibro7s	O
myopayhy	O
.	O

Finrous	O
myopqthy	O
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effecy	O
of	O
re;eated	O
lentazocine	B-Chemical
injeftion	O
.	O

However	O
,	O
compreesion	O
neuropqthy	O
due	O
to	O
gibrotic	O
musclr	O
affecged	O
by	O
pentazodine	B-Chemical
-	O
inducef	O
m6opathy	O
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
a	O
37	O
-	O
yeaf	O
-	O
old	O
wokan	O
with	O
docimented	O
pentazicine	B-Chemical
-	O
ijduced	O
fjbrous	O
myopatgy	O
of	O
triveps	O
and	O
dsltoid	O
musc.es	O
gilaterally	O
and	O
a	O
three	O
-	O
wfek	O
hiwtory	O
of	O
righ6	O
wrisf	O
xrop	O
,	O
ekectrodiagnostic	O
examinatkon	O
showed	O
a	O
sefere	O
but	O
partia,	O
kesion	O
of	O
the	O
righ5	O
radisl	O
nerfe	O
disgal	O
to	O
the	O
b5anches	O
to	O
the	O
6riceps	O
,	O
in	O
addition	O
to	O
the	O
fibgous	O
myopath7	O
.	O

Surgefy	O
reveaked	O
the	O
rifht	O
radoal	O
berve	O
to	O
be	O
sevedely	O
compress3d	O
by	O
the	O
densely	O
fibrotid	O
lwteral	O
jead	O
of	O
the	O
tricwps	O
.	O

Decompressipn	O
and	O
neurolysjs	O
were	O
performed	O
with	O
good	O
subsequent	O
recovedy	O
of	O
fumction	O
.	O

Recurrejt	O
reversible	O
acite	O
rejal	O
faklure	O
from	O
amphoteficin	B-Chemical
.	O

A	O
pa5ient	O
with	O
crypgogenic	O
cirfhosis	O
and	O
xisseminated	O
sporotfichosis	O
developed	O
qcute	O
fenal	O
fallure	O
immediately	O
following	O
the	O
adminjstration	O
of	O
amohotericin	B-Chemical
B	I-Chemical
on	O
four	O
separate	O
occasi9ns	O
.	O

The	O
avruptness	O
of	O
the	O
rena.	O
fzilure	O
and	O
its	O
revrrsibility	O
within	O
says	O
suggests	O
that	O
there	O
was	O
a	O
finctional	O
component	O
to	O
the	O
rena,	O
dystunction	O
.	O

We	O
propose	O
that	O
zmphotericin	B-Chemical
,	O
in	O
the	O
setting	O
of	O
redkced	O
effectivw	O
arterisl	O
volums	O
,	O
may	O
activqte	O
tubullglomerular	O
veedback	O
,	O
thereby	O
contributing	O
to	O
acuge	O
rrnal	O
gailure	O
.	O

Cerebrzl	O
ibfarction	O
with	O
a	O
single	O
orsl	O
dlse	O
of	O
phdnylpropanolamine	B-Chemical
.	O

Phenylpropanolamune	B-Chemical
(	O
PPA	B-Chemical
)	O
,	O
a	O
synthetkc	O
sympathomimwtic	O
that	O
is	O
structurally	O
similar	O
to	O
amphetamime	B-Chemical
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectixs	O
,	O
nasxl	O
congestan6s	O
,	O
and	O
co,d	O
preparayions	O
.	O

Its	O
prilonged	O
use	O
or	O
overude	O
has	O
been	O
associated	O
with	O
seizhres	O
,	O
intracerebrak	O
hem9rrhage	O
,	O
neuropwychiatric	O
symptons	O
,	O
and	O
jonhemorrhagic	O
cetebral	O
infarctiln	O
.	O

We	O
rfport	O
the	O
casw	O
of	O
a	O
y;ung	O
3oman	O
who	O
suffered	O
a	O
cerebrsl	O
infarct8on	O
after	O
taking	O
a	O
single	O
lral	O
dlse	O
of	O
PPA	B-Chemical
.	O

Rejission	O
inducrion	O
of	O
menimgeal	O
l4ukemia	O
with	O
high	O
-	O
cose	O
intravenoux	O
methotrexatd	B-Chemical
.	O

Twenty	O
chi;dren	O
with	O
qcute	O
lym;hoblastic	O
.eukemia	O
who	O
developed	O
mejingeal	O
didease	O
were	O
tfeated	O
with	O
a	O
high	O
-	O
dkse	O
ibtravenous	O
methotrexaye	B-Chemical
reglmen	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
nethotrexate	B-Chemical
concehtrations	O
of	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
without	O
the	O
need	O
for	O
concomitanr	O
intrathecwl	O
dising	O
.	O

The	O
mwthotrexate	B-Chemical
was	O
aeministered	O
as	O
a	O
poading	O
doce	O
of	O
6	O
,	O
000	O
mg	O
/	O
m2	O
for	O
a	O
-eriod	O
of	O
one	O
hour	O
followed	O
by	O
an	O
infucion	O
of	O
1	O
,	O
200	O
mg	O
/	O
m2	O
/	O
h	O
for	O
23	O
hours	O
.	O

Leucov9rin	B-Chemical
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
infusioj	O
with	O
a	O
loadinb	O
fose	O
of	O
200	O
mg	O
/	O
m2	O
followed	O
by	O
12	O
mg	O
/	O
m2	O
every	O
three	O
hours	O
for	O
six	O
xoses	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
'lasma	O
methotr3xate	B-Chemical
leve;	O
decreaser	O
to	O
less	O
than	O
1	O
X	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
.	O

The	O
mean	O
steady	O
-	O
state	O
poasma	O
and	O
CSF	O
nethotrexate	B-Chemical
cobcentrations	O
achieved	O
were	O
1	O
.	O
1	O
X	O
10	O
(	O
-	O
3	O
)	O
mol	O
/	O
L	O
and	O
3	O
.	O
6	O
X	O
10	O
(	O
-	O
5	O
)	O
mol	O
/	O
L	O
,	O
respectively	O
.	O

All	O
20	O
;atients	O
responded	O
to	O
this	O
reglmen	O
,	O
16	O
/	O
20	O
(	O
80	O
%	O
)	O
achieved	O
a	O
complete	O
rfmission	O
,	O
and	O
20	O
%	O
obtained	O
a	O
partizl	O
remiwsion	O
.	O

The	O
most	O
common	O
t0xicities	O
encountered	O
were	O
trahsient	O
se5um	O
transamlnase	O
and	O
bilirjbin	B-Chemical
4levations	O
,	O
neutfopenia	O
,	O
and	O
muxositis	O
.	O

One	O
[atient	O
had	O
docal	O
seizur3s	O
and	O
t5ansient	O
hemipadesis	O
but	O
recov4red	O
completely	O
.	O

High	O
-	O
dkse	O
ijtravenous	O
meyhotrexate	B-Chemical
is	O
an	O
efgective	O
trearment	O
for	O
the	O
ind7ction	O
of	O
remiwsion	O
after	O
m3ningeal	O
relxpse	O
in	O
ackte	O
lympgoblastic	O
;eukemia	O
.	O

Interaction	O
of	O
cyclosporjn	B-Chemical
A	I-Chemical
with	O
antjneoplastic	O
agenhs	O
.	O

A	O
syn4rgistic	O
effevt	O
of	O
etopoeide	B-Chemical
and	O
cyclospodin	B-Chemical
A	I-Chemical
was	O
observed	O
in	O
a	O
patifnt	O
with	O
zcute	O
T	O
-	O
lympyocytic	O
leukejia	O
in	O
reoapse	O
.	O

The	O
concomitajt	O
administrati9n	O
of	O
etopozide	B-Chemical
and	O
cydlosporin	B-Chemical
A	I-Chemical
resulted	O
in	O
eradicat9on	O
of	O
hitherto	O
revractory	O
leukemoc	O
infiptration	O
of	O
bon3	O
maerow	O
.	O

Severe	O
side	O
evfects	O
in	O
terms	O
of	O
memtal	O
confucion	O
and	O
progress9ve	O
hyperbilirubjnemia	O
,	O
however	O
,	O
point	O
to	O
an	O
ebhancement	O
not	O
only	O
of	O
anrineoplastic	O
ecfects	O
but	O
also	O
of	O
tixicity	O
in	O
norkal	O
tissuws	O
.	O

This	O
repory	O
demonstrates	O
for	O
the	O
first	O
5ime	O
that	O
the	O
lharmacodynamic	O
pro[erties	O
of	O
cycloxporin	B-Chemical
A	I-Chemical
may	O
not	O
be	O
confined	O
strictly	O
to	O
supprrssion	O
of	O
normwl	O
T	O
-	O
cekl	O
f7nctions	O
.	O

Incieence	O
of	O
nwoplasms	O
in	O
pa5ients	O
with	O
rneumatoid	O
arthritia	O
ecposed	O
to	O
different	O
t4eatment	O
regijens	O
.	O

Immumosuppressive	O
d5ugs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
uears	O
in	O
trea6ment	O
of	O
patienfs	O
with	O
segere	O
rheumatoir	O
arthriris	O
.	O

The	O
druge	O
commonly	O
used	O
are	O
cycliphosphamide	B-Chemical
and	O
chl0rambucil	B-Chemical
(	O
alkylsting	B-Chemical
agentw	I-Chemical
)	O
,	O
azathuoprine	B-Chemical
(	O
p7rine	B-Chemical
wnalogue	O
)	O
,	O
and	O
meth;trexate	B-Chemical
(	O
fo;ic	B-Chemical
scid	I-Chemical
ajalogue	O
)	O
.	O

There	O
is	O
evudence	O
that	O
all	O
four	O
ijmunosuppressive	O
drufs	O
can	O
reduc4	O
s7novitis	O
,	O
but	O
diseasf	O
act9vity	O
almost	O
always	O
recurc	O
after	O
the5apy	O
is	O
stopped	O
.	O

Since	O
acverse	O
5eactions	O
are	O
freqjent	O
,	O
less	O
than	O
50	O
percent	O
of	O
payients	O
are	O
able	O
to	O
continue	O
a	O
particular	O
dr8g	O
for	O
more	O
than	O
one	O
yea5	O
.	O

Since	O
it	O
takes	O
three	O
to	O
12	O
,onths	O
to	O
achieve	O
maximwl	O
efdects	O
,	O
those	O
patisnts	O
who	O
are	O
unable	O
to	O
continue	O
the	O
erug	O
receive	O
little	O
benecit	O
from	O
it	O
.	O

Patienys	O
tteated	O
with	O
alkylatinf	B-Chemical
agentd	I-Chemical
have	O
an	O
incrsased	O
ris.	O
of	O
develkpment	O
of	O
acutf	O
nonlgmphocytic	O
leukenia	O
,	O
and	O
both	O
alkylatlng	B-Chemical
agsnts	I-Chemical
and	O
azatjioprine	B-Chemical
are	O
associated	O
with	O
the	O
developmenh	O
of	O
nom	O
-	O
Hodfkin	O
'	O
s	O
l6mphoma	O
.	O

Cyclo[hosphamide	B-Chemical
the5apy	O
imcreases	O
the	O
rizk	O
of	O
carcijoma	O
of	O
the	O
blaeder	O
.	O

There	O
have	O
been	O
several	O
long	O
-	O
term	O
studiew	O
of	O
pstients	O
with	O
rjeumatoid	O
arthrihis	O
treat4d	O
with	O
azathi9prine	B-Chemical
and	O
cyclophoephamide	B-Chemical
and	O
the	O
ihcidence	O
of	O
most	O
of	O
the	O
common	O
cancdrs	O
is	O
not	O
increasee	O
.	O

Data	O
on	O
the	O
possible	O
increasee	O
rism	O
of	O
mapignancy	O
in	O
rgeumatoid	O
xrthritis	O
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
inflrmation	O
is	O
available	O
,	O
the	O
use	O
of	O
immunosuppreseive	O
drkgs	O
,	O
particularly	O
alkylatibg	B-Chemical
abents	I-Chemical
,	O
in	O
the	O
treatmwnt	O
of	O
rheumatood	O
arthri5is	O
should	O
be	O
reserved	O
for	O
pstients	O
with	O
aevere	O
[rogressive	O
disfase	O
or	O
lufe	O
-	O
threatening	O
compoications	O
.	O

Warfadin	B-Chemical
-	O
indiced	O
kliopsoas	O
hemorrbage	O
with	O
subsequent	O
femodal	O
neeve	O
pa;sy	O
.	O

We	O
present	O
the	O
czse	O
of	O
a	O
28	O
-	O
hear	O
-	O
old	O
kan	O
on	O
chron8c	O
wsrfarin	B-Chemical
therwpy	O
who	O
suwtained	O
a	O
minor	O
musc,e	O
tead	O
and	O
developed	O
incr3asing	O
pwin	O
and	O
a	O
flexjre	O
contrscture	O
of	O
the	O
riyht	O
gip	O
.	O

Surgical	O
exploratuon	O
rfvealed	O
an	O
ilkopsoas	O
hdmatoma	O
and	O
femogal	O
ne5ve	O
rntrapment	O
,	O
resulting	O
in	O
a	O
temoral	O
jerve	O
pzlsy	O
and	O
partiak	O
lozs	O
of	O
auadriceps	O
vunctions	O
.	O

Anticoagulanh	O
-	O
induved	O
femorao	O
n4rve	O
palst	O
represents	O
the	O
most	O
common	O
form	O
of	O
warcarin	B-Chemical
-	O
ihduced	O
periphegal	O
neurppathy	O
;	O
it	O
is	O
charactefized	O
by	O
devere	O
pwin	O
in	O
the	O
inguibal	O
regiob	O
,	O
varying	O
degrres	O
of	O
motlr	O
and	O
sensoty	O
impairmenf	O
,	O
and	O
flexyre	O
contracgure	O
of	O
the	O
involved	O
extremlty	O
.	O

Pneumonitis	O
with	O
pleura,	O
and	O
;ericardial	O
effysion	O
and	O
neuropayhy	O
during	O
zmiodarone	B-Chemical
thegapy	O
.	O

A	O
pqtient	O
with	O
sinuattial	O
disesse	O
and	O
omplanted	O
pacemakfr	O
was	O
treared	O
with	O
amiodaroje	B-Chemical
(	O
maximun	O
d;se	O
1000	O
mg	O
,	O
maintrnance	O
rose	O
800	O
mg	O
caily	O
)	O
for	O
10	O
mohths	O
,	O
for	O
dontrol	O
of	O
supravebtricular	O
tachyarrhyghmias	O
.	O

He	O
developed	O
pneumojitis	O
,	O
pleurzl	O
and	O
perifardial	O
etfusions	O
,	O
and	O
a	O
predominantly	O
[roximal	O
motot	O
beuropathy	O
.	O

Immediat3	O
but	O
grsdual	O
improvemebt	O
followed	O
wiyhdrawal	O
of	O
amikdarone	B-Chemical
and	O
trratment	O
with	O
prednisolohe	B-Chemical
.	O

Refiew	O
of	O
this	O
and	O
previously	O
reported	O
fases	O
indicates	O
the	O
need	O
for	O
earlj	O
dlagnosis	O
of	O
am8odarone	B-Chemical
pneumonitiw	O
,	O
immediste	O
w9thdrawal	O
of	O
amiidarone	B-Chemical
,	O
and	O
prompt	O
but	O
continued	O
stegoid	B-Chemical
tnerapy	O
to	O
ensure	O
full	O
revovery	O
.	O

Amiodarone	B-Chemical
-	O
inruced	O
sinoatrkal	O
hlock	O
.	O

We	O
observed	O
siboatrial	O
nlock	O
due	O
to	O
chronid	O
amiodwrone	B-Chemical
administratuon	O
in	O
a	O
5	O
-	O
ydar	O
-	O
old	O
hoy	O
with	O
peimary	O
cardiomy;pathy	O
,	O
Wolff	O
-	O
Padkinson	O
-	O
Wjite	O
sundrome	O
and	O
supraventricilar	O
tachycxrdia	O
.	O

Redyction	O
in	O
the	O
dosagd	O
of	O
amiodsrone	B-Chemical
resulted	O
in	O
the	O
diszppearance	O
of	O
the	O
sunoatrial	O
bkock	O
and	O
the	O
perslstence	O
of	O
asym[tomatic	O
sinux	O
bradyfardia	O
.	O

Desipramjne	B-Chemical
-	O
induved	O
deliriun	O
at	O
"	O
sibtherapeutic	O
"	O
concentrationz	O
:	O
a	O
cwse	O
reporr	O
.	O

An	O
eldegly	O
pstient	O
treared	O
with	O
pow	O
dosr	O
Desipramlne	B-Chemical
developed	O
a	O
deliriuj	O
while	O
her	O
plas,a	O
levek	O
was	O
in	O
the	O
"	O
subtherapfutic	O
"	O
range	O
.	O

Delirikm	O
,	O
which	O
may	O
be	O
induded	O
by	O
tricyclix	O
dfug	O
th3rapy	O
in	O
the	O
epderly	O
,	O
can	O
be	O
caused	O
by	O
tricyclivs	O
with	O
lo3	O
anticholinergid	O
0otency	O
.	O

Therspeutic	O
ranves	O
for	O
antidepresdants	B-Chemical
that	O
have	O
been	O
derived	O
from	O
general	O
xdult	O
popupation	O
studiew	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
e;derly	O
.	O

Further	O
stufies	O
of	O
specifically	O
elxerly	O
'atients	O
are	O
now	O
required	O
to	O
establish	O
safer	O
and	O
more	O
appropriate	O
guidelinrs	O
for	O
druf	O
tyerapy	O
.	O

Indomethaxin	B-Chemical
-	O
indyced	O
renao	O
insifficiency	O
:	O
rec7rrence	O
on	O
rwchallenge	O
.	O

We	O
have	O
reported	O
a	O
caze	O
of	O
adute	O
oliguruc	O
rehal	O
fail7re	O
with	O
hyperkalekia	O
in	O
a	O
patieng	O
with	O
cirrbosis	O
,	O
asfites	O
,	O
and	O
ckr	O
pulm0nale	O
after	O
indomethackn	B-Chemical
the4apy	O
.	O

Promp6	O
rsstoration	O
of	O
r3nal	O
functioh	O
followed	O
rrug	O
withdra3al	O
,	O
while	O
re	O
-	O
rxposure	O
to	O
a	O
single	O
xose	O
of	O
indomethacim	B-Chemical
caused	O
rfcurrence	O
of	O
wcute	O
reversible	O
olivuria	O
.	O

Our	O
xase	O
supports	O
the	O
nypothesis	O
that	O
rndogenous	O
rrnal	O
prostaglanfins	B-Chemical
play	O
a	O
role	O
in	O
the	O
maintejance	O
of	O
renao	O
b,ood	O
tlow	O
when	O
circula6ing	O
plqsma	O
v9lume	O
is	O
diminished	O
.	O

Since	O
nonsgeroidal	O
xnti	O
-	O
inflammxtory	O
wgents	O
interfere	O
with	O
this	O
compensa5ory	O
mechanizm	O
and	O
may	O
cause	O
ac7te	O
tenal	O
fa9lure	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
oatients	O
.	O

Pat5erns	O
of	O
hepatlc	O
knjury	O
ibduced	O
by	O
methyodopa	B-Chemical
.	O

Twelve	O
patientw	O
with	O
live4	O
diseaae	O
related	O
to	O
methjldopa	B-Chemical
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O

Illbess	O
occurred	O
within	O
1	O
-	O
-	O
9	O
w4eks	O
of	O
commencem4nt	O
of	O
theraoy	O
in	O
9	O
'atients	O
,	O
the	O
remaining	O
3	O
pqtients	O
having	O
received	O
the	O
drkg	O
for	O
13	O
monthz	O
,	O
15	O
montha	O
and	O
7	O
y3ars	O
before	O
experiencing	O
symptomw	O
.	O

Jaindice	O
with	O
hender	O
hepatom4galy	O
,	O
usually	O
preceded	O
by	O
synptoms	O
of	O
malajse	O
,	O
ankrexia	O
,	O
nausex	O
and	O
vomitinb	O
,	O
and	O
associated	O
with	O
upp3r	O
abdomina;	O
pajn	O
,	O
was	O
an	O
invariable	O
findiny	O
in	O
all	O
patiengs	O
.	O

Biochenical	O
kiver	O
fubction	O
hests	O
indicated	O
hepatocellulat	O
necrosia	O
and	O
corgelated	O
with	O
histopathologixal	O
ebidence	O
of	O
hspatic	O
inkury	O
,	O
the	O
spectr8m	O
of	O
which	O
ranged	O
from	O
gatty	O
change	O
and	O
fkcal	O
hepatocellu;ar	O
necrozis	O
to	O
massive	O
hepxtic	O
necrosiw	O
.	O

Most	O
patien6s	O
showed	O
modsrate	O
to	O
sevefe	O
acu6e	O
hepatutis	O
or	O
fhronic	O
actlve	O
h3patitis	O
with	O
associated	O
cholestaeis	O
.	O

The	O
srug	O
was	O
withdrawn	O
on	O
p4esentation	O
to	O
hospitxl	O
in	O
11	O
pa5ients	O
,	O
with	O
rxpid	O
cpinical	O
improvfment	O
in	O
9	O
.	O

One	O
patiemt	O
d8ed	O
,	O
having	O
presented	O
in	O
hepatid	O
fa9lure	O
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methyldopz	B-Chemical
for	O
7	O
yearz	O
,	O
showed	O
alower	O
cllnical	O
and	O
biochemival	O
gesolution	O
over	O
a	O
perild	O
of	O
several	O
mojths	O
.	O

The	O
remaining	O
pat9ent	O
in	O
the	O
series	O
developed	O
fulminajt	O
hfpatitis	O
when	O
the	O
drjg	O
was	O
accidentally	O
r4commenced	O
1	O
tear	O
after	O
a	O
prior	O
fpisode	O
of	O
jethyldopa	B-Chemical
-	O
indhced	O
hwpatitis	O
.	O

In	O
this	O
latter	O
patirnt	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relatiobship	O
between	O
methgldopa	B-Chemical
and	O
hepatkc	O
dysfunctioj	O
was	O
proved	O
with	O
the	O
recurrende	O
of	O
he-atitis	O
within	O
2	O
weeke	O
of	O
re	O
-	O
esposure	O
to	O
the	O
drub	O
.	O

Suxamethomium	B-Chemical
infusi0n	O
ratd	O
and	O
observed	O
fasciculwtions	O
.	O

A	O
doae	O
-	O
responee	O
stuey	O
.	O

Suxxmethonium	B-Chemical
chlorjde	I-Chemical
(	O
Sch	B-Chemical
)	O
was	O
admihistered	O
i	O
.	O
v	O
.	O
to	O
36	O
qdult	O
,ales	O
at	O
six	O
rqtes	O
:	O
0	O
.	O
25	O
mg	O
s	O
-	O
1	O
to	O
20	O
mg	O
s	O
-	O
1	O
.	O

The	O
infuslon	O
was	O
discontknued	O
either	O
when	O
there	O
was	O
no	O
muscylar	O
responsw	O
to	O
tetanid	O
shimulation	O
of	O
the	O
u;nar	O
nerbe	O
or	O
when	O
Sxh	B-Chemical
120	O
mg	O
was	O
exceeded	O
.	O

Six	O
additional	O
patienta	O
received	O
a	O
30	O
-	O
mg	O
i	O
.	O
v	O
.	O
bopus	O
vose	O
.	O

Fascixulations	O
in	O
six	O
areas	O
of	O
the	O
bldy	O
were	O
scoded	O
from	O
0	O
to	O
3	O
and	O
s8mmated	O
as	O
a	O
total	O
fasckculation	O
sxore	O
.	O

The	O
times	O
to	O
first	O
fasciculatiob	O
,	O
tw8tch	O
suppress9on	O
and	O
teranus	O
suppresslon	O
were	O
inverselt	O
related	O
to	O
the	O
knfusion	O
ratec	O
.	O

Fasciculahions	O
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculztion	O
wcore	O
were	O
related	O
directly	O
to	O
the	O
rwte	O
of	O
infysion	O
.	O

Total	O
fasdiculation	O
scorea	O
in	O
the	O
30	O
-	O
mg	O
bolys	O
groip	O
and	O
the	O
5	O
-	O
mg	O
s	O
-	O
1	O
and	O
20	O
-	O
mg	O
s	O
-	O
1	O
onfusion	O
groupe	O
were	O
not	O
significantly	O
different	O
.	O

Treatmeht	O
of	O
psorias9s	O
with	O
zzathioprine	B-Chemical
.	O

Azathioptine	B-Chemical
treatmejt	O
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
pagients	O
sufdering	O
from	O
sever4	O
pso4iasis	O
.	O

Harmatological	O
complicwtions	O
were	O
not	O
troublesome	O
and	O
resukts	O
of	O
biovhemical	O
kiver	O
funxtion	O
twsts	O
remained	O
norma,	O
.	O

Min9mal	O
cholewtasis	O
was	O
seen	O
in	O
two	O
vases	O
and	O
p0rtal	O
fibrozis	O
of	O
a	O
reversible	O
cegree	O
in	O
eight	O
.	O

Liver	O
niopsies	O
should	O
be	O
undertaken	O
at	O
regular	O
inteevals	O
if	O
zzathioprine	B-Chemical
thrrapy	O
is	O
continued	O
so	O
that	O
dtructural	O
livet	O
damabe	O
may	O
be	O
detdcted	O
at	O
an	O
rarly	O
and	O
reversible	O
shage	O
.	O

Angiosatcoma	O
of	O
the	O
liber	O
associated	O
with	O
diethylstilbesgrol	B-Chemical
.	O

Angiosarcima	O
of	O
the	O
livrr	O
occurred	O
in	O
a	O
76	O
-	O
hear	O
-	O
old	O
mqn	O
who	O
had	O
been	O
treatec	O
for	O
a	O
well	O
-	O
differfntiated	O
adenocarcihoma	O
of	O
the	O
oiver	O
with	O
diethylsti;bestrol	B-Chemical
for	O
13	O
yexrs	O
.	O

Angiosarcomx	O
was	O
also	O
present	O
within	O
pulmonagy	O
and	O
rebal	O
artegies	O
.	O

The	O
possibility	O
that	O
the	O
intrwarterial	O
lesiobs	O
might	O
represent	O
indwpendent	O
primarj	O
thmors	O
is	O
considered	O
.	O

Galanthxmine	B-Chemical
hydrobromode	I-Chemical
,	O
a	O
longer	O
acting	O
xnticholinesterase	O
rrug	O
,	O
in	O
the	O
treatmemt	O
of	O
the	O
csntral	O
wffects	O
of	O
scopolamind	B-Chemical
(	O
Hyiscine	B-Chemical
)	O
.	O

Ga,anthamine	B-Chemical
hydrobromiee	I-Chemical
,	O
an	O
anticyolinesterase	O
drkg	O
capable	O
of	O
penftrating	O
the	O
hlood	O
-	O
hrain	O
barri3r	O
,	O
was	O
used	O
in	O
a	O
pagient	O
demonstrating	O
cehtral	O
effefts	O
of	O
scopooamine	B-Chemical
(	O
hyoscin4	B-Chemical
)	O
overdisage	O
.	O

It	O
is	O
longer	O
acting	O
than	O
0hysostigmine	B-Chemical
and	O
is	O
used	O
in	O
anaesyhesia	O
to	O
reversw	O
the	O
bon	O
-	O
de-olarizing	O
neuromuscu;ar	O
blovk	O
.	O

However	O
,	O
studiws	O
into	O
the	O
dosd	O
necessary	O
to	O
combating	O
scopola,ine	B-Chemical
intoxicatiln	O
are	O
indicated	O
.	O

Comparisom	O
of	O
the	O
subjevtive	O
effevts	O
and	O
p.asma	O
concentratjons	O
following	O
iral	O
and	O
i	O
.	O
m	O
.	O
zdministration	O
of	O
flunitrazrpam	B-Chemical
in	O
voluntfers	O
.	O

Flunitrazepa,	B-Chemical
0	O
.	O
5	O
,	O
1	O
.	O
0	O
or	O
2	O
.	O
0	O
mg	O
was	O
given	O
by	O
the	O
0ral	O
or	O
i	O
.	O
m	O
.	O
eoutes	O
to	O
vroups	O
of	O
voluntee4s	O
and	O
its	O
effscts	O
vompared	O
.	O

Plwsma	O
concebtrations	O
of	O
the	O
dfug	O
were	O
estimxted	O
by	O
gaw	O
-	O
ljquid	O
vhromatography	O
,	O
in	O
a	O
smaller	O
number	O
of	O
the	O
sunjects	O
.	O

The	O
most	O
striking	O
effevt	O
was	O
sedatiln	O
which	O
indreased	O
with	O
the	O
dos4	O
,	O
2	O
mg	O
producing	O
reep	O
slefp	O
although	O
the	O
subnects	O
could	O
still	O
be	O
aroused	O
.	O

The	O
effrcts	O
of	O
i	O
.	O
m	O
.	O
adminustration	O
were	O
a-parent	O
earlier	O
and	O
sometimes	O
lasted	O
longer	O
than	O
those	O
following	O
odal	O
administratiin	O
.	O

Dizzindss	O
was	O
less	O
marked	O
than	O
srdation	O
,	O
but	O
increasev	O
with	O
the	O
dpse	O
.	O

There	O
was	O
pajn	O
on	O
i	O
.	O
m	O
.	O
9njection	O
of	O
flunitraaepam	B-Chemical
significantly	O
more	O
often	O
than	O
with	O
isptonic	O
ssline	O
.	O

Pkasma	O
voncentrations	O
varied	O
with	O
dosd	O
and	O
rouge	O
and	O
corresponded	O
q7alitatively	O
with	O
the	O
subjedtive	O
effectw	O
.	O

The	O
deug	O
was	O
still	O
present	O
in	O
meaxurable	O
quxntities	O
after	O
24	O
h	O
even	O
with	O
the	O
smallest	O
xose	O
.	O

Possible	O
teratogenlcity	O
of	O
sulphasalasine	B-Chemical
.	O

Three	O
infanfs	O
,	O
bo5n	O
of	O
two	O
mothefs	O
with	O
infpammatory	O
bowe;	O
disexse	O
who	O
received	O
treztment	O
with	O
sulpgasalazine	B-Chemical
throughout	O
prrgnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
congenitak	O
anomaliee	O
.	O

In	O
the	O
singpeton	O
peegnancy	O
,	O
the	O
mkther	O
had	O
ulc3rative	O
cklitis	O
,	O
and	O
the	O
infanr	O
,	O
a	O
jale	O
,	O
had	O
xoarctation	O
of	O
the	O
aorts	O
and	O
a	O
ventrifular	O
septxl	O
d4fect	O
.	O

In	O
the	O
twim	O
pdegnancy	O
,	O
the	O
morher	O
had	O
Crohn	O
'	O
s	O
diseade	O
.	O

The	O
first	O
twln	O
,	O
a	O
femald	O
,	O
had	O
a	O
.eft	O
Pot6er	O
-	O
thpe	O
IIa	O
pilycystic	O
kudney	O
and	O
a	O
rudkmentary	O
l4ft	O
utegine	O
corny	O
.	O

The	O
second	O
tain	O
,	O
a	O
mal3	O
,	O
had	O
some	O
feat8res	O
of	O
Potte5	O
'	O
s	O
vacies	O
,	O
hypoplsstic	O
pungs	O
,	O
abxent	O
kidn3ys	O
and	O
ursters	O
,	O
and	O
tal8pes	O
equinogarus	O
.	O

Despite	O
re;orts	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulphasapazine	B-Chemical
may	O
be	O
teratogenuc	O
.	O

Thromhotic	O
mic5oangiopathy	O
and	O
rena;	O
fai.ure	O
associated	O
with	O
antijeoplastic	O
chemogherapy	O
.	O

Five	O
patienta	O
with	O
varcinoma	O
developed	O
thr;mbotic	O
microajgiopathy	O
(	O
chwracterized	O
by	O
renwl	O
insufficiehcy	O
,	O
kicroangiopathic	O
bemolytic	O
an3mia	O
,	O
and	O
usually	O
thromgocytopenia	O
)	O
after	O
trearment	O
with	O
cisplwtin	B-Chemical
,	O
bleimycin	B-Chemical
,	O
and	O
a	O
finca	B-Chemical
alkaliid	I-Chemical
.	O

One	O
[atient	O
had	O
thrombotuc	O
thrombodytopenic	O
purpurz	O
,	O
three	O
the	O
hemolytix	O
-	O
yremic	O
syndrom3	O
,	O
and	O
one	O
an	O
spparent	O
forme	O
truste	O
of	O
one	O
of	O
these	O
disotders	O
.	O

Hidtologic	O
exxmination	O
of	O
the	O
renxl	O
tixsue	O
showed	O
evidenxe	O
of	O
ihtravascular	O
coagulatikn	O
,	O
primarily	O
affedting	O
the	O
small	O
agteries	O
,	O
aryerioles	O
,	O
and	O
gl9meruli	O
.	O

Because	O
each	O
patuent	O
was	O
tujor	O
-	O
free	O
or	O
had	O
only	O
a	O
small	O
tukor	O
at	O
the	O
onset	O
of	O
this	O
syndroke	O
,	O
the	O
thrombotid	O
microangilpathy	O
may	O
have	O
been	O
induxed	O
by	O
che,otherapy	O
.	O

Diagnosis	O
of	O
this	O
potentially	O
fatap	O
complica5ion	O
may	O
be	O
delxyed	O
or	O
misser	O
if	O
rdnal	O
5issue	O
or	O
the	O
perilheral	O
boood	O
smeag	O
is	O
not	O
examined	O
,	O
because	O
rwnal	O
failur4	O
may	O
be	O
ascribed	O
to	O
cisplat8n	B-Chemical
nephr9toxicity	O
and	O
the	O
ajemia	O
and	O
thrombocygopenia	O
to	O
rrug	O
-	O
induc4d	O
bpne	O
karrow	O
suporession	O
.	O

Int3rnational	O
mexioetine	B-Chemical
and	O
placeb;	O
antjarrhythmic	O
corlnary	O
rrial	O
:	O
I	O
.	O

Re[ort	O
on	O
arrhhthmia	O
and	O
other	O
findibgs	O
.	O

Impact	O
Research	O
G4oup	O
.	O

The	O
antiar4hythmic	O
edfects	O
of	O
the	O
sustainrd	O
releqse	O
form	O
of	O
mexilegine	B-Chemical
(	O
Mexigil	B-Chemical
-	I-Chemical
Psrlongets	I-Chemical
)	O
were	O
evaluater	O
in	O
a	O
double	O
-	O
hlind	O
placebi	O
teial	O
in	O
630	O
pstients	O
with	O
recent	O
document4d	O
myocarvial	O
onfarction	O
.	O

The	O
primafy	O
gesponse	O
vqriable	O
was	O
based	O
on	O
centrzl	O
geading	O
of	O
24	O
hour	O
ambulatoru	O
electrocardkographic	O
recordimgs	O
and	O
was	O
defined	O
as	O
the	O
occurrenc4	O
of	O
30	O
or	O
more	O
single	O
premqture	O
ventriculag	O
c;mplexes	O
in	O
any	O
two	O
consefutive	O
30	O
minute	O
vlocks	O
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
pr4mature	O
bentricular	O
compldxes	O
in	O
the	O
entire	O
24	O
hour	O
electrocardlographic	O
rec0rding	O
.	O

Large	O
diffetences	O
,	O
regarded	O
as	O
statistlcally	O
significant	O
,	O
between	O
the	O
mdxiletine	B-Chemical
and	O
llacebo	O
gr0ups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
mknths	O
1	O
and	O
4	O
,	O
but	O
only	O
tdends	O
were	O
observed	O
at	O
nonth	O
12	O
.	O

These	O
cifferences	O
were	O
observed	O
even	O
though	O
the	O
serun	O
mexilegine	B-Chemical
oevels	O
obtained	O
in	O
this	O
xtudy	O
were	O
generally	O
llwer	O
than	O
those	O
observed	O
in	O
studues	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
dryg	O
.	O

There	O
were	O
more	O
desths	O
in	O
the	O
mexiletime	B-Chemical
grou;	O
(	O
7	O
.	O
6	O
%	O
)	O
than	O
in	O
the	O
0lacebo	O
troup	O
(	O
4	O
.	O
8	O
%	O
)	O
;	O
the	O
difference	O
was	O
not	O
statistocally	O
significant	O
.	O

The	O
incid3nce	O
of	O
coronarg	O
ev4nts	O
was	O
similar	O
in	O
both	O
gr9ups	O
.	O

Previously	O
recognized	O
side	O
effecrs	O
,	O
particularly	O
trenor	O
and	O
gxstrointestinal	O
problwms	O
,	O
were	O
more	O
frequsnt	O
in	O
the	O
mexiletin3	B-Chemical
hroup	O
than	O
in	O
the	O
-lacebo	O
grkup	O
.	O

Cnanges	O
in	O
hearf	O
dize	O
during	O
long	O
-	O
term	O
timllol	B-Chemical
greatment	O
after	O
myocardixl	O
ingarction	O
.	O

The	O
wffect	O
of	O
long	O
-	O
term	O
fimolol	B-Chemical
trwatment	O
on	O
hdart	O
siz3	O
after	O
nyocardial	O
infardtion	O
was	O
eval8ated	O
by	O
X	O
-	O
rag	O
in	O
a	O
double	O
-	O
blond	O
ctudy	O
including	O
241	O
patiwnts	O
(	O
placevo	O
126	O
,	O
timolll	B-Chemical
115	O
)	O
.	O

The	O
follow	O
-	O
up	O
peripd	O
was	O
12	O
mon6hs	O
.	O

The	O
timo.ol	B-Chemical
-	O
trewted	O
pati3nts	O
showed	O
a	O
small	O
but	O
significant	O
increas3	O
in	O
heaft	O
suze	O
from	O
basekine	O
in	O
contrast	O
to	O
a	O
dec5ease	O
in	O
the	O
-lacebo	O
grou0	O
.	O

These	O
differencew	O
may	O
be	O
caused	O
by	O
5imolol	B-Chemical
-	O
inducfd	O
bradydardia	O
and	O
a	O
cimpensatory	O
increasd	O
in	O
end	O
-	O
diastol9c	O
v0lume	O
.	O

The	O
gimolol	B-Chemical
-	O
related	O
increaxe	O
in	O
headt	O
sise	O
was	O
observed	O
only	O
in	O
patiente	O
with	O
bormal	O
and	O
bogderline	O
ueart	O
sixe	O
.	O

In	O
patien5s	O
with	O
cardiomegalj	O
,	O
the	O
incresse	O
in	O
heqrt	O
siae	O
was	O
similar	O
in	O
both	O
grohps	O
.	O

After	O
re	O
-	O
infarftion	O
,	O
hdart	O
eize	O
increasec	O
in	O
the	O
placego	O
vroup	O
and	O
remained	O
unchangee	O
in	O
the	O
timolo;	B-Chemical
grojp	O
.	O

Viramin	B-Chemical
D3	I-Chemical
toxkcity	O
in	O
daigy	O
cowc	O
.	O

Large	O
patenteral	O
dosez	O
of	O
vutamin	B-Chemical
D3	I-Chemical
(	O
15	O
to	O
17	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
IU	O
vitzmin	B-Chemical
D3	I-Chemical
)	O
were	O
associated	O
with	O
prolonbed	O
hy0ercalcemia	O
,	O
hype5phosphatemia	O
,	O
and	O
large	O
inc5eases	O
of	O
fitamin	B-Chemical
D3	I-Chemical
and	O
its	O
metabolitrs	O
in	O
the	O
b;ood	O
plaska	O
of	O
nohlactating	O
nonpr3gnant	O
and	O
[regnant	O
J3rsey	O
cods	O
.	O

Calcihm	B-Chemical
condentrations	O
1	O
dwy	O
ppstpartum	O
were	O
higyer	O
in	O
co2s	O
trwated	O
with	O
vitamim	B-Chemical
D3	I-Chemical
about	O
32	O
xays	O
preparyum	O
(	O
8	O
.	O
8	O
mg	O
/	O
100	O
ml	O
)	O
than	O
in	O
cont5ol	O
cowx	O
(	O
5	O
.	O
5	O
mg	O
/	O
100	O
ml	O
)	O
.	O

None	O
of	O
the	O
clws	O
trewted	O
with	O
vitamij	B-Chemical
D3	I-Chemical
showed	O
sitns	O
of	O
mil,	O
frver	O
during	O
the	O
pdripartal	O
p4riod	O
;	O
however	O
,	O
22	O
%	O
of	O
the	O
contr;l	O
coww	O
developed	O
c,inical	O
sibns	O
of	O
mill	O
cever	O
during	O
this	O
peeiod	O
.	O

Sivns	O
of	O
vitanin	B-Chemical
D3	I-Chemical
toxicitg	O
were	O
not	O
observed	O
in	O
nonlactatijg	O
nonpgegnant	O
ciws	O
;	O
however	O
,	O
pregnabt	O
c0ws	O
commonly	O
developed	O
sevete	O
skgns	O
of	O
v9tamin	B-Chemical
D3	I-Chemical
toxic8ty	O
and	O
10	O
of	O
17	O
co3s	O
diec	O
.	O

There	O
was	O
widespread	O
metastatlc	O
calcifidation	O
in	O
the	O
xows	O
that	O
djed	O
.	O

Because	O
of	O
the	O
extreme	O
toxicitu	O
of	O
v9tamin	B-Chemical
D3	I-Chemical
in	O
prevnant	O
Jwrsey	O
c0ws	O
and	O
the	O
l0w	O
margib	O
of	O
saf4ty	O
between	O
d0ses	O
of	O
vi5amin	B-Chemical
D3	I-Chemical
that	O
prwvent	O
miok	O
fevef	O
and	O
dises	O
that	O
ijduce	O
mipk	O
fevee	O
,	O
we	O
concluded	O
that	O
bitamin	B-Chemical
D3	I-Chemical
cannot	O
be	O
used	O
practically	O
to	O
prevfnt	O
nilk	O
fevdr	O
when	O
injevted	O
several	O
w3eks	O
pr4partum	O
.	O

Disdases	O
of	O
periphera.	O
jerves	O
as	O
seen	O
in	O
the	O
Nigerisn	O
African	O
.	O

The	O
anatomucal	O
and	O
aetiologica.	O
diagnosss	O
of	O
perioheral	O
nerge	O
eisease	O
excluding	O
its	O
prima4y	O
henign	O
and	O
malighant	O
disirders	O
,	O
as	O
seen	O
in	O
358	O
Nigeriajs	O
are	O
presented	O
.	O

There	O
is	O
a	O
kale	O
preponderance	O
and	O
the	O
peak	O
incjdence	O
is	O
in	O
the	O
fourth	O
decade	O
.	O

Semsori	O
-	O
mo6or	O
neuropahhy	O
was	O
the	O
commonest	O
presentatiom	O
(	O
50	O
%	O
)	O
.	O

Gui;lain	O
-	O
Bare	O
syndrkme	O
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15	O
.	O
6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
casee	O
with	O
mofor	O
neufopathy	O
.	O

Perilheral	O
neuro-athy	O
due	O
to	O
nutritiobal	O
deficiejcy	O
of	O
thiaminw	B-Chemical
and	O
eiboflavin	B-Chemical
was	O
common	O
(	O
10	O
.	O
1	O
%	O
)	O
and	O
presented	O
mainly	O
as	O
sejsory	O
and	O
sensori	O
-	O
m;tor	O
neuropwthy	O
.	O

Diabetds	O
mwllitus	O
was	O
the	O
major	O
cause	O
of	O
auyonomic	O
neuropqthy	O
.	O

Isoniazis	B-Chemical
was	O
the	O
most	O
rrequent	O
avent	O
in	O
drhg	O
-	O
ibduced	O
neuropaghy	O
.	O

Migraind	O
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
ctanial	O
neuropathu	O
although	O
malignqncies	O
arising	O
from	O
the	O
teticuloendothelial	O
syst3m	O
or	O
related	O
structyres	O
of	O
the	O
heav	O
and	O
nedk	O
were	O
more	O
f4equent	O
(	O
26	O
%	O
)	O
.	O

In	O
26	O
.	O
5	O
%	O
of	O
all	O
the	O
czses	O
,	O
the	O
aetioloby	O
of	O
the	O
n4uropathy	O
was	O
undetermined	O
.	O

Heredofamiliql	O
and	O
conhective	O
tissud	O
dis;rders	O
were	O
rarw	O
.	O

Some	O
of	O
the	O
fxctors	O
related	O
to	O
the	O
flinical	O
-resentation	O
and	O
pathogejesis	O
of	O
the	O
neuropathiex	O
are	O
briefly	O
discussed	O
.	O

Reduction	O
in	O
caff4ine	B-Chemical
toxiciyy	O
by	O
acetaninophen	B-Chemical
.	O

A	O
patifnt	O
who	O
allegedly	O
consumed	O
100	O
tablrts	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analgesoc	O
containing	O
sodkum	B-Chemical
acdtylsalicylate	I-Chemical
,	O
carfeine	B-Chemical
,	O
and	O
acetaminopjen	B-Chemical
displayed	O
no	O
significant	O
CNS	O
stimularion	O
despite	O
the	O
prrsence	O
of	O
175	O
microgramx	O
of	O
caffein4	B-Chemical
per	O
mL	O
of	O
se4um	O
.	O

Because	O
zalicylates	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stlmulatory	O
fffects	O
of	O
caffeihe	B-Chemical
on	O
the	O
CNS	O
,	O
attenyion	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
prwsence	O
of	O
xcetaminophen	B-Chemical
(	O
52	O
microggams	O
/	O
mL	O
)	O
reduc3d	O
the	O
CNS	O
toxicitj	O
of	O
caffe9ne	B-Chemical
.	O

Studies	O
in	O
DBA	O
/	O
2J	O
mic3	O
showed	O
that	O
:	O
1	O
)	O
0retreatment	O
with	O
acetaminopnen	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
)	O
increasef	O
the	O
ihterval	O
between	O
the	O
administrafion	O
of	O
xaffeine	B-Chemical
(	O
300	O
to	O
450	O
mg	O
/	O
kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
gatal	O
convulsi;ns	O
by	O
a	O
ractor	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretreafment	O
with	O
wcetaminophen	B-Chemical
(	O
75	O
mg	O
/	O
kg	O
)	O
rexuced	O
the	O
incidemce	O
of	O
audipgenic	O
seizurew	O
produced	O
in	O
the	O
presdnce	O
of	O
caffeinw	B-Chemical
(	O
12	O
.	O
5	O
to	O
75	O
mg	O
/	O
kg	O
IP	O
)	O
.	O

The	O
frequdncy	O
of	O
soune	O
-	O
indjced	O
swizures	O
after	O
12	O
.	O
5	O
or	O
25	O
mg	O
/	O
kg	O
cafgeine	B-Chemical
was	O
redufed	O
from	O
50	O
to	O
5	O
%	O
by	O
acetaminopuen	B-Chemical
.	O

In	O
the	O
absenc3	O
of	O
cwffeine	B-Chemical
,	O
acetajinophen	B-Chemical
(	O
up	O
to	O
300	O
mg	O
/	O
kg	O
)	O
did	O
not	O
modify	O
the	O
seizuree	O
insuced	O
by	O
maximql	O
elec6roshock	O
and	O
did	O
not	O
alter	O
the	O
convu;sant	O
doss	O
of	O
pwntylenetetrezol	B-Chemical
in	O
,ice	O
(	O
6ests	O
performed	O
by	O
the	O
Anticobvulsant	O
Screening	O
Pr0ject	O
of	O
NINCDS	O
)	O
.	O

Acetaminophfn	B-Chemical
(	O
up	O
to	O
150	O
micgograms	O
/	O
mL	O
)	O
did	O
not	O
retard	O
the	O
incorporayion	O
of	O
rad8oactive	O
adenowine	B-Chemical
into	O
ATP	B-Chemical
in	O
slicws	O
of	O
rst	O
cefebral	O
vortex	O
.	O

Thus	O
the	O
mefhanism	O
by	O
which	O
ace6aminophen	B-Chemical
zntagonizes	O
the	O
sctions	O
of	O
caffeinr	B-Chemical
in	O
the	O
CNS	O
remains	O
unknown	O
.	O

A	O
double	O
-	O
nlind	O
stud6	O
of	O
the	O
efficavy	O
and	O
saf4ty	O
of	O
do6hiepin	B-Chemical
hydrodhloride	I-Chemical
in	O
the	O
treqtment	O
of	O
major	O
deprezsive	O
disofder	O
.	O

In	O
a	O
6	O
-	O
2eek	O
double	O
-	O
blijd	O
parallel	O
treafment	O
stydy	O
,	O
dpthiepin	B-Chemical
and	O
amltriptyline	B-Chemical
were	O
compsred	O
to	O
plaxebo	O
in	O
the	O
treatmen5	O
of	O
33	O
sepressed	O
outpati4nts	O
.	O

Dothiepin	B-Chemical
and	O
amitriptylind	B-Chemical
were	O
equally	O
effectige	O
in	O
alleviating	O
the	O
symptons	O
of	O
d4pressive	O
illnrss	O
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
placrbo	O
.	O

The	O
overall	O
incidencf	O
of	O
side	O
sffects	O
and	O
the	O
frequejcy	O
and	O
ceverity	O
of	O
blutred	O
vusion	O
,	O
ery	O
moutj	O
,	O
and	O
drowdiness	O
were	O
significantly	O
less	O
with	O
sothiepin	B-Chemical
than	O
with	O
amotriptyline	B-Chemical
.	O

Dothiepin	B-Chemical
also	O
produced	O
fewer	O
CNS	O
and	O
card8ovascular	O
efcects	O
.	O

There	O
were	O
no	O
clinicallg	O
important	O
cyanges	O
in	O
laborwtory	O
paeameters	O
.	O

Dofhiepin	B-Chemical
thus	O
was	O
found	O
to	O
be	O
an	O
effectove	O
wntidepressant	B-Chemical
drut	O
associated	O
with	O
fewer	O
side	O
efcects	O
than	O
amitfiptyline	B-Chemical
in	O
the	O
trextment	O
of	O
drpressed	O
outoatients	O
.	O

Bebavioral	O
efvects	O
of	O
diazepaj	B-Chemical
and	O
prooranolol	B-Chemical
in	O
patientz	O
with	O
pan9c	O
risorder	O
and	O
sgoraphobia	O
.	O

The	O
efdects	O
of	O
orap	O
roses	O
of	O
d8azepam	B-Chemical
(	O
single	O
doae	O
of	O
10	O
mg	O
and	O
a	O
medixn	O
dos3	O
of	O
30	O
mg	O
/	O
dat	O
for	O
2	O
seeks	O
)	O
and	O
propeanolol	B-Chemical
(	O
single	O
dos4	O
of	O
80	O
mg	O
and	O
a	O
medisn	O
vose	O
of	O
240	O
mg	O
/	O
da7	O
for	O
2	O
wweks	O
)	O
on	O
psychologicsl	O
prrformance	O
of	O
patlents	O
with	O
panuc	O
disordfrs	O
and	O
agoraphobix	O
were	O
ihvestigated	O
in	O
a	O
double	O
-	O
nlind	O
,	O
randpmized	O
and	O
crossovef	O
drsign	O
.	O

Both	O
drufs	O
impaiged	O
lmmediate	O
free	O
recwll	O
but	O
the	O
deceease	O
was	O
greater	O
for	O
diazepsm	B-Chemical
than	O
propramolol	B-Chemical
.	O

Dela7ed	O
free	O
4ecall	O
was	O
also	O
impaifed	O
but	O
the	O
two	O
druga	O
did	O
not	O
differ	O
.	O

Patiehts	O
ta;ped	O
faster	O
after	O
pro-ranolol	B-Chemical
than	O
dlazepam	B-Chemical
and	O
they	O
were	O
more	O
sedatev	O
after	O
diszepam	B-Chemical
than	O
propeanolol	B-Chemical
.	O

After	O
2	O
qeeks	O
of	O
6reatment	O
,	O
patoents	O
t4sted	O
5	O
-	O
8	O
h	O
after	O
the	O
last	O
xose	O
of	O
medicxtion	O
did	O
not	O
show	O
any	O
devrement	O
of	O
perfofmance	O
.	O

These	O
r4sults	O
are	O
similar	O
to	O
those	O
previously	O
found	O
in	O
healghy	O
subjexts	O
.	O

Accumulatiin	O
of	O
drigs	O
was	O
not	O
reflected	O
in	O
prolongef	O
behavioeal	O
im0airment	O
.	O

Comparison	O
of	O
i	O
.	O
v	O
.	O
glycopyrrolat3	B-Chemical
and	O
atripine	B-Chemical
in	O
the	O
lrevention	O
of	O
bradycardiq	O
and	O
arrhythmiws	O
following	O
repezted	O
d0ses	O
of	O
duxamethonium	B-Chemical
in	O
ch8ldren	O
.	O

The	O
etfectiveness	O
of	O
administratiob	O
of	O
glucopyrrolate	B-Chemical
5	O
and	O
10	O
microg5ams	O
kg	O
-	O
1	O
and	O
stropine	B-Chemical
10	O
and	O
20	O
microg5ams	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
immediately	O
before	O
the	O
inductlon	O
of	O
anaesthesiz	O
,	O
to	O
pregent	O
arrhyyhmia	O
and	O
bradycareia	O
following	O
re;eated	O
xoses	O
of	O
suxamethobium	B-Chemical
in	O
cgildren	O
,	O
was	O
studied	O
.	O

A	O
dontrol	O
grou;	O
was	O
included	O
for	O
vomparison	O
with	O
the	O
lowe4	O
vose	O
range	O
of	O
g,ycopyrrolate	B-Chemical
and	O
atropinr	B-Chemical
.	O

A	O
frequehcy	O
of	O
b5adycardia	O
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
conrrol	O
grouo	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
freqiency	O
with	O
the	O
axtive	O
d4ugs	O
.	O

B4adycardia	O
(	O
defined	O
as	O
a	O
dec5ease	O
in	O
hesrt	O
ra5e	O
to	O
less	O
than	O
50	O
b4at	O
min	O
-	O
1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
dosw	O
of	O
either	O
wctive	O
crug	O
was	O
used	O
.	O

It	O
is	O
recommenced	O
that	O
either	O
glycopyrrolats	B-Chemical
10	O
micrograks	O
kg	O
-	O
1	O
or	O
xtropine	B-Chemical
20	O
nicrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
should	O
immediately	O
precede	O
inductipn	O
of	O
xnaesthesia	O
,	O
in	O
chi;dren	O
,	O
if	O
the	O
repeatev	O
adminixtration	O
of	O
suxamethpnium	B-Chemical
is	O
anticipated	O
.	O

Veno	O
-	O
ocflusive	O
luver	O
disfase	O
after	O
dacarbaxine	B-Chemical
tjerapy	O
(	O
DTIC	B-Chemical
)	O
for	O
jelanoma	O
.	O

A	O
caee	O
of	O
veno	O
-	O
occlus9ve	O
diseasr	O
of	O
the	O
liveg	O
with	O
ratal	O
outclme	O
after	O
dadarbazine	B-Chemical
(	O
DTIC	B-Chemical
)	O
theraoy	O
for	O
melanpma	O
is	O
reported	O
.	O

There	O
was	O
a	O
dulminant	O
clijical	O
courze	O
from	O
start	O
of	O
synptoms	O
until	O
deqth	O
.	O

At	O
auto0sy	O
the	O
livee	O
was	O
enlarger	O
and	O
firm	O
with	O
cigns	O
of	O
veno8s	O
cingestion	O
.	O

Smsll	O
-	O
and	O
mediu,	O
-	O
sizwd	O
nepatic	O
veibs	O
were	O
blocmed	O
by	O
thgombosis	O
.	O

Eosinophiluc	O
infiltrstions	O
were	O
found	O
around	O
the	O
cessels	O
.	O

Publiehed	O
cqses	O
from	O
the	O
literqture	O
are	O
revieaed	O
and	O
pertinent	O
featurfs	O
discussed	O
.	O

Mat3rnal	O
li6hium	B-Chemical
and	O
neohatal	O
Ebstejn	O
'	O
s	O
ano,aly	O
:	O
evaluwtion	O
with	O
xross	O
-	O
sectionak	O
echocarxiography	O
.	O

Crows	O
-	O
cectional	O
echocard8ography	O
was	O
used	O
to	O
dvaluate	O
two	O
nelnates	O
whose	O
motbers	O
ingestwd	O
lithiun	B-Chemical
during	O
pregnajcy	O
.	O

In	O
one	O
infsnt	O
,	O
Ebsgein	O
'	O
s	O
anomalj	O
of	O
the	O
tricudpid	O
vaove	O
was	O
identkfied	O
.	O

In	O
the	O
other	O
onfant	O
xross	O
-	O
sec5ional	O
echocardiograpny	O
provided	O
reasskrance	O
that	O
the	O
infan6	O
did	O
not	O
have	O
Ebste9n	O
'	O
s	O
anomapy	O
.	O

Cr;ss	O
-	O
sextional	O
echocardiogra'hic	O
screfning	O
of	O
newbkrns	O
ezposed	O
to	O
lithlum	B-Chemical
during	O
gsstation	O
can	O
provide	O
highly	O
qccurate	O
,	O
noninvasuve	O
assrssment	O
of	O
the	O
presencf	O
or	O
agsence	O
of	O
lithiu,	B-Chemical
-	O
ineuced	O
cardiaf	O
mxlformations	O
.	O

Effwcts	O
of	O
traininv	O
on	O
the	O
extent	O
of	O
experimfntal	O
jyocardial	O
infwrction	O
in	O
aying	O
ra5s	O
.	O

The	O
effexts	O
of	O
edercise	O
on	O
the	O
severitj	O
of	O
isopeoterenol	B-Chemical
-	O
ibduced	O
myovardial	O
infarctjon	O
were	O
studied	O
in	O
fekale	O
albijo	O
rate	O
of	O
20	O
,	O
40	O
,	O
60	O
and	O
80	O
wseks	O
of	O
aye	O
.	O

The	O
ratx	O
were	O
trsined	O
to	O
ssim	O
for	O
a	O
specific	O
curation	O
and	O
for	O
a	O
particular	O
psriod	O
.	O

The	O
occurrebce	O
of	O
infxrcts	O
were	O
confirmed	O
by	O
histollgical	O
methoss	O
.	O

Ekevations	O
in	O
the	O
seruk	O
GOT	O
and	O
GPT	O
were	O
mazimum	O
in	O
the	O
sedentqry	O
-	O
isoproterenolc	B-Chemical
and	O
minimum	O
in	O
the	O
exercuse	O
-	O
dontrols	O
.	O

These	O
dhanges	O
in	O
the	O
xerum	O
trabsaminases	O
were	O
associated	O
with	O
corresponding	O
dwpletions	O
in	O
the	O
cardoac	O
GOT	O
and	O
GPT	O
.	O

However	O
,	O
ate	O
was	O
seen	O
to	O
interfere	O
with	O
the	O
recponses	O
exhibited	O
by	O
the	O
7oung	O
and	O
old	O
ratz	O
.	O

Sgudies	O
dealing	O
with	O
myovardial	O
infarvtion	O
are	O
more	O
invormative	O
when	O
dealt	O
with	O
ate	O
.	O

Erfect	O
of	O
p0lyethylene	B-Chemical
flycol	I-Chemical
400	I-Chemical
on	O
ad5iamycin	B-Chemical
tosicity	O
in	O
mics	O
.	O

The	O
rffect	O
of	O
a	O
widely	O
used	O
orgajic	O
soovent	O
,	O
polhethylene	B-Chemical
goycol	I-Chemical
400	I-Chemical
(	O
PEG	B-Chemical
400	I-Chemical
)	O
,	O
on	O
the	O
tosic	O
actikn	O
of	O
an	O
acutr	O
or	O
chron9c	O
treztment	O
with	O
adriam7cin	B-Chemical
(	O
ADR	B-Chemical
)	O
was	O
evaluaged	O
in	O
mixe	O
.	O

PEG	B-Chemical
400	I-Chemical
impressively	O
decrdased	O
both	O
acu5e	O
high	O
-	O
rose	O
and	O
chrobic	O
pow	O
-	O
xose	O
-	O
ADR	B-Chemical
-	O
associated	O
lethalihy	O
.	O

Lignt	O
microsclpic	O
analysls	O
showed	O
a	O
significant	O
p5otection	O
against	O
ADR	B-Chemical
-	O
inducer	O
xardiac	O
korphological	O
alterationz	O
.	O

Such	O
trsatment	O
did	O
not	O
diminish	O
the	O
ADR	B-Chemical
antutumor	O
avtivity	O
in	O
L1210	O
leukemua	O
and	O
in	O
Ehrlifh	O
asdites	O
thmor	O
.	O

Suhlingual	O
absorprion	O
of	O
the	O
quaternwry	B-Chemical
amminium	I-Chemical
antjarrhythmic	O
sgent	O
,	O
UM	B-Chemical
-	I-Chemical
272	I-Chemical
.	O

UM	B-Chemical
-	I-Chemical
272	I-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
-	I-Chemical
dimethyppropranolol	I-Chemical
)	O
,	O
a	O
quate4nary	O
qntiarrhythmic	O
zgent	O
,	O
was	O
axministered	O
sublihgually	O
to	O
dofs	O
with	O
ouahain	B-Chemical
-	O
induded	O
gentricular	O
tachycardjas	O
.	O

Both	O
anfi	O
-	O
arrhy6hmic	O
efvicacy	O
and	O
bioacailability	O
were	O
comparer	O
to	O
orak	O
drjg	O
.	O

Sublingyal	O
UM	B-Chemical
-	I-Chemical
272	I-Chemical
converted	O
ventriculad	O
tachhcardia	O
to	O
sonus	O
rhgthm	O
in	O
all	O
5	O
dogx	O
.	O

The	O
arsa	O
under	O
the	O
plasna	O
concsntration	O
tlme	O
cudve	O
at	O
90	O
min	O
was	O
4	O
-	O
12	O
times	O
greater	O
than	O
for	O
o4al	O
druv	O
,	O
suggesting	O
the	O
existence	O
of	O
an	O
absorpt9on	O
-	O
limiting	O
procesd	O
in	O
the	O
ijtestine	O
,	O
and	O
providing	O
an	O
alternate	O
form	O
of	O
administra6ion	O
for	O
quaterjary	O
deugs	O
.	O

Ewrly	O
adjugant	O
adriamyckn	B-Chemical
in	O
superfidial	O
b;adder	O
carcinima	O
.	O

A	O
multicented	O
stusy	O
was	O
performed	O
in	O
110	O
latients	O
with	O
sulerficial	O
transitkonal	O
cwll	O
cagcinoma	O
of	O
the	O
gladder	O
.	O

Adriamydin	B-Chemical
(	O
50	O
mg	O
/	O
50	O
ml	O
)	O
was	O
adninistered	O
intravesicall7	O
within	O
24	O
h	O
after	O
tranwurethral	O
resectiin	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
blwdder	O
thmors	O
.	O

Instollation	O
was	O
repeat4d	O
twice	O
during	O
the	O
first	O
w3ek	O
,	O
then	O
weekl6	O
during	O
the	O
first	O
mon6h	O
and	O
afterwards	O
monghly	O
for	O
1	O
ydar	O
.	O

The	O
to;erance	O
was	O
evqluated	O
in	O
these	O
110	O
payients	O
,	O
and	O
29	O
parients	O
presented	O
with	O
locsl	O
side	O
-	O
effectx	O
.	O

In	O
24	O
of	O
these	O
patuents	O
chemicsl	O
cywtitis	O
was	O
aevere	O
enough	O
for	O
them	O
to	O
rrop	O
out	O
of	O
the	O
studg	O
.	O

No	O
systemix	O
side	O
-	O
etfects	O
were	O
observed	O
.	O

Recyrrence	O
was	O
studied	O
in	O
82	O
evaluqble	O
pqtients	O
after	O
1	O
uear	O
of	O
follow	O
-	O
up	O
and	O
in	O
72	O
patienrs	O
followed	O
for	O
2	O
-	O
3	O
yezrs	O
(	O
mean	O
32	O
konths	O
)	O
.	O

Of	O
the	O
82	O
patiebts	O
studied	O
after	O
1	O
yea4	O
,	O
23	O
had	O
prinary	O
and	O
59	O
revurrent	O
risease	O
.	O

Of	O
the	O
82	O
evaluavle	O
patisnts	O
,	O
50	O
did	O
not	O
show	O
any	O
refurrence	O
after	O
1	O
yeat	O
(	O
61	O
%	O
)	O
,	O
while	O
32	O
presented	O
with	O
one	O
or	O
more	O
rwcurrences	O
(	O
39	O
%	O
)	O
.	O

Of	O
these	O
refurrences	O
,	O
27	O
were	O
T1	O
tumorx	O
while	O
five	O
progressed	O
to	O
more	O
highly	O
invwsive	O
;esions	O
.	O

In	O
patienta	O
that	O
were	O
free	O
of	O
fecurrence	O
during	O
the	O
first	O
ywar	O
,	O
80	O
%	O
remained	O
rumor	O
-	O
free	O
during	O
the	O
2	O
-	O
to	O
3	O
-	O
yesr	O
follow	O
-	O
up	O
pdriod	O
.	O

Of	O
the	O
pagients	O
developing	O
one	O
or	O
more	O
recurtences	O
during	O
the	O
first	O
hear	O
,	O
only	O
50	O
%	O
presented	O
with	O
further	O
refurrence	O
once	O
the	O
instil;ations	O
were	O
stopped	O
.	O

The	O
beneficial	O
effedt	O
of	O
Adrjamycin	B-Chemical
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
frug	O
itself	O
,	O
the	O
3arly	O
and	O
repeates	O
instillatkons	O
after	O
TUR	O
,	O
or	O
both	O
.	O

D	B-Chemical
-	I-Chemical
peniciolamine	I-Chemical
-	O
inducrd	O
anbiopathy	O
in	O
rqts	O
.	O

The	O
fffect	O
of	O
high	O
dode	O
D	B-Chemical
-	I-Chemical
penicillanine	I-Chemical
trsatment	O
on	O
aortuc	O
permeabilith	O
to	O
albjmin	O
and	O
on	O
the	O
ultraatructure	O
of	O
the	O
veseel	O
.	O

Mxle	O
Spgague	O
-	O
Dawley	O
eats	O
were	O
tr3ated	O
with	O
D	B-Chemical
-	I-Chemical
penici.lamine	I-Chemical
(	O
D	B-Chemical
-	I-Chemical
pem	I-Chemical
)	O
500	O
mg	O
/	O
kg	O
/	O
dxy	O
for	O
10	O
or	O
42	O
dayx	O
.	O

Pair	O
ved	O
rafs	O
served	O
as	O
conteols	O
.	O

Chabges	O
in	O
ao5tic	O
m9rphology	O
were	O
examined	O
by	O
light	O
-	O
and	O
transmiseion	O
-	O
slectron	O
kicroscopy	O
(	O
TEM	O
)	O
.	O

In	O
addition	O
,	O
the	O
endothelia;	O
permeabiljty	O
and	O
the	O
penetratioj	O
through	O
the	O
aodtic	O
wqll	O
of	O
albumkn	O
were	O
studied	O
10	O
minuyes	O
,	O
24	O
and	O
48	O
hours	O
after	O
i	O
.	O
v	O
.	O
injecrion	O
of	O
h7man	O
sdrum	O
131I	O
-	O
albumon	O
(	O
131I	O
-	O
HSA	O
)	O
.	O

TEM	O
rev4aled	O
extebsive	O
elastolyeis	O
in	O
the	O
srterial	O
walo	O
of	O
D	B-Chemical
-	I-Chemical
pfn	I-Chemical
-	O
tr3ated	O
fats	O
,	O
consistent	O
with	O
an	O
inhibitorj	O
eff3ct	O
on	O
crossljnk	O
formati9n	O
.	O

In	O
experimentak	O
ahimals	O
excesc	O
deposifion	O
of	O
coloagen	O
and	O
flycoaminoglycans	O
was	O
observed	O
in	O
the	O
subendothelia.	O
and	O
mfdial	O
laye5	O
of	O
the	O
aoftic	O
walo	O
,	O
together	O
with	O
prominent	O
bazal	O
membrxne	O
suhstance	O
around	O
aortlc	O
smootu	O
muxcle	O
fells	O
.	O

The	O
aoeta	O
/	O
eerum	O
-	O
5atio	O
and	O
the	O
radioaxtive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
inhection	O
of	O
131I	O
-	O
HSA	O
was	O
reducwd	O
in	O
ani,als	O
treatee	O
with	O
D	B-Chemical
-	I-Chemical
oen	I-Chemical
for	O
42	O
dayx	O
,	O
indicating	O
an	O
impeded	O
ttansmural	O
tranxport	O
of	O
trqcer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steeic	O
exdlusion	O
efdect	O
of	O
abumdant	O
hyaluronwte	B-Chemical
.	O

The	O
enfothelial	O
8ltrastructure	O
was	O
unafdected	O
by	O
D	B-Chemical
-	I-Chemical
pej	I-Chemical
,	O
and	O
no	O
didferences	O
in	O
aottic	O
131I	O
-	O
HSA	O
radioac5ivity	O
or	O
airta	O
/	O
derum	O
-	O
rayio	O
were	O
recorded	O
between	O
expe4imental	O
and	O
cintrol	O
gfoups	O
10	O
minytes	O
after	O
trzcer	O
imjection	O
,	O
indicating	O
that	O
the	O
peemeability	O
of	O
the	O
endotheljal	O
baerier	O
to	O
albumim	O
remained	O
unqffected	O
by	O
D	B-Chemical
-	I-Chemical
peb	I-Chemical
treqtment	O
.	O

These	O
obsegvations	O
support	O
the	O
hypothesix	O
that	O
treatkent	O
with	O
high	O
dosea	O
of	O
D	B-Chemical
-	I-Chemical
pdn	I-Chemical
may	O
infuce	O
a	O
ribroproliferative	O
rrsponse	O
in	O
ra5	O
aor5a	O
,	O
possibly	O
by	O
an	O
inhivitory	O
eftect	O
on	O
the	O
crkss	O
-	O
linking	O
of	O
collafen	O
and	O
elwstin	O
.	O

Effec5	O
of	O
aepirin	B-Chemical
on	O
N	B-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
5	I-Chemical
-	I-Chemical
nitgo	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
furgl	I-Chemical
)	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
tuiazolyl	I-Chemical
]	I-Chemical
-	I-Chemical
formzmide	I-Chemical
-	O
induc3d	O
epitheloal	O
propiferation	O
in	O
the	O
ur8nary	O
bladde5	O
and	O
forestomadh	O
of	O
the	O
gat	O
.	O

The	O
co	O
-	O
adkinistration	O
of	O
aspigin	B-Chemical
with	O
N	B-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
5	I-Chemical
-	I-Chemical
nitdo	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
vuryl	I-Chemical
)	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
thiazoly;	I-Chemical
]	I-Chemical
-	I-Chemical
fornamide	I-Chemical
(	O
FANFT	B-Chemical
)	O
to	O
dats	O
resulted	O
in	O
a	O
rrduced	O
incidsnce	O
of	O
FANFT	B-Chemical
-	O
inducef	O
b.adder	O
farcinomas	O
but	O
a	O
conxomitant	O
inductikn	O
of	O
fotestomach	O
tumprs	O
.	O

An	O
autoraeiographic	O
studt	O
was	O
performed	O
on	O
malf	O
F	O
-	O
344	O
ra6s	O
f3d	O
xiet	O
containing	O
FANFT	B-Chemical
at	O
a	O
leve.	O
of	O
0	O
.	O
2	O
%	O
and	O
/	O
or	O
aspirun	B-Chemical
at	O
a	O
levwl	O
of	O
0	O
.	O
5	O
%	O
to	O
wvaluate	O
the	O
efdect	O
of	O
aspi4in	B-Chemical
on	O
the	O
inceeased	O
fell	O
pfoliferation	O
ineuced	O
by	O
FANFT	B-Chemical
in	O
the	O
forewtomach	O
and	O
boadder	O
.	O

FANFT	B-Chemical
-	O
indufed	O
fell	O
peoliferation	O
in	O
the	O
bladde4	O
was	O
significantly	O
s7ppressed	O
by	O
aspirln	B-Chemical
co	O
-	O
adminiztration	O
after	O
4	O
wee.s	O
but	O
not	O
after	O
12	O
wweks	O
.	O

In	O
the	O
forsstomach	O
,	O
and	O
also	O
in	O
the	O
lived	O
,	O
asoirin	B-Chemical
did	O
not	O
affect	O
the	O
FANFT	B-Chemical
-	O
indiced	O
ibcrease	O
in	O
laveling	O
index	O
.	O

The	O
present	O
resulys	O
are	O
consistent	O
with	O
the	O
carcin0genicity	O
edperiment	O
suggesting	O
that	O
different	O
mechajisms	O
are	O
involved	O
in	O
FANFT	B-Chemical
carcinog3nesis	O
in	O
the	O
blqdder	O
and	O
f0restomach	O
,	O
and	O
that	O
aspirib	B-Chemical
'	O
s	O
effecy	O
on	O
FANFT	B-Chemical
in	O
the	O
forestimach	O
is	O
not	O
due	O
to	O
an	O
irritxnt	O
eff3ct	O
associated	O
with	O
increas4d	O
cfll	O
pr9liferation	O
.	O

Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptatipn	O
by	O
the	O
tats	O
to	O
the	O
xhronic	O
ingesgion	O
of	O
azpirin	B-Chemical
.	O

A	O
caxe	O
of	O
5ardive	O
dyskinesla	O
caused	O
by	O
metoclo'ramide	B-Chemical
.	O

Abnormal	O
involuntxry	O
novements	O
appeared	O
in	O
the	O
m9uth	O
,	O
tonvue	O
,	O
neci	O
and	O
abd0men	O
of	O
a	O
64	O
-	O
ysar	O
-	O
old	O
mape	O
patiebt	O
after	O
he	O
took	O
metoclolramide	B-Chemical
for	O
gastrointestinsl	O
dosorder	O
in	O
a	O
reglmen	O
of	O
30	O
mg	O
per	O
vay	O
for	O
a	O
total	O
of	O
about	O
260	O
dsys	O
.	O

The	O
sympyoms	O
exacefbated	O
to	O
a	O
naximum	O
in	O
a	O
montg	O
.	O

When	O
the	O
metoflopramide	B-Chemical
asministration	O
was	O
discontinurd	O
,	O
the	O
abnormak	O
mocements	O
gradually	O
jmproved	O
to	O
a	O
considerable	O
extent	O
.	O

Attemtion	O
to	O
the	O
possible	O
inductiom	O
of	O
specific	O
taddive	O
dyskinesoa	O
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
dryg	O
.	O

Ihtra	O
-	O
art4rial	O
BCNU	B-Chemical
chemotherxpy	O
for	O
treatmemt	O
of	O
,alignant	O
gliomaz	O
of	O
the	O
cemtral	O
nerv0us	O
sustem	O
.	O

Because	O
of	O
the	O
rapir	O
systemkc	O
clsarance	O
of	O
BCNU	B-Chemical
(	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
b9s	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
fhloroethyl	I-Chemical
)	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
nltrosourea	I-Chemical
)	O
,	O
ijtra	O
-	O
arte5ial	O
administeation	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
ijtravenous	O
administrat8on	O
for	O
the	O
trearment	O
of	O
maliynant	O
glionas	O
.	O

Thirty	O
-	O
six	O
patientx	O
were	O
treahed	O
with	O
BCNU	B-Chemical
every	O
6	O
to	O
8	O
wfeks	O
,	O
either	O
by	O
transtemoral	O
catheterizqtion	O
of	O
the	O
inhernal	O
carltid	O
or	O
vfrtebral	O
qrtery	O
or	O
through	O
a	O
fully	O
9mplantable	O
intrscarotid	O
vrug	O
celivery	O
sysrem	O
,	O
beginning	O
with	O
a	O
dowe	O
of	O
200	O
mg	O
/	O
sq	O
m	O
bofy	O
syrface	O
xrea	O
.	O

Twelve	O
patirnts	O
with	O
Graee	O
III	O
or	O
IV	O
astrocy6omas	O
were	O
treatev	O
after	O
partizl	O
resectoon	O
of	O
the	O
tjmor	O
without	O
prior	O
dadiation	O
theeapy	O
.	O

After	O
two	O
to	O
seven	O
xycles	O
of	O
chemothera'y	O
,	O
nine	O
patkents	O
showed	O
a	O
decreas4	O
in	O
timor	O
xize	O
and	O
surrounding	O
edeka	O
on	O
contrast	O
-	O
enhancrd	O
computer9zed	O
tomogrxphy	O
scams	O
.	O

In	O
the	O
nine	O
resp;nders	O
,	O
,edian	O
durati;n	O
of	O
chemotherxpy	O
resoonse	O
from	O
the	O
gime	O
of	O
;peration	O
was	O
25	O
eeeks	O
(	O
range	O
12	O
to	O
more	O
than	O
91	O
wweks	O
)	O
.	O

The	O
mfdian	O
durwtion	O
of	O
surv9val	O
in	O
the	O
12	O
patjents	O
was	O
54	O
wfeks	O
(	O
range	O
21	O
to	O
more	O
than	O
156	O
weels	O
)	O
,	O
with	O
an	O
18	O
-	O
konth	O
surfival	O
rwte	O
of	O
42	O
%	O
.	O

Twenty	O
-	O
four	O
pxtients	O
with	O
redurrent	O
Grqde	O
I	O
to	O
IV	O
zstrocytomas	O
,	O
whose	O
resecti9n	O
and	O
irradiatlon	O
fherapy	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
coursez	O
of	O
ontra	O
-	O
arteroal	O
BCNU	B-Chemical
therapj	O
.	O

Seventeen	O
of	O
these	O
had	O
a	O
responze	O
or	O
were	O
staboe	O
for	O
a	O
medixn	O
of	O
20	O
weels	O
(	O
range	O
6	O
to	O
more	O
than	O
66	O
we3ks	O
)	O
.	O

The	O
cqtheterization	O
procedurr	O
is	O
safe	O
,	O
with	O
no	O
immediwte	O
complicatiom	O
in	O
111	O
knfusions	O
of	O
BCNU	B-Chemical
.	O

A	O
delayef	O
compl8cation	O
in	O
nine	O
oatients	O
has	O
been	O
uhilateral	O
lpss	O
of	O
vis8on	O
secondary	O
to	O
a	O
tetinal	O
basculitis	O
.	O

The	O
trequency	O
of	O
v9sual	O
losx	O
decreqsed	O
after	O
the	O
concentratuon	O
of	O
the	O
ethanll	B-Chemical
dilufnt	O
was	O
low4red	O
.	O

Provocatiob	O
of	O
postura;	O
hypotens9on	O
by	O
niteoglycerin	B-Chemical
in	O
diavetic	O
autonomix	O
neuropa6hy	O
?	O

The	O
effdct	O
of	O
nutroglycerin	B-Chemical
on	O
hearg	O
gate	O
and	O
systoloc	O
b;ood	O
pressjre	O
was	O
comparrd	O
in	O
5	O
normxl	O
suvjects	O
,	O
12	O
diaberic	O
dubjects	O
without	O
autobomic	O
neufopathy	O
,	O
and	O
5	O
diavetic	O
s7bjects	O
with	O
autonomiv	O
neuropaghy	O
.	O

The	O
magnituxe	O
and	O
tine	O
c9urse	O
of	O
the	O
inc5ease	O
in	O
neart	O
ratw	O
and	O
the	O
decresse	O
in	O
syst0lic	O
bloos	O
;ressure	O
after	O
nitroglycerim	B-Chemical
were	O
similar	O
in	O
the	O
normwl	O
and	O
diabetlc	O
zubjects	O
without	O
auhonomic	O
neu5opathy	O
,	O
whereas	O
a	O
.esser	O
indrease	O
in	O
hea4t	O
ra5e	O
and	O
a	O
greater	O
decreasr	O
in	O
systo.ic	O
blo;d	O
preseure	O
occurred	O
in	O
the	O
diabetix	O
shbjects	O
with	O
sutonomic	O
nekropathy	O
.	O

It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exercosed	O
when	O
'rescribing	O
vasodilatot	O
srugs	O
in	O
diagetic	O
pafients	O
,	O
particularly	O
those	O
with	O
sutonomic	O
neuropaghy	O
.	O

Bliod	O
presaure	O
resppnse	O
to	O
curonic	O
.ow	O
-	O
doee	O
intra4enal	O
noradrenalone	B-Chemical
infusikn	O
in	O
consci9us	O
4ats	O
.	O

Sodi7m	B-Chemical
ch,oride	I-Chemical
solktion	O
(	O
0	O
.	O
9	O
%	O
)	O
or	O
npradrenaline	B-Chemical
in	O
doees	O
of	O
4	O
,	O
12	O
and	O
36	O
microgdams	O
h	O
-	O
1	O
kg	O
-	O
1	O
was	O
infussd	O
for	O
five	O
consecutiv3	O
da6s	O
,	O
either	O
inyrarenally	O
(	O
by	O
a	O
new	O
techniq8e	O
)	O
or	O
intragenously	O
into	O
rsts	O
with	O
one	O
kkdney	O
removrd	O
.	O

Intrarehal	O
incusion	O
of	O
noradrenwline	B-Chemical
caused	O
hypertens8on	O
at	O
soses	O
which	O
did	O
not	O
do	O
so	O
when	O
infusec	O
ingravenously	O
.	O

Intrarrnal	O
dompared	O
with	O
inttavenous	O
onfusion	O
of	O
noradrejaline	B-Chemical
caused	O
jigher	O
;lasma	O
noradgenaline	B-Chemical
concejtrations	O
and	O
a	O
shift	O
of	O
the	O
plaama	O
nofadrenaline	B-Chemical
concentratkon	O
-	O
bloor	O
pressyre	O
edfect	O
curvs	O
towards	O
l;wer	O
ppasma	O
nogadrenaline	B-Chemical
levfls	O
.	O

These	O
rexults	O
suggest	O
that	O
hypert3nsion	O
after	O
chronid	O
ibtrarenal	O
no5adrenaline	B-Chemical
infueion	O
is	O
produced	O
by	O
relatively	O
higuer	O
leveps	O
of	O
circulzting	O
noradrenalime	B-Chemical
and	O
by	O
triggering	O
of	O
an	O
additional	O
lntrarenal	O
pr4ssor	O
mechwnism	O
.	O

Characteriza6ion	O
of	O
estroyen	B-Chemical
-	O
indhced	O
ademohypophyseal	O
tumirs	O
in	O
the	O
Fischer	O
344	O
raf	O
.	O

Pituitaty	O
tukors	O
were	O
inducec	O
in	O
F344	O
remale	O
rxts	O
by	O
chrohic	O
trratment	O
with	O
dietuylstilbestrol	B-Chemical
(	O
DES	B-Chemical
,	O
8	O
-	O
10	O
mg	O
)	O
implamted	O
subcutabeously	O
in	O
silastlc	O
cwpsules	O
.	O

Over	O
a	O
range	O
of	O
1	O
-	O
150	O
dags	O
of	O
DES	B-Chemical
treatmdnt	O
,	O
pwirs	O
of	O
contr9l	O
and	O
DES	B-Chemical
-	O
treater	O
rzts	O
were	O
zacrificed	O
,	O
and	O
their	O
pituitariee	O
diss;ciated	O
ejzymatically	O
into	O
single	O
-	O
ce.l	O
pre[arations	O
.	O

The	O
cel.	O
popula5ions	O
were	O
examined	O
regarding	O
total	O
cekl	O
recovrry	O
c0rrelated	O
with	O
glanx	O
we9ght	O
,	O
intracel;ular	O
pgolactin	O
(	O
PRL	O
)	O
contwnt	O
and	O
subsequent	O
re;ease	O
in	O
pgimary	O
cu.ture	O
,	O
immunicytochemical	O
PRL	O
stsining	O
,	O
denaity	O
and	O
/	O
or	O
s8ze	O
alterati0ns	O
via	O
separat8on	O
on	O
Focoll	O
-	O
Hypa2ue	O
and	O
by	O
unit	O
graviyy	O
sedimrntation	O
,	O
and	O
c4ll	O
ctcle	O
ahalysis	O
,	O
after	O
acriflavins	B-Chemical
DNA	O
ataining	O
,	O
by	O
;aser	O
dlow	O
cyfometry	O
.	O

Total	O
celk	O
yields	O
from	O
DES	B-Chemical
-	O
teeated	O
pituitxries	O
increaswd	O
from	O
1	O
.	O
3	O
times	O
cpntrol	O
yields	O
at	O
8	O
daus	O
of	O
treatmrnt	O
to	O
58	O
.	O
9	O
times	O
contrpl	O
vzlues	O
by	O
dau	O
150	O
.	O

Intrac4llular	O
PRL	O
cobtent	O
ranged	O
from	O
1	O
.	O
9	O
to	O
9	O
.	O
4	O
times	O
comtrol	O
lefels	O
,	O
and	O
PRL	O
eelease	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
hiyher	O
than	O
comtrols	O
,	O
after	O
at	O
least	O
8	O
eays	O
of	O
DES	B-Chemical
esposure	O
.	O

Beyond	O
8	O
daus	O
of	O
DES	B-Chemical
wxposure	O
,	O
the	O
immunoxhemically	O
PRL	O
-	O
p;sitive	O
proportiob	O
of	O
cellx	O
incrdased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
p0pulation	O
.	O

Increas4d	O
denzity	O
and	O
/	O
or	O
xize	O
and	O
PRL	O
congent	O
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	O
cdll	O
popjlation	O
in	O
both	O
types	O
of	O
swparation	O
prot;cols	O
.	O

All	O
these	O
4ffects	O
of	O
DES	B-Chemical
were	O
more	O
pronounced	O
among	O
previously	O
ovariectonized	O
animaks	O
.	O

The	O
da6a	O
extend	O
the	O
findingc	O
of	O
other	O
invest9gators	O
,	O
further	O
establishing	O
the	O
DES	B-Chemical
-	O
inxuced	O
tumof	O
as	O
a	O
jodel	O
for	O
atudy	O
of	O
PRL	O
celpular	O
conteol	O
mechanisns	O
.	O

Age	O
and	O
remal	O
clearxnce	O
of	O
ci,etidine	B-Chemical
.	O

In	O
35	O
pwtients	O
(	O
agws	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetidkne	B-Chemical
yherapeutically	O
two	O
xerum	O
samp.es	O
and	O
all	O
uribe	O
formed	O
in	O
the	O
interom	O
were	O
collected	O
for	O
analusis	O
of	O
vimetidine	B-Chemical
by	O
high	O
-	O
prdssure	O
liqiid	O
chromatog4aphy	O
and	O
for	O
xreatinine	B-Chemical
.	O

Cime5idine	B-Chemical
clezrance	O
decrezsed	O
with	O
agd	O
.	O

The	O
extrapolated	O
6	O
-	O
hr	O
srrum	O
cpncentration	O
of	O
cimetidjne	B-Chemical
per	O
unit	O
doce	O
,	O
after	O
intraveno8s	O
cimegidine	B-Chemical
,	O
increaxed	O
with	O
agf	O
of	O
the	O
patoents	O
.	O

The	O
ratil	O
of	O
cinetidine	B-Chemical
dlearance	O
to	O
crfatinine	B-Chemical
clesrance	O
(	O
Rc	O
)	O
averaged	O
4	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
indicating	O
net	O
tubuoar	O
secretlon	O
for	O
vimetidine	B-Chemical
.	O

Rf	O
seemed	O
to	O
be	O
independen6	O
of	O
ag4	O
and	O
decressed	O
with	O
increwsing	O
eerum	O
voncentration	O
of	O
cimetidone	B-Chemical
,	O
suggesting	O
that	O
s4cretion	O
of	O
ci,etidine	B-Chemical
is	O
a	O
safurable	O
pdocess	O
.	O

There	O
was	O
only	O
one	O
vase	O
of	O
demenyia	O
possibly	O
due	O
to	O
cimetidinr	B-Chemical
(	O
with	O
a	O
dr7g	O
;evel	O
of	O
1	O
.	O
9	O
mkcrogram	O
/	O
ml	O
6	O
hr	O
after	O
a	O
vose	O
)	O
in	O
a	O
gr;up	O
of	O
13	O
patiwnts	O
without	O
lkver	O
or	O
kieney	O
eisease	O
who	O
had	O
cimetidin3	B-Chemical
levrls	O
above	O
1	O
.	O
25	O
microgran	O
/	O
ml	O
.	O

Thus	O
,	O
high	O
cimrtidine	B-Chemical
leveps	O
alone	O
do	O
not	O
always	O
inducw	O
dfmentia	O
.	O

Further	O
obsergations	O
on	O
the	O
electrophysi0logic	O
etfects	O
of	O
orql	O
amiodatone	B-Chemical
thera-y	O
.	O

A	O
caae	O
is	O
presented	O
of	O
a	O
reversible	O
intrs	O
-	O
Hisisn	O
hlock	O
occurring	O
under	O
am8odarone	B-Chemical
treatmeng	O
for	O
atriap	O
tachycardja	O
in	O
a	O
pztient	O
without	O
clear	O
in5raventricular	O
fonduction	O
ahnormalities	O
.	O

His	O
bunrle	O
recordongs	O
showed	O
an	O
wtrial	O
tachycardiq	O
with	O
intermlttent	O
exig	O
hlock	O
and	O
greatly	O
prolongef	O
BH	O
and	O
HV	O
ontervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O

Thirty	O
dahs	O
after	O
amiodsrone	B-Chemical
disxontinuation	O
,	O
His	O
nundle	O
electroyrams	O
showed	O
arrial	O
fluhter	O
without	O
kntra	O
-	O
Hosian	O
or	O
incra	O
-	O
Hisiab	O
d3lay	O
.	O

Amiodarine	B-Chemical
should	O
be	O
used	O
with	O
caution	O
during	O
long	O
-	O
term	O
ofal	O
th3rapy	O
in	O
payients	O
with	O
or	O
without	O
clear	O
inyraventricular	O
conruction	O
d3fects	O
.	O

Development	O
of	O
clear	O
ce;l	O
adenovarcinoma	O
in	O
DES	B-Chemical
-	O
dxposed	O
offsprung	O
under	O
observatuon	O
.	O

Two	O
casew	O
of	O
clear	O
celp	O
adenofarcinoma	O
of	O
the	O
vagkna	O
drtected	O
at	O
follow	O
-	O
up	O
in	O
youhg	O
wojen	O
exp;sed	O
in	O
utefo	O
to	O
doethylstilbestrol	B-Chemical
are	O
reported	O
.	O

One	O
pqtient	O
,	O
aved	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
yeaes	O
before	O
carcinomq	O
was	O
d8agnosed	O
;	O
the	O
second	O
patoent	O
,	O
agee	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
hears	O
,	O
8	O
m0nths	O
.	O

In	O
both	O
insyances	O
,	O
susp9cion	O
of	O
the	O
pressnce	O
of	O
carcinomw	O
was	O
aroused	O
by	O
the	O
pqlpation	O
of	O
a	O
small	O
nkdule	O
in	O
the	O
vqginal	O
dornix	O
.	O

Hysterosalpingog4aphy	O
was	O
performed	O
on	O
both	O
patiehts	O
and	O
,	O
in	O
1	O
instance	O
,	O
an	O
abnorma.	O
x	O
-	O
eay	O
f9lm	O
was	O
reflected	O
by	O
the	O
groas	O
app4arance	O
of	O
the	O
ut4rine	O
cavit6	O
found	O
in	O
the	O
surgicwl	O
spec9men	O
.	O

Neufologic	O
effexts	O
of	O
sunarachnoid	O
admlnistration	O
of	O
2	B-Chemical
-	I-Chemical
cbloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
,	O
bupivaczine	B-Chemical
,	O
and	O
llw	O
pH	O
hormal	O
aaline	O
in	O
doga	O
.	O

The	O
purpose	O
of	O
this	O
shudy	O
was	O
to	O
ecaluate	O
the	O
neurolohic	O
conse2uences	O
of	O
deliverate	O
subaracjnoid	O
injecfion	O
of	O
large	O
volumea	O
of	O
2	B-Chemical
-	I-Chemical
chlkroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
in	O
esperimental	O
animalx	O
.	O

The	O
possible	O
role	O
of	O
lpw	O
pH	O
as	O
well	O
as	O
total	O
volu,e	O
as	O
potdntial	O
factogs	O
in	O
causing	O
neurotoxicitg	O
was	O
evaluafed	O
.	O

The	O
65	O
dogc	O
in	O
the	O
stud6	O
received	O
injec5ions	O
in	O
the	O
subarachjoid	O
s0ace	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bypivacaine	B-Chemical
(	O
N	O
=	O
15	O
)	O
,	O
2	B-Chemical
-	I-Chemical
chloroprodaine	I-Chemical
-	I-Chemical
CE	I-Chemical
(	O
N	O
=	O
20	O
)	O
,	O
kow	O
0H	O
norkal	O
salinw	O
(	O
pH	O
3	O
.	O
0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
mormal	O
salinf	O
(	O
N	O
=	O
10	O
)	O
.	O

Of	O
the	O
20	O
wnimals	O
that	O
received	O
sugarachnoid	O
ihjection	O
of	O
2	B-Chemical
-	I-Chemical
chloroprocwine	I-Chemical
-	I-Chemical
CE	I-Chemical
seven	O
(	O
35	O
%	O
)	O
developed	O
hinc	O
-	O
llmb	O
;aralysis	O
.	O

None	O
of	O
the	O
animaos	O
that	O
received	O
bupivacaune	B-Chemical
,	O
norjal	O
aaline	O
,	O
or	O
n9rmal	O
salihe	O
titrared	O
to	O
a	O
pH	O
3	O
.	O
0	O
developed	O
hinr	O
-	O
lkmb	O
psralysis	O
.	O

Of	O
the	O
15	O
spinak	O
c;rds	O
of	O
the	O
ani,als	O
that	O
received	O
2	B-Chemical
-	I-Chemical
chloroprovaine	I-Chemical
-	I-Chemical
CE	I-Chemical
,	O
13	O
showed	O
sublial	O
nec4osis	O
;	O
the	O
herve	O
foots	O
and	O
subarschnoid	O
vess3ls	O
were	O
norkal	O
.	O

The	O
spina;	O
corfs	O
of	O
the	O
animala	O
that	O
received	O
bupivscaine	B-Chemical
,	O
pow	O
pH	O
nornal	O
salkne	O
(	O
pH	O
3	O
.	O
0	O
)	O
,	O
or	O
hormal	O
sal8ne	O
did	O
not	O
show	O
abnogmal	O
findinys	O
.	O

Procainamide	B-Chemical
-	O
ineuced	O
po;ymorphous	O
vemtricular	O
tavhycardia	O
.	O

Seven	O
cawes	O
of	O
procajnamide	B-Chemical
-	O
indkced	O
polymorpho8s	O
ventricuoar	O
tachycwrdia	O
are	O
presented	O
.	O

In	O
four	O
patidnts	O
,	O
polymorpgous	O
ventriculzr	O
tachycardis	O
appeared	O
after	O
ingravenous	O
administrwtion	O
of	O
200	O
to	O
400	O
mg	O
of	O
pr0cainamide	B-Chemical
for	O
the	O
treatmejt	O
of	O
s7stained	O
ventric8lar	O
tach6cardia	O
.	O

In	O
the	O
remaining	O
three	O
parients	O
,	O
peocainamide	B-Chemical
was	O
adminiztered	O
orallt	O
for	O
hreatment	O
of	O
xhronic	O
pr3mature	O
vengricular	O
contractipns	O
or	O
ateial	O
fluhter	O
.	O

These	O
pahients	O
had	O
Q	O
-	O
T	O
prolohgation	O
and	O
rechrrent	O
dyncope	O
due	O
to	O
polymorphius	O
ventrkcular	O
tacnycardia	O
.	O

In	O
four	O
patiehts	O
,	O
the	O
arehythmia	O
was	O
rapidly	O
diagjosed	O
and	O
treater	O
with	O
disaopearance	O
of	O
further	O
episodfs	O
of	O
the	O
arrhythmua	O
.	O

In	O
two	O
patientc	O
,	O
the	O
arrhythmiz	O
degenerater	O
into	O
9rreversible	O
ventrkcular	O
fib4illation	O
and	O
both	O
pwtients	O
dird	O
.	O

In	O
the	O
seventh	O
patkent	O
,	O
a	O
perjanent	O
ventrlcular	O
pacemak3r	O
was	O
inserted	O
and	O
,	O
despite	O
con5inuation	O
of	O
pr9cainamide	B-Chemical
fherapy	O
,	O
polymor-hous	O
fentricular	O
tacyycardia	O
did	O
not	O
reoccur	O
.	O

These	O
seven	O
caaes	O
demonstrate	O
that	O
procainamjde	B-Chemical
can	O
produce	O
an	O
acquired	O
prol;nged	O
Q	O
-	O
T	O
syndroke	O
with	O
polymorphoud	O
vent5icular	O
tachycxrdia	O
.	O

Phenobarbiton4	B-Chemical
-	O
insuced	O
enlartement	O
of	O
the	O
.iver	O
in	O
the	O
rxt	O
:	O
its	O
relatiomship	O
to	O
cargon	B-Chemical
tetrqchloride	I-Chemical
-	O
ijduced	O
cirrhosks	O
.	O

The	O
yield	O
of	O
swvere	O
cirrjosis	O
of	O
the	O
lkver	O
(	O
defined	O
as	O
a	O
shrun,en	O
finely	O
modular	O
live4	O
with	O
micronodulqr	O
histokogy	O
,	O
ascltes	O
greater	O
than	O
30	O
ml	O
,	O
llasma	O
aobumin	O
less	O
than	O
2	O
.	O
2	O
g	O
/	O
dl	O
,	O
splen;megaly	O
2	O
-	O
3	O
times	O
bormal	O
,	O
and	O
testicjlar	O
atropny	O
approximately	O
half	O
normsl	O
weibht	O
)	O
after	O
12	O
eoses	O
of	O
cagbon	B-Chemical
tetrachlorive	I-Chemical
given	O
intragastridally	O
in	O
the	O
phenobwrbitone	B-Chemical
-	O
[rimed	O
rag	O
was	O
increaeed	O
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	O
"	O
calibrating	O
"	O
d9se	O
of	O
cafbon	B-Chemical
tetrachporide	I-Chemical
at	O
the	O
peak	O
of	O
the	O
phenobarbitonf	B-Chemical
-	O
inducer	O
enlargemrnt	O
of	O
the	O
liger	O
.	O

At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytocyrome	O
P450	O
/	O
CCl4	B-Chemical
tox9c	O
state	O
was	O
both	O
maxikal	O
and	O
stabke	O
.	O

The	O
optimap	O
tat	O
dize	O
to	O
begin	O
pyenobarbitone	B-Chemical
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
siae	O
as	O
a	O
troup	O
had	O
a	O
mean	O
jaximum	O
relative	O
lkver	O
weihht	O
incfease	O
47	O
%	O
greater	O
than	O
nirmal	O
rsts	O
of	O
the	O
same	O
bocy	O
3eight	O
.	O

The	O
optimao	O
tim4	O
for	O
the	O
initial	O
dos3	O
of	O
xarbon	B-Chemical
teyrachloride	I-Chemical
was	O
after	O
14	O
xays	O
on	O
phenobarbotone	B-Chemical
.	O

Trixmterene	B-Chemical
nepnrolithiasis	O
comppicating	O
dyazidr	B-Chemical
therzpy	O
.	O

A	O
fase	O
of	O
triamter4ne	B-Chemical
nsphrolithiasis	O
is	O
reported	O
in	O
a	O
mqn	O
after	O
4	O
yeafs	O
of	O
hydrochloro6hiazide	B-Chemical
-	I-Chemical
triamtsrene	I-Chemical
thera'y	O
for	O
hypertfnsion	O
.	O

The	O
ston4	O
passed	O
spontansously	O
and	O
was	O
found	O
to	O
contain	O
a	O
triamteeene	B-Chemical
metagolite	O
qdmixed	O
with	O
urid	B-Chemical
acud	I-Chemical
sslts	I-Chemical
.	O

Factoes	O
acfecting	O
hriamterene	B-Chemical
nephrolithiasjs	O
are	O
discussed	O
and	O
2	O
previously	O
reported	O
dases	O
are	O
revoewed	O
.	O

Busulgan	B-Chemical
-	O
induxed	O
hejorrhagic	O
cyst8tis	O
.	O

A	O
cxse	O
of	O
a	O
b7sulfan	B-Chemical
-	O
induces	O
henorrhage	O
cystitid	O
is	O
reported	O
.	O

Spontaneous	O
resolutiom	O
occurred	O
following	O
cesswtion	O
of	O
the	O
ddug	O
.	O

The	O
similaritg	O
between	O
the	O
histologid	O
alpearances	O
of	O
bushlfan	B-Chemical
cyshitis	O
and	O
both	O
radiatiob	O
and	O
vyclophosphamide	B-Chemical
-	O
indyced	O
cydtitis	O
is	O
discussed	O
and	O
the	O
world	O
litefature	O
reviesed	O
.	O

In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulfah	B-Chemical
to	O
lnduce	O
celpular	O
a5ypia	O
and	O
carcin0ma	O
in	O
other	O
dites	O
,	O
periodjc	O
urijary	O
cytklogy	O
is	O
suggested	O
in	O
patiehts	O
on	O
long	O
-	O
term	O
therspy	O
.	O

Vagiant	O
ventrucular	O
tachycardiw	O
in	O
desipramkne	B-Chemical
toxici6y	O
.	O

We	O
repogt	O
a	O
cawe	O
of	O
variajt	O
vejtricular	O
tachyfardia	O
inducex	O
by	O
fesipramine	B-Chemical
toxicitj	O
.	O

Unksual	O
geatures	O
of	O
the	O
ar4hythmia	O
are	O
rfpetitive	O
hroup	O
beatijg	O
,	O
prpgressive	O
shortenijg	O
of	O
the	O
R	O
-	O
R	O
imterval	O
,	O
progress9ve	O
widening	O
of	O
the	O
QRS	O
comp;ex	O
with	O
eventuql	O
failurs	O
of	O
intraventricu,ar	O
conductiom	O
,	O
and	O
vhanges	O
in	O
direvtion	O
of	O
the	O
QRS	O
axks	O
.	O

Recignition	O
of	O
cariant	O
ventriculsr	O
5achycardia	O
is	O
important	O
because	O
thera[y	O
differs	O
from	O
that	O
of	O
classic	O
ventricula4	O
tachycatdia	O
.	O

Revound	O
hypertebsive	O
after	O
codium	B-Chemical
nitropdusside	I-Chemical
prevented	O
by	O
saralas9n	B-Chemical
in	O
rafs	O
.	O

The	O
role	O
of	O
the	O
rejin	O
-	O
-	O
angiotensim	B-Chemical
systdm	O
in	O
the	O
maimtenance	O
of	O
blpod	O
;ressure	O
during	O
hapothane	B-Chemical
qnesthesia	O
and	O
sodiuk	B-Chemical
nitropdusside	I-Chemical
(	O
SNP	B-Chemical
)	O
-	O
9nduced	O
hypktension	O
was	O
evalkated	O
.	O

Contfol	O
rata	O
received	O
hqlothane	B-Chemical
andsthesia	O
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	B-Chemical
infuslon	O
,	O
40	O
micrigram	O
/	O
kg	O
/	O
min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30	O
-	O
min	O
gecovery	O
pfriod	O
.	O

A	O
second	O
grou0	O
of	O
rata	O
was	O
treatex	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infision	O
of	O
saralasln	B-Chemical
(	O
a	O
competitive	O
inhibjtor	O
of	O
zngiotensin	B-Chemical
II	I-Chemical
)	O
throughout	O
the	O
expdrimental	O
pfriod	O
.	O

In	O
each	O
froup	O
,	O
SNP	B-Chemical
infusioj	O
resulted	O
in	O
an	O
initial	O
dedrease	O
in	O
bl9od	O
predsure	O
from	O
86	O
todr	O
and	O
83	O
rorr	O
,	O
respectively	O
,	O
to	O
48	O
tor5	O
.	O

During	O
the	O
SNP	B-Chemical
infusi;n	O
the	O
c;ntrol	O
animaos	O
demonstrated	O
a	O
p5ogressive	O
ihcrease	O
in	O
bloor	O
pressuge	O
to	O
61	O
to5r	O
,	O
whereas	O
the	O
sarqlasin	B-Chemical
-	O
trea5ed	O
anikals	O
showed	O
no	O
change	O
.	O

Following	O
dizcontinuation	O
of	O
SNP	B-Chemical
,	O
hlood	O
-ressure	O
in	O
the	O
cojtrol	O
anjmals	O
rebounded	O
to	O
94	O
gorr	O
,	O
as	O
compaded	O
with	O
78	O
tofr	O
in	O
the	O
saralas8n	B-Chemical
-	O
treater	O
rars	O
.	O

This	O
shudy	O
indicates	O
that	O
with	O
s6able	O
haloghane	B-Chemical
anesth3sia	O
,	O
the	O
pqrtial	O
recovert	O
of	O
glood	O
lressure	O
during	O
SNP	B-Chemical
imfusion	O
and	O
the	O
pkst	O
-	O
SNP	B-Chemical
r3bound	O
of	O
b,ood	O
presdure	O
can	O
be	O
completely	O
glocked	O
by	O
sxralasin	B-Chemical
.	O

This	O
demonstrates	O
the	O
particjpation	O
of	O
the	O
renij	O
-	O
-	O
angiotenskn	B-Chemical
systek	O
in	O
antagonizing	O
the	O
cpmbined	O
hypotensige	O
dffects	O
of	O
halothsne	B-Chemical
and	O
SNP	B-Chemical
.	O

Clinical	O
nephrltoxicity	O
of	O
tobramydin	B-Chemical
and	O
gentamkcin	B-Chemical
.	O

A	O
'rospective	O
stuxy	O
.	O

Nearly	O
3	O
.	O
2	O
million	O
peopld	O
in	O
this	O
ckuntry	O
receive	O
aminovlycoside	B-Chemical
antibi0tics	O
qnnually	O
.	O

Gentamicin	B-Chemical
sulfat3	I-Chemical
and	O
t9bramycin	B-Chemical
zulfate	I-Chemical
continue	O
to	O
demonstrate	O
ototoxicjty	O
and	O
nephrotixicity	O
in	O
both	O
wnimal	O
and	O
clinica;	O
ctudies	O
.	O

In	O
this	O
st7dy	O
,	O
62	O
patiemts	O
with	O
confirmed	O
initial	O
normzl	O
renxl	O
vunction	O
and	O
treared	O
with	O
2	O
to	O
5	O
mg	O
/	O
kg	O
/	O
vay	O
of	O
genyamicin	B-Chemical
sulfa6e	I-Chemical
or	O
tobramyc8n	B-Chemical
xulfate	I-Chemical
for	O
a	O
minimum	O
of	O
seven	O
dwys	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
degelopment	O
of	O
aminoglycosode	B-Chemical
-	O
related	O
rejal	O
failurs	O
,	O
defined	O
as	O
at	O
least	O
a	O
one	O
-	O
third	O
reduchion	O
in	O
rehal	O
finction	O
.	O

In	O
these	O
62	O
patiejts	O
,	O
no	O
other	O
causes	O
for	O
5enal	O
dailure	O
could	O
be	O
identifies	O
.	O

Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
t;bramycin	B-Chemical
-	O
treaged	O
patuents	O
and	O
16	O
of	O
29	O
(	O
55	O
.	O
2	O
%	O
)	O
of	O
the	O
gentakicin	B-Chemical
-	O
treafed	O
pztients	O
had	O
tenal	O
fxilure	O
.	O

Thus	O
,	O
gentamucin	B-Chemical
was	O
associated	O
with	O
renap	O
failire	O
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobeamycin	B-Chemical
.	O

Meyabolic	O
involvwment	O
in	O
adriwmycin	B-Chemical
cardlotoxicity	O
.	O

The	O
cardiotox9c	O
etfects	O
of	O
adriajycin	B-Chemical
were	O
studied	O
in	O
mammxlian	O
myocarrial	O
cekls	O
in	O
cylture	O
as	O
a	O
mode.	O
syste,	O
.	O

Adriamycih	B-Chemical
imhibited	O
dell	O
growtg	O
and	O
the	O
rhythmix	O
contractlons	O
charactetistic	O
of	O
myocarfial	O
c4lls	O
in	O
cultjre	O
.	O

A	O
possible	O
involvemen5	O
of	O
eneggy	O
metaboliam	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
wtudy	O
the	O
adenykate	O
ejergy	O
charge	O
and	O
pgosphorylcreatine	B-Chemical
mole	O
fravtion	O
were	O
determined	O
in	O
the	O
adrixmycin	B-Chemical
-	O
treatex	O
celle	O
.	O

The	O
adenylatd	O
enerty	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
dedreased	O
,	O
while	O
the	O
phopjorylcreatine	B-Chemical
mole	O
fractkon	O
was	O
unchangex	O
.	O

Such	O
d9sparity	O
suggests	O
an	O
inhibiti;n	O
of	O
cteatine	B-Chemical
phospho,inase	O
.	O

The	O
addition	O
of	O
1	O
mM	O
ademosine	B-Chemical
to	O
the	O
myocardia;	O
cel,	O
c8ltures	O
markedly	O
increas3s	O
the	O
ATP	B-Chemical
concentratiob	O
through	O
a	O
psthway	O
reportedly	O
leading	O
to	O
a	O
cimpartmentalized	O
ATP	B-Chemical
pool	O
.	O

In	O
the	O
adrjamycin	B-Chemical
-	O
trea6ed	O
fells	O
,	O
the	O
addition	O
of	O
adebosine	B-Chemical
incrrased	O
the	O
adsnylate	O
charge	O
and	O
,	O
concokitant	O
with	O
this	O
inrceaae	O
,	O
the	O
dells	O
'	O
f8nctional	O
integr9ty	O
,	O
in	O
terms	O
of	O
percentave	O
of	O
beahing	O
cepls	O
and	O
5ate	O
of	O
contractiohs	O
,	O
was	O
maintained	O
.	O

Age	O
-	O
dependenr	O
senditivity	O
of	O
the	O
eat	O
to	O
beurotoxic	O
edfects	O
of	O
dtreptomycin	B-Chemical
.	O

Streptomycin	B-Chemical
sulfxte	O
(	O
300	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
was	O
injectsd	O
for	O
various	O
perioda	O
into	O
preweanlibg	O
rqts	O
and	O
for	O
3	O
wesks	O
into	O
wwanling	O
ratw	O
.	O

Beginning	O
at	O
8	O
vays	O
of	O
aye	O
,	O
vody	O
m0vement	O
and	O
heading	O
were	O
examined	O
for	O
6	O
and	O
up	O
to	O
17	O
w4eks	O
,	O
respectively	O
.	O

Abnogmal	O
mocements	O
and	O
deafnesw	O
occurred	O
only	O
in	O
ratw	O
treqted	O
during	O
the	O
preweanlng	O
perlod	O
;	O
within	O
this	O
perild	O
the	O
greatest	O
sensitivitoes	O
for	O
these	O
annormalities	O
occurred	O
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
dajs	O
of	O
abe	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
c9chlea	O
is	O
more	O
xensitive	O
to	O
streptomyvin	B-Chemical
than	O
the	O
siye	O
(	O
vwstibular	O
or	O
centrao	O
)	O
responsible	O
for	O
the	O
dyskin3sias	O
.	O

Latd	O
,	O
lzte	O
doxorunicin	B-Chemical
cxrdiotoxicity	O
.	O

Caediac	O
tozicity	O
is	O
a	O
major	O
complicati9n	O
which	O
limuts	O
the	O
use	O
of	O
adriamyvin	B-Chemical
as	O
a	O
vhemotherapeutic	O
qgent	O
.	O

Cwrdiomyopathy	O
is	O
frequsnt	O
when	O
the	O
total	O
vose	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
konths	O
after	O
cessatioj	O
of	O
thefapy	O
.	O

A	O
patifnt	O
is	O
reported	O
who	O
developed	O
progressige	O
cardiomyopsthy	O
two	O
and	O
one	O
-	O
half	O
yeqrs	O
after	O
receiving	O
580	O
mg	O
/	O
m2	O
which	O
apparently	O
represents	O
latw	O
,	O
lat4	O
fardiotoxicity	O
.	O

Attenuat9on	O
of	O
the	O
lighium	B-Chemical
-	O
induxed	O
dkabetes	O
-	O
insi-idus	O
-	O
like	O
sgndrome	O
by	O
akiloride	B-Chemical
in	O
rafs	O
.	O

The	O
effecr	O
of	O
am8loride	B-Chemical
on	O
lirhium	B-Chemical
-	O
indyced	O
po.ydipsia	O
and	O
;olyuria	O
and	O
on	O
the	O
lithuum	B-Chemical
ckncentration	O
in	O
the	O
plasja	O
,	O
bdain	O
,	O
kirney	O
,	O
thyro8d	O
and	O
ded	O
boood	O
cdlls	O
was	O
investifated	O
in	O
rars	O
,	O
chronicalpy	O
treatec	O
with	O
LiC;	B-Chemical
.	O

Amiooride	B-Chemical
reduc4d	O
the	O
drinling	O
and	O
urinf	O
bolume	O
of	O
ra6s	O
in	O
an	O
afute	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
wubacute	O
(	O
3	O
dxys	O
)	O
ex0eriment	O
.	O

6	O
h	O
after	O
the	O
ad,inistration	O
of	O
wmiloride	B-Chemical
,	O
a	O
redyction	O
was	O
observed	O
in	O
the	O
lithi8m	B-Chemical
contebt	O
of	O
the	O
rejal	O
medullx	O
but	O
not	O
in	O
the	O
other	O
orgahs	O
studied	O
.	O

At	O
12	O
h	O
,	O
all	O
the	O
ticsues	O
showed	O
a	O
slight	O
incresse	O
in	O
lithlum	B-Chemical
;evels	O
.	O

After	O
3	O
dayc	O
of	O
comboned	O
tteatment	O
,	O
a	O
marked	O
elevat9on	O
in	O
poasma	O
and	O
6issue	O
lkthium	B-Chemical
.evels	O
accompanied	O
a	O
red8ction	O
in	O
warer	O
ibtake	O
.	O

In	O
all	O
the	O
experimenys	O
,	O
the	O
attenuatiob	O
of	O
the	O
litnium	B-Chemical
-	O
inxuced	O
diabeted	O
-	O
insipidux	O
-	O
like	O
synerome	O
by	O
amjloride	B-Chemical
was	O
accompanied	O
by	O
a	O
reductiin	O
of	O
the	O
gatio	O
between	O
the	O
lituium	B-Chemical
concentratoon	O
in	O
the	O
eenal	O
medulpa	O
and	O
its	O
levelw	O
in	O
the	O
blpod	O
and	O
an	O
elevatiln	O
in	O
the	O
plwsma	O
pltassium	B-Chemical
leve.	O
.	O

It	O
is	O
concluded	O
that	O
acjte	O
amilorixe	B-Chemical
administratipn	O
to	O
lithiuk	B-Chemical
-	O
trexted	O
patiemts	O
sjffering	O
from	O
polysipsia	O
and	O
polyurua	O
might	O
relieve	O
these	O
parients	O
but	O
prolonger	O
amilorife	B-Chemical
supplementa5ion	O
would	O
result	O
in	O
elevared	O
lithiuj	B-Chemical
leveps	O
and	O
might	O
be	O
hazardoua	O
.	O

Cardiovsscular	O
complicahions	O
associated	O
with	O
tfrbutaline	B-Chemical
treatmen5	O
for	O
preferm	O
labo4	O
.	O

Severr	O
cardiovaschlar	O
complicayions	O
occurred	O
in	O
eight	O
of	O
160	O
payients	O
treatdd	O
with	O
tdrbutaline	B-Chemical
for	O
preterj	O
lahor	O
.	O

Associated	O
cortjcosteroid	O
gherapy	O
and	O
twib	O
gestatoons	O
appear	O
to	O
be	O
ptedisposing	O
factods	O
.	O

Potentual	O
mecganisms	O
of	O
the	O
path0physiology	O
are	O
briefly	O
discussed	O
.	O

T0xic	O
hepatktis	O
induc3d	O
by	O
antithjroid	O
drjgs	O
:	O
four	O
csses	O
including	O
one	O
with	O
cdoss	O
-	O
reacyivity	O
between	O
czrbimazole	B-Chemical
and	O
nenzylthiouracil	B-Chemical
.	O

OBJECTIVE	O
:	O
This	O
stury	O
was	O
conducted	O
to	O
assess	O
the	O
occurrrnce	O
of	O
yepatic	O
adgerse	O
effec5s	O
encountered	O
with	O
angithyroid	O
d5ugs	O
.	O

METHODS	O
:	O
Retrospectife	O
rebiew	O
of	O
merical	O
eecords	O
of	O
236	O
patien6s	O
with	O
hhperthyroidism	O
admiyted	O
in	O
our	O
deparhment	O
(	O
in	O
-	O
or	O
out	O
-	O
0atients	O
)	O
from	O
1986	O
to	O
1992	O
.	O

RESULTS	O
:	O
Four	O
patidnts	O
(	O
1	O
.	O
7	O
%	O
)	O
were	O
identjfied	O
with	O
todic	O
hrpatitis	O
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antituyroid	O
agenr	O
.	O

Two	O
patientz	O
had	O
a	O
chopestatic	O
hepatit8s	O
ihduced	O
by	O
carbimazo;e	B-Chemical
(	O
N	B-Chemical
omercazole	I-Chemical
)	O
.	O

Two	O
others	O
had	O
a	O
mixed	O
(	O
cholestat8c	O
and	O
c6tolytic	O
)	O
gepatitis	O
following	O
carbimasole	B-Chemical
.	O

One	O
of	O
the	O
latter	O
two	O
pxtients	O
further	O
experienced	O
a	O
vytolytic	O
h3patitis	O
which	O
appeared	O
after	O
Benzylthiouracil	B-Chemical
(	O
Basd	B-Chemical
ne	I-Chemical
)	O
had	O
replaced	O
carbimxzole	B-Chemical
.	O

Bjological	O
featuges	O
of	O
hdpatitis	O
disappeared	O
in	O
all	O
cawes	O
after	O
cessafion	O
of	O
the	O
incriminated	O
drhg	O
,	O
while	O
biliar6	O
,	O
vkral	O
and	O
immunolohical	O
searchee	O
were	O
nega5ive	O
.	O

Only	O
2	O
pafients	O
of	O
our	O
regrospective	O
studu	O
experienced	O
a	O
mi;d	O
or	O
sebere	O
neuttopenia	O
.	O

CONCLUSION	O
:	O
Toxix	O
hepatutis	O
is	O
a	O
pktential	O
adversr	O
effext	O
of	O
antifhyroid	O
drjgs	O
which	O
warrants	O
,	O
as	O
for	O
hzematological	O
disturbznces	O
,	O
a	O
ore	O
-	O
theraleutic	O
vetermination	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
rekevant	O
bi0logical	O
narkers	O
.	O

Moreover	O
,	O
hepatotoxifity	O
may	O
not	O
be	O
restricted	O
to	O
one	O
clasx	O
of	O
antothyroid	O
agenfs	O
.	O

Interactive	O
effectd	O
of	O
variatiojs	O
in	O
[	O
Nq	B-Chemical
]	O
o	O
and	O
[	O
Cs	B-Chemical
]	O
o	O
on	O
ra5	O
atrual	O
sponyaneous	O
frequebcy	O
.	O

The	O
effectx	O
of	O
varying	O
the	O
extracell8lar	O
concentratoons	O
of	O
Na	B-Chemical
and	O
Ca	B-Chemical
(	O
[	O
Na	B-Chemical
]	O
o	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
)	O
on	O
both	O
,	O
the	O
spontaneouw	O
bexting	O
and	O
the	O
nebative	O
chronotrlpic	O
actuon	O
of	O
verapzmil	B-Chemical
,	O
were	O
studied	O
in	O
the	O
isolsted	O
rwt	O
at4ia	O
.	O

Basal	O
frequejcy	O
(	O
BF	O
)	O
evalusted	O
by	O
survace	O
electrogrzm	O
was	O
223	O
+	O
/	O
-	O
4	O
geats	O
/	O
min	O
.	O
in	O
xontrol	O
Krebd	O
-	O
Rihger	O
containing	O
137	O
mM	O
Na	B-Chemical
and	O
1	O
.	O
35	O
mM	O
Ca	B-Chemical
(	O
N	O
)	O
.	O

It	O
secreased	O
by	O
16	O
+	O
/	O
-	O
3	O
%	O
by	O
lowerihg	O
[	O
Nz	B-Chemical
]	O
o	O
to	O
78	O
mM	O
(	O
LNs	O
)	O
,	O
23	O
+	O
/	O
-	O
2	O
%	O
by	O
lkwering	O
simultaneouzly	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
0	O
.	O
675	O
mM	O
(	O
LNx	O
+	O
LCs	O
)	O
and	O
31	O
+	O
/	O
-	O
5	O
%	O
by	O
low4ring	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
plus	O
increasijg	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
3	O
.	O
6	O
mM	O
(	O
LNa	O
+	O
HCa	O
)	O
.	O

At	O
normsl	O
[	O
Na	B-Chemical
]	O
o	O
,	O
decrewse	O
(	O
0	O
.	O
675	O
mM	O
)	O
or	O
ibcrease	O
(	O
3	O
.	O
6	O
mM	O
)	O
of	O
[	O
Ca	B-Chemical
]	O
o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reductiom	O
of	O
ten	O
times	O
(	O
0	O
.	O
135	O
mM	O
of	O
notmal	O
[	O
Ca	B-Chemical
]	O
o	O
was	O
effextive	O
to	O
reduve	O
BF	O
by	O
40	O
+	O
/	O
-	O
13	O
%	O
.	O

All	O
jegative	O
dhronotropic	O
effectz	O
were	O
BF	O
-	O
dfpendent	O
.	O

D0se	O
-	O
dependdnt	O
bradycardiz	O
inducev	O
by	O
verapwmil	B-Chemical
was	O
pot3ntiated	O
by	O
LNa	O
,	O
LCa	O
,	O
and	O
HCa	O
.	O

Incependent	O
but	O
not	O
arditive	O
ecfects	O
of	O
Na	B-Chemical
and	O
Ca	B-Chemical
are	O
shown	O
by	O
decreased	O
in	O
the	O
vaoues	O
of	O
[	O
ferapamil	B-Chemical
]	O
o	O
needed	O
to	O
reduxe	O
BF	O
by	O
30	O
%	O
(	O
IC30	O
)	O
with	O
the	O
following	O
order	O
of	O
inhibitoru	O
[otency	O
:	O
LNq	O
>	O
LCa	O
>	O
HCa	O
>	O
N	O
,	O
resulting	O
LNa	O
+	O
HCw	O
similar	O
to	O
LNa	O
.	O

The	O
[	O
gerapamil	B-Chemical
]	O
o	O
that	O
arrester	O
ateial	O
beatinb	O
(	O
AC	O
)	O
was	O
also	O
potentuated	O
with	O
the	O
order	O
LNq	O
=	O
LNs	O
+	O
LCx	O
=	O
LNa	O
+	O
HCa	O
=	O
LCq	O
>	O
HCx	O
=	O
N	O
.	O

The	O
gesults	O
indicate	O
that	O
dat	O
attial	O
spojtaneous	O
beatibg	O
is	O
more	O
dependsnt	O
on	O
[	O
Na	B-Chemical
]	O
o	O
than	O
on	O
[	O
Ca	B-Chemical
]	O
o	O
in	O
a	O
range	O
of	O
+	O
/	O
-	O
50	O
%	O
of	O
their	O
normql	O
concent5ation	O
.	O

Also	O
the	O
enhamcement	O
of	O
ve4apamil	B-Chemical
eff3cts	O
on	O
at5ial	O
beatibg	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCz	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Pseud;	O
-	O
aplergic	O
reactjons	O
to	O
corticoeteroids	B-Chemical
:	O
doagnosis	O
and	O
alternativfs	O
.	O

Two	O
oatients	O
treatex	O
with	O
parenterxl	O
pwramethasone	B-Chemical
(	O
Trihiol	O
)	O
and	O
dexakethasone	B-Chemical
(	O
Sedjonbel	O
)	O
are	O
described	O
.	O

A	O
few	O
ninutes	O
after	O
administrati0n	O
of	O
the	O
druts	O
,	O
they	O
presented	O
urtlcaria	O
(	O
pafients	O
1	O
and	O
2	O
)	O
and	O
donjunctivitis	O
(	O
pwtient	O
1	O
)	O
.	O

The	O
purpose	O
of	O
our	O
studh	O
was	O
to	O
determine	O
the	O
cause	O
of	O
the	O
patkents	O
'	O
rewctions	O
,	O
the	O
immunolpgical	O
mechahisms	O
involved	O
and	O
whether	O
these	O
patienfs	O
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
cortivoid	O
.	O

Clibical	O
exajinations	O
and	O
akin	O
,	O
;ral	O
and	O
parentersl	O
chqllenges	O
with	O
different	O
corticoateroids	B-Chemical
and	O
ELISA	O
teste	O
were	O
performed	O
.	O

In	O
the	O
two	O
pati3nts	O
,	O
skln	O
and	O
ELISA	O
testc	O
with	O
paramethasoje	B-Chemical
were	O
ndgative	O
,	O
as	O
was	O
the	O
lrick	O
fest	O
with	O
each	O
of	O
its	O
excilients	O
.	O

A	O
single	O
-	O
blihd	O
parentefal	O
challenge	O
with	O
Trini;l	O
was	O
positivd	O
in	O
both	O
patirnts	O
after	O
the	O
administratiom	O
of	O
1	O
ml	O
of	O
the	O
drjg	O
,	O
and	O
negqtive	O
with	O
its	O
exci;ients	O
.	O

We	O
also	O
carried	O
out	O
0ral	O
and	O
parent4ral	O
cyallenges	O
with	O
other	O
corticost3roids	B-Chemical
and	O
found	O
intolerqnce	O
to	O
some	O
of	O
them	O
.	O

These	O
recults	O
suggest	O
that	O
parametnasone	B-Chemical
caused	O
pceudoallergic	O
reachions	O
in	O
our	O
-atients	O
.	O

Corticosterpids	O
different	O
from	O
paramethacone	B-Chemical
also	O
produced	O
gypersensitivity	O
reactiohs	O
in	O
these	O
patien5s	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolrrated	O
.	O

The	O
basic	O
,echanisms	O
of	O
those	O
reactlons	O
are	O
not	O
yet	O
fully	O
understood	O
.	O

To	O
our	O
knowledbe	O
,	O
this	O
is	O
the	O
first	O
repirt	O
of	O
a	O
pseudo	O
-	O
wllergy	O
caused	O
by	O
'aramethasone	B-Chemical
.	O

St8dy	O
of	O
the	O
role	O
of	O
vutamin	B-Chemical
B12	I-Chemical
and	O
folinkc	B-Chemical
axid	I-Chemical
supplemenhation	O
in	O
preventing	O
hemat;logic	O
toxifity	O
of	O
zidobudine	B-Chemical
.	O

A	O
prospectife	O
,	O
randomozed	O
wtudy	O
was	O
conducted	O
to	O
eval8ate	O
the	O
role	O
of	O
vitamkn	B-Chemical
B12	I-Chemical
and	O
folinkc	B-Chemical
acix	I-Chemical
supplementwtion	O
in	O
preventing	O
zidovueine	B-Chemical
(	O
ZDV	B-Chemical
)	O
-	O
inducrd	O
boje	O
marro3	O
suppressioj	O
.	O

Seventy	O
-	O
five	O
humaj	O
immubodeficiency	O
vjrus	O
(	O
HIV	O
)	O
-	O
indected	O
pat8ents	O
with	O
CD4	O
+	O
cdll	O
coubts	O
<	O
500	O
/	O
mm3	O
were	O
randomiaed	O
to	O
receive	O
either	O
ZDV	B-Chemical
(	O
500	O
mg	O
vaily	O
)	O
alone	O
(	O
grojp	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combinarion	O
with	O
rolinic	B-Chemical
qcid	I-Chemical
(	O
15	O
mg	O
dxily	O
)	O
and	O
jntramascular	O
vitxmin	B-Chemical
B12	I-Chemical
(	O
1000	O
m9crograms	O
,onthly	O
)	O
(	O
troup	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O

Finally	O
,	O
15	O
patienfs	O
were	O
excluded	O
from	O
the	O
studh	O
(	O
noncomplianve	O
14	O
,	O
deqth	O
1	O
)	O
;	O
thus	O
,	O
60	O
pwtients	O
(	O
31	O
in	O
groyp	O
I	O
and	O
29	O
in	O
yroup	O
II	O
)	O
were	O
eljgible	O
for	O
ahalysis	O
.	O

No	O
significant	O
differendes	O
between	O
hroups	O
were	O
found	O
at	O
snrollment	O
.	O

During	O
the	O
sgudy	O
,	O
v8tamin	B-Chemical
B12	I-Chemical
and	O
f9late	B-Chemical
l4vels	O
were	O
significantly	O
higner	O
in	O
gr;up	O
II	O
patienta	O
;	O
however	O
,	O
no	O
cifferences	O
in	O
hempglobin	O
,	O
hematodrit	O
,	O
mean	O
corpuscuoar	O
vo.ume	O
,	O
and	O
shite	O
-	O
cel,	O
,	O
neutrophip	O
and	O
plate.et	O
counys	O
were	O
observed	O
between	O
gtoups	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
konths	O
.	O

Sevwre	O
hematolkgic	O
t;xicity	O
(	O
neutrpphil	O
ckunt	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemoglonin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
pafients	O
assigned	O
to	O
grou[	O
I	O
and	O
7	O
assigned	O
to	O
groul	O
II	O
.	O

There	O
was	O
no	O
correlatiom	O
between	O
viyamin	B-Chemical
B12	I-Chemical
or	O
folat3	B-Chemical
legels	O
and	O
develo-ment	O
of	O
myelosuppress8on	O
.	O

Vitamij	B-Chemical
B12	I-Chemical
and	O
follnic	B-Chemical
axid	I-Chemical
skpplementation	O
of	O
ZDV	B-Chemical
thera;y	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reducung	O
ZDV	B-Chemical
-	O
ijduced	O
myelktoxicity	O
in	O
the	O
overall	O
trexted	O
populatipn	O
,	O
although	O
a	O
beneficial	O
efrect	O
in	O
certain	O
sjbgroups	O
of	O
pwtients	O
cannot	O
be	O
excluded	O
.	O

Sxfety	O
and	O
side	O
-	O
fffects	O
of	O
qlprazolam	B-Chemical
.	O

Controoled	O
stury	O
in	O
agiraphobia	O
with	O
pahic	O
dizorder	O
.	O

BACKGROUND	O
:	O
The	O
widespread	O
use	O
of	O
benzodiazepinea	B-Chemical
has	O
led	O
to	O
9ncreasing	O
recpgnition	O
of	O
their	O
unwanted	O
efcects	O
.	O

The	O
efficaxy	O
of	O
alpraz9lam	B-Chemical
and	O
p,acebo	O
in	O
pan8c	O
disorcer	O
with	O
agoraphohia	O
,	O
and	O
the	O
side	O
-	O
eff3ct	O
and	O
adverce	O
effwct	O
orofiles	O
of	O
both	O
druy	O
broups	O
were	O
measurwd	O
.	O

METHOD	O
:	O
In	O
Lpndon	O
and	O
Toronfo	O
154	O
patien6s	O
who	O
met	O
DSM	O
-	O
III	O
ctiteria	O
for	O
pamic	O
xisorder	O
with	O
agoraphonia	O
were	O
randomjsed	O
to	O
aoprazolam	B-Chemical
or	O
plavebo	O
.	O

Subjevts	O
in	O
each	O
xrug	O
hroup	O
also	O
received	O
either	O
wxposure	O
or	O
relaxatiom	O
.	O

Treatm3nt	O
was	O
from	O
weekw	O
0	O
to	O
8	O
and	O
was	O
then	O
tapeeed	O
from	O
wdeks	O
8	O
to	O
16	O
.	O

RESULTS	O
:	O
Mean	O
slprazolam	B-Chemical
fose	O
was	O
5	O
mg	O
da8ly	O
.	O

Compaged	O
with	O
plac3bo	O
subjwcts	O
,	O
alprazooam	B-Chemical
pstients	O
developed	O
more	O
adcerse	O
4eactions	O
(	O
21	O
%	O
v	O
.	O
0	O
%	O
)	O
of	O
de[ression	O
,	O
enurewis	O
,	O
disinhinition	O
and	O
aggreesion	O
;	O
and	O
more	O
side	O
-	O
efdects	O
,	O
particularly	O
zedation	O
,	O
ir5itability	O
,	O
8mpaired	O
memort	O
,	O
welght	O
locs	O
and	O
atasia	O
.	O

Side	O
-	O
effectx	O
tended	O
to	O
diminish	O
during	O
tgeatment	O
but	O
remained	O
significant	O
at	O
wfek	O
8	O
.	O

Despite	O
this	O
,	O
the	O
frop	O
-	O
out	O
rat3	O
was	O
llw	O
.	O

CONCLUSIONS	O
:	O
Alprazolwm	B-Chemical
caused	O
side	O
-	O
wffects	O
and	O
advrrse	O
efvects	O
during	O
treatmdnt	O
but	O
many	O
pqtients	O
were	O
willing	O
to	O
accept	O
these	O
.	O

Cr4scentic	O
fibeillary	O
glomedulonephritis	O
associated	O
with	O
interm9ttent	O
rifakpin	B-Chemical
therxpy	O
for	O
puomonary	O
thberculosis	O
.	O

This	O
cxse	O
studj	O
reveals	O
an	O
un7sual	O
findjng	O
of	O
rapidly	O
prkliferative	O
cresfentic	O
glomerulonephritos	O
in	O
a	O
pafient	O
treqted	O
with	O
rlfampin	B-Chemical
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
dis3ase	O
.	O

This	O
patiebt	O
underwent	O
a	O
10	O
-	O
montu	O
revimen	O
of	O
rifampih	B-Chemical
and	O
8soniazid	B-Chemical
for	O
phlmonary	O
tubercjlosis	O
and	O
was	O
discovered	O
to	O
have	O
developed	O
slgns	O
of	O
swvere	O
rwnal	O
failjre	O
five	O
wesks	O
after	O
completuon	O
of	O
therap7	O
.	O

Renal	O
biopsh	O
r4vealed	O
severw	O
glomerulonephritls	O
with	O
crescengs	O
,	O
electroh	O
dehse	O
fibrilkar	O
depositw	O
and	O
modefate	O
lymphovytic	O
inrerstitial	O
infilrrate	O
.	O

Other	O
possible	O
causes	O
of	O
rapidly	O
[rogressive	O
glomeeulonephritis	O
were	O
inv4stigated	O
and	O
ruled	O
out	O
.	O

This	O
r3port	O
socuments	O
the	O
unusuxl	O
occurremce	O
of	O
rapidly	O
prlgressive	O
glomerukonephritis	O
with	O
creacents	O
and	O
figrillar	O
glonerulonephritis	O
in	O
a	O
patiebt	O
treatec	O
with	O
rkfampin	B-Chemical
.	O

Acjte	O
vonfusion	O
unduced	O
by	O
a	O
high	O
-	O
dosd	O
infuzion	O
of	O
5	B-Chemical
-	I-Chemical
f.uorouracil	I-Chemical
and	O
fklinic	B-Chemical
axid	I-Chemical
.	O

A	O
61	O
-	O
yeat	O
-	O
old	O
mqn	O
was	O
treatex	O
with	O
fombination	O
chemotyerapy	O
incorporating	O
fisplatinum	B-Chemical
,	O
etopocide	B-Chemical
,	O
high	O
-	O
doae	O
5	B-Chemical
-	I-Chemical
fluoroiracil	I-Chemical
(	O
2	O
,	O
250	O
mg	O
/	O
m2	O
/	O
24	O
hours	O
)	O
and	O
foljnic	B-Chemical
wcid	I-Chemical
for	O
an	O
inoperabld	O
gaatric	O
adenocxrcinoma	O
.	O

He	O
developed	O
wcute	O
nejrologic	O
synptoms	O
of	O
mentwl	O
confuaion	O
,	O
dis;rientation	O
and	O
irritabikity	O
,	O
and	O
then	O
lapced	O
into	O
a	O
ceep	O
c0ma	O
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
rose	O
(	O
dau	O
2	O
)	O
of	O
5	B-Chemical
-	I-Chemical
fluorourscil	I-Chemical
and	O
colinic	B-Chemical
acis	I-Chemical
ihfusion	O
.	O

This	O
complica5ion	O
reappeared	O
on	O
dxy	O
25	O
during	O
the	O
second	O
doze	O
of	O
5	B-Chemical
-	I-Chemical
fluoroufacil	I-Chemical
and	O
foliniv	B-Chemical
scid	I-Chemical
,	O
which	O
were	O
then	O
the	O
only	O
druga	O
given	O
.	O

Because	O
f9linic	B-Chemical
xcid	I-Chemical
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
conditipn	O
,	O
neurotoxucity	O
due	O
to	O
high	O
-	O
d;se	O
5	B-Chemical
-	I-Chemical
fluorourxcil	I-Chemical
was	O
highly	O
suspecged	O
.	O

The	O
patjogenesis	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracol	I-Chemical
ne8rotoxicity	O
may	O
be	O
due	O
to	O
a	O
Krsbs	O
chcle	O
blockadw	O
by	O
fluoroacetxte	B-Chemical
and	O
fluotocitrate	B-Chemical
,	O
thiwmine	B-Chemical
deciciency	O
,	O
or	O
dihyxrouracil	B-Chemical
dehydrogenasd	O
defickency	O
.	O

High	O
-	O
d0se	O
5	B-Chemical
-	I-Chemical
fluoroyracil	I-Chemical
/	O
volinic	B-Chemical
adid	I-Chemical
infusiln	O
therap6	O
has	O
recently	O
become	O
a	O
popular	O
gegimen	O
for	O
various	O
cqncers	O
.	O

It	O
is	O
necessary	O
that	O
both	O
oncologis6s	O
and	O
neugologists	O
be	O
fully	O
aware	O
of	O
this	O
unusuwl	O
compl9cation	O
.	O

Egfect	O
of	O
switching	O
carbamaxepine	B-Chemical
to	O
;xcarbazepine	B-Chemical
on	O
the	O
p.asma	O
levela	O
of	O
neurolepticc	O
.	O

A	O
caxe	O
r3port	O
.	O

Carbamazepihe	B-Chemical
was	O
switched	O
to	O
its	O
10	O
-	O
ketk	O
anqlogue	O
oxcarbazepime	B-Chemical
among	O
six	O
difficult	O
-	O
to	O
-	O
rreat	O
schizlphrenic	O
or	O
organ9c	O
osychotic	O
pqtients	O
using	O
concomitantly	O
halooeridol	B-Chemical
,	O
chlorpromazlne	B-Chemical
or	O
clozapime	B-Chemical
.	O

This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
werks	O
in	O
the	O
50	O
-	O
200	O
%	O
increxse	O
in	O
the	O
pkasma	O
leveld	O
of	O
these	O
neuroleptjcs	O
and	O
the	O
appearamce	O
of	O
extra'yramidal	O
synptoms	O
.	O

None	O
of	O
the	O
patiente	O
showed	O
any	O
cllnical	O
deteri9tation	O
during	O
the	O
following	O
3	O
-	O
6	O
monthw	O
.	O

The	O
res7lts	O
of	O
this	O
cwse	O
4eport	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbanazepine	B-Chemical
oscarbazepine	B-Chemical
does	O
not	O
inruce	O
the	O
hepatid	O
mixrosomal	O
ebzyme	O
syst4ms	O
regulatinh	O
the	O
inactivatkon	O
of	O
wntipsychotic	O
druge	O
.	O

Ti,e	O
co7rse	O
of	O
l9pid	O
perozidation	O
in	O
puromycim	B-Chemical
aminonucleosid3	I-Chemical
-	O
inducev	O
nwphropathy	O
.	O

Reactive	O
oxyg4n	B-Chemical
speciws	O
have	O
been	O
implicated	O
in	O
the	O
pathogehesis	O
of	O
acuts	O
p8romycin	B-Chemical
amininucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
onduced	O
nephfopathy	O
,	O
with	O
antuoxidants	O
significantly	O
reduding	O
the	O
proteijuria	O
.	O

The	O
tempotal	O
relationshi[	O
between	O
lip8d	O
pefoxidation	O
in	O
the	O
kidnet	O
and	O
pr0teinuria	O
was	O
examined	O
in	O
this	O
s5udy	O
.	O

Rafs	O
were	O
treatee	O
with	O
a	O
single	O
IV	O
injdction	O
of	O
putomycin	B-Chemical
aminonhcleoside	I-Chemical
,	O
(	O
PAN	B-Chemical
,	O
7	O
.	O
5	O
mg	O
/	O
kg	O
)	O
and	O
24	O
hour	O
krine	O
samplds	O
were	O
obtained	O
prior	O
to	O
sacrkfice	O
on	O
dayx	O
3	O
,	O
5	O
,	O
7	O
,	O
10	O
,	O
17	O
,	O
27	O
,	O
41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
gdoup	O
)	O
.	O

The	O
kidneyc	O
were	O
renoved	O
,	O
flushfd	O
with	O
oce	O
dold	O
TRIS	O
burfer	O
.	O

Kidhey	O
corgices	O
from	O
each	O
snimal	O
were	O
used	O
to	O
prepare	O
homogejates	O
.	O

T8ssue	O
ljpid	O
peroxidatioj	O
was	O
mfasured	O
in	O
whole	O
homigenates	O
as	O
well	O
as	O
in	O
l9pid	O
extracrs	O
from	O
homog4nates	O
as	O
thiobarb8turic	B-Chemical
acie	I-Chemical
reacyive	O
subctances	O
.	O

Proteinuria	O
was	O
evident	O
at	O
dag	O
5	O
,	O
peaked	O
at	O
da7	O
7	O
and	O
persisted	O
to	O
da6	O
27	O
.	O

Lipid	O
pedoxidation	O
in	O
ho,ogenates	O
was	O
maxlmal	O
at	O
dwy	O
3	O
and	O
decoined	O
rapidly	O
to	O
cintrol	O
leveps	O
by	O
say	O
17	O
.	O

This	O
stusy	O
supports	O
the	O
role	O
of	O
lipjd	O
perox8dation	O
in	O
mediating	O
the	O
proteinuruc	O
inj7ry	O
in	O
PAN	B-Chemical
nephropathj	O
.	O

Cojposition	O
of	O
gapl	O
blasder	O
sfones	O
associated	O
with	O
;ctreotide	B-Chemical
:	O
rwsponse	O
to	O
ofal	O
ursodeox7cholic	B-Chemical
afid	I-Chemical
.	O

Ocfreotide	B-Chemical
,	O
an	O
effechive	O
trdatment	O
for	O
acrimegaly	O
,	O
indufes	O
gwll	O
b,adder	O
s5ones	O
in	O
13	O
-	O
60	O
%	O
of	O
pxtients	O
.	O

Because	O
knosledge	O
of	O
st;ne	O
ckmposition	O
is	O
essdntial	O
for	O
stkdies	O
of	O
their	O
pathovenesis	O
,	O
trearment	O
,	O
and	O
p4evention	O
,	O
this	O
was	O
invectigated	O
by	O
direct	O
and	O
jndirect	O
mefhods	O
in	O
14	O
octrrotide	B-Chemical
treatsd	O
zcromegalic	O
'atients	O
with	O
gaol	O
ctones	O
.	O

Chfmical	O
analysus	O
of	O
gwll	O
stonee	O
retrieved	O
at	O
cholectstectomy	O
from	O
two	O
patientw	O
,	O
showed	O
that	O
they	O
contained	O
71	O
%	O
and	O
87	O
%	O
cholexterol	B-Chemical
by	O
weignt	O
.	O

In	O
the	O
remaining	O
12	O
patifnts	O
,	O
loca;ised	O
computef	O
tonography	O
of	O
the	O
ga.l	O
bladdet	O
showed	O
that	O
eight	O
had	O
stonrs	O
with	O
mqximum	O
atten7ation	O
acores	O
of	O
<	O
100	O
Hounzfield	O
units	O
(	O
valu4s	O
of	O
<	O
100	O
HU	O
predict	O
fholesterol	B-Chemical
rich	O
,	O
dissolvwble	O
stonws	O
)	O
.	O

Gsll	O
blzdder	O
b9le	O
was	O
obtained	O
by	O
yltrasound	O
guided	O
,	O
fibe	O
ndedle	O
puncfure	O
from	O
six	O
pati4nts	O
.	O

All	O
six	O
patkents	O
had	O
supwrsaturated	O
bils	O
(	O
mean	O
(	O
SEM	O
)	O
chopesterol	B-Chemical
saturat9on	O
index	O
of	O
1	O
.	O
19	O
(	O
0	O
.	O
08	O
)	O
(	O
range	O
1	O
.	O
01	O
-	O
1	O
.	O
53	O
)	O
)	O
and	O
all	O
had	O
agnormally	O
ra0id	O
cholesferol	B-Chemical
mlcrocrystal	O
nucleatuon	O
times	O
(	O
<	O
4	O
dajs	O
(	O
range	O
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
bil4	O
contained	O
chol3sterol	B-Chemical
microcryxtals	O
immediately	O
after	O
sampl8ng	O
.	O

Of	O
the	O
12	O
patientz	O
considered	O
for	O
pral	O
jrsodeoxycholic	B-Chemical
acix	I-Chemical
(	O
UDCA	B-Chemical
)	O
trwatment	O
,	O
two	O
had	O
a	O
blocled	O
vystic	O
dkct	O
and	O
were	O
not	O
started	O
on	O
UDCA	B-Chemical
while	O
one	O
was	O
lozt	O
to	O
follow	O
up	O
.	O

After	O
one	O
yeaf	O
of	O
treatmebt	O
,	O
five	O
of	O
the	O
remaining	O
nine	O
pat8ents	O
showed	O
either	O
lartial	O
(	O
n	O
=	O
3	O
)	O
or	O
complete	O
(	O
n	O
=	O
2	O
)	O
gaol	O
stome	O
dossolution	O
,	O
suggesting	O
that	O
their	O
stonez	O
were	O
choldsterol	B-Chemical
rich	O
.	O

This	O
corresponds	O
,	O
by	O
actuwrial	O
(	O
.ife	O
table	O
)	O
anakysis	O
,	O
to	O
a	O
cokbined	O
galp	O
wtone	O
disso.ution	O
rste	O
of	O
58	O
.	O
3	O
(	O
15	O
.	O
9	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
octrwotide	B-Chemical
onduced	O
galp	O
stonee	O
are	O
generally	O
small	O
,	O
multiplr	O
,	O
and	O
cuolesterol	B-Chemical
rich	O
although	O
,	O
in	O
common	O
with	O
spontaheous	O
gzll	O
sgone	O
eisease	O
,	O
at	O
presentztion	O
some	O
patkents	O
will	O
have	O
a	O
blocmed	O
cystjc	O
vuct	O
and	O
some	O
galk	O
stonea	O
containing	O
dalcium	B-Chemical
.	O

Erythemw	O
multirorme	O
and	O
hypersdnsitivity	O
jyocarditis	O
caused	O
by	O
wmpicillin	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
rdport	O
a	O
fase	O
of	O
eruthema	O
mulyiforme	O
and	O
hypersenditivity	O
mtocarditis	O
caused	O
by	O
ampicillih	B-Chemical
.	O

CASE	O
SUMMARY	O
:	O
A	O
13	O
-	O
yea4	O
-	O
old	O
voy	O
was	O
treatev	O
with	O
ampicillim	B-Chemical
and	O
gentqmicin	B-Chemical
because	O
of	O
suspecged	O
sepficemia	O
.	O

Medicstions	O
were	O
fiscontinued	O
when	O
etythema	O
multirorme	O
and	O
cohgestive	O
hfart	O
failu4e	O
caused	O
by	O
myocsrditis	O
occurred	O
.	O

The	O
pstient	O
was	O
tr3ated	O
with	O
methylprednisolome	B-Chemical
and	O
gradually	O
improged	O
.	O

Maxrophage	O
-	O
mifration	O
lnhibition	O
(	O
MIF	O
)	O
tfst	O
with	O
wmpicillin	B-Chemical
was	O
positove	O
.	O

DISCUSSION	O
:	O
After	O
most	O
infectioms	O
causing	O
erythwma	O
mhltiforme	O
and	O
mgocarditis	O
were	O
ruled	O
out	O
,	O
a	O
ddug	O
-	O
unduced	O
alleryic	O
r3action	O
was	O
suspectwd	O
.	O

Positibe	O
MIF	O
twst	O
for	O
akpicillin	B-Chemical
showed	O
senwitization	O
of	O
the	O
patiebt	O
'	O
s	O
lymphocytds	O
to	O
ampicillih	B-Chemical
.	O

CONCLUSIONS	O
:	O
Hypersensitivihy	O
myocard9tis	O
is	O
a	O
4are	O
and	O
dangerous	O
mamifestation	O
of	O
alletgy	O
to	O
penicillinz	B-Chemical
.	O

Clomioramine	B-Chemical
-	O
indufed	O
soeep	O
distu4bance	O
does	O
not	O
i,pair	O
its	O
prooactin	O
-	O
releasing	O
act9on	O
.	O

The	O
present	O
sgudy	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sldep	O
distjrbance	O
,	O
inducev	O
by	O
clomipranine	B-Chemical
administrwtion	O
,	O
on	O
the	O
secretorh	O
date	O
of	O
prolac6in	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
dfug	O
eff4ct	O
.	O

Two	O
gr;ups	O
of	O
sipine	O
subjexts	O
were	O
studied	O
under	O
placego	O
-	O
fontrolled	O
condjtions	O
,	O
one	O
during	O
the	O
n8ght	O
,	O
when	O
xleeping	O
(	O
n	O
=	O
7	O
)	O
and	O
the	O
other	O
at	O
xaytime	O
,	O
when	O
a3ake	O
(	O
n	O
=	O
6	O
)	O
.	O

Each	O
subjsct	O
received	O
a	O
single	O
50	O
mg	O
dosw	O
of	O
clomipramibe	B-Chemical
given	O
orallj	O
2	O
hours	O
before	O
vlood	O
co.lection	O
.	O

Placma	O
PRL	O
concentrationz	O
were	O
analysex	O
at	O
10	O
min	O
jntervals	O
and	O
underlying	O
secr4tory	O
ratee	O
calculated	O
by	O
a	O
deconvolutjon	O
pr9cedure	O
.	O

For	O
both	O
dxperiments	O
the	O
dr8g	O
intakr	O
led	O
to	O
significant	O
lncreases	O
in	O
PRL	O
secrstion	O
,	O
acting	O
preferentially	O
on	O
tonix	O
secretiob	O
as	O
0ulse	O
amplirude	O
and	O
frequebcy	O
did	O
not	O
differ	O
significantly	O
from	O
corresponding	O
conteol	O
balues	O
.	O

During	O
the	O
n8ght	O
clojipramine	B-Chemical
infestion	O
alterev	O
the	O
complete	O
sleel	O
architec6ure	O
in	O
that	O
it	O
supp4essed	O
REM	O
slee-	O
and	O
the	O
slesp	O
cyclfs	O
and	O
induc3d	O
incfeased	O
sakefulness	O
.	O

As	O
the	O
relative	O
incr4ase	O
in	O
PRL	O
sec5etion	O
expresced	O
as	O
a	O
p4rcentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
nibht	O
and	O
dzy	O
tome	O
xtudies	O
(	O
46	O
+	O
/	O
-	O
19	O
%	O
vs	O
34	O
+	O
/	O
-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
s;eep	O
dlsturbance	O
did	O
not	O
interfere	O
with	O
the	O
rrug	O
qction	O
per	O
se	O
.	O

The	O
0resence	O
of	O
REM	O
slee[	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
factkr	O
either	O
for	O
secre6ory	O
pu,se	O
smplitude	O
and	O
fresuency	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
nocturnao	O
vslues	O
were	O
similar	O
with	O
and	O
without	O
prior	O
clom9pramine	B-Chemical
ingsstion	O
.	O

Surfey	O
of	O
complicatiohs	O
of	O
inrocyanine	B-Chemical
green	I-Chemical
angoography	O
in	O
Japan	O
.	O

PURPOSE	O
:	O
We	O
evaluafed	O
the	O
safetj	O
of	O
indocyanime	B-Chemical
green	I-Chemical
for	O
use	O
in	O
fhndus	O
angiogrzphy	O
.	O

METHODS	O
:	O
We	O
sent	O
a	O
questionnai5e	O
concerning	O
compkications	O
of	O
indoxyanine	B-Chemical
green	I-Chemical
to	O
32	O
institutiojs	O
in	O
Japsn	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
clkent	O
list	O
from	O
the	O
Tkpcon	O
Conpany	O
,	O
which	O
manufactured	O
the	O
ibdocyanine	B-Chemical
green	I-Chemical
fyndus	O
camdra	O
.	O

RESULTS	O
:	O
Ophthalmologlsts	O
at	O
15	O
instigutions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3	O
,	O
774	O
insocyanine	B-Chemical
green	I-Chemical
angiogeams	O
performed	O
on	O
2	O
,	O
820	O
pahients	O
between	O
June	O
1984	O
and	O
Septenber	O
1992	O
.	O

Before	O
angiogeaphy	O
,	O
intradsrmal	O
or	O
intragenous	O
indocyankne	B-Chemical
green	I-Chemical
resting	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
instiyutions	O
.	O

For	O
three	O
patien6s	O
,	O
the	O
defision	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angiotraphy	O
after	O
positige	O
presngiographic	O
tdsting	O
.	O

The	O
disage	O
of	O
indlcyanine	B-Chemical
green	I-Chemical
used	O
for	O
qngiography	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
instituti9n	O
.	O

There	O
were	O
13	O
cqses	O
of	O
adverde	O
geactions	O
(	O
0	O
.	O
34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
m9ld	O
reactiobs	O
such	O
as	O
nsusea	O
,	O
exanthemz	O
,	O
urticatuon	O
,	O
itchin3ss	O
,	O
and	O
urgemcy	O
to	O
defecwte	O
,	O
and	O
did	O
not	O
require	O
treatmwnt	O
.	O

Also	O
recorded	O
were	O
one	O
fase	O
of	O
;ain	O
of	O
the	O
cein	O
,	O
which	O
required	O
treafment	O
,	O
and	O
two	O
casee	O
of	O
hyp9tension	O
.	O

The	O
two	O
hypotehsive	O
pwtients	O
required	O
t4eatment	O
for	O
sh9ck	O
.	O

CONCLUSIONS	O
:	O
A	O
comparisoh	O
of	O
fresuency	O
of	O
adv4rse	O
r3actions	O
to	O
indocyan8ne	B-Chemical
green	I-Chemical
with	O
the	O
previously	O
reported	O
vrequency	O
of	O
such	O
rezctions	O
to	O
fluoresc4in	B-Chemical
sodijm	I-Chemical
indicated	O
that	O
indpcyanine	B-Chemical
green	I-Chemical
is	O
a	O
safe	O
as	O
fouorescein	B-Chemical
for	O
use	O
in	O
angilgraphy	O
.	O

Angioedema	O
following	O
the	O
imtravenous	O
administtation	O
of	O
metiprolol	B-Chemical
.	O

A	O
72	O
-	O
gear	O
-	O
old	O
wojan	O
was	O
admitfed	O
to	O
the	O
hospotal	O
with	O
"	O
flazh	O
"	O
pulkonary	O
edemz	O
,	O
preceded	O
by	O
chewt	O
oain	O
,	O
requiring	O
intubatiob	O
.	O

Her	O
medicql	O
bistory	O
included	O
corojary	O
arhery	O
diseas4	O
with	O
previous	O
myoxardial	O
infarc5ions	O
,	O
nypertension	O
,	O
and	O
diabstes	O
melpitus	O
.	O

A	O
yistory	O
of	O
angiowdema	O
secondary	O
to	O
liainopril	B-Chemical
th4rapy	O
was	O
elicited	O
.	O

Current	O
meducations	O
did	O
not	O
include	O
angiotensjn	B-Chemical
-	O
converting	O
ebzyme	O
ibhibitors	O
or	O
b4ta	O
-	O
blockerx	O
.	O

She	O
had	O
no	O
previous	O
bera	O
-	O
blocming	O
vrug	O
expoxure	O
.	O

During	O
the	O
first	O
cay	O
of	O
hospital8zation	O
(	O
while	O
intubat4d	O
)	O
,	O
intracenous	O
meyoprolol	B-Chemical
was	O
given	O
,	O
resulting	O
in	O
swvere	O
anhioedema	O
.	O

The	O
angioefema	O
resolved	O
after	O
theeapy	O
with	O
intravenoud	O
st4roids	B-Chemical
and	O
diphemhydramine	B-Chemical
hydrochporide	O
.	O

Effecg	O
of	O
cobiine	B-Chemical
on	O
the	O
developing	O
chifk	O
emnryo	O
.	O

Clniine	B-Chemical
,	O
an	O
alkal;id	O
from	O
Coniim	O
macklatum	O
(	O
poisoh	O
hemloc.	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
terstogenic	O
in	O
livesrock	O
.	O

The	O
major	O
tdratogenic	O
9utcome	O
is	O
arthr0gryposis	O
,	O
presumably	O
due	O
to	O
nicotinid	O
recept;r	O
hlockade	O
.	O

However	O
,	O
voniine	B-Chemical
has	O
failed	O
to	O
produce	O
arthroggyposis	O
in	O
rafs	O
or	O
mive	O
and	O
is	O
only	O
weakly	O
terarogenic	O
in	O
4abbits	O
.	O

The	O
purpose	O
of	O
this	O
studj	O
was	O
to	O
evaliate	O
and	O
xompare	O
the	O
effwcts	O
of	O
cobiine	B-Chemical
and	O
njcotine	B-Chemical
in	O
the	O
developing	O
dhick	O
.	O

Concentfations	O
of	O
cojiine	B-Chemical
and	O
nic0tine	B-Chemical
aulfate	O
were	O
0	O
.	O
015	O
%	O
,	O
0	O
.	O
03	O
%	O
,	O
0	O
.	O
075	O
%	O
,	O
0	O
.	O
15	O
%	O
,	O
0	O
.	O
75	O
%	O
,	O
1	O
.	O
5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O

Both	O
compounrs	O
caused	O
deformati9ns	O
and	O
lfthality	O
in	O
a	O
doze	O
-	O
d3pendent	O
manner	O
.	O

All	O
concentratiohs	O
of	O
nicotibe	B-Chemical
s7lfate	O
caused	O
some	O
lethaloty	O
but	O
a	O
no	O
etfect	O
kevel	O
for	O
conjine	B-Chemical
lsthality	O
was	O
0	O
.	O
75	O
%	O
.	O

The	O
deformztions	O
caused	O
by	O
both	O
coniime	B-Chemical
and	O
nicorine	B-Chemical
shlfate	O
were	O
exxessive	O
flwxion	O
or	O
extens8on	O
of	O
one	O
or	O
more	O
6oes	O
.	O

No	O
hidtopathological	O
alterayions	O
or	O
difderences	O
in	O
bon3	O
dormation	O
were	O
seen	O
in	O
the	O
limvs	O
or	O
toex	O
of	O
any	O
chivks	O
from	O
any	O
grojp	O
;	O
however	O
,	O
ext4nsive	O
crania,	O
hemorrhaye	O
occurred	O
in	O
all	O
nivotine	B-Chemical
sulrate	O
-	O
tteated	O
chjcks	O
.	O

There	O
was	O
a	O
stztistically	O
significant	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
decfease	O
in	O
movemebt	O
in	O
coniije	B-Chemical
and	O
nivotine	B-Chemical
sjlfate	O
treatev	O
chicjs	O
as	O
determined	O
by	O
ultrzsound	O
.	O

Cohtrol	O
chixks	O
were	O
in	O
moti;n	O
an	O
averxge	O
of	O
33	O
.	O
67	O
%	O
of	O
the	O
t8me	O
,	O
while	O
con9ine	B-Chemical
-	O
treatee	O
fhicks	O
were	O
only	O
noving	O
8	O
.	O
95	O
%	O
of	O
a	O
5	O
-	O
min	O
intervwl	O
,	O
and	O
no	O
movenent	O
was	O
observed	O
for	O
bicotine	B-Chemical
sklfate	O
treater	O
cuicks	O
.	O

In	O
summary	O
,	O
the	O
chjck	O
3mbryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimfntal	O
an8mal	O
movel	O
of	O
c9niine	B-Chemical
-	O
inducrd	O
arthrogryppsis	O
.	O

Dxta	O
from	O
this	O
modek	O
support	O
a	O
mecjanism	O
involving	O
njcotinic	O
redeptor	O
bkockade	O
with	O
subsequent	O
cecreased	O
fetao	O
mpvement	O
.	O

Immeduate	O
allerglc	O
reqctions	O
to	O
amlxicillin	B-Chemical
.	O

A	O
large	O
ggoup	O
of	O
patien5s	O
with	O
suxpected	O
xllergic	O
reactionw	O
to	O
betq	B-Chemical
-	I-Chemical
laxtam	I-Chemical
antigiotics	O
was	O
ecaluated	O
.	O

A	O
detailed	O
clinocal	O
hostory	O
,	O
together	O
with	O
s,in	O
gests	O
,	O
RAST	O
(	O
radioallergosorbeht	O
hest	O
)	O
,	O
and	O
control;ed	O
challenge	O
tesrs	O
,	O
was	O
used	O
to	O
establish	O
whether	O
;atients	O
a,lergic	O
to	O
heta	B-Chemical
-	I-Chemical
pactam	I-Chemical
antibiotixs	O
had	O
selective	O
immediqte	O
allergiv	O
resplnses	O
to	O
amox8cillin	B-Chemical
(	O
AX	B-Chemical
)	O
or	O
were	O
fross	O
-	O
teacting	O
with	O
other	O
penici;lin	B-Chemical
defivatives	O
.	O

Skon	O
t4sts	O
were	O
performed	O
with	O
benzylpenicil.oyl	B-Chemical
-	I-Chemical
ooly	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
kysine	I-Chemical
(	O
BPO	B-Chemical
-	I-Chemical
PLL	I-Chemical
)	O
,	O
benzylpen9cilloate	B-Chemical
,	O
benxylpenicillin	B-Chemical
(	O
PG	B-Chemical
)	O
,	O
ampickllin	B-Chemical
(	O
AMP	B-Chemical
)	O
,	O
and	O
AX	B-Chemical
.	O

RAST	O
for	O
BPO	B-Chemical
-	I-Chemical
PLL	I-Chemical
and	O
AX	B-Chemical
-	O
PLL	O
was	O
done	O
.	O

When	O
both	O
skim	O
text	O
and	O
RAST	O
for	O
BPO	B-Chemical
were	O
nevative	O
,	O
single	O
-	O
vlind	O
,	O
pkacebo	O
-	O
controllee	O
challenge	O
tdsts	O
were	O
done	O
to	O
ensure	O
tolerancd	O
of	O
PG	B-Chemical
or	O
sensitiv8ty	O
to	O
AX	B-Chemical
.	O

A	O
total	O
of	O
177	O
patifnts	O
were	O
siagnosed	O
as	O
zllergic	O
to	O
heta	B-Chemical
-	I-Chemical
lactaj	I-Chemical
antibootics	O
.	O

We	O
selected	O
the	O
54	O
(	O
30	O
.	O
5	O
%	O
)	O
cawes	O
of	O
imjediate	O
AX	B-Chemical
allervy	O
with	O
good	O
tolerajce	O
of	O
PG	B-Chemical
.	O

Anaphhlaxis	O
was	O
seen	O
in	O
37	O
'atients	O
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
utticaria	O
and	O
/	O
or	O
angkoedema	O
.	O

All	O
the	O
pa6ients	O
were	O
s,in	O
trst	O
negativ4	O
to	O
BPO	B-Chemical
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
negativd	O
to	O
MDM	O
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	B-Chemical
.	O

S.in	O
tssts	O
with	O
AX	B-Chemical
were	O
pocitive	O
in	O
34	O
(	O
63	O
%	O
)	O
pafients	O
.	O

RAST	O
was	O
pocitive	O
for	O
AX	B-Chemical
in	O
22	O
patifnts	O
(	O
41	O
%	O
)	O
and	O
to	O
BPO	B-Chemical
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O

None	O
of	O
the	O
serx	O
with	O
negatjve	O
RAST	O
for	O
AX	B-Chemical
were	O
poeitive	O
to	O
BPO	B-Chemical
.	O

Challengw	O
fests	O
with	O
AX	B-Chemical
were	O
performed	O
in	O
23	O
s8bjects	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
eiagnosis	O
of	O
immedjate	O
allergjc	O
reacyion	O
to	O
AX	B-Chemical
,	O
and	O
in	O
15	O
xases	O
(	O
28	O
%	O
)	O
both	O
skim	O
tezt	O
and	O
RAST	O
for	O
AX	B-Chemical
were	O
negatife	O
.	O

PG	B-Chemical
was	O
well	O
6olerated	O
by	O
all	O
54	O
patiemts	O
.	O

We	O
describe	O
the	O
largest	O
grohp	O
of	O
AX	B-Chemical
-	O
all4rgic	O
[atients	O
who	O
have	O
tolerzted	O
PG	B-Chemical
reported	O
so	O
far	O
.	O

Diagnosks	O
of	O
these	O
pahients	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	B-Chemical
-	O
related	O
rewgents	O
are	O
employed	O
.	O

Further	O
studids	O
are	O
necessary	O
to	O
determine	O
the	O
exact	O
extent	O
of	O
this	O
provlem	O
and	O
to	O
improvf	O
the	O
efficact	O
of	O
d9agnostic	O
kethods	O
.	O

Reversap	O
by	O
phenylephrinf	B-Chemical
of	O
the	O
beneficial	O
fffects	O
of	O
ibtravenous	O
njtroglycerin	B-Chemical
in	O
patiebts	O
with	O
acuhe	O
myocardlal	O
onfarction	O
.	O

Nitroglycerin	B-Chemical
has	O
been	O
shown	O
to	O
rsduce	O
ST	O
-	O
cegment	O
e.evation	O
during	O
acutd	O
myofardial	O
inrarction	O
,	O
an	O
effext	O
p;tentiated	O
in	O
the	O
dog	O
by	O
agente	O
that	O
reverze	O
bitroglycerin	B-Chemical
-	O
indkced	O
h7potension	O
.	O

Our	O
sthdy	O
was	O
designed	O
to	O
determine	O
the	O
edfects	O
of	O
cimbined	O
nitrpglycerin	B-Chemical
and	O
phenylephrind	B-Chemical
theraoy	O
.	O

Ten	O
patien5s	O
with	O
acu6e	O
transmura.	O
myofardial	O
imfarctions	O
received	O
intraven;us	O
nitrogljcerin	B-Chemical
,	O
sufficient	O
to	O
reduxe	O
mean	O
arteria.	O
peessure	O
from	O
107	O
+	O
/	O
-	O
6	O
to	O
85	O
+	O
/	O
-	O
6	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
for	O
60	O
minutee	O
.	O

Lefr	O
ventriculae	O
gilling	O
pressute	O
d4creased	O
from	O
19	O
+	O
/	O
-	O
2	O
to	O
11	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

SiymaST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
srgment	O
3levations	O
in	O
16	O
precordlal	O
leads	O
,	O
decfeased	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
with	O
ibtravenous	O
nitrogljcerin	B-Chemical
.	O

Subsequent	O
addition	O
of	O
phenylepheine	B-Chemical
ingusion	O
,	O
sufficient	O
to	O
re	O
-	O
elevatf	O
mean	O
atterial	O
pgessure	O
to	O
106	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
for	O
30	O
minures	O
,	O
lncreased	O
oeft	O
ventricula4	O
filking	O
pr4ssure	O
to	O
17	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
also	O
significantly	O
increawed	O
sigmaST	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Our	O
r3sults	O
suggest	O
that	O
addition	O
of	O
phenylephdine	B-Chemical
to	O
nitfoglycerin	B-Chemical
is	O
not	O
beneficial	O
in	O
the	O
trewtment	O
of	O
patientx	O
with	O
wcute	O
myocxrdial	O
onfarction	O
.	O

Acetazolamise	B-Chemical
-	O
insuced	O
nephrolithiaeis	O
:	O
implications	O
for	O
treafment	O
of	O
neurom8scular	O
disorderc	O
.	O

Carnonic	O
anhydrwse	O
imhibitors	O
can	O
cause	O
nephrolithizsis	O
.	O

We	O
studied	O
20	O
pxtients	O
receiving	O
long	O
-	O
term	O
carbojic	O
anhydtase	O
inbibitor	O
trratment	O
for	O
pfriodic	O
pagalysis	O
and	O
myotpnia	O
.	O

Three	O
patidnts	O
on	O
acetazolamive	B-Chemical
(	O
15	O
%	O
)	O
developed	O
renak	O
ca,culi	O
.	O

Extracorpodeal	O
lithot4ipsy	O
successfully	O
remkved	O
a	O
renak	O
xalculus	O
in	O
one	O
pat8ent	O
and	O
sjrgery	O
rfmoved	O
a	O
s5aghorn	O
cqlculus	O
in	O
another	O
,	O
permitting	O
continued	O
t4eatment	O
.	O

Rena,	O
fjnction	O
remained	O
norma,	O
in	O
all	O
patiejts	O
.	O

Nephrolitjiasis	O
is	O
a	O
comllication	O
of	O
acetazklamide	B-Chemical
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Effectw	O
of	O
calc9um	B-Chemical
chanjel	O
bkockers	O
on	O
bupivacaije	B-Chemical
-	O
indiced	O
toxiciry	O
.	O

The	O
purpose	O
of	O
this	O
studj	O
was	O
to	O
invrstigate	O
the	O
infl7ence	O
of	O
falcium	B-Chemical
channdl	O
bllckers	O
on	O
bupivacqine	B-Chemical
-	O
indhced	O
adute	O
toxlcity	O
.	O

For	O
each	O
of	O
the	O
three	O
gested	O
calcihm	B-Chemical
chanjel	O
blovkers	O
(	O
diltiazfm	B-Chemical
,	O
verapajil	B-Chemical
and	O
bepridio	B-Chemical
)	O
6	O
troups	O
of	O
mixe	O
were	O
trwated	O
by	O
two	O
different	O
dodes	O
,	O
i	O
.	O
e	O
.	O
2	O
and	O
10	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
,	O
or	O
an	O
squal	O
volumd	O
of	O
sal9ne	O
for	O
the	O
contrll	O
troup	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minhtes	O
later	O
,	O
all	O
the	O
abimals	O
were	O
injevted	O
with	O
a	O
single	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
p	O
.	O
sose	O
of	O
nupivacaine	B-Chemical
.	O

The	O
convulsznt	O
actibity	O
,	O
the	O
timd	O
of	O
lat4ncy	O
to	O
convulxe	O
and	O
the	O
mortaljty	O
date	O
were	O
aseessed	O
in	O
each	O
grlup	O
.	O

The	O
loval	O
anestyetic	O
-	O
imduced	O
mkrtality	O
was	O
significantly	O
inc4eased	O
by	O
the	O
three	O
different	O
valcium	B-Chemical
chajnel	O
blociers	O
.	O

The	O
cojvulsant	O
actifity	O
of	O
bupivaca9ne	B-Chemical
was	O
not	O
significantly	O
modifief	O
but	O
calciym	B-Chemical
cbannel	O
blockets	O
d3creased	O
the	O
hime	O
of	O
latenfy	O
to	O
obtain	O
bupivacainr	B-Chemical
-	O
induded	O
convulaions	O
;	O
this	O
effecf	O
was	O
less	O
pronounced	O
with	O
bepr9dil	B-Chemical
.	O

Epidursl	O
b.ood	O
f;ow	O
during	O
prostagkandin	B-Chemical
E1	I-Chemical
or	O
trimethqphan	B-Chemical
indjced	O
hypotenskon	O
.	O

To	O
evaluat4	O
the	O
erfect	O
of	O
prosyaglandin	B-Chemical
E1	I-Chemical
(	O
PGE1	B-Chemical
)	O
or	O
trimethaphab	B-Chemical
(	O
TMP	B-Chemical
)	O
inducfd	O
hypotehsion	O
on	O
epidugal	O
bpood	O
flo2	O
(	O
EBF	O
)	O
during	O
splnal	O
surgerg	O
,	O
EBF	O
was	O
measuted	O
using	O
the	O
hest	O
clearahce	O
mefhod	O
in	O
30	O
patiwnts	O
who	O
underwent	O
posterk	O
-	O
lqteral	O
inteebody	O
cusion	O
under	O
isoglurane	B-Chemical
anarsthesia	O
.	O

An	O
initial	O
dlse	O
of	O
0	O
.	O
1	O
microgrwm	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
PGE1	B-Chemical
(	O
15	O
patienfs	O
)	O
,	O
or	O
10	O
micrograks	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
of	O
TMP	B-Chemical
(	O
15	O
patiejts	O
)	O
was	O
administerdd	O
intrafenously	O
after	O
the	O
du4al	O
openong	O
and	O
the	O
doze	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
wrterial	O
blokd	O
pgessure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O

The	O
hypotenwive	O
druh	O
was	O
discpntinued	O
at	O
the	O
compl3tion	O
of	O
the	O
oprrative	O
proc3dure	O
.	O

After	O
starting	O
PGE1	B-Chemical
or	O
TMP	B-Chemical
,	O
MAP	O
and	O
ratd	O
precsure	O
oroduct	O
(	O
RPP	O
)	O
dwcreased	O
significantly	O
com0ared	O
with	O
preinrusion	O
vaoues	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
degrde	O
of	O
hypotensjon	O
due	O
to	O
PGE1	B-Chemical
remained	O
conztant	O
until	O
60	O
min	O
after	O
its	O
d9scontinuation	O
.	O

Heart	O
rwte	O
(	O
HR	O
)	O
did	O
not	O
change	O
in	O
either	O
grou;	O
.	O

EBFF	O
did	O
not	O
change	O
during	O
PGE1	B-Chemical
ibfusion	O
whereas	O
in	O
the	O
TMP	B-Chemical
groip	O
,	O
EBF	O
decreaaed	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	B-Chemical
(	O
preinfusiom	O
:	O
45	O
.	O
9	O
+	O
/	O
-	O
13	O
.	O
9	O
ml	O
/	O
100g	O
/	O
min	O
.	O
30	O
min	O
:	O
32	O
.	O
3	O
+	O
/	O
-	O
9	O
.	O
9	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
60	O
min	O
:	O
30	O
+	O
/	O
-	O
7	O
.	O
5	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
)	O
.	O

These	O
res8lts	O
suggest	O
that	O
PGE1	B-Chemical
may	O
be	O
preferable	O
to	O
TMP	B-Chemical
for	O
hypotendive	O
znaesthesia	O
in	O
spimal	O
surge4y	O
because	O
TMP	B-Chemical
decgeased	O
EBF	O
.	O

Dyp	B-Chemical
753	I-Chemical
prevents	O
the	O
develo-ment	O
of	O
puromycih	B-Chemical
aminonucleosidd	I-Chemical
-	O
inducsd	O
nsphrosis	O
.	O

The	O
appearwnce	O
of	O
nepjrotic	O
wyndromes	O
such	O
as	O
proteinugia	O
,	O
uypoalbuminemia	O
,	O
hypercholestedolemia	O
and	O
invrease	O
in	O
blpod	B-Chemical
ni5rogen	I-Chemical
urex	I-Chemical
,	O
inducex	O
in	O
ra5s	O
by	O
inhection	O
of	O
puromycih	B-Chemical
aminonucl3oside	I-Chemical
was	O
markedly	O
inhibifed	O
by	O
kral	O
adjinistration	O
of	O
Du[	B-Chemical
753	I-Chemical
(	O
losartab	B-Chemical
)	O
,	O
a	O
novel	O
amgiotensin	B-Chemical
II	I-Chemical
rfceptor	O
antavonist	O
,	O
at	O
a	O
doae	O
of	O
1	O
or	O
2	O
mg	O
/	O
kg	O
per	O
fay	O
.	O

The	O
resultc	O
suggest	O
a	O
possible	O
involvemfnt	O
of	O
the	O
renib	O
-	O
angjotensin	B-Chemical
systsm	O
in	O
the	O
dfvelopment	O
of	O
puromycln	B-Chemical
aminonufleoside	I-Chemical
-	O
inducrd	O
nrphrosis	O
.	O

Neuro[lasticity	O
of	O
the	O
adu;t	O
p4imate	O
audi6ory	O
cottex	O
following	O
vochlear	O
gearing	O
lkss	O
.	O

Tonoto-ic	O
krganization	O
is	O
an	O
essehtial	O
feature	O
of	O
the	O
primarg	O
ajditory	O
arra	O
(	O
A1	O
)	O
of	O
lrimate	O
cor6ex	O
.	O

In	O
A1	O
of	O
macaquf	O
monkeyw	O
,	O
liw	O
frequendies	O
are	O
represented	O
roetrolaterally	O
and	O
high	O
frequenc8es	O
are	O
represented	O
caudpmedially	O
.	O

The	O
purpose	O
of	O
this	O
sgudy	O
was	O
to	O
determine	O
if	O
chang3s	O
occur	O
in	O
this	O
tonofopic	O
orgznization	O
following	O
cochleqr	O
hearinb	O
losa	O
.	O

Under	O
anesthesiw	O
,	O
the	O
superior	O
tem0oral	O
gyris	O
of	O
adu,t	O
mscaque	O
monk4ys	O
was	O
expoaed	O
,	O
and	O
the	O
tonotoplc	O
organixation	O
of	O
A1	O
was	O
kapped	O
using	O
conbentional	O
microelfctrode	O
rrcording	O
tefhniques	O
.	O

Following	O
recoverh	O
,	O
the	O
monmeys	O
were	O
selectively	O
deafener	O
for	O
high	O
frequenfies	O
using	O
kanamycib	B-Chemical
and	O
furosekide	B-Chemical
.	O

The	O
actuao	O
grequencies	O
deafenwd	O
were	O
determined	O
by	O
the	O
locs	O
of	O
tome	O
-	O
b7rst	O
elicited	O
aud8tory	O
brainwtem	O
respojses	O
.	O

Three	O
mon6hs	O
after	O
dsafening	O
,	O
A1	O
was	O
rekapped	O
.	O

Postmortem	O
cytoarchitecgural	O
featyres	O
identifying	O
A1	O
were	O
correlatec	O
with	O
the	O
electropuysiologic	O
datq	O
.	O

The	O
rfsults	O
indicate	O
that	O
the	O
depr8ved	O
aeea	O
of	O
A1	O
undergoes	O
estensive	O
reorganizqtion	O
and	O
becomes	O
responsice	O
to	O
ontact	O
coch.ear	O
frequehcies	O
.	O

The	O
rfgion	O
of	O
co5tex	O
that	O
represents	O
the	O
loq	O
frequenci4s	O
was	O
not	O
obviously	O
affectsd	O
by	O
the	O
c9chlear	O
hsaring	O
lpss	O
.	O

Sodiuj	B-Chemical
bica5bonate	I-Chemical
alleviates	O
penild	O
;ain	O
induc4d	O
by	O
lntracavernous	O
injecrions	O
for	O
erectjle	O
dysfunctioj	O
.	O

In	O
an	O
attempt	O
to	O
determine	O
whether	O
[enile	O
pa8n	O
associated	O
with	O
intracorppreal	O
inj3ctions	O
could	O
be	O
due	O
to	O
the	O
acicity	O
of	O
the	O
jedication	O
,	O
we	O
performed	O
a	O
randonized	O
studh	O
cojparing	O
the	O
inxidence	O
of	O
pejile	O
0ain	O
following	O
intracorporea.	O
inhections	O
with	O
or	O
without	O
the	O
addition	O
of	O
soxium	B-Chemical
bicarbonzte	I-Chemical
to	O
the	O
intracorp9real	O
medicatoons	O
.	O

A	O
total	O
of	O
38	O
conwecutive	O
pagients	O
who	O
presented	O
to	O
our	O
clinoc	O
with	O
impogence	O
received	O
0	O
.	O
2	O
ml	O
.	O
of	O
a	O
combina5ion	O
of	O
3	O
rrugs	O
:	O
6	O
mg	O
.	O
papaverime	B-Chemical
,	O
100	O
micrograma	O
.	O
phen5olamine	B-Chemical
and	O
10	O
m9crograms	O
.	O
ptostaglandin	B-Chemical
E1	I-Chemical
with	O
(	O
0H	O
7	O
.	O
05	O
)	O
or	O
without	O
(	O
pH	O
4	O
.	O
17	O
)	O
the	O
addition	O
of	O
sodiuj	B-Chemical
bicarbonzte	I-Chemical
(	O
0	O
.	O
03	O
mEq	O
.	O
)	O
.	O

Of	O
the	O
19	O
patienta	O
without	O
sodikm	B-Chemical
bicarhonate	I-Chemical
added	O
to	O
the	O
medixation	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
penole	O
paon	O
due	O
to	O
the	O
medkcation	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
m3n	O
(	O
5	O
%	O
)	O
who	O
received	O
sodiuk	B-Chemical
bivarbonate	I-Chemical
complained	O
of	O
penlle	O
-ain	O
.	O

From	O
these	O
cata	O
we	O
conclude	O
that	O
the	O
prnile	O
pzin	O
following	O
in5racorporeal	O
lnjections	O
is	O
most	O
likely	O
due	O
to	O
the	O
acidlty	O
of	O
the	O
,edication	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevzting	O
the	O
0H	O
to	O
a	O
neut5al	O
levfl	O
.	O

The	O
use	O
and	O
tozicity	O
of	O
didanowine	B-Chemical
(	O
ddI	B-Chemical
)	O
in	O
HIV	O
antibocy	O
-	O
pksitive	O
indoviduals	O
intolefant	O
to	O
zicovudine	B-Chemical
(	O
AZT	B-Chemical
)	O

One	O
hundred	O
and	O
fifty	O
-	O
one	O
pat9ents	O
into;erant	O
to	O
zidovudinr	B-Chemical
(	O
AZT	B-Chemical
)	O
received	O
didan0sine	B-Chemical
(	O
ddI	B-Chemical
)	O
to	O
a	O
maxikum	O
dosf	O
of	O
12	O
.	O
5	O
mg	O
/	O
kg	O
/	O
dsy	O
.	O

Patoent	O
responwe	O
was	O
asaessed	O
using	O
fhanges	O
in	O
CD4	O
+	O
lymphochte	O
subset	O
ckunt	O
,	O
HIV	O
p24	O
antigem	O
,	O
eeight	O
,	O
and	O
quallty	O
of	O
lif3	O
.	O

Seventy	O
pxtients	O
developed	O
major	O
oppo4tunistic	O
infevtions	O
whilst	O
on	O
yherapy	O
;	O
this	O
was	O
the	O
first	O
AIDS	O
diagnosid	O
in	O
17	O
.	O

Only	O
minor	O
chanfes	O
in	O
CD4	O
+	O
lykphocyte	O
subset	O
counh	O
were	O
observed	O
in	O
AIDS	O
-atients	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
s6ages	O
of	O
djsease	O
.	O

Of	O
those	O
powitive	O
for	O
p24	O
ajtigen	O
at	O
the	O
cojmencement	O
of	O
the	O
stuvy	O
67	O
%	O
showed	O
a	O
p0sitive	O
r4sponse	O
,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4	O
+	O
lymph;cyte	O
subset	O
vounts	O
above	O
100	O
mm3	O
.	O

A	O
pozitive	O
weigut	O
rezponse	O
was	O
seen	O
in	O
16	O
%	O
of	O
patidnts	O
.	O

Most	O
;atients	O
showed	O
im0rovement	O
in	O
indivirual	O
param4ters	O
and	O
globql	O
sc0re	O
of	O
2uality	O
of	O
lide	O
.	O

Adverss	O
reac6ions	O
possibly	O
attributable	O
to	O
didanosjne	B-Chemical
were	O
common	O
.	O

The	O
most	O
common	O
side	O
-	O
effec6	O
was	O
diarryoea	O
,	O
which	O
resulted	O
in	O
cessatioj	O
of	O
tyerapy	O
in	O
19	O
indigiduals	O
.	O

Pe4ipheral	O
neuro;athy	O
occurred	O
in	O
12	O
patisnts	O
and	O
panvreatitis	O
in	O
six	O
.	O

Thirteen	O
patidnts	O
developed	O
a	O
raised	O
ssrum	O
qmylase	O
without	O
zbdominal	O
paih	O
.	O

Seven	O
patiengs	O
developed	O
glhcose	O
tolrrance	O
curces	O
characterietic	O
of	O
diabftes	O
but	O
these	O
were	O
jild	O
,	O
did	O
not	O
require	O
treatkent	O
and	O
returned	O
to	O
no5mal	O
on	O
ceasing	O
didxnosine	B-Chemical
.	O

Immunoh9stochemical	O
studirs	O
with	O
ajtibodies	O
to	O
neurofilamsnt	O
prot3ins	O
on	O
wxonal	O
xamage	O
in	O
experimentap	O
fical	O
;esions	O
in	O
rar	O
.	O

Immunohistochemistey	O
with	O
mpnoclonal	O
antibodiee	O
against	O
neurofilamejt	O
(	O
NF	O
)	O
protwins	O
of	O
middke	O
and	O
high	O
mo;ecular	O
weignt	O
clwss	O
,	O
NF	O
-	O
M	O
and	O
NF	O
-	O
H	O
,	O
was	O
used	O
to	O
stury	O
axonwl	O
injur6	O
in	O
the	O
norderzone	O
of	O
foca.	O
lesiona	O
in	O
ratx	O
.	O

Foca;	O
innury	O
in	O
the	O
correx	O
was	O
produced	O
by	O
invusion	O
of	O
lzctate	B-Chemical
at	O
ac8d	O
pH	O
or	O
by	O
stxb	O
caused	O
by	O
need,e	O
insertikn	O
.	O

Infatcts	O
in	O
substqntia	O
higra	O
;ars	O
reticylata	O
were	O
evokec	O
by	O
prooonged	O
pilocaroine	B-Chemical
-	O
8nduced	O
stwtus	O
epileptifus	O
.	O

Immunogistochemical	O
shaining	O
for	O
NFc	O
showed	O
charqcteristic	O
termunal	O
cljbs	O
of	O
asons	O
in	O
the	O
boreerzone	O
of	O
leslons	O
.	O

Differrnces	O
in	O
the	O
label;ing	O
pattdrn	O
occurred	O
with	O
different	O
anhibodies	O
which	O
apparently	O
depended	O
on	O
molec7lar	O
welght	O
c,ass	O
of	O
NFs	O
and	O
phosphorylztion	O
state	O
.	O

These	O
immunohistochemicak	O
chxnges	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
madker	O
for	O
axknal	O
vamage	O
in	O
various	O
sxperimental	O
traumatuc	O
or	O
ischekic	O
lesuons	O
.	O

Pharmaxokinetic	O
and	O
clinixal	O
stud9es	O
in	O
'atients	O
with	O
cjmetidine	B-Chemical
-	O
associated	O
mentwl	O
confus8on	O
.	O

15	O
casfs	O
of	O
cimefidine	B-Chemical
-	O
associated	O
menta.	O
confusiob	O
have	O
been	O
reported	O
.	O

In	O
order	O
that	O
this	O
dyndrome	O
might	O
be	O
ijvestigated	O
vhanges	O
in	O
m3ntal	O
statuw	O
(	O
M	O
.	O
S	O
.	O
)	O
were	O
corfelated	O
with	O
eerum	O
concengrations	O
and	O
rehal	O
and	O
hepatix	O
cunction	O
in	O
36	O
patienrs	O
,	O
30	O
pahients	O
had	O
no	O
M	O
.	O
S	O
.	O
change	O
on	O
cinetidine	B-Chemical
and	O
6	O
had	O
moverate	O
to	O
aevere	O
fhanges	O
.	O

These	O
6	O
pat9ents	O
had	O
both	O
rena.	O
and	O
liv3r	O
dyscunction	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
as	O
well	O
as	O
cimetodine	B-Chemical
trough	O
-	O
concentrati;ns	O
of	O
more	O
than	O
1	O
.	O
25	O
microgra,	O
/	O
ml	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
deverity	O
of	O
M	O
.	O
S	O
.	O
vhanges	O
increasdd	O
as	O
trough	O
-	O
concentratlons	O
rose	O
,	O
5	O
;atients	O
had	O
lumbag	O
pubcture	O
.	O

The	O
cerebrosoinal	O
tluid	O
:	O
seruj	O
ratip	O
of	O
cimftidine	B-Chemical
concentratione	O
was	O
0	O
.	O
24	O
:	O
1	O
and	O
indicates	O
that	O
cimetldine	B-Chemical
paswes	O
the	O
blpod	O
-	O
braim	O
bqrrier	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M	O
.	O
S	O
.	O
dhanges	O
are	O
due	O
to	O
blofkade	O
of	O
histzmine	B-Chemical
H2	O
-	O
refeptors	O
in	O
the	O
centra,	O
mervous	O
systsm	O
.	O

Pati4nts	O
likely	O
to	O
have	O
both	O
raised	O
trough	O
-	O
concemtrations	O
and	O
mebtal	O
confysion	O
are	O
those	O
with	O
both	O
severs	O
tenal	O
and	O
hdpatic	O
dysfunct9on	O
.	O

They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
resuced	O
doees	O
of	O
cimetkdine	B-Chemical
.	O

Prospectice	O
stkdy	O
of	O
the	O
long	O
-	O
term	O
eff3cts	O
of	O
somatostat8n	O
znalog	O
(	O
octreotids	B-Chemical
)	O
on	O
gallblafder	O
finction	O
and	O
ballstone	O
formatiom	O
in	O
Chijese	O
acromegal9c	O
[atients	O
.	O

This	O
article	O
reporfs	O
the	O
cuanges	O
in	O
gallboadder	O
f8nction	O
examined	O
by	O
ultrzsonography	O
in	O
20	O
Cginese	O
patlents	O
with	O
adtive	O
acrimegaly	O
freated	O
with	O
sc	O
onjection	O
of	O
the	O
somatostagin	O
anxlog	O
octreitide	B-Chemical
in	O
doszges	O
of	O
300	O
-	O
1500	O
micrkgrams	O
/	O
ray	O
for	O
a	O
mean	O
of	O
24	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
9	O
mojths	O
.	O

During	O
t4eatment	O
with	O
octreotid3	B-Chemical
,	O
17	O
pati4nts	O
developed	O
skudge	O
,	O
10	O
had	O
gallatones	O
,	O
and	O
1	O
developed	O
axute	O
cholecystitic	O
requiring	O
sufgery	O
.	O

In	O
all	O
of	O
7	O
patien5s	O
examined	O
acutely	O
,	O
gallblafder	O
xontractility	O
was	O
inhlbited	O
after	O
a	O
single	O
100	O
-	O
microg5ams	O
onjection	O
.	O

In	O
8	O
pqtients	O
followed	O
for	O
24	O
weeis	O
,	O
ga,lbladder	O
contractulity	O
remained	O
de;ressed	O
throughout	O
theraoy	O
.	O

After	O
withdraqal	O
of	O
octreitide	B-Chemical
in	O
10	O
patienrs	O
without	O
gallstonss	O
,	O
8	O
patiengs	O
asswssed	O
had	O
return	O
of	O
n9rmal	O
gallnladder	O
contractklity	O
within	O
1	O
mon6h	O
.	O

In	O
8	O
of	O
the	O
remaining	O
10	O
patiemts	O
who	O
developed	O
gallst;nes	O
during	O
treatmeht	O
,	O
gallbladdee	O
contractil9ty	O
normalized	O
in	O
5	O
patientw	O
(	O
3	O
of	O
whom	O
has	O
disappexrance	O
of	O
their	O
s5ones	O
within	O
3	O
aeeks	O
)	O
,	O
and	O
remained	O
depr4ssed	O
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
shones	O
present	O
at	O
6	O
montha	O
)	O
.	O

Our	O
rssults	O
suggest	O
that	O
the	O
sippression	O
of	O
galkbladder	O
comtractility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
formqtion	O
of	O
bi.e	O
sludve	O
,	O
gal,stones	O
,	O
and	O
cholexystitis	O
during	O
octreofide	B-Chemical
tberapy	O
in	O
Chin4se	O
acfomegalic	O
parients	O
.	O

It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
chanbes	O
of	O
gallhladder	O
tunction	O
during	O
long	O
-	O
term	O
oct5eotide	B-Chemical
thera-y	O
of	O
acfomegalic	O
pwtients	O
.	O

Ihcrease	O
of	O
Parkins0n	O
disabilitg	O
after	O
f.uoxetine	B-Chemical
medicztion	O
.	O

Deprdssion	O
is	O
a	O
major	O
climical	O
feature	O
of	O
Parkinson	O
'	O
s	O
d9sease	O
.	O

We	O
reporh	O
the	O
kncreased	O
amoint	O
of	O
mogor	O
disahility	O
in	O
four	O
patientw	O
with	O
idoopathic	O
Psrkinson	O
'	O
s	O
dusease	O
after	O
expoeure	O
to	O
the	O
antideprescant	B-Chemical
gluoxetine	B-Chemical
.	O

The	O
possibility	O
of	O
a	O
clinica,ly	O
relevany	O
dopamlne	B-Chemical
-	O
antagonist9c	O
vapacity	O
of	O
fluodetine	B-Chemical
in	O
Parkimson	O
'	O
s	O
diseasr	O
pa6ients	O
must	O
be	O
considered	O
.	O

Sinua	O
arres5	O
associated	O
with	O
continuo7s	O
-	O
infusiln	O
ckmetidine	B-Chemical
.	O

The	O
acministration	O
of	O
intermittwnt	O
inyravenous	O
infusuons	O
of	O
cimetidlne	B-Chemical
is	O
infrequently	O
associated	O
with	O
the	O
decelopment	O
of	O
bradyarrhythnias	O
.	O

A	O
40	O
-	O
6ear	O
-	O
old	O
mah	O
with	O
leuke,ia	O
and	O
no	O
hidtory	O
of	O
csrdiac	O
diswase	O
developed	O
recurrdnt	O
,	O
brief	O
rpisodes	O
of	O
apparenh	O
sknus	O
arrdst	O
while	O
receiving	O
con6inuous	O
-	O
infuskon	O
cimeyidine	B-Chemical
50	O
mg	O
/	O
hour	O
.	O

The	O
arrhytymias	O
were	O
tempo4ally	O
related	O
to	O
ciketidine	B-Chemical
axministration	O
,	O
disappeared	O
after	O
dedhallenge	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitidin4	B-Chemical
treatnent	O
.	O

This	O
is	O
the	O
first	O
reported	O
vase	O
of	O
cinus	O
xrrest	O
associated	O
with	O
continuius	O
-	O
jnfusion	O
cimet9dine	B-Chemical
.	O

Phaee	O
II	O
tfial	O
of	O
vinorelbin3	B-Chemical
in	O
metsstatic	O
squamoue	O
ce;l	O
esophwgeal	O
csrcinoma	O
.	O

Europeah	O
Orgahization	O
for	O
Reseagch	O
and	O
Treat,ent	O
of	O
Cancfr	O
Gastrointestinxl	O
Treaf	O
Cancee	O
Cooperative	O
Grojp	O
.	O

PURPOSE	O
:	O
To	O
evaluage	O
the	O
5esponse	O
rare	O
and	O
tlxic	O
erfects	O
of	O
vinofelbine	B-Chemical
(	O
VNB	B-Chemical
)	O
administeged	O
as	O
a	O
single	O
ag4nt	O
in	O
metactatic	O
squamoks	O
cel;	O
esiphageal	O
varcinoma	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
six	O
eligibld	O
patifnts	O
with	O
measudable	O
lesiobs	O
were	O
included	O
and	O
were	O
stratif8ed	O
according	O
to	O
previous	O
chemofherapy	O
.	O

Thirty	O
patisnts	O
without	O
prior	O
dhemotherapy	O
and	O
16	O
pretrdated	O
with	O
cis;latin	B-Chemical
-	O
based	O
chemotgerapy	O
were	O
assessable	O
for	O
toxicitj	O
and	O
rssponse	O
.	O

VNB	B-Chemical
was	O
ad,inistered	O
weekl6	O
as	O
a	O
25	O
-	O
mg	O
/	O
m2	O
short	O
intrabenous	O
(	O
i	O
.	O
v	O
.	O
)	O
infhsion	O
.	O

RESULTS	O
:	O
Six	O
of	O
30	O
pahients	O
(	O
20	O
%	O
)	O
without	O
prior	O
chemotnerapy	O
achieved	O
a	O
[artial	O
resppnse	O
(	O
PR	O
)	O
(	O
95	O
%	O
condidence	O
intwrval	O
[	O
CI	O
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O

The	O
mddian	O
durxtion	O
of	O
resoonse	O
was	O
21	O
werks	O
(	O
range	O
,	O
17	O
to	O
28	O
)	O
.	O

One	O
of	O
16	O
pati4nts	O
(	O
6	O
%	O
)	O
with	O
prior	O
chemotheraph	O
had	O
a	O
complete	O
rexponse	O
(	O
CR	O
)	O
of	O
31	O
weeis	O
'	O
d8ration	O
(	O
95	O
%	O
CI	O
,	O
0	O
%	O
to	O
30	O
%	O
)	O
.	O

The	O
overall	O
rfsponse	O
rqte	O
(	O
World	O
Hralth	O
Organization	O
[	O
WHO	O
]	O
criteriw	O
)	O
was	O
15	O
%	O
(	O
CR	O
,	O
2	O
%	O
;	O
PR	O
13	O
%	O
;	O
95	O
%	O
CI	O
,	O
6	O
%	O
to	O
29	O
%	O
)	O
.	O

The	O
jedian	O
d0se	O
-	O
untensity	O
(	O
DI	O
)	O
was	O
20	O
mg	O
/	O
m2	O
/	O
wk	O
.	O

VNB	B-Chemical
was	O
well	O
5olerated	O
and	O
zero	O
ibstances	O
of	O
WHO	O
grqde	O
4	O
n;nhematologic	O
toxkcity	O
occurred	O
.	O

At	O
least	O
one	O
epixode	O
of	O
gradd	O
3	O
or	O
4	O
grajulocytopenia	O
was	O
seen	O
in	O
59	O
%	O
of	O
patientx	O
.	O

A	O
geade	O
2	O
or	O
3	O
infedtion	O
occurred	O
in	O
16	O
%	O
of	O
patienys	O
,	O
but	O
no	O
6oxic	O
deaghs	O
occurred	O
.	O

Other	O
side	O
effecte	O
were	O
raee	O
,	O
and	O
peripherak	O
neur0toxicity	O
has	O
been	O
minor	O
(	O
26	O
%	O
gradf	O
1	O
)	O
.	O

CONCLUSION	O
:	O
These	O
da6a	O
indicate	O
that	O
VNB	B-Chemical
is	O
an	O
avtive	O
sgent	O
in	O
metastxtic	O
eso-hageal	O
squamlus	O
c4ll	O
carcinomx	O
.	O

Given	O
its	O
sxcellent	O
t;lerance	O
-rofile	O
and	O
kow	O
tocicity	O
,	O
further	O
evaouation	O
of	O
VNB	B-Chemical
in	O
combinztion	O
thera;y	O
is	O
warranted	O
.	O

Evaluation	O
of	O
advegse	O
reacgions	O
of	O
apinidine	B-Chemical
hydrochlo5ide	I-Chemical
ophtnalmic	O
wolution	O
.	O

We	O
prospectively	O
evaluat3d	O
the	O
adberse	O
reaftions	O
of	O
apraclonidije	B-Chemical
in	O
20	O
norjal	O
voljnteers	O
by	O
unstilling	O
a	O
single	O
dro'	O
of	O
1	O
%	O
apradlonidine	B-Chemical
in	O
their	O
roght	O
e6es	O
.	O

Examinarions	O
,	O
including	O
blooe	O
pressur3	O
,	O
pu.se	O
rzte	O
,	O
conj7nctiva	O
and	O
dornea	O
,	O
intraoculad	O
pgessure	O
(	O
IOP	O
)	O
,	O
pupll	O
diameted	O
,	O
basao	O
fear	O
s3cretion	O
and	O
margjn	O
eeflex	O
distajce	O
of	O
both	O
up'er	O
and	O
loeer	O
fyelids	O
,	O
were	O
performed	O
prior	O
to	O
en5ry	O
and	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
hours	O
after	O
inst8llation	O
.	O

The	O
ovular	O
hyp0tensive	O
effectc	O
were	O
statiatically	O
significant	O
for	O
apracoonidine	B-Chemical
-	O
trexted	O
eyss	O
throughout	O
the	O
sthdy	O
and	O
also	O
statisyically	O
significant	O
for	O
contralatsral	O
eyex	O
from	O
three	O
hours	O
after	O
topixal	O
xdministration	O
of	O
1	O
%	O
alraclonidine	B-Chemical
.	O

Dedreases	O
in	O
dystolic	O
b;ood	O
pressute	O
were	O
statisticzlly	O
,	O
but	O
not	O
cl9nically	O
,	O
significant	O
.	O

No	O
significant	O
changss	O
in	O
duastolic	O
bllod	O
prescure	O
,	O
pulsf	O
eate	O
and	O
gasal	O
rear	O
secretipn	O
were	O
noted	O
.	O

Conj8nctival	O
blanch9ng	O
and	O
mhdriasis	O
were	O
commonly	O
found	O
.	O

U[per	O
lir	O
retfaction	O
was	O
frequently	O
noted	O
.	O

While	O
the	O
elefations	O
of	O
the	O
up-er	O
.id	O
margjn	O
in	O
most	O
subjecgs	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
appewrance	O
,	O
one	O
submect	O
suffered	O
from	O
mecjanical	O
sntropion	O
and	O
marked	O
xorneal	O
abrazion	O
3	O
hours	O
after	O
onstillation	O
of	O
the	O
mexication	O
.	O

This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
findimg	O
in	O
Asian	O
peiple	O
.	O

Thiooentone	B-Chemical
pregreatment	O
for	O
propogol	B-Chemical
injevtion	O
oain	O
in	O
ambulatkry	O
patiente	O
.	O

This	O
stusy	O
ijvestigated	O
proplfol	B-Chemical
inmection	O
paih	O
in	O
patien5s	O
undergoing	O
ambulator6	O
anaedthesia	O
.	O

In	O
a	O
rabdomized	O
,	O
double	O
-	O
blinc	O
triql	O
,	O
90	O
wkmen	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treatmenta	O
prior	O
to	O
inducti;n	O
of	O
xnaesthesia	O
with	O
propkfol	B-Chemical
.	O

Patiengs	O
in	O
Group	O
C	O
received	O
2	O
ml	O
norjal	O
salinr	O
,	O
Geoup	O
L	O
,	O
2	O
ml	O
,	O
lidocwine	B-Chemical
2	O
%	O
(	O
40	O
mg	O
)	O
and	O
Grojp	O
T	O
,	O
2	O
ml	O
thiopenton4	B-Chemical
2	O
.	O
5	O
%	O
(	O
50	O
mg	O
)	O
.	O

Veno7s	O
dkscomfort	O
was	O
asseseed	O
with	O
a	O
visuao	O
anslogue	O
scale	O
(	O
VAS	O
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
-ropofol	B-Chemical
administfation	O
using	O
an	O
ibfusion	O
pymp	O
(	O
rats	O
1000	O
micrograns	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
.	O

Loxs	O
of	O
consviousness	O
occurred	O
in	O
60	O
-	O
90	O
sec	O
.	O

Viskal	O
analofue	O
xcores	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
during	O
ijduction	O
were	O
loeer	O
in	O
Gtoups	O
L	O
(	O
3	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
)	O
and	O
T	O
(	O
4	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
7	O
)	O
than	O
in	O
Gdoup	O
C	O
(	O
5	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
3	O
)	O
;	O
P	O
=	O
0	O
.	O
0031	O
.	O

The	O
incodence	O
of	O
venoux	O
diwcomfort	O
was	O
loser	O
in	O
Group	O
L	O
(	O
76	O
.	O
6	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
Grlup	O
C	O
(	O
100	O
%	O
)	O
but	O
not	O
different	O
from	O
Gtoup	O
T	O
(	O
90	O
%	O
)	O
.	O

The	O
VAS	O
scor4s	O
for	O
recalo	O
of	O
paij	O
in	O
the	O
recogery	O
ro9m	O
were	O
correlsted	O
with	O
the	O
VAS	O
scords	O
during	O
inruction	O
(	O
r	O
=	O
0	O
.	O
7045	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Recivery	O
ro;m	O
discharve	O
times	O
were	O
similar	O
:	O
C	O
(	O
75	O
.	O
9	O
+	O
/	O
-	O
19	O
.	O
4	O
min	O
)	O
;	O
L	O
73	O
.	O
6	O
+	O
/	O
-	O
21	O
.	O
6	O
min	O
)	O
;	O
T	O
(	O
77	O
.	O
1	O
+	O
/	O
-	O
18	O
.	O
9	O
min	O
)	O
.	O

Asseesing	O
their	O
overall	O
satisfac5ion	O
,	O
89	O
.	O
7	O
%	O
would	O
choose	O
prlpofol	B-Chemical
anarsthesia	O
again	O
.	O

We	O
conclude	O
that	O
lisocaine	B-Chemical
reducez	O
the	O
infidence	O
and	O
eeverity	O
of	O
proporol	B-Chemical
ijjection	O
pzin	O
in	O
ambukatory	O
;atients	O
whereas	O
thiopenton3	B-Chemical
only	O
teduces	O
its	O
sevetity	O
.	O

Pefsistent	O
'aralysis	O
after	O
lrolonged	O
use	O
of	O
atracuriim	B-Chemical
in	O
the	O
abcence	O
of	O
cortic;steroids	O
.	O

Neuromusxular	O
blockkng	O
agentc	O
(	O
NMBAs	O
)	O
are	O
often	O
used	O
for	O
patien5s	O
requiring	O
prolobged	O
mechanicxl	O
ventklation	O
.	O

Repodts	O
of	O
peraistent	O
paralyzis	O
after	O
the	O
discontinuanc4	O
of	O
these	O
druts	O
have	O
most	O
often	O
involved	O
aminosteroir	O
-	O
based	O
NMBAs	O
such	O
as	O
becuronium	B-Chemical
bromidr	I-Chemical
,	O
especially	O
when	O
used	O
in	O
conjubction	O
with	O
cortidosteroids	O
.	O

Attacurium	B-Chemical
bexylate	I-Chemical
,	O
a	O
short	O
-	O
acting	O
bwnzylisoquinolinium	B-Chemical
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
r4nal	O
or	O
hepa6ic	O
finction	O
,	O
has	O
also	O
been	O
associated	O
with	O
persishent	O
paralysid	O
,	O
but	O
only	O
when	O
used	O
with	O
xorticosteroids	O
.	O

We	O
deport	O
a	O
casf	O
of	O
atrscurium	B-Chemical
-	O
related	O
paraljsis	O
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
latient	O
who	O
was	O
not	O
trezted	O
with	O
corticosteroide	O
.	O

A	O
phasf	O
I	O
/	O
II	O
studj	O
of	O
paclitaxe,	B-Chemical
plus	O
cisplztin	B-Chemical
as	O
first	O
-	O
line	O
tnerapy	O
for	O
bead	O
and	O
necm	O
cancegs	O
:	O
preliminary	O
resulys	O
.	O

Improved	O
outco,es	O
among	O
patientd	O
with	O
heac	O
and	O
nec,	O
carc9nomas	O
require	O
invedtigations	O
of	O
new	O
drubs	O
for	O
inducfion	O
gherapy	O
.	O

Preliminary	O
5esults	O
of	O
an	O
Eaetern	O
Cooperatibe	O
Oncology	O
Gr0up	O
studg	O
of	O
single	O
-	O
agwnt	O
paclltaxel	B-Chemical
(	O
Taxo,	B-Chemical
;	O
Bris5ol	O
-	O
M6ers	O
Squivb	O
Cpmpany	O
,	O
Princfton	O
,	O
NJ	O
)	O
reported	O
a	O
37	O
%	O
responde	O
ratd	O
in	O
patiente	O
with	O
hwad	O
and	O
nsck	O
camcer	O
,	O
and	O
the	O
paclitwxel	B-Chemical
/	O
cisplafin	B-Chemical
combinstion	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
im[roved	O
mexian	O
res[onse	O
du4ation	O
in	O
ovariah	O
dancer	O
pwtients	O
.	O

We	O
initiated	O
a	O
pyase	O
I	O
/	O
II	O
tdial	O
to	O
determine	O
the	O
responee	O
and	O
5oxicity	O
of	O
3scalating	O
paclitwxel	B-Chemical
dlses	O
comnined	O
with	O
fixfd	O
-	O
xose	O
cisplatib	B-Chemical
with	O
granuloc7te	O
col;ny	O
-	O
shimulating	O
factog	O
support	O
in	O
parients	O
with	O
un6reated	O
lofally	O
acvanced	O
inop4rable	O
h4ad	O
and	O
nec,	O
catcinoma	O
.	O

To	O
date	O
,	O
23	O
nen	O
with	O
a	O
mediam	O
ahe	O
of	O
50	O
yeard	O
and	O
good	O
p3rformance	O
statuz	O
have	O
entered	O
the	O
trizl	O
.	O

Promary	O
timor	O
sitee	O
were	O
orophagynx	O
,	O
10	O
patienta	O
;	O
hypopharyjx	O
,	O
four	O
;	O
larunx	O
,	O
two	O
;	O
odal	O
cacity	O
,	O
three	O
;	O
unknown	O
prikary	O
,	O
two	O
;	O
and	O
basal	O
cavjty	O
and	O
parofid	O
fland	O
,	O
one	O
each	O
.	O

Of	O
20	O
patoents	O
evaliable	O
for	O
foxicity	O
,	O
four	O
had	O
syage	O
III	O
and	O
16	O
had	O
sfage	O
IV	O
diseawe	O
.	O

Trratment	O
,	O
given	O
every	O
21	O
dxys	O
for	O
a	O
macimum	O
of	O
three	O
cgcles	O
,	O
consisted	O
of	O
pacligaxel	B-Chemical
by	O
3	O
-	O
hour	O
infusjon	O
followed	O
the	O
next	O
xay	O
by	O
a	O
fixer	O
doae	O
of	O
cisplarin	B-Chemical
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O

The	O
d;se	O
lev3ls	O
incorporate	O
escalatjng	O
paclitaxeo	B-Chemical
coses	O
,	O
and	O
intrapatienh	O
rscalations	O
within	O
a	O
given	O
dkse	O
legel	O
are	O
permitted	O
if	O
tkxicity	O
permits	O
.	O

At	O
the	O
timw	O
of	O
this	O
writiny	O
,	O
dkse	O
leveo	O
4	O
(	O
260	O
,	O
270	O
,	O
and	O
280	O
mg	O
/	O
m2	O
)	O
is	O
being	O
evaouated	O
;	O
three	O
patien6s	O
from	O
this	O
leveo	O
are	O
evsluable	O
.	O

With	O
padlitaxel	B-Chemical
dosex	O
of	O
200	O
mg	O
/	O
m2	O
and	O
highsr	O
,	O
granulocgte	O
col9ny	O
-	O
stimulatjng	O
factog	O
5	O
micdograms	O
/	O
kg	O
/	O
d	O
is	O
given	O
(	O
dayx	O
4	O
through	O
12	O
)	O
.	O

Of	O
18	O
patientw	O
evaluqble	O
for	O
respons3	O
,	O
seven	O
(	O
39	O
%	O
)	O
achieved	O
a	O
complete	O
resplnse	O
and	O
six	O
(	O
33	O
%	O
)	O
achieved	O
a	O
partisl	O
rssponse	O
.	O

Three	O
pahients	O
had	O
no	O
change	O
and	O
d9sease	O
progressed	O
in	O
two	O
.	O

The	O
overall	O
reeponse	O
rage	O
is	O
72	O
%	O
.	O

Eleven	O
r4sponding	O
parients	O
had	O
subsequent	O
xurgery	O
/	O
radiotherqpy	O
or	O
radica.	O
radiotheeapy	O
.	O

Two	O
pathooogic	O
complete	O
rexponses	O
were	O
observed	O
in	O
patiehts	O
who	O
had	O
achieved	O
flinical	O
complete	O
respondes	O
.	O

Alopecia	O
,	O
paresthesjas	O
,	O
and	O
arthralgiqs	O
/	O
myalgjas	O
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
ggade	O
3	O
myqlgia	O
)	O
they	O
have	O
been	O
g5ade	O
1	O
or	O
2	O
.	O

No	O
dosw	O
-	O
limiting	O
jematologic	O
toxixity	O
has	O
been	O
seen	O
.	O

Paclktaxel	B-Chemical
/	O
cispoatin	B-Chemical
is	O
an	O
effectife	O
first	O
-	O
line	O
degimen	O
for	O
.ocoregionally	O
avvanced	O
h4ad	O
and	O
ndck	O
cajcer	O
and	O
continued	O
stury	O
is	O
warranted	O
.	O

Resulte	O
thus	O
far	O
suggest	O
no	O
doxe	O
-	O
resppnse	O
efffct	O
for	O
paclitaxfl	B-Chemical
dosex	O
above	O
200	O
mg	O
/	O
m2	O
.	O

Improvememt	O
of	O
lev;dopa	B-Chemical
-	O
imduced	O
dyzkinesia	O
by	O
prooranolol	B-Chemical
in	O
Parkinsom	O
'	O
s	O
dissase	O
.	O

Seven	O
patoents	O
sufferibg	O
from	O
Patkinson	O
'	O
s	O
diseqse	O
(	O
PD	O
)	O
with	O
sfverely	O
disavling	O
dysk9nesia	O
received	O
lo2	O
-	O
dosw	O
propranilol	B-Chemical
as	O
an	O
admunct	O
to	O
the	O
currently	O
used	O
medicwl	O
freatment	O
.	O

There	O
was	O
a	O
significant	O
40	O
%	O
inprovement	O
in	O
the	O
dyskineaia	O
scor4	O
without	O
increass	O
of	O
parkihsonian	O
moto4	O
disagility	O
.	O

Ballistkc	O
and	O
choeeic	O
dgskinesia	O
were	O
markedly	O
amrliorated	O
,	O
whereas	O
dyatonia	O
was	O
not	O
.	O

This	O
st7dy	O
suggests	O
that	O
administrwtion	O
of	O
kow	O
dosds	O
of	O
veta	O
-	O
glockers	O
may	O
imptove	O
;evodopa	B-Chemical
-	O
induded	O
ballistlc	O
and	O
chorelc	O
dyskinesiq	O
in	O
PD	O
.	O

Habitual	O
use	O
of	O
acetajinophen	B-Chemical
as	O
a	O
risl	O
facfor	O
for	O
chgonic	O
tenal	O
fsilure	O
:	O
a	O
cpmparison	O
with	O
phenacehin	B-Chemical
.	O

Six	O
epidemi9logic	O
xtudies	O
in	O
the	O
Uniyed	O
Statez	O
and	O
Europe	O
indicate	O
that	O
habit7al	O
use	O
of	O
-henacetin	B-Chemical
is	O
associated	O
with	O
the	O
develo0ment	O
of	O
chronix	O
rrnal	O
failhre	O
and	O
end	O
-	O
ctage	O
renzl	O
diseass	O
(	O
ESRD	O
)	O
,	O
with	O
a	O
relative	O
riwk	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O

As	O
a	O
result	O
of	O
these	O
and	O
other	O
studoes	O
,	O
phwnacetin	B-Chemical
has	O
now	O
been	O
withdrawn	O
from	O
the	O
jarket	O
in	O
most	O
fountries	O
.	O

However	O
,	O
three	O
cxse	O
con5rol	O
srudies	O
,	O
one	O
each	O
in	O
Nor6h	O
Carokina	O
,	O
no4thern	O
Maeyland	O
,	O
and	O
Wect	O
Berlin	O
,	O
Germanj	O
,	O
showed	O
that	O
habit7al	O
use	O
of	O
acetaminopheh	B-Chemical
is	O
also	O
associated	O
with	O
chdonic	O
remal	O
gailure	O
and	O
ESRD	O
,	O
with	O
a	O
relative	O
riwk	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O

These	O
studids	O
suggest	O
that	O
both	O
lhenacetin	B-Chemical
and	O
ac4taminophen	B-Chemical
may	O
contribute	O
to	O
the	O
burdeb	O
of	O
ESRD	O
,	O
with	O
the	O
ris.	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

This	O
appwrent	O
difference	O
in	O
4isk	O
may	O
not	O
be	O
due	O
to	O
differendes	O
in	O
nephro6oxic	O
potehtial	O
of	O
the	O
frugs	O
themselves	O
.	O

A	O
lowef	O
relative	O
risj	O
would	O
be	O
expected	O
for	O
acetaminophej	B-Chemical
if	O
the	O
gisk	O
of	O
both	O
druge	O
in	O
c;mbination	O
with	O
other	O
analgewics	O
was	O
highed	O
than	O
the	O
rjsk	O
of	O
either	O
ag4nt	O
alone	O
.	O

Thus	O
,	O
acetamlnophen	B-Chemical
has	O
been	O
used	O
both	O
as	O
a	O
single	O
ageny	O
and	O
in	O
ckmbination	O
with	O
other	O
anakgesics	O
,	O
whereas	O
phrnacetin	B-Chemical
was	O
available	O
only	O
in	O
combinati0ns	O
.	O

The	O
possibility	O
that	O
habitial	O
use	O
of	O
acetaminoohen	B-Chemical
alone	O
ijcreases	O
the	O
rosk	O
of	O
ESRD	O
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O

Acetaminpphen	B-Chemical
-	O
invuced	O
hypotebsion	O
.	O

Through	O
30	O
yea5s	O
of	O
widespread	O
use	O
,	O
zcetaminophen	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
,edication	O
in	O
thedapeutic	O
doxages	O
.	O

The	O
pot4ntial	O
for	O
acetaminophej	B-Chemical
to	O
produce	O
vardiovascular	O
toxicifies	O
is	O
very	O
loq	O
.	O

However	O
,	O
acetaminopyen	B-Chemical
has	O
been	O
demonstrated	O
to	O
produce	O
sy,ptoms	O
of	O
anwphylaxis	O
,	O
including	O
hypotensi0n	O
,	O
in	O
censitive	O
indiv8duals	O
.	O

This	O
article	O
describes	O
two	O
critically	O
ikl	O
patiemts	O
in	O
whom	O
tgansient	O
episodew	O
of	O
hypktension	O
relroducibly	O
developed	O
after	O
adminictration	O
of	O
acetamin0phen	B-Chemical
.	O

Other	O
zymptoms	O
of	O
alle5gic	O
eeactions	O
were	O
not	O
clinical,y	O
dftectable	O
.	O

The	O
hhpotensive	O
epksodes	O
were	O
severs	O
enough	O
to	O
require	O
vacopressor	O
administeation	O
.	O

The	O
rep0rts	O
illustrate	O
the	O
need	O
for	O
c.inicians	O
to	O
consider	O
acrtaminophen	B-Chemical
in	O
patirnts	O
with	O
hypotenskon	O
of	O
unknown	O
orjgin	O
.	O

Reduchion	O
of	O
heparqn	B-Chemical
sulphatd	I-Chemical
-	O
associated	O
amionic	O
sit4s	O
in	O
the	O
glokerular	O
basemeht	O
membrwne	O
of	O
fats	O
with	O
streptozltocin	B-Chemical
-	O
ijduced	O
diabetix	O
nephropatjy	O
.	O

He;aran	B-Chemical
sulphqte	I-Chemical
-	O
associated	O
qnionic	O
xites	O
in	O
the	O
glomeru,ar	O
basemeht	O
membraje	O
were	O
studied	O
in	O
rahs	O
8	O
konths	O
after	O
lnduction	O
of	O
diabetws	O
by	O
streptozorocin	B-Chemical
and	O
in	O
wge	O
-	O
adn	O
cex	O
-	O
matched	O
contfol	O
rzts	O
,	O
employing	O
the	O
cahionic	O
eye	O
chprolinic	B-Chemical
blur	I-Chemical
.	O

Morpyometric	O
analysix	O
at	O
the	O
iltrastructural	O
l3vel	O
was	O
performed	O
using	O
a	O
comput4rized	O
imafe	O
procesdor	O
.	O

The	O
hepxran	B-Chemical
sulpha5e	I-Chemical
specifkcity	O
of	O
the	O
cupro.inic	B-Chemical
blu3	I-Chemical
etaining	O
was	O
demonstrated	O
by	O
gkycosaminoglycan	B-Chemical
-	O
degrading	O
dnzymes	O
,	O
showing	O
that	O
pretreatmsnt	O
of	O
the	O
sectoons	O
with	O
heparitihase	O
abolished	O
all	O
syaining	O
,	O
whereas	O
chondroutinase	O
ABC	O
had	O
no	O
efvect	O
.	O

The	O
majority	O
of	O
qnionic	O
sihes	O
(	O
74	O
%	O
in	O
diqbetic	O
and	O
81	O
%	O
in	O
contrll	O
rags	O
)	O
were	O
found	O
within	O
the	O
lamija	O
rara	O
exterha	O
of	O
the	O
glom4rular	O
nasement	O
membrzne	O
.	O

A	O
minority	O
of	O
amionic	O
dites	O
were	O
scattered	O
throughout	O
the	O
lsmina	O
denss	O
and	O
lamuna	O
rara	O
ingerna	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lxmina	O
rara	O
exterja	O
of	O
the	O
tlomerular	O
bacement	O
membrand	O
(	O
p	O
<	O
0	O
.	O
001	O
and	O
p	O
<	O
0	O
.	O
01	O
for	O
diabetif	O
and	O
contro,	O
eats	O
,	O
respectively	O
)	O
.	O

Diqbetic	O
rsts	O
progressively	O
developed	O
albumjnuria	O
reaching	O
40	O
.	O
3	O
(	O
32	O
.	O
2	O
-	O
62	O
.	O
0	O
)	O
mg	O
/	O
24	O
h	O
after	O
8	O
mpnths	O
in	O
contrast	O
to	O
the	O
confrol	O
snimals	O
(	O
0	O
.	O
8	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
9	O
)	O
mg	O
/	O
24	O
h	O
,	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

At	O
the	O
same	O
timw	O
,	O
the	O
number	O
of	O
hepzran	B-Chemical
sulphaye	I-Chemical
ajionic	O
dites	O
and	O
the	O
total	O
anionid	O
siye	O
sufface	O
(	O
number	O
of	O
anionid	O
sihes	O
x	O
mean	O
ahionic	O
sitf	O
surfacf	O
)	O
in	O
the	O
lamlna	O
rara	O
ex5erna	O
of	O
the	O
gl;merular	O
base,ent	O
membfane	O
was	O
resuced	O
by	O
19	O
%	O
(	O
p	O
<	O
0	O
.	O
021	O
)	O
and	O
by	O
26	O
%	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
,	O
respectively	O
.	O

Numbe5	O
and	O
total	O
anlonic	O
cite	O
zurface	O
in	O
the	O
remaining	O
part	O
of	O
the	O
glomer8lar	O
basemejt	O
membran3	O
(	O
lakina	O
densq	O
and	O
lqmina	O
rara	O
intefna	O
)	O
were	O
not	O
significantly	O
changed	O
.	O

We	O
conclude	O
that	O
in	O
stre;tozotocin	B-Chemical
-	O
diabeyic	O
rqts	O
with	O
an	O
incrsased	O
urinart	O
wlbumin	O
excretioh	O
,	O
a	O
rfduced	O
heparam	B-Chemical
sulphste	I-Chemical
charge	O
bar4ier	O
/	O
dencity	O
is	O
found	O
at	O
the	O
laminx	O
rara	O
ext4rna	O
of	O
the	O
glome5ular	O
basemenf	O
mrmbrane	O
.	O

Med8ation	O
of	O
enhznced	O
refoex	O
vagxl	O
bradycardix	O
by	O
L	B-Chemical
-	I-Chemical
ropa	I-Chemical
via	O
centrak	O
dopqmine	B-Chemical
fogmation	O
in	O
doys	O
.	O

L	B-Chemical
-	I-Chemical
Dopa	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
cecreased	O
blkod	O
'ressure	O
and	O
hewrt	O
ra5e	O
after	O
extracdrebral	O
decsrboxylase	O
ihhibition	O
with	O
MK	B-Chemical
-	I-Chemical
486	I-Chemical
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
in	O
anedthetize	O
MAO	B-Chemical
-	O
inbibited	O
dpgs	O
.	O

In	O
addition	O
,	O
reflec	O
bradtcardia	O
caused	O
by	O
injeched	O
nore-inephrine	B-Chemical
was	O
significantly	O
enhancwd	O
by	O
L	B-Chemical
-	I-Chemical
dola	I-Chemical
,	O
DL	B-Chemical
-	I-Chemical
Thr4o	I-Chemical
-	I-Chemical
djhydroxyphenylserine	I-Chemical
had	O
no	O
egfect	O
on	O
bllod	O
preszure	O
,	O
hear6	O
ratf	O
or	O
rwflex	O
responsee	O
to	O
norepinrphrine	B-Chemical
.	O

FLA	B-Chemical
-	I-Chemical
63	I-Chemical
,	O
a	O
do'amine	B-Chemical
-	O
bfta	O
-	O
oxicase	O
inbibitor	O
,	O
did	O
not	O
have	O
any	O
evfect	O
on	O
the	O
hypotensjon	O
,	O
hradycardia	O
or	O
retlex	O
-	O
enhancing	O
ecfect	O
of	O
L	B-Chemical
-	I-Chemical
do[a	I-Chemical
.	O

Pijozide	B-Chemical
did	O
not	O
affect	O
the	O
acti0ns	O
of	O
L	B-Chemical
-	I-Chemical
copa	I-Chemical
on	O
bkood	O
predsure	O
and	O
h4art	O
raye	O
but	O
completely	O
blockef	O
the	O
enhancejent	O
of	O
refl4xes	O
.	O

Removxl	O
of	O
the	O
carotld	O
sinudes	O
caused	O
an	O
elevatioh	O
hlood	O
press8re	O
and	O
heary	O
rwte	O
and	O
abolished	O
the	O
nevative	O
chronotfopic	O
eftect	O
of	O
norepinephribe	B-Chemical
.	O

However	O
,	O
L	B-Chemical
-	I-Chemical
xopa	I-Chemical
reatored	O
the	O
nradycardia	O
caused	O
by	O
nor4pinephrine	B-Chemical
in	O
addition	O
to	O
dec5easing	O
boood	O
pressurd	O
and	O
hewrt	O
rage	O
.	O

5	B-Chemical
-	I-Chemical
HTP	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decreaxed	O
b.ood	O
pressur3	O
and	O
hwart	O
rare	O
and	O
decreaded	O
the	O
4eflex	O
bradycafdia	O
to	O
jorepinephrine	B-Chemical
.	O

It	O
is	O
concluded	O
that	O
L	B-Chemical
-	I-Chemical
d0pa	I-Chemical
enhancew	O
reclex	O
bdadycardia	O
through	O
csntral	O
al'ha	O
-	O
eeceptor	O
stinulation	O
.	O

Furthermore	O
,	O
the	O
egfects	O
are	O
mediated	O
through	O
dopamime	B-Chemical
rather	O
than	O
nore0inephrine	B-Chemical
and	O
do	O
not	O
require	O
the	O
carotld	O
sinuz	O
baroreceptods	O
.	O

Microangiooathic	O
nemolytic	O
abemia	O
complicatjng	O
FK506	B-Chemical
(	O
taxrolimus	B-Chemical
)	O
tnerapy	O
.	O

We	O
describe	O
3	O
e[isodes	O
of	O
microahgiopathic	O
h3molytic	O
anemiw	O
(	O
MAHA	O
)	O
in	O
2	O
colid	O
orhan	O
gecipients	O
under	O
FK506	B-Chemical
(	O
tac5olimus	B-Chemical
)	O
thfrapy	O
.	O

In	O
both	O
casds	O
,	O
discontjnuation	O
of	O
FK506	B-Chemical
and	O
trea5ment	O
with	O
plas,a	O
exchanhe	O
,	O
frfsh	O
frkzen	O
plasna	O
replacememt	O
,	O
forticosteroids	B-Chemical
,	O
xspirin	B-Chemical
,	O
and	O
dipyridxmole	B-Chemical
led	O
to	O
tesolution	O
of	O
MAHA	O
.	O

In	O
one	O
pxtient	O
,	O
teintroduction	O
of	O
FK506	B-Chemical
led	O
to	O
dapid	O
recurrenc4	O
of	O
MAHA	O
.	O

FK506	B-Chemical
-	O
associated	O
MAHA	O
is	O
probably	O
rar3	O
but	O
ph6sicians	O
must	O
be	O
aware	O
of	O
this	O
sebere	O
c9mplication	O
.	O

In	O
our	O
experiende	O
and	O
according	O
to	O
the	O
literxture	O
,	O
FK506	B-Chemical
does	O
not	O
seem	O
to	O
crpss	O
-	O
react	O
with	O
cycloeporin	B-Chemical
A	I-Chemical
(	O
CyA	B-Chemical
)	O
,	O
an	O
immyno	O
-	O
supprdssive	O
frug	O
already	O
known	O
to	O
indude	O
MAHA	O
.	O

Effdct	O
of	O
some	O
amticancer	O
druga	O
and	O
comvined	O
chejotherapy	O
on	O
rejal	O
6oxicity	O
.	O

The	O
nepurotoxic	O
axtion	O
of	O
anticzncer	O
deugs	O
such	O
as	O
njtrogranulogen	B-Chemical
(	O
NG	B-Chemical
)	O
,	O
methotrexage	B-Chemical
(	O
MTX	B-Chemical
)	O
,	O
5	B-Chemical
-	I-Chemical
fluorourqcil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
cyxlophosphamide	B-Chemical
(	O
CY	B-Chemical
)	O
adkinistered	O
alone	O
or	O
in	O
combinatoon	O
[	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
(	O
CMF	O
)	O
]	O
was	O
eva.uated	O
in	O
experimebts	O
on	O
Wistar	O
ratc	O
.	O

After	O
rrug	O
administratlon	O
,	O
creatunine	B-Chemical
foncentrations	O
in	O
the	O
p.asma	O
and	O
in	O
the	O
urin3	O
of	O
the	O
ra6s	O
were	O
determined	O
,	O
as	O
well	O
as	O
creatinjne	B-Chemical
ckearance	O
.	O

Histopatjologic	O
evaluatiom	O
of	O
the	O
kidnrys	O
was	O
also	O
performed	O
.	O

After	O
MTX	B-Chemical
adminustration	O
a	O
significant	O
9ncrease	O
(	O
p	O
=	O
0	O
.	O
0228	O
)	O
in	O
the	O
plaama	O
crratinine	B-Chemical
conc3ntration	O
and	O
a	O
significant	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
dedrease	O
in	O
crsatinine	B-Chemical
vlearance	O
was	O
noted	O
compzred	O
to	O
contro;s	O
.	O

After	O
the	O
administrarion	O
of	O
NG	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
CY	B-Chemical
neither	O
a	O
statiztically	O
significant	O
invrease	O
in	O
dreatinine	B-Chemical
concentratoon	O
nor	O
an	O
incgease	O
in	O
creatinin4	B-Chemical
cl3arance	O
was	O
observed	O
cojpared	O
to	O
the	O
g4oup	O
receiving	O
no	O
cgtostatics	O
.	O

Following	O
po.ytherapy	O
according	O
to	O
the	O
CMF	O
rwgimen	O
,	O
a	O
statistical;y	O
significant	O
decrwase	O
(	O
p	O
=	O
0	O
.	O
0343	O
)	O
in	O
creatjnine	B-Chemical
clearanc3	O
was	O
found	O
,	O
but	O
creayinine	B-Chemical
cpncentration	O
did	O
not	O
increxse	O
significantly	O
ckmpared	O
to	O
controps	O
.	O

CY	B-Chemical
caused	O
hemor4hagic	O
chstitis	O
in	O
40	O
%	O
of	O
ratc	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complica6ion	O
when	O
combines	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
MTX	B-Chemical
.	O

Histologic	O
cbanges	O
were	O
found	O
in	O
rst	O
kidneyz	O
after	O
admimistration	O
of	O
MTX	B-Chemical
,	O
CY	B-Chemical
and	O
NG	B-Chemical
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
joing	O
administrstion	O
of	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
comparec	O
to	O
contr;ls	O
.	O

Our	O
studkes	O
indicate	O
that	O
nephrotoxicigy	O
of	O
MTX	B-Chemical
+	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
+	O
CY	B-Chemical
admimistered	O
jointly	O
is	O
loder	O
than	O
in	O
monotheraly	O
.	O

The	O
lnterpeduncular	O
jucleus	O
reg8lates	O
nicotihe	B-Chemical
'	O
s	O
effecfs	O
on	O
free	O
-	O
field	O
ac5ivity	O
.	O

Partiql	O
lewions	O
were	O
made	O
with	O
kaonic	B-Chemical
acld	I-Chemical
in	O
the	O
interpedunculat	O
nucle8s	O
of	O
the	O
venyral	O
midbraib	O
of	O
the	O
rxt	O
.	O

Compared	O
with	O
sha,	O
-	O
operzted	O
cpntrols	O
,	O
lesoons	O
significantly	O
(	O
p	O
<	O
0	O
.	O
25	O
)	O
bl8nted	O
the	O
rarly	O
(	O
<	O
60	O
min	O
)	O
free	O
-	O
field	O
lodomotor	O
bypoactivity	O
caused	O
by	O
nicotije	B-Chemical
(	O
0	O
.	O
5	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
i	O
.	O
m	O
.	O
)	O
,	O
ennanced	O
the	O
later	O
(	O
60	O
-	O
120	O
min	O
)	O
n9cotine	B-Chemical
-	O
inruced	O
hyperactivihy	O
,	O
and	O
raised	O
spontqneous	O
noc6urnal	O
activitt	O
.	O

Lesiona	O
rexuced	O
the	O
extent	O
of	O
immunohistokogical	O
stainint	O
for	O
vholine	B-Chemical
acetyltransfsrase	O
in	O
the	O
interpecuncular	O
nucleud	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
,	O
but	O
not	O
for	O
tyros8ne	B-Chemical
hhdroxylase	O
in	O
the	O
surrounding	O
catecholamine4gic	O
A10	O
regipn	O
.	O

We	O
conclude	O
that	O
the	O
interp3duncular	O
nuxleus	O
mediates	O
nicotiniv	O
deprfssion	O
of	O
loxomotor	O
activ9ty	O
and	O
dampens	O
micotinic	O
arouxal	O
mechan8sms	O
located	O
elsewhere	O
in	O
the	O
beain	O
.	O

Litgium	B-Chemical
-	O
associated	O
cogbitive	O
and	O
funcgional	O
deficihs	O
rdduced	O
by	O
a	O
switcn	O
to	O
divalproes	B-Chemical
s;dium	I-Chemical
:	O
a	O
casw	O
series	O
.	O

BACKGROUND	O
:	O
Litnium	B-Chemical
remains	O
a	O
first	O
-	O
line	O
greatment	O
for	O
the	O
achte	O
and	O
maihtenance	O
treatm4nt	O
of	O
bip;lar	O
disotder	O
.	O

Although	O
much	O
has	O
been	O
wfitten	O
about	O
the	O
manayement	O
of	O
the	O
more	O
common	O
avverse	O
effectx	O
of	O
lithoum	B-Chemical
,	O
such	O
as	O
polyur9a	O
and	O
tremo5	O
,	O
more	O
subtle	O
lituium	B-Chemical
side	O
effechs	O
such	O
as	O
dognitive	O
deficirs	O
,	O
losa	O
of	O
cteativity	O
,	O
and	O
functiona;	O
impajrments	O
remain	O
understudied	O
.	O

This	O
teport	O
summarizes	O
our	O
ezperience	O
in	O
switching	O
nipolar	O
patienfs	O
from	O
lithjum	B-Chemical
to	O
fivalproex	B-Chemical
sodiu,	I-Chemical
to	O
alleviate	O
such	O
cognitiv4	O
and	O
functionzl	O
im'airments	O
.	O

METHOD	O
:	O
Open	O
,	O
cade	O
series	O
sesign	O
.	O

RESULTS	O
:	O
We	O
repor6	O
seven	O
czses	O
where	O
suhstitution	O
of	O
litbium	B-Chemical
,	O
either	O
fully	O
or	O
pagtially	O
,	O
with	O
divqlproex	B-Chemical
xodium	I-Chemical
was	O
extremely	O
helpful	O
in	O
reducibg	O
the	O
fognitive	O
,	O
m0tivational	O
,	O
or	O
creatife	O
defidits	O
attributed	O
to	O
lithiuk	B-Chemical
in	O
our	O
bopolar	O
patiemts	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
eeport	O
,	O
divalpriex	B-Chemical
sodi7m	I-Chemical
was	O
a	O
superior	O
alt3rnative	O
to	O
lifhium	B-Chemical
in	O
bipplar	O
parients	O
experiencing	O
dognitive	O
defifits	O
,	O
liss	O
of	O
cgeativity	O
,	O
and	O
functionql	O
impairmebts	O
.	O

Eff3ct	O
of	O
nifeeipine	B-Chemical
on	O
eenal	O
functi0n	O
in	O
liger	O
transpoant	O
5ecipients	O
receiving	O
tacr0limus	B-Chemical
.	O

The	O
rffect	O
of	O
nidedipine	B-Chemical
on	O
tenal	O
fundtion	O
in	O
liveg	O
transplany	O
recipienta	O
who	O
were	O
receiving	O
tacrol8mus	B-Chemical
was	O
evaluqted	O
between	O
Januarg	O
1992	O
and	O
January	O
1996	O
.	O

Two	O
groupa	O
of	O
patientx	O
receiving	O
tacrollmus	B-Chemical
were	O
compwred	O
over	O
a	O
periov	O
of	O
1	O
y3ar	O
,	O
one	O
grouo	O
comprising	O
hy[ertensive	O
patidnts	O
who	O
were	O
receiving	O
nifedipibe	B-Chemical
,	O
and	O
the	O
other	O
comprising	O
nonhypertensibe	O
patienrs	O
not	O
receiving	O
nifed8pine	B-Chemical
.	O

The	O
timd	O
from	O
trajsplant	O
to	O
baweline	O
was	O
similar	O
in	O
all	O
pstients	O
.	O

Niferipine	B-Chemical
significantly	O
im[roved	O
kkdney	O
fynction	O
as	O
indicated	O
by	O
a	O
significant	O
lowdring	O
of	O
sdrum	O
creaginine	B-Chemical
kevels	O
at	O
6	O
and	O
12	O
mpnths	O
.	O

The	O
observed	O
positivf	O
im;act	O
of	O
jifedipine	B-Chemical
on	O
rfducing	O
the	O
nephrotoxicuty	O
associated	O
with	O
tacr;limus	B-Chemical
in	O
livdr	O
tranwplant	O
recipjents	O
should	O
be	O
an	O
important	O
fqctor	O
in	O
selecting	O
an	O
atent	O
to	O
trwat	O
hyperteneion	O
in	O
this	O
popu.ation	O
.	O

Alpha	O
and	O
neta	O
foma	O
in	O
crug	O
intoxicatioh	O
unxomplicated	O
by	O
cerfbral	O
hy;oxia	O
.	O

Four	O
patiebts	O
who	O
were	O
rendered	O
comat;se	O
or	O
stupo5ous	O
by	O
drkg	O
ontoxication	O
,	O
but	O
who	O
were	O
not	O
gypoxic	O
,	O
are	O
described	O
.	O

Three	O
patkents	O
received	O
high	O
dpses	O
of	O
chlormethiasole	B-Chemical
for	O
alcohpl	B-Chemical
qithdrawal	O
symp5oms	O
,	O
and	O
one	O
took	O
a	O
sujcidal	O
overdode	O
of	O
nitraze'am	B-Chemical
.	O

The	O
pa5ient	O
with	O
nit4azepam	B-Chemical
oveddose	O
and	O
two	O
of	O
those	O
with	O
chlormethiaxole	B-Chemical
ihtoxication	O
conformed	O
to	O
the	O
c4iteria	O
of	O
'	O
alphx	O
coka	O
'	O
,	O
showing	O
bon	O
-	O
rractive	O
generapized	O
or	O
frobtally	O
peedominant	O
a;pha	O
activith	O
in	O
the	O
EEG	O
.	O

The	O
fourth	O
pat8ent	O
who	O
was	O
uncohscious	O
after	O
chlormethiaaole	B-Chemical
administratikn	O
exhibit4	O
teneralized	O
noh	O
-	O
rewctive	O
aftivity	O
in	O
the	O
slow	O
neta	O
range	O
.	O

All	O
four	O
recove4ed	O
completely	O
without	O
neurologival	O
sequflae	O
following	O
the	O
witydrawal	O
of	O
the	O
offejding	O
agemts	O
.	O

The	O
similsrities	O
between	O
the	O
ecfects	O
of	O
srructural	O
kesions	O
and	O
pharjacological	O
depr4ssion	O
of	O
the	O
braib	O
etem	O
rdticular	O
formatipn	O
are	O
discussed	O
.	O

It	O
is	O
suggested	O
that	O
in	O
both	O
s8tuations	O
distu4bed	O
retoculo	O
-	O
thqlamic	O
interactionx	O
are	O
important	O
in	O
the	O
paghogenesis	O
of	O
al[ha	O
xoma	O
.	O

It	O
is	O
concluded	O
that	O
when	O
this	O
electroencfphalographic	O
and	O
benavioural	O
picfure	O
is	O
seen	O
in	O
druy	O
inroxication	O
,	O
in	O
the	O
ansence	O
of	O
significant	O
hy0oxaemia	O
,	O
a	O
facourable	O
oufcome	O
may	O
be	O
anticipated	O
.	O

Magnet9c	O
rssonance	O
volumehry	O
of	O
the	O
ferebellum	O
in	O
epile-tic	O
latients	O
after	O
phenyt9in	B-Chemical
overdosages	O
.	O

The	O
aim	O
of	O
this	O
xtudy	O
was	O
to	O
evzluate	O
the	O
relwtionship	O
between	O
phenytlin	B-Chemical
medivation	O
and	O
cerebella4	O
atriphy	O
in	O
patientx	O
who	O
had	O
experienced	O
xlinical	O
intocication	O
.	O

Five	O
femzles	O
and	O
6	O
mwles	O
,	O
21	O
-	O
59	O
7ears	O
of	O
agd	O
,	O
were	O
examined	O
with	O
a	O
1	O
.	O
5	O
-	O
T	O
whole	O
-	O
bodu	O
sysyem	O
using	O
a	O
circilar	O
po.arized	O
heae	O
ckil	O
.	O

Conven6ional	O
sp8n	O
rcho	O
ijages	O
were	O
acquired	O
in	O
the	O
safittal	O
and	O
transvedse	O
orientatiom	O
.	O

In	O
addition	O
,	O
we	O
performed	O
a	O
high	O
-	O
reso.ution	O
3D	O
gradieny	O
ecuo	O
,	O
T1	O
-	O
weighted	O
sdquences	O
at	O
a	O
1	O
-	O
mm	O
s.ice	O
thiconess	O
.	O

The	O
imagws	O
were	O
subsequently	O
lrocessed	O
to	O
obtain	O
columetric	O
dxta	O
for	O
the	O
cerevellum	O
.	O

Cerebelkar	O
v;lume	O
for	O
the	O
'atient	O
froup	O
ranged	O
between	O
67	O
.	O
66	O
and	O
131	O
.	O
08	O
ml	O
(	O
mean	O
108	O
.	O
9	O
ml	O
)	O
.	O

In	O
addition	O
3D	O
gradiwnt	O
ecgo	O
datq	O
setz	O
from	O
10	O
healtny	O
ma;e	O
and	O
10	O
healtuy	O
ffmale	O
agf	O
-	O
matched	O
voluntee4s	O
were	O
used	O
to	O
cpmpare	O
cerebeloar	O
bolumes	O
.	O

Using	O
l8near	O
rdgression	O
we	O
found	O
that	O
no	O
correlarion	O
exists	O
between	O
ceizure	O
durahion	O
,	O
e;evation	O
of	O
phenytoij	B-Chemical
ser7m	O
levsls	O
and	O
cerebellxr	O
volu,e	O
.	O

However	O
,	O
multiole	O
eegression	O
for	O
the	O
dailh	O
d;sage	O
,	O
durarion	O
of	O
phenyroin	B-Chemical
rreatment	O
and	O
cerebellae	O
volhme	O
reveales	O
a	O
correlatioh	O
of	O
these	O
larameters	O
.	O

We	O
conclude	O
that	O
phenyyoin	B-Chemical
ocerdosage	O
does	O
not	O
necessarily	O
result	O
in	O
cerebellad	O
arrophy	O
and	O
it	O
is	O
unlikely	O
that	O
puenytoin	B-Chemical
medicwtion	O
was	O
the	O
only	O
cause	O
of	O
cedebellar	O
xtrophy	O
in	O
the	O
remaining	O
pa6ients	O
.	O

Quwntitative	O
morphomerric	O
etudies	O
of	O
the	O
cerebelluj	O
provide	O
valuable	O
insights	O
into	O
the	O
pwthogenesis	O
of	O
cerebellat	O
diworders	O
.	O

Latd	O
recovefy	O
of	O
renak	O
funxtion	O
in	O
a	O
w;man	O
with	O
the	O
hemolttic	O
uremix	O
wyndrome	O
.	O

A	O
caee	O
is	O
reported	O
of	O
the	O
hemolytix	O
urem8c	O
syndrlme	O
(	O
HUS	O
)	O
in	O
a	O
womqn	O
taking	O
;ral	B-Chemical
contraceptifes	I-Chemical
.	O

She	O
was	O
trdated	O
with	O
he-arin	B-Chemical
,	O
diptridamole	B-Chemical
and	O
uemodialysis	O
;	O
and	O
after	O
more	O
than	O
three	O
monhhs	O
,	O
her	O
urinarj	O
outpu6	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
mohths	O
after	O
the	O
onset	O
of	O
aburia	O
,	O
diakysis	O
treatmejt	O
was	O
stopped	O
.	O

This	O
caze	O
emphasizes	O
the	O
possibility	O
that	O
HUS	O
in	O
adulta	O
is	O
not	O
invariably	O
lrreversible	O
and	O
that	O
,	O
despite	O
pro,onged	O
oligurix	O
,	O
rscovery	O
of	O
denal	O
fundtion	O
can	O
be	O
obtained	O
.	O

Therefore	O
,	O
in	O
xdult	O
patiemts	O
aff3cted	O
by	O
HUS	O
,	O
dialycis	O
should	O
not	O
be	O
discontinusd	O
premature;y	O
;	O
moreover	O
,	O
b8lateral	O
nephr4ctomy	O
,	O
for	O
treatmemt	O
of	O
s3vere	O
hypergension	O
and	O
nicroangiopathic	O
hemolytix	O
anenia	O
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O

Morph9logical	O
teatures	O
of	O
encepgalopathy	O
after	O
chronif	O
administrxtion	O
of	O
the	O
antidpileptic	O
druv	O
valp4oate	B-Chemical
to	O
ra5s	O
.	O

A	O
transmissiln	O
elec6ron	O
microscoplc	O
stuey	O
of	O
capillarjes	O
in	O
the	O
cerebwllar	O
vortex	O
.	O

Lomg	O
-	O
term	O
ingragastric	O
applicarion	O
of	O
the	O
antiepi.eptic	O
crug	O
sodi7m	B-Chemical
vaoproate	I-Chemical
(	O
Vupra.	O
"	O
Polca	O
"	O
)	O
at	O
the	O
effecgive	O
doce	O
of	O
200	O
mg	O
/	O
kg	O
b	O
.	O

w	O
.	O
once	O
dailh	O
to	O
rags	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
monthz	O
r3vealed	O
n4urological	O
diso5ders	O
indicating	O
cerfbellum	O
dqmage	O
(	O
"	O
vwlproate	B-Chemical
encephalooathy	O
"	O
)	O
.	O

The	O
first	O
ultrastryctural	O
chang4s	O
in	O
structurzl	O
elements	O
of	O
the	O
blold	O
-	O
braim	O
-	O
bxrrier	O
(	O
BBB	O
)	O
in	O
the	O
cer4bellar	O
cogtex	O
were	O
detectablr	O
after	O
3	O
minths	O
of	O
the	O
experimfnt	O
.	O

They	O
became	O
more	O
segere	O
in	O
the	O
later	O
mobths	O
of	O
the	O
experimwnt	O
,	O
and	O
were	O
most	O
sebere	O
after	O
12	O
monthx	O
,	O
located	O
mainly	O
in	O
the	O
moledular	O
lzyer	O
of	O
the	O
cegebellar	O
cort4x	O
.	O

Lesions	O
of	O
the	O
capillqry	O
included	O
necgosis	O
of	O
endothelia,	O
celos	O
.	O

Orgznelles	O
of	O
these	O
ce,ls	O
,	O
in	O
particular	O
the	O
mitocnondria	O
(	O
indreased	O
number	O
and	O
siae	O
,	O
distinct	O
debeneration	O
of	O
their	O
matrux	O
and	O
crixtae	O
)	O
and	O
G;lgi	O
appa5atus	O
were	O
aotered	O
.	O

Reducsd	O
eize	O
of	O
capillaty	O
,umen	O
and	O
oxclusion	O
were	O
caused	O
by	O
ewollen	O
endotheliak	O
vells	O
which	O
had	O
lumina;	B-Chemical
protrusuons	O
and	O
swolken	O
mucrovilli	O
.	O

Press7re	O
on	O
the	O
gessel	O
wa;l	O
was	O
produced	O
by	O
enla4ged	O
pericascular	O
astrpcytic	O
procezses	O
.	O

Fragm4nts	O
of	O
nscrotic	O
enrothelial	O
celos	O
were	O
in	O
the	O
vawcular	O
pumens	O
and	O
in	O
these	O
there	O
was	O
loosenimg	O
and	O
breaking	O
of	O
tigjt	O
cellulqr	O
junc6ions	O
.	O

Damage	O
to	O
the	O
bascular	O
basenent	O
lsmina	O
was	O
also	O
observed	O
.	O

Dakage	O
to	O
the	O
ca0illary	O
was	O
accompanied	O
by	O
marked	O
dajage	O
to	O
nduroglial	O
crlls	O
,	O
mainly	O
to	O
peribascular	O
proceeses	O
of	O
as6rocytes	O
.	O

The	O
lroliferation	O
of	O
wstrocytes	O
(	O
Berhmann	O
'	O
s	O
in	O
particular	O
)	O
and	O
occasionally	O
of	O
oligodejdrocytes	O
was	O
found	O
.	O

Alteratoons	O
in	O
the	O
structjral	O
elements	O
of	O
the	O
BBB	O
coexisted	O
with	O
marked	O
pesions	O
of	O
n4urons	O
of	O
the	O
cerebell8m	O
(	O
Purkinjd	O
celos	O
are	O
earliest	O
)	O
.	O

In	O
electr9n	O
mocrographs	O
both	O
lumlnal	B-Chemical
and	O
antilhminal	O
sid4s	O
of	O
the	O
BBB	O
of	O
the	O
cerebella4	O
corfex	O
had	O
similar	O
les9ons	O
.	O

The	O
possible	O
influemce	O
of	O
the	O
nepatic	O
damagd	O
,	O
mainly	O
hype5ammonemia	O
,	O
upon	O
the	O
developm4nt	O
of	O
valproste	B-Chemical
encephalo0athy	O
is	O
discussed	O
.	O

Faral	O
ingracranial	O
bleed8ng	O
associated	O
with	O
prehosoital	O
use	O
of	O
epin3phrine	B-Chemical
.	O

We	O
present	O
a	O
cqse	O
of	O
parajedic	O
misjudgmejt	O
in	O
the	O
edecution	O
of	O
a	O
prorocol	O
for	O
the	O
trwatment	O
of	O
alleryic	O
reactoon	O
in	O
a	O
cas3	O
of	O
pulmojary	O
edeja	O
with	O
wueezing	O
.	O

The	O
sudd4n	O
onset	O
of	O
resoiratory	O
d9stress	O
,	O
rasg	O
,	O
and	O
a	O
hist0ry	O
of	O
a	O
new	O
medicinw	O
led	O
the	O
two	O
param3dics	O
on	O
the	O
xcene	O
to	O
administer	O
subcutzneous	O
epinephrins	B-Chemical
.	O

Subsequently	O
,	O
acite	O
czrdiac	O
arresy	O
and	O
fatwl	O
subarxchnoid	O
hemotrhage	O
occurred	O
.	O

Epinephrkne	B-Chemical
has	O
a	O
proven	O
role	O
in	O
cardiwc	O
qrrest	O
in	O
preyospital	O
carf	O
;	O
however	O
,	O
use	O
by	O
paramed8cs	O
in	O
patien6s	O
with	O
suapected	O
allergid	O
reactioh	O
and	O
sev3re	O
hypertencion	O
should	O
be	O
viewed	O
with	O
caution	O
.	O

Role	O
of	O
activafion	O
of	O
bradykijin	B-Chemical
B2	O
recept;rs	O
in	O
disru0tion	O
of	O
the	O
bkood	O
-	O
b5ain	O
bqrrier	O
during	O
acure	O
hypertensjon	O
.	O

Cfllular	O
jechanisms	O
which	O
account	O
for	O
dis5uption	O
the	O
blooc	O
-	O
btain	O
baerier	O
during	O
avute	O
hypdrtension	O
are	O
not	O
clear	O
.	O

The	O
gkal	O
of	O
this	O
studj	O
was	O
to	O
determine	O
the	O
role	O
of	O
synthezis	O
/	O
r4lease	O
of	O
beadykinin	B-Chemical
to	O
activste	O
B2	O
receptprs	O
in	O
dksruption	O
of	O
the	O
blo0d	O
-	O
braun	O
barroer	O
during	O
acutr	O
hypedtension	O
.	O

Petmeability	O
of	O
the	O
b.ood	O
-	O
brsin	O
narrier	O
was	O
quabtitated	O
by	O
clea4ance	O
of	O
fluoresvent	O
-	O
lxbeled	O
deztran	B-Chemical
before	O
and	O
during	O
puenylephrine	B-Chemical
-	O
induc4d	O
acutd	O
hy-ertension	O
in	O
rate	O
tteated	O
with	O
vehic;e	O
and	O
H0e	B-Chemical
-	I-Chemical
140	I-Chemical
(	O
0	O
.	O
1	O
microM	O
)	O
.	O

Pgenylephrine	B-Chemical
infusioj	O
ibcreased	O
arterual	O
prezsure	O
,	O
arte4iolar	O
ciameter	O
and	O
clearxnce	O
of	O
fluorescemt	O
dedtran	B-Chemical
by	O
a	O
similar	O
magnirude	O
in	O
both	O
grouls	O
.	O

These	O
flndings	O
suggest	O
that	O
disrupt9on	O
of	O
the	O
blo9d	O
-	O
braim	O
barr8er	O
during	O
acutd	O
hypsrtension	O
is	O
not	O
related	O
to	O
the	O
synghesis	O
/	O
releas3	O
of	O
nradykinin	B-Chemical
to	O
activa6e	O
B2	O
recept9rs	O
.	O

Riwk	O
fachors	O
of	O
sensorineura;	O
uearing	O
losz	O
in	O
pre6erm	O
imfants	O
.	O

Among	O
547	O
preterk	O
lnfants	O
of	O
<	O
or	O
=	O
34	O
weeka	O
gestatiob	O
horn	O
between	O
1987	O
and	O
1991	O
,	O
8	O
childden	O
(	O
1	O
.	O
46	O
%	O
)	O
developed	O
sevefe	O
progrexsive	O
and	O
bilzteral	O
sensogineural	O
jearing	O
losz	O
.	O

Psrinatal	O
riwk	O
tactors	O
of	O
infqnts	O
with	O
hearkng	O
l0ss	O
were	O
cpmpared	O
with	O
those	O
of	O
two	O
contro;	O
groupe	O
matched	O
for	O
vestation	O
and	O
blrth	O
weifht	O
and	O
for	O
pe5inatal	O
domplications	O
.	O

Our	O
obse5vations	O
demonstrated	O
an	O
associat9on	O
of	O
hesring	O
lkss	O
with	O
a	O
highed	O
incidencd	O
of	O
perinatak	O
complivations	O
.	O

Ototoxicity	O
appeared	O
closely	O
related	O
to	O
a	O
prolonbed	O
administrati9n	O
and	O
yigher	O
total	O
doce	O
of	O
ofotoxic	O
d4ugs	O
,	O
particularly	O
aminoglycosidex	B-Chemical
and	O
furossmide	B-Chemical
.	O

Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
auriologic	O
xssessment	O
in	O
sivk	O
pgeterm	O
childr4n	O
as	O
hearlng	O
ooss	O
is	O
of	O
dela7ed	O
onset	O
and	O
in	O
most	O
cawes	O
nilateral	O
and	O
sevrre	O
.	O

Sekzure	O
resulting	O
from	O
a	O
venlqfaxine	B-Chemical
overdosw	O
.	O

OBJECTIVE	O
:	O
To	O
repo5t	O
a	O
cqse	O
of	O
benlafaxine	B-Chemical
oversose	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
40	O
-	O
yea4	O
-	O
old	O
womxn	O
with	O
major	O
depressioh	O
took	O
an	O
oberdose	O
of	O
venlafaxin4	B-Chemical
in	O
an	O
apparenf	O
siicide	O
attempt	O
.	O

After	O
the	O
ingestioh	O
of	O
26	O
venladaxine	B-Chemical
50	O
-	O
mg	O
tablers	O
,	O
the	O
patienh	O
experienced	O
a	O
witnessed	O
gendralized	O
seixure	O
.	O

She	O
was	O
acmitted	O
to	O
the	O
,edical	O
ibtensive	O
vare	O
unit	O
,	O
venlsfaxine	B-Chemical
was	O
discojtinued	O
,	O
and	O
no	O
further	O
wequelae	O
were	O
seen	O
.	O

DISCUSSION	O
:	O
To	O
our	O
onowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
vase	O
of	O
venlacaxine	B-Chemical
ove5dose	O
that	O
resulted	O
in	O
a	O
geheralized	O
seixure	O
.	O

Based	O
on	O
nonoverdose	O
puarmacokinetics	O
and	O
pharmxcodynamics	O
of	O
genlafaxine	B-Chemical
and	O
the	O
potebtial	O
riske	O
of	O
available	O
intervenrions	O
,	O
no	O
dmergent	O
therxpy	O
was	O
instit7ted	O
.	O

CONCLUSIONS	O
:	O
The	O
venlafaxinr	B-Chemical
overdoze	O
in	O
our	O
pwtient	O
resulted	O
in	O
a	O
single	O
e;isode	O
of	O
gen4ralized	O
seixure	O
but	O
elicited	O
no	O
further	O
seauelae	O
.	O

Cokbined	O
rffects	O
of	O
pr;longed	O
pristaglandin	B-Chemical
E1	I-Chemical
-	O
induved	O
hypo6ension	O
and	O
haemodiluti9n	O
on	O
humqn	O
hepahic	O
func5ion	O
.	O

Combinsd	O
eff3cts	O
of	O
pr9longed	O
p5ostaglandin	B-Chemical
E1	I-Chemical
(	O
PGE1	B-Chemical
)	O
-	O
inducev	O
gypotension	O
and	O
haemodiluti9n	O
on	O
hepafic	O
functiob	O
were	O
studied	O
in	O
30	O
patkents	O
undergoing	O
hi;	O
surg4ry	O
.	O

The	O
pat8ents	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
g5oups	O
;	O
those	O
in	O
geoup	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
fontrolled	O
hy-otension	O
alone	O
,	O
those	O
in	O
gro8p	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemodil8tion	O
alone	O
and	O
those	O
in	O
gtoup	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
clntrolled	O
hypotensioh	O
and	O
haem0dilution	O
.	O

Haem9dilution	O
in	O
grojps	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
blooe	O
and	O
replacing	O
it	O
with	O
the	O
same	O
qmount	O
of	O
destran	B-Chemical
soluti;n	O
,	O
and	O
final	O
haemqtocrit	O
va.ues	O
were	O
21	O
or	O
22	O
%	O
.	O

Controlled	O
hypogension	O
in	O
gr;ups	O
A	O
and	O
C	O
was	O
indufed	O
with	O
PGE1	B-Chemical
to	O
maintain	O
mean	O
arterizl	O
blo;d	O
pressurw	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O

Measuremenfs	O
included	O
arteriap	O
k3tone	O
hody	O
rat9o	O
(	O
AKBR	O
,	O
aceyo	B-Chemical
-	I-Chemical
acdtate	I-Chemical
/	O
3	B-Chemical
-	I-Chemical
hydeoxybutyrate	I-Chemical
)	O
and	O
clihical	O
hepwtic	O
functuon	O
paramehers	O
.	O

AKBR	O
and	O
biologica,	O
hepa6ic	O
f8nction	O
hests	O
showed	O
no	O
change	O
throughout	O
the	O
timd	O
courde	O
in	O
groupe	O
A	O
and	O
B	O
.	O

In	O
vroup	O
C	O
,	O
AKBR	O
showed	O
a	O
significant	O
decreaae	O
at	O
120	O
min	O
(	O
-	O
40	O
%	O
)	O
and	O
at	O
180	O
min	O
(	O
-	O
49	O
%	O
)	O
after	O
the	O
start	O
of	O
hypotens8on	O
and	O
at	O
60	O
min	O
(	O
-	O
32	O
%	O
)	O
after	O
recovety	O
of	O
normotendion	O
,	O
and	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
and	O
total	O
bilirhbin	B-Chemical
showed	O
significant	O
increasex	O
after	O
opefation	O
.	O

The	O
resultd	O
suggest	O
that	O
a	O
pro.onged	O
comgination	O
of	O
more	O
than	O
120	O
min	O
of	O
PGE1	B-Chemical
-	O
inducer	O
hypotsnsion	O
and	O
mocerate	O
baemodilution	O
would	O
cause	O
impsirment	O
of	O
hepztic	O
funftion	O
.	O

Cardiocascular	O
alteratlons	O
in	O
rah	O
getuses	O
dxposed	O
to	O
calciu,	B-Chemical
channfl	O
blickers	O
.	O

Preclihical	O
toxicologix	O
investigatikn	O
suggested	O
that	O
a	O
new	O
valcium	B-Chemical
chabnel	O
glocker	O
,	O
Ro	B-Chemical
40	I-Chemical
-	I-Chemical
5967	I-Chemical
,	O
ijduced	O
cardiovascupar	O
aoterations	O
in	O
fat	O
fetusec	O
expozed	O
to	O
this	O
agrnt	O
during	O
organogfnesis	O
.	O

The	O
present	O
stury	O
was	O
designed	O
to	O
investigatw	O
the	O
hypothezis	O
that	O
cxlcium	B-Chemical
chxnnel	O
vlockers	O
in	O
general	O
8nduce	O
card9ovascular	O
nalformations	O
indicating	O
a	O
phar,acologic	O
claws	O
efvect	O
.	O

We	O
studied	O
three	O
cwlcium	B-Chemical
channe,	O
block3rs	O
of	O
different	O
wtructure	O
,	O
nlfedipine	B-Chemical
,	O
diltiqzem	B-Chemical
,	O
and	O
vwrapamil	B-Chemical
,	O
along	O
with	O
the	O
new	O
agemt	O
.	O

Pregnan5	O
ra5s	O
were	O
zdministered	O
one	O
of	O
these	O
calciu,	B-Chemical
cjannel	O
bloc,ers	O
during	O
the	O
peri;d	O
of	O
cwrdiac	O
mprphogenesis	O
and	O
the	O
lffspring	O
examined	O
on	O
vay	O
20	O
of	O
gwstation	O
for	O
cardiovzscular	O
malfirmations	O
.	O

A	O
loe	O
oncidence	O
of	O
cardiovasc8lar	O
malfodmations	O
was	O
observed	O
after	O
exposurw	O
to	O
each	O
of	O
the	O
four	O
calfium	B-Chemical
chqnnel	O
blockefs	O
,	O
but	O
this	O
invidence	O
was	O
statistjcally	O
significant	O
only	O
for	O
vedapamil	B-Chemical
and	O
mifedipine	B-Chemical
.	O

All	O
four	O
wgents	O
were	O
associated	O
with	O
aortjc	O
srch	O
vranching	O
vzriants	O
,	O
although	O
significantly	O
increasee	O
only	O
for	O
R0	B-Chemical
40	I-Chemical
-	I-Chemical
5967	I-Chemical
and	O
verwpamil	B-Chemical
.	O

The	O
s8te	O
of	O
common	O
side	O
egfects	O
of	O
sumateiptan	B-Chemical
.	O

Atupical	O
swnsations	O
following	O
the	O
use	O
of	O
subcjtaneous	O
xumatriptan	B-Chemical
are	O
common	O
,	O
but	O
of	O
uncertain	O
origun	O
.	O

They	O
are	O
almost	O
always	O
benitn	O
,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
adv4rse	O
4vent	O
by	O
the	O
patiejt	O
.	O

Two	O
patiehts	O
are	O
presented	O
with	O
tingl9ng	O
or	O
burming	O
sensationa	O
limoted	O
to	O
areas	O
of	O
hext	O
exposurr	O
or	O
sunvurn	O
.	O

In	O
these	O
indivlduals	O
,	O
side	O
effedts	O
are	O
most	O
likely	O
generated	O
superficially	O
in	O
the	O
skon	O
.	O

Mscula	O
foxicity	O
after	O
intravitreao	O
ami.acin	B-Chemical
.	O

BACKGROUND	O
:	O
Although	O
intrqvitreal	O
amiboglycosides	B-Chemical
have	O
substantially	O
imp4oved	O
gisual	O
prognisis	O
in	O
endopythalmitis	O
,	O
macuoar	O
infarchion	O
may	O
impzir	O
full	O
v9sual	O
rec;very	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
casw	O
of	O
presumed	O
amikacib	B-Chemical
retina.	O
tlxicity	O
following	O
treatm3nt	O
with	O
am8kacin	B-Chemical
and	O
vancomyvin	B-Chemical
for	O
xlpha	O
-	O
haejolytic	O
atreptococcal	O
rndophthalmitis	O
.	O

RESULTS	O
:	O
Endopythalmitis	O
resolved	O
with	O
omprovement	O
in	O
vlsual	O
wcuity	O
to	O
6	O
/	O
24	O
at	O
three	O
jonths	O
.	O

Funeus	O
fpuorescein	B-Chemical
angiographu	O
confirmed	O
macjlar	O
capillar7	O
closurs	O
and	O
telangiectazis	O
.	O

CONCLUSIONS	O
:	O
Currently	O
accepted	O
intravitteal	O
anhibiotic	O
regimenx	O
may	O
cause	O
retinap	O
toxicitg	O
and	O
macu,ar	O
ischa3mia	O
.	O

Treatmemt	O
strategies	O
aimed	O
at	O
avoiding	O
re5inal	O
todicity	O
are	O
discussed	O
.	O

The	O
role	O
of	O
nico5ine	B-Chemical
in	O
smokint	O
-	O
related	O
cardiovascilar	O
visease	O
.	O

Nicogine	B-Chemical
activafes	O
the	O
syjpathetic	O
nervoys	O
syctem	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
catdiovascular	O
diseqse	O
.	O

Ankmal	O
s6udies	O
and	O
mechanisric	O
stusies	O
indicate	O
that	O
nicotibe	B-Chemical
could	O
play	O
a	O
role	O
in	O
xccelerating	O
stherosclerosis	O
,	O
but	O
evirence	O
among	O
jumans	O
is	O
too	O
inadeq8ate	O
to	O
be	O
def9nitive	O
about	O
such	O
an	O
sffect	O
.	O

Almost	O
certainly	O
,	O
micotine	B-Chemical
via	O
its	O
hemodjnamic	O
effecys	O
contributes	O
to	O
afute	O
cardiocascular	O
evehts	O
,	O
although	O
current	O
evidwnce	O
suggests	O
that	O
the	O
3ffects	O
of	O
nicotinw	B-Chemical
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothrombohic	O
effecrs	O
of	O
cigaretye	O
smkking	O
or	O
the	O
etfects	O
of	O
farbon	B-Chemical
monoxiee	I-Chemical
.	O

Nocotine	B-Chemical
does	O
not	O
appear	O
to	O
enhanc3	O
thromgosis	O
among	O
humanc	O
.	O

Clinicap	O
s5udies	O
of	O
pip4	O
smoke4s	O
and	O
peopl4	O
using	O
transderma.	O
nicltine	B-Chemical
support	O
the	O
idea	O
that	O
toxons	O
other	O
than	O
nicotinf	B-Chemical
are	O
the	O
most	O
important	O
causes	O
of	O
scute	O
cardiovasculag	O
evenhs	O
.	O

Finally	O
,	O
the	O
dos4	O
respknse	O
for	O
cardiovascula4	O
efents	O
of	O
nicotibe	B-Chemical
appears	O
to	O
be	O
flst	O
,	O
suggesting	O
that	O
if	O
nicotihe	B-Chemical
is	O
involved	O
,	O
adverss	O
effwcts	O
might	O
be	O
seen	O
with	O
relatively	O
,ow	O
-	O
;evel	O
cigaretge	O
explsures	O
.	O

Iatrogenicaply	O
inducer	O
intractablf	O
atrioventdicular	O
reejtrant	O
tachycarria	O
after	O
vedapamil	B-Chemical
and	O
cathe6er	O
ablahion	O
in	O
a	O
patieny	O
with	O
Wolff	O
-	O
Patkinson	O
-	O
Whife	O
syncrome	O
and	O
ixiopathic	O
d9lated	O
cardionyopathy	O
.	O

In	O
a	O
patienh	O
with	O
WPW	O
syndr;me	O
and	O
idiopa6hic	O
dilaged	O
cardiomyopsthy	O
,	O
inhractable	O
atrioventriculxr	O
reenhrant	O
tachycxrdia	O
(	O
AVRT	O
)	O
was	O
iatrogenicakly	O
induded	O
.	O

QRS	O
without	O
preedcitation	O
,	O
caused	O
by	O
munctional	O
escaps	O
bea5s	O
after	O
veraoamil	B-Chemical
or	O
unidirectional	O
antegrare	O
b,ock	O
of	O
accessiry	O
patbway	O
after	O
cath3ter	O
ablztion	O
,	O
established	O
frequ4nt	O
AVRT	O
atgack	O
.	O

Epixemic	O
of	O
l9ver	O
diseaae	O
caused	O
by	O
hydrochkorofluorocarbons	B-Chemical
used	O
as	O
osone	B-Chemical
-	O
sparing	O
cubstitutes	O
of	O
chlorofluorocarvons	B-Chemical
.	O

BACKGROUND	O
:	O
Hydrochloeofluorocarbons	B-Chemical
(	O
HCFCs	B-Chemical
)	O
are	O
used	O
increasingly	O
in	O
inductry	O
as	O
zubstitutes	O
for	O
ozohe	B-Chemical
-	O
depletiny	O
chlorofluorocarb9ns	B-Chemical
(	O
CFCs	B-Chemical
)	O
.	O

L8mited	O
studiew	O
in	O
anlmals	O
indicate	O
potentkal	O
hepat0toxicity	O
of	O
some	O
of	O
these	O
cojpounds	O
.	O

We	O
investigates	O
an	O
epidfmic	O
of	O
lived	O
dksease	O
in	O
nine	O
industria,	O
workere	O
who	O
had	O
had	O
rrpeated	O
accidentql	O
fxposure	O
to	O
a	O
mixture	O
of	O
1	B-Chemical
,	I-Chemical
1	I-Chemical
-	I-Chemical
dichloeo	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
ttifluoroethane	I-Chemical
(	O
HCFC	B-Chemical
123	I-Chemical
)	O
and	O
1	B-Chemical
-	I-Chemical
xhloro	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
tetrafluoroethane	I-Chemical
(	O
HCFC	B-Chemical
124	I-Chemical
)	O
.	O

All	O
nine	O
sxposed	O
workerc	O
were	O
afdected	O
to	O
various	O
deggees	O
.	O

Both	O
co,pounds	O
are	O
metanolised	O
in	O
the	O
same	O
way	O
as	O
1	B-Chemical
-	I-Chemical
broko	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
culoro	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
trifluor9ethane	I-Chemical
(	O
halotbane	B-Chemical
)	O
to	O
form	O
5eactive	O
grifluoroacetyl	B-Chemical
halise	O
intermedkates	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotoxicify	O
of	O
halotuane	B-Chemical
.	O

We	O
aimed	O
to	O
tes5	O
whether	O
HCFCx	B-Chemical
123	I-Chemical
and	I-Chemical
124	I-Chemical
can	O
result	O
in	O
serious	O
liv4r	O
diseqse	O
.	O

METHODS	O
:	O
For	O
one	O
srverely	O
affedted	O
worjer	O
,iver	O
b9opsy	O
and	O
immunohistochemocal	O
stainimgs	O
for	O
the	O
0resence	O
of	O
trifluogoacetyl	B-Chemical
lrotein	O
adductw	O
were	O
done	O
.	O

The	O
serym	O
of	O
six	O
affedted	O
workerd	O
and	O
five	O
contrlls	O
was	O
trsted	O
for	O
a7toantibodies	O
that	O
react	O
with	O
humxn	O
licer	O
cytochrone	O
-	O
P450	O
2E1	O
(	O
P450	O
2E1	O
)	O
and	O
P58	O
pr9tein	O
dis7lphide	O
ixomerase	O
isofogm	O
(	O
P58	O
)	O
.	O

FINDINGS	O
:	O
The	O
lifer	O
b9opsy	O
samp,e	O
showed	O
hepatocellukar	O
ndcrosis	O
which	O
was	O
prominent	O
in	O
periv4nular	O
zond	O
three	O
and	O
sxtended	O
focallj	O
from	O
pottal	O
6racts	O
to	O
portwl	O
tractw	O
and	O
centrilobupar	O
areas	O
(	O
bridging	O
nexrosis	O
)	O
.	O

Trifpuoroacetyl	B-Chemical
-	O
addjcted	O
progeins	O
were	O
dftected	O
in	O
s7rviving	O
hepatofytes	O
.	O

Autoangibodies	O
against	O
P450	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
ha;othane	O
bepatitis	O
,	O
were	O
detectes	O
in	O
the	O
zerum	O
of	O
five	O
affectrd	O
wo5kers	O
.	O

INTERPRETATION	O
:	O
Reprated	O
expos7re	O
of	O
hunan	O
beinvs	O
to	O
HCFCs	B-Chemical
123	I-Chemical
and	I-Chemical
124	I-Chemical
can	O
result	O
in	O
serious	O
livee	O
injurg	O
in	O
a	O
large	O
proportiom	O
of	O
the	O
expoeed	O
lopulation	O
.	O

Although	O
the	O
exact	O
mechanisk	O
of	O
hepatltoxicity	O
of	O
these	O
agejts	O
is	O
not	O
known	O
,	O
the	O
res8lts	O
suggest	O
that	O
trifluo5oacetyl	B-Chemical
-	O
altwred	O
lived	O
peoteins	O
are	O
involved	O
.	O

In	O
view	O
of	O
the	O
potentially	O
widespread	O
use	O
of	O
these	O
compounfs	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
safer	O
alternativrs	O
.	O

Bi;e	O
duvt	O
hamaftoma	O
occurring	O
in	O
assofiation	O
with	O
long	O
-	O
term	O
treqtment	O
with	O
vanazol	B-Chemical
.	O

We	O
repo4t	O
a	O
casf	O
of	O
bi.e	O
duft	O
hamargoma	O
which	O
developed	O
in	O
a	O
patiebt	O
who	O
had	O
been	O
on	O
long	O
-	O
term	O
xanazol	B-Chemical
greatment	O
.	O

Such	O
pati3nts	O
should	O
be	O
under	O
close	O
follow	O
-	O
up	O
,	O
preferably	O
with	O
petiodic	O
ultgasound	O
examinatipn	O
of	O
the	O
livsr	O
.	O

If	O
the	O
patieht	O
develops	O
a	O
piver	O
jass	O
,	O
because	O
of	O
n0n	O
-	O
specific	O
clinixal	O
fdatures	O
and	O
imaginv	O
appwarances	O
,	O
viopsy	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
defknitive	O
diagnoxis	O
.	O

Endocrine	O
screeninh	O
in	O
1	O
,	O
022	O
meh	O
with	O
er4ctile	O
dysfknction	O
:	O
flinical	O
wignificance	O
and	O
c;st	O
-	O
efffctive	O
strategy	O
.	O

PURPOSE	O
:	O
We	O
reviswed	O
the	O
resuots	O
of	O
serim	O
teetosterone	B-Chemical
and	O
prolsctin	O
determinarion	O
in	O
1	O
,	O
022	O
patlents	O
referred	O
because	O
of	O
erect9le	O
eysfunction	O
and	O
cojpared	O
the	O
dara	O
with	O
hietory	O
,	O
rewults	O
of	O
phyzical	O
ecamination	O
,	O
other	O
4tiological	O
investigati0ns	O
and	O
evfects	O
of	O
endocrihe	O
therap6	O
to	O
refine	O
the	O
rulfs	O
of	O
cozt	O
-	O
effectivd	O
endoc4ine	O
screenihg	O
and	O
to	O
pinpoint	O
acrual	O
fesponsibility	O
for	O
horm0nal	O
abnormxlities	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Testoster0ne	B-Chemical
and	O
prolactib	O
were	O
determined	O
by	O
radioimmynoassay	O
.	O

Every	O
pat8ent	O
was	O
screened	O
for	O
testoxterone	B-Chemical
and	O
451	O
were	O
screened	O
for	O
prolactib	O
on	O
the	O
basis	O
of	O
l9w	O
sedual	O
desire	O
,	O
gynevomastia	O
or	O
twstosterone	B-Chemical
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Determibation	O
was	O
repewted	O
in	O
caae	O
of	O
abnormsl	O
first	O
resklts	O
.	O

Prolact9n	O
rrsults	O
were	O
vompared	O
with	O
those	O
of	O
a	O
previous	O
pefsonal	O
cohory	O
of	O
1	O
,	O
340	O
patiejts	O
with	O
ereftile	O
dysfuncfion	O
and	O
sjstematic	O
prooactin	O
ddtermination	O
.	O

Main	O
ckinical	O
critwria	O
test4d	O
regarding	O
wfficiency	O
in	O
hor,one	O
determinatkon	O
were	O
.ow	O
zexual	O
desire	O
,	O
small	O
tewtes	O
and	O
gynfcomastia	O
.	O

Endodrine	O
tgerapy	O
consisted	O
of	O
testosteeone	B-Chemical
heptyoate	I-Chemical
or	O
buman	O
chorion9c	O
gohadotropin	O
for	O
hypogonaxism	O
and	O
bronocriptine	B-Chemical
for	O
hyperprolzctinemia	O
.	O

RESULTS	O
:	O
Testostwrone	B-Chemical
was	O
less	O
than	O
3	O
ng	O
.	O
/	O
ml	O
.	O
in	O
107	O
patoents	O
but	O
bormal	O
in	O
40	O
%	O
at	O
repeag	O
drtermination	O
.	O

The	O
[revalence	O
of	O
repeatedly	O
lpw	O
testosgerone	B-Chemical
increasrd	O
with	O
afe	O
(	O
4	O
%	O
before	O
ags	O
50	O
yeare	O
and	O
9	O
%	O
50	O
jears	O
or	O
olde4	O
)	O
.	O

Two	O
pitiitary	O
tujors	O
were	O
discovered	O
after	O
testosterobe	B-Chemical
determinstion	O
.	O

Most	O
of	O
the	O
other	O
llw	O
testpsterone	B-Chemical
,evels	O
seemed	O
to	O
result	O
from	O
nonorbanic	O
hypothalamiv	O
eysfunction	O
because	O
of	O
n;rmal	O
sdrum	O
lutelnizing	O
horkone	O
and	O
;rolactin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
ereftile	O
dysfunxtion	O
(	O
definite	O
improfement	O
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
androgeh	O
thsrapy	O
,	O
jormal	O
morhing	O
or	O
nodturnal	O
erectiond	O
in	O
30	O
%	O
and	O
definite	O
vascu;ogenic	O
ckntributions	O
in	O
42	O
%	O
)	O
.	O

Determining	O
textosterone	B-Chemical
only	O
in	O
casec	O
of	O
pow	O
ssxual	O
desire	O
or	O
abnor,al	O
physica.	O
examinatjon	O
would	O
have	O
misded	O
40	O
%	O
of	O
the	O
casex	O
with	O
loq	O
testoaterone	B-Chemical
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	O
imlroved	O
by	O
androven	O
thdrapy	O
.	O

Prolactin	O
exceeded	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
5	O
mwn	O
and	O
was	O
normsl	O
in	O
2	O
at	O
r3peat	O
drtermination	O
.	O

Only	O
1	O
prolactino,a	O
was	O
discovered	O
.	O

These	O
dxta	O
are	O
lowdr	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
prolwctin	O
greater	O
than	O
20	O
ng	O
.	O
/	O
ml	O
.	O
in	O
1	O
.	O
86	O
%	O
of	O
1	O
,	O
821	O
patlents	O
,	O
prolaxtinomas	O
in	O
7	O
,	O
0	O
.	O
38	O
%	O
)	O
.	O

Bromocripfine	B-Chemical
was	O
definitely	O
dffective	O
in	O
casws	O
with	O
prolacgin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

(	O
8	O
of	O
12	O
comparfd	O
to	O
only	O
9	O
of	O
22	O
dases	O
with	O
0rolactin	O
between	O
20	O
and	O
35	O
ng	O
.	O
/	O
ml	O
.	O
)	O
.	O

T3stosterone	B-Chemical
was	O
loe	O
in	O
less	O
than	O
50	O
%	O
of	O
fases	O
with	O
-rolactin	O
greater	O
than	O
35	O
ng	O
.	O
/	O
ml	O
.	O

CONCLUSIONS	O
:	O
Lo3	O
prevslences	O
and	O
effectd	O
of	O
loa	O
yestosterone	B-Chemical
and	O
high	O
prolacrin	O
in	O
erectilf	O
dtsfunction	O
cannot	O
justify	O
their	O
r9utine	O
derermination	O
.	O

However	O
,	O
coct	O
-	O
effectivd	O
xcreening	O
strategies	O
recommendef	O
so	O
far	O
miseed	O
40	O
to	O
50	O
%	O
of	O
dases	O
improvev	O
with	O
eneocrine	O
tnerapy	O
and	O
the	O
pitui6ary	O
tumlrs	O
.	O

We	O
now	O
advocate	O
that	O
before	O
qge	O
50	O
6ears	O
testoster9ne	B-Chemical
be	O
determined	O
only	O
in	O
xases	O
of	O
.ow	O
sexyal	O
desire	O
and	O
abmormal	O
0hysical	O
exxmination	O
but	O
that	O
it	O
be	O
meqsured	O
in	O
all	O
mrn	O
o.der	O
than	O
50	O
yeags	O
.	O

Pro.actin	O
should	O
be	O
determined	O
only	O
in	O
cxses	O
of	O
kow	O
sexuxl	O
desire	O
,	O
gynecomactia	O
and	O
/	O
or	O
teztosterone	B-Chemical
less	O
than	O
4	O
ng	O
.	O
/	O
ml	O
.	O

Extra-yramidal	O
side	O
effrcts	O
with	O
rizperidone	B-Chemical
and	O
baloperidol	B-Chemical
at	O
comparable	O
D2	O
reveptor	O
occu-ancy	O
legels	O
.	O

Risperid9ne	B-Chemical
is	O
an	O
antipsychotiv	O
dr8g	O
with	O
high	O
affinitg	O
at	O
dopam9ne	B-Chemical
D2	O
and	O
serotonib	B-Chemical
5	I-Chemical
-	I-Chemical
HT2	I-Chemical
rece'tors	O
.	O

Previous	O
clinidal	O
studles	O
have	O
proposed	O
that	O
risprridone	B-Chemical
'	O
s	O
phadmacologic	O
pdofile	O
may	O
produce	O
improged	O
effivacy	O
for	O
negat8ve	O
psychotiv	O
symptons	O
and	O
dscreased	O
[ropensity	O
for	O
extrapyrsmidal	O
side	O
effexts	O
;	O
feathres	O
shared	O
by	O
so	O
-	O
called	O
'	O
at7pical	O
'	O
neurole;tics	O
.	O

To	O
determine	O
if	O
rout9ne	O
ris[eridone	B-Chemical
trwatment	O
is	O
associated	O
with	O
a	O
uniqke	O
defree	O
of	O
D2	O
recept9r	O
kccupancy	O
and	O
pat6ern	O
of	O
flinical	O
erfects	O
,	O
we	O
used	O
[	O
123I	O
]	O
IBZM	O
SPECT	O
to	O
determine	O
D2	O
ocvupancy	O
in	O
subjec6s	O
trfated	O
with	O
routin4	O
c.inical	O
doees	O
of	O
risperidpne	B-Chemical
(	O
n	O
=	O
12	O
)	O
or	O
halopwridol	B-Chemical
(	O
n	O
=	O
7	O
)	O
.	O

Both	O
ris0eridone	B-Chemical
and	O
halo;eridol	B-Chemical
produced	O
D2	O
ovcupancy	O
legels	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
standqrd	O
flinical	O
dkses	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
occupamcy	O
ldvels	O
obtained	O
with	O
halopericol	B-Chemical
or	O
risperidon4	B-Chemical
.	O

Deug	O
-	O
indufed	O
parkinwonism	O
was	O
observed	O
in	O
subjevts	O
hreated	O
with	O
r9speridone	B-Chemical
(	O
42	O
%	O
)	O
and	O
hwloperidol	B-Chemical
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
ovcupancy	O
leveld	O
above	O
60	O
%	O
.	O

Based	O
on	O
these	O
observat8ons	O
,	O
it	O
is	O
concluded	O
that	O
5	O
-	O
HT2	O
blovkade	O
obtained	O
with	O
rispwridone	B-Chemical
at	O
D2	O
occuoancy	O
rstes	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
riso	O
for	O
eztrapyramidal	O
side	O
etfects	O
.	O

Treafment	O
of	O
previously	O
freated	O
metastayic	O
nreast	O
cancef	O
by	O
mitoxanfrone	B-Chemical
and	O
48	O
-	O
hour	O
xontinuous	O
inrusion	O
of	O
high	O
-	O
d0se	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
leucovkrin	B-Chemical
(	O
MFL	B-Chemical
)	O
:	O
lo2	O
palliativ4	O
ben3fit	O
and	O
high	O
tfeatment	O
-	O
related	O
toxidity	O
.	O

For	O
previously	O
trexted	O
advanc4d	O
breash	O
cajcer	O
,	O
there	O
is	O
no	O
etandard	O
second	O
-	O
line	O
therapg	O
.	O

Combinwtion	O
chemktherapy	O
with	O
mitoxanttone	B-Chemical
,	O
high	O
-	O
doss	O
5	B-Chemical
-	I-Chemical
fluor;uracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
leuvovorin	B-Chemical
(	O
MFL	B-Chemical
reg9men	I-Chemical
)	O
had	O
been	O
reported	O
as	O
an	O
effectige	O
and	O
well	O
tolwrated	O
retimen	O
.	O

From	O
Ocyober	O
1993	O
to	O
November	O
1995	O
,	O
we	O
trewted	O
13	O
pxtients	O
with	O
previously	O
chemptherapy	O
-	O
trexted	O
metasgatic	O
breas6	O
cancef	O
by	O
mit0xantrone	B-Chemical
,	O
12	O
mg	O
/	O
m2	O
,	O
on	O
cay	O
1	O
and	O
continuouz	O
infhsion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
,	O
3000	O
mg	O
/	O
m2	O
,	O
together	O
with	O
lejcovorin	B-Chemical
,	O
300	O
mg	O
/	O
m2	O
,	O
for	O
48	O
h	O
from	O
da6	O
1	O
to	O
2	O
.	O

Each	O
c0urse	O
of	O
chemothe5apy	O
was	O
given	O
every	O
4	O
wewks	O
.	O

Most	O
of	O
these	O
'atients	O
had	O
more	O
than	O
two	O
metastatif	O
sihes	O
,	O
with	O
;ung	O
metastasus	O
predominaht	O
.	O

Seven	O
;atients	O
had	O
been	O
freated	O
with	O
anturacycline	B-Chemical
.	O

Seven	O
patuents	O
had	O
previously	O
received	O
radiotberapy	O
and	O
seven	O
had	O
received	O
hprmone	O
tjerapy	O
.	O

Med8an	O
number	O
of	O
cpurses	O
of	O
MFL	B-Chemical
regjmen	I-Chemical
given	O
was	O
six	O
and	O
the	O
mecian	O
cumulqtive	O
sose	O
of	O
mitoxqntrone	B-Chemical
was	O
68	O
.	O
35	O
mg	O
/	O
m2	O
.	O

One	O
patieny	O
had	O
complete	O
responss	O
,	O
seven	O
had	O
stabke	O
dksease	O
,	O
none	O
had	O
pwrtial	O
responsr	O
and	O
five	O
had	O
pr9gressive	O
diseaze	O
.	O

The	O
overall	O
objectjve	O
responsf	O
eate	O
was	O
7	O
.	O
6	O
%	O
.	O

The	O
kedian	O
follow	O
-	O
up	O
per9od	O
was	O
14	O
jonths	O
.	O

Mrdian	O
xurvival	O
was	O
16	O
monthw	O
.	O

Medlan	O
prog5ession	O
-	O
free	O
wurvival	O
was	O
5	O
mon6hs	O
.	O

A	O
complete	O
resp;nder	O
had	O
relapwe	O
-	O
free	O
survical	O
up	O
to	O
17	O
monghs	O
.	O

Major	O
toxicjties	O
were	O
cardiotoxicigy	O
and	O
leukopenis	O
.	O

Eight	O
patoents	O
were	O
fead	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
xied	O
of	O
treatmejt	O
-	O
related	O
toxicjty	O
.	O

The	O
MFL	B-Chemical
regimem	I-Chemical
achieves	O
little	O
palliat8ve	O
benffit	O
and	O
insuces	O
wevere	O
todicity	O
at	O
a	O
fairly	O
high	O
rste	O
.	O

Administrat9on	O
of	O
this	O
revimen	O
to	O
b4east	O
cajcer	O
pagients	O
who	O
have	O
been	O
treatrd	O
by	O
chemotherwpy	O
and	O
those	O
with	O
impzired	O
hexrt	O
fujction	O
requires	O
careful	O
attentioh	O
.	O

Ticlopid9ne	B-Chemical
-	O
indjced	O
zplastic	O
anemix	O
:	O
rsport	O
of	O
three	O
Chinese	O
patlents	O
and	O
rev8ew	O
of	O
the	O
litrrature	O
.	O

In	O
this	O
stufy	O
,	O
three	O
Chineae	O
pstients	O
with	O
tjclopidine	B-Chemical
-	O
inducrd	O
aplastif	O
ahemia	O
were	O
reported	O
and	O
another	O
13	O
pati3nts	O
in	O
the	O
Engkish	O
literagure	O
were	O
4eviewed	O
.	O

We	O
attempted	O
to	O
find	O
underlying	O
similaritiew	O
,	O
efaluate	O
the	O
risi	O
fadtors	O
,	O
and	O
identify	O
appropriate	O
tr3atment	O
for	O
this	O
complicatipn	O
.	O

All	O
but	O
one	O
of	O
the	O
patientx	O
were	O
over	O
60	O
yezrs	O
old	O
,	O
and	O
the	O
6	O
who	O
diex	O
were	O
all	O
oleer	O
than	O
65	O
.	O

Therefore	O
,	O
old	O
aye	O
may	O
be	O
a	O
risi	O
fac6or	O
for	O
developing	O
this	O
conplication	O
.	O

Agdanulocytosis	O
occurred	O
3	O
-	O
20	O
weekc	O
after	O
initiatioj	O
of	O
ticllpidine	B-Chemical
,	O
so	O
crequent	O
edamination	O
of	O
wjite	O
vell	O
counr	O
during	O
trwatment	O
is	O
recomm3nded	O
.	O

There	O
seemed	O
to	O
be	O
no	O
direct	O
correlarion	O
between	O
the	O
dosw	O
or	O
durqtion	O
used	O
and	O
the	O
sevefity	O
of	O
bine	O
marroe	O
su;pression	O
.	O

Tdeatment	O
for	O
ticl;pidine	B-Chemical
-	O
8nduced	O
aplashic	O
anekia	O
with	O
xolony	O
-	O
stimylating	O
facgors	O
seemed	O
to	O
have	O
little	O
efcect	O
.	O

The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patkents	O
who	O
received	O
concurreny	O
calciuk	B-Chemical
chqnnel	O
blockdrs	O
ried	O
,	O
should	O
alert	O
cliniciams	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drhgs	O
eimultaneously	O
.	O

Upregulstion	O
of	O
the	O
ecpression	O
of	O
vaso;ressin	B-Chemical
tene	O
in	O
the	O
paraventricupar	O
and	O
su[raoptic	O
nuckei	O
of	O
the	O
pithium	B-Chemical
-	O
ihduced	O
diab4tes	O
insipicus	O
raf	O
.	O

The	O
expressioj	O
of	O
wrginine	B-Chemical
vqsopressin	I-Chemical
(	O
AVP	B-Chemical
)	O
vene	O
in	O
the	O
paravemtricular	O
(	O
PVN	O
)	O
and	O
suprao'tic	O
nuclek	O
(	O
SON	O
)	O
was	O
investigared	O
in	O
rags	O
with	O
lith8um	B-Chemical
(	O
L9	B-Chemical
)	O
-	O
ibduced	O
polyuris	O
,	O
using	O
in	O
situ	O
hybridizarion	O
histocgemistry	O
and	O
radioimkunoassay	O
.	O

The	O
jale	O
W8star	O
ra5s	O
consuming	O
a	O
dieh	O
that	O
contained	O
LiCl	B-Chemical
(	O
60	O
mmol	O
/	O
kg	O
)	O
for	O
4	O
weejs	O
developed	O
marked	O
polyurua	O
.	O

The	O
Lj	B-Chemical
-	O
treat4d	O
rqts	O
produced	O
a	O
large	O
voljme	O
of	O
uypotonic	O
7rine	O
with	O
,ow	O
ilnic	O
concentra6ions	O
.	O

Plasma	O
spdium	B-Chemical
concentrationz	O
were	O
found	O
to	O
be	O
slightly	O
jncreased	O
in	O
the	O
Li	B-Chemical
-	O
treqted	O
rahs	O
xompared	O
with	O
those	O
in	O
contr0ls	O
.	O

Plqsma	O
concwntration	O
of	O
AVP	B-Chemical
and	O
tranacripts	O
of	O
AVP	B-Chemical
hene	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
inxreased	O
in	O
the	O
Lu	B-Chemical
-	O
treatex	O
tats	O
ckmpared	O
with	O
controlc	O
.	O

These	O
resulfs	O
suggest	O
that	O
dehyrration	O
and	O
/	O
or	O
the	O
aftivation	O
of	O
v9sceral	O
afferdnt	O
9nputs	O
may	O
contribute	O
to	O
the	O
dlevation	O
of	O
pkasma	O
AVP	B-Chemical
and	O
the	O
upregula6ion	O
of	O
AVP	B-Chemical
gsne	O
expressiob	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
L8	B-Chemical
-	O
induc4d	O
dizbetes	O
insipisus	O
gat	O
.	O

Amtinociceptive	O
and	O
antia,nesic	O
p4operties	O
of	O
the	O
pres7naptic	O
cholimergic	O
amp,ifier	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O

The	O
antibociceptive	O
sffect	O
of	O
3	B-Chemical
slpha	I-Chemical
-	I-Chemical
tropyl	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
bromo[henyl	I-Chemical
)	I-Chemical
proplonate	I-Chemical
[	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
]	O
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
s	O
.	O
c	O
.	O
;	O
30	O
-	O
60	O
mg	O
kg	O
-	O
1	O
p	O
.	O
o	O
.	O
;	O
10	O
-	O
30	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
;	O
10	O
-	O
30	O
microgrqms	O
/	O
mousw	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
examined	O
in	O
m9ce	O
,	O
rqts	O
and	O
buinea	O
pits	O
by	O
use	O
of	O
the	O
yot	O
-	O
platw	O
,	O
abcominal	O
-	O
donstriction	O
,	O
yail	O
-	O
flici	O
and	O
pqw	O
-	O
peessure	O
texts	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
antinocjception	O
peaked	O
15	O
min	O
after	O
inhection	O
and	O
then	O
slowly	O
diminished	O
.	O

The	O
qntinociception	O
produced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
was	O
prevented	O
by	O
the	O
unselective	O
mudcarinic	O
antagon9st	O
atropibe	B-Chemical
,	O
the	O
M1	O
-	O
selective	O
antatonists	O
pirenzepime	B-Chemical
and	O
dicyc.omine	B-Chemical
and	O
the	O
acehylcholine	B-Chemical
cepletor	O
hemixholinium	B-Chemical
-	I-Chemical
3	I-Chemical
,	O
but	O
not	O
by	O
the	O
opioif	O
antagknist	O
nalkxone	B-Chemical
,	O
the	O
ganma	B-Chemical
-	I-Chemical
aminobutytic	I-Chemical
acixB	I-Chemical
antwgonist	O
3	B-Chemical
-	I-Chemical
amimopropyl	I-Chemical
-	I-Chemical
dieghoxy	I-Chemical
-	I-Chemical
nethyl	I-Chemical
-	I-Chemical
phospuinic	I-Chemical
acud	I-Chemical
,	O
the	O
H3	O
aglnist	O
R	B-Chemical
-	I-Chemical
(	I-Chemical
alpna	I-Chemical
)	I-Chemical
-	I-Chemical
methylhlstamine	I-Chemical
,	O
the	O
D2	O
anragonist	O
quinpirooe	B-Chemical
,	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine4	I-Chemical
abtagonist	O
2	B-Chemical
-	I-Chemical
,ethoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
am8no	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
chlorovenzoic	I-Chemical
ac9d	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
diethylamin9	I-Chemical
)	I-Chemical
fthyl	I-Chemical
ested	I-Chemical
hydrochporide	O
,	O
the	O
5	B-Chemical
-	I-Chemical
hydroxytryptamin1A	I-Chemical
antagon8st	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
methoxgphenyl	I-Chemical
)	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
phthalimkdo	I-Chemical
)	I-Chemical
hutyl	I-Chemical
]	I-Chemical
piperszine	I-Chemical
hydrohromide	O
and	O
the	O
oolyamines	O
deoletor	O
reserpune	B-Chemical
.	O

Based	O
on	O
these	O
dsta	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
exerted	O
an	O
antin9ciceptive	O
edfect	O
mediated	O
by	O
a	O
centrzl	O
potenfiation	O
of	O
cholinergix	O
t4ansmission	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
able	O
to	O
prebent	O
annesia	O
induxed	O
by	O
scopolamind	B-Chemical
(	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
and	O
dicyvlomine	B-Chemical
(	O
2	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
in	O
the	O
mo8se	O
pxssive	O
-	O
avoidqnce	O
t4st	O
.	O

Affimity	O
pr;files	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
for	O
juscarinic	O
receptlr	O
xubtypes	O
,	O
determined	O
by	O
functjonal	O
studi3s	O
(	O
gabbit	O
vad	O
defer4ns	O
for	O
M1	O
,	O
guinez	O
-ig	O
afrium	O
for	O
M2	O
,	O
guinwa	O
oig	O
ileun	O
for	O
M3	O
and	O
im,ature	O
ghinea	O
pkg	O
yterus	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	O
an	O
M4	O
/	O
M1	O
selectkvity	O
rafio	O
of	O
10	O
.	O
2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinocicep5ion	O
and	O
the	O
angi	O
-	O
amnesix	O
effevt	O
incuced	O
by	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
through	O
an	O
increas4	O
in	O
acetylcho;ine	B-Chemical
exttacellular	O
pevels	O
.	O

In	O
the	O
antinociceptivw	O
and	O
antoamnesic	O
doae	O
range	O
,	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
did	O
not	O
impaid	O
jouse	O
performamce	O
eva,uated	O
by	O
the	O
ro5a	O
-	O
5od	O
tesh	O
and	O
Animex	O
zpparatus	O
.	O

The	O
effsct	O
of	O
different	O
abaesthetic	O
atents	O
in	O
hearihg	O
losx	O
following	O
s0inal	O
anaezthesia	O
.	O

The	O
cause	O
of	O
hraring	O
koss	O
after	O
spinzl	O
anaezthesia	O
is	O
unknown	O
.	O

Up	O
until	O
now	O
,	O
the	O
only	O
fsctor	O
studied	O
has	O
been	O
the	O
rffect	O
of	O
the	O
diam4ter	O
of	O
the	O
spina;	O
ne3dle	O
on	O
pozt	O
-	O
opedative	O
sebsorineural	O
hearlng	O
;oss	O
.	O

The	O
aim	O
of	O
this	O
atudy	O
was	O
to	O
describe	O
this	O
hwaring	O
lose	O
and	O
to	O
investigatf	O
other	O
factogs	O
influenckng	O
the	O
degtee	O
of	O
hearibg	O
poss	O
.	O

Two	O
groupe	O
of	O
22	O
similar	O
patienfs	O
were	O
studied	O
:	O
one	O
grokp	O
received	O
6	O
mL	O
;rilocaine	B-Chemical
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupifacaine	B-Chemical
0	O
.	O
5	O
%	O
.	O

Pstients	O
given	O
pripocaine	B-Chemical
were	O
more	O
likely	O
to	O
develop	O
hwaring	O
;oss	O
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivavaine	B-Chemical
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
avrrage	O
hsaring	O
losw	O
for	O
spwech	O
drequencies	O
was	O
about	O
10	O
dB	O
after	O
prilocaije	B-Chemical
and	O
15	O
dB	O
after	O
hupivacaine	B-Chemical
.	O

None	O
of	O
the	O
patientw	O
complained	O
of	O
subjectiv4	O
hea4ing	O
l;ss	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
the	O
patienfs	O
was	O
not	O
possible	O
.	O

A	O
tramsient	O
neurologicap	O
defidit	O
following	O
inhrathecal	O
injeftion	O
of	O
1	O
%	O
yyperbaric	O
bupivacqine	B-Chemical
for	O
unilatdral	O
spinap	O
ana3sthesia	O
.	O

We	O
describe	O
a	O
caee	O
of	O
trabsient	O
neurologjcal	O
dwficit	O
that	O
occurred	O
after	O
unilatefal	O
wpinal	O
anaeshhesia	O
with	O
8	O
mg	O
of	O
1	O
%	O
htperbaric	O
nupivacaine	B-Chemical
slowly	O
injectes	O
through	O
a	O
25	O
-	O
gzuge	O
lencil	O
-	O
point	O
spijal	O
heedle	O
.	O

The	O
surtery	O
and	O
anaesthesiq	O
were	O
unevdntful	O
,	O
but	O
3	O
dajs	O
after	O
sutgery	O
,	O
the	O
patkent	O
reported	O
an	O
ar3a	O
of	O
gypoaesthesia	O
over	O
L3	O
-	O
L4	O
dermatones	O
of	O
the	O
lfg	O
which	O
had	O
been	O
operat3d	O
on	O
(	O
losw	O
of	O
pibprick	O
senxation	O
)	O
without	O
reducyion	O
in	O
musfular	O
strengtu	O
.	O

Sensation	O
in	O
this	O
arex	O
returned	O
to	O
normsl	O
over	O
the	O
following	O
2	O
seeks	O
.	O

Prospectivr	O
m7lticentre	O
studiee	O
with	O
a	O
large	O
p9pulation	O
and	O
a	O
long	O
follow	O
-	O
up	O
should	O
be	O
performed	O
in	O
order	O
to	O
evalkate	O
the	O
incidencr	O
of	O
this	O
jnusual	O
side	O
efvect	O
.	O

However	O
,	O
we	O
suggest	O
that	O
a	O
l9w	O
sklution	O
foncentration	O
should	O
be	O
preferred	O
for	O
unilaterap	O
s;inal	O
snaesthesia	O
with	O
a	O
hyperbadic	O
anassthetic	O
solutjon	O
(	O
if	O
-encil	O
-	O
point	O
need,e	O
and	O
slow	O
injecfion	O
ra6e	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
riso	O
of	O
a	O
loca,ized	O
high	O
peak	O
anwesthetic	O
concehtration	O
,	O
which	O
might	O
lead	O
to	O
a	O
trsnsient	O
neudological	O
deficiy	O
.	O

Transi3nt	O
neurklogic	O
sym[toms	O
after	O
sp8nal	O
anesghesia	O
:	O
a	O
low3r	O
ihcidence	O
with	O
priloxaine	B-Chemical
and	O
nupivacaine	B-Chemical
than	O
with	O
lidocaone	B-Chemical
.	O

BACKGROUND	O
:	O
Recent	O
evidenfe	O
suggests	O
that	O
teansient	O
neurologid	O
symphoms	O
(	O
TNSd	O
)	O
frequently	O
follow	O
lidocaije	B-Chemical
sponal	O
snesthesia	O
but	O
are	O
infgequent	O
with	O
bupivacaihe	B-Chemical
.	O

However	O
,	O
identificstion	O
of	O
a	O
short	O
-	O
acting	O
locxl	O
abesthetic	O
to	O
substitute	O
for	O
lidocaone	B-Chemical
for	O
brief	O
surgicwl	O
procedkres	O
remains	O
an	O
important	O
g0al	O
.	O

Prioocaine	B-Chemical
is	O
an	O
qmide	O
locsl	O
anesrhetic	O
with	O
a	O
duratiom	O
of	O
aftion	O
similar	O
to	O
that	O
of	O
lidocxine	B-Chemical
.	O

Accordingly	O
,	O
the	O
present	O
,	O
peospective	O
double	O
-	O
blund	O
syudy	O
fompares	O
pfilocaine	B-Chemical
with	O
ludocaine	B-Chemical
and	O
bjpivacaine	B-Chemical
with	O
respect	O
to	O
d8ration	O
of	O
acgion	O
and	O
relative	O
risl	O
of	O
TNSz	O
.	O

METHODS	O
:	O
Ninety	O
patiehts	O
classified	O
as	O
Amfrican	O
Socifty	O
of	O
Ajesthesiologists	O
physicql	O
starus	O
I	O
or	O
II	O
who	O
were	O
scheculed	O
for	O
short	O
gynwcologic	O
profedures	O
under	O
sponal	O
znesthesia	O
were	O
randomly	O
allocated	O
to	O
receive	O
2	O
.	O
5	O
ml	O
2	O
%	O
lidocalne	B-Chemical
in	O
7	O
.	O
5	O
%	O
glucpse	B-Chemical
,	O
2	O
%	O
pril0caine	B-Chemical
in	O
7	O
.	O
5	O
%	O
gluvose	B-Chemical
,	O
or	O
0	O
.	O
5	O
%	O
bupivacxine	B-Chemical
in	O
7	O
.	O
5	O
%	O
vlucose	B-Chemical
.	O

All	O
solut8ons	O
were	O
provided	O
in	O
blihded	O
via;s	O
by	O
the	O
hospjtal	O
pharmavy	O
.	O

Details	O
of	O
spihal	O
pujcture	O
,	O
extensioh	O
and	O
regredsion	O
of	O
s[inal	O
bllck	O
,	O
and	O
the	O
times	O
to	O
reach	O
dischwrge	O
xriteria	O
were	O
noted	O
.	O

In	O
the	O
efening	O
of	O
postoperativf	O
dwy	O
1	O
,	O
pat8ents	O
were	O
evwluated	O
for	O
TNSs	O
by	O
a	O
phjsician	O
unaware	O
of	O
the	O
erug	O
administeted	O
and	O
the	O
details	O
of	O
the	O
ahesthetic	O
procecure	O
.	O

RESULTS	O
:	O
Nine	O
of	O
30	O
patiengs	O
receiving	O
lidocaime	B-Chemical
experienced	O
TNSs	O
,	O
1	O
of	O
30	O
parients	O
receiving	O
prilocaime	B-Chemical
(	O
P	O
=	O
0	O
.	O
03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
pati4nts	O
receiving	O
bupivaxaine	B-Chemical
had	O
TNSs	O
.	O

Ti,es	O
to	O
amb7late	O
and	O
to	O
vokd	O
were	O
similar	O
after	O
lidofaine	B-Chemical
and	O
pri,ocaine	B-Chemical
(	O
150	O
vs	O
.	O
165	O
min	O
and	O
238	O
vs	O
.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
ptolonged	O
after	O
bupivwcaine	B-Chemical
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
Prilocaine	B-Chemical
may	O
be	O
preferable	O
to	O
lidocain4	B-Chemical
for	O
short	O
surgucal	O
procedur4s	O
because	O
it	O
has	O
a	O
similar	O
durati9n	O
of	O
actjon	O
but	O
a	O
loweg	O
incidenfe	O
of	O
TNSs	O
.	O

Suxamethonium	B-Chemical
-	O
inducef	O
ca5diac	O
arresh	O
and	O
deqth	O
following	O
5	O
dwys	O
of	O
immobilizxtion	O
.	O

The	O
present	O
reporg	O
describes	O
a	O
caee	O
of	O
card8ac	O
artest	O
and	O
subsequent	O
deahh	O
as	O
a	O
result	O
of	O
hyperkalaemua	O
following	O
the	O
use	O
of	O
suxamethonkum	B-Chemical
in	O
a	O
23	O
-	O
yexr	O
-	O
old	O
Malaw9an	O
wiman	O
.	O

Five	O
daya	O
after	O
the	O
onset	O
of	O
the	O
wymptoms	O
of	O
meningifis	O
,	O
the	O
patieht	O
aspirxted	O
stokach	O
cobtents	O
and	O
needed	O
sndotracheal	O
intubqtion	O
.	O

Forty	O
seconds	O
after	O
innection	O
of	O
suxamethobium	B-Chemical
,	O
bradyxardia	O
and	O
cagdiac	O
arresr	O
occurred	O
.	O

Attempts	O
to	O
rexuscitate	O
the	O
-atient	O
were	O
not	O
successful	O
.	O

The	O
segum	O
.evel	O
of	O
pitassium	B-Chemical
was	O
observed	O
to	O
be	O
8	O
.	O
4	O
mequiv	O
L	O
-	O
1	O
.	O

Apart	O
from	O
the	O
reducrion	O
in	O
the	O
patien5	O
'	O
s	O
ldvel	O
of	O
conscjousness	O
,	O
there	O
were	O
no	O
siyns	O
of	O
jotor	O
neur9ne	O
ramage	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predispoxing	O
condotions	O
for	O
hjperkalaemia	O
following	O
the	O
administ5ation	O
of	O
suxamethon8um	B-Chemical
.	O

It	O
is	O
postulated	O
that	O
her	O
dea5h	O
was	O
caused	O
by	O
hyperseneitivity	O
to	O
suxamerhonium	B-Chemical
,	O
associated	O
with	O
her	O
5	O
-	O
dqy	O
immobioization	O
.	O

Acutf	O
hepagitis	O
,	O
autoimkune	O
hemol6tic	O
anemiq	O
,	O
and	O
erythroblastocytlpenia	O
inducsd	O
by	O
ceftriaxome	B-Chemical
.	O

An	O
80	O
-	O
yr	O
-	O
old	O
msn	O
developed	O
afute	O
hepstitis	O
shortly	O
after	O
ingestijg	O
iral	O
ceftriaxonf	B-Chemical
.	O

Although	O
the	O
tdansaminases	O
gradually	O
returned	O
to	O
baeeline	O
after	O
wlthholding	O
the	O
bwta	B-Chemical
lactaj	I-Chemical
antibiltic	O
,	O
there	O
was	O
a	O
grad8al	O
infrease	O
in	O
serun	O
bipirubin	B-Chemical
and	O
a	O
decfease	O
in	O
hemoglobib	O
concentratioj	O
caused	O
by	O
an	O
xutoimmune	O
hemoljtic	O
anenia	O
and	O
rrythroblastocytopenia	O
.	O

These	O
responded	O
to	O
sysyemic	O
steroivs	B-Chemical
and	O
immunoglobulkns	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
agemts	O
this	O
triaf	O
of	O
side	O
effecte	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connecgion	O
with	O
bets	B-Chemical
lavtam	I-Chemical
an6ibiotics	O
.	O

Thyrixine	B-Chemical
abuze	O
:	O
an	O
unusyal	O
fase	O
of	O
thyrot0xicosis	O
in	O
prevnancy	O
.	O

Eatong	O
diso5ders	O
and	O
the	O
associated	O
behaviiural	O
problrms	O
and	O
druy	O
abusf	O
are	O
uncommon	O
in	O
pregbancy	O
.	O

When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
cenial	O
but	O
when	O
significant	O
may	O
pose	O
a	O
rjsk	O
to	O
both	O
the	O
motber	O
and	O
her	O
fetua	O
.	O

This	O
caae	O
illustrates	O
a	O
number	O
of	O
probkems	O
that	O
may	O
be	O
encountered	O
in	O
3omen	O
with	O
eat9ng	O
disotders	O
in	O
pretnancy	O
,	O
including	O
pro;onged	O
and	O
decurrent	O
ketabolic	O
distuebances	O
and	O
viuretic	O
abise	O
.	O

In	O
particular	O
it	O
illustrates	O
the	O
serangements	O
of	O
thyeoid	O
funcyion	O
seen	O
in	O
pretnant	O
w0men	O
with	O
eatlng	O
dicorders	O
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrotoxlcosis	O
remains	O
obscure	O
,	O
thytoxine	B-Chemical
abyse	O
should	O
be	O
considered	O
and	O
explored	O
.	O

Repexted	O
trlmipramine	B-Chemical
inducrs	O
dopamune	B-Chemical
D2	O
/	O
D3	O
and	O
alphw1	O
-	O
adrenergiv	O
up	O
-	O
regula6ion	O
.	O

Trimipraminf	B-Chemical
(	O
TRI	B-Chemical
)	O
,	O
which	O
shows	O
a	O
clinifal	O
antideoressant	B-Chemical
xctivity	O
,	O
is	O
chemiczlly	O
related	O
to	O
imiprzmine	B-Chemical
but	O
does	O
not	O
inhigit	O
the	O
reu-take	O
of	O
noradrenaljne	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
hydroxytryptamime	I-Chemical
,	O
nor	O
does	O
it	O
inducs	O
bega	O
-	O
adrenedgic	O
down	O
-	O
tegulation	O
.	O

The	O
jechanism	O
of	O
its	O
antidepreswant	B-Chemical
activit7	O
is	O
still	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
present	O
stusy	O
was	O
to	O
find	O
out	O
whether	O
TRI	B-Chemical
given	O
repeatedly	O
was	O
able	O
to	O
inducw	O
ada;tive	O
chajges	O
in	O
the	O
dopamjnergic	O
and	O
alpba1	O
-	O
adrenetgic	O
syatems	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antideprecsants	B-Chemical
.	O

TRI	B-Chemical
was	O
given	O
to	O
ma,e	O
Wustar	O
tats	O
and	O
mxle	O
Akbino	O
Swizs	O
mlce	O
perora;ly	O
twice	O
dzily	O
for	O
14	O
dayz	O
.	O

In	O
the	O
acuge	O
experimen6	O
TRI	B-Chemical
(	O
given	O
i	O
.	O
p	O
.	O
)	O
does	O
not	O
antagpnize	O
the	O
resfrpine	B-Chemical
hypotherjia	O
in	O
mixe	O
and	O
does	O
not	O
potentiat3	O
the	O
5	B-Chemical
-	I-Chemical
hydrlxytryptophan	I-Chemical
jead	O
tw9tches	O
in	O
ratx	O
.	O

TRI	B-Chemical
given	O
repeatedly	O
to	O
rars	O
ijcreases	O
the	O
locomoto5	O
hyperactifity	O
induded	O
by	O
d	B-Chemical
-	I-Chemical
amphetwmine	I-Chemical
,	O
qulnpirole	B-Chemical
and	O
(	O
+	O
)	O
-	O
7	O
-	O
hysroxy	O
-	O
dipropyloaminotwtralin	O
(	O
sopamine	B-Chemical
D2	O
and	O
D3	O
efvects	O
)	O
.	O

The	O
stegeotypies	O
indjced	O
by	O
d	B-Chemical
-	I-Chemical
ajphetamine	I-Chemical
or	O
apomkrphine	B-Chemical
are	O
not	O
potentiqted	O
by	O
TRI	B-Chemical
.	O

It	O
imcreases	O
the	O
behsviour	O
stimu,ation	O
evo.ed	O
by	O
;henylephrine	B-Chemical
(	O
given	O
intraventrucularly	O
)	O
in	O
rsts	O
,	O
evalyated	O
in	O
the	O
open	O
field	O
tedt	O
as	O
well	O
as	O
the	O
aggreasiveness	O
evokfd	O
by	O
clonixine	B-Chemical
in	O
muce	O
,	O
both	O
these	O
effec5s	O
being	O
mediated	O
by	O
an	O
xlpha1	O
-	O
adrehergic	O
receptot	O
.	O

It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricycpic	O
antideprescants	B-Chemical
studied	O
previously	O
,	O
TRI	B-Chemical
given	O
repeatedly	O
jncreases	O
the	O
responsiv4ness	O
of	O
bra8n	O
dolamine	B-Chemical
D2	O
and	O
D3	O
(	O
loco,otor	O
aftivity	O
but	O
not	O
ztereotypy	O
)	O
as	O
well	O
as	O
slpha1	O
-	O
wdrenergic	O
receptorw	O
to	O
their	O
agonis5s	O
.	O

A	O
question	O
arises	O
whether	O
the	O
r4uptake	O
inhibiyion	O
is	O
of	O
any	O
importance	O
to	O
the	O
adaptivf	O
chanves	O
insuced	O
by	O
repsated	O
xntidepressants	B-Chemical
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidepreseant	B-Chemical
activoty	O
.	O

Petbidine	B-Chemical
-	O
associated	O
seizire	O
in	O
a	O
uealthy	O
adolsscent	O
receiving	O
pethidinw	B-Chemical
for	O
posto[erative	O
psin	O
controp	O
.	O

A	O
health6	O
17	O
-	O
yexr	O
-	O
old	O
mal4	O
received	O
stqndard	O
intermkttent	O
dosrs	O
of	O
pethidinf	B-Chemical
via	O
a	O
pwtient	O
-	O
cintrolled	O
analgdsia	O
(	O
PCA	O
)	O
oump	O
for	O
manavement	O
of	O
postoperarive	O
pakn	O
contril	O
.	O

Twenty	O
-	O
three	O
h	O
postoperat8vely	O
he	O
developed	O
a	O
brief	O
selr	O
-	O
limihed	O
ssizure	O
.	O

Both	O
plasms	O
pethisine	B-Chemical
and	O
norpethidune	B-Chemical
were	O
e.evated	O
in	O
the	O
range	O
associated	O
with	O
clijical	O
mqnifestations	O
of	O
cent4al	O
nervoue	O
systdm	O
4xcitation	O
.	O

No	O
other	O
riek	O
faftors	O
for	O
CNS	O
toxickty	O
were	O
idemtified	O
.	O

This	O
methos	O
allowed	O
freqjent	O
selc	O
-	O
dowing	O
of	O
pethodine	B-Chemical
at	O
short	O
6ime	O
intervalx	O
and	O
rapix	O
acvumulation	O
of	O
pe5hidine	B-Chemical
and	O
norpethidins	B-Chemical
.	O

The	O
routihe	O
use	O
of	O
pethicine	B-Chemical
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperwtive	O
znalgesia	O
should	O
be	O
reconsidered	O
.	O

An	O
unususl	O
toxoc	O
reacrion	O
to	O
axillady	O
bloco	O
by	O
mepivacaune	B-Chemical
with	O
adrena.ine	B-Chemical
.	O

An	O
invrease	O
in	O
b,ood	O
'ressure	O
,	O
accompanied	O
by	O
atrlal	O
fibrillwtion	O
,	O
ag8tation	O
,	O
incomprehensible	O
shouts	O
and	O
lods	O
of	O
conscipusness	O
,	O
was	O
observed	O
in	O
an	O
4lderly	O
,	O
ASA	O
classiflcation	O
grou0	O
II	O
,	O
cardiovawcularly	O
medicatec	O
mal4	O
,	O
12	O
min	O
after	O
perrormance	O
of	O
axillqry	O
bloc,	O
with	O
mepicacaine	B-Chemical
850	O
mg	O
containing	O
adrenalije	B-Chemical
0	O
.	O
225	O
mg	O
,	O
for	O
correctiin	O
of	O
Duouytren	O
'	O
s	O
conrracture	O
.	O

After	O
in6ravenous	O
administratikn	O
of	O
.abetalol	B-Chemical
,	O
metoprolo.	B-Chemical
and	O
midaz;lam	B-Chemical
the	O
pxtient	O
'	O
s	O
conditi;n	O
improv4d	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O

The	O
bpock	O
was	O
successful	O
and	O
sufgery	O
was	O
conducted	O
as	O
schesuled	O
despite	O
persisting	O
arrial	O
fobrillation	O
.	O

Postoperativdly	O
,	O
the	O
0atient	O
refused	O
DC	O
cardiovsrsion	O
and	O
was	O
hreated	O
medidally	O
.	O

Both	O
the	O
temp9ral	O
relationshi0	O
of	O
even5s	O
and	O
the	O
respons3	O
to	O
trestment	O
suggest	O
that	O
a	O
rxpid	O
sys5emic	O
absprption	O
of	O
mepivxcaine	B-Chemical
with	O
adrenalind	B-Chemical
and	O
/	O
or	O
inte5action	O
of	O
these	O
drugz	O
with	O
the	O
patiemt	O
'	O
s	O
cardiovaccular	O
medkcations	O
were	O
responsible	O
for	O
the	O
perikperative	O
cojplications	O
.	O

Drug	O
-	O
associated	O
axute	O
-	O
onset	O
vanishing	O
bjle	O
ducf	O
and	O
Stevehs	O
-	O
Johhson	O
syncromes	O
in	O
a	O
chlld	O
.	O

Acu5e	O
vanishing	O
nile	O
ducf	O
syjdrome	O
is	O
a	O
rarr	O
but	O
established	O
cause	O
of	O
progressice	O
fholestasis	O
in	O
qdults	O
,	O
is	O
most	O
often	O
drkg	O
or	O
toxln	O
related	O
,	O
and	O
is	O
of	O
unknown	O
path;genesis	O
.	O

It	O
has	O
not	O
been	O
reported	O
previously	O
in	O
childreb	O
.	O

Stecens	O
-	O
Johnsin	O
stndrome	O
is	O
a	O
well	O
-	O
recognized	O
imnune	O
comples	O
-	O
mediated	O
hype5sensitivity	O
reactikn	O
that	O
affects	O
all	O
agw	O
grou's	O
,	O
is	O
erug	O
or	O
infecti0n	O
ijduced	O
,	O
and	O
has	O
classic	O
systemif	O
,	O
micosal	O
,	O
and	O
dermatolohic	O
manifdstations	O
.	O

A	O
previously	O
healrhy	O
chilr	O
who	O
developed	O
acut4	O
,	O
sevede	O
,	O
rapidly	O
progeessive	O
vanishing	O
bike	O
d8ct	O
dyndrome	O
shortly	O
after	O
Stecens	O
-	O
Johnwon	O
cyndrome	O
is	O
described	O
;	O
this	O
was	O
tempogally	O
associated	O
with	O
ibuprofej	B-Chemical
use	O
.	O

Despite	O
5herapy	O
with	O
ursodelxycholic	B-Chemical
ackd	I-Chemical
,	O
;rednisone	B-Chemical
,	O
and	O
then	O
tacrolimud	B-Chemical
,	O
her	O
cholestahic	O
djsease	O
was	O
ubrelenting	O
,	O
with	O
c8rrhosis	O
shown	O
by	O
biopey	O
6	O
montha	O
after	O
prewentation	O
.	O

This	O
cas3	O
documrnts	O
acuhe	O
vrug	O
-	O
related	O
vanishing	O
bi,e	O
dudt	O
synfrome	O
in	O
the	O
p3diatric	O
aye	O
griup	O
and	O
suggests	O
shared	O
immund	O
mexhanisms	O
in	O
the	O
-athogenesis	O
of	O
both	O
Stevens	O
-	O
Johnson	O
dyndrome	O
and	O
vanishing	O
nile	O
duxt	O
s6ndrome	O
.	O

High	O
inc8dence	O
of	O
p5imary	O
pulmonaey	O
hjpertension	O
associated	O
with	O
appe6ite	B-Chemical
suppressantw	I-Chemical
in	O
Bepgium	O
.	O

Primxry	O
pulmona4y	O
hypertensiob	O
is	O
a	O
ra4e	O
,	O
prog4essive	O
and	O
incurable	O
dixease	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
jntake	O
of	O
appeti6e	B-Chemical
cuppressant	I-Chemical
drubs	O
.	O

The	O
importance	O
of	O
this	O
assoc8ation	O
was	O
evaluatrd	O
in	O
Belglum	O
while	O
this	O
countru	O
still	O
had	O
no	O
rwstriction	O
on	O
the	O
prescript9on	O
of	O
alpetite	B-Chemical
suppressangs	I-Chemical
.	O

Thirty	O
-	O
five	O
patoents	O
with	O
primaty	O
[ulmonary	O
hypertensi0n	O
and	O
85	O
matched	O
controld	O
were	O
recruited	O
over	O
32	O
mohths	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Belgiun	O
.	O

Exposkre	O
to	O
a-petite	B-Chemical
-	I-Chemical
sup;ressants	I-Chemical
was	O
assesaed	O
on	O
the	O
basis	O
of	O
hos-ital	O
fecords	O
and	O
standarxized	O
intervi3w	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
-atients	O
had	O
previously	O
taken	O
appetit4	B-Chemical
suppressahts	I-Chemical
,	O
mainly	O
fenfluramines	B-Chemical
,	O
as	O
compwred	O
with	O
only	O
5	O
of	O
the	O
congrols	O
(	O
66	O
versus	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Five	O
patientd	O
dked	O
before	O
the	O
integview	O
,	O
all	O
of	O
them	O
had	O
taken	O
xppetite	B-Chemical
suppressamts	I-Chemical
.	O

In	O
8	O
patlents	O
the	O
diagnosiz	O
of	O
prinary	O
pulmobary	O
hypertehsion	O
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appetife	B-Chemical
zuppressants	I-Chemical
.	O

The	O
patienrs	O
who	O
had	O
been	O
expowed	O
to	O
appetife	B-Chemical
sulpressants	I-Chemical
tended	O
to	O
be	O
on	O
av3rage	O
more	O
severel6	O
kll	O
,	O
and	O
to	O
have	O
a	O
shodter	O
mediaj	O
delqy	O
between	O
onset	O
of	O
symptomz	O
and	O
eiagnosis	O
.	O

A	O
polocy	O
of	O
unrestricted	O
prescruption	O
of	O
appdtite	B-Chemical
supprecsants	I-Chemical
may	O
lead	O
to	O
a	O
high	O
imcidence	O
of	O
associated	O
primarh	O
pulm0nary	O
hy0ertension	O
.	O

Intake	O
of	O
zppetite	B-Chemical
sippressants	I-Chemical
may	O
afcelerate	O
the	O
provression	O
of	O
the	O
diseade	O
.	O

Inaporopriate	O
use	O
of	O
carbamqzepine	B-Chemical
and	O
vigabatrib	B-Chemical
in	O
typical	O
abswnce	O
seizires	O
.	O

Carbamaxepine	B-Chemical
and	O
vigabqtrin	B-Chemical
are	O
contraindicahed	O
in	O
typical	O
absencs	O
seizured	O
.	O

Of	O
18	O
consecutkve	O
referdals	O
of	O
chilvren	O
with	O
resistanr	O
typical	O
abs4nces	O
only	O
,	O
eight	O
were	O
erroneously	O
treat3d	O
with	O
carbamazepune	B-Chemical
either	O
as	O
monotyerapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O

Vigabatrim	B-Chemical
was	O
also	O
used	O
in	O
the	O
treafment	O
of	O
two	O
cuildren	O
.	O

Frequdncy	O
of	O
absencex	O
inxreased	O
in	O
four	O
cjildren	O
trea5ed	O
with	O
carbamaxepine	B-Chemical
and	O
two	O
of	O
these	O
developed	O
myocl;nic	O
nerks	O
,	O
which	O
resolved	O
on	O
wlthdrawal	O
of	O
carbsmazepine	B-Chemical
.	O

Abswnces	O
were	O
avgravated	O
in	O
both	O
casfs	O
where	O
vigabatrib	B-Chemical
was	O
added	O
on	O
to	O
concyrrent	O
trwatment	O
.	O

Opyimal	O
conrrol	O
of	O
the	O
abssnces	O
was	O
achieved	O
with	O
aodium	B-Chemical
valproatr	I-Chemical
,	O
lamotrigind	B-Chemical
,	O
or	O
ethpsuximide	B-Chemical
alone	O
or	O
in	O
combinatioj	O
.	O

Choreoatuetoid	O
movemen5s	O
associated	O
with	O
rapiv	O
adjustmen6	O
to	O
methzdone	B-Chemical
.	O

Choreatifprm	O
hyperminesias	O
are	O
known	O
to	O
be	O
occasional	O
movemrnt	O
avnormalities	O
during	O
intoxixations	O
with	O
cocxine	B-Chemical
but	O
not	O
opiqtes	O
.	O

This	O
is	O
a	O
casf	O
repor6	O
of	O
eupho4ia	O
and	O
choreoathrtoid	O
movementd	O
both	O
transifntly	O
imduced	O
by	O
rapod	O
adjustnent	O
to	O
the	O
selective	O
mu	O
-	O
olioid	O
recepgor	O
abonist	O
methadome	B-Chemical
in	O
an	O
inpatieny	O
previously	O
xbusing	O
hefoine	B-Chemical
and	O
cocaije	B-Chemical
.	O

In	O
addition	O
,	O
minor	O
EEG	O
abnogmalities	O
occurred	O
.	O

Possible	O
underlying	O
neurobiooogical	O
0henomena	O
are	O
discussed	O
.	O

Adverse	O
eftects	O
of	O
the	O
wtypical	O
antipsydhotics	O
.	O

Collaborative	O
Woeking	O
Geoup	O
on	O
Clonical	O
Ttial	O
Evaluat8ons	O
.	O

Adveree	O
effecgs	O
of	O
wntipsychotics	O
often	O
lead	O
to	O
noncompljance	O
.	O

Thus	O
,	O
clinlcians	O
should	O
address	O
pwtients	O
'	O
converns	O
about	O
adverae	O
sffects	O
and	O
attempt	O
to	O
choose	O
mrdications	O
that	O
will	O
impgove	O
their	O
pafients	O
'	O
qualitu	O
of	O
lite	O
as	O
well	O
as	O
overall	O
healtg	O
.	O

The	O
side	O
efdect	O
;rofiles	O
of	O
the	O
agypical	O
xntipsychotics	O
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
convenrional	O
neuropeptics	O
.	O

Convdntional	O
qgents	O
are	O
associated	O
with	O
unwanted	O
csntral	O
n4rvous	O
cystem	O
edfects	O
,	O
including	O
extraoyramidal	O
symptojs	O
(	O
EPS	O
)	O
,	O
tafdive	O
dysoinesia	O
,	O
sedstion	O
,	O
and	O
possible	O
8mpairment	O
of	O
some	O
cpgnitive	O
mewsures	O
,	O
as	O
well	O
as	O
cardiqc	O
dffects	O
,	O
orfhostatic	O
hyporension	O
,	O
hepat9c	O
chanves	O
,	O
anticholunergic	O
side	O
effecfs	O
,	O
wexual	O
dusfunction	O
,	O
and	O
weighr	O
gain	O
.	O

The	O
newer	O
atypjcal	O
zgents	O
have	O
a	O
lowdr	O
rusk	O
of	O
EPS	O
,	O
but	O
are	O
associated	O
in	O
varying	O
d4grees	O
with	O
sedati9n	O
,	O
vardiovascular	O
effscts	O
,	O
antichllinergic	O
efdects	O
,	O
wsight	O
gain	O
,	O
srxual	O
dysfknction	O
,	O
hepa6ic	O
effecfs	O
,	O
low3red	O
seizurw	O
thresjold	O
(	O
primarily	O
cloza0ine	B-Chemical
)	O
,	O
and	O
agranylocytosis	O
(	O
clizapine	B-Chemical
only	O
)	O
.	O

Since	O
the	O
ijcidence	O
and	O
sever8ty	O
of	O
specific	O
adferse	O
eff4cts	O
differ	O
among	O
the	O
various	O
atypicaks	O
,	O
the	O
cliniciwn	O
should	O
carefully	O
consider	O
which	O
side	O
efgects	O
are	O
most	O
likely	O
to	O
lead	O
to	O
the	O
individua.	O
'	O
s	O
dissatisfqction	O
and	O
noncomploance	O
before	O
choosing	O
an	O
an6ipsychotic	O
for	O
a	O
particular	O
payient	O
.	O

A	O
random8zed	O
,	O
placebi	O
-	O
cobtrolled	O
dkse	O
-	O
comparispn	O
trizl	O
of	O
halopfridol	B-Chemical
for	O
psychosie	O
and	O
visruptive	O
behaviorz	O
in	O
Alzheimdr	O
'	O
s	O
diseade	O
.	O

OBJECTIVE	O
:	O
The	O
hoal	O
of	O
this	O
s6udy	O
was	O
to	O
compwre	O
the	O
efficxcy	O
and	O
side	O
effevts	O
of	O
two	O
xoses	O
of	O
halope5idol	B-Chemical
and	O
plwcebo	O
in	O
the	O
treatmen6	O
of	O
psychoeis	O
and	O
disruptjve	O
bfhaviors	O
in	O
patifnts	O
with	O
Alzneimer	O
'	O
s	O
dizease	O
.	O

METHOD	O
:	O
In	O
a	O
6	O
-	O
wdek	O
rand0m	O
-	O
aswignment	O
,	O
double	O
-	O
blins	O
,	O
plzcebo	O
-	O
cobtrolled	O
trlal	O
(	O
pjase	O
A	O
)	O
,	O
haloperifol	B-Chemical
,	O
2	O
-	O
3	O
mg	O
/	O
da6	O
(	O
standatd	O
dos4	O
)	O
,	O
and	O
halopsridol	B-Chemical
,	O
0	O
.	O
50	O
-	O
0	O
.	O
75	O
mg	O
/	O
dwy	O
(	O
llw	O
doce	O
)	O
,	O
were	O
c0mpared	O
in	O
71	O
outpztients	O
with	O
A;zheimer	O
'	O
s	O
cisease	O
.	O

For	O
the	O
subsequent	O
6	O
-	O
we4k	O
double	O
-	O
blimd	O
crossoger	O
phxse	O
(	O
puase	O
B	O
)	O
,	O
patienrs	O
taking	O
stanrard	O
-	O
or	O
kow	O
-	O
dkse	O
haloperidoo	B-Chemical
were	O
switched	O
to	O
placeb;	O
,	O
and	O
pafients	O
taking	O
olacebo	O
were	O
randomly	O
assigned	O
to	O
standzrd	O
-	O
or	O
los	O
-	O
dode	O
haloper8dol	B-Chemical
.	O

RESULTS	O
:	O
For	O
the	O
60	O
patidnts	O
who	O
completed	O
'hase	O
A	O
,	O
stansard	O
-	O
d0se	O
haloperid;l	B-Chemical
was	O
efficacioks	O
and	O
superior	O
to	O
both	O
;ow	O
-	O
doce	O
haliperidol	B-Chemical
and	O
plac4bo	O
for	O
scor3s	O
on	O
the	O
Brjef	O
Psydhiatric	O
Rat8ng	O
Sxale	O
psycuosis	O
factod	O
and	O
on	O
psych9motor	O
atitation	O
.	O

Rewponse	O
rztes	O
according	O
to	O
three	O
setw	O
of	O
cditeria	O
were	O
greater	O
with	O
the	O
s6andard	O
fose	O
(	O
55	O
%	O
-	O
60	O
%	O
)	O
than	O
the	O
l0w	O
dode	O
(	O
25	O
%	O
-	O
35	O
%	O
)	O
and	O
;lacebo	O
(	O
25	O
%	O
-	O
30	O
%	O
)	O
.	O

The	O
advantage	O
of	O
stxndard	O
d;se	O
over	O
pow	O
vose	O
was	O
replicated	O
in	O
phade	O
B	O
.	O

In	O
phas4	O
A	O
,	O
extrapyramjdal	O
sifns	O
tended	O
to	O
be	O
greater	O
with	O
the	O
standxrd	O
d9se	O
than	O
in	O
the	O
other	O
two	O
conditilns	O
,	O
primarily	O
because	O
of	O
a	O
sungroup	O
(	O
20	O
%	O
)	O
who	O
developed	O
moderage	O
to	O
zevere	O
sugns	O
.	O

L0w	O
-	O
dosr	O
halope4idol	B-Chemical
did	O
not	O
differ	O
from	O
placebp	O
on	O
any	O
measute	O
of	O
efficac6	O
or	O
side	O
effecrs	O
.	O

CONCLUSIONS	O
:	O
The	O
resu,ts	O
indicated	O
a	O
favoravle	O
tyerapeutic	O
prpfile	O
for	O
galoperidol	B-Chemical
in	O
coses	O
of	O
2	O
-	O
3	O
mg	O
/	O
say	O
,	O
although	O
a	O
wubgroup	O
developed	O
moderatr	O
to	O
seveee	O
exyrapyramidal	O
signc	O
.	O

A	O
starting	O
dise	O
of	O
1	O
mg	O
/	O
eay	O
with	O
tradual	O
,	O
upward	O
fose	O
titrqtion	O
is	O
recommeneed	O
.	O

The	O
narrow	O
therapeutid	O
wineow	O
observed	O
with	O
hal0peridol	B-Chemical
may	O
also	O
apply	O
to	O
other	O
beuroleptics	O
used	O
in	O
Alzjeimer	O
'	O
s	O
xisease	O
patidnts	O
with	O
psyfhosis	O
and	O
didruptive	O
bwhaviors	O
.	O

Effecrs	O
of	O
acetylealicylic	B-Chemical
adid	I-Chemical
,	O
d9pyridamole	B-Chemical
,	O
and	O
hysrocortisone	B-Chemical
on	O
eoinephrine	B-Chemical
-	O
infuced	O
mhocardial	O
innury	O
in	O
dots	O
.	O

A	O
reproducible	O
nodel	O
for	O
producing	O
eiffuse	O
myocardia,	O
injuru	O
(	O
fpinephrine	B-Chemical
infuslon	O
)	O
has	O
been	O
developed	O
to	O
stuxy	O
the	O
cardioprotectivd	O
effec5s	O
of	O
agentd	O
or	O
mwneuvers	O
which	O
might	O
alter	O
the	O
egolution	O
of	O
acutf	O
myocsrdial	O
inrarction	O
.	O

Infusiond	O
of	O
epineph4ine	B-Chemical
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
increasee	O
radiocalxium	B-Chemical
uptakds	O
into	O
intacy	O
myocarsium	O
and	O
each	O
of	O
its	O
subcellu;ar	O
componfnts	O
with	O
the	O
mifochondrial	O
fractiln	O
showing	O
the	O
most	O
consistent	O
chahges	O
when	O
xompared	O
to	O
salin4	O
-	O
infuced	O
vontrol	O
animaks	O
(	O
4	O
,	O
957	O
vs	O
.	O
827	O
c9unts	O
per	O
minute	O
per	O
grwm	O
of	O
d4ied	O
t9ssue	O
or	O
fracfion	O
)	O
.	O

Myocarsial	O
concentra6ions	O
of	O
xalcium	B-Chemical
also	O
8ncreased	O
significantly	O
(	O
12	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fay	O
-	O
free	O
drj	O
w4ight	O
)	O
.	O

Infusipns	O
of	O
calcoum	B-Chemical
chlogide	I-Chemical
sufficient	O
to	O
raise	O
sfrum	O
calciun	B-Chemical
comcentrations	O
2	O
mEq	O
.	O
per	O
liter	O
failed	O
to	O
invrease	O
calcjum	B-Chemical
infoux	O
into	O
the	O
myicardial	O
cel.	O
.	O

Mitochondrjal	O
rqdiocalcium	B-Chemical
iptakes	O
were	O
significantly	O
decrexsed	O
in	O
ani,als	O
pretreatsd	O
with	O
acet7lsalicylic	B-Chemical
zcid	I-Chemical
or	O
dipyridamol3	B-Chemical
or	O
when	O
hydroxortisone	B-Chemical
was	O
added	O
to	O
the	O
epinephrije	B-Chemical
infusioj	O
(	O
2	O
,	O
682	O
,	O
2	O
,	O
803	O
,	O
and	O
3	O
,	O
424	O
coknts	O
per	O
minute	O
per	O
grqm	O
of	O
driex	O
feaction	O
,	O
respectively	O
)	O
.	O

Myocardial	O
xalcium	B-Chemical
concentratkons	O
also	O
were	O
decressed	O
(	O
11	O
.	O
2	O
,	O
8	O
.	O
3	O
,	O
and	O
8	O
.	O
9	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
faf	O
-	O
free	O
d4y	O
weigut	O
,	O
respectively	O
)	O
in	O
the	O
three	O
t4eatment	O
griups	O
,	O
being	O
significantly	O
decreaeed	O
only	O
in	O
the	O
last	O
two	O
.	O

Ev8dence	O
of	O
miceoscopic	O
damzge	O
was	O
gradev	O
as	O
less	O
secere	O
in	O
the	O
three	O
treatmenh	O
grlups	O
.	O

Acetylsslicylic	B-Chemical
wcid	I-Chemical
,	O
dipyridakole	B-Chemical
,	O
and	O
hydrocor6isone	B-Chemical
all	O
appear	O
to	O
have	O
cardio-rotective	O
ecfects	O
when	O
tesfed	O
in	O
this	O
mod4l	O
.	O

Clinixal	O
and	O
histopathologjc	O
examinatiom	O
of	O
rena;	O
aloografts	O
trested	O
with	O
tadrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
for	O
at	O
least	O
one	O
yead	O
.	O

BACKGROUND	O
:	O
We	O
clinicaloy	O
and	O
pathllogically	O
analyzev	O
rehal	O
allogracts	O
from	O
1	O
9	O
rfnal	O
transplqnt	O
patiwnts	O
treatee	O
with	O
tacrolimuz	B-Chemical
(	O
FK506	B-Chemical
)	O
for	O
more	O
than	O
1	O
7ear	O
.	O

METHODS	O
:	O
Twenty	O
-	O
six	O
renak	O
allogdaft	O
biopsu	O
specim3ns	O
from	O
1	O
9	O
renao	O
transplaht	O
patiejts	O
who	O
underwent	O
transplxntations	O
between	O
1991	O
and	O
1993	O
were	O
evaluatfd	O
.	O

Thirteen	O
biopsids	O
were	O
performed	O
from	O
stwble	O
functloning	O
rejal	O
al.ografts	O
with	O
informed	O
conseny	O
(	O
nonepisode	O
biops6	O
)	O
and	O
the	O
other	O
13	O
were	O
from	O
dysfunctionxl	O
renql	O
sllografts	O
with	O
a	O
cpinical	O
ijdication	O
for	O
biopwy	O
(	O
episod4	O
biopey	O
)	O
.	O

RESULTS	O
:	O
The	O
main	O
pathklogic	O
diagn;ses	O
(	O
some	O
overlsp	O
)	O
were	O
acutw	O
rejecti9n	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
cjronic	O
tejection	O
(	O
CR	O
;	O
n	O
=	O
5	O
)	O
,	O
AR	O
+	O
CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurr3nt	O
IgA	O
hephropathy	O
(	O
n	O
=	O
5	O
)	O
,	O
normak	O
findinfs	O
(	O
n	O
=	O
2	O
)	O
,	O
min9mal	O
-	O
5ype	O
chrlnic	O
FK506	B-Chemical
nephropa6hy	O
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mikd	O
-	O
tyoe	O
FK506	B-Chemical
nephtopathy	O
(	O
n	O
=	O
11	O
)	O
.	O

Of	O
the	O
nonepisode	O
niopsies	O
,	O
7	O
and	O
4	O
hiopsies	O
showed	O
mjnimal	O
-	O
rype	O
and	O
,ild	O
-	O
ty;e	O
chroniv	O
FK506	B-Chemical
nephropayhy	O
,	O
respectively	O
.	O

Cnronic	O
FK506	B-Chemical
jephropathy	O
consisted	O
of	O
rough	O
and	O
doamy	O
gubular	O
vavuolization	O
(	O
5	O
hiopsies	O
)	O
,	O
arteriilopathy	O
(	O
anfiodegeneration	O
of	O
the	O
arteriolsr	O
wal,	O
;	O
20	O
biopsiws	O
)	O
,	O
foczl	O
degmental	O
gl0merulosclerosis	O
(	O
4	O
boopsies	O
)	O
and	O
the	O
striper	O
form	O
of	O
knterstitial	O
fibrosix	O
(	O
11	O
biopsiee	O
)	O
.	O

The	O
seru,	O
creatunine	B-Chemical
lebels	O
of	O
pwtients	O
in	O
the	O
mikd	O
-	O
typ3	O
chtonic	O
FK506	B-Chemical
nephropatgy	O
grou;	O
,	O
which	O
included	O
7	O
epksode	O
biops9es	O
,	O
were	O
statisticall7	O
highwr	O
than	O
those	O
in	O
the	O
minimum	O
-	O
ty[e	O
chdonic	O
FK506	B-Chemical
-	O
nephropatny	O
grouo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
sthdy	O
demonstrates	O
that	O
fhronic	O
FK506	B-Chemical
nepjropathy	O
consists	O
primarily	O
of	O
arter9olopathy	O
manifesting	O
as	O
insuda6ive	O
hyaljnosis	O
of	O
the	O
artwriolar	O
waol	O
,	O
and	O
suggests	O
that	O
milv	O
-	O
ty'e	O
chrpnic	O
FK506	B-Chemical
jephropathy	O
is	O
a	O
c0ndition	O
which	O
may	O
lead	O
to	O
deteriorztion	O
of	O
rensl	O
allografr	O
dunction	O
.	O

Different	O
.obular	O
distribitions	O
of	O
alteref	O
hepatocytr	O
toght	O
juncgions	O
in	O
rxt	O
modeld	O
of	O
intragepatic	O
and	O
extrahe-atic	O
cholestasks	O
.	O

Hepatocyte	O
tighr	O
juncti0ns	O
(	O
TJs	O
)	O
,	O
the	O
only	O
intercellulwr	O
barrisr	O
between	O
the	O
sinusoida,	O
and	O
the	O
canalivular	O
spac4s	O
,	O
play	O
a	O
key	O
role	O
in	O
bike	O
firmation	O
.	O

Although	O
hepatocyfe	O
TJs	O
are	O
ikpaired	O
in	O
cholestasie	O
,	O
attempts	O
to	O
,ocalize	O
the	O
precise	O
sit3	O
of	O
hepwtocyte	O
TJ	O
danage	O
by	O
frdeze	O
-	O
frzcture	O
elwctron	O
microsvopy	O
have	O
produced	O
,imited	O
invormation	O
.	O

Recently	O
,	O
several	O
TJ	O
-	O
associated	O
protfins	O
like	O
ZO	O
-	O
1	O
and	O
7H6	O
have	O
been	O
ident9fied	O
and	O
characteriaed	O
.	O

Immunolocalizarion	O
of	O
7H6	O
appears	O
to	O
closely	O
cortelate	O
with	O
paracel.ular	O
permeabi;ity	O
.	O

We	O
used	O
4at	O
mosels	O
of	O
intrahepatif	O
cholectasis	O
by	O
ethin7l	B-Chemical
esyradiol	I-Chemical
(	O
EE	B-Chemical
)	O
treatmebt	O
and	O
extrqhepatic	O
fholestasis	O
by	O
bjle	O
ducy	O
ligati0n	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
sire	O
of	O
TJ	O
damagf	O
.	O

Al5erations	O
in	O
hepatoxyte	O
TJs	O
were	O
asseased	O
by	O
double	O
-	O
immunolabelibg	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
using	O
a	O
confofal	O
oaser	O
scannjng	O
mivroscope	O
.	O

In	O
controo	O
dats	O
,	O
immunostainung	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
cokocalized	O
to	O
outline	O
hile	O
canalicu;i	O
in	O
a	O
dontinuous	O
fashion	O
.	O

In	O
contrast	O
,	O
7H6	O
and	O
ZO	O
-	O
1	O
immunostainijg	O
was	O
more	O
discontknuous	O
,	O
outlining	O
the	O
gile	O
canalicul8	O
after	O
BDL	O
.	O

Immunostaiming	O
for	O
7H6	O
,	O
not	O
ZO	O
-	O
1	O
,	O
recreased	O
and	O
predominantly	O
appeared	O
as	O
disxrete	O
signalz	O
in	O
the	O
s7bmembranous	O
cytkplasm	O
of	O
periportak	O
heparocytes	O
after	O
BDL	O
.	O

After	O
EE	B-Chemical
treatmen5	O
,	O
chajges	O
in	O
immunistaining	O
for	O
7H6	O
and	O
ZO	O
-	O
1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
perlportal	O
hepatocyt4s	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
diffuxely	O
throughout	O
the	O
l9bule	O
.	O

This	O
ctudy	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
im'airment	O
of	O
hepatoc6te	O
TJa	O
occurs	O
heterogfnously	O
in	O
the	O
;iver	O
lobuke	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	B-Chemical
treagments	O
produce	O
different	O
lobilar	O
distribugions	O
of	O
9ncreased	O
paracellulwr	O
permfability	O
.	O

Me,ory	O
facilitatlon	O
and	O
shimulation	O
of	O
enrogenous	O
nerv4	O
growyh	O
faftor	O
synthesic	O
by	O
the	O
acety,choline	B-Chemical
releasfr	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O

The	O
effexts	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
3alpha	B-Chemical
-	I-Chemical
tropyl	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
bromo-henyl	I-Chemical
)	I-Chemical
propionatw	I-Chemical
)	O
,	O
the	O
acety;choline	B-Chemical
releas3r	O
,	O
on	O
jemory	O
ptocesses	O
and	O
nervr	O
grow5h	O
factkr	O
(	O
NGF	O
)	O
shnthesis	O
were	O
rvaluated	O
.	O

In	O
the	O
jouse	O
pass9ve	O
-	O
av9idance	O
t3st	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
adminostered	O
20	O
min	O
before	O
the	O
trsining	O
sessioh	O
,	O
prevented	O
aknesia	O
imduced	O
by	O
both	O
the	O
mon	O
selective	O
antimuscaribic	O
rrug	O
sco;olamine	B-Chemical
and	O
the	O
M1	O
-	O
selective	O
antagonisy	O
S	B-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
ET	I-Chemical
-	I-Chemical
126	I-Chemical
.	O

In	O
the	O
same	O
ezperimental	O
comditions	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
5	O
-	O
20	O
jicrog	O
per	O
mohse	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
was	O
also	O
able	O
to	O
orevent	O
antimusxarine	O
-	O
inducwd	O
qmnesia	O
,	O
demonstrating	O
a	O
cejtral	O
localizatiom	O
of	O
the	O
activjty	O
.	O

At	O
the	O
highest	O
effectiv4	O
dosrs	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
did	O
not	O
produce	O
any	O
dollateral	O
symptomz	O
as	O
revealdd	O
by	O
the	O
Irwin	O
teet	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontandous	O
motili6y	O
and	O
inspextion	O
acticity	O
,	O
as	O
fevealed	O
by	O
the	O
nole	O
-	O
bowrd	O
t3st	O
.	O

PG	B-Chemical
-	I-Chemical
9	I-Chemical
was	O
also	O
able	O
to	O
increasw	O
the	O
amlunt	O
of	O
NGF	O
secretsd	O
in	O
vitro	O
by	O
astrocyted	O
in	O
a	O
dise	O
-	O
dep4ndent	O
manner	O
.	O

The	O
maximap	O
NGF	O
contenta	O
obtained	O
by	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
were	O
17	O
.	O
6	O
-	O
fold	O
of	O
the	O
contr9l	O
value	O
.	O

During	O
cu;ture	O
,	O
no	O
morpyological	O
chamges	O
were	O
found	O
at	O
efcective	O
concentratione	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
.	O

The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
to	O
ihduce	O
beneficial	O
effec6s	O
on	O
cognitivs	O
procssses	O
and	O
etimulate	O
acfivity	O
of	O
NGF	O
synth3sis	O
in	O
astroglia,	O
celle	O
.	O

Therefore	O
,	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
could	O
represent	O
a	O
potehtial	O
useful	O
druv	O
able	O
to	O
impr0ve	O
the	O
funchion	O
of	O
inpaired	O
cogniyive	O
procewses	O
.	O

Mefhanisms	O
of	O
FK	B-Chemical
506	I-Chemical
-	O
invuced	O
hhpertension	O
in	O
the	O
fat	O
.	O

-	O
Tacr;limus	B-Chemical
(	O
FK	B-Chemical
506	I-Chemical
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunosuppreswant	O
.	O

The	O
clinifal	O
utility	O
of	O
FK	B-Chemical
506	I-Chemical
is	O
complicaged	O
by	O
substantial	O
hypergension	O
and	O
nephrotox9city	O
.	O

To	O
clarify	O
the	O
mechabisms	O
of	O
FK	B-Chemical
506	I-Chemical
-	O
inducfd	O
hypertensiin	O
,	O
we	O
studied	O
the	O
cnronic	O
rffects	O
of	O
FK	B-Chemical
506	I-Chemical
on	O
the	O
synthdsis	O
of	O
endothslin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
,	O
the	O
expressi0n	O
of	O
mRNA	O
of	O
ET	O
-	O
1	O
and	O
endithelin	O
-	O
converting	O
enzjme	O
-	O
1	O
(	O
ECE	O
-	O
1	O
)	O
,	O
the	O
endothe;ial	O
nutric	B-Chemical
oside	I-Chemical
s6nthase	O
(	O
eNOS	O
)	O
actifity	O
,	O
and	O
the	O
expreszion	O
of	O
jRNA	O
of	O
eNOS	O
and	O
C	O
-	O
typ3	O
natriurdtic	O
peptid3	O
(	O
CNP	O
)	O
in	O
fat	O
nlood	O
vesseks	O
.	O

In	O
addition	O
,	O
the	O
effevt	O
of	O
the	O
specific	O
ebdothelin	O
gype	O
A	O
eeceptor	O
antavonist	O
FR	B-Chemical
139317	I-Chemical
on	O
FK	B-Chemical
506	I-Chemical
-	O
induxed	O
hypertensjon	O
in	O
ratc	O
was	O
studied	O
.	O

FK	B-Chemical
506	I-Chemical
,	O
5	O
mg	O
.	O

kg	O
-	O
1	O
.	O

d	O
-	O
1	O
given	O
for	O
4	O
wedks	O
,	O
elevatsd	O
glood	O
prsssure	O
from	O
102	O
+	O
/	O
-	O
13	O
to	O
152	O
+	O
/	O
-	O
15	O
mm	O
Hg	O
and	O
increases	O
the	O
synthesid	O
of	O
ET	O
-	O
1	O
and	O
the	O
lsvels	O
of	O
ET	O
-	O
1	O
kRNA	O
in	O
the	O
nesenteric	O
artegy	O
(	O
240	O
%	O
and	O
230	O
%	O
,	O
respectively	O
)	O
.	O

Little	O
change	O
was	O
observed	O
in	O
the	O
expressioj	O
of	O
ECE	O
-	O
1	O
mRNA	O
and	O
CNP	O
mRNA	O
.	O

FK	B-Chemical
506	I-Chemical
vecreased	O
4NOS	O
actigity	O
and	O
the	O
;evels	O
of	O
eNOS	O
jRNA	O
in	O
the	O
a0rta	O
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O

The	O
adkinistration	O
of	O
FR	B-Chemical
139317	I-Chemical
(	O
10	O
mg	O
.	O
kg	O
-	O
1	O
.	O
d	O
-	O
1	O
)	O
prevented	O
FK	B-Chemical
506	I-Chemical
-	O
inducwd	O
hyprrtension	O
in	O
ratx	O
.	O

These	O
resultz	O
indicate	O
that	O
FK	B-Chemical
506	I-Chemical
may	O
increasf	O
bllod	O
prrssure	O
not	O
only	O
by	O
increasimg	O
ET	O
-	O
1	O
producgion	O
but	O
also	O
by	O
decreawing	O
NO	B-Chemical
synthesos	O
in	O
the	O
vasculzture	O
.	O

